PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Essen, LO; Perisic, O; Cheung, R; Katan, M; Williams, RL				Essen, LO; Perisic, O; Cheung, R; Katan, M; Williams, RL			Crystal structure of a mammalian phosphoinositide-specific phospholipase C delta	NATURE			English	Article							BACILLUS-CEREUS; BOVINE BRAIN; PHOSPHATIDYLINOSITOL; REFINEMENT; C-DELTA-1; PROGRAM	Mammalian phosphoinositide-specific phospholipase C enzymes (PI-PLC) act as signal transducers that generate two second messengers, inositol-1,4,5-trisphosphate and diacylglycerol. The 2.4-Angstrom structure of phospholipase C delta 1 reveals a multidomain protein incorporating modules shared by many signalling proteins. The structure suggests a mechanism for membrane attachment and Ca2+-dependent hydrolysis of second-messenger precursors. The regulation and reversible membrane association of PI-PLC may serve as a model for understanding other multidomain enzymes involved in phospholipid signalling.	UNIV CAMBRIDGE, CTR MRC, CTR PROT RES, CAMBRIDGE CB2 2QH, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND	University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Williams, Roger/0000-0001-7754-4207; Perisic, Olga/0000-0002-3842-2896	Medical Research Council [MC_U105184308] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; BURKHARD R, 1993, J MOL BIOL, V232, P584; CCP4, 1979, CCP4 SUITE PROGRAMS; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LIN GL, 1990, BIOCHEMISTRY-US, V29, P277; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKASHIMA S, 1995, BIOCHEM BIOPH RES CO, V211, P364, DOI 10.1006/bbrc.1995.1822; Nicholls A., 1992, GRASP GRAPHICAL REPR; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; QUIOCHO FA, 1989, T AM CRYST ASS, V25, P23; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHEDLER DJA, 1992, DISS ABSTR INT B, V53, P4118; SEITZ SP, 1992, BIOORG MED CHEM LETT, V2, P171, DOI 10.1016/S0960-894X(01)80444-3; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; SIMOES AP, 1995, FEBS LETT, V365, P155; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	50	504	515	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1996	380	6575					595	602		10.1038/380595a0	http://dx.doi.org/10.1038/380595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602259				2022-12-01	WOS:A1996UF74100036
J	Kwok, RPS; Laurance, ME; Lundblad, JR; Goldman, PS; Shih, HM; Connor, LM; Marriott, SJ; Goodman, RH				Kwok, RPS; Laurance, ME; Lundblad, JR; Goldman, PS; Shih, HM; Connor, LM; Marriott, SJ; Goodman, RH			Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP	NATURE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; PROTEIN; BINDING; ELEMENT; GENE; SEQUENCES	The Tax protein of human T-lymphotrophic virus (HTLV)-1 activates expression of the HTLV-1 long terminal repeat through a DNA element that resembles the cellular cyclic AMP-regulated enhancer (CRE)(1,2). Tax contains a transcriptional activation domain(3), but its ability to activate gene expression depends on interactions with cellular CRE-binding proteins such as CREB. Whether Tax can activate the expression of cellular CRE-containing genes has been controversial. Here we show that Tax can activate both the HTLV-1 and consensus cellular CREs, and propose that this activation may occur through mechanisms that are differentially dependent on CREB phosphorylation. Tax not only increases the binding of CREB to the viral CRE but also recruits the transcriptional co-activator CBP4,5 in a manner independent of CREB phosphorylation. In contrast, association of Tax with the cellular CRE occurs through CBP which, in turn, is recruited only in the presence of phosphorylated CREB.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Oregon Health & Science University; Baylor College of Medicine			Shih, Hsiu-Ming/S-7023-2018					BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; FELBER BK, 1985, SCIENCE, V229, P54; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1991, ONCOGENE, V6, P2349; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Langton B., 1988, MED VIROL, V8, P295; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	24	300	302	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					642	646		10.1038/380642a0	http://dx.doi.org/10.1038/380642a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602268				2022-12-01	WOS:A1996UF74100051
J	Schreibmayer, W; Dessauer, CW; Vorobiov, D; Gilman, AG; Lester, HA; Davidson, N; Dascal, N				Schreibmayer, W; Dessauer, CW; Vorobiov, D; Gilman, AG; Lester, HA; Davidson, N; Dascal, N			Inhibition of an inwardly rectifying K+ channel by G-protein alpha-subunits	NATURE			English	Article							BETA-GAMMA; RECEPTORS; EXPRESSION	Cholinergic muscarinic, serotonergic, opioid and several other G-protein-coupled neurotransmitter receptors activate inwardly rectifying K+ channels of the GIRK family, slowing the heartbeat and decreasing the excitability of neuronal cells'. Inhibitory modulation of GIRKs by G-protein-coupled receptors may have important implications in cardiac and brain physiology, Previously G alpha and G beta gamma subunits of heterotrimeric G proteins have both been implicated in channel opening(2,3), but recent studies attribute this role primarily to the G beta gamma dimer that activates GIRKs in a membrane-delimited fashion, probably by direct binding to the channel protein(4-8). We report here that free GTP gamma S-activated G(alpha i1), but not G(alpha i2) or G(alpha i3), potently inhibits G(beta 1 gamma 2)-induced GIRK activity in excised membrane patches of Xenopus oocytes expressing GIRK1. High-affinity but partial inhibition is produced by G(alpha s)-GTP gamma S. G(alpha i1)-GTP gamma S also inhibits G(beta 1 gamma 2)-activated GIRK in atrial myocytes. Antagonistic interactions between G(alpha) and G(beta gamma) may be among the mechanisms determining specificity of G protein coupling to GIRKs.	GRAZ UNIV,INST MED PHYS & BIOPHYS,A-8010 GRAZ,AUSTRIA; UNIV TEXAS,SW MED SCH,DEPT PHARMACOL,DALLAS,TX 75235; TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 RAMAT AVIV,ISRAEL; CALTECH,DIV BIOL,PASADENA,CA 91125	University of Graz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tel Aviv University; Sackler Faculty of Medicine; California Institute of Technology			Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146; Schreibmayer, Wolfgang/0000-0002-4631-7922				ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HEDIN KE, IN PRESS NEURON; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INABOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MATESIC DF, 1991, MOL PHARMACOL, V40, P347; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; PFAFFINGER PJ, 1985, NATURE, V317, P538; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TRAUTWEIN W, 1990, REV PHYSL, V52, P257; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	30	97	99	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					624	627		10.1038/380624a0	http://dx.doi.org/10.1038/380624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602262				2022-12-01	WOS:A1996UF74100045
J	Lasic, DD				Lasic, DD			Doxorubicin in sterically stabilized liposomes	NATURE			English	Article							LONG-CIRCULATING LIPOSOMES; CLEARANCE											BANGHAM AD, 1995, BIOESSAYS, V17, P1081, DOI 10.1002/bies.950171213; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; CEH B, 1995, LANGMUIR, V11, P3356, DOI 10.1021/la00009a016; DAEMEN T, 1995, INT J CANCER, V61, P716, DOI 10.1002/ijc.2910610520; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; GABIZON A, 1994, CANCER RES, V54, P987; GABIZON A, 1994, ACTA ONCOL, V33, P779, DOI 10.3109/02841869409083948; GREGORIADIS G, 1980, FEBS LETT, V119, P43, DOI 10.1016/0014-5793(80)80994-X; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; ISRAELACHVILI JN, 1985, SURFACE INTERPARTICL; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KUHL TL, 1994, BIOPHYS J, V66, P1479, DOI 10.1016/S0006-3495(94)80938-5; Lasic D.D., 1995, STEALTH LIPOSOMES; LASIC DD, 1992, FEBS LETT, V312, P255, DOI 10.1016/0014-5793(92)80947-F; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1994, ANGEW CHEM INT EDIT, V33, P1685, DOI 10.1002/anie.199416851; LASIC DD, 1995, BBA-BIOMEMBRANES, V1239, P145, DOI 10.1016/0005-2736(95)00159-Z; LASIC DD, 1993, LIPOSOMES PHYSICS AP; LASIC DD, 1995, CHEM REV, V96, P1601; MAYHEW EG, 1992, INT J CANCER, V51, P302, DOI 10.1002/ijc.2910510221; Needham D., 1992, J LIPOSOME RES, V2, P411, DOI [10.3109/08982109209010218, DOI 10.3109/08982109209010218]; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11640; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; VAAGE J, 1992, INT J CANCER, V51, P942, DOI 10.1002/ijc.2910510618; WILLIAMS SS, 1993, CANCER RES, V53, P3964; Zheng S., 2008, LIPOSOME ENCAPSULATE, V3, P575, DOI [10.3109/08982109309150740, DOI 10.3109/08982109309150740]	28	253	265	3	49	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					561	562		10.1038/380561a0	http://dx.doi.org/10.1038/380561a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606781				2022-12-01	WOS:A1996UE66300061
J	Guttman, A				Guttman, A			High-resolution carbohydrate profiling by capillary gel electrophoresis	NATURE			English	Article								Capillary gel electrophoresis with laser-induced fluorescent detection has been found to be a powerful separation and characterization tool for fluorescently labelled carbohydrates.			Guttman, A (corresponding author), BECKMAN INSTRUMENTS INC,2500 HARBOUR BLVD,FULLERTON,CA 92634, USA.		Guttman, András/GLT-9077-2022					CHIESA C, 1993, J CHROMATOGR, V645, P337, DOI 10.1016/0021-9673(93)83394-8; EVANGELISTA RA, 1995, ANAL CHEM, V67, P2239, DOI 10.1021/ac00109a051; GUTTMAN A, 1995, ELECTROPHORESIS, V16, P1906, DOI 10.1002/elps.11501601314; Guttman A, 1996, ANAL BIOCHEM, V233, P234, DOI 10.1006/abio.1996.0034; Guttman A, 1996, ELECTROPHORESIS, V17, P412, DOI 10.1002/elps.1150170221; JACKSON P, 1994, ANAL BIOCHEM, V216, P243, DOI 10.1006/abio.1994.1038; TOWNSEND RR, 1995, CARBOHYDRATE ANAL; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	8	111	113	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					461	462		10.1038/380461a0	http://dx.doi.org/10.1038/380461a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602248				2022-12-01	WOS:A1996UD59000069
J	Seaman, J; Mercer, AJ; Sondorp, HE; Herwaldt, BL				Seaman, J; Mercer, AJ; Sondorp, HE; Herwaldt, BL			Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources	ANNALS OF INTERNAL MEDICINE			English	Article							KALA-AZAR; SODIUM STIBOGLUCONATE; PARASITIC DISEASE; MALNUTRITION; RISK; POPULATION; INFECTION; ADULTS	Objectives: 1) To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes. Design: Cohort study. Setting: Medicins sans Frontieres-Holland's treatment center in Duar, Western Upper Nile province, an area in southern Sudan that has been severely affected by Sudan's civil war and a massive epidemic of visceral leishmaniasis. Patients: 3076 consecutive patients who had visceral leishmaniasis, were admitted to the treatment center the first year the center was operational (August 1990 to July 1991), and were treated with the pentavalent antimonial compound sodium stibogluconate. Measurements: Patient characteristics on admission and four mutually exclusive treatment outcomes (default during first admission, death during first admission, discharge and readmission for retreatment [relapse], and discharge and no readmission for retreatment [successful treatment]). Results: The patients had a median age of 15 years and were notably anemic (median hemoglobin level, 77 g/L) and malnourished (median body mass index of adults [greater than or equal to 18 years of age], 15.2 kg/m(2)); most (91.0%) had been sick less than 5 months. Although patients could not be monitored after treatment to document cure, most (2562 [83.3%]) were successfully treated; 336 (10.9%) died during their first admission, and 79 are known to have relapsed (3.0% of those discharged alive [that is, those whose final treatment outcome was successful treatment or relapse]). In univariable analysis, young and older age (<5 or greater than or equal to 45 years of age), long duration of illness (greater than or equal to 5 months), markedly low hemoglobin level or body mass index, large spleen, high parasite density, and vomiting at least once during the treatment course were associated with death. In multiple logistic regression analysis of data for a subgroup of 1207 adults (those who did not default or relapse and for whom data were recorded on age, sex, duration of illness, hemoglobin level, body mass index, and spleen size), the approximate risk ratios for death were 2.2 (95% CI, 1.4 to 3.6) for those with a long duration of illness, 3.6 (CI, 2.1 to 5.9) for those 45 years of age or older, 4.6 (CI, 2.2 to 9.4) for those with a hemoglobin level less than 60 g/L, and 12.2 (CI, 3.2 to 47.2) for those with a body mass index less than 12 kg/m(2). Conclusion: Despite the severe debility of the patients and the exceptionally difficult circumstances under which they were treated, most fared remarkably well.	CTR DIS CONTROL & PREVENT, DIV PARASIT DIS, ATLANTA, GA 30341 USA; MED SANS FRONTIERES HOLLAND, AMSTERDAM, NETHERLANDS	Centers for Disease Control & Prevention - USA								ASHFORD RW, 1992, T ROY SOC TROP MED H, V86, P379, DOI 10.1016/0035-9203(92)90229-6; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639; BAKER RJ, 1978, GLIM MANUAL RELEASE; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; DEBEER P, 1990, LANCET, V335, P224, DOI 10.1016/0140-6736(90)90313-T; DEBEER P, 1991, AM J TROP MED HYG, V44, P283, DOI 10.4269/ajtmh.1991.44.283; DYE C, 1993, P ROY SOC B-BIOL SCI, V254, P33, DOI 10.1098/rspb.1993.0123; GASSER RA, 1994, CLIN INFECT DIS, V18, P83, DOI 10.1093/clinids/18.1.83; GOLDEN MHN, 1993, LANCET, V342, P360, DOI 10.1016/0140-6736(93)91491-4; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; HARRISON LH, 1986, REV INFECT DIS, V8, P447; HENRY CJK, 1990, EUR J CLIN NUTR, V44, P329; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; LIGHTNER LK, 1983, AM J TROP MED HYG, V32, P296, DOI 10.4269/ajtmh.1983.32.296; MANSONBAHR PE, 1987, MANSONS TROPICAL DIS, P43; MENGESHA B, 1978, TROP GEOGR MED, V30, P199; PEARSON RD, 1992, AM J TROP MED HYG, V47, P8, DOI 10.4269/ajtmh.1992.47.8; PEREA WA, 1991, T ROY SOC TROP MED H, V85, P48, DOI 10.1016/0035-9203(91)90152-O; SEAMAN J, 1993, J INFECT DIS, V168, P715, DOI 10.1093/infdis/168.3.715; SEAMAN J, 1995, CLIN INFECT DIS, V21, P188, DOI 10.1093/clinids/21.1.188; SEAMAN J, 1992, ANN TROP MED PARASIT, V86, P481, DOI 10.1080/00034983.1992.11812697; SEAMAN J, IN PRESS INT J EPIDE; THAKUR CP, 1991, AM J TROP MED HYG, V45, P435, DOI 10.4269/ajtmh.1991.45.435; THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7; *UN, 1985, WORLD POP PROSP EST; ZIJLSTRA EE, 1992, J TROP PEDIATRICS, V38, P17, DOI 10.1093/tropej/38.1.17; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P365, DOI 10.1016/0035-9203(91)90293-8; 1991, TROPICALDIS RES NEWS, V37, P1; 1991, TROPICAL DIS RES NEW, V37, P1	34	88	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					664	672		10.7326/0003-4819-124-7-199604010-00007	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607595				2022-12-01	WOS:A1996UB51300007
J	Kopczynski, CC; Davis, GW; Goodman, CS				Kopczynski, CC; Davis, GW; Goodman, CS			A neural tetraspanin, encoded by late bloomer, that facilitates synapse formation	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; INCLUDING CD9; ANTIGEN; DROSOPHILA; SUPERFAMILY; CD53; PROTEINS; MELANOMA; CD37	Upon contacting its postsynaptic target, a neuronal growth cone transforms into a presynaptic terminal. A membrane component on the growth cone that facilitates synapse formation was identified by means of a complementary DNA-based screen followed by genetic analysis. The late bloomer (lbl) gene in Drosophila encodes a member of the tetraspanin family of cell surface proteins. LBL protein is transiently expressed on motor axons, growth cones, and terminal arbors. In lbl mutant embryos, the growth cone of the RP3 motoneuron contacts its target muscles, but synapse formation is delayed and neighboring motoneurons display an increase in ectopic sprouting.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANTON ES, 1995, J NEUROSCI, V15, P584; BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; BROADIE K, 1993, DEVELOPMENT, P227; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DALBY B, 1995, GENETICS, V139, P757; DAVERN KM, 1991, MOL BIOCHEM PARASIT, V48, P67, DOI 10.1016/0166-6851(91)90165-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EMI N, 1993, IMMUNOGENETICS, V37, P193; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, IN PRESS ANN REV NEU; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1995, J IMMUNOL, V155, P1229; Jarecki J, 1995, J NEUROSCI, V15, P8177; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KITANI S, 1991, J BIOL CHEM, V266, P1903; KOPCZYNSKI CC, UNPUB; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; RASMUSSEN AM, 1994, J IMMUNOL, V153, P4997; ROBERTS JJ, 1995, BRIT J HAEMATOL, V89, P853; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; SINK H, 1991, DEVELOPMENT, V112, P307; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TOLE S, 1993, DEV DYNAM, V197, P94, DOI 10.1002/aja.1001970203; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5	44	147	149	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1867	1870		10.1126/science.271.5257.1867	http://dx.doi.org/10.1126/science.271.5257.1867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596956				2022-12-01	WOS:A1996UC77800047
J	Welker, E; ArmstrongJames, M; Bronchti, G; Ourednik, W; GheorghitaBaechler, F; Dubois, R; Guernsey, DL; VanderLoos, H; Neumann, PE				Welker, E; ArmstrongJames, M; Bronchti, G; Ourednik, W; GheorghitaBaechler, F; Dubois, R; Guernsey, DL; VanderLoos, H; Neumann, PE			Altered sensory processing in the somatosensory cortex of the mouse mutant barrelless	SCIENCE			English	Article							OCULAR DOMINANCE COLUMNS; VISUAL-CORTEX; THALAMOCORTICAL AFFERENTS; STRUCTURAL ORGANIZATION; TERMINAL ARBORS; ADULT-RAT; LAYER-IV; MORPHOLOGY; VIBRISSAE; UNITS	Mice homozygous for the barrelless (brl) mutation, mapped here to chromosome 11, lack barrel-shaped arrays of cell clusters termed ''barrels'' in the primary somatosensory cortex. Deoxyglucose uptake demonstrated that the topology of the cortical whisker representation is nevertheless preserved. Anterograde tracers revealed a lack of spatial segregation of thalamic afferents into individual barrel territories, and single-cell recordings demonstrated a lack of temporal discrimination of center from surround information. Thus, structural segregation of thalamic inputs is not essential to generate topological order in the somatosensory cortex, but it is required for discrete spatiotemporal relay of sensory information to the cortex.	UNIV LONDON QUEEN MARY & WESTFIELD COLL, DEPT PHYSIOL, LONDON E1 4NS, ENGLAND; DALHOUSIE UNIV, DEPT ANAT & NEUROBIOL, HALIFAX, NS B3H 4H7, CANADA; DALHOUSIE UNIV, DEPT PATHOL, DIV MOL PATHOL & MOL GENET, HALIFAX, NS B3H 4H7, CANADA	University of London; Queen Mary University London; Dalhousie University; Dalhousie University	Welker, E (corresponding author), UNIV LAUSANNE, INST ANAT, RUE BUGNON 9, CH-1005 LAUSANNE, SWITZERLAND.			Neumann, Paul/0000-0002-8480-4799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGMON A, 1993, J NEUROSCI, V13, P5365, DOI 10.1523/JNEUROSCI.13-12-05365.1993; ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P193, DOI 10.1002/cne.903030203; ARMSTRONGJAMES M, 1987, J COMP NEUROL, V263, P265, DOI 10.1002/cne.902630209; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Blue ME, 1991, CEREB CORTEX, V1, P380, DOI 10.1093/cercor/1.5.380; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CATALANO SM, 1995, P NATL ACAD SCI USA, V92, P2549, DOI 10.1073/pnas.92.7.2549; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOLLEMANVANDERWEEL MJ, 1994, J NEUROSCI METH, V51, P9, DOI 10.1016/0165-0270(94)90021-3; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FOX K, 1994, J NEUROSCI, V14, P7665; GARRAGHTY PE, 1990, J COMP NEUROL, V294, P583, DOI 10.1002/cne.902940406; HUBEL DH, 1972, J COMP NEUROL, V146, P421, DOI 10.1002/cne.901460402; JENSEN KF, 1987, J NEUROSCI, V7, P3544; JENSEN KF, 1987, J NEUROSCI, V7, P3529; JHAVERI S, 1991, P NATL ACAD SCI USA, V88, P4489, DOI 10.1073/pnas.88.10.4489; LEVAY S, 1975, J COMP NEUROL, V159, P559, DOI 10.1002/cne.901590408; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; Lorente de No R., 1922, TRAB LAB BIOL U MADR, V20, P41; MA PM, 1991, J COMP NEUROL, V309, P161, DOI 10.1002/cne.903090202; SCHLAGGAR BL, 1994, J COMP NEUROL, V346, P80, DOI 10.1002/cne.903460106; Senft SL, 1991, CEREB CORTEX, V1, P308, DOI 10.1093/cercor/1.4.308; SIMONS DJ, 1985, J NEUROPHYSIOL, V54, P615, DOI 10.1152/jn.1985.54.3.615; STRYKER MP, 1986, J NEUROSCI, V6, P2117; VANDERLOOS H, 1976, NEUROSCI LETT, V2, P1, DOI 10.1016/0304-3940(76)90036-7; VANDERLOOS H, 1986, J HERED, V77, P66, DOI 10.1093/oxfordjournals.jhered.a110201; VONDERMALSBURG C, 1987, NEURAL MOL BASES LEA, P00411; WELKER E, 1993, EUR J NEUROSCI, V5, P691, DOI 10.1111/j.1460-9568.1993.tb00534.x; WELKER E, 1992, J NEUROSCI, V12, P153; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WOOLSEY TA, 1975, J COMP NEUROL, V164, P79, DOI 10.1002/cne.901640107; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	34	124	126	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1864	1867		10.1126/science.271.5257.1864	http://dx.doi.org/10.1126/science.271.5257.1864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596955				2022-12-01	WOS:A1996UC77800046
J	Forsthuber, T; Yip, HC; Lehmann, PV				Forsthuber, T; Yip, HC; Lehmann, PV			Induction of T(H)1 and T(H)2 immunity in neonatal mice	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MEMORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; TOLERANCE INDUCTION; MIGRATION PATHWAYS; DETERMINANT; PEPTIDE; SPLEEN	The neonatal period has been thought of as a window in ontogeny, during which the developing immune system is particularly susceptible to tolerization. In the present study, the classic system for induction of neonatal tolerance to protein antigens was reexamined in mice. The presumably tolerogenic protocol was found to trigger a vigorous T helper cell type 2 (T(H)2) immune response. Thus, neonatal ''tolerization'' induces immune deviation, not tolerance in the immunological sense. Neonates are not immune privileged but generate T(H)2 or T(H)1 responses, depending on the mode of immunization.	CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36219-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOWICZ D, 1990, EUR J IMMUNOL, V20, P1647, DOI 10.1002/eji.1830200805; ASHERSON GL, 1965, IMMUNOLOGY, V9, P205; ASHERSON GL, 1967, BRIT MED BULL, V23, P24, DOI 10.1093/oxfordjournals.bmb.a070510; BERNARD CCA, 1977, CLIN EXP IMMUNOL, V29, P100; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BURNET FM, 1949, PRODUCTION ANTIBODIE, P102; CHEN H, 1995, TRANSPLANTATION, V60, P1182; Chen NX, 1995, TRANSPLANTATION, V60, P1187; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; DORSCH S, 1975, NATURE, V258, P233, DOI 10.1038/258233a0; EINSTEIN ER, 1968, IMMUNOCHEMISTRY, V5, P567, DOI 10.1016/0019-2791(68)90092-X; FALK GA, 1969, J IMMUNOL, V103, P1248; FORSTHUBER T, UNPUB; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; GAMMON GM, 1986, J EXP MED, V164, P667, DOI 10.1084/jem.164.2.667; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JUNG TM, 1988, J IMMUNOL, V141, P4110; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MACKAY CR, 1992, EUR J IMMUNOL, V22, P887, DOI 10.1002/eji.1830220402; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; Owen R. D., 1946, JOUR HEREDITY, V37, P291; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PABST R, 1988, IMMUNOL TODAY, V9, P43, DOI 10.1016/0167-5699(88)91258-3; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; PATERSON PY, 1958, ANN NY ACAD SCI, V73, P811, DOI 10.1111/j.1749-6632.1959.tb40860.x; POWELL TJ, 1990, J IMMUNOL, V144, P854; QIN Y, 1989, EUR J IMMUNOL, V19, P373, DOI 10.1002/eji.1830190223; RIEGER M, 1977, J IMMUNOGENET, V4, P61; SWIERKOS.JE, 1974, FED PROC, V33, P814; SWIERKOSZ JE, 1975, J IMMUNOL, V115, P631; WELCH AM, 1976, EUR J IMMUNOL, V6, P910, DOI 10.1002/eji.1830061214	35	581	601	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1728	1730		10.1126/science.271.5256.1728	http://dx.doi.org/10.1126/science.271.5256.1728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596934				2022-12-01	WOS:A1996UB15100047
J	Myers, MP; WagerSmith, K; RothenfluhHilfiker, A; Young, MW				Myers, MP; WagerSmith, K; RothenfluhHilfiker, A; Young, MW			Light-induced degradation of TIMELESS and entrainment of the Drosophila circadian clock	SCIENCE			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; MELANOGASTER; RHYTHMS	Two genes, period (per) and timeless (tim), are required for production of circadian rhythms in Drosophila. The proteins encoded by these genes (PER and TIM) physically interact, and the timing of their association and nuclear localization is believed to promote cycles of per and tim transcription through an autoregulatory feedback loop. Here it is shown that TIM protein may also couple this molecular pacemaker to the environment, because TIM is rapidly degraded after exposure to light. TIM accumulated rhythmically in nuclei of eyes and in pacemaker cells of the brain. The phase of these rhythms was differentially advanced or delayed by light pulses delivered at different times of day, corresponding with phase shifts induced in the behavioral rhythms.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NSF,SCI & TECHNO CTR BIOL TRIMING,NEW YORK,NY 10021; ROCKEFELLER UNIV,LAB GENET,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Rothenfluh, Adrian/0000-0002-3813-5723				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARGIELLO TA, 1984, P NATL ACAD SCI-BIOL, V81, P2142, DOI 10.1073/pnas.81.7.2142; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MATSUMOTO A, 1994, J NEUROGENET, V9, P141, DOI 10.3109/01677069409167276; MYERS M, UNPUB; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REDDY P, 1984, CELL, V38, P701, DOI 10.1016/0092-8674(84)90265-4; ROTHENFLUHHILFI.A, UNPUB; RUTILA J, COMMUNICATION; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEHGAL A, UNPUB; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WAGERSMITH K, UNPUB; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	29	395	402	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1736	1740		10.1126/science.271.5256.1736	http://dx.doi.org/10.1126/science.271.5256.1736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596937				2022-12-01	WOS:A1996UB15100050
J	Mazzaferro, V; Regalia, E; Doci, R; Andreola, S; Pulvirenti, A; Bozzetti, F; Montalto, F; Ammatuna, M; Morabito, A; Gennari, L				Mazzaferro, V; Regalia, E; Doci, R; Andreola, S; Pulvirenti, A; Bozzetti, F; Montalto, F; Ammatuna, M; Morabito, A; Gennari, L			Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; RESECTION; CANCER; MALIGNANCY; RECURRENCE	Background. The role of orthotopic liver transplantation in the treatment of patients with cirrhosis and hepatocellular carcinoma is controversial, and determining which patients are likely to have a good outcome after liver transplantation is difficult. Methods. We studied 48 patients with cirrhosis who had small, unresectable hepatocellular carcinomas and who underwent liver transplantation. In 94 percent of the patients, the cirrhosis was related to infection with hepatitis B virus, hepatitis C virus, or both. The presence of tumor was confirmed by biopsy or serum alpha-fetoprotein assay. The criteria for eligibility for transplantation were the presence of a tumor 5 cm or less in diameter in patients with single hepatocellular carcinomas and no more than three tumor nodules, each 3 cm or less in diameter, in patients with multiple tumors. Twenty-eight patients with sufficient hepatic function underwent treatment for the tumor, mainly chemoembolization, before transplantation. After liver transplantation, the patients were followed prospectively for a median of 26 months (range, 9 to 54), No anticancer treatment was given after transplantation. Results. The overall mortality rate was 17 percent. After four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent. Hepatocellular carcinoma recurred in four patients (8 percent). The overall and recurrence-free survival rates at four years among the 35 patients (73 percent of the total) who met the predetermined criteria for the selection of small hepatocellular carcinomas at pathological review of the explanted liver were 85 percent and 92 percent, respectively, whereas the rates in the 13 patients (27 percent) whose tumors exceeded these limits were 50 percent and 59 percent, respectively (P=0.01 for overall survival; P=0.002 for recurrence-free survival). In this group of 48 patients with early-stage tumors, tumor-node-metastasis status, the number of tumors, the serum alphafetoprotein concentration, treatment received before transplantation, and 10 other variables were not significantly correlated with survival. Conclusions. Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis.	NATL CANC INST,DEPT PATHOL,I-20133 MILAN,ITALY; NATL CANC INST,DEPT ANESTHESIA,I-20133 MILAN,ITALY; UNIV MILAN,INST MED STAT & BIOMETRY,MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan			Regalia, Enrico/L-9933-2017; Mazzaferro, Vincenzo/C-2726-2017; Mazzaferro, Vincenzo/AAL-4707-2020	Regalia, Enrico/0000-0002-9528-5859; Mazzaferro, Vincenzo/0000-0002-4013-8085; 				BARBARA L, 1992, HEPATOLOGY, V16, P132, DOI 10.1002/hep.1840160122; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; COLOMBO M, 1993, SEMIN LIVER DIS, V13, P374; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; *EUR LIV TRANSPL R, 1994, REP EUR LIV TRANSPL; HAUG CE, 1992, TRANSPLANTATION, V53, P376, DOI 10.1097/00007890-199202010-00021; HERMANEK P, 1987, TNM CLASSIFICATION M, P53; ISMAIL T, 1990, BRIT J SURG, V77, P983, DOI 10.1002/bjs.1800770908; IWATSUKI S, 1985, ANN SURG, V202, P401, DOI 10.1097/00000658-198510000-00001; IWATSUKI S, 1991, ANN SURG, V214, P221, DOI 10.1097/00000658-199109000-00005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAZZAFERRO V, 1994, TRANSPLANT P, V26, P3557; MORENO E, 1992, AM J SURG, V163, P395; OGRADY JG, 1988, ANN SURG, V207, P373, DOI 10.1097/00000658-198804000-00002; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; OKUDA K, 1991, OXFORD TXB CLIN HEPA, V2, P1019; OLTHOFF KM, 1990, ARCH SURG-CHICAGO, V125, P1261; PENN I, 1991, SURGERY, V110, P726; RINGE B, 1989, ANN SURG, V209, P88, DOI 10.1097/00000658-198901000-00013; RINGE B, 1991, WORLD J SURG, V15, P270, DOI 10.1007/BF01659064; SELBY R, 1995, WORLD J SURG, V19, P53, DOI 10.1007/BF00316980; SPREAFICO C, 1994, RADIOLOGY, V192, P687, DOI 10.1148/radiology.192.3.8058934; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1985, J PEDIATR-US, V106, P604, DOI 10.1016/S0022-3476(85)80081-0; STEVES MA, 1992, AM SURGEON, V58, P608; TAN KC, 1995, BRIT J SURG, V82, P253, DOI 10.1002/bjs.1800820239; TREY C, 1966, NEW ENGL J MED, V274, P473, DOI 10.1056/NEJM196603032740901; TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013; UTSUNOMIYA T, 1992, HEPATOLOGY, V16, P694, DOI 10.1002/hep.1840160313; YOKOYAMA I, 1990, HEPATO-GASTROENTEROL, V37, P188; YOKOYAMA I, 1991, CANCER, V68, P2095, DOI 10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y	33	5093	5343	7	438	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					693	699		10.1056/NEJM199603143341104	http://dx.doi.org/10.1056/NEJM199603143341104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594428				2022-12-01	WOS:A1996TZ52800004
J	Ohta, M; Inoue, H; Cotticelli, MG; Kastury, K; Baffa, R; Palazzo, J; Siprashvili, Z; Mori, M; McCue, P; Druck, T; Croce, CM; Huebner, K				Ohta, M; Inoue, H; Cotticelli, MG; Kastury, K; Baffa, R; Palazzo, J; Siprashvili, Z; Mori, M; McCue, P; Druck, T; Croce, CM; Huebner, K			The FHIT gene, spanning the chromosome 3p14.2 fragile site acid renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers	CELL			English	Article							PROTEIN-KINASE-C; ESOPHAGEAL CANCER; CGG REPEAT; TRANSLOCATION; REGION; INSTABILITY; DNA; SEQUENCE; CHINA	A 200-300 kb region of chromosome 3p14.2, including the fragile site locus FRA3B, is homozygously deleted in multiple tumor-derived cell lines. Exon amplification from cosmids covering this deleted region allowed identification of the human FHIT gene, a member of the histidine triad gene family, which encodes a protein with 69% similarity to an S. pombe enzyme, diadenosine 5', 5triple prime P-1, P-4-tetraphosphate asymmetrical hydrolase. The FHIT locus is composed of ten exons distributed over at least 500 kb, with three 5' untranslated exons centromeric to the renal carcinoma-associated 3p14.2 breakpoint, the remaining exons telomeric to this translocation breakpoint, and exon 5 within the homozygously deleted fragile region. aberrant transcripts of the FHIT locus were found in similar to 50% of esophageal, stomach, and colon carcinomas.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC CTR, PHILADELPHIA, PA 19107 USA; KYUSHU UNIV, MED INST BIOREGULAT, DEPT SURG, BEPPU, OITA 874, JAPAN	Jefferson University; Kyushu University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA051083, R35CA039860, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA21124, CA39860, CA51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BOLDOG FL, 1994, GENE CHROMOSOME CANC, V11, P216, DOI 10.1002/gcc.2870110403; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DRUCK T, 1995, CANCER RES, V55, P5348; FONG LYY, 1978, J NATL CANCER I, V61, P145, DOI 10.1093/jnci/61.1.145; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1988, CANCER GENET CYTOGEN, V31, P69, DOI 10.1016/0165-4608(88)90013-1; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; KASTURY K, 1996, IN PRESS GENOMICS; KASTURY K, 1996, IN PRESS CANC RES; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; LO KW, 1994, INT J ONCOL, V4, P1359; LUBINSKI J, 1994, CANCER RES, V54, P3710; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MICHAELIS SC, 1995, CANCER GENET CYTOGEN, V81, P1, DOI 10.1016/0165-4608(94)00208-8; MOZIER NM, 1991, FEBS LETT, V279, P14, DOI 10.1016/0014-5793(91)80238-X; OHTA M, 1995, IN PRESS INT J CANC; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; RASSOOL FV, 1992, AM J HUM GENET, V50, P1243; ROCHE J, 1994, HUM MOL GENET, V3, P215, DOI 10.1093/hmg/3.1.215; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; SERAPHIN B, 1994, HUM MOL GENET, V3, P215; SUTHERLAND GR, 1991, GENET ANAL TECH APPL, V8, P1616; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YANG CS, 1980, CANCER RES, V40, P2633; YANG GC, 1987, J NATL CANCER I, V79, P1241; YOKOTA J, 1989, CANCER RES, V49, P3598; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	37	957	1133	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1996	84	4					587	597		10.1016/S0092-8674(00)81034-X	http://dx.doi.org/10.1016/S0092-8674(00)81034-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598045	Bronze			2022-12-01	WOS:A1996TX17600011
J	Patten, PA; Gray, NS; Yang, PL; Marks, CB; Wedemayer, GJ; Boniface, JJ; Stevens, RC; Schultz, PG				Patten, PA; Gray, NS; Yang, PL; Marks, CB; Wedemayer, GJ; Boniface, JJ; Stevens, RC; Schultz, PG			The immunological evolution of catalysis	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; IMMUNE-RESPONSE; HYPERVARIABLE REGIONS; ANTIBODY DIVERSITY; SOMATIC MUTATION; MATURATION; BINDING; GENERATION; EXPRESSION; FRAGMENT	The germline genes used by the mouse to generate the esterolytic antibody 48G7 were cloned and expressed in an effort to increase our understanding of the detailed molecular mechanisms by which the immune system evolves catalytic function. The nine replacement mutations that were fixed during affinity maturation increased affinity for the transition state analogue by a factor of 10(4), primarily the result of a decrease in the dissociation rate of the hapten-antibody complex. There was a corresponding increase in the rate of reaction of antibody with substrate, k(cat)/K-m, from 1.7 x 10(2) M(-1) min(-1) to 1.4 x 10(4) M(-1) min-l The three-dimensional crystal structure of the 48G7-transition state analogue complex at 2.0 angstroms resolution indicates that none of the nine residues in which somatic mutations have been fixed directly contact the hapten. Thus, in the case of 48G7, affinity maturation appears to play a conformational role, either in reorganizing the active site geometry or limiting side-chain and backbone flexibility of the germline antibody. The crystal structure and analysis of somatic and directed active site mutants underscore the role of transition state stabilization in the evolution of this catalytic antibody.	UNIV CALIF BERKELEY,DEPT CHEM,HOWARD HUGHES MED INST,BERKELEY,CA 94720; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; Stanford University			Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725; Yang, Priscilla/0000-0001-7456-2557; Gray, Nathanael/0000-0001-5354-7403	PHS HHS [R01 AL24695] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRAISTED AC, 1994, J AM CHEM SOC, V116, P2211, DOI 10.1021/ja00084a098; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHEN C, 1995, EMBO J, V14, P2784, DOI 10.1002/j.1460-2075.1995.tb07278.x; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLINELLIPIMPAN.B, 1994, CURR BIOL, V2, P175; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Haldane J.B.S., 1930, ENZYMES; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; JACOBS JW, 1989, THESIS U CALIFORNIA; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JESKE DJ, 1984, J IMMUNOL, V133, P1090; JONES TA, O COMPUTER GRAPHICS; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KAUFFMAN SA, 1988, MATURATION IMMUNE RE, V2, P349; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; MALMBORG AC, 1992, SCAND J IMMUNOL, V35, P643, DOI 10.1111/j.1365-3083.1992.tb02970.x; PADLAN EA, 1985, ANN INST PASTEUR IMM, VC136, P271, DOI 10.1016/S0769-2625(85)80058-1; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI DOI 10.1021/CEN-V024N010.P1375; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SCHIFF C, 1986, J EXP MED, V163, P573, DOI 10.1084/jem.163.3.573; SCHULTZ PG, 1995, SCIENCE, V269, P835; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; STEINER LA, 1967, J EXP MED, V126, P1143, DOI 10.1084/jem.126.6.1143; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; THERIAULT TP, 1991, J MOL BIOL, V221, P257; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; VANVRANKEN DL, 1994, TETRAHEDRON LETT, V35, P3873, DOI 10.1016/S0040-4039(00)76689-5; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444; [No title captured]	47	198	205	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1086	1091		10.1126/science.271.5252.1086	http://dx.doi.org/10.1126/science.271.5252.1086			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599084	Green Submitted			2022-12-01	WOS:A1996TW70100029
J	Druey, KM; Blumer, KJ; Kang, VH; Kehrl, JH				Druey, KM; Blumer, KJ; Kang, VH; Kehrl, JH			Inhibition of C-protein-mediated MAP kinase activation by a new mammalian gene family	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; G1 ARREST; A-FACTOR; DESENSITIZATION; PHOSPHORYLATION; RECEPTOR	A GENERAL property of signal transduction pathways is that prolonged stimulation decreases responsiveness, a phenomenon termed desensitization. Yeast cells stimulated with mating pheromone activate a heterotrimeric G-protein-linked, MAP-kinase-dependent signalling pathway that induces G1-phase cell-cycle arrest and morphological differentiation (reviewed in refs 1, 2). Eventually the cells desensitize to pheromone and resume growth(3). Genetic studies have demonstrated the relative importance of a desensitization mechanism that uses the SST2 gene product, Sst2p(4-7). Here we identify a mammalian gene family termed RGS (for regulator of G-protein signalling) that encodes structural and functional homologues of Sst2p. Introduction of RGS family members into yeast blunts signal transduction through the pheromone-response pathway. Like SST2 (refs 8-10), they negatively regulate this pathway at a point upstream or at the level of the G protein. The RGS family members also markedly impair MAP kinase activation by mammalian G-protein-linked receptors, indicating the existence and importance of an SST2-like desensitization mechanism in mammalian cells.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL)			Kehrl, John/AAE-6292-2019; Blumer, Kendall J/C-5268-2012	Kehrl, John/0000-0002-6526-159X				ADAMS TH, 1992, MOL CELL BIOL, V12, P3827, DOI 10.1128/MCB.12.9.3827; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HONG JX, 1993, J IMMUNOL, V150, P3895; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KURJAN J, 1993, ANNU REV GENET, V27, P147; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MAZER BD, 1992, J CLIN INVEST, V90, P759, DOI 10.1172/JCI115948; MOORE SA, 1984, J BIOL CHEM, V259, P1004; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SPRAGUE GF, 1992, PHEROMONE RESPONSE S, P657; STEVEN BJ, 1989, MOL GEN GENET, V219, P421, DOI 10.1007/BF00259615; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; VANLINT J, 1993, MOL CELL BIOCHEM, V128, P171, DOI 10.1007/BF01076768; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	28	412	430	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					742	746		10.1038/379742a0	http://dx.doi.org/10.1038/379742a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602223	Green Submitted			2022-12-01	WOS:A1996TW56700057
J	Davie, AP; Francis, CM; Love, MP; Caruana, L; Starkey, IR; Shaw, TRD; Sutherland, GR; McMurray, JJV				Davie, AP; Francis, CM; Love, MP; Caruana, L; Starkey, IR; Shaw, TRD; Sutherland, GR; McMurray, JJV			Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; FRANCIS CM, 1995, BRIT MED J, V310, P634, DOI 10.1136/bmj.310.6980.634; MACALLAN DC, 1990, J ROY SOC MED, V83, P559, DOI 10.1177/014107689008300909; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; WHEELDON NM, 1993, Q J MED, V86, P17	5	185	189	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					222	222						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563589				2022-12-01	WOS:A1996TT48600029
J	Margossian, SP; Li, HL; Zassenhaus, HP; Butow, RA				Margossian, SP; Li, HL; Zassenhaus, HP; Butow, RA			The DExH box protein Suv3p is a component of a yeast mitochondrial 3'-to-5' exoribonuclease that suppresses group I intron toxicity	CELL			English	Article							CONSERVED DODECAMER SEQUENCE; TETRAHYMENA-THERMOPHILA RIBOZYME; SACCHAROMYCES-CEREVISIAE; POSTTRANSCRIPTIONAL PROCESSES; KINETIC DESCRIPTION; ENCODED PROTEIN; MESSENGER-RNAS; ACTIVE-SITE; GENE; PURIFICATION	The yeast mitochondrial protein Suv3p is a putative NTP-dependent RNA helicase. Here we report that in cells lacking Suv3p, there is an similar to 50-fold increase in the excised form of the group I intron omega of the mitochondrial 21S rRNA gene. Surprisingly, little mature 21S rRNA accumulates in those cells; instead, unligated 21S rRNA exons appear. Intron overaccumulation could lead to spliced exon reopening via a reaction known to be catalyzed by group I introns in vitro. We also show that Suv3p is a functional component of a novel mitochondrial NTP-dependent 3'-to-5' exoribonuclease activity that can degrade group I intron RNAs. These findings account for group I intron overaccumulation in cells lacking Suv3p and define a novel function for putative RNA helicases in direct RNA degradation.	ST LOUIS UNIV, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, ST LOUIS, MO 63104 USA	Saint Louis University	Margossian, SP (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022525, R37GM022525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; CONRAD H, 1987, THESIS OHIO STATE U; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; DAKE E, 1988, J BIOL CHEM, V263, P7691; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; FAYE G, 1976, FEBS LETT, V69, P167, DOI 10.1016/0014-5793(76)80678-3; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GARRIGA G, 1984, CELL, V39, P631, DOI 10.1016/0092-8674(84)90470-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LOCKER J, 1981, PLASMID, V6, P302, DOI 10.1016/0147-619X(81)90038-X; MAHESHWARI KK, 1984, BIOCHIM BIOPHYS ACTA, V781, P153, DOI 10.1016/0167-4781(84)90133-7; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; MIN JJ, 1993, J BIOL CHEM, V268, P7350; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; OSINGA KA, 1984, EMBO J, V3, P829, DOI 10.1002/j.1460-2075.1984.tb01892.x; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; ROSE MD, 1988, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEPIEN PP, 1995, CURR GENET, V27, P234, DOI 10.1007/BF00326154; TABAK HF, 1984, CELL, V39, P623, DOI 10.1016/0092-8674(84)90469-0; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VONTIGERSTROM RG, 1982, BIOCHEMISTRY-US, V21, P6397, DOI 10.1021/bi00268a012; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZHU H, 1987, MOL CELL BIOL, V7, P2530, DOI 10.1128/MCB.7.7.2530; ZHU H, 1989, MOL CELL BIOL, V9, P1507, DOI 10.1128/MCB.9.4.1507	44	102	104	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					199	209		10.1016/S0092-8674(00)80975-7	http://dx.doi.org/10.1016/S0092-8674(00)80975-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565066	Bronze			2022-12-01	WOS:A1996TR59500007
J	Warner, KE; Fulton, GA; Nicolas, P; Grimes, DR				Warner, KE; Fulton, GA; Nicolas, P; Grimes, DR			Employment implications of declining tobacco product sales for the regional economies of the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine whether declines in tobacco product sales significantly reduce employment in the United States, as the tobacco industry claims. Design.-Computer simulation of the economies of the Southeast Tobacco region and 8 nontobacco regions of the United States, with domestic tobacco expenditures eliminated or reduced and the equivalent spending redistributed, according to consumers' normal spending patterns, We compared these results with baseline forecasts of the regional economies that include normal tobacco expenditures. Main Outcome Measure.-Number of jobs. Results.-Had there been no spending on tobacco products in the United States in 1993, the Southeast Tobacco region would have had 303 000 fewer jobs. Collectively, however, the 8 nontobacco regions would have gained enough employment to completely offset losses in the Southeast Tobacco region, with every nontobacco region gaining jobs. By the year 2000, the absence of tobacco spending would mean a loss of 222 000 jobs in the Southeast Tobacco region, but a gain of 355 000 throughout the rest of the country. In the more realistic scenario of doubling the downward trend in tobacco consumption, the Southeast Tobacco region would lose 6300 jobs in 1993 (0.03% of regional employment) and 36 600 jobs by 2000 (0.2%). The 8 nontobacco regions would gain 6400 jobs in 1993 and 56 300 jobs in 2000, with each of the nontobacco regions gaining employment in every year. Conclusions.-Contrary to the tobacco industry's claims, reductions in spending on tobacco products will boost employment in every one of the 8 nontobacco regions and will not diminish employment in the Southeast Tobacco region by as much as the industry estimates. The primary concern about tobacco should be the enormity of its toll on health and not its impact on employment.	UNIV MICHIGAN,INST LABOR & IND RELAT,ANN ARBOR,MI; UNIV MICHIGAN,DEPT ECON,ANN ARBOR,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Warner, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH MANAGEMENT & POLICY,109 S OBSERV,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776				ALLEN RC, 1993, FALSE DILEMMA IMPACT; Bartlett J. C., 1994, Morbidity and Mortality Weekly Report, V43, P469; Buck D, 1995, TOBACCO AND JOBS; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; KOOP CE, 1984, JM JON LECT ANN M AM; SCHELLING TC, 1986, PREV MED, V15, P549, DOI 10.1016/0091-7435(86)90030-7; *TOB I, 1995, TAX BURD TOB HIST CO, V29; *TOB MERCH ASS, 1995, TOB CONTR NAT EC; Treyz G. I., 1993, REGIONAL EC MODELING; TREYZ GI, 1992, INT REGIONAL SCI REV, V14, P221, DOI 10.1177/016001769201400301; *U MI, 1994, EC OUTL 1995; *U PA, 1979, STUD TOB IND EC CONT; *US BUR CENS, 1992, GEOGR AR SER 1992 CE; *US BUR EC AN, 1995, STAT PERS INC 1929 9; *US BUR LAB STAT, 1993, AM WORKF 1992 2005; WARNER KE, 1994, JAMA-J AM MED ASSOC, V271, P771, DOI 10.1001/jama.271.10.771; WARNER KE, 1987, JAMA-J AM MED ASSOC, V258, P2080, DOI 10.1001/jama.258.15.2080; 1986, ROCHESTER CITY  1016, V1, P6; 1985, EC IMPACT TOBACCO IN, V1, pV3; 1990, EC IMPACT TOBACCO IN; 1992, EC IMPACT TOBACCO IN; 1993, MON LABOR REV, V11, P3	22	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1241	1246		10.1001/jama.275.16.1241	http://dx.doi.org/10.1001/jama.275.16.1241			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601955				2022-12-01	WOS:A1996UF47800027
J	Miyazaki, T; Dierich, A; Benoist, C; Mathis, D				Miyazaki, T; Dierich, A; Benoist, C; Mathis, D			Independent modes of natural killing distinguished in mice lacking Lag3	SCIENCE			English	Article							BONE-MARROW ALLOGRAFTS; KILLER-CELLS; T-CELLS; ANTIGEN RECOGNITION; GENE-COMPLEX; MOUSE NKR-P1; NK CLONES; EXPRESSION; SPECIFICITY; LY-49	The LAG3 protein has several features in common with CD4, suggesting that it may be important in controlling T cell reactivity. However, mice with a Lag3 null mutation have now been shown to exhibit a defect in the natural killer cell, rather than the T cell, compartment. Killing of certain tumor targets by natural killer cells from these mice was inhibited or even abolished, whereas lysis of cells displaying major histocompatibility complex class I disparities remained intact. It appears that LAG3 is a receptor or coreceptor that defines different modes of natural killing.	CU STRASBOURG,STRASBOURG,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Miyazaki, T (corresponding author), ULP,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,1 RUE LAURENT FRIES,F-67404 ILLKIRCH GRAFFENS,FRANCE.							BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BYRNE BC, 1988, NUCLEIC ACIDS RES, V16, P4165, DOI 10.1093/nar/16.19.9342; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DENNERT G, 1988, J IMMUNOL, V140, P2472; GIORDA R, 1991, J IMMUNOL, V147, P1701; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; KARLHOFER FM, 1995, J EXP MED, V181, P1785, DOI 10.1084/jem.181.5.1785; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P7; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MIYAZAKI T, IN PRESS INT IMMUNOL; Miyazaki T., UNPUB; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; PIONTEK GE, 1985, J IMMUNOL, V135, P4281; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; RYAN JC, 1995, J EXP MED, V181, P1911, DOI 10.1084/jem.181.5.1911; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SENTMAN CL, 1994, J IMMUNOL, V153, P5482; SENTMAN CL, 1989, J IMMUNOL, V142, P1847; STONEMAN ER, 1995, J EXP MED, V182, P305, DOI 10.1084/jem.182.2.305; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; TRIEBEL F, 1995, EUR J IMMUNOL, V25, P2718; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; YOKOYAMA WM, 1995, CURR OPIN IMMUNOL, V7, P110, DOI 10.1016/0952-7915(95)80036-0; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; ZAJAC AJ, 1995, INT IMMUNOL, V7, P1545, DOI 10.1093/intimm/7.10.1545; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228	45	121	130	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					405	408		10.1126/science.272.5260.405	http://dx.doi.org/10.1126/science.272.5260.405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602528				2022-12-01	WOS:A1996UG25200045
J	Heierhorst, J; Kobe, B; Feil, SC; Parker, MW; Benian, GM; Weiss, KR; Kemp, BE				Heierhorst, J; Kobe, B; Feil, SC; Parker, MW; Benian, GM; Weiss, KR; Kemp, BE			Ca2+/S100 regulation of giant protein kinases	NATURE			English	Article							CALCIUM-BINDING; PEPTIDE COMPLEX; CALMODULIN; ELEGANS	Protein phosphorylation by protein kinases plays a central regulatory role in cellular processes and these kinases are themselves tightly regulated(1). One common mechanism of regulation involves Ca2+-binding proteins (CaBP) such as calmodulin (CaM)(2). Here we report a Ca2+-effector mechanism for protein kinase activation by demonstrating the specific and >1,000-fold activation of the myosin-associated giant protein kinase twitchin by Ca2+/S100A1(2). S100A1(2) is a member of a large CaBP family that is implicated in various cellular processes, including cell growth, differentiation and motility, but whose molecular actions are largely unknown(3). The S100A1(2)-binding site is a part of the autoregulatory sequence positioned in the active site that is responsible for intrasteric autoinhibition of twitchin kinase; the mechanism of autoinhibition based on the crystal structures of two twitchin kinase fragments is described elsewhere(4). Ca2+/S100 represents a likely physiological activator for the entire family of giant protein kinases involved in muscle contractions and cytoskeletal structure(2,5-9).	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	St. Vincent's Institute of Medical Research; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Emory University			Kemp, Bruce/G-9602-2019; Kobe, Bostjan/D-1292-2009; Kemp, Bruce E/L-2633-2014; Parker, Michael W/F-9069-2013	Kemp, Bruce/0000-0001-6735-5082; Kobe, Bostjan/0000-0001-9413-9166; Kemp, Bruce E/0000-0001-6735-5082; Parker, Michael W/0000-0002-3101-1138				AYMESOUTHGATE A, 1995, J CELL BIOL, V128, P393, DOI 10.1083/jcb.128.3.393; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATO K, 1986, J NEUROCHEM, V46, P15555; KEMP BE, 1994, PROTEIN KINASES, P30; KOBE B, UNPUB NATURE STRUCTB; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEI JY, 1994, J BIOL CHEM, V269, P21078; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEADOR WE, 1993, SCIENCE, V262, P17185; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAYLOR SS, 1994, PROTEIN KINASES, P1; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	26	119	121	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					636	639		10.1038/380636a0	http://dx.doi.org/10.1038/380636a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602266				2022-12-01	WOS:A1996UF74100049
J	Smith, CB; Betz, WJ				Smith, CB; Betz, WJ			Simultaneous independent measurement of endocytosis and exocytosis	NATURE			English	Article							BOVINE CHROMAFFIN CELLS; CAPACITANCE MEASUREMENTS; SECRETION	STUDIES of membrane traffic between the cytoplasm and surface of a cell suggest that membrane internalization is tightly coupled to secretion. Studies using the capacitance technique show that endocytosis can follow evoked exocytosis within a second or less(1-3). The capacitance technique, however, measures only the net change in cell surface area, and thus separating exocytosis from endocytosis requires that the two events do not overlap in time. This condition is probably met with small, brief stimuli(1-5), but during prolonged stimulation it is more likely that exocytosis and endocytosis occur simultaneously(6). We used FM1-43 fluorescence, which provides a cumulative measure of exocytosis, independent of endocytosis, in combination with capacitance monitoring to track unidirectional movements of membrane simultaneously and in real time in bovine adrenal chromaffin cells. We confirm that, with relatively small stimuli, exocytosis ceases before endocytosis begins (no overlap). In contrast, during prolonged stimulation, the onset of endocytosis is delayed by 2-3 min, but then the rate of endocytosis quickly grows to equal that of exocytosis. The delayed onset of endocytosis may be an emergency defence against catastrophic cell swelling.	UNIV COLORADO,SCH MED,DEPT PHYSIOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,PROGRAM NEUROSCI,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BURGOYNE RD, 1995, PFLUG ARCH EUR J PHY, V430, P213, DOI 10.1007/BF00374652; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GREER MA, 1992, HORMONE METAB RES, V24; GRINVALD A, 1982, BIOPHYS J, V39, P301, DOI 10.1016/S0006-3495(82)84520-7; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HARTMANN J, 1995, J PHYSIOL-LONDON, V483, P201, DOI 10.1113/jphysiol.1995.sp020578; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENKEL AW, IN PRESS P NATL ACAD; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KRASZEWSKI K, 1995, NEUROSCIENCE, V15, P4328; MOLLARD P, 1995, P NATL ACAD SCI USA, V92, P3065, DOI 10.1073/pnas.92.7.3065; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OBERHAUSER AF, 1995, BIOPHYS J, V69, P451, DOI 10.1016/S0006-3495(95)79918-0; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0	30	202	204	3	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					531	534		10.1038/380531a0	http://dx.doi.org/10.1038/380531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606773				2022-12-01	WOS:A1996UE66300051
J	Hengst, L; Reed, SI				Hengst, L; Reed, SI			Translational control of p27(Kip1) accumulation during the cell cycle	SCIENCE			English	Article							KINASES; TUMOR	Cell cycle phase transitions in eukaryotic cells are driven by regulation of the activity of protein kinases known as cyclin-dependent kinases (Cdks). A broad spectrum Cdk-inhibitory activity associated with a 28-kilodalton protein (p28(lck1)) was induced in cells treated with the drug lovastatin or upon density-mediated growth arrest and was periodic in the cell cycle, with peak activity in G(1). The p28(lck1) protein was shown to be identical to p27(Kip1), and the periodic or induced inhibitory activity resulted from a periodic accumulation of the protein. Variations in the amount of p27 protein occurred, whereas the abundance of the p27 messenger RNA remained unchanged. In every instance investigated, the posttranscriptional alteration of p27 protein levels was achieved in part by a mechanism of translational control, although in density-arrested fibroblasts and thymidine-arrested HeLa cells the half-life of the protein was also changed.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Hengst, Ludger/0000-0002-0605-0223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNCE CM, 1994, LEUKEMIA, V8, P595; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1994, MOL CELL BIOL, V14, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HENGST L, UNPUB; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATRSUOKA S, 1995, GENE DEV, V9, P650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	814	840	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1861	1864		10.1126/science.271.5257.1861	http://dx.doi.org/10.1126/science.271.5257.1861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596954				2022-12-01	WOS:A1996UC77800045
J	Cane, EJ; Portmann, BC; Naoumov, NV; Smith, HM; Underhill, JA; Donaldson, PT; Maertens, G; Williams, R				Cane, EJ; Portmann, BC; Naoumov, NV; Smith, HM; Underhill, JA; Donaldson, PT; Maertens, G; Williams, R			Long-term outcome of hepatitis C infection after liver transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; VIRUS	Background. End-stage cirrhosis related to hepatitis C virus (HCV) is a common reason for liver transplantation, although viremia is known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis. Methods. A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group, A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation. Results. Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P = 0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median followup, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype Ib was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable. Conclusions. After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection. (C) 1996, Massachusetts Medical Society.	UNIV LONDON KINGS COLL, SCH MED & DENT, INST LIVER STUDIES, LONDON SE5 9PJ, ENGLAND; IMMUNOGENET, GHENT, BELGIUM	University of London; King's College London			Yang, Chen/G-1379-2010					ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1994, Lancet, V344, P423; Armitage P, 1994, STAT METHODS MED RES; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BALLARDINI G, 1995, J CLIN INVEST, V95, P2067, DOI 10.1172/JCI117893; BOTARELLI P, 1993, GASTROENTEROLOGY, V104, P580, DOI 10.1016/0016-5085(93)90430-K; BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110; CASAVILLA A, 1994, HEPATOLOGY, V20, pA133; CHAZOUILLERES O, 1994, GASTROENTEROLOGY, V106, P994, DOI 10.1016/0016-5085(94)90759-5; Cox DR., 1984, ANAL SURVIVAL DATA; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1002/hep.1840170611; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; FERAY C, 1995, GASTROENTEROLOGY, V108, P1088, DOI 10.1016/0016-5085(95)90207-4; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; FERRARI C, 1994, HEPATOLOGY, V19, P286; Gane EJ, 1996, GASTROENTEROLOGY, V110, P167, DOI 10.1053/gast.1996.v110.pm8536853; GRETCH D, 1993, HEPATOLOGY, V18, pA108, DOI 10.1016/0270-9139(93)91960-Z; IZOPET J, 1994, HEPATOLOGY, V20, pA241; KONIG V, 1992, HEPATOLOGY, V16, P1137, DOI 10.1016/0270-9139(92)90005-T; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; LIM HL, 1994, GASTROENTEROLOGY, V106, P248, DOI 10.1016/S0016-5085(94)95829-7; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MCHUTCHISON G, 1993, HEPATOLOGY, V18, pA87; MONDELLI M, 1986, CLIN EXP IMMUNOL, V63, P147; NAGAYAMA R, 1993, J CLIN INVEST, V92, P1529, DOI 10.1172/JCI116731; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; POZZATO G, 1994, J MED VIROL, V43, P291, DOI 10.1002/jmv.1890430318; QU D, 1994, J HEPATOL, V21, P70, DOI 10.1016/S0168-8278(94)80139-8; Rosen H. R., 1995, Hepatology, V22, p132A; SCHLUGER LK, 1994, GASTROENTEROLOGY, V106, pA978; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHAH GJ, 1992, GASTROENTEROLOGY, V103, P323, DOI 10.1016/0016-5085(92)91130-V; SHEINER PA, 1995, HEPATOLOGY, V21, P30, DOI 10.1016/0270-9139(95)90404-2; TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7; TERASAKI PI, 1974, DHEW NIH75545 PUBL, P67; TILSTON P, 1994, LANCET, V344, P201, DOI 10.1016/S0140-6736(94)92809-6; VANDOORN LJ, 1994, J HEPATOL, V21, P122, DOI 10.1016/S0168-8278(94)80148-7; WEINSTEIN JS, 1994, HEPATOLOGY, V20, pA133; WILLEMS M, 1994, J MED VIROL, V44, P266, DOI 10.1002/jmv.1890440310; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YUKI N, 1995, J HEPATOL, V22, P457, DOI 10.1016/0168-8278(95)80109-X; ZHOU S, 1994, HEPATOLOGY, V20, pA134	45	774	780	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					815	820		10.1056/NEJM199603283341302	http://dx.doi.org/10.1056/NEJM199603283341302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596547	Bronze			2022-12-01	WOS:A1996UB95000002
J	Xie, XL; Kokubo, T; Cohen, SL; Mirza, UA; Hoffmann, A; Chait, BT; Roeder, RG; Nakatani, Y; Burley, SK				Xie, XL; Kokubo, T; Cohen, SL; Mirza, UA; Hoffmann, A; Chait, BT; Roeder, RG; Nakatani, Y; Burley, SK			Structural similarity between TAFs and the heterotetrameric core of the histone octamer	NATURE			English	Article							TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; CRYSTAL-STRUCTURE; NUCLEOSOME; RESOLUTION; INITIATION; INTERACTS; DOMAIN; DNA	A complex of two TFIID TATA hox-binding protein-associated factors (TAF(II)s) is described at 2.0 Angstrom resolution. The amino-terminal portions of dTAF(II)42 and dTAF(II)62 from Drosophila adopt the canonical histone fold, consisting of two short alpha-helices flanking a long central alpha-helix. Like histones H3 and H4, dTAF(II)42 and dTAF(II)62 form an intimate heterodimer by extensive hydrophobic contacts between the paired molecules. In solution and in the crystalline state, the dTAF(II)42/dTAF(II)62 complex exists as a heterotetramer, resembling the (H3/H4), heterotetrameric core of the histone octamer, suggesting that TFIID contains a histone octamer-like substructure.	ROCKEFELLER UNIV,LAB MOLEC BIOPHYS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY & GASEOUS ION CHEM LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NICHHD,NIH,BETHESDA,MD 20892	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Burley, Stephen/0000-0002-2487-9713				ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURLEY SK, IN PRESS A REV BIOCH, V65; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DARCY A, 1994, ACTA CRYSTALLOGR D, V50, P469, DOI 10.1107/S0907444993014362; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; KARANTZA V, IN PRESS BIOCHEMISTR, V35; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATTMAN E, 1982, SCIENCE, V216, P1016, DOI 10.1126/science.7079748; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	226	231	2	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					316	322		10.1038/380316a0	http://dx.doi.org/10.1038/380316a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598927				2022-12-01	WOS:A1996UC37900050
J	Pisacane, A; Impagliazzo, N; DeCaprio, C; Criscuolo, L; Inglese, A; daSilva, MCMP				Pisacane, A; Impagliazzo, N; DeCaprio, C; Criscuolo, L; Inglese, A; daSilva, MCMP			Breast feeding and tonsillectomy	BRITISH MEDICAL JOURNAL			English	Article											Pisacane, A (corresponding author), UNIV NAPLES,DEPT PAEDIAT,I-80131 NAPLES,ITALY.							BISSET AF, 1994, BRIT MED J, V308, P1129, DOI 10.1136/bmj.308.6937.1129; BRODSKY L, 1989, PEDIATR CLIN N AM, V36, P1551; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; MAW AR, 1986, ARCH DIS CHILD, V61, P421, DOI 10.1136/adc.61.5.421; PISACANE A, 1995, BRIT MED J, V310, P836, DOI 10.1136/bmj.310.6983.836	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					746	747						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605462	Green Published			2022-12-01	WOS:A1996UC16600028
J	Deng, CX; WynshawBoris, A; Zhou, F; Kuo, A; Leder, P				Deng, CX; WynshawBoris, A; Zhou, F; Kuo, A; Leder, P			Fibroblast growth factor receptor 3 is a negative regulator of bone growth	CELL			English	Article							EXPRESSION PATTERN; MOUSE; FAMILY; MUTATION; PROTEINS; ORGANOGENESIS; DISRUPTION; CARTILAGE; ONCOGENE; MEMBER	Endochondral ossification is a major mode of bone formation that occurs as chondrocytes undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth. This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate. Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis. In light of these mouse results, certain human disorders, such as achondroplasia, can be interpreted as gain-of-function mutations that activate the fundamentally negative growth control exerted by the FGFR-3 kinase.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute			deng, chuxia/N-6713-2016		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHITAYAT D, 1995, AM J MED GENET, V55, P147, DOI 10.1002/ajmg.1320550203; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GILBERT SF, 1994, DEV BIOL; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKUSICK VA, 1973, J MED GENET, V10, P11, DOI 10.1136/jmg.10.1.11; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NILSSON A, 1986, SCIENCE, V233, P571, DOI 10.1126/science.3523759; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORIOLI I, 1979, J MED GENET, V23, P328; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS KG, 1992, DEVELOPMENT, V114, P233; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STARK KL, 1991, DEVELOPMENT, V113, P641; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	43	852	885	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					911	921		10.1016/S0092-8674(00)81069-7	http://dx.doi.org/10.1016/S0092-8674(00)81069-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601314	Bronze			2022-12-01	WOS:A1996UC38100012
J	Muslin, AJ; Tanner, JW; Allen, PM; Shaw, AS				Muslin, AJ; Tanner, JW; Allen, PM; Shaw, AS			Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine	CELL			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; KINASE-C; PHOSPHORYLATION; TYROSINE; RAF-1; IDENTIFICATION; PURIFICATION; MATURATION; TECHNOLOGY	The highly conserved and ubiquitously expressed 14-3-3 family of proteins bind to a variety of proteins involved in signal transduction and cell cycle regulation. The nature and specificity of 14-3-3 binding is, however, not known. Here we show that 14-3-3 is a specific phosphoserine-binding protein. Using a panel of phosphorylated peptides based on Raf-1, we have defined the 14-3-3 binding motif and show that most of the known 14-3-3 binding proteins contain the motif. Peptides containing the motif could disrupt 14-3-3 complexes and inhibit maturation of Xenopus laevis oocytes. These results suggest that the interactions of 14-3-3 with signaling proteins are critical for the activation of signaling proteins. Our findings also suggest novel roles for serine/threonine phosphorylation in the assembly of protein-protein complexes.	WASHINGTON UNIV, SCH MED, DEPT PHYSIOL & CELL BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV CARDIOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.			Shaw, Andrey/0000-0001-5685-0272	NIAID NIH HHS [AI-34094] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034094] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LORENZ RG, 1989, J EXP MED, V170, P203, DOI 10.1084/jem.170.1.203; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TANJI M, 1994, J NEUROCHEM, V63, P1908; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	44	1181	1218	1	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					889	897		10.1016/S0092-8674(00)81067-3	http://dx.doi.org/10.1016/S0092-8674(00)81067-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601312	Bronze			2022-12-01	WOS:A1996UC38100010
J	OHare, JP; Hopper, A; Madhaven, C; Charny, M; Purewal, TS; Harney, B; Griffiths, J				OHare, JP; Hopper, A; Madhaven, C; Charny, M; Purewal, TS; Harney, B; Griffiths, J			Adding retinal photography to screening for diabetic retinopathy: A prospective study in primary care	BRITISH MEDICAL JOURNAL			English	Article							NONMYDRIATIC FUNDUS PHOTOGRAPHY; OPHTHALMOSCOPY	Objective-To evaluate whether adding retinal photography improved community screening for diabetic retinopathy. Setting-Mobile screening unit at rural and urban general practices in south west England. Subjects-1010 diabetic patients from primary care. Design-Prospective study; patients were examined by ophthalmoscopy by general practitioners or opticians without fundal photographs and again with photographs, and assessments were compared to those of an ophthalmologist. Main outcome measures-Whether fundal photography improved the sensitivity of detection of retinopathy and referrable diabetic retinopathy, and whether this sensitivity could be improved by including a review of the films by the specialist. Results-Diabetic retinopathy was detected by the ophthalmologist in 205 patients (20.5%) and referrable retinopathy in 49 (4.9%). The sensitivity of the general practitioners and opticians for referrable retinopathy with ophthalmoscopy was 65% and improved to 84% with retinal photographs. General practitioners' sensitivity in detecting background retinopathy improved with photographs from 22% to 65%; opticians' sensitivity in detecting background retinopathy improved from 43% to 71%. The sensitivity of detecting referrable retinopathy by general practitioners improved from 56% to 80% with photographs; for opticians it improved from 75% to 88%. Conclusion-Combining modalities of screening by providing photography with specialist review of all films in addition to direct ophthalmoscopy through dilated pupils improves assessment and referral for diabetic retinopathy by general practitioners and opticians. With further training and experience, primary care screeners should be able to achieve a sensitivity that will achieve an effective, acceptable, and economical community based screening programme for this condition.	ROYAL UNITED HOSP,DEPT OPHTHALMOL,BATH BA1 3NG,AVON,ENGLAND; WILTSHIRE & BATH HLTH COMMISS,DEVIZES SN10 5EQ,WILTS,ENGLAND		OHare, JP (corresponding author), ROYAL UNITED HOSP,DEPT MED,COMBE PK,BATH BA1 3NG,AVON,ENGLAND.							[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; CLARK JB, 1994, BRIT J OPHTHALMOL, V78, P741, DOI 10.1136/bjo.78.10.741; FINLAY R, 1991, HLTH TRENDS, V23, P104; Government Statistical Service, 1988, CAUS BLINDN PART SIG; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; LEE VS, 1993, OPHTHALMOLOGY, V100, P1504; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MOLLENTZE WF, 1990, S AFR MED J, V78, P248; OWENS DR, 1991, DIABETIC MED, V8, pS4, DOI 10.1111/j.1464-5491.1991.tb02148.x; ROHAN T, 1989, BRIT MED J, V289, P1192; RYDER REJ, 1995, BRIT MED J, V331, P207; RYDER REJ, 1994, DIABETIC MED S2, V11, pS44; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1991, DIABETIC MED, V8, P607, DOI 10.1111/j.1464-5491.1991.tb01665.x; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; 1983, DIABETES, V32, P1010; 1993, NEW ENGL J MED, V329, P977	19	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					679	682						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597737				2022-12-01	WOS:A1996UB11000029
J	Erwin, J; Britten, N; Jones, R				Erwin, J; Britten, N; Jones, R			General practitioners' views on over the counter sales by community pharmacists	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; Department of Health, 1994, HLTH PERS SOC SERV S; FORD S, 1995, BRIT MED J, V310, P1620, DOI 10.1136/bmj.310.6995.1620; SPENCER JA, 1992, BRIT MED J, V304, P1670, DOI 10.1136/bmj.304.6843.1670; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	5	27	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					617	618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595339				2022-12-01	WOS:A1996TZ84000029
J	Hicks, RCJ; Golledge, J; MirHasseine, R; Powell, JT				Hicks, RCJ; Golledge, J; MirHasseine, R; Powell, JT			Vasoactive effects of fibrinogen on saphenous vein	NATURE			English	Article							ENDOTHELIUM; SMOKING	Normal plasma fibrinogen concentrations are critical to haemostasis. Higher fibrinogen concentrations are associated with increasing risk of atherosclerotic disease(1) and with graft stenosis and occlusion after saphenous vein bypass surgery(2,3). Vein graft stenosis is characterized by the localized proliferation of intimal smooth muscle cells, causing narrowing of the graft with increased risk of thrombotic occlusion. In rabbit arteries, fibrinopeptide B is reported to have both vasoconstrictor and mitogenic properties(4,5). We report here that fibrinopeptides had no vasoactive effects on saphenous vein rings; however, fibrinogen (0-2 mu M) affected an endothelium-dependent relaxation, followed by recontraction at higher concentrations. The fibrinogen-mediated relaxation was inhibited by K+-channel blockers and antibodies to ICAM-1. Coupled signalling pathways for the synthesis of vasoactive mediators and mitogens could underlie the association between fibrinogen and the development of vein graft pathology.			Hicks, RCJ (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,CARDIOVASC & PULM RES DIV,LONDON W6 8RF,ENGLAND.		golledge, jonathan/I-2371-2013; Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; HICKS RC, 1995, J VASC SURG, V9, P415; HIGMAN DJ, 1993, BRIT J SURG, V80, P1242, DOI 10.1002/bjs.1800801007; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEVENSON J, 1995, ARTERIOSCL THROM VAS, V15, P1263, DOI 10.1161/01.ATV.15.9.1263; MOORE PK, 1988, J PHARM PHARMACOL, V40, P558, DOI 10.1111/j.2042-7158.1988.tb05302.x; NAGAO T, 1993, AM J RESP CELL MOL, V8, P1; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; SINGH TM, 1990, AM J SURG, V160, P156, DOI 10.1016/S0002-9610(05)80297-1; WALDMAN SA, 1988, J CARDIOVASC PHARM, V12, pS115; WISEMAN S, 1989, BRIT MED J, V299, P643, DOI 10.1136/bmj.299.6700.643	11	43	46	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					818	820		10.1038/379818a0	http://dx.doi.org/10.1038/379818a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587603				2022-12-01	WOS:A1996TX50100056
J	Berg, JM; Shi, YG				Berg, JM; Shi, YG			The galvanization of biology: A growing appreciation for the roles of zinc	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; FINGER DNA RECOGNITION; ACID BINDING-PROTEIN; NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; DEPENDENT STRUCTURE; IRON-METABOLISM; METAL-BINDING; 5S RNA	Zinc ions are key structural components of a large number of proteins. The binding of zinc stabilizes the folded conformations of domains so that they may facilitate interactions between the proteins and other macromolecules such as DNA. The modular nature of some of these zinc-containing proteins has allowed the rational design of site-specific DNA binding proteins. The ability of zinc to be bound specifically within a range of tetrahedral sites appears to be responsible for the evolution of the wide range of zinc-stabilized structural domains now known to exist. The lack of redox activity for the zinc ion and its binding and exchange kinetics also may be important in the use of zinc for specific functional roles.			Berg, JM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963; Shi, Yigong/0000-0003-2030-168X				ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EIGEN M, 1963, PURE APPL CHEM, V6, P105; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figgis B.N., 1966, INTRO LIGAND FIELDS; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; HU HM, 1994, J BIOL CHEM, V269, P30069; HUANG RC, 1993, P NATL ACAD SCI USA, V90, P11806, DOI 10.1073/pnas.90.24.11806; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; Keilin D, 1940, BIOCHEM J, V34, P1163, DOI 10.1042/bj0341163; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORIUCHI H, 1994, VIROLOGY, V205, P238, DOI 10.1006/viro.1994.1639; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NELBACH ME, 1972, BIOCHEMISTRY-US, V11, P315, DOI 10.1021/bi00753a002; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON RG, 1969, SURVERY PROGR CHEM, V1, pCH1; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; ROBERTS WJ, 1989, BIOCHEMISTRY-US, V28, P10043, DOI 10.1021/bi00452a024; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	81	1613	1737	5	279	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1081	1085		10.1126/science.271.5252.1081	http://dx.doi.org/10.1126/science.271.5252.1081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599083				2022-12-01	WOS:A1996TW70100028
J	Festenstein, R; Tolaini, M; Corbella, P; Mamalaki, C; Parrington, J; Fox, M; Miliou, A; Jones, M; Kioussis, D				Festenstein, R; Tolaini, M; Corbella, P; Mamalaki, C; Parrington, J; Fox, M; Miliou, A; Jones, M; Kioussis, D			Locus control region function and heterochromatin-induced position effect variegation	SCIENCE			English	Article							HUMAN CD2 GENE; TRANSGENIC MICE; GLOBIN GENE; MONOCLONAL-ANTIBODIES; DEPENDENT EXPRESSION; FAR UPSTREAM; HIGH-LEVEL; DROSOPHILA; BOUNDARIES; SEQUENCES	Human CD2 locus control region (LCR) sequences are shown here to be essential for establishing an open chromatin configuration. Transgenic mice carrying an hCD2 minigene attached only to the 3' CD2 transcriptional enhancer exhibited variegated expression when the transgene integrated in the centromere. In contrast, mice carrying a transgene with additional 3' sequences showed no variegation even when the latter integrated in centromeric positions. This result suggests that LCRs operate by ensuring an open chromatin configuration and that a short region, with no enhancer activity, functions in the establishment, maintenance, or both of an open chromatin domain.	UNIV LONDON UNIV COLL, MRC, HUMAN BIOCHEM GENET UNIT, GALTON LAB, LONDON NW1 2HE, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PATHOL, OXFORD OX3 9DU, ENGLAND	University of London; University College London; University of Oxford	Festenstein, R (corresponding author), NATL INST MED RES, DIV MOLEC IMMUNOL, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.				Telethon [TGT95000, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CARSON S, 1993, NUCLEIC ACIDS RES, V21, P2065, DOI 10.1093/nar/21.9.2065; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; FESTENSTEIN R, UNPUB; GHARIB B, 1993, ANN HUM GENET, V57, P9, DOI 10.1111/j.1469-1809.1993.tb00882.x; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; KARPEN GH, 1992, GENETICS, V132, P737; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORETTA A, 1986, EUR J IMMUNOL, V16, P1427, DOI 10.1002/eji.1830161118; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PARRINGTON J, UNPUB; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRAVTCHEVA DD, 1994, J EXP ZOOL, V268, P452, DOI 10.1002/jez.1402680606; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANOPOULOU E, 1990, THESIS U LONDON; VERBI W, 1982, EUR J IMMUNOL, V12, P81, DOI 10.1002/eji.1830120115; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819	39	303	313	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1123	1125		10.1126/science.271.5252.1123	http://dx.doi.org/10.1126/science.271.5252.1123			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599090				2022-12-01	WOS:A1996TW70100040
J	Martin, WD; Hicks, GG; Mendiratta, SK; Leva, HI; Ruley, HE; VanKaer, L				Martin, WD; Hicks, GG; Mendiratta, SK; Leva, HI; Ruley, HE; VanKaer, L			H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection	CELL			English	Article							HLA-DR MOLECULES; INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; POSITIVE SELECTION; MHC; GENES; COMPLEX; SELF	H2-M is a nonconventional major histocompatibility complex (MHC) class II molecule that has been implicated in the loading of peptides onto conventional class II molecules. We generated mice with a targeted mutation in the H2-Ma gene, which encodes a subunit for H2-M. Although the mutant mice express normal class II cell surface levels, these are structurally distinct from the compact SDS-resistant complexes expressed by wild-type cells and are predominantly bound by class II-associated invariant chain peptides (CLIPs). Cells from these animals are unable to present intact protein antigens to class II-restricted T cells and show reduced capacity to present exogenous peptides. Numbers of mature CD4(+) T lymphocytes in mutant mice are reduced 3- to 4-fold and exhibit altered reactivities. Overall, this phenotype establishes an important role for H2-M in regulating MHC class II function in vivo and supports the notion that self-peptides contribute to the specificity of T cell positive selection.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Vanderbilt University	Martin, WD (corresponding author), VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309; Hicks, Geoffrey/0000-0003-4688-2312				ALDRICH CJ, 1994, P NATL ACAD SCI USA, V91, P6525, DOI 10.1073/pnas.91.14.6525; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P1464; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CEMAN S, 1992, J IMMUNOL, V149, P754; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EASTMAN S, 1996, IN PRESS EUR J IMMUN; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NOSSAL GJV, 1994, CELL, V76, P219; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SCHMID SL, 1994, NATURE, V369, P103, DOI 10.1038/369103a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	42	269	272	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					543	550		10.1016/S0092-8674(00)81030-2	http://dx.doi.org/10.1016/S0092-8674(00)81030-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598041	Bronze			2022-12-01	WOS:A1996TX17600007
J	Rubin, N; Nakayama, K; Shapley, R				Rubin, N; Nakayama, K; Shapley, R			Enhanced perception of illusory contours in the lower versus upper visual hemifields	SCIENCE			English	Article							RANDOM-DOT STEREOGRAMS; STRIATE CORTEX; COMPLETION; MECHANISMS; ANISOTROPY; DYNAMICS; ISOTROPY; FIELD; FORM	The visual world consciously perceived is very different from the spatial array of photoreceptor activation present on our retinae; it is composed of segregated surfaces, organized into distinct objects. An important component of this organizational process, the segmentation of an image into figures and background, is shown to be performed much better in the lower visual field. This finding is demonstrated by the performance in two tasks that involve the perception of illusory contours. This asymmetry indicates a neural specialization that may be related to the anatomical discontinuity along the representation of the horizontal meridian in extrastriate visual cortex.	NYU,CTR NEURAL SCI,NEW YORK,NY 10003	New York University	Rubin, N (corresponding author), HARVARD UNIV,VIS SCI LAB,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.		Rubin, Nava/J-5189-2012		NEI NIH HHS [EY-01472] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001472] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON JC, 1993, CEREB CORTEX, V3, P412, DOI 10.1093/cercor/3.5.412; ANGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; BLOMFIELD S, 1973, NATURE-NEW BIOL, V245, P256, DOI 10.1038/newbio245256a0; BREITMEYER B, 1975, SCIENCE, V187, P269, DOI 10.1126/science.1111104; Chernjavsky A, 1990, NEURAL COMPUT, V2, P334, DOI 10.1162/neco.1990.2.3.334; EDELMAN GM, 1987, NEURAL DARWINISM, pCH6; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FINKEL LH, 1992, NEURAL COMPUT, V4, P901, DOI 10.1162/neco.1992.4.6.901; Fletcher R., 2013, PRACTICAL METHODS OP; Gibson J.J., 1950, PERCEPTION VISUAL WO, DOI DOI 10.2307/1419017; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; GULYAS B, 1993, FUNCTIONAL ORG HUMAN, P346; HEITGER F, 1993, P INT C COMP VISION, V4, P32; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HOLMES G, 1945, PROC R SOC SER B-BIO, V132, P348, DOI 10.1098/rspb.1945.0002; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; HORTON JC, 1991, BRAIN, V114, P1703, DOI 10.1093/brain/114.4.1703; JULESZ B, 1976, PERCEPTION, V5, P129, DOI 10.1068/p050129; JULESZ B, 1971, F CYCLOPEAN VISION; Kanizsa G., 1979, ORG VISION; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P405; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; Nitzberg M., 1993, FILTERING SEGMENTATI; PETERHANS E, 1989, J NEUROSCI, V9, P1749; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; Petry S., 1987, PERCEPTION ILLUSORY; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; RINGACH D, 1993, PERCEPTION S, V22, P51; RUBIN N, UNPUB; Tyler C. W., 1991, BINOCULAR VISION; ULLMAN S, 1976, BIOL CYBERN, V25, P1; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; WASSERSTEIN J, 1984, BRAIN COGNITION, V3, P51, DOI 10.1016/0278-2626(84)90006-X; WASSERSTEIN J, 1987, BRAIN COGNITION, V6, P1, DOI 10.1016/0278-2626(87)90042-X; WILLIAMS LR, 1995, P INT C COMP VIS, V5, P408	40	156	161	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					651	653		10.1126/science.271.5249.651	http://dx.doi.org/10.1126/science.271.5249.651			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571128				2022-12-01	WOS:A1996TT87000047
J	Abbott, A; Cohen, B; Howlett, R				Abbott, A; Cohen, B; Howlett, R			Complexity limits the powers of prediction	NATURE			English	Editorial Material																			0	4	4	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					390	390						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559236				2022-12-01	WOS:A1996TT30400016
J	Mayhew, M; daSilva, ACR; Martin, J; ErdjumentBromage, H; Tempst, P; Hartl, FU				Mayhew, M; daSilva, ACR; Martin, J; ErdjumentBromage, H; Tempst, P; Hartl, FU			Protein folding in the central cavity of the GroEL-GroES chaperonin complex	NATURE			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; ATP HYDROLYSIS; BINDING; SUBSTRATE; CYCLE	The chaperonin GroEL is able to mediate protein folding in its central cavity. GroEL-bound dihydrofolate reductase assumes its native conformation when the GroES cofactor caps one end of the GroEL cylinder, thereby discharging the unfolded polypeptide into an enclosed cage. Folded dihydrofolate reductase emerges upon ATF-dependent GroES release. Other proteins, such as rhodanese, may leave GroEL after having attained a conformation that is committed to fold. Incompletely folded polypeptide rebinds to GroEL, resulting in structural rearrangement for another folding trial in the chaperonin cavity.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	Erdjument-Bromage, Hediye/0000-0003-0224-3594				BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ELLIS RJ, 1994, OPIN STRUCT BIOL, V4, P117; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P615; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; HODAN R, 1995, NAT STRUCT BIOL, V2, P587; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, REV BIOPHSY BIOMOL S, V23, P645; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	47	324	330	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					420	426		10.1038/379420a0	http://dx.doi.org/10.1038/379420a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559246				2022-12-01	WOS:A1996TT30400050
J	GoodrichBlair, H; Shub, DA				GoodrichBlair, H; Shub, DA			Beyond homing: Competition between intron endonucleases confers a selective advantage on flanking genetic markers	CELL			English	Article							BACILLUS-SUBTILIS BACTERIOPHAGE-SPO1; DNA-POLYMERASE GENE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; SITE; MECHANISM; SEQUENCE; PROTEIN; SUBUNIT; RECOMBINATION	The closely related B. subtilis bacteriophages SPO1 and SP82 have similar introns inserted into a conserved domain of their DNA polymerase genes. These introns encode endonucleases with unique properties. Other intron-encoded ''homing'' endonucleases cleave both strands of intronless DNA; subsequent repair results in unidirectional gene conversion to the intron-containing allele. In contrast, the enzymes described here cleave one strand on both intron-containing and intronless targets at different distances from their common intron insertion site. Most surprisingly, each enzyme prefers DNA of the heterologous phage. The SP82-encoded endonuclease is responsible for exclusion of the SPO1 intron and flanking genetic markers from the progeny of mixed infections, a novel selective advantage imparted by an intron to the genome in which it resides.	SUNY ALBANY, CTR GENET MOLEC, DEPT BIOL SCI, ALBANY, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany				Goodrich-Blair, Heidi/0000-0003-1934-2636	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037746] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYK M, 1995, J MOL BIOL, V247, P197, DOI 10.1006/jmbi.1994.0133; CULL M, 1990, METHOD ENZYMOL, V182, P147; CURRAN JF, 1985, VIROLOGY, V142, P78, DOI 10.1016/0042-6822(85)90424-6; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DUJON B, 1989, GENE, V82, P115, DOI 10.1016/0378-1119(89)90035-8; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GLASSBERG J, 1977, J VIROL, V21, P147, DOI 10.1128/JVI.21.1.147-152.1977; GOODRICHBLAIR H, 1994, NUCLEIC ACIDS RES, V22, P3715, DOI 10.1093/nar/22.18.3715; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; HARDY KG, 1985, DNA CLONING PRACTICA, V2, P1; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MARSHALL P, 1992, NUCLEIC ACIDS RES, V20, P6401, DOI 10.1093/nar/20.23.6401; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MUELLER JE, 1993, NUCLEASES, P111; MULBRY WW, 1989, J BACTERIOL, V171, P5322, DOI 10.1128/jb.171.10.5322-5324.1989; NAKAGAWA K, 1992, EMBO J, V11, P2707, DOI 10.1002/j.1460-2075.1992.tb05336.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; RUSSELL RL, 1974, GENETICS, V78, P989; SAYRE MH, 1988, J VIROL, V62, P3455, DOI 10.1128/JVI.62.9.3455-3462.1988; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SHARMA M, 1994, J BACTERIOL, V176, P6439, DOI 10.1128/JB.176.21.6439-6448.1994; SHARMA M, 1992, P NATL ACAD SCI USA, V89, P6658, DOI 10.1073/pnas.89.14.6658; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; SHUB DA, 1987, COLD SPRING HARB SYM, V52, P193, DOI 10.1101/SQB.1987.052.01.024; Shub DA, 1991, CURR OPIN GENET DEV, V1, P478, DOI 10.1016/S0959-437X(05)80195-9; Stewart Charles R., 1993, P813; STEWART CR, 1981, J VIROL, V38, P1081, DOI 10.1128/JVI.38.3.1081-1083.1981; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TURMEL M, 1995, NUCLEIC ACIDS RES, V23, P2519, DOI 10.1093/nar/23.13.2519	40	74	75	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					211	221		10.1016/S0092-8674(00)80976-9	http://dx.doi.org/10.1016/S0092-8674(00)80976-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565067	Bronze			2022-12-01	WOS:A1996TR59500008
J	Hargreaves, RM; Slack, MPE; Howard, AJ; Anderson, E; Ramsay, ME				Hargreaves, RM; Slack, MPE; Howard, AJ; Anderson, E; Ramsay, ME			Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme	BRITISH MEDICAL JOURNAL			English	Article									GWYNEDD PUBL HLTH LAB,BANGOR,GWYNEDD,WALES; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND	Public Health England	Hargreaves, RM (corresponding author), JOHN RADCLIFFE HOSP,HAEMOPHILUS REFERENCE UNIT,OXFORD PUBL HLTH LAB,OXFORD OX3 9DU,ENGLAND.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ANDERSON EC, 1995, EPIDEMIOL INFECT, V115, P89, DOI 10.1017/S0950268800058155; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; SLACK MPE, 1993, PHLS MICROBIOL DIG, V10, P122; 1991, PAEDIATRICS, V88, P169	5	77	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					160	161						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563536				2022-12-01	WOS:A1996TR32500024
J	Gilbert, L; Nicholl, J; Alex, S; Smethurst, I; Mander, A; Andrews, A; Patrick, J				Gilbert, L; Nicholl, J; Alex, S; Smethurst, I; Mander, A; Andrews, A; Patrick, J			Ethnic differences in the outcome of serum screening for Down's syndrome	BRITISH MEDICAL JOURNAL			English	Article									OLDHAM NHS TRUST,DEPT OBSTET & GYNAECOL,OLDHAM OL1 2PN,ENGLAND; UNIV SHEFFIELD,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; OLDHAM NHS TRUST,DEPT CLIN PATHOL,OLDHAM OL1 2PN,ENGLAND; ST MARYS HOSP,REG CYTOGENET DEPT,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Sheffield; University of Manchester			Gilbert, Lucy/M-6879-2019; Nicholl, Jon/B-8257-2008	Gilbert, Lucy/0000-0001-8605-5472; 				BOGART MH, 1991, AM J OBSTET GYNECOL, V165, P663, DOI 10.1016/0002-9378(91)90305-B; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; GARDNER MJ, 1989, STATISTICS CONFIDENC; REYNOLDS TN, 1989, NN CLIN BIOCH, V26, P26; RODGERS MS, 1986, BRIT J OBSTET GYNAEC, V93, P587	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					94	95						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555938				2022-12-01	WOS:A1996TQ16800025
J	Joseph, KS; Blais, L; Ernst, P; Suissa, S				Joseph, KS; Blais, L; Ernst, P; Suissa, S			Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEATH; SCHIZOPHRENIA; CHILDHOOD; RISK	Objective - To assess the potentially increased risk of death or near death from asthma in asthmatic patients with psychosis. Design - Case-control study. Setting - The computerised health databases of the Canadian province of Saskatchewan. Subjects - 131 cases of death or near death from asthma identified within a cohort of asthmatic patients; 3930 matched non-cases. Exposure and outcome measures - The exposure of interest was the use of major tranquillisers in the period before an outcome event. Outcomes included death or near death from asthma. Results - Crude analyses showed that asthmatic patients who had used major tranquillisers in the previous 12 months were at a 3.2 (95% confidence interval 1.4 to 7.5) times greater risk of death or near death from asthma than asthmatic patients who did not use major tranquillisers. Past users of major tranquillisers who had recently discontinued use were at a particularly high risk (relative risk 6.6; 2.5 to 17.6). Adjustment for use of antiasthma drugs and other confounders abolished this excess risk. Conclusions - Asthmatic patients who use major tranquillisers seem to be at an increased risk of death or near death from asthma. Physicians treating asthmatic patients with a history of use of major tranquillisers should exercise greater caution with regard to management of such patients.	MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ H3A 1A2, CANADA	McGill University				Joseph, K.S./0000-0003-2317-5607				BALDESSARINI RJ, 1990, GOODMAN GILMANS PHAR, P391; Banks T, 1993, Aust Fam Physician, V22, P1467; BENNET DR, 1994, DRUG EVALAUTION ANN, P272; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P94; BUDA M, 1988, ARCH GEN PSYCHIAT, V45, P283; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; FRITZ GK, 1987, AM J ORTHOPSYCHIAT, V57, P253, DOI 10.1111/j.1939-0025.1987.tb03535.x; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P257; MASCIA A V, 1974, Journal of Asthma Research, V12, P73, DOI 10.3109/02770907409098935; MASTERSON E, 1984, BRIT J PSYCHIAT, V145, P429, DOI 10.1192/bjp.145.4.429; MCFADDEN ER, 1994, PRINCIPLES INTERNAL, P1172; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MIETTINEN OS, 1989, J CLIN EPIDEMIOL, V42, P491, DOI 10.1016/0895-4356(89)90143-1; MILLER BD, 1987, J ALLERGY CLIN IMMUN, V80, P481, DOI 10.1016/0091-6749(87)90080-7; MORTENSEN PB, 1989, J EPIDEMIOL COMMUN H, V43, P43, DOI 10.1136/jech.43.1.43; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SAUGSTAD LF, 1979, ACTA PSYCHIAT SCAND, V59, P431; SHERMAN S, 1992, EMERGENCY MED COMPRE; SONIN L, 1984, ARCH INTERN MED, V144, P554, DOI 10.1001/archinte.144.3.554; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; TYRER PJ, 1980, DRUGS, V20, P300, DOI 10.2165/00003495-198020040-00004; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1; WEST R, 1987, AM J PREV MED S2, V4, P25; 1992, CLIN EXP ALLERGY S1, V22, P1; 1990, EGRET EPIDEMIOLOGICA, P289	29	54	56	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	1996	312	7023					79	82						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ168	8555932				2022-12-01	WOS:A1996TQ16800019
J	Taunton, J; Hassig, CA; Schreiber, SL				Taunton, J; Hassig, CA; Schreiber, SL			A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ACETYLATION; NUCLEOSOME; ACTIVATION; LOCI	Trapoxin is a microbially derived cyclotetrapeptide that inhibits histone deacetylation in vivo and causes mammalian cells to arrest in the cell cycle. A trapoxin affinity matrix was used to isolate two nuclear proteins that copurified with histone deacetylase activity. Both proteins were identified by peptide microsequencing, and a complementary DNA encoding the histone deacetylase catalytic subunit (HD1) was cloned from a human Jurkat T cell library. As the predicted protein is very similar to the yeast transcriptional regulator Rpd3p, these results support a role for histone deacetylase as a key regulator of eukaryotic transcription.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; STILLMAN DJ, 1994, GENETICS, V136, P781; TAUNTON J, UNPUB; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/0092-8674(93)90673-E; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	20	1463	1587	3	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					408	411		10.1126/science.272.5260.408	http://dx.doi.org/10.1126/science.272.5260.408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602529				2022-12-01	WOS:A1996UG25200046
J	Allain, FHT; Gubser, CC; Howe, PWA; Nagai, K; Neuhaus, D; Varani, G				Allain, FHT; Gubser, CC; Howe, PWA; Nagai, K; Neuhaus, D; Varani, G			Specificity of ribonucleoprotein interaction determined by RNA folding during complex formation	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; U1A PROTEIN; CRYSTAL-STRUCTURE; PREMESSENGER RNA; NMR-SPECTROSCOPY; BINDING DOMAIN; POLYADENYLATION; CONFORMATION	Many proteins involved in pre-mRNA processing contain one or more copies of a 70-90-amino-acid alpha beta module called the ribonucleoprotein domain(1-4). RNA maturation depends on the specific recognition by ribonucleoproteins of RNA elements within pre-mRNAs and small nuclear RNAs. The human U1A protein binds an RNA hairpin during splicing(5-8), and regulates its own expression by binding an internal loop(9) in the 3'-untranslated region of its pre mRNA, preventing polyadenylation3. Here we report the nuclear magnetic resonance structure of the complex between the regulatory element of the U1A 3'-untranslated region (UTR)(9-11) and the U1A protein RNA-binding domain. Specific intermolecular recognition requires the interaction of the variable loops of the ribonucleoprotein domain with the well-structured helical regions of the RNA. Formation of the complex then orders the flexible RNA single-stranded loop against the protein beta-sheet surface, and reorganizes the carboxy-terminal region of the protein to maximize surface complementarity and functional group recognition.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 1QB,ENGLAND	MRC Laboratory Molecular Biology								ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; AVIS J, 1996, J MOL BIOL; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRUNGER AT, 1990, XPLOR 3 1 SYSTEM XRA; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DIAMOND R, 1995, ACTA CRYSTALLOGR D, V51, P127, DOI 10.1107/S0907444994010723; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Gubser CC, 1996, BIOCHEMISTRY-US, V35, P2253, DOI 10.1021/bi952319f; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Liljas A, 1995, CURR OPIN STRUC BIOL, V5, P721, DOI 10.1016/0959-440X(95)80003-4; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	30	233	237	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					646	650		10.1038/380646a0	http://dx.doi.org/10.1038/380646a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602269				2022-12-01	WOS:A1996UF74100052
J	Donnan, GA				Donnan, GA			Posterior leucoencephalopathy syndrome	LANCET			English	Editorial Material							CYCLOSPORINE				Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR,DEPT NEUROL,MELBOURNE,VIC,AUSTRALIA.			Donnan, Geoffrey/0000-0001-6324-3403				BENIGNI A, 1992, TRANSPLANTATION, V54, P775, DOI 10.1097/00007890-199211000-00002; BYROM FB, 1954, LANCET, V2, P201; DAHMUS MA, 1992, AM J OBSTET GYNECOL, V167, P935, DOI 10.1016/S0002-9378(12)80015-9; FISHER M, 1985, ANN NEUROL, V18, P268, DOI 10.1002/ana.410180219; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Hughes EC., 1972, OBSTET GYNECOLOGIC T; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Oppenheimer BS, 1928, ARCH INTERN MED, V41, P264, DOI 10.1001/archinte.1928.00130140126010; ROBERTSON DM, 1970, AM J PATHOL, V59, P115; WILL AD, 1987, NEUROLOGY, V37, P1555, DOI 10.1212/WNL.37.9.1555	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					988	988		10.1016/S0140-6736(96)90142-7	http://dx.doi.org/10.1016/S0140-6736(96)90142-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606611				2022-12-01	WOS:A1996UF38000007
J	Gunel, M; Awad, IA; Finberg, K; Anson, JA; Steinberg, GR; Batjer, PH; Kopitnik, TA; Morrison, L; Giannotta, SL; NelsonWilliams, C; Lifton, RP				Gunel, M; Awad, IA; Finberg, K; Anson, JA; Steinberg, GR; Batjer, PH; Kopitnik, TA; Morrison, L; Giannotta, SL; NelsonWilliams, C; Lifton, RP			A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; FAMILIAL OCCURRENCE; ANGIOMAS; BRAIN	Background. Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage. Familial and sporadic cases are recognized, and a gene causing familial disease has been mapped to chromosome 7. Hispanic Americans have a higher prevalence of cavernous malformation than do other ethnic groups, raising the possibility that affected persons in this population have inherited the same mutation from a common ancestor. Methods. We compared the segregation of genetic markers and clinical cases of cavernous malformation in Hispanic-American kindreds with familial disease; we also compared the alleles for markers linked to cavernous malformation in patients with familial and sporadic cases. Results. All kindreds with familial disease showed linkage of cavernous malformation to a short segment of chromosome 7 (odds supporting linkage, 4x10(10):1), Forty-seven affected members of 14 kindreds shared identical alleles for up to 15 markers linked to the cavernous-malformation gene, demonstrating that they had inherited the same mutation from a common ancestor. Ten patients with sporadic cases also shared these same alleles, indicating that they too had inherited the same mutation. Thirty-three asymptomatic carriers of the disease gene were identified, demonstrating the variability and age dependence of the development of symptoms and explaining the appearance of apparently sporadic cases. Conclusions. Virtually all cases of familial and sporadic cavernous malformation among Hispanic Americans of Mexican descent are due to the inheritance of the same mutation from a common ancestor. (C) 1996, Massachusetts Medical Society.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,NEW HAVEN,CT 06510; YALE UNIV,NEUROSURG SECT,NEW HAVEN,CT; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT; YALE UNIV,DEPT MED & GENET,NEW HAVEN,CT; UNIV NEW MEXICO,DEPT NEUROSURG,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,DEPT NEUROL,ALBUQUERQUE,NM 87131; STANFORD UNIV,DEPT NEUROSURG,PALO ALTO,CA 94304; STANFORD UNIV,DEPT NEUROL,PALO ALTO,CA 94304; STANFORD UNIV,DEPT NEUROSURG,PALO ALTO,CA 94304; NORTHWESTERN UNIV,DEPT NEUROSURG,CHICAGO,IL 60611; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV SO CALIF,DEPT NEUROSURG,LOS ANGELES,CA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; University of New Mexico; University of New Mexico; Stanford University; Stanford University; Stanford University; Northwestern University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Southern California				Morrison, Leslie/0000-0002-0092-193X				Armitage P., 1987, STAT METHODS MED RES; Barrow D., 1993, CAVERNOUS MALFORMATI, P65; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BICKNELL JM, 1978, ARCH NEUROL-CHICAGO, V35, P746, DOI 10.1001/archneur.1978.00500350050010; CLARK JV, 1970, J NEUROL NEUROSUR PS, V33, P871, DOI 10.1136/jnnp.33.6.871; DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702; DOBYNS WB, 1987, ANN NEUROL, V21, P578, DOI 10.1002/ana.410210609; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; GANGEMI M, 1990, Neurological Research, V12, P131; GUNEL M, 1995, P NATL ACAD SCI USA, V92, P6620, DOI 10.1073/pnas.92.14.6620; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HASTBACKA J, 1992, NAT GENET, V2, P343; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HAYMAN LA, 1982, AM J MED GENET, V11, P147, DOI 10.1002/ajmg.1320110205; HSU FPK, 1993, CAVERNOUS MALFORMATI, P13; HUHN SL, 1993, CAVERNOUS MALFORMATI, P87; JOHNSON PC, 1993, CAVERNOUS MALFORMATI, P1; KIDD HA, 1947, LANCET, V1, P747; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MASON I, 1988, NEUROLOGY, V38, P324, DOI 10.1212/WNL.38.2.324; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Ojemann R G, 1993, Clin Neurosurg, V40, P98; OTTEN P, 1989, NEUROCHIRURGIE, V35, P82; PERL J, 1993, CAVERNOUS MALFORMATI, P37; RIGAMONTI D, 1987, J NEUROSURG, V67, P518, DOI 10.3171/jns.1987.67.4.0518; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; ROBINSON JR, 1993, NEUROSURGERY, V32, P730, DOI 10.1227/00006123-199305000-00005; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; SPENCER DD, 1984, NEUROLOGY, V34, P432, DOI 10.1212/WNL.34.4.432; STEICHENGERSDORF E, 1992, EUR J PEDIATR, V151, P861, DOI 10.1007/BF01957941; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422	32	172	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					946	951		10.1056/NEJM199604113341503	http://dx.doi.org/10.1056/NEJM199604113341503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596595				2022-12-01	WOS:A1996UD59600003
J	Back, AL; Wallace, JI; Starks, HE; Pearlman, RA				Back, AL; Wallace, JI; Starks, HE; Pearlman, RA			Physician-assisted suicide and euthanasia in Washington State - Patient requests and physician responses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH; DECISIONS; LIFE	Objectives.-To estimate how often physicians receive requests for physician-assisted suicide and euthanasia and to describe a case series of patient requests for physician-assisted suicide and euthanasia, including physician responses to these requests. Design.-A mailed, anonymous two-part questionnaire. Participants.-A total of 828 physicians returned questionnaires sent to 1453 potential respondents, for a response rate of 57%. Questionnaires were mailed to a random sample (25%) of primary care physicians and all physicians in selected medical subspecialties in Washington State. Main Outcome Measures.-The frequency of explicit patient requests for physician-assisted suicide and euthanasia reported by physicians and individual case descriptions of patient characteristics, physician perceptions of patient concerns, and physician responses to patient requests. Results.-In the past year, 12% of responding physicians received one or more explicit requests for physician-assisted suicide, and 4% received one or more requests for euthanasia. These physicians provided 207 case descriptions. The diagnoses most often associated with requests were cancer, neurological disease, and the acquired immunodeficiency syndrome (AIDS). The patient concerns most often perceived by physicians were worries about loss of control, being a burden, being dependent on others for personal care, and loss of dignity, Physicians provided assistance more often to patients with physical symptoms. Physicians infrequently sought advice from colleagues, Of 156 patients who requested physician-assisted suicide, 38 (24%) received prescriptions, and 21 of these died as a result. Of 58 patients who requested euthanasia, 14 (24%) received parenteral medication and died. Conclusions.-Patient requests for physician-assisted suicide and euthanasia are not rare, As perceived by physicians, the most common patient concerns at the time these requests are made are nonphysical, Physicians occasionally provide these practices, even though they are currently illegal in Washington State. Physicians do not consult colleagues often about these requests. These findings raise the question of how to ensure quality in the evaluation of patient requests for physician-assisted death.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT HLTH SERV, SEATTLE, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Back, AL (corresponding author), VET AFFAIRS PUGET SOUND HLTH CARE SYST, MED SERV, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.				NIA NIH HHS [AG00615-02] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BATTIN MP, 1995, ACAD MED, V70, P583; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSELL EJ, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3563319; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FINS JJ, 1995, J AM GERIATR SOC, V43, P563, DOI 10.1111/j.1532-5415.1995.tb06107.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GIRSH FJ, 1992, WESTERN J MED, V157, P188; Humphry D, 1991, FINAL EXIT PRACTICAL; JECKER NS, 1994, J AM GERIATR SOC, V42, P672, DOI 10.1111/j.1532-5415.1994.tb06869.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PEARLMAN RA, 1993, THEOR MED, V14, P197, DOI 10.1007/BF00995162; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PELLEGRINO ED, 1995, J CLIN ETHIC, V6, P161; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; *WA STAT DEP HLTH, 1994, WASH STAT VIT STAT; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, J AM GERIATR SOC, V43, P579	37	258	258	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					919	925		10.1001/jama.275.12.919	http://dx.doi.org/10.1001/jama.275.12.919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA563	8598619				2022-12-01	WOS:A1996UA56300031
J	Nightingale, SL				Nightingale, SL			National surveillance program for changes in antimicrobial susceptibilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, MMWR-MORBID MORTAL W, V45, P110	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-01	WOS:A1996UA56300011
J	Bond, CM; Bradley, C				Bond, CM; Bradley, C			Over the counter drugs - The interface between the community pharmacist and patients .3.	BRITISH MEDICAL JOURNAL			English	Article								Pharmacists play an important part in primary health care, and their accessibility is a key factor. Their NHS payments relate predominantly to the dispensing of prescribed medicines; to recognise the service element of their advisory role, an NHS funded professional fee could be built into the cost structure for pharmacy medicines. The increased number of medicines available over the counter has need for training for counter assistants; it will become compulsory in July 1996, and some family health services authorities are providing this. The shift to care in the community could mean that pharmacists will have an even greater role in the primary health care team. Encouraging the public to seek advice from the community pharmacist may lead to a greater proportion of visits to doctors resulting from referrals from the pharmacist. Joint development by pharmacists and doctors of guidelines for advice on, and recommendation of, over the counter medicines is needed.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Bond, CM (corresponding author), UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN,SCOTLAND.							BLENKINSOPP A, 1994, OTCS PRESCRIPTION HE; Bond C M, 1995, Health Bull (Edinb), V53, P26; Bond CM, 1995, INT J PHARM PRACT, V3, P85; BOND CM, 1992, PHARM J, V249, pR6; *COMM INQ PHARM, 1986, REP NUFF FDN; DARRACOTT R, 1995, PHARM J, V254, P497; Eaton G, 1979, Sociol Health Illn, V1, P69, DOI 10.1111/1467-9566.ep11006781; EVANS D, 1994, PHARM J, V252, P631; FLINT JF, 1995, PHARM J, V254, P28; GOODBURN E, 1991, BMJ-BRIT MED J, V302, P440, DOI 10.1136/bmj.302.6774.440; HARGIE ODW, 1987, INT PHARM J, V1, P175; Jepson M, 1991, CONSUMER EXPECTATION; KRSKA J, 1994, PHARM J, V252, P936; National Audit Office, 1992, COMM PHARM ENGL; *ROYAL PHARM SOC, 1992, PHARM CAR FUT ROL CO; TAPSTER JV, 1994, PHARM J, V253, P112; 1987, CM249	17	35	35	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					758	760						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605465				2022-12-01	WOS:A1996UC16600039
J	Ogilvie, AD; Battersby, S; Bubb, VJ; Fink, G; Harmar, AJ; Goodwin, GM; Smith, CAD				Ogilvie, AD; Battersby, S; Bubb, VJ; Fink, G; Harmar, AJ; Goodwin, GM; Smith, CAD			Polymorphism in serotonin transporter gene associated with susceptibility to major depression	LANCET			English	Article							HYDROXYLASE GENE; DISORDERS	Background The serotonin transporter of the brain provides the primary target for the action of selective antidepressant drugs. We set out to identify polymorphisms of the serotonin transporter gene and to find out whether there was a relation between any such polymorphisms and the occurrence of affective disorder. Methods A comparison of a polymorphic region of the human serotonin transporter gene was carried out between two groups. The study group comprised 83 patients (39 unipolar depressive disorder, 44 bipolar disorder) with major affective disorder. The control group comprised 122 anonymous blood donors, and 71 volunteers who had been screened for psychiatric disorders. Findings We detected three novel alleles of the variable-number-tandem-repeat (VNTR) region (STin2.9, STin2.10, and STin2.12) containing nine, ten and 12 copies of the VNTR element, respectively. The frequencies of the different forms of the allele in the control group were compared with those in the affective disorder group. There was a significant difference between the control and affective disorder groups, largely explained by the excess of the STin2.9 allele in the unipolar group (chi(2)=10.05, p<0.004 [Bonferroni corrected]). The presence of the allele with nine copies of the repeat was significantly associated with risk of unipolar disorder (odds ratio=6.95 [95% CI 1.8-27.2]). Interpretation This association, for an obvious candidate gene, may provide a critical starting point for an understanding of the likely polygenic contributions towards susceptibility to affective disorder.	ROYAL EDINBURGH & ASSOCIATED HOSP,MRC,BRAIN METAB UNIT,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,CRC LABS,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh				Fink, George/0000-0002-0713-527X; Harmar, Anthony/0000-0002-3838-9264				American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; ANDERSON IM, 1994, J PSYCHOPHARMACOL, V8, P238, DOI 10.1177/026988119400800407; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BOYER WF, 1991, SEROTONIN HYPOTHESIS, P71; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; GOLTSOV AA, 1992, AM J HUM GENET, V51, P627; HUDSON JI, 1990, AM J PSYCHIAT, V147, P552; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1995, BIOL PSYCHIAT, V37, P215, DOI 10.1016/0006-3223(94)00147-U; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; OWENS MJ, 1994, CLIN CHEM, V40, P288; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013	15	460	492	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					731	733		10.1016/S0140-6736(96)90079-3	http://dx.doi.org/10.1016/S0140-6736(96)90079-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602004				2022-12-01	WOS:A1996TZ98200012
J	Harada, K; Martin, SS; Frankel, AD				Harada, K; Martin, SS; Frankel, AD			Selection of RNA-binding peptides in vivo	NATURE			English	Article							BACTERIOPHAGE-LAMBDA; N-PROTEIN; RECOGNITION; ANTITERMINATION; REQUIRES; RESIDUES	Many principles of sequence-specific DNA recognition have been established over the past decade, largely from structural studies of protein-DNA and drug-DNA complexes. On the basis of these principles, it has been possible to design or select variants of known structural motifs, including zinc-fingers(1-3) and minor groove-binding drugs', that bind desired sequences. Here we describe a strategy, based on transcriptional termination in bacteria, to identify specific RNA-binding peptides using the arginine-rich RNA-binding motifs as a framework. Peptides were isolated from two combinatorial libraries that bind tightly and specifically to the Rev response element of HIV. It appears that a-helical peptides resembling Rev were selected from one library whereas new peptides that probably do not form helices were selected from the other, suggesting that the arginine-rich motif may be a particularly versatile framework for recognizing RNA structures.			Harada, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; FRANKLIN NC, 1993, J MOL BIOL, V231, P343, DOI 10.1006/jmbi.1993.1287; FRANKLIN NC, 1989, J BACTERIOL, V171, P2513, DOI 10.1128/jb.171.5.2513-2522.1989; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JONES KA, 1994, REV BICOH, V63, P717; KJERNS J, 1992, EMBO J, V11, P1119; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Sambrook J., 1989, MOL CLONING; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9	23	110	113	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					175	179		10.1038/380175a0	http://dx.doi.org/10.1038/380175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600395				2022-12-01	WOS:A1996TZ97800056
J	Campuzano, V; Montermini, L; Molto, MD; Pianese, L; Cossee, M; Cavalcanti, F; Monros, E; Rodius, F; Duclos, F; Monticelli, A; Zara, F; Canizares, J; Koutnikova, H; Bidichandani, SI; Gellera, C; Brice, A; Trouillas, P; DeMichele, G; Filla, A; DeFrutos, R; Palau, F; Patel, PI; DiDonato, S; Mandel, JL; Cocozza, S; Koenig, M; Pandolfo, M				Campuzano, V; Montermini, L; Molto, MD; Pianese, L; Cossee, M; Cavalcanti, F; Monros, E; Rodius, F; Duclos, F; Monticelli, A; Zara, F; Canizares, J; Koutnikova, H; Bidichandani, SI; Gellera, C; Brice, A; Trouillas, P; DeMichele, G; Filla, A; DeFrutos, R; Palau, F; Patel, PI; DiDonato, S; Mandel, JL; Cocozza, S; Koenig, M; Pandolfo, M			Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion	SCIENCE			English	Article							MYOTONIC-DYSTROPHY; MUTATION; DNA; IDENTIFICATION; CHROMOSOME-9; LINKAGE; GENE	Friedreich's ataxia (FRDA) is an autosomal recessive, degenerative disease that involves the central and peripheral nervous systems and the heart. A gene, X25, was identified in the critical region for the FRDA locus on chromosome 9q13. The gene encodes a 210-amino acid protein, frataxin, that has homologs in distant species such as Caenorhabditis elegans and yeast. A few FRDA patients were found to have point mutations in X25, but the majority were homozygous for an unstable GAA trinucleotide expansion in the first X25 intron.	UNIV STRASBOURG 1,INST BIOL & BIOL MOLEC & CELLULAIRE,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE; CHU,F-67404 ILLKIRCH GRAFFENS,FRANCE; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; CNR,CTR ENDOCRINOL ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; IST MEDITERRANEO NEUROSCI SANATRIX,I-86077 POZZILLI,ISERNIA,ITALY; UNIV HOSP LA FE,UNIDAD GENET,E-46006 VALENCIA,SPAIN; UNIV VALENCIA,DEPT GENET,E-46100 BURJASSOT,VALENCIA,SPAIN; IST NAZL NEUROL C BESTA,DIV BIOCHIM & GENET SISTEMA NERVOSO,I-20133 MILAN,ITALY; HOP LA PITIE SALPETRIERE,F-75651 PARIS 13,FRANCE; HOP NEUROL,F-69003 LYON,FRANCE; UNIV NAPLES FEDERICO II,DIV NEUROL 2,DIPARTIMENTO PATOL SISTEMA,I-80131 NAPLES,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Baylor College of Medicine; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Valencia; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; University of Naples Federico II			Campuzano, Victoria/ABG-7429-2020; brice, alexis/AAE-8275-2019; Canizares, Joaquin/M-3255-2014; Koutnikova, Hana/I-7758-2017; Gellera, Cinzia/J-7887-2016; Campuzano, V/G-1826-2014; CAMPUZANO, VICTORIA/K-7883-2019; Brice, Alexis/A-2170-2009; Palau, Francesc/A-9391-2014; Pandolfo, Massimo/B-2853-2010; Zara, Federico/U-3477-2017; Cocozza, Sergio/F-6488-2010; Di Donato, Stefano/B-9717-2012; Canizares, Joaquin/X-9702-2019; CAVALCANTI, FRANCESCA/I-3651-2014; Cavalcanti, Francesca/N-3901-2019; Patel, Pragna/H-9129-2017	Campuzano, Victoria/0000-0001-8128-2641; brice, alexis/0000-0002-0941-3990; Canizares, Joaquin/0000-0001-9002-5516; Gellera, Cinzia/0000-0002-3582-665X; Campuzano, V/0000-0001-8128-2641; Palau, Francesc/0000-0002-8635-5421; Zara, Federico/0000-0001-9744-5222; Canizares, Joaquin/0000-0001-9002-5516; CAVALCANTI, FRANCESCA/0000-0001-5769-4582; Cavalcanti, Francesca/0000-0001-5769-4582; COSSEE, Mireille/0000-0002-5931-7454; Molto, Maria Dolores/0000-0001-5219-2022; Patel, Pragna/0000-0003-3584-1072; Bidichandani, Sanjay/0000-0001-6191-6475	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34192] Funding Source: Medline; Telethon [722] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BIDICHANDANI SI, UNPUB; CAMPUZANO V, UNPUB; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINOCCHIARO G, 1988, NEUROLOGY, V38, P1292, DOI 10.1212/WNL.38.8.1292; Friedreich N, 1863, VIRCHOWS ARCH PATHOL, V26, P391, DOI 10.1515/9783112391280-017; FROHMAN MA, 1989, TECHNIQUE, V1, P165; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; GACY AM, 1995, CELL, V81, P533; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; GEOFFROY G, 1984, HEREDITARY ATAXIAS R; HANAUER A, 1990, AM J HUM GENET, V46, P133; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1983, Q J MED, V52, P489; HEWER RL, 1968, BRIT MED J, V3, P649, DOI 10.1136/bmj.3.5619.649; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HUGHES JT, 1968, BRAIN, V91, P803, DOI 10.1093/brain/91.4.803; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; JITPIMOLMARD S, 1993, ACTA NEUROPATHOL, V86, P29, DOI 10.1007/BF00454895; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KLOCKGETHER T, 1990, J NEUROL NEUROSUR PS, V53, P297, DOI 10.1136/jnnp.53.4.297; KOCH KS, 1995, NUCLEIC ACIDS RES, V23, P1098, DOI 10.1093/nar/23.7.1098; LAMARCHE JB, 1984, CAN J NEUROL SCI, V11, P592, DOI 10.1017/S0317167100035113; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MONROS E, UNPUB; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PANDOLFO M, 1994, BIOCHEM MED METAB B, V52, P115, DOI 10.1006/bmmb.1994.1041; PENTLAND B, 1983, J NEUROL NEUROSUR PS, V46, P1138, DOI 10.1136/jnnp.46.12.1138; ROMEO G, 1983, AM J HUM GENET, V35, P523; SAID G, 1986, NEUROLOGY, V36, P1292, DOI 10.1212/WNL.36.10.1292; Saleeba Jennifer A., 1992, Human Mutation, V1, P63, DOI 10.1002/humu.1380010110; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SKRE H, 1975, CLIN GENET, V7, P287; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALDMANN TA, 1983, ANN INTERN MED, V99, P367, DOI 10.7326/0003-4819-99-3-367	49	2143	2215	3	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1423	1427		10.1126/science.271.5254.1423	http://dx.doi.org/10.1126/science.271.5254.1423			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596916				2022-12-01	WOS:A1996TY96100048
J	Mittal, R; Erickson, JW; Cerione, RA				Mittal, R; Erickson, JW; Cerione, RA			Uncoupling of GTP binding from target stimulation by a single mutation in the transducin alpha subunit	SCIENCE			English	Article							INTRINSIC FLUORESCENCE; REGULATORY PROTEINS; ACTIVATION; PHOSPHODIESTERASE; DEACTIVATION; KINETICS; CGMP	Glutamic acid-203 of the alpha subunit of transducin (alpha(T)) resides within a domain that undergoes a guanosine triphosphate (GTP)-induced conformational change that is essential for effector recognition. Changing the glutamic acid to an alanine in bovine alpha(T) yielded an alpha subunit (alpha(T)E203A) that was fully dependent on rhodopsin for GTP-guanosine diphosphate (GDP) exchange and showed GTP hydrolytic activity similar to that measured for wild-type alpha(T). However, unlike the wild-type protein, the GDP-bound form of alpha(T)E203A was constitutively active toward the effector of transducin, the cyclic guanosine monophosphate phosphodiesterase. Thus, the alpha(T)E203A mutant represents a short-circuited protein switch that no longer requires GTP for the activation of the effector target phosphodiesterase.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University								ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GOSWAMI BB, 1991, BIOTECHNIQUES, V5, P626; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MITTAL R, UNPUB; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; YEE R, 1978, J BIOL CHEM, V253, P8902	16	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1413	1416		10.1126/science.271.5254.1413	http://dx.doi.org/10.1126/science.271.5254.1413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596913				2022-12-01	WOS:A1996TY96100045
J	Verheij, M; Bose, R; Lin, XH; Yao, B; Jarvis, WD; Grant, S; Birrer, MJ; Szabo, E; Zon, LI; Kyriakis, JM; HaimovitzFriedman, A; Fuks, Z; Kolesnick, RN				Verheij, M; Bose, R; Lin, XH; Yao, B; Jarvis, WD; Grant, S; Birrer, MJ; Szabo, E; Zon, LI; Kyriakis, JM; HaimovitzFriedman, A; Fuks, Z; Kolesnick, RN			Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis	NATURE			English	Article							KINASE; DEATH	The induction of programmed cell death, or apoptosis, involves activation of a signalling system, many elements of which remain unknown(1). The sphingomyelin pathway, initiated by hydrolysis of the phospholipid sphingomyelin in the cell membrane to generate the second messenger ceramide(2,3), is thought to mediate apoptosis in response to tumour-necrosis factor (TNF)-alpha(2,3), to Fas ligand(4) and to X-rays(5). It is not known whether it plays a role in the stimulation of other forms of stress-induced apoptosis. Given that environmental stresses also stimulate a stress-activated protein kinase (SAPR/JNK)(6-12), the sphingomyelin and SAPK/ JNK signalling systems may be coordinated in induction of apoptosis. Here we report that ceramide initiates apoptosis through the SAPK cascade and provide evidence for a signalling mechanism that integrates cytokine- and stress-activated apoptosis.	MEM SLOAN KETTERING CANC CTR,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV HEMATOL ONCOL,RICHMOND,VA 23298; NCI,DIV CANC PREVENT & CONTROL,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,DANA FARBER CANC INST,CHILDRENS HOSP,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,MED SERV,DIABET RES LAB,BOSTON,MA 02129	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital			Verheij, Marcel/O-9652-2018	Szabo, Eva/0000-0003-3891-0942				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; BROWN PH, 1994, ONCOGENE, V9, P791; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HAM J, 1995, CELL, V14, P927; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	30	1696	1756	1	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					75	79		10.1038/380075a0	http://dx.doi.org/10.1038/380075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598911				2022-12-01	WOS:A1996TY87700060
J	Goldstein, ST; Juranek, DD; Ravenholt, O; Hightower, AW; Martin, DG; Mesnik, JL; Griffiths, SD; Bryant, AJ; Reich, RR; Herwaldt, BL				Goldstein, ST; Juranek, DD; Ravenholt, O; Hightower, AW; Martin, DG; Mesnik, JL; Griffiths, SD; Bryant, AJ; Reich, RR; Herwaldt, BL			Cryptosporidiosis: An outbreak associated with drinking water despite state-of-the-art water treatment	ANNALS OF INTERNAL MEDICINE			English	Article							SUPPLIES; GIARDIA	Objective: To determine the magnitude and source of an outbreak of cryptosporidiosis among persons with human immunodeficiency virus (HIV) infection and to determine whether the outbreak extended into the immunocompetent population. Design: Matched case-control study and environmental investigation. Setting: Clark County, Nevada. Participants: Adults with HIV infection (36 case-patients with laboratory-confirmed Cryptosporidium parvum infection and 107 controls), matched by physician or clinic and by CD4(+) cell count category. Measurements: Potential risk factors for infection, death rates, and data on water quality. Results: Review of surveillance and microbiology records identified 3 cases of cryptosporidiosis in 1992 (the first year that cryptosporidiosis was reportable in Nevada), 23 cases in 1993, and 78 cases in the first quarter of 1994. Of the 78 laboratory-confirmed cases in the first quarter of 1994, 61 (78.2%) were in HIV-infected adults. Of these 61 adults, 32 (52.5%) had died by 30 June 1994; at least 20 of the 32 (62.5%) had cryptosporidiosis listed on their death certificates. In the case-control study, persons who drank any unboiled tap water were four times more likely than persons who drank only bottled water to have had cryptosporidiosis (odds ratio, 4.22 [95% CI, 1.22 to 14.65]; P = 0.02). For persons with CD4(+) cell counts less than 100 cells/mm(3), the association between tap water and cryptosporidiosis was even stronger (odds ratio, 13.52 [CI, 1.78 to 102.92]; P = 0.01). Additional data indicate that this outbreak also affected persons who were not infected with HIV. No elevated turbidity values or coliform counts and no Cryptosporidium oocysts were found in testing of source (Lake Mead) or finished (treated) water during the study period, but so-called presumptive oocysts were intermittently found after the investigation in samples of source water, filter backwash, and finished water. Conclusions: A cryptosporidiosis outbreak was associated with municipal drinking water, despite state-of-the-art water treatment and water quality better than that required by current federal standards. This outbreak highlights the importance of surveillance for cryptosporidiosis and the need for guidelines for the prevention of waterborne-Cryptosporidium infection among HIV-infected persons.	CDCP, DIV PARASIT DIS, ATLANTA, GA 30341 USA; CLARK CTY DIST HLTH DEPT, LAS VEGAS, NV 89106 USA; CDCP, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BADENOCH J, 1990, CRYPTOSPORIDIUM WATE; Boyce TG, 1996, PEDIATR INFECT DIS J, V15, P87, DOI 10.1097/00006454-199601000-00019; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P661; CIESIELSKI C, 1995, 2ND NAT C HUM RETR R; CLANCY JL, 1994, J AM WATER WORKS ASS, V86, P89; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; HAAS CN, 1994, 1994 P ANN C AM WAT, P517; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JURANEK DD, 1995, CLIN INFECT DIS, V21, pS57, DOI 10.1093/clinids/21.Supplement_1.S57; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P159; LECHAVALLIER MW, 1994, PREVENTING WATERBORN, P2; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2610, DOI 10.1128/AEM.57.9.2610-2616.1991; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; Moore Anne C., 1993, Morbidity and Mortality Weekly Report, V42, P1; MUSIAL CE, 1987, APPL ENVIRON MICROB, V53, P687, DOI 10.1128/AEM.53.4.687-692.1987; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; SORVILLO F, 1994, EPIDEMIOL INFECT, V113, P313, DOI 10.1017/S0950268800051748; SORVILLO FJ, 1994, AM J TROP MED HYG, V51, P326, DOI 10.4269/ajtmh.1994.51.326; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; 1993, 1993 BOOK ASTM STAND, P899; 1989, FED REGISTER, V54, P27486	23	168	174	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					459	+		10.7326/0003-4819-124-5-199603010-00001	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602703				2022-12-01	WOS:A1996TW77300001
J	Smith, PL; Baukrowitz, T; Yellen, G				Smith, PL; Baukrowitz, T; Yellen, G			The inward rectification mechanism of the HERG cardiac potassium channel	NATURE			English	Article							K+ CHANNELS; INACTIVATION; CELLS	A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel(1). The HERG K+ channel is unusual in that it seems to have the architectural plan of the depolarization-activated K+ channel family (six putative transmembrane segments), yet it exhibits rectification like that of the inward-rectifying K+ channels, a family with different molecular structure (two transmembrane segments)(2-4). We have studied HERG channels expressed in mammalian cells and find that this inward rectification arises from a rapid and voltage-dependent inactivation process that reduces conductance at positive voltages. The inactivation gating mechanism resembles that of C-type inactivation, often considered to be the 'slow inactivation' mechanism of other K+ channels. The characteristics of this gating suggest a specific role for this channel in the normal suppression of arrhythmias.	MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Yellen, Gary/0000-0003-4228-7866; Baukrowitz, Thomas/0000-0003-4562-0505	NINDS NIH HHS [R01 NS029693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Baukrowitz T, 1996, SCIENCE, V271, P653, DOI 10.1126/science.271.5249.653; CAO YW, 1995, J BIOL CHEM, V270, P17697, DOI 10.1074/jbc.270.30.17697; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; JUNNAN ME, 1994, BIOTECHNIQUES, V17, P876; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	639	650	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					833	836		10.1038/379833a0	http://dx.doi.org/10.1038/379833a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587608				2022-12-01	WOS:A1996TX50100061
J	Lloyd, SE; Pearce, SHS; Fisher, SE; Steinmeyer, K; Schwappach, B; Scheinman, SJ; Harding, B; Bolino, A; Devoto, M; Goodyer, P; Rigden, SPA; Wrong, O; Jentsch, TJ; Craig, IW; Thakker, RV				Lloyd, SE; Pearce, SHS; Fisher, SE; Steinmeyer, K; Schwappach, B; Scheinman, SJ; Harding, B; Bolino, A; Devoto, M; Goodyer, P; Rigden, SPA; Wrong, O; Jentsch, TJ; Craig, IW; Thakker, RV			A common molecular basis for three inherited kidney stone diseases	NATURE			English	Article							LINKED RECESSIVE NEPHROLITHIASIS; MUSCLE CHLORIDE CHANNEL; EXPRESSION; MUTATIONS; GENE	KIDNEY stones (nephrolithiasis), which affect 12% of males and 5% of females in the western world, are familial in 45% of patients(1,2) and are most commonly associated with hypercalciuria(1). Three disorders of hypercalciuric nephrolithiasis (Dent's disease(3), X-linked recessive nephrolithiasis (XRN)(4), and X-linked recessive hypophosphataemic rickets (XLRH)(5)) have been mapped to Xp11.22 (refs 5-7). A microdeletion(6) in one Dent's disease kindred allowed the identification of a candidate gene, CLCN5 (refs 8,9) which encodes a putative renal chloride channel. Here we report the investigation of 11 kindreds with these renal tubular disorders for CLCN5 abnormalities; this identified three nonsense, four missense and two donor splice site mutations, together with one intragenic deletion and one microdeletion encompassing the entire gene. Heterologous expression of wild-type CLCN5 in Xenopus oocytes yielded outwardly rectifying chloride currents, which were either abolished or markedly reduced by the mutations. The common aetiology for Dent's disease, XRN and XLRH indicates that CLCN5 may be involved in other renal tubular disorders associated with kidney stones.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; UNIV OXFORD,GENET LAB,OXFORD OX1 3QU,ENGLAND; UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY 13210; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; HOP MONTREAL ENFANTS,MONTREAL,PQ H3H 1P3,CANADA; GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND; MIDDLESEX HOSP,DEPT NEPHROL,LONDON W1N 8AA,ENGLAND	Imperial College London; University of Oxford; University of Hamburg; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London			Pearce, Simon/AAB-3692-2019; Fisher, Simon E./E-9130-2012; Craig, Ian/AAF-9167-2019; Bolino, Alessandra/O-2933-2013; Devoto, Marcella/AAP-7595-2021; Bolino, Alessandra/AAN-5442-2020	Pearce, Simon/0000-0001-8384-8063; Fisher, Simon E./0000-0002-3132-1996; Bolino, Alessandra/0000-0002-8980-4878; Schwappach, Blanche/0000-0003-0225-6432; Craig, Ian/0000-0002-4063-1005; Jentsch, Thomas/0000-0002-3509-2553; Thakker, Rajesh/0000-0002-1438-3220; DEVOTO, MARCELLA/0000-0002-4431-5114				ADACHI S, 1994, J BIOL CHEM, V269, P17677; Bolino A., 1993, European Journal of Human Genetics, V1, P269; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; FISHER SE, 1995, GENOMICS, V29, P598, DOI 10.1006/geno.1995.9960; FISHER SE, 1994, HUM MOL GENET, V3, P2053; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; FRYMOYER PA, 1991, NEW ENGL J MED, V325, P681, DOI 10.1056/NEJM199109053251003; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; HIGGINS JT, 1977, PFLUG ARCH EUR J PHY, V371, P87, DOI 10.1007/BF00580776; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POOK MA, 1993, HUM MOL GENET, V2, P2129, DOI 10.1093/hmg/2.12.2129; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; SAMBROOK J, 1989, LABORATORY MANUAL; SCHEINMAN SJ, 1993, J CLIN INVEST, V91, P2351, DOI 10.1172/JCI116467; SMITH LH, 1989, J UROLOGY, V141, P707, DOI 10.1016/S0022-5347(17)40990-6; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; THAKKER RV, 1993, J CLIN INVEST, V91, P2815, DOI 10.1172/JCI116524; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; WRONG OM, 1994, Q J MED, V87, P473	28	580	595	2	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					445	449		10.1038/379445a0	http://dx.doi.org/10.1038/379445a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559248	Green Submitted			2022-12-01	WOS:A1996TT30400058
J	Glanz, K; Yang, H				Glanz, K; Yang, H			Communicating about risk of infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCEPTIONS; RADON				Glanz, K (corresponding author), UNIV HAWAII,CANC RES CTR HAWAII,PREVENT & CONTROL PROGRAM,1236 LAUHALA ST,HONOLULU,HI 96813, USA.							ALLEN FW, 1987, SCI TECHNOL HUM VAL, V12, P138; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHALK R, 1987, SCI TECHNOL HUM VAL, V12, P11; DUTTON DB, 1987, SCI TECHNOL HUM VAL, V12, P48; FISCHHOFF B, 1987, SCI TECHNOL HUM VAL, V12, P13; Garrett Laurie, 1994, COMING PLAGUE NEWLY; GLANZ K, 1990, HLTH BEHAVIOR HLTH E; GOODMAN RA, 1994, PRINCIPLES PRACTICE, P150; Hovland C., 1953, COMMUNICATION PERSUA; KULIK JA, 1987, HEALTH PSYCHOL, V6, P15, DOI 10.1037/0278-6133.6.1.15; Lederberg J., 1992, EMERGING INFECT MICR; McGuire William, 1985, HDB SOCIAL PSYCHOL, P233; MCLEROY K R, 1989, Health Education Research, V4, P169, DOI 10.1093/her/4.2.169; PLOUGH A, 1987, SCI TECHNOL HUM VAL, V12, P4; SANDMAN PM, 1993, HEALTH EDUC QUART, V20, P471, DOI 10.1177/109019819302000408; SHORT JF, 1984, AM SOCIOL REV, V49, P711, DOI 10.2307/2095526; SLOVIC P, 1993, RISK ANAL, V13, P675, DOI 10.1111/j.1539-6924.1993.tb01329.x; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Slovic P., 1981, ASSESSMENT PERCEPTIO; Van der Velde F.W., 1992, PSYCHOL HEALTH, V6, P23, DOI DOI 10.1080/08870449208402018; WEINSTEIN ND, 1993, HEALTH PSYCHOL, V12, P324, DOI 10.1037/0278-6133.12.4.324; WEINSTEIN ND, 1993, RISK ANAL, V13, P103, DOI 10.1111/j.1539-6924.1993.tb00733.x; WEINSTEIN ND, 1988, AM J PUBLIC HEALTH, V78, P796, DOI 10.2105/AJPH.78.7.796; WEINSTEIN ND, 1992, HEALTH PSYCHOL, V11, P170, DOI 10.1037/0278-6133.11.3.170; WEINSTEIN ND, 1984, HEALTH PSYCHOL, V3, P431, DOI 10.1037/0278-6133.3.5.431; 1989, IMPROVING RISK COMMU; 1994, MMWR-MORBID MORTAL W, V43, P1	27	23	23	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					253	256		10.1001/jama.275.3.253	http://dx.doi.org/10.1001/jama.275.3.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP282	8604182				2022-12-01	WOS:A1996TP28200037
J	Kononen, M; Waltimo, A; Nystrom, M				Kononen, M; Waltimo, A; Nystrom, M			Does clicking in adolescence lead to painful temporomandibular joint locking?	LANCET			English	Article							DYSFUNCTION	Background It has been assumed that clicking of the temporomandibular joint (TMJ) may predispose to closed locking. Although jaw clicking is a common complaint, locking of the TMJ is rare. Methods To assess whether clicking is a reliable predictor of locking, we examined longitudinally over 9 years the variation of reported and recorded TMJ clicking in 128 young Finnish adults. Subjects were interviewed and examined at the ages of 14, 15, 18, and 23 years. Findings Reported and recorded TMJ clicking both increased significantly with age, varying from 11% to 31% and from 11% to 34%, respectively. However, clicking showed no predictable pattern, and only a few subjects consistently reported clicking (2%) or had it recorded (2%). None developed locking. Interpretation Because none of the young adults developed locking of the TMJ, we suggest treatment for clicking should be conservative.	UNIV HELSINKI,DEPT PEDODONT & ORTHODONT,HELSINKI,FINLAND	University of Helsinki	Kononen, M (corresponding author), UNIV HELSINKI,DEPT PROSTH DENT,POB 41,SF-00014 HELSINKI,FINLAND.							Annandale T, 1887, LANCET, V129, P411; BROOKE RI, 1988, ORAL SURG ORAL MED O, V65, P668, DOI 10.1016/0030-4220(88)90005-9; DOLWICK MF, 1983, J PROSTHET DENT, V49, P415, DOI 10.1016/0022-3913(83)90287-1; Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301; GREENE CS, 1988, J AM DENT ASSOC, V117, P461, DOI 10.1016/S0002-8177(88)73018-4; GROSS A, 1983, J AM DENT ASSOC, V107, P932, DOI 10.14219/jada.archive.1983.0354; Kononen Mauno, 1993, Journal of Orofacial Pain, V7, P329; RANDOLPH CS, 1990, AM J ORTHOD DENTOFAC, V77, P77; WANMAN A, 1990, ORAL SURG ORAL MED O, V69, P2, DOI 10.1016/0030-4220(90)90259-U	9	72	73	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1080	1081		10.1016/S0140-6736(96)90280-9	http://dx.doi.org/10.1016/S0140-6736(96)90280-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602059				2022-12-01	WOS:A1996UG04200013
J	Takeda, K; Tanaka, T; Shi, W; Matsumoto, M; Minami, M; Kashiwamura, S; Nakanishi, K; Yoshida, N; Kishimoto, T; Akira, S				Takeda, K; Tanaka, T; Shi, W; Matsumoto, M; Minami, M; Kashiwamura, S; Nakanishi, K; Yoshida, N; Kishimoto, T; Akira, S			Essential role of Stat6 in IL-4 signalling	NATURE			English	Article							RESTING B-CELLS; INTERLEUKIN-4; EXPRESSION; LIPOPOLYSACCHARIDE; LYMPHOKINE; RECEPTOR	Interleukin-4(IL-4) is a pleiotropic lymphokine which plays an important role in the immune system(1). IL-4 activates two distinct signalling pathways through tyrosine phosphorylation of Stat6, a signal transducer and activator of transcription, and of a 170K protein called 4PS(2-7). To investigate the functional role of Stat6 in IL-4 signalling, we generated mice deficient in Stat6 by gene targeting. We report here that in the mutant mice, expression of CD23 and major histocompatibility complex (MHC) class II in resting B cells was not enhanced in response to IL-4. IL-4-induced B-cell proliferation costimulated by anti-IgM antibody was abolished. The T-cell proliferative response was also notably reduced. Furthermore, production of Th2 cytokines from T cells as well as IgE and IgG1 responses after nematode infection were profoundly reduced. These findings agreed with those obtained in IL4-deficient mice(8,9) or using antibodies to IL-4(10) and the IL-4 receptor(11). We conclude that Stat6 plays a central role in exerting IL-4-mediated biological responses.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN; HYOGO MED UNIV, DEPT IMMUNOL & MED ZOOL, NISHINOMIYA, HYOGO 663, JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH, RES INST, IZUMI, OSAKA 59002, JAPAN	Osaka University; Osaka University; Hyogo College of Medicine; University of Hyogo			Takeda, Kiyoshi/C-9331-2009; Akira, Shizuo/C-3134-2009; Tanaka, Takashi/O-8254-2015; Kishimoto, Tadamitsu/C-8470-2009					CONRAD DH, 1988, J IMMUNOL, V141, P1091; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HULI J, 1987, J EXP MED, V165, P157, DOI 10.1084/jem.165.1.157; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; PAUL WE, 1991, BLOOD, V77, P1859; PEMIS A, 1995, P NATL ACAD SCI USA, V92, P7971; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; RABIN EM, 1986, J EXP MED, V164, P517, DOI 10.1084/jem.164.2.517; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROTHMAN P, 1993, RES IMMUNOL, V144, P579, DOI 10.1016/S0923-2494(05)80006-9; STREET NE, 1990, J IMMUNOL, V144, P1629; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	28	1234	1265	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1996	380	6575					627	630		10.1038/380627a0	http://dx.doi.org/10.1038/380627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602263				2022-12-01	WOS:A1996UF74100046
J	Sadato, N; PascualLeone, A; Grafman, J; Ibanez, V; Deiber, MP; Dold, G; Hallett, M				Sadato, N; PascualLeone, A; Grafman, J; Ibanez, V; Deiber, MP; Dold, G; Hallett, M			Activation of the primary visual cortex by Braille reading in blind subjects	NATURE			English	Article							MONKEY; MACAQUE	PRIMARY visual cortex receives visual input from the eyes through the lateral geniculate nuclei, but is not known to receive input from other sensory modalities'. Its level of activity, both at rest and during auditory or tactile tasks, is higher in blind subjects than in normal controls(2), suggesting that it can subserve nonvisual functions; however, a direct effect of non-visual tasks on activation has not been demonstrated(2-4). To determine whether the visual cortex receives input from the somatosensory system(5-8), we used positron emission tomography (PET) to measure activation during tactile discrimination tasks in normal subjects and in Braille readers blinded in early life. Blind subjects showed activation of primary and secondary visual cortical areas during tactile tasks, whereas normal controls showed deactivation, A simple tactile stimulus that did not require discrimination produced no activation of visual areas in either group. Thus, in blind subjects, cortical areas normally reserved for vision may be activated by other sensory modalities.	NINCDS, HUMAN MOTOR CONTROL SECT, NIH, BETHESDA, MD 20892 USA; NINCDS, COGNIT NEUROSCI SECT, MED NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; FUKUI MED SCH, BIOMED IMAGING RES CTR, MATUOKA, FUKUI 91011, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Fukui			Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011; Deiber, Marie-Pierre/M-5949-2014; Deiber, Marie-Pierre/ABF-9026-2020	Pascual-Leone, Alvaro/0000-0001-8975-0382; Sadato, Norihiro/0000-0002-9786-3907; Grafman, Jordan H./0000-0001-8645-4457; Deiber, Marie-Pierre/0000-0002-4984-7363				BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Heller Morton, 1991, PSYCHOL TOUCH; Hollins M., 1989, UNDERSTANDING BLINDN; HYVARINEN J, 1981, NEUROSCI LETT, V26, P239, DOI 10.1016/0304-3940(81)90139-7; Kennedy John., 1993, DRAWING BLIND PICTUR; LEBIHAN D, 1993, P NATL ACAD SCI USA, V90, P11802, DOI 10.1073/pnas.90.24.11802; MEYER E, 1991, ANN NEUROL, V29, P440, DOI 10.1002/ana.410290418; Millar Susanna, 1994, UNDERSTANDING REPRES, DOI 10.1093/acprof:oso/9780198521426.001.0001; Morgan MichaelJ., 1977, MOLYNEUXS QUESTION V; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; ROLAND PE, 1989, EUR J NEUROSCI, V1, P3, DOI 10.1111/j.1460-9568.1989.tb00769.x; SADATO N, 1995, NEUROLOGY, V45, pA426; SHIPP S, 1989, EUR J NEUROSCI, V1, P309, DOI 10.1111/j.1460-9568.1989.tb00798.x; Talairach J., 1988, APPROACH CEREBRAL IM; UHL F, 1994, ELECTROEN CLIN NEURO, V91, P249, DOI 10.1016/0013-4694(94)90188-0; UHL F, 1991, NEUROSCI LETT, V124, P256, DOI 10.1016/0304-3940(91)90107-5; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	24	790	801	0	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					526	528		10.1038/380526a0	http://dx.doi.org/10.1038/380526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606771				2022-12-01	WOS:A1996UE66300049
J	Werler, MM; Louik, C; Shapiro, S; Mitchell, AA				Werler, MM; Louik, C; Shapiro, S; Mitchell, AA			Prepregnant weight in relation to risk of neural tube defects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the relation between prepregnant weight and the risk of neural tube defects (NTDs). Design.-Data were collected from 1988 to 1994 in a case-control surveillance program of birth defects. Setting.-Study subjects were ascertained at tertiary care centers and birth hospitals in the greater metropolitan areas of Boston, Mass, and Philadelphia, Pa, and in southeastern Ontario. Participants.-Cases were 604 fetuses or infants with an NTD identified within 6 months of delivery. Controls were 1658 fetuses or infants with other major malformations identified within 6 months of delivery. For 1992 to 1994, there were 93 control infants without major malformations. Main Outcome Measure.-Relative risk of NTDs in infants or fetuses for different maternal weights. Results.-Relative to women who weighed 50 to 59 kg, risk of NTDs increased from 1.9 (95% confidence interval [CI], 1.2 to 2.9) for women weighing 80 to 89 kg to 4.0 (95% CI, 1.6 to 9.9) for women weighing 110 kg or more. When women were classified according to daily intake above or below the recommended level of 400 mu g of folate, approximate threefold increases in risk were estimated for the heaviest weights in both groups. Intakes of 400 mu g of folate or more reduced risk of NTDs by 40% among women weighing less than 70 kg, but no risk reduction was observed among heavier women. Conclusion.-The risk of NTDs increased with increasing prepregnant weight, independent of the effects of folate intake.			Werler, MM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084	NICHD NIH HHS [R01-HD27697] Funding Source: Medline; PHS HHS [MCJ-2505667] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMITAGE P, 1971, STAT ASPECTS MED RES; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; GOLDENBERG RL, 1995, JAMA-J AM MED ASSOC, V274, P463, DOI 10.1001/jama.274.6.463; HADDOW JE, 1995, AM J OBSTET GYNECOL, V172, P245, DOI 10.1016/0002-9378(95)90139-6; HADDOW JE, 1981, CLIN CHEM, V27, P133; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEMIRE RJ, 1988, JAMA-J AM MED ASSOC, V259, P558, DOI 10.1001/jama.259.4.558; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; *NAT AC SCI, 1990, NUTR PREGN, P5; Shaw G. M., 1995, Teratology, V51, P196; SHAW GM, 1995, LANCET, V345, P393; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; WATKINS M, 1994, AM J EPIDEMIOL, V139, pS11; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WOLFE HM, 1990, OBSTET GYNECOL, V76, P339; 1992, MMWR-MORBID MORTAL W, V41, P1	17	249	250	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1089	1092		10.1001/jama.275.14.1089	http://dx.doi.org/10.1001/jama.275.14.1089			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601927				2022-12-01	WOS:A1996UD02700024
J	Pennacchio, LA; Lehesjoki, AE; Stone, NE; Willour, VL; Virtaneva, K; Miao, JM; DAmato, E; Ramirez, L; Faham, M; Koskiniemi, M; Warrington, JA; Norio, R; delaChapelle, A; Cox, DR; Myers, RM				Pennacchio, LA; Lehesjoki, AE; Stone, NE; Willour, VL; Virtaneva, K; Miao, JM; DAmato, E; Ramirez, L; Faham, M; Koskiniemi, M; Warrington, JA; Norio, R; delaChapelle, A; Cox, DR; Myers, RM			Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)	SCIENCE			English	Article							FAMILIAL NEONATAL CONVULSIONS; CYSTEINE-PROTEINASE-INHIBITOR; CHROMOSOME-20; LOCALIZATION; EXPRESSION; LINKAGE	Progressive myoclonus epilepsy of the Unverricht-Lundborg type (EPM1) is an autosomal recessive inherited form of epilepsy, previously linked to human chromosome 21q22.3. The gene encoding cystatin B was shown to be localized to this region, and levels of messenger RNA encoded by this gene were found to be decreased in cells from affected individuals. Two mutations, a 3' splice site mutation and a stop codon mutation, were identified in the gene encoding cystatin B in EPM1 patients but were not present in unaffected individuals. These results provide evidence that mutations in the gene encoding cystatin B are responsible for the primary defect in patients with EPM1.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI,FINLAND; FINNISH POPULAT & FAMILY WELF FEDERAT,DEPT MED GENET,SF-00100 HELSINKI,FINLAND	Stanford University; Stanford University; University of Helsinki; University of Helsinki; Family Federation of Finland				Pennacchio, Len/0000-0002-8748-3732; Willour, Virginia/0000-0002-6639-487X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024610] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017502] Funding Source: NIH RePORTER; NHGRI NIH HHS [P50 HG-00206] Funding Source: Medline; NICHD NIH HHS [HD-24610] Funding Source: Medline; NIGMS NIH HHS [IF32GM17502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON M, 1989, HUM GENET, V82, P223, DOI 10.1007/BF00291159; BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; ELDRIDGE R, 1983, LANCET, V2, P838, DOI 10.1016/s0140-6736(83)90749-3; FAHAM M, UNPUB; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GREENBERG DA, 1988, AM J MED GENET, V31, P185, DOI 10.1002/ajmg.1320310125; JARVINEN M, 1982, BIOCHIM BIOPHYS ACTA, V708, P210, DOI 10.1016/0167-4838(82)90222-9; JERALA R, 1988, FEBS LETT, V239, P41, DOI 10.1016/0014-5793(88)80541-6; JOU YS, 1994, GENOMICS, V24, P410, DOI 10.1006/geno.1994.1643; KOSKINIEMI M, 1974, EPILEPSIA, V15, P537, DOI 10.1111/j.1528-1157.1974.tb04027.x; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P333; KOSKINIEMI M, 1974, ACTA NEUROL SCAND, V50, P307; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; LIU AW, 1995, AM J HUM GENET, V57, P68; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUNDBORG H, 1903, PROGR MYOCLONUS EPIL, P1; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NORIO R, 1979, CLIN GENET, V15, P382; OTTMAN R, 1995, NAT GENET, V10, P56, DOI 10.1038/ng0595-56; PENNACCHIO LA, UNPUB; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SERRATOSA JM, 1995, HUM MOL GENET, V4, P1657; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Stone NE, 1996, GENOME RES, V6, P218, DOI 10.1101/gr.6.3.218; TAHVANAINEN E, 1994, P NATL ACAD SCI USA, V91, P7267, DOI 10.1073/pnas.91.15.7267; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; UNVERRICHT H, 1891, MYOCLONIE, P1; Unverricht H., 1891, DTSCH Z NERVENHEILKD, V7, P32, DOI [10.1007/BF01833165, DOI 10.1007/BF01833165]; VIRTANEVA K, UNPUB	35	459	472	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1731	1734		10.1126/science.271.5256.1731	http://dx.doi.org/10.1126/science.271.5256.1731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596935				2022-12-01	WOS:A1996UB15100048
J	Bach, JF; Chalons, S; Forier, E; Elana, G; Jouanelle, J; Kayemba, S; Delbois, D; Mosser, A; SaintAime, C; Berchel, C				Bach, JF; Chalons, S; Forier, E; Elana, G; Jouanelle, J; Kayemba, S; Delbois, D; Mosser, A; SaintAime, C; Berchel, C			10-year educational programme aimed at rheumatic fever in two French Caribbean islands	LANCET			English	Article							UNITED-STATES; RESURGENCE; DISEASE	Background In less developed countries, rheumatic fever still occurs. We started a long-term educational programme in two French Caribbean islands that was directed at the public and at health-care workers to see whether we could reduce the incidence of rheumatic fever. Methods Our 10-year programme started in 1981 in Martinique and Guadeloupe, and was based in the community and in clinics and hospitals. The programme established a registry of all cases of primary and secondary rheumatic fever (diagnosed by Jones' modified criteria), with systematic hospital admission of children. We graded carditis as severe, mild, or subclinical, and acute glomerulonephritis was defined by oedema, proteinuria, and haematuria for less than 3 months. The educational part of the programme targeted the public and healthcare workers, including doctors, with written information distributed in schools or via radio and television broadcasts or videotapes. For the public, the benign clinical presentation of the initial streptococcal infection was contrasted with the severity of later heart disease. Findings The first months of the programme led to a 10-20% increase in the number of rheumatic fever cases admitted to hospital, because of the renewed attention paid to the disease. Therefore we took 1982 as the baseline year. In 1982-83 the incidence of rheumatic fever was 19.6 per 100 000 inhabitants aged under 20 in Martinique, and 17.4 per 100 000 in Guadeloupe. In 100 Martinique children and 97 Guadeloupe children in 1982-83, 40 and 71% had carditis, respectively (severe in 10 and 32%). Rheumatic fever was preceded by symptomatic sore throat in 52 and 41% of cases, respectively. The disease was not seen in children with active streptococcal cutaneous infections. Disease frequency was highest in the poorest areas and families, a finding that persisted over time. The programme was associated with a progressive decline in the frequency of rheumatic fever: final reduction of 78% in Martinique and 74% in Guadeloupe. The frequency of carditis also fell. Apart from two outbreaks in one hospital, the frequency of acute glomerulonephritis also declined; 31% of cases had had sore throat, while 56% had shin infections, The cost of the programme during the 4 most intensive years was FFr 250 000 (US$ 44 500) in each island. The cost of childhood rheumatic fever, excluding late sequelae, was initially (in 1982) about FFr 7.8 million (US$ 1 426 000). The cost fell to an average of FFr 550 000 (US$ 100 000) per year in 1991-92. Interpretation A rapid decline in rheumatic fever incidence was achieved at modest cost. Such a programme needs to be continued because of the risk of disease resurgence.	DDASS, FORT DE FRANCE, Martinique, FRANCE; DASD, PMI, JARRYBALE MANHAULT, Guadeloupe, FRANCE; HOP PIERRE ZOBDA QUITMAN, MICROBIOL LAB, FORT DE FRANCE, Martinique, FRANCE; HOP LOUIS DOMMERGUE, LA TRINITE, Martinique, FRANCE; HOP REDOURTE, FORT DE FRANCE, Martinique, FRANCE; CHU POINTE PITRE, SERV PEDIAT, POINTE A PITRE, Guadeloupe, FRANCE	CHU Martinique; CHU Guadeloupe	Bach, JF (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE.		KAYEMBA-KAY'S, SIMON/F-3503-2012; KAYEMBA-KAY'S, KABANGU/AAE-4573-2021	KAYEMBA-KAY'S, SIMON/0000-0002-5239-844X; 				AGIS F, 1985, THESIS U PARIS 5; AYOUB EM, 1992, POSTGRAD MED, V92, P133; Canterin A A, 1978, Arch Sci Med (Torino), V135, P623; CARDONA PN, 1988, REV CUBANA PEDIATR, V60, P32; DEWALS P, 1983, MED MALADIES INFECT, V13, P420, DOI 10.1016/S0399-077X(83)80022-5; DODU S R A, 1989, World Health Forum, V10, P203; EISENBERG MJ, 1993, EUR HEART J, V14, P122, DOI 10.1093/eurheartj/14.1.122; Gharagozloo R A, 1976, Acta Trop, V33, P215; GORDIS L, 1969, J CHRON DIS, V21, P655, DOI 10.1016/0021-9681(69)90037-X; KASSEM AS, 1992, PEDIATR ANN, V21, P835, DOI 10.3928/0090-4481-19921201-10; MARKOWITZ M, 1991, PEDIATR INFECT DIS J, V10, pS11, DOI 10.1097/00006454-199110001-00003; MARKOWITZ M, 1980, STREPTOCOCCAL DIS IM, P741; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MONPLAISIR N, 1986, TISSUE ANTIGENS, V28, P209, DOI 10.1111/j.1399-0039.1986.tb00484.x; PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0; POONKING T, 1980, STREPTOCOCCAL DISEAS, P523; QUINN RW, 1978, SOUTHERN MED J, V71, P242, DOI 10.1097/00007611-197803000-00006; QUINN RW, 1980, SOUTHERN MED J, V73, P288, DOI 10.1097/00007611-198003000-00007; ROTTA J, 1980, STREPTOCOCCAL DIS IM, P751; RUTSTEIN DD, 1956, CIRCULATION, V13, P617, DOI 10.1161/01.CIR.13.4.617; Svartman M, 1980, STREPTOCOCCAL DIS IM, P669; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; VLAJINAC H, 1989, MICROBIOL IMMUNOL, V3, P471	23	85	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					644	648		10.1016/S0140-6736(96)91202-7	http://dx.doi.org/10.1016/S0140-6736(96)91202-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596378				2022-12-01	WOS:A1996TZ28500010
J	Blenkinsopp, A; Bradley, C				Blenkinsopp, A; Bradley, C			Over the counter drugs: Patients, society, and the increase in self medication	BRITISH MEDICAL JOURNAL			English	Article								Self medication with over the counter medicines has long been a feature of the lay health system. With the reclassification of certain drugs, the public can buy preparations that were previously available only on prescription. Sales of over the counter medicines are now equivalent to a third of the NHS drugs bill; governments throughout the world see self medication as a way of shifting some of the cost of health care onto consumers. The trend towards increased self care and with it the increasing empowerment of patients has many potential benefits; collaboration between doctors and pharmacists will be critical.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Blenkinsopp, A (corresponding author), KEELE UNIV,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				ANDERSEN M, 1994, BRIT MED J, V309, P494; BLENKINSOPP A, 1991, BR J GEN PRACT, V41, P16; BRADLEY B, 1994, J CLIN PHARM THER, V19, P7, DOI 10.1111/j.1365-2710.1994.tb00802.x; BRANSTAD JO, 1994, SOC SCI MED, V39, P207, DOI 10.1016/0277-9536(94)90329-8; Emmerton L, 1994, INT J PHARM PRACT, V3, P27; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HANNAY DR, 1989, SYMPTOM ICEBERG STUD; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; LAWSON D, 1995, OTC DIRECTORY 1995 9; MORLEY A, 1983, PHARM J, V231, P387; *NUFF FDN, 1986, PHARM COMM INQ APP N; PLATTEN A, 1994, MODEL STANDARDS SELF, V9; *PROPR ASS GREAT B, 1995, ANN REP; *PROPR ASS GREAT B, 1987, EVER HLTH CAR CONS S; *PROPR ASS GREAT B, 1995, OTC DIR 1995 96; RAITH H, 1992, SCRIP MAGAZINE   MAR, P20; *ROYAL PHARM SOC G, 1995, MED ETH PRACT; SMITH FJ., 1993, INT J PHARM PRACT, V2, P86; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; WHITAKER MJ, 1994, PHARM J, V253, P867; Wilson M., 1992, INT J PHARM PRACT, V1, P152; 1994, LANCET, V343, P1374	23	136	142	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					629	632						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595343				2022-12-01	WOS:A1996TZ84000034
J	Frankel, DH				Frankel, DH			Skin cancer	LANCET			English	Editorial Material																		HEANEY S, 1969, DOOR DARK, P47	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					634	634		10.1016/S0140-6736(96)91199-X	http://dx.doi.org/10.1016/S0140-6736(96)91199-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596375				2022-12-01	WOS:A1996TZ28500007
J	Ramirez, VD				Ramirez, VD			How do steroids act?	LANCET			English	Editorial Material							RAT				Ramirez, VD (corresponding author), UNIV ILLINOIS,DEPT MOLEC & INTEGRAT PHYSIOL,URBANA,IL 61801, USA.							BLACKMORE PF, 1993, CELL SIGNAL, V5, P531, DOI 10.1016/0898-6568(93)90048-Q; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; KOENIG H, 1989, CIRC RES, V64, P415, DOI 10.1161/01.RES.64.3.415; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; RAMIREZ VD, IN PRESS FRONTIERS N; RAMIREZ VD, IN PRESS CELL MOL NE; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; WEHLING M, 1995, STEROIDS, V60, P153, DOI 10.1016/0039-128X(94)00027-A; WEHLING M, 1995, GENOMIC NON GENOMIC	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					630	631		10.1016/S0140-6736(96)91195-2	http://dx.doi.org/10.1016/S0140-6736(96)91195-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596371				2022-12-01	WOS:A1996TZ28500003
J	Halfen, JA; Mahapatra, S; Wilkinson, EC; Kaderli, S; Young, VG; Que, L; Zuberbuhler, AD; Tolman, WB				Halfen, JA; Mahapatra, S; Wilkinson, EC; Kaderli, S; Young, VG; Que, L; Zuberbuhler, AD; Tolman, WB			Reversible cleavage and formation of the dioxygen O-O band within a dicopper complex	SCIENCE			English	Article							MONOOXYGENASE CATALYTIC CYCLE; WATER-OXIDATION; RIBONUCLEOTIDE REDUCTASE; COPPER(II) COMPLEXES; OXYGEN EVOLUTION; ACTIVE-SITES; METHANE; MODEL; HEMOCYANIN; REACTIVITY	A key step in dioxygen evolution during photosynthesis is the oxidative generation of the O-O bond from water by a manganese cluster consisting of M(2)(mu-O)(2) units (where M is manganese). The reverse reaction, reductive cleavage of the dioxygen O-O bond, is performed at a variety of dicopper and di-iron active sites in enzymes that catalyze important organic oxidations. Both processes can be envisioned to involve the interconversion of dimetal-dioxygen adducts, M(2)(O-2), and isomers having M(2)(mu-O)(2) cores. The viability of this notion has been demonstrated by the identification of an equilibrium between synthetic complexes having [Cu-2(mu-eta(2):eta(2)-O-2)](2+) and [Cu-2(mu-O)(2)](2+) cores through kinetic, spectroscopic, and crystallographic studies.	UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; UNIV BASEL, INST ORGAN CHEM, CH-4056 BASEL, SWITZERLAND	University of Minnesota System; University of Minnesota Twin Cities; University of Basel					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033162, R01GM047365, R01GM033162, R37GM047365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33162, GM47365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; de Montellano P. R. Ortiz, 1986, CYTOCHROME P 450 STR; DONG YH, 1995, J AM CHEM SOC, V117, P2778, DOI 10.1021/ja00115a013; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; GESELOWITZ D, 1990, INORG CHEM, V29, P3894, DOI 10.1021/ic00344a048; GILBERT JA, 1985, J AM CHEM SOC, V107, P3855, DOI 10.1021/ja00299a017; Hodgson DJ, 1975, PROG INORG CHEM, V19, P173; HOUSER RP, 1995, J AM CHEM SOC, V117, P10745, DOI 10.1021/ja00148a018; KARLIN KD, 1993, J AM CHEM SOC, V115, P9506, DOI 10.1021/ja00074a015; KARLIN KD, 1988, J AM CHEM SOC, V110, P1196, DOI 10.1021/ja00212a031; KARLIN KD, 1991, J AM CHEM SOC, V113, P5868, DOI 10.1021/ja00015a054; KITAJIMA N, 1992, J AM CHEM SOC, V114, P1277, DOI 10.1021/ja00030a025; LEE SC, 1993, INORG CHEM, V32, P4745, DOI 10.1021/ic00074a016; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIU KE, 1994, J AM CHEM SOC, V116, P7465, DOI 10.1021/ja00095a083; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MAHAPATRA S, 1995, J AM CHEM SOC, V117, P8865, DOI 10.1021/ja00139a026; MAHAPATRA S, 1994, J AM CHEM SOC, V116, P9785, DOI 10.1021/ja00100a068; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PECORARO VL, 1994, CHEM REV, V94, P807, DOI 10.1021/cr00027a012; PROSERPIO DM, 1992, J AM CHEM SOC, V114, P4374, DOI 10.1021/ja00037a052; QUE L, 1990, PROG INORG CHEM, V38, P97; RAMARAJ R, 1986, ANGEW CHEM INT EDIT, V25, P825, DOI 10.1002/anie.198608252; REINAUD OM, 1994, J AM CHEM SOC, V116, P6979, DOI 10.1021/ja00094a080; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; SAUER K, 1992, MANGANESE REDOX ENZY, P141; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1994, CHEM REV, V94, P827, DOI 10.1021/cr00027a013; WATKINSON M, 1994, J CHEM SOC CHEM COMM, P2141, DOI 10.1039/c39940002141; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; ZANG Y, 1995, J AM CHEM SOC, V117, P1169, DOI 10.1021/ja00108a050	37	462	463	1	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1996	271	5254					1397	1400		10.1126/science.271.5254.1397	http://dx.doi.org/10.1126/science.271.5254.1397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596910				2022-12-01	WOS:A1996TY96100040
J	Hensel, WA				Hensel, WA			My living will	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					588	588		10.1001/jama.275.8.588	http://dx.doi.org/10.1001/jama.275.8.588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594232				2022-12-01	WOS:A1996TW62700007
J	Smeal, T; Claus, J; Kennedy, B; Cole, F; Guarente, L				Smeal, T; Claus, J; Kennedy, B; Cole, F; Guarente, L			Loss of transcriptional silencing causes sterility in old mother cells of S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERE LENGTH; HUMAN FIBROBLASTS; DNA-REPLICATION; LIFE-SPAN; GENE; ACTIVATION; AGE; RECOMBINATION; INHERITANCE	We show that sterility is an aging-specific phenotype in S. cerevisiae and, by genetic and physical means, demonstrate that this phenotype results from a loss of silencing in most old cells by the SIR complex at the HM loci. This loss of silencing is specific because transcription of genes, such as MEI4 and DCM1, normally induced by sporulation, is not observed, while transcription of HMRa is observed. These findings pinpoint the molecular cause of an aging-specific phenotype in yeast. Further, they provide direct evidence for a breakdown of silencing in old cells, as predicted from earlier findings that SIR4 is a determinant of life span in this organism.			Smeal, T (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Cole, Francesca/0000-0001-6391-2363	NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Ballou CE, 1982, MOL BIOL YEAST SACCH; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BERTRAND H, 1985, CELL, V41, P877, DOI 10.1016/S0092-8674(85)80068-4; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; CABIB E, 1971, J BIOL CHEM, V246, P152; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EGLIMEZ NK, 1990, J GERONTOL, V45, pB9; Finch CE., 1990, LONGEVITY SENESCENCE; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GILLEY D, 1994, P NATL ACAD SCI USA, V91, P1955, DOI 10.1073/pnas.91.5.1955; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JAZWINSKI SM, 1989, EXP GERONTOL, V24, P423; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOLNAR JA, 1986, BIOCHEM J, V240, P431, DOI 10.1042/bj2400431; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; RINE J, 1987, GENETICS, V116, P9; SCHEKMAN R, 1982, MOL BIOL YEAST SACCH; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WOLDRINGH CL, 1995, YEAST, V11, P361, DOI 10.1002/yea.320110409; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	45	211	219	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					633	642		10.1016/S0092-8674(00)81038-7	http://dx.doi.org/10.1016/S0092-8674(00)81038-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598049	Bronze			2022-12-01	WOS:A1996TX17600015
J	Gems, D; Riddle, DL				Gems, D; Riddle, DL			Longevity in Caenorhabditis elegans reduced by mating but not gamete production	NATURE			English	Article							FERTILIZATION-DEFECTIVE MUTANTS; FEMALE DROSOPHILA-MELANOGASTER; LIFE-SPAN; WILD-TYPE; SPERM; EVOLUTION; MALES; GENE	THEORIES Of life-history evolution propose that trade-offs occur between fitness components, including longevity and maximal reproduction(1-3). In Drosophila, female lifespan is shortened by increased egg production(4), receipt of male accessory fluid(5) and courting(6), Male lifespan is also reduced by courting and/or mating(7). Here we show that in the nematode Caenorhabditis elegans, mating with males reduces the lifespan of hermaphrodites by a mechanism independent of egg production or receipt of sperm, Conversely, males appear unaffected by mating, Thus, in C. elegans there is no apparent trade-off between longevity and increased egg or sperm production, but there is a substantial cost to hermaphrodites associated with copulation.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Gems, D (corresponding author), UNIV MISSOURI, PROGRAM MOLEC BIOL, COLUMBIA, MO 65211 USA.			Gems, David/0000-0002-6653-4676				ARGON Y, 1980, GENETICS, V96, P413; BRENNER S, 1974, GENETICS, V77, P71; CHAPMAN T, 1992, J INSECT PHYSIOL, V38, P223, DOI 10.1016/0022-1910(92)90070-T; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; FRIEDMAN DB, 1988, GENETICS, V118, P75; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HODGKIN J, 1983, GENETICS, V103, P43; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimble J, 1988, NEMATODE CAENORHABDI, P191; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; LHEMAULT SW, 1988, GENETICS, V120, P435; PARTRIDGE L, 1988, SCIENCE, V241, P1449, DOI 10.1126/science.241.4872.1449; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; PARTRIDGE L, 1981, NATURE, V294, P580, DOI 10.1038/294580a0; SCHEDL T, 1988, GENETICS, V119, P43; SCOTT D, 1987, ANIM BEHAV, V35, P142, DOI 10.1016/S0003-3472(87)80219-1; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WARD S, 1978, GENETICS, V88, P285; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; WILKINSON L, 1989, SYSTAT SYSTEMS STATI; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	24	152	158	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					723	725		10.1038/379723a0	http://dx.doi.org/10.1038/379723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602217				2022-12-01	WOS:A1996TW56700051
J	Snowdon, DA; Kemper, SJ; Mortimer, JA; Greiner, LH; Wekstein, DR; Markesbery, WR				Snowdon, DA; Kemper, SJ; Mortimer, JA; Greiner, LH; Wekstein, DR; Markesbery, WR			Linguistic ability in early life and cognitive function and Alzheimer's disease in late life - Findings from the Nun Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; ADULTS; SENTENCES; AGE; POPULATION; PREVALENCE; DEMENTIA; SPAN	Objective.-To determine if linguistic ability in early life is associated with cognitive function and Alzheimer's disease in late life. Design.- Two measures of linguistic ability in early life, idea density and grammatical complexity, were derived from autobiographies written at a mean age of 22 yearr. Approximately 58 years later, the women who wrote these autobiographies participated in an assessment of cognitive function, and those who subsequently died were evaluated neuropathologically, Setting.-Convents in the United States participating in the Nun Study; primarily convents in the Milwaukee, Wis, area. Participants.-Cognitive function was investigated in 93 participants who were aged 75 to 95 years at the time of their assessments, and Alzheimer's disease was investigated in the 14 participants who died at 79 to 96 years of age. Main Outcome Measures.-Seven neuropsychological tests and neuropathologically confirmed Alzheimer's disease. Results.-Low idea density and low grammatical complexity in autobiographies written in early life were associated with low cognitive test scores in late life, Low idea density in early life had stronger and more consistent associations with poor cognitive function than did low grammatical complexity. Among the 14 sisters who died, neuropathologically confirmed Alzheimer's disease was present in all of those with low idea density in early life and in none of those with high idea density. Conclusions.-Low linguistic ability in early life was a strong predictor of poor cognitive function and Alzheimer's disease in late life.	UNIV KENTUCKY, DEPT PREVENT MED, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PHYSIOL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT NEUROL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PATHOL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KANSAS, DEPT PSYCHOL, LAWRENCE, KS USA; UNIV MINNESOTA, VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT EPIDEMIOL, MINNEAPOLIS, MN 55455 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kansas; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Snowdon, DA (corresponding author), UNIV KENTUCKY, SANDERS BROWN CTR AGING, COLL MED, 101 SANDERS BROWN BLDG, LEXINGTON, KY 40536 USA.				NATIONAL INSTITUTE ON AGING [K04AG000443, R01AG009862, K04AG000553] Funding Source: NIH RePORTER; NIA NIH HHS [K04AG00553, R01AG09862, K04AG00443] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; BOURAS C, 1994, CEREB CORTEX, V4, P138, DOI 10.1093/cercor/4.2.138; CHEUNG H, 1992, APPL PSYCHOLINGUIST, V13, P53, DOI 10.1017/S0142716400005427; CROPLEY AJ, 1977, LIFELONG ED PSYCHOL; DARCY C, 1994, NEUROBIOL AGING, V15, pS40; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; GATZ M, 1994, GERONTOLOGIST, V34, P251, DOI 10.1093/geront/34.2.251; KEMPER S, 1993, ARCH NEUROL-CHICAGO, V50, P81, DOI 10.1001/archneur.1993.00540010075021; KEMPER S, 1989, APPL PSYCHOLINGUIST, V10, P49, DOI 10.1017/S0142716400008419; KEMPER S, 1990, DISCOURSE PROCESS, V13, P207, DOI 10.1080/01638539009544754; Kemper S., 1990, EUR J COGN PSYCHOL, V2, P205, DOI [10.1080/09541449008406205, DOI 10.1080/09541449008406205, https://doi.org/10.1080/09541449008406205]; Kemper S., 1992, EVERYDAY MEMORY AGIN, P138, DOI [10.1007/978-1-4613-9151-7_9, DOI 10.1007/978-1-4613-9151-7_9]; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KINTSCH W, 1973, COGNITIVE PSYCHOL, V5, P257, DOI 10.1016/0010-0285(73)90036-4; KURIANSKY J, 1976, INT J AGING HUM DEV, V7, P343, DOI 10.2190/X45L-TWW7-WXXY-KA6K; LAZAR I, 1982, LASTING EFFECTS EARL; LYONS K, 1993, AGING COGNITION, V50, P81; MCKEOWN MG, 1987, NATURE VOCABULARY AC; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mortimer J. A., 1988, ETIOLOGY DEMENTIA AL, P39; MORTIMER JA, 1993, NEUROLOGY, V43, pS39; NAGY Z, 1995, DEMENTIA, V6, P21, DOI 10.1159/000106918; OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P476; ROSENBERG S, 1987, APPL PSYCHOLINGUIST, V8, P19, DOI 10.1017/S0142716400000047; ROTH M, 1986, BRIT MED BULL, V42, P42, DOI 10.1093/oxfordjournals.bmb.a072097; Snedecor G.W., 1980, STAT METHODS, V7; SNOWDON DA, 1989, AM J EPIDEMIOL, V130, P999, DOI 10.1093/oxfordjournals.aje.a115433; SNOWDON DA, 1989, J CLIN EPIDEMIOL, V42, P1055, DOI 10.1016/0895-4356(89)90047-4; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; STERNBERG RJ, 1983, AM PSYCHOL, V38, P878, DOI 10.1037/0003-066X.38.8.878; Turner A., 1977, CONSTRUCTION USE PRO; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1985, SAS USERS GUIDE STAT	37	703	714	3	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					528	532		10.1001/jama.275.7.528	http://dx.doi.org/10.1001/jama.275.7.528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV569	8606473				2022-12-01	WOS:A1996TV56900029
J	Warriner, HE; Idziak, SHJ; Slack, NL; Davidson, P; Safinya, CR				Warriner, HE; Idziak, SHJ; Slack, NL; Davidson, P; Safinya, CR			Lamellar biogels: Fluid-membrane-based hydrogels containing polymer lipids	SCIENCE			English	Article							SYNCHROTRON X-RAY; DIBLOCK COPOLYMERS; MULTIMEMBRANE; PHASES; SEGREGATION; CURVATURE; RIGIDITY; VESICLES; SYSTEM; GELS	A class of lamellar biological hydrogels comprised of fluid membranes of lipids and surfactants with small amounts of low molecular weight poly(ethylene glycol)-derived polymer lipids (PEG-lipids) were studied by x-ray diffraction, polarized light microscopy, and rheometry, In contrast to isotropic hydrogels of polymer networks, these membrane-based birefringent liquid crystalline biogels, labeled L(alpha,g), form the gel phase when water is added to the liquid-like lamellar L(alpha) phase, which reenters a liquid-like mixed phase upon further dilution. Furthermore, gels with larger water content require less PEG-lipid to remain stable, Although concentrated (similar to 50 weight percent) mixtures of free PEG (molecular weight, 5000) and water do not gel, gelation does occur in mixtures containing as little as 0.5 weight percent PEG-lipid, A defining signature of the L(alpha,g) regime as it sets in from the fluid lamellar L(alpha) phase is the proliferation of layer-dislocalion-type defects, which are stabilized by the segregation of PEG-lipids to the defect regions of high membrane curvature that connect the membranes.	UNIV CALIF SANTA BARBARA,DEPT MAT,MAT RES LAB,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,INTERDEPT BIOCHEM,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,PROGRAM MOLEC BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Davidson, Patrick/Q-6691-2019; Davidson, Patrick/F-7874-2017	Davidson, Patrick/0000-0002-1363-6062; Davidson, Patrick/0000-0002-1363-6062				ALEXANDER S, 1977, J PHYS-PARIS, V38, P977, DOI 10.1051/jphys:01977003808097700; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; ASHER SA, 1979, BIOPHYS J, V27, P393, DOI 10.1016/S0006-3495(79)85225-X; Bailey F.E., 1976, POLYETHYLENE OXIDE; BENSHAUI A, 1994, MICELLES MEMBRANES M; BOLTENHAGEN P, 1992, PHYS REV A, V46, pR1743, DOI 10.1103/PhysRevA.46.R1743; CAO BH, 1994, FARADAY DISCUSS, V98, P245, DOI 10.1039/fd9949800245; DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; DEGENNES PG, 1976, J PHYS LES ULIS, V37, P1443; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HELFRICH W, 1985, CHEM SCR, V25, P2; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; KAWAKATSU T, 1993, J PHYS II, V3, P971, DOI 10.1051/jp2:1993177; KAWASAKI K, 1990, PHYS REV A, V42, P3664, DOI 10.1103/PhysRevA.42.3664; KEMWORTHY AK, 1995, BIOPHYS J, V68, P1921; KUHL TL, BIOPHYS J, V6619, P94; Lasic D.D., 1995, STEALTH LIPOSOMES; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LASIC DD, 1993, LIPOSOMES PHYSICS AP; MACKINTOSH FC, COMMUNICATION; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MATSUO ES, 1992, NATURE, V358, P482, DOI 10.1038/358482a0; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y; OSADA Y, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0593-82; Osada Y., 1991, POLYM GELS FUNDAMENT; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; PINCUS P, UNPUB; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P273, DOI 10.1051/jphys:01984004502027300; SEIFERT U, 1993, PHYS REV LETT, V70, P1335, DOI 10.1103/PhysRevLett.70.1335; Small D.M., 1986, HDB LIPID RES, V4; SMITH GS, 1990, J CHEM PHYS, V92, P4519, DOI 10.1063/1.457764; SMITH GS, 1988, PHYS REV LETT, V60, P813, DOI 10.1103/PhysRevLett.60.813; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WANG ZG, 1990, J PHYS-PARIS, V51, P185, DOI 10.1051/jphys:01990005102018500; WARRINER HE, UNPUB; [No title captured]	44	160	169	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					969	973		10.1126/science.271.5251.969	http://dx.doi.org/10.1126/science.271.5251.969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584932				2022-12-01	WOS:A1996TV70400043
J	Zhao, FZ; Murray, C; Spinaci, S; Styblo, K; Broekmans, J; Zou, JQ; Dai, YS; Chi, YH; Du, X; Cao, JP; Chen, YL; Li, LM; Li, NW; Liu, CJ; Liu, HQ; Lu, Q; Tang, DR; Wang, PF; Wang, ZH; Wu, PE; Zhang, FD; Zhang, FS; Zhu, GL				Zhao, FZ; Murray, C; Spinaci, S; Styblo, K; Broekmans, J; Zou, JQ; Dai, YS; Chi, YH; Du, X; Cao, JP; Chen, YL; Li, LM; Li, NW; Liu, CJ; Liu, HQ; Lu, Q; Tang, DR; Wang, PF; Wang, ZH; Wu, PE; Zhang, FD; Zhang, FS; Zhu, GL			Results of directly observed short-course chemotherapy in 112842 Chinese patients with smear-positive tuberculosis	LANCET			English	Article							PROGRAM	Background Tuberculosis remains a substantial public health burden in China. The cure rate in treatment programmes has been about 50%. In 1991, a new project based on directly observed short-course chemotherapy was introduced. We report the results of the first 112 842 patients treated. Methods Patients with symptoms suggesting tuberculosis are referred by general health services to the tuberculosis county dispensary for physical examination and fluoroscopy. Those with suspicious findings submit three sputum samples for smear examination. Village doctors deliver free, directly observed therapy to ail smear-positive patients on an outpatient basis. New cases are treated with streptomycin (750 mg), isoniazid (600 mg), pyrazinamide (2000 mg), and rifampicin (600 mg) every other day for 2 months, followed by 4 months of alternate-day isoniazid plus rifampicin. Previously treated patients receive streptomycin, isoniazid, pyrazinamide, rifampicin, and ethambutol (1250 mg) every other day for 2 months, followed by 6 months of isoniazid, rifampicin. and ethambutol. Patients are re-examined and smears are repeated at 2 months (then 3 months if still positive) and at 5 and 6 months (new cases) or 5 and 8 months (previously treated cases). Findings Nearly 1.6 million patients with suspected tuberculosis were referred for fluoroscopy between 1991 and 1994. 48% had suspicious findings on fluoroscopy and underwent sputum examination. 104 444 new smear positive cases and 95616 previously treated smear positive cases have been diagnosed. Results of treatment for those enrolled up to the first quarter of 1994 show cure rates of 89.7% among new cases (55 213) and 81.1% among those previously treated (57 629). The failure rate in previously treated cases, an indicator of drug resistance, fell from 17.6% among 437 patients enrolled in 1991 to 62% among 7822 patients enrolled in the first quarter of 1994. Interpretation Our experience shows that high rates of compliance and cure can be achieved on a mass scale and in a short time by means of directly observed short-course chemotherapy and the WHO technical strategy for effective tuberculosis control.	HARVARD UNIV,CTR POPULAT & DEV STUDIES,CAMBRIDGE,MA 02138	Harvard University								BELL J, 1988, S AFR MED J, V73, P31; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BROEKMANS JF, 1994, TUBERCULOSIS BACK FU, P171; CHEUNG R, 1988, EUR J CLIN PHARMACOL, V35, P401, DOI 10.1007/BF00561372; Farmer P, 1991, Semin Respir Infect, V6, P254; MANOLO F, 1990, AM REV RESPIR DIS, V142, P1301; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; MORISKY DE, 1990, HEALTH EDUC QUART, V17, P253, DOI 10.1177/109019819001700303; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447; MURRAY CJL, 1990, B INT UNION TUBERC, V65, P2; VALEZA FS, 1990, LANCET, V335, P473, DOI 10.1016/0140-6736(90)90705-A; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; 1990, 1989 NAT TUB I ANN R; WHOTB9417; 1988, NATIONWIDE RANDOM SU; 1981, NATIONWIDE RANDOM SU; 1995, WHOGTBCARG959 MIN PU; 1992, NATIONWIDE RANDOM SU	19	129	133	2	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					358	362						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598701				2022-12-01	WOS:A1996TU69500009
J	Kraemer, KH				Kraemer, KH			Xeroderma pigmentosum knockouts	LANCET			English	Editorial Material											Kraemer, KH (corresponding author), NCI,MOLEC CARCINOGENESIS LAB,BLDG 37,BETHESDA,MD 20892, USA.			Kraemer, Kenneth/0000-0002-2689-3316	Intramural NIH HHS [Z01 BC004517-31] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; GASPARI AA, 1993, J CLIN INVEST, V92, P1135, DOI 10.1172/JCI116682; HANAWALT PC, 1995, MUTAT RES-DNA REPAIR, V336, P101, DOI 10.1016/0921-8777(94)00061-A; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; NAKANE T, 1995, NATURE, V377, P165; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					278	279		10.1016/S0140-6736(96)90462-6	http://dx.doi.org/10.1016/S0140-6736(96)90462-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569358				2022-12-01	WOS:A1996TT48500005
J	Glazewski, S; Chen, CM; Silva, A; Fox, K				Glazewski, S; Chen, CM; Silva, A; Fox, K			Requirement for alpha-CaMKII in experience-dependent plasticity of the barrel cortex	SCIENCE			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; PROTEIN-KINASE; GENE-EXPRESSION; STRIATE CORTEX; CALMODULIN; HISTOCHEMISTRY; SYSTEM; BRAIN	The mammalian sensory neocortex exhibits experience-dependent plasticity such that neurons modify their response properties according to changes in sensory experience. The synaptic plasticity mechanism of long-term potentiation requiring calcium-calmodulin-dependent kinase type II (CaMKII) could underlie experience-dependent plasticity. Plasticity in adult mice can be induced by changes in the patterns of tactile input to the barrel cortex. This response is strongly depressed in adult mice that lack the gene encoding alpha-CaMKII, although adolescent animals are unaffected. Thus, alpha-CaMKII is necessary either for the induction or for the expression of plasticity in adult mice.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of Minnesota System; University of Minnesota Twin Cities; Cold Spring Harbor Laboratory			Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X	PHS HHS [27759] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONGJAMES M, 1987, J COMP NEUROL, V263, P265, DOI 10.1002/cne.902630209; BENSON DL, 1992, NEUROSCIENCE, V46, P825, DOI 10.1016/0306-4522(92)90188-8; BURGIN KE, 1990, J NEUROSCI, V10, P1788; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; FOX K, 1994, J NEUROSCI, V14, P7665; FOX K, 1992, J NEUROSCI, V12, P1286; GLAZEWSKI S, 1996, J NEUROPHYSIOL, V74, P1714; Gordon J. A., 1994, Society for Neuroscience Abstracts, V20, P465; Hand PJ, 1982, CHANGING CONCEPTS NE, P49; HENDRY SHC, 1986, P NATL ACAD SCI USA, V83, P1536, DOI 10.1073/pnas.83.5.1536; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KOSSUT M, 1992, PROG NEUROBIOL, V39, P389, DOI 10.1016/0301-0082(92)90013-5; LI XR, 1995, J COMP NEUROL, V357, P465, DOI 10.1002/cne.903570310; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; NEVE RL, 1989, P NATL ACAD SCI USA, V86, P4781, DOI 10.1073/pnas.86.12.4781; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; VIDEEN TO, 1986, BRAIN RES, V371, P1, DOI 10.1016/0006-8993(86)90803-6; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105	31	126	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					421	423		10.1126/science.272.5260.421	http://dx.doi.org/10.1126/science.272.5260.421			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602534				2022-12-01	WOS:A1996UG25200051
J	Sakaguchi, S; Katamine, S; Nishida, N; Moriuchi, R; Shigematsu, K; Sugimoto, T; Nakatani, A; Kataoka, Y; Houtani, T; Shirabe, S; Okada, H; Hasegawa, S; Miyamoto, T; Noda, T				Sakaguchi, S; Katamine, S; Nishida, N; Moriuchi, R; Shigematsu, K; Sugimoto, T; Nakatani, A; Kataoka, Y; Houtani, T; Shirabe, S; Okada, H; Hasegawa, S; Miyamoto, T; Noda, T			Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted Prp gene	NATURE			English	Article							PROTEIN; SCRAPIE; BRAIN	PRION protein (PrP) is a glycoprotein constitutively expressed on the neuronal cell surface. A protease-resistant isoform of prion protein is implicated in the pathogenesis of a series of transmissible spongiform encephalopathies(1). We have developed a line of mice homozygous for a disrupted PrP gene in which the whole PrP-coding sequence is replaced by a drug-resistant gene(2). In keeping with pre,ious results(3-8), we find that homozygous loss of the PrP gene has no deleterious effect on the development of these mice and renders them resistant to prion(2). The PrP-null mice grew normally after birth, but at about 70 weeks of age all began to show progressive symptoms of ataxia. Impaired motor coordination in these ataxic mice was evident in a rotorod test. Pathological examination revealed an extensive loss of Purkinje cells in the vast majority of cerebellar folia, suggesting that PrP plays a role in the long-term survival of Purkinje neurons.	NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PATHOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; KANSAI MED UNIV,DEPT ANAT,MORIGUCHI,OSAKA 570,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOKYO 170,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Kansai Medical University; Japanese Foundation for Cancer Research			Noda, Tetsuo/B-1667-2016; hasegawa, sumitaka/A-4020-2012					BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197	15	400	408	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					528	531		10.1038/380528a0	http://dx.doi.org/10.1038/380528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606772				2022-12-01	WOS:A1996UE66300050
J	Nader, S				Nader, S			Female judoists: Their hormones, muscles, and bones	LANCET			English	Editorial Material							EXERCISE; RUNNERS				Nader, S (corresponding author), UNIV TEXAS,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,HOUSTON,TX 77025, USA.							BARROW GW, 1988, AM J SPORT MED, V16, P209, DOI 10.1177/036354658801600302; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; DE CREE C, 1995, J CLIN ENDOCR METAB, V80, P3639, DOI 10.1210/jc.80.12.3639; KEIZER HA, 1990, SPORTS MED, V10, P218, DOI 10.2165/00007256-199010040-00002; ROGOL AD, 1992, ENDOCRIN METAB CLIN, V21, P817, DOI 10.1016/S0889-8529(18)30190-7; SANBORN CF, 1982, AM J OBSTET GYNECOL, V143, P859, DOI 10.1016/0002-9378(82)90463-X; SCHACHTER M, 1994, FERTIL STERIL, V62, P1; YEN SSC, 1993, ENDOCRIN METAB CLIN, V22, P29, DOI 10.1016/S0889-8529(18)30179-8	8	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					919	920		10.1016/S0140-6736(96)91411-7	http://dx.doi.org/10.1016/S0140-6736(96)91411-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598753				2022-12-01	WOS:A1996UD59100006
J	Will, RG; Ironside, JW; Zeidler, M; Cousens, SN; Estibeiro, K; Alperovitch, A; Poser, S; Pocchiari, M; Hofman, A; Smith, PG				Will, RG; Ironside, JW; Zeidler, M; Cousens, SN; Estibeiro, K; Alperovitch, A; Poser, S; Pocchiari, M; Hofman, A; Smith, PG			A new variant of Creutzfeldt-Jakob disease in the UK	LANCET			English	Article								Background Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) was reinstituted in the UK in 1990 to identify any changes in the occurrence of this disease after the epidemic of bovine spongiform encephalopathy (BSE) in cattle. Methods Case ascertainment of CJD was mostly by direct referral from neurologists and neuropathologists. Death certificates on which CJD was mentioned were also obtained. Clinical details were obtained for all referred cases, and information on potential risk factors for CJD was obtained by a standard questionnaire administered to patients' relatives. Neuropathological examination was carried out on approximately 70% of suspect cases. Epidemiological studies of CJD using similar methodology to the UK study have been carried out in France, Germany, Italy, and the Netherlands between 1993 and 1995. Findings Ten cases of CJD have been identified in the UK in recent months with a new neuropathological profile. Other consistent features that are unusual include the young age of the cases, clinical findings, and the absence of the electroencephalogram features typical for CJD. Similar cases have not been identified in other countries in the European surveillance system. Interpretation These cases appear to represent a new variant of CJD, which may be unique to the UK. This raises the possibility that they are causally linked to BSE. Although this may be the most plausible explanation for this cluster of cases, a link with BSE cannot be confirmed on the basis of this evidence alone. It is essential to obtain further information on the current and past clinical and neuropathological profiles of CJD in the UK and elsewhere.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND; HOP LA PITIE SALPETRIERE,INSERM,PARIS,FRANCE; UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,W-3400 GOTTINGEN,GERMANY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS	University of London; London School of Hygiene & Tropical Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Istituto Superiore di Sanita (ISS); Erasmus University Rotterdam	Will, RG (corresponding author), WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486; Smith, Peter/0000-0003-0080-7560; Ironside, James/0000-0001-5869-2108				BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BERMAN PH, 1988, PEDIATR NEUROSCI, V14, P42, DOI 10.1159/000120361; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DELASNERIELAUPRETRE N, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92735-2; Fraser H., 1979, Aspects of slow and persistent virus infections, P30; GOODBRAND IA, 1995, NEUROSCI LETT, V183, P127, DOI 10.1016/0304-3940(94)11131-2; HOWARD RS, 1996, LANCET, V347, P945; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; MONREAL J, 1981, J NEUROL SCI, V52, P341, DOI 10.1016/0022-510X(81)90015-0; *NAT CJD SURV UN D, 1995, 4 LOND SCH HYG TROP; PACKER RJ, 1980, NEUROLOGY, V30, P492, DOI 10.1212/WNL.30.5.492; WELLER RO, 1986, NEUROPATH APPL NEURO, V12, P117, DOI 10.1111/j.1365-2990.1986.tb00045.x	18	2040	2102	0	150	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					921	925		10.1016/S0140-6736(96)91412-9	http://dx.doi.org/10.1016/S0140-6736(96)91412-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598754				2022-12-01	WOS:A1996UD59100007
J	Bourne, Y; Watson, MH; Hickey, MJ; Holmes, W; Rocque, W; Reed, SI; Tainer, JA				Bourne, Y; Watson, MH; Hickey, MJ; Holmes, W; Rocque, W; Reed, SI; Tainer, JA			Crystal structure and mutational analysis the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1	CELL			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SCHIZOSACCHAROMYCES-POMBE; DIVISION CYCLE; CDC2; GENE; PHOSPHORYLATION; P34(CDC2); BINDING	The 2.6 Angstrom crystal structure for human cyclin-dependent kinase 2 (CDK2) in complex with CksHs1, a human homolog of essential yeast cell cycle-regulatory proteins suc1 and Cks1, reveals that CksHs1 binds via all four beta strands to the kinase C-terminal robe. This interface is biologically critical, based upon mutational analysis, but far from the CDK2 N-terminal lobe, cyclin, and regulatory phosphorylation sites. CDK2 binds the Cks single domain conformation and interacts with conserved hydrophobic residues plus His-60 and Glu-63 in their closed beta-hinge motif conformation. The beta hinge opening to form the Cks beta-interchanged dimer sterically precludes CDK2 binding, providing a possible mechanism regulating CDK2-Cks interactions. One face of the complex exposes the sequence-conserved phosphate-binding region on Cks and the ATP-binding site on CDK2, suggesting that Cks may target CDK2 to other phosphoproteins during the cell cycle.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; GLAXO WELLCOME, RES TRIANGLE PK, NC 27709 USA	Scripps Research Institute; GlaxoSmithKline			Tainer, John/GWQ-4878-2022; Bourne, Yves/AAC-4635-2022	Tainer, John/0000-0003-1659-2429; Bourne, Yves/0000-0003-3850-0548				ARVAI AS, 1995, PROTEINS, V21, P70, DOI 10.1002/prot.340210109; ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; AZZI L, 1994, J BIOL CHEM, V269, P13279; Boume Y., 1995, P NATL ACAD SCI USA, V92, P10232; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENDICOTT JA, 1995, STRUCTURE, V3, P321, DOI 10.1016/S0969-2126(01)00162-9; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	59	208	212	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					863	874		10.1016/S0092-8674(00)81065-X	http://dx.doi.org/10.1016/S0092-8674(00)81065-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601310	Bronze			2022-12-01	WOS:A1996UC38100008
J	Foucar, E				Foucar, E			Carcinoma-in-situ of the breast: Have pathologists run amok?	LANCET			English	Editorial Material							LESIONS				Foucar, E (corresponding author), PRESBYTERIAN HOSP,DEPT PATHOL,POB 26666,ALBUQUERQUE,NM 87125, USA.							Foote FW, 1941, AM J PATHOL, V17, P491; HAYAKAWA SI, 1990, LANGUAGE THOUGHT ACT, P111; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; MORROW M, 1994, ARCH SURG-CHICAGO, V129, P1091; Morrow M, 1996, JAMA-J AM MED ASSOC, V275, P61; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; ROSAI J, 1996, BREAST ACKERMANS SUR, P1596; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; SILVERSTEIN MJ, 1991, AM J CLIN ONCOL-CANC, V14, P534, DOI 10.1097/00000421-199112000-00014; SIMPSON JF, 1994, CANCER, V73, P2352, DOI 10.1002/1097-0142(19940501)73:9<2352::AID-CNCR2820730918>3.0.CO;2-X; STEWART FW, 1950, ATLAS TUMOUR PATHOL, P18; TAVASSOLI FA, 1994, MODERN PATHOL, V7, P813; WALT AJ, 1992, ARCH SURG-CHICAGO, V127, P904; WINCHESTER DP, 1995, ANN SURG ONCOL, V2, P207, DOI 10.1007/BF02307025	15	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					707	708		10.1016/S0140-6736(96)90073-2	http://dx.doi.org/10.1016/S0140-6736(96)90073-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601998				2022-12-01	WOS:A1996TZ98200006
J	Finn, PJ; Plank, LD; Clark, MA; Connolly, AB; Hill, GL				Finn, PJ; Plank, LD; Clark, MA; Connolly, AB; Hill, GL			Progressive cellular dehydration and proteolysis in critically ill patients	LANCET			English	Article							BODY-WATER; NUTRITION; MUSCLE	Background According to a recent hypothesis, the profound loss of body protein that occurs in critically ill patients is triggered and maintained by cell shrinkage secondary to cellular dehydration. We tested this hypothesis by studying sequential changes in intracellular water, total body protein, total body potassium, and intracellular potassium in patients receiving intensive care for blunt trauma or sepsis. Methods Nine patients with multiple blunt trauma and 11 with severe sepsis were studied in an intensive care unit for 21 days. Intracellular water was measured in two ways--by subtraction of extracellular water (bromide dilution) from total body water (tritium dilution), and by bioimpedance spectroscopy. Total body protein was measured by whole-body neutron activation analysis and total body potassium by whole-body counting. Findings Over the study period intracellular water decreased by 15-20%, total body protein by 15%, and total body potassium by about 20%. Intracellular potassium concentration did not change, and was similar to that in healthy adult volunteers. In the trauma patients, sequential measurements of the ratio of potassium to protein In lost tissue indicated that cells were losing water in quantities greater than would be expected from protein losses. Interpretation The loss of protein and potassium from body stores in major trauma or sepsis is accompanied by progressive cellular dehydration. This insight opens up new therapeutic options for limiting the loss of body protein in critically ill patients.	UNIV AUCKLAND, DEPT SURG, AUCKLAND HOSP, AUCKLAND 3, NEW ZEALAND	Auckland City Hospital; University of Auckland				Plank, Lindsay/0000-0003-2737-0151				BAXTER CR, 1966, CARE TRAUMA PATIENT, P541; BERGSTROM J, 1979, ACTA CHIR SCAND    S, V494, P356; BERGSTROM JP, 1987, ACTA CHIR SCAND, V153, P261; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHANDRA RK, 1994, J NUTR, V124, pS1433, DOI 10.1093/jn/124.suppl_8.1433S; Cuthbertson DP, 1942, LANCET, V1, P433; ELWYN DH, 1975, ANN SURG, V182, P76, DOI 10.1097/00000658-197507000-00015; GATZEN C, 1992, SURGERY, V112, P181; HALLBRUCKER C, 1991, EUR J BIOCHEM, V197, P717, DOI 10.1111/j.1432-1033.1991.tb15963.x; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER O, 1995, CLIN NUTR, V14, P4, DOI 10.1016/S0261-5614(06)80003-8; HILL GL, 1992, JPEN-PARENTER ENTER, V16, P197, DOI 10.1177/0148607192016003197; Hill GL, 1993, METABOLIC SUPPORT CR, P3; *ICRP, 1975, 23 IRCP REP; KARNER J, 1981, J PARENT ENT NUTR, V5, P368; LINDSTEDT E, 1975, ANN SURG, V181, P842, DOI 10.1097/00000658-197506000-00014; LUCAS CE, 1983, SURG CLIN N AM, V63, P439; McGee JO, 1992, OXFORD TXB PATHOLOGY; MITRA S, 1989, PHYS MED BIOL, V34, P61, DOI 10.1088/0031-9155/34/1/006; MITRA S, 1993, PHYS MED BIOL, V38, P1971, DOI 10.1088/0031-9155/38/12/019; MONK DN, IN PRESS ANN SURG; ROTH E, 1985, CLIN CHEM, V31, P1305; STREAT SJ, 1985, METABOLISM, V34, P688, DOI 10.1016/0026-0495(85)90099-X; VANLOAN MD, 1993, BASIC LIFE SCI, P67; WINDSOR J A, 1988, Australian and New Zealand Journal of Surgery, V58, P711, DOI 10.1111/j.1445-2197.1988.tb01101.x; WINDSOR JA, 1988, ANN SURG, V207, P290, DOI 10.1097/00000658-198803000-00011; Ziegler T. R., 1993, Clinical Nutrition, V12, pS82, DOI 10.1016/S0261-5614(09)90014-0; [No title captured]	28	121	134	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					654	656		10.1016/S0140-6736(96)91204-0	http://dx.doi.org/10.1016/S0140-6736(96)91204-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596380				2022-12-01	WOS:A1996TZ28500012
J	Abramovitz, DL; Friedman, RA; Pyle, AM				Abramovitz, DL; Friedman, RA; Pyle, AM			Catalytic role of 2'-hydroxyl groups within a group II intron active site	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; TERTIARY INTERACTIONS; MESSENGER-RNA; MECHANISM; BINDING; RIBOSE; SUBSTRATE; DOMAIN-5; CORE	Domain 5 is an essential active-site component of group II intron ribozymes. The role of backbone substituents in D5 function was explored through synthesis of a series of derivatives containing deoxynucleotides at each position along the D5 strand. Kinetic screens revealed that eight 2'-hydroxyl groups were likely to be critical for activity of D5. Through two separate methods, including competitive inhibition and direct kinetic analysis, effects on binding and chemistry were distinguished. Depending on their function, important 2'-hydroxyl groups lie on opposite faces of the molecule, defining distinct loci for molecular recognition and catalysis by D5.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041371, R01GM050313] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41371, GM50313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ D, UNPUB; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHANFREAU G, 1994, SCIENCE, V266, P1383, DOI 10.1126/science.7973729; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; DOUDNA JA, 1995, RNA, V1, P36; FERSHT A, 1985, ENZYME STRUCTURE MEC, P102; FRANZEN JS, 1993, NUCLEIC ACIDS RES, V21, P627, DOI 10.1093/nar/21.3.627; FRIEDMAN RA, 1992, BIOPOLYMERS, V32, P145, DOI 10.1002/bip.360320205; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KNITT DS, 1994, BIOCHEMISTRY-US, V33, P13864, DOI 10.1021/bi00250a041; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KWAKMAN JHJM, 1990, J BIOMOL STRUCT DYN, V8, P413, DOI 10.1080/07391102.1990.10507813; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAJOR F, 1991, SCIENCE, V253, P1255, DOI 10.1126/science.1716375; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; PEEBLES CL, 1995, P NATL ACAD SCI USA, V92, P4422, DOI 10.1073/pnas.92.10.4422; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PODAR M, 1995, MOL CELL BIOL, V15, P4466; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P13856, DOI 10.1021/bi00250a040; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; PYLE AM, 1995, CURR OPIN STRUC BIOL, V5, P303, DOI 10.1016/0959-440X(95)80091-3; PYLE AM, IN PRESS NUCLEIC ACI; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YU YT, 1995, RNA, V1, P46	41	99	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1410	1413		10.1126/science.271.5254.1410	http://dx.doi.org/10.1126/science.271.5254.1410			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596912				2022-12-01	WOS:A1996TY96100044
J	Lehtinen, M; Dillner, J; Knekt, P; Luostarinen, T; Aromaa, A; Kimbauer, R; Koskela, P; Paavonen, J; Peto, R; Schiller, JT; Hakama, M				Lehtinen, M; Dillner, J; Knekt, P; Luostarinen, T; Aromaa, A; Kimbauer, R; Koskela, P; Paavonen, J; Peto, R; Schiller, JT; Hakama, M			Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To study human papillomavirus type 16 in the aetiology of cervical c Design-Within a cohort of 18 814 Finnish women followed for up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. Subjects-72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. Main outcome measure- Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. Results-After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P < 0.001). Conclusion-This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.	TAMPERE UNIV, TAMPERE SCH PUBL HLTH, SF-33101 TAMPERE, FINLAND; NATL PUBL HLTH INST, OULU, FINLAND; NATL PUBL HLTH INST, DEPT CHRON VIRAL DIS, SF-00300 HELSINKI, FINLAND; KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, STOCKHOLM, SWEDEN; SOCIAL INSURANCE INST, CTR RES & DEV, SF-00381 HELSINKI, FINLAND; FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND; UNIV VIENNA, SCH MED, DEPT IMMUNODERMATOL, VIENNA, AUSTRIA; HELSINKI UNIV, HELSINKI, FINLAND; UNIV OXFORD, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND; UNIV OXFORD, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD, ENGLAND; NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA	Tampere University; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Karolinska Institutet; Finnish Cancer Registry; University of Vienna; University of Helsinki; University of Oxford; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Schiller, John/ABK-8287-2022	Luostarinen, Tapio/0000-0003-3231-8550; lehtinen, matti/0000-0002-9481-0535				Breslow NE., 1980, IARC SCI PUBLICATION, V32; Chabaud Martine, 1994, P59; DILLNER J, 1994, CANCER RES, V54, P134; DILLNER J, 1995, INT J CANCER, V60, P377; HAKAMA M, 1993, AM J EPIDEMIOL, V137, P166, DOI 10.1093/oxfordjournals.aje.a116656; HANNA L, 1980, J CLIN MICROBIOL, V12, P409, DOI 10.1128/JCM.12.3.409-412.1980; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; KIMBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494; LEHTINEN M, 1986, EUR J CLIN MICROBIOL, V5, P596, DOI 10.1007/BF02017713; MARDH PA, 1989, CHLAMYDIA, P1; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; NONNENMACHER B, 1995, J INFECT DIS, V172, P19, DOI 10.1093/infdis/172.1.19; PAAVONEN J, 1996, SEXUALLY TRANSMITTED; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958	14	132	136	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1996	312	7030					537	539		10.1136/bmj.312.7030.537	http://dx.doi.org/10.1136/bmj.312.7030.537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595281	Green Published			2022-12-01	WOS:A1996TY88500021
J	Roberts, J				Roberts, J			Light and dark in life and death	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					466	466		10.1136/bmj.312.7029.466a	http://dx.doi.org/10.1136/bmj.312.7029.466a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597675	Green Published			2022-12-01	WOS:A1996TX38300018
J	Jain, RK				Jain, RK			Delivery of molecular medicine to solid tumors	SCIENCE			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	Jain, RK (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,EDWIN L STEELE LAB,BOSTON,MA 02114, USA.		Berk, David A/A-4863-2012; Swartz, Melody A./F-9563-2011; Jain, Rakesh K/I-1384-2017	Berk, David A/0000-0002-3855-6886; Jain, Rakesh K/0000-0001-7571-3548				[Anonymous], 1996, B MED ETHICS; BAXTER LT, 1995, CANCER RES, V55, P4611; Beardsley T, 1994, SCI AM, V270, P118; DEDRICK RL, 1973, J PHARMACOKINET BIOP, V1, P435, DOI 10.1007/BF01059667; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; GURA T, 1995, SCIENCE, V270, P575, DOI 10.1126/science.270.5236.575; HALL SS, 1995, SCIENCE, V270, P915, DOI 10.1126/science.270.5238.915; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JAIN RK, IN PRESS ANN BIOMED; Jobe P C, 1994, Physiologist, V37, P79; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; REESE DM, 1995, NATURE, V378, P532, DOI 10.1038/378532c0; WADMAN M, 1995, NATURE, V378, P655, DOI 10.1038/378655a0; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122	14	270	315	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1079	1080		10.1126/science.271.5252.1079	http://dx.doi.org/10.1126/science.271.5252.1079			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599082				2022-12-01	WOS:A1996TW70100027
J	Hamilton, BA; Frankel, WN; Kerrebrock, AW; Hawkins, TL; FitzHugh, W; Kusumi, K; Russell, LB; Mueller, KL; vanBerkel, V; Birren, BW; Kruglyak, L; Lander, ES				Hamilton, BA; Frankel, WN; Kerrebrock, AW; Hawkins, TL; FitzHugh, W; Kusumi, K; Russell, LB; Mueller, KL; vanBerkel, V; Birren, BW; Kruglyak, L; Lander, ES			Disruption of the nuclear hormone receptor ROR alpha in staggerer mice	NATURE			English	Article							MUTANT MICE; PURKINJE-CELLS; MULTIPLE INNERVATION; CEREBELLAR CORTEX; CLIMBING FIBERS; MOUSE; ABNORMALITIES	HOMOZYGOUS staggerer (sg) mice show a characteristic severe cerebellar ataxia due to a cell-autonomous defect in the development of Purkinje cells(1,2). These cells show immature morphology, synaptic arrangement, biochemical properties and gene expression, and are reduced in numbers(3-12). In addition, sg heterozygotes show accelerated dendritic atrophy and cell loss(13), suggesting that sg has a role in mature Purkinje cells. Effects of this mutation on cerebellar development have been studied for 25 years, but its molecular basis has remained unknown, We have genetically mapped staggerer to an interval of 160 kilobases on mouse chromosome 9 which was found to contain the gene encoding ROR alpha, a member of the nuclear hormone-receptor superfamily. Staggerer mice were found to carry a deletion within the ROR alpha gene that prevents translation of the ligand-binding homology domain. We propose a model based on these results, in which ROR alpha interacts with the thyroid hormone signalling pathway to induce Purkinje-cell maturation.	JACKSON LAB, BAR HARBOR, ME 04609 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	Jackson Laboratory; Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Oak Ridge National Laboratory	Hamilton, BA (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012; van Berkel, Victor/AAC-1956-2021	Kusumi, Kenro/0000-0002-1458-4540; Hamilton, Bruce/0000-0001-5599-9139				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; CREPEL F, 1980, NATURE, V283, P483, DOI 10.1038/283483a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; HATTEN ME, 1978, NATURE, V276, P504, DOI 10.1038/276504a0; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HERRUP K, 1979, BRAIN RES, V172, P1, DOI 10.1016/0006-8993(79)90891-6; HERRUP K, 1979, BRAIN RES, V178, P443, DOI 10.1016/0006-8993(79)90705-4; Herrup K, 1983, Brain Res, V313, P267; HERRUP K, 1981, DEV BRAIN RES, V1, P475, DOI 10.1016/0165-3806(81)90002-X; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LANDIS DMD, 1978, J COMP NEUROL, V179, P831, DOI 10.1002/cne.901790408; LEGRAND J, 1979, TRENDS NEUROSCI, V2, P234, DOI 10.1016/0166-2236(79)90091-2; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MESSER A, 1988, J NEUROCHEM, V51, P888, DOI 10.1111/j.1471-4159.1988.tb01825.x; Sambrook J., 1989, MOL CLONING LAB MANU; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SOTELO C, 1975, ADV NEUROL, V12, P335; SOTELO C, 1974, BRAIN RES, V67, P519, DOI 10.1016/0006-8993(74)90499-5; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TRENKNER E, 1979, NATURE, V277, P566, DOI 10.1038/277566a0; TRENKNER E, 1986, J NEUROSCI, V6, P1733; ZANJANI HS, 1992, DEV BRAIN RES, V67, P153, DOI 10.1016/0165-3806(92)90216-J; ZHOU L, 1994, J BIOL CHEM, V269, P13346	30	411	424	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					736	739		10.1038/379736a0	http://dx.doi.org/10.1038/379736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602221				2022-12-01	WOS:A1996TW56700055
J	Chua, SC; Chung, WK; WuPeng, XS; Zhang, YY; Liu, SM; Tartaglia, L; Leibel, RL				Chua, SC; Chung, WK; WuPeng, XS; Zhang, YY; Liu, SM; Tartaglia, L; Leibel, RL			Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; HUMAN DNA; OBESITY; YEAST; CONSTRUCTION; INSERTS; CLONING; MODEL; MICE	Mice harboring mutations in the obese (ob) and diabetes (db) genes display similar phenotypes, and it has been proposed that these genes encode the ligand and receptor, respectively, for a physiologic pathway that regulates body weight. The cloning of ob, and the demonstration that it encodes a secreted protein (leptin) that binds specifically to a receptor (OB-R) in the brain, have validated critical aspects of this hypothesis. Here it is shown by genetic mapping and genomic analysis that mouse db, rat fatty (a homolog of db), and the gene encoding the OB-R are the same gene.	ROCKEFELLER UNIV,HUMAN BEHAV & METAB LAB,NEW YORK,NY 10021; MILLENNIUM PHARMACEUT,CAMBRIDGE,MA 02139	Rockefeller University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals					NICHD NIH HHS [HD28047] Funding Source: Medline; NIDDK NIH HHS [DK47473, DK26687] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047473, P30DK026687] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUBERT R, 1985, J NUTR, V115, P327, DOI 10.1093/jn/115.3.327; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHUA SJ, UNPUB; CHUNG WK, 1995, 2ND CHROM ONE M VIEN; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KERSHAW EE, 1995, GENOMICS, V27, P149, DOI 10.1006/geno.1995.1017; KOLETSKY S, 1973, EXP MOL PATHOL, V19, P53, DOI 10.1016/0014-4800(73)90040-3; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEIBEL RL, 1993, CRIT REV FOOD SCI, V33, P351, DOI 10.1080/10408399309527632; LEITER EH, 1980, DIABETOLOGIA, V19, P66, DOI 10.1007/BF00258314; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093	28	954	991	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					994	996		10.1126/science.271.5251.994	http://dx.doi.org/10.1126/science.271.5251.994			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584938				2022-12-01	WOS:A1996TV70400051
J	RoelkeParker, ME; Munson, L; Packer, C; Kock, R; Cleaveland, S; Carpenter, M; OBrien, SJ; Pospischil, A; HofmannLehmann, R; Lutz, H; Mwamengele, GLM; Mgasa, MN; Machange, GA; Summers, BA; Appel, MJG				RoelkeParker, ME; Munson, L; Packer, C; Kock, R; Cleaveland, S; Carpenter, M; OBrien, SJ; Pospischil, A; HofmannLehmann, R; Lutz, H; Mwamengele, GLM; Mgasa, MN; Machange, GA; Summers, BA; Appel, MJG			A canine distemper virus epidemic in Serengeti lions (Panthera leo)	NATURE			English	Article								CANINE distemper virus (CDV) is thought to have caused several fatal epidemics in canids within the Serengeti-Mara ecosystem of East Africa, affecting silver-backedjackals (Canis mesomelas) and bat-cared foxes (Otocyon megalotis) in 1978 (ref. 1), and African wild dogs (Lycaon pictus) in 1991 (refs 2, 3). The large, closely monitored Serengeti lion population(4,5) was not affected in these epidemics. However, an epidemic caused by a morbillivirus closely related to CDV emerged abruptly in the lion population of the Serengeti National Pack, Tanzania, in early 1994, resulting in fatal neurological disease characterized by grand mal seizures and myoclonus; the lions that died had encephalitis and pneumonia. Here we report the identification of CDV from these lions, and the close phylogenetic relationship between CDV isolates from lions and domestic dogs. By August 1994, 85% of the Serengeti lion population had anti-CDV antibodies, and the epidemic spread north to lions in the Maasai Mara National reserve, Kenya, and uncounted hyaenas, bat-eared foxes, and leopards were also affected.	UNIV TENNESSEE,COLL VET MED,DEPT PATHOL,KNOXVILLE,TN 37901; SERENGETI WILDLIFE RES INST,TANZANIA NATL PARKS,ARUSHA,TANZANIA; MESSERLI FDN,ZURICH,SWITZERLAND; UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,ST PAUL,MN 55108; KENYA WILDLIFE SERV,NAIROBI,KENYA; INST ZOOL,LONDON NW1 4RY,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; UNIV ZURICH,INST VET PATHOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,DEPT VET INTERNAL MED,CH-8057 ZURICH,SWITZERLAND; SOKOINE UNIV AGR,DEPT VET PATHOL,MOROGORO,TANZANIA; VET INVEST CTR,ARUSHA,TANZANIA; CORNELL UNIV,COLL VET MED,DEPT PATHOL,ITHACA,NY 14853; CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Minnesota System; University of Minnesota Twin Cities; University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zurich; University of Zurich; Sokoine University of Agriculture; Cornell University; Cornell University			Hofmann-Lehmann, Regina/C-6528-2009; OBRIEN, STEPHEN/ABD-1346-2020	Hofmann-Lehmann, Regina/0000-0001-9750-4296; Kock, Richard/0000-0002-6561-3209; OBRIEN, STEPHEN/0000-0001-7857-0757; Carpenter, Margaret/0000-0003-1606-1986				ALEXANDER KA, 1994, J WILDLIFE DIS, V30, P481, DOI 10.7589/0090-3558-30.4.481; APPEL M, 1973, AM J VET RES, V34, P1459; APPEL MJ, 1987, VIRUS INFECT CARNIVO, P00133; APPEL MJG, 1992, J VET DIAGN INVEST, V4, P258, DOI 10.1177/104063879200400306; APPEL MJG, 1994, J VET DIAGN INVEST, V6, P277, DOI 10.1177/104063879400600301; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BROWN EW, 1993, J ZOO WILDLIFE MED, V24, P357; BROWN EW, 1994, J VIROL, V68, P5953, DOI 10.1128/JVI.68.9.5953-5968.1994; CARMICHAEL LE, 1980, AM J VET RES, V41, P784; FELSTEINSTEIN J, 1995, PHYLOGENY INFERENCE; GILBERT DA, 1991, J HERED, V82, P378, DOI 10.1093/oxfordjournals.jhered.a111107; Hofer Heribert, 1993, Symposia of the Zoological Society of London, V65, P347; MACDONALD DW, 1992, NATURE, V360, P633, DOI 10.1038/360633b0; Moehlman PD, 1983, RECENT ADV STUDY MAM, P423; MONTALI RJ, 1991, VIRUS INFECTIONS CAR, P437; ORVELL C, 1985, J GEN VIROL, V66, P443, DOI 10.1099/0022-1317-66-3-443; Packer C., 1988, P363; PACKER C, 1995, AM NAT, V145, P833, DOI 10.1086/285771; SWAFFORD DL, 1984, PHYLOGENETIC ANAL US; WILDT DE, 1987, NATURE, V329, P328, DOI 10.1038/329328a0	20	520	548	5	163	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					441	445		10.1038/379441a0	http://dx.doi.org/10.1038/379441a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559247	Green Published, Bronze			2022-12-01	WOS:A1996TT30400057
J	Hilleman, MR				Hilleman, MR			Cooperation between government and industry in combating a perceived emerging pandemic - The 1976 swine influenza vaccination program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Hilleman, MR (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,MERCK INST THERAPEUT RES,WP53C-350,W POINT,PA 19486, USA.							HILLEMAN M R, 1958, Mil Med, V123, P23; LANGMUIR AD, 1979, J ROY SOC MED, V72, P660, DOI 10.1177/014107687907200908; Neustadt RE, 1978, SWINE FLU AFFAIR DEC, DOI [10.17226/12660, DOI 10.17226/12660]; OSBORN JE, 1977, HIST SCI POLITICS IN; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P1005; Silverstein ArthurM., 1981, PURE POLITICS IMPURE; SOFRANOK TJ, 1991, AM J EPIDEMIOL, V133, P940; WEBSTER RG, 1994, SEMIN VIROL, V5, P103, DOI 10.1006/smvy.1994.1011; 1976, L94380 PUB; 1976, L94266 PUB, P890	10	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					241	243		10.1001/jama.275.3.241	http://dx.doi.org/10.1001/jama.275.3.241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604179				2022-12-01	WOS:A1996TP28200034
J	Tait, DR; Ward, KN; Brown, DWG; Miller, E				Tait, DR; Ward, KN; Brown, DWG; Miller, E			Measles and rubella misdiagnosed in infants as Exanthem subitum (roseola infantum)	BRITISH MEDICAL JOURNAL			English	Article							HUMAN HERPESVIRUS-6		UNIV LONDON,ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,ENTER & RESP VIRUS DIV,LONDON NW9 5HT,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND	Imperial College London; University of London; Public Health England; Public Health England								BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; JURETIC M, 1963, HELVETICA PAEDIATRIC, V1, P80; Miller E, 1994, Commun Dis Rep CDR Rev, V4, pR146; WARD KN, 1993, J MED VIROL, V39, P131, DOI 10.1002/jmv.1890390209; YAMANISHI K, 1988, LANCET, V1, P1065	5	42	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					101	102						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555893				2022-12-01	WOS:A1996TQ16800030
J	YOUNG, TK; GELSKEY, DE				YOUNG, TK; GELSKEY, DE			IS NONCENTRAL OBESITY METABOLICALLY BENIGN - IMPLICATIONS FOR PREVENTION FROM A POPULATION SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BODY-FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; RISK-FACTORS; MEN BORN; PARTICIPANTS; LIPIDS; FOLLOW; MASS	Objective.-To determine if individuals who are overall obese but have low waist-to-hip ratios have unfavorable lipid profiles, blood pressures, and glucose statuses. Design.-Cross-sectional study. Setting.-The Manitoba Heart Health Survey surveyed a representative sample of residents of the Canadian province of Manitoba. Participants.-A total of 2792 adults aged 18 to 74 years were interviewed, 2339 of whom underwent clinical examinations. Main Outcome Measures.-Blood pressure, fasting plasma glucose, total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein measurements were compared across categories of body mass index (BMI) and waist-to-hip ratio (WHR). Main Results.--Manitobans with noncentral obesity tend to occupy positions between those of the nonobese and the centrally obese in terms of the effect on blood pressure, plasma lipids, and glucose. In multiple linear regression models involving age, BMI, and WHR as independent variables and one of the metabolic variables as dependent variables, both BMI and WHR are significant independent predictors of most metabolic variables. Where both are significant, BMI tends to be the stronger predictor, with a larger standardized regression coefficient. Conclusions.-Noncentral obesity is not metabolically benign; BMI as an overall measure of obesity is as important as, and sometimes more important than, WHR in predicting metabolic effects. The recognition of the epidemiological significance of the WHR as a centrality measure of obesity should not divert attention from the metabolic risk status of noncentrally obese individuals who require continued health education to reduce weight.	CADHAM PROV LAB,WINNIPEG,MB,CANADA		YOUNG, TK (corresponding author), UNIV MANITOBA,FAC MED,DEPT COMMUNITY HLTH SCI,7509 BANNATYNE AVE,WINNIPEG,MB R3E 0W3,CANADA.							CONNELLY PW, 1992, CAN MED ASSOC J, V146, P1977; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GELSKEY DE, 1994, J CLIN EPIDEMIOL, V47, P547, DOI 10.1016/0895-4356(94)90301-8; HODGE AM, 1993, INT J OBESITY, V17, P399; ISO H, 1991, INT J EPIDEMIOL, V20, P88, DOI 10.1093/ije/20.1.88; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; YOUNG TK, 1989, AM J CLIN NUTR, V49, P786, DOI 10.1093/ajcn/49.5.786	10	41	43	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1939	1941		10.1001/jama.274.24.1939	http://dx.doi.org/10.1001/jama.274.24.1939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568989				2022-12-01	WOS:A1995TL16900037
J	Nightingale, SL				Nightingale, SL			Nicotine nasal spray approved for smoking cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-01	WOS:A1996UF47800007
J	Tosini, G; Menaker, M				Tosini, G; Menaker, M			Circadian rhythms in cultured mammalian retina	SCIENCE			English	Article							SUPRACHIASMATIC NUCLEUS; SYSTEM; MELATONIN; PINEAL; CLOCK; LESIONS; LIGHT	Many retinal functions are circadian, but in most instances the location of the clock that drives the rhythm is not known. Cultured neural retinas of the golden hamster (Mesocricetus auratus) exhibited circadian rhythms of melatonin synthesis for at least 5 days at 27 degrees C. The rhythms were entrained by light cycles applied in vitro and were free-running in constant darkness. Retinas from hamsters homozygous for the circadian mutation tau, which shortens the free-running period of the circadian activity rhythm by 4 hours, showed a shortened free-running period of melatonin synthesis. The mammalian retina contains a genetically programmed circadian oscillator that regulates its synthesis of melatonin.	UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22903 USA; UNIV VIRGINIA, NATL SCI FDN CTR BIOL TIMING, CHARLOTTESVILLE, VA 22903 USA	University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; tosini, gianluca/0000-0003-3645-4533	NICHD NIH HHS [HD13162] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013162] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CAHILL GM, 1991, J NEUROSCI, V11, P2959; FALCON J, 1991, CELL TISSUE RES, V265, P601, DOI 10.1007/BF00340884; JANIK DS, 1990, J COMP PHYSIOL A, V166, P811; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; MENAKER M, IN PRESS 6 SAPP S BI; OOKASOUDA S, 1993, NEUROSCI LETT, V164, P33, DOI 10.1016/0304-3940(93)90850-K; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REME CE, 1991, J BIOL RHYTHM, V6, P5, DOI 10.1177/074873049100600104; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; Straume M, 1991, TOPICS FLUORESCENCE, P177, DOI DOI 10.1007/B112907; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1982, J NEUROSCI, V2, P815; TERMAN JS, 1993, BRAIN RES, V605, P256; TERMAN M, 1985, ANN NY ACAD SCI, V453, P147, DOI 10.1111/j.1749-6632.1985.tb11807.x; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	18	587	596	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1996	272	5260					419	421		10.1126/science.272.5260.419	http://dx.doi.org/10.1126/science.272.5260.419			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602533				2022-12-01	WOS:A1996UG25200050
J	Naldini, L; Blomer, U; Gallay, P; Ory, D; Mulligan, R; Gage, FH; Verma, IM; Trono, D				Naldini, L; Blomer, U; Gallay, P; Ory, D; Mulligan, R; Gage, FH; Verma, IM; Trono, D			In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector	SCIENCE			English	Article							VIRUS TYPE-1 RNA; RETROVIRAL VECTORS; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS; HIGH-TITER; INFECTION; DNA; EXPRESSION; PROTEIN; TROPISM	A retroviral vector system based on the human immunodeficiency virus (HIV) was developed that, in contrast to a murine leukemia virus-based counterpart, transduced heterologous sequences into HeLa cells and rat fibroblasts blocked in the cell cycle, as well as into human primary macrophages. Additionally, the HIV vector could mediate stable in vivo gene transfer into terminally differentiated neurons. The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Salk Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X	NIAID NIH HHS [AI37510] Funding Source: Medline; NIA NIH HHS [AG10435, AG08514] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG008514, R01AG008514, P01AG010435] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ANSARILARI MA, 1995, VIROLOGY, V211, P332, DOI 10.1006/viro.1995.1412; BERKOWITZ RD, 1995, VIROLOGY, V212, P718, DOI 10.1006/viro.1995.1530; BUCHSCHACHER GL, 1992, J VIROL, V66, P2731, DOI 10.1128/JVI.66.5.2731-2739.1992; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BYRNES JJ, 1984, MOL CELL BIOCHEM, V62, P13; CARROLL R, 1994, J VIROL, V68, P6047, DOI 10.1128/JVI.68.9.6047-6051.1994; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN A, 1983, J BIOL CHEM, V258, P2334; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; FINER MH, 1994, BLOOD, V83, P43; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; GALLAY P, UNPUB; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAYE JF, 1995, J VIROL, V69, P6588, DOI 10.1128/JVI.69.10.6588-6592.1995; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KNOWLES RM, 1995, NEW ENGL J MED, V333, P823; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MCCORMICK PJ, 1983, BIOCHIM BIOPHYS ACTA, V755, P36; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAIDINI L, UNPUB; NALDININ L, UNPUB; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDSON JH, 1995, J GEN VIROL, V76, P691, DOI 10.1099/0022-1317-76-3-691; RICHARDSON JH, 1993, J VIROL, V67, P3997, DOI 10.1128/JVI.67.7.3997-4005.1993; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VERMA IM, 1994, MOL MED, V1, P2; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILLIAMS RS, 1995, NAT MED, V1, P1137, DOI 10.1038/nm1195-1137; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	66	3767	4299	6	399	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					263	267		10.1126/science.272.5259.263	http://dx.doi.org/10.1126/science.272.5259.263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602510				2022-12-01	WOS:A1996UE72900040
J	Lu, KP; Hanes, SD; Hunter, T				Lu, KP; Hanes, SD; Hunter, T			A human peptidyl-prolyl isomerase essential for regulation of mitosis	NATURE			English	Article							PROTEIN-KINASE; ASPERGILLUS-NIDULANS; YEAST; GENE; INDUCTION; NIMA	THE NIMA kinase is essential for progression through mitosis in Aspergillus nidulans(1-6), and there is evidence for a similar pathway in other eukaryotic cells(5-8). Here we describe the human protein Pin1, a peptidyl-prolyl cis/trans isomerase (PPIase) that interacts with NIMA. PPIases are important in protein folding, assembly and/or transport(9-13), but none has so far been shown to be required for cell viability(9-11). Pin1 is nuclear PPIase containing a WW protein interaction domain, and is structurally and functionally related to Ess1/Ptf1, an essential protein in budding yeast(14,15). PPIase activity is necessary for Ess1/Pin1 function in yeast. Depletion of Pin1/Ess1 from yeast or HeLa cells induces mitotic arrest, whereas HeLa cells overexpressing Pin1 arrest in the G2 phase of the cell cycle. Pin1 is thus an essential PPIase that regulates mitosis presumably by interacting with MMA and attenuating its mitosis-promoting activity.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR, LAB DEV GENET, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Lu, KP (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; FISCHER G, 1994, ANGEW CHEM INT EDIT, V63, P67; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPECTOR DL, 1993, REV CELL BIOL, V9, P265; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247	30	781	830	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					544	547						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606777				2022-12-01	WOS:A1996UE66300055
J	Savin, VJ; Sharma, R; Sharma, M; McCarthy, ET; Swan, SK; Ellis, E; Lovell, H; Warady, B; Gunwar, S; Chonko, AM; Artero, M; Vincenti, F; Fine, R; Wood, E; Trachtman, H				Savin, VJ; Sharma, R; Sharma, M; McCarthy, ET; Swan, SK; Ellis, E; Lovell, H; Warady, B; Gunwar, S; Chonko, AM; Artero, M; Vincenti, F; Fine, R; Wood, E; Trachtman, H			Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHANGE NEPHROTIC SYNDROME; ISOLATED RAT GLOMERULI; RENAL-TRANSPLANTATION; LYMPHOCYTE-T; CHILDREN; SCLEROSIS; PLASMA; PROTEINURIA; ALLOGRAFTS; LESION	Background, Heavy proteinuria and progressive renal injury recur after transplantation in up to 40 percent of patients with renal failure caused by idiopathic focal segmental glomerulosclerosis. A circulating factor may be responsible for this recurrence. Methods. To determine whether patients with focal segmental glomerulosclerosis have a circulating factor capable of causing glomerular injury, we tested serum samples from 100 patients with the disorder in an in vitro assay of glomerular permeability to albumin. Of the 56 patients who had undergone renal transplantation, 33 had recurrences, Sixty-four patients, many of whom had undergone transplantation, were being treated with dialysis. Thirty-one patients with other renal diseases and nine normal subjects were also studied, Results. The 33 patients with recurrent focal segmental glomerulosclerosis after transplantation had a higher mean (+/-SE) value for permeability to albumin (0.47+/-0.06) than the normal subjects (0.06+/-0.07) or the patients who did not have recurrences (0.14+/-0.06), After plasmapheresis in six patients with recurrences, the permeability was reduced (from 0.79+/-0.06 to 0.10+/-0.05, P=0.008), and proteinuria was significantly decreased, Patients with corticosteroid-sensitive nephrotic syndrome or with membranous nephropathy after transplantation had low levels of serum activity. The circulating factor bound to protein A and hydrophobic-interaction columns and had an apparent molecular mass of about 50 kd. Conclusions, A circulating factor found in some patients with focal segmental glomerulosclerosis is associated with recurrent disease after renal transplantation and may be responsible for initiating the renal injury.	MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA; HENNEPIN CTY MED CTR, DEPT MED, MINNEAPOLIS, MN USA; ARKANSAS CHILDRENS HOSP, LITTLE ROCK, AR 72202 USA; UNIV NEBRASKA, MED CTR, DEPT PEDIAT, OMAHA, NE USA; CHILDRENS MERCY HOSP, KANSAS CITY, KS USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT MED, KANSAS CITY, KS 66103 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA	Medical College of Wisconsin; Hennepin County Medical Center; Arkansas Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of California System; University of California San Francisco			Trachtman, Howard/GSE-2340-2022		NIDDK NIH HHS [DK 22040] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022040] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; ARTERO ML, 1994, AM J KIDNEY DIS, V23, P574, DOI 10.1016/S0272-6386(12)80381-7; BAKKER WW, 1986, KIDNEY INT, V30, P633; COCHAT P, 1993, PEDIATR NEPHROL, V7, P50, DOI 10.1007/BF00861567; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; DILEEPAN KN, 1993, J LAB CLIN MED, V121, P797; HESLAN JM, 1986, NEPHRON, V42, P187, DOI 10.1159/000183664; HOYER JR, 1972, LANCET, V2, P343; INGULLI E, 1991, PEDIATR NEPHROL, V5, P393, DOI 10.1007/BF01453661; INGULLI E, 1991, TRANSPLANTATION, V51, P401, DOI 10.1097/00007890-199102000-00025; JONES JMB, 1983, CLIN NEPHROL, V20, P72; KOYAMA A, 1991, KIDNEY INT, V40, P453, DOI 10.1038/ki.1991.232; LAGRUE G, 1975, BIOMED EXPRESS, V23, P73; LAUFER J, 1988, TRANSPLANTATION, V46, P540, DOI 10.1097/00007890-198810000-00014; LEWIS EJ, 1982, KIDNEY INT, V22, P315, DOI 10.1038/ki.1982.173; LI JZ, 1994, KIDNEY INT, V46, P1025, DOI 10.1038/ki.1994.363; MALEKZADEH MH, 1979, J PEDIATR-US, V95, P249; MENDOZA SA, 1992, J AM SOC NEPHROL, V3, P889; MORALES JM, 1989, NEPHRON, V53, P283, DOI 10.1159/000185762; MORALES JM, 1988, NEPHRON, V48, P241, DOI 10.1159/000184924; SAVIN VJ, 1994, KIDNEY INT, V46, P382, DOI 10.1038/ki.1994.285; SAVIN VJ, 1981, KIDNEY INT, V20, P188, DOI 10.1038/ki.1981.121; SAVIN VJ, 1992, J AM SOC NEPHROL, V3, P1260; SAVIN VJ, 1993, AM J KIDNEY DIS, V21, P347, DOI 10.1016/S0272-6386(12)80260-5; SENGGUTUVAN P, 1990, PEDIATR NEPHROL, V4, P21, DOI 10.1007/BF00858431; SHALHOUB RJ, 1974, LANCET, V2, P556; SWAN SK, 1991, CLIN TRANSPLANT, V5, P90; TEJANI A, 1988, KIDNEY INT, V33, P729, DOI 10.1038/ki.1988.59; Tejani Amir, 1993, Journal of the American Society of Nephrology, V4, P289; TIBOR N, 1994, RENAL PAHTOLOGY CLIN, P330; TIEBOSCH ATMG, 1987, KIDNEY INT, V32, P112, DOI 10.1038/ki.1987.179; TOMIZAWA S, 1985, NEPHRON, V41, P157, DOI 10.1159/000183572; TRACHTMAN H, 1987, AM J NEPHROL, V7, P13, DOI 10.1159/000167422; VERANI RR, 1986, AM J NEPHROL, V6, P263, DOI 10.1159/000167173; WILKINSON AH, 1989, CLIN SCI, V77, P43, DOI 10.1042/cs0770043; WINETZ JA, 1981, AM J KIDNEY DIS, V1, P91, DOI 10.1016/S0272-6386(81)80035-2; Work T.S., 1969, LAB TECHNIQUES BIOCH; YOSHIZAWA N, 1989, NEPHRON, V51, P370, DOI 10.1159/000185325; ZIMMERMAN SW, 1985, NEPHRON, V40, P241, DOI 10.1159/000183469; ZIMMERMAN SW, 1984, CLIN NEPHROL, V22, P32	40	570	581	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					878	883		10.1056/NEJM199604043341402	http://dx.doi.org/10.1056/NEJM199604043341402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596570	Bronze			2022-12-01	WOS:A1996UD37400002
J	Murphy, EL; Bryzman, S; Williams, AE; CoChien, H; Schreiber, GB; Ownby, HE; Gilcher, RO; Kleinman, SH; Matijas, L; Thomson, RA; Nemo, GJ				Murphy, EL; Bryzman, S; Williams, AE; CoChien, H; Schreiber, GB; Ownby, HE; Gilcher, RO; Kleinman, SH; Matijas, L; Thomson, RA; Nemo, GJ			Demographic determinants of hepatitis C virus seroprevalence among blood donors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; UNITED-STATES; INFECTION; ANTIBODIES; ASSOCIATION; SEROEPIDEMIOLOGY; EPIDEMIOLOGY; PREVALENCE; VIREMIA; DISEASE	Objective.-To measure demographic determinants of hepatitis C virus (HCV) seroprevalence among blood donors in the United States. Design.-Cross-sectional epidemiological study. Setting.-Five blood centers in different regions of the United States. Subjects.-A total of 862 398 consecutive volunteer blood donors with one or more nonautologous donations from March 1992 through December 1993. Methods.-Demographic data collection, serological screening with second-generation anti-HCV enzyme immunoassay, and confirmation with anti-HCV recombinant immunoblot. Results.-There were 3126 donors with at least one blood donation confirmed HCV-seropositive, for a crude prevalence of 3.6 per 1000. Age-specific HCV seroprevalence rose from 0.5 per 1000 in donors younger than 20 years to a maximum of 6.9 per 1000 in donors aged 30 to 39 years and declined in older age groups. There was interaction between age and educational attainment, with 30- to 49-year-olds with less than a high school diploma at highest risk of HCV infection (odds ratio [OR], 33.0; 95% confidence interval [CI], 23.0 to 47.2 compared with those younger than 30 years with a bachelor's degree or higher degree), Other independent risk factors for HCV seropositivity included male sex (OR, 1.9, 95% CI, 1.8 to 2.1), black race (OR, 1.7, 95% CI, 1.6 to 1.9), Hispanic ethnicity (OR, 1.3, 95% CI, 1.1 to 1.5), previous blood transfusion (OR, 2.8; 95% CI, 2.5 to 3.1), and first/only time donor status (OR, 4.2; 95% CI, 3.9 to 4.5, compared with repeat donors), Seropositivity for human T-lymphotropic virus types I and II, human immunodeficiency virus, or hepatitis B core antigen was highly associated with HCV seropositivity (OR, 10.4; 95% CI, 9.6 to 11.4 for one vs no marker). Conclusions.-Despite a low overall HCV prevalence in blood donors in the United States, there is marked variation in HCV seroprevalence by demographic subgroup, even after controlling for prior blood transfusion, a recognized risk factor for HCV. Further study of the prevalence of other parenteral risk factors such as past injection drug use among blood donors is needed.	HIGHLAND GEN HOSP,OAKLAND,CA; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD; WESTAT CORP,ROCKVILLE,MD; AMER RED CROSS,BLOOD SERV,DETROIT,MI; OKLAHOMA BLOOD INST,OKLAHOMA CITY,OK; UNIV CALIF LOS ANGELES,BLOOD & PLATELET CTR,LOS ANGELES,CA 90024; NHLBI,BETHESDA,MD 20892	American Red Cross; Westat; American Red Cross; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Murphy, EL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT LAB MED,BOX 0884,SAN FRANCISCO,CA 94143, USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097079, N01HB097077] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97079, N01-HB-97077, N01-HB-97078] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1328; ABDELAAL M, 1994, TRANSFUSION, V34, P135, DOI 10.1046/j.1537-2995.1994.34294143941.x; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ARCHER GT, 1992, MED J AUSTRALIA, V157, P225, DOI 10.5694/j.1326-5377.1992.tb137122.x; CHIARAMONTE M, 1991, ITAL J GASTROENTEROL, V23, P555; *CTR BIOL EV RES, 1992, MEM REG BLOOD EST RE; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; ESTEBAN JI, 1989, LANCET, V2, P294; ESTEBAN R, 1993, J HEPATOL, V17, pS67, DOI 10.1016/S0168-8278(05)80427-1; GARSON JA, 1992, VOX SANG, V62, P218, DOI 10.1111/j.1423-0410.1992.tb01202.x; HOLSEN DS, 1993, EUR J CLIN MICROBIOL, V12, P673, DOI 10.1007/BF02009378; KALDOR JM, 1992, MED J AUSTRALIA, V157, P227, DOI 10.5694/j.1326-5377.1992.tb137123.x; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KHAN M, 1993, GASTROENTEROL JPN, V28, P28, DOI 10.1007/BF02989200; LAI ME, 1993, J MED VIROL, V41, P282, DOI 10.1002/jmv.1890410405; LEE SD, 1991, HEPATOLOGY, V13, P830, DOI 10.1016/0270-9139(91)90249-U; LIN CK, 1992, VOX SANG, V62, P98, DOI 10.1111/j.1423-0410.1992.tb01178.x; MELE A, 1994, AM J PUBLIC HEALTH, V84, P1640, DOI 10.2105/AJPH.84.10.1640; MOORE SB, 1995, TRANSFUSION, V35, P308, DOI 10.1046/j.1537-2995.1995.35495216079.x; NAKAGIRI I, 1993, J CLIN MICROBIOL, V31, P2974, DOI 10.1128/JCM.31.11.2974-2980.1993; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; SCHOUB BD, 1992, T ROY SOC TROP MED H, V86, P431, DOI 10.1016/0035-9203(92)90255-B; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; *US BUR CENS, 1993, 1993 STAT ABSTR US; WATANABE J, 1993, VOX SANG, V65, P199, DOI 10.1111/j.1423-0410.1993.tb02148.x; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; WILLIAMS A, 1993, TRANSFUSION, V33, pS59; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x	33	99	101	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					995	1000		10.1001/jama.275.13.995	http://dx.doi.org/10.1001/jama.275.13.995			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596257				2022-12-01	WOS:A1996UC12300026
J	Gallagher, RB				Gallagher, RB			Enter Listeria, unruffled	SCIENCE			English	Editorial Material														Gallagher, Richard/0000-0001-5639-2187				Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3	4	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1825	1825		10.1126/science.271.5257.1825	http://dx.doi.org/10.1126/science.271.5257.1825			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596949				2022-12-01	WOS:A1996UC77800034
J	Sarzotti, M; Robbins, DS; Hoffman, PM				Sarzotti, M; Robbins, DS; Hoffman, PM			Induction of protective CTL responses in newborn mice by a murine retrovirus	SCIENCE			English	Article							CELL-MEDIATED-IMMUNITY; LEUKEMIA-VIRUS INFECTION; CYTOTOXIC T-CELL; INVIVO; TOLERANCE; LYMPHOCYTES; ONTOGENY; MATURATION; EXPRESSION; PARALYSIS	The susceptibility of neonates to virus-induced disease is thought to reflect, in part, the immaturity of their immune systems. However, inoculation of newborn mice with low doses of Cas-Br-M murine leukemia virus induced a protective cytotoxic T lymphocyte (CTL) response. The inability of neonates to develop a CTL response to high doses of virus was not the result of immunological immaturity but correlated with the induction of a nonprotective type 2 cytokine response. Thus, the initial viral dose is critical in the development of protective immunity in newborns.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT NEUROL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Sarzotti, M (corresponding author), VET AFFAIRS MED CTR, RES SERV, 10 N GREENE ST, BALTIMORE, MD 21201 USA.			Hoffman, Paul/0000-0003-2055-6455				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; ADKINS B, 1994, J IMMUNOL, V153, P3378; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FUCHS EJ, 1996, SCIENCE, V271, P1723; GARDNER MB, 1973, JNCI-J NATL CANCER I, V51, P1243, DOI 10.1093/jnci/51.4.1243; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOFFMAN PM, 1991, J NEUROIMMUNOL, V33, P157, DOI 10.1016/0165-5728(91)90059-G; HOFFMAN PM, 1984, J VIROL, V52, P734, DOI 10.1128/JVI.52.3.734-738.1984; HOFFMAN PM, 1981, J NEUROIMMUNOL, V1, P275, DOI 10.1016/0165-5728(81)90031-X; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HULI J, 1989, J IMMUNOL, V142, P800; JAMIESON BD, 1988, P NATL ACAD SCI USA, V85, P2265, DOI 10.1073/pnas.85.7.2265; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lafferty K J, 1986, Prog Clin Biol Res, V224, P87; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LU CY, 1980, P NATL ACAD SCI-BIOL, V77, P1597, DOI 10.1073/pnas.77.3.1597; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MOSIER DE, 1975, J EXP MED, V141, P216, DOI 10.1084/jem.141.1.216; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; OLIFF A, 1981, BLOOD, V58, P244; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PIGUET PF, 1981, J EXP MED, V154, P581, DOI 10.1084/jem.154.3.581; PILARSKI LM, 1977, J EXP MED, V146, P887, DOI 10.1084/jem.146.3.887; POWELL TJ, 1990, J IMMUNOL, V144, P854; ROBBINS DS, 1995, J VIROL, V69, P6847, DOI 10.1128/JVI.69.11.6847-6851.1995; ROBBINS DS, 1991, J NEUROIMMUNOL, V31, P9, DOI 10.1016/0165-5728(91)90081-H; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SARZOTTI M, 1994, AIDS RES HUM RETROV, V10, P1695, DOI 10.1089/aid.1994.10.1695; SARZOTTI M, 1991, MODERN APPROACHES NE, P355; SARZOTTI M, UNPUB; Sarzotti Marcella, 1993, Viral Immunology, V6, P207, DOI 10.1089/vim.1993.6.207; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SPEAR PG, 1974, J EXP MED, V139, P249, DOI 10.1084/jem.139.2.249; ZAMOYSKA R, 1989, EUR J IMMUNOL, V19, P111, DOI 10.1002/eji.1830190118	43	366	375	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	1996	271	5256					1726	1728		10.1126/science.271.5256.1726	http://dx.doi.org/10.1126/science.271.5256.1726			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596933				2022-12-01	WOS:A1996UB15100046
J	Pellmyr, O; LeebensMack, J; Huth, CJ				Pellmyr, O; LeebensMack, J; Huth, CJ			Non-mutualistic yucca moths and their evolutionary consequences	NATURE			English	Article							SEQUENCE	Interspecific mutualisms are regarded as having evolved from antagonistic or commensalistic interactions, with most mutualisms remaining facultative but some having coevolved into obligate reciprocal dependency(1-4). Underlying mutualism is an intrinsic conflict between the parties, in that each is under selection for increased exploitation of the other(3-7). Theoretical models suggest that this conflict is a source of evolutionary instability, and that evolution of 'cheating' by one party may lead to reciprocal extinction(4,6,7). Here we present phylogenetic evidence for reversal of an obligate mutualism: within the yucca moth complex, distinct cheater species derived from obligate pollinators inflict a heavy cost on their yucca hosts by laying their eggs but not pollinating the yucca. Phylogenetic data show the cheaters to have existed for a long time. Coexisting pollinators and cheaters are not sister taxa, supporting predictions that evolution of cheating within a single pollinator is evolutionarily unstable. Several lines of evidence support a hypothesis that host shifts preceded the reversal of obligate mutualism. Host or partner shifts is a mechanism that can provide a route of evolutionary escape among obligate mutualists in general.			Pellmyr, O (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.		Leebens-Mack, James/AAF-6770-2019	Leebens-Mack, James/0000-0003-4811-2231				AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; BROWN JL, ANN ENTOMOL SOC AM, V87, P795; BULL JJ, 1991, J THEOR BIOL, V149, P63, DOI 10.1016/S0022-5193(05)80072-4; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; Dawkins Richard, 1989, SELFISH GENE; FEIST MA, 1995, THESIS U CINCINNATI; Felsenstein J., 1993, PHYLOGENETIC INFEREN; GALIL J, 1969, Tijdschrift voor Entomologie, V112, P1; GARGAS A, 1995, SCIENCE, V268, P1492, DOI 10.1126/science.7770775; KEELEY JE, 1986, AM MIDL NAT, V115, P1, DOI 10.2307/2425831; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; MAINERO JS, 1985, BIOL MUTUALISM, P192; MCKELVEY S, 1947, YUCCAS SW US; MILES N J, 1983, Journal of the Lepidopterists' Society, V37, P207; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; PELLMYR O, 1992, P NATL ACAD SCI USA, V89, P2927, DOI 10.1073/pnas.89.7.2927; POWELL JA, 1992, TRENDS ECOL EVOL, V7, P10, DOI 10.1016/0169-5347(92)90191-D; RICHTER KS, 1995, NATURE, V376, P557, DOI 10.1038/376557b0; Riley C.V., 1892, ANN REP MO BOT GARD, P99; Riley CV, 1881, P AM ASS ADV SCI, V29, P617; Swofford D, 1993, PHYLOGENETIC ANAL US; Thompson J.N., 1994, COEVOLUTIONARY PROCE; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; TYRE AJ, 1993, OECOLOGIA, V94, P173, DOI 10.1007/BF00341314; VICKERY WL, 1991, AM NAT, V137, P847, DOI 10.1086/285197; WIEBES JT, 1994, P K NED AKAD WETENSC, V97, P491; Wright S, 1969, THEORY GENE FREQUENC, V2; YAMAUCHI A, 1995, AM NAT, V145, P434, DOI 10.1086/285748; [No title captured]	30	150	156	3	109	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					155	156		10.1038/380155a0	http://dx.doi.org/10.1038/380155a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600388				2022-12-01	WOS:A1996TZ97800049
J	Metzker, ML; Lu, J; Gibbs, RA				Metzker, ML; Lu, J; Gibbs, RA			Electrophoretically uniform fluorescent dyes for automated DNA sequencing	SCIENCE			English	Article								A class of dyes, BODIPY fluorophores, has been identified for automated DNA sequencing that has improved spectral characteristics compared with conventional fluorescein and rhodamine dyes. Single and double BODIPY dye primers were characterized in commercially available DNA sequencers and showed uniform electrophoretic mobilities and high fluorescence intensities. The improved physical properties of BODIPY dye primers were demonstrated by direct base-calling from the unprocessed fluorescent signals and improved heterozygote analyses of mixed-base populations. The high sensitivity of BODIPY dye primers requires at least 33 percent less reagent consumed per reaction than conventional dye primers, which should affect the costs of large genome-sequencing efforts.			Metzker, ML (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000823, P30HG000210] Funding Source: NIH RePORTER; NHGRI NIH HHS [1 RO1 HG00823, 1 P30 HG00210] Funding Source: Medline; NIAID NIH HHS [AI07483] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; FORESTER T, 1965, MODERN QUANTUM CHE 3, P93; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; METZKER ML, 1994, NUCLEIC ACIDS RES, V22, P4259, DOI 10.1093/nar/22.20.4259; METZKER ML, 1995, COMPUT APPL BIOSCI, V11, P187; METZKER ML, UNPUB; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	13	129	147	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1420	1422		10.1126/science.271.5254.1420	http://dx.doi.org/10.1126/science.271.5254.1420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596915				2022-12-01	WOS:A1996TY96100047
J	Nellen, JFJB; Smulders, YM; Frissen, PHJ; Slaats, EH; Silberbusch, J				Nellen, JFJB; Smulders, YM; Frissen, PHJ; Slaats, EH; Silberbusch, J			Lesson of the week - Hypovitaminosis D in immigrant women: Slow to be diagnosed	BRITISH MEDICAL JOURNAL			English	Article											Nellen, JFJB (corresponding author), ONZE LIEVE VROUW HOSP,DEPT INTERNAL MED,1E OOSTERPARKSTR 279,POB 95500,1090 HM AMSTERDAM,NETHERLANDS.		Smulders, YM/AAG-7506-2021					KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; Parfitt AM, 1990, METABOLIC BONE DIS C, P329; PEACH H, 1983, LANCET, V2, P1347; PEACH H, 1982, J CLIN PATHOL, V35, P625, DOI 10.1136/jcp.35.6.625; PREECE MA, 1973, LANCET, V1, P907; THALASSINOS NC, 1970, BMJ-BRIT MED J, V1, P76, DOI 10.1136/bmj.1.5688.76	6	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					570	572		10.1136/bmj.312.7030.570	http://dx.doi.org/10.1136/bmj.312.7030.570			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595292	Green Published			2022-12-01	WOS:A1996TY88500036
J	Harpaz, R; VonSeidlein, L; Averhoff, FM; Tormey, MP; Sinha, SD; Kotsopoulou, K; Lambert, SB; Robertson, BH; Cherry, JD; Shapiro, CN				Harpaz, R; VonSeidlein, L; Averhoff, FM; Tormey, MP; Sinha, SD; Kotsopoulou, K; Lambert, SB; Robertson, BH; Cherry, JD; Shapiro, CN			Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE WORKERS; SURFACE-ANTIGEN; OPERATING-ROOM; EXPOSURE; BLOOD; RISK; CONTAMINATION; OUTBREAK	Background. Although about 1 percent of surgeons are infected with hepatitis B virus (HBV), transmission from surgeons to patients is thought to be uncommon, In July 1992, a 47-year-old woman became ill with acute hepatitis B after undergoing a thymectomy in which a thoracic-surgery resident who had had acute hepatitis B six months earlier assisted. Methods. To determine whether the surgeon transmitted HBV to this patient and others, we conducted chart reviews, interviews, and serologic testing of thoracic-surgery patients at the two hospitals where the surgeon worked from July 1991 to July 1992, Hepatitis B surface antigen (HBsAg) subtypes and DNA sequences from the surgeon and from infected patients were determined. Results. Of 144 susceptible patients in whose surgery the infected surgeon participated, 19 had evidence of recent HBV infection (13 percent), One of the hospitals was selected for additional study, and none of the 124 susceptible patients of the other thoracic surgeons at this hospital had evidence of recent HBV infection (relative risk, infinity; 95 percent confidence interval, 4.7 to infinity). NO evidence was found for any common source of HBV other than the infected surgeon, The HBsAg subtype and the partial HBV DNA sequences from the surgeon were identical to those in the infected patients, Transmission of the infection was associated with cardiac transplantation (relative risk, 4.9; 95 percent confidence interval, 1,5 to 15.5) but not with other surgical procedures, The surgeon was positive for hepatitis B e antigen and had a high serum HBV DNA concentration (15 ng per milliliter), Our investigations identified no deficiencies in the surgeon's infection-control practices. Conclusions. In this outbreak there was surgeon-to-patient HBV transmission despite apparent compliance with recommended infection-control practices, We could not identify any specific events that led to transmission.	CTR DIS CONTROL & PREVENT,HEPATITIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,NATL CTR INFECT DIS,ATLANTA,GA 30333; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA	Centers for Disease Control & Prevention - USA; University of California System; University of California Los Angeles								ALTER HJ, 1975, NEW ENGL J MED, V292, P454, DOI 10.1056/NEJM197502272920904; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BELL DM, 1995, SURG CLIN N AM, V75, P1189; CARL M, 1982, LANCET, V1, P731; COUTINHO RA, 1982, LANCET, V1, P345; Dean A. G., 1990, EPI INFO VERSION 5 W; DODD RY, 1973, AM J EPIDEMIOL, V97, P111, DOI 10.1093/oxfordjournals.aje.a121487; FELL M, 1989, ANN ROY COLL SURG, V71, P7; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HARPAZ R, 1994, INFECT CONT HOSP EP, V15, P352; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HOSIE KB, 1988, LANCET, V2, P1500; Johnston B L, 1992, Can Commun Dis Rep, V18, P89; LABRECQUE DR, 1986, HEPATOLOGY, V6, P205, DOI 10.1002/hep.1840060209; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; MEYERS JD, 1978, JAMA-J AM MED ASSOC, V240, P1725, DOI 10.1001/jama.240.16.1725; OLSEN RJ, 1993, JAMA-J AM MED ASSOC, V270, P350, DOI 10.1001/jama.270.3.350; PATE JW, 1990, ANN THORAC SURG, V50, P248, DOI 10.1016/0003-4975(90)90743-P; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; PRENDERGAST TJ, 1991, WESTERN J MED, V154, P353; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; QUEBBEMAN EJ, 1992, ARCH SURG-CHICAGO, V127, P213; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; ROBERTSON BH, 1991, J INFECT DIS, V163, P286, DOI 10.1093/infdis/163.2.286; ROSE DA, 1994, INFECT CONT HOSP EP, V15, P349; SHAFRITZ DA, 1982, P NATL ACAD SCI-BIOL, V79, P5675, DOI 10.1073/pnas.79.18.5675; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; WELCH J, 1989, LANCET, V1, P205; WILLIAMS SV, 1975, JAMA-J AM MED ASSOC, V232, P1231, DOI 10.1001/jama.232.12.1231; WONG PS, 1993, ANN THORAC SURG, V56, P108, DOI 10.1016/0003-4975(93)90412-B; 1994, HOSP STAT AHA PROFIL; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, PROGRAM MANUAL GCG P	36	170	174	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					549	554		10.1056/NEJM199602293340901	http://dx.doi.org/10.1056/NEJM199602293340901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569821				2022-12-01	WOS:A1996TW69600001
J	Hoge, CW; Shlim, DR; Echeverria, P; Rajah, R; Herrmann, JE; Cross, JH				Hoge, CW; Shlim, DR; Echeverria, P; Rajah, R; Herrmann, JE; Cross, JH			Epidemiology of diarrhea among expatriate residents living in a highly endemic environment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TRAVELERS DIARRHEA; MONOCLONAL-ANTIBODIES; CAMPYLOBACTER-JEJUNI; FOREIGN RESIDENTS; ANTIGEN-DETECTION; UNITED-STATES; MEXICO; CELLS; GASTROENTERITIS	Objective.-To determine the etiology of diarrhea among expatriate residents living in a developing country and identify risk factors for travelers' diarrhea that are difficult to evaluate in tourist populations. Design.-Clinic-based case-control study. Setting.-Primary care travel medicine clinic in Kathmandu, Nepal. Participants.-A total of 69 expatriate residents with diarrhea, compared with 120 tourists with diarrhea, and 112 asymptomatic resident and tourist controls, selected systematically during a 1-year period. Main Outcome Measures.-Risk factors for diarrhea assessed by questionnaire and pathogen prevalence assessed by microbiologic analysis of stool specimens. Results.-The dominant risk factors for diarrhea among expatriate residents included younger age (P=.003), shorter duration of stay in Nepal (P<.001), and eating out in restaurants ((=.01). Eating raw vegetables, salads, fresh fruit, or ice served in restaurants was not significantly associated with diarrhea. Longer duration of residence was linearly correlated with protection. Enteric pathogens were identified in 44 (64%) of 69 residents with diarrhea compared with 100 (83%) of 120 tourists with diarrhea, with enterotoxigenic Escherichia coli, Campylobacter, and Shigella predominant for both groups. Pathogens were also found in stools;from 32 (37%) of 87 asymptomatic resident controls and 13 (52%) of 25 tourist controls. The attack rate of diarrhea among expatriates was estimated to be 49% (95% confidence interval, 37% to 61%) per month during the first 2 years of residence. The highest-risk months were April through July. Conclusions.-Diarrhea among expatriates in a highly endemic environment is a persistent risk. The extremely high prevalence of enteric pathogens among asymptomatic persons reflects widespread exposure. The most important risk factors for travelers' diarrhea are difficult to modify, including younger age, duration of stay, eating in restaurants, and seasonality. Preventive dietary recommendations may not be fully protective, suggesting that pretravel advice should emphasize empiric treatment in addition to strategies to avoid exposure.	ARMED FORCES RES INST MED SCI,DEPT BACTERIOL IMMUNOL & MOLEC GENET,BANGKOK 10400,THAILAND; CIWEC CLIN,KATMANDU,NEPAL; UNIV MASSACHUSETTS,MED CTR,DIV INFECT DIS,WORCESTER,MA; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Massachusetts System; University of Massachusetts Worcester; Uniformed Services University of the Health Sciences - USA								BLACK RE, 1990, REV INFECT DIS, V12, pS73; CHANG TW, 1978, ANN INTERN MED, V89, P428, DOI 10.7326/0003-4819-89-3-428_2; CROSS J H, 1968, Chinese Journal of Microbiology, V1, P117; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; Dean AG, 1994, EPI INFO VERSION 6 0; DUPONT HL, 1977, AM J EPIDEMIOL, V105, P37, DOI 10.1093/oxfordjournals.aje.a112353; ECHEVERRIA P, 1991, J INFECT DIS, V164, P550, DOI 10.1093/infdis/164.3.550; ECHEVERRIA P, 1990, P95; ENG TR, 1993, MORBIDITY MORTALITY; ERICSSON CD, 1980, GASTROENTEROLOGY, V79, P812; HABERBERGER RL, 1994, AM J TROP MED HYG, V51, P870, DOI 10.4269/ajtmh.1994.51.870; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KNUTTON S, 1991, INFECT IMMUN, V59, P365, DOI 10.1128/IAI.59.1.365-371.1991; KOLLARITSCH H, 1989, EUR J EPIDEMIOL, V5, P74, DOI 10.1007/BF00145049; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; MERSON MH, 1976, NEW ENGL J MED, V294, P1299, DOI 10.1056/NEJM197606102942401; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; OKHUYSEN PC, 1992, MED CLIN N AM, V6, P1357; ORSKOV F, 1975, ACTA PATH MICRO IM B, V83, P595; PICKERING LK, 1977, J INFECT DIS, V135, P1003, DOI 10.1093/infdis/135.6.1003; RYDER RW, 1981, J INFECT DIS, V144, P442, DOI 10.1093/infdis/144.5.442; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; TAYLOR DN, 1986, REV INFECT DIS, V8, pS136; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; WANG WLL, 1983, J CLIN MICROBIOL, V18, P803, DOI 10.1128/JCM.18.4.803-807.1983; 1992, WKLY EPIDEMIOL REC, V67, P273	33	77	77	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					533	538		10.1001/jama.275.7.533	http://dx.doi.org/10.1001/jama.275.7.533			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606474				2022-12-01	WOS:A1996TV56900030
J	Melcher, T; Maas, S; Herb, A; Sprengel, R; Seeburg, PH; Higuchi, M				Melcher, T; Maas, S; Herb, A; Sprengel, R; Seeburg, PH; Higuchi, M			A mammalian RNA editing enzyme	NATURE			English	Article							MOLECULAR-CLONING; CHANNELS; RECEPTOR	EDITING of RNA(1) by site-selective adcnosine deamination alters codons in brain-expressed pre-messenger RNAs for glutamate receptor (GluR) subunits(2-4) including a codon for a channel determinant (Q/R site) in GluR-B, which controls the Ca2+ permeability of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors(5,6). Editing of GluR pre-mRNAs requires a double-stranded RNA (dsRNA) structure formed by esonic and intronic sequences(4,7) and is catalysed by an unknown dsRNA adenosine deaminase. Here we report the cloning of complementary DNA for RED1, a dsRNA adenosine deaminase expressed in brain and peripheral tissues that efficiently edits the Q/R site in GluR-B pre-mRNA in vitro. This site is poorly edited by DRADA, which is distantly sequence related to RED1. Both deaminases edit the R/G site in GluR-B pre-mRNA, indicating that members of an emerging gene family catalyse adenosine deamination in nuclear transcripts with distinct but overlapping substrate specificities.	UNIV HEIDELBERG, ZMBH, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	29	425	437	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 1	1996	379	6564					460	464		10.1038/379460a0	http://dx.doi.org/10.1038/379460a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559253				2022-12-01	WOS:A1996TT30400063
J	Kinomura, S; Larsson, J; Gulyas, B; Roland, PE				Kinomura, S; Larsson, J; Gulyas, B; Roland, PE			Activation by attention of the human reticular formation and thalamic intralaminar nuclei	SCIENCE			English	Article							NEURONS; WAKING; STATES; BRAIN; CORE; CAT	It has been known for over 45 years that electrical stimulation of the midbrain reticular formation and of the thalamic intralaminar nuclei of the brain alerts animals. However, lesions of these sectors fail to impair arousal and vigilance in some cases, making the role of the ascending activating reticular system controversial. Here, a positron emission tomographic study showed activation of the midbrain reticular formation and of thalamic intralaminar nuclei when human participants went from a relaxed awake state to an attention-demanding reaction-time task. These results confirm the role of these areas of the brain and brainstem in arousal and vigilance.	KAROLINSKA INST,DEPT NEUROSCI,DIV HUMAN BRAIN RES,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Gulyas, Balazs/F-9508-2015					[Anonymous], 1993, BRAIN ACTIVATION; BERGSTROM M, 1981, J COMPUT ASSIST TOMO, V5, P136, DOI 10.1097/00004728-198102000-00027; DECETY J, 1992, NEUROREPORT, V3, P761, DOI 10.1097/00001756-199209000-00010; DENOYER M, 1991, BRAIN RES, V539, P287, DOI 10.1016/0006-8993(91)91633-C; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; GLENN LL, 1982, J NEUROSCI, V2, P1387; GREENBERG J, 1979, Acta Neurologica Scandinavica Supplementum, V60, P12; HU B, 1989, NEUROSCIENCE, V31, P1, DOI 10.1016/0306-4522(89)90026-2; INGVAR DH, 1964, ARCH NEUROL-CHICAGO, V11, P13, DOI 10.1001/archneur.1964.00460190017002; KAWASHIMA R, 1995, CEREB CORTEX, V2, P111; KETY SS, 1950, AM J MED, V8, P205, DOI 10.1016/0002-9343(50)90363-9; KITSIKIS A, 1981, BEHAV BRAIN RES, V3, P361, DOI 10.1016/0166-4328(81)90005-X; LINDSLEY DB, 1950, ELECTROEN CLIN NEURO, V2, P483, DOI 10.1016/0013-4694(50)90086-1; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OSULLIVAN BT, 1994, EUR J NEUROSCI, V6, P137, DOI 10.1111/j.1460-9568.1994.tb00255.x; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Roland P E, 1994, Hum Brain Mapp, V1, P173, DOI 10.1002/hbm.460010303; ROLAND P E, 1976, Archives of Neurology, V33, P551; ROLAND PE, 1987, J NEUROSCI, V7, P2373; SALLANON M, 1988, ARCH ITAL BIOL, V126, P87; Schaltenbrand G., 1959, EINFUHRUNG STEREOTAK; Scheibel ME, 1958, RETICULAR FORMATION, P31; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352, DOI 10.1152/jn.1982.48.2.352; STERIADE M, 1982, BRAIN RES, V238, P13, DOI 10.1016/0006-8993(82)90767-3; STERIADE M, 1982, EXP BRAIN RES, V46, P37; WEBSTER HH, 1988, BRAIN RES, V458, P285, DOI 10.1016/0006-8993(88)90471-4	28	460	478	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					512	515		10.1126/science.271.5248.512	http://dx.doi.org/10.1126/science.271.5248.512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560267				2022-12-01	WOS:A1996TR32200044
J	Richardson, A; Parsons, JT				Richardson, A; Parsons, JT			A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125(FAK)	NATURE			English	Article							FOCAL ADHESIONS; EXPRESSION; PP125FAK	FOCAL adhesion kinase(1,2) (pp125(FAK)) is a member of a growing family of structurally distinct protein tyrosine kinases that includes the recently identified FakB(3) and PYK2/CAK beta/RAFTK(4,6). Activation of pp125(FAK) has been functionally linked to the formation of focal adhesions, integrin-mediated sites of contact between the cell and the extracellular matrix(7,8). The carboxy-terminal domain of pp125(FAK) is also expressed as a separate protein called pp41/43(FRNK) (where FRNK represents pp125(FAK)-related non-kinase)(9). Here we show that pp41/43(FRNK) acts as an inhibitor of pp125(FAK) by transiently blocking the formation of focal adhesions on fibronectin and constitutively reducing tyrosine phosphorylation of both pp125(FAK) and of two focal adhesion proteins, tensin and paxillin. These inhibitory effects of pp41/43(FRNK) are reversed by co-expression of pp125(FAK), suggesting that pp125(FAK) and pp41/43(FRNK) compete for a common binding protein(s) whose association with pp125(FAK) is necessary for signalling by pp125(FAK). We propose that pp41/43F RNK functions as an endogenous regulator of pp125(FAK), thus providing an unusual means to regulate both tyrosine kinase activity and cellular adhesion to the extracellular matrix.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Virginia			Richardson, Alan/E-7615-2010; Richardson, Alan/I-4631-2015	Richardson, Alan/0000-0003-1825-3375				ABRAHAM S, 1995, J BIOL CHEM, V270, P27742; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; COLINGE M, 1992, MOL CELL BIOL, V12, P2359; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOSSELMAN S, 1994, CANCER RES, V54, P220; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561	22	441	453	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					538	540		10.1038/380538a0	http://dx.doi.org/10.1038/380538a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606775				2022-12-01	WOS:A1996UE66300053
J	RamirezLatorre, J; Yu, CR; Qu, X; Perin, F; Karlin, A; Role, L				RamirezLatorre, J; Yu, CR; Qu, X; Perin, F; Karlin, A; Role, L			Functional contributions of alpha 5 subunit to neuronal acetylcholine receptor channels	NATURE			English	Article							ANTISENSE OLIGONUCLEOTIDES; GENE FAMILY; EXPRESSION; SUBTYPES; LIGAND	LIGAND-GATED ion channels are multi-subunit complexes where each subunit-type is encoded by several related genes. Heterologous expression of any one of the neuronal nicotinic acetylcholine receptors (nAChR) alpha-type subunits, either alone or with any beta-type subunit, typically yields functional nAChR channels(1-5). A striking exception is the nAChR alpha 5 subunit: although apparently complexed with beta 2 and beta 4 nAChR subunits in neurons(6-8), and expressed in a subset of neurons within the central and peripheral nervous systems(9,10), heterologous expression of alpha 5, either alone or with any beta-type subunit has failed to yield functional channels(1.11). We demonstrate here that alpha 5 does participate in nAChRs expressed in heterologous systems and in primary neurons, and further that alpha 5 contributes to the lining of functionally unique nAChR channels, but only if coexpressed with both another alpha- and beta-type subunit. Furthermore, channels containing the alpha 5 subunit are potently activated and desensitized by nanomolar concentrations of nicotine.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,ECOLE NORMALE SUPER,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR MOL RECOGNIT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X; KARLIN, ARTHUR/0000-0002-4813-752X				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BRUSSAARD AB, 1994, PFLUG ARCH EUR J PHY, V429, P27, DOI 10.1007/BF02584027; CHEN J, 1995, BIOPHYS J, V69, P849, DOI 10.1016/S0006-3495(95)79959-3; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN S, 1991, CLIN NEUROPHARMACOL, V14, pS45, DOI 10.1097/00002826-199114001-00007; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; YU C, 1993, DEV GENET, V14, P296, DOI 10.1002/dvg.1020140407	28	319	320	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					347	351		10.1038/380347a0	http://dx.doi.org/10.1038/380347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598930				2022-12-01	WOS:A1996UC37900061
J	Lee, CG; Parikh, V; Itsukaichi, T; Bae, K; Edery, I				Lee, CG; Parikh, V; Itsukaichi, T; Bae, K; Edery, I			Resetting the Drosophila clock by photic regulation of PER and a PER-TIM complex	SCIENCE			English	Article							MESSENGER-RNA LEVELS; CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; PROTEIN-SYNTHESIS; MOSAIC ANALYSIS; VISUAL-SYSTEM; GENE-PRODUCT; RHYTHMS; LIGHT; MELANOGASTER	Circadian clocks can be reset by light stimulation. To investigate the mechanism of this phase shifting, the effects of light pulses on the protein and messenger RNA products of the Drosophila clock gene period (per) were measured. Photic stimuli perturbed the timing of the PER protein and messenger RNA cycles in a manner consistent with the direction and magnitude of the phase shift. In addition, the recently identified clock protein TIM (for timeless) interacted with PER in vivo, and this association was rapidly decreased by light. This disruption of the PER-TIM complex in the cytoplasm was accompanied by a delay in PER phosphorylation and nuclear entry and disruption in the nucleus by an advance in PER phosphorylation and disappearance. These results suggest a mechanism for how a unidirectional environmental signal elicits a bidirectional clock response.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,GRAD PROGRAM MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick								ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HALL JC, 1987, TRENDS GENET, V3, P185, DOI 10.1016/0168-9525(87)90231-9; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HSTINGS JW, 1991, NEURAL INTEGRATIVE A, P435; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; Lee C., UNPUB; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SAUNDERS DS, 1994, J INSECT PHYSL, V40, P947; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; YOUNG MW, 1989, NEURONAL CELLULAR OS, P529; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	39	229	236	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1740	1744		10.1126/science.271.5256.1740	http://dx.doi.org/10.1126/science.271.5256.1740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596938				2022-12-01	WOS:A1996UB15100051
J	Palmer, SR; Biffin, AH; Craig, PS; Walters, TM				Palmer, SR; Biffin, AH; Craig, PS; Walters, TM			Control of hydatid disease in Wales	BRITISH MEDICAL JOURNAL			English	Article							ECHINOCOCCUS-GRANULOSUS; CONTROL SCHEME; DOGS	Objectives-To evaluate the success of the south Powys hydatid control progamme by analysis of trends in cystic disease in humans and sheep and dog infestation. Design-A review of hospital admissions for human hydatid disease in 1984-90, abattoir prevalence surveys of hydatid cysts in adult sheep, arecoline acetarsol and coproantigen surveys of prevalence of Echinococcus infestation in dogs. Setting-All hospitals in England and Wales, three abattoirs, and dog populations in mid and south east Wales. Subjects-Residents of England and Wales admitted to hospital between 1984 and 1990 with a new diagnosis of human hydatid disease (International Classification of Diseases (ICD), ninth revision, code 122) acquired in the United Kingdom. Results-The average annual incidence of human hydatid disease in Powys, mid-Wales, fell from 3.9x10(-5) in 1974-83 to 2.3x10(-5) in 1984-90. Age specific incidence rates in Wales declined over this period only in children, and no cases occurred in children (<15 years) in Powys. Two Welsh children who lived in Gwent and mid-Glamorgan were infected. Prevalence of hydatid cysts in old sheep from south Wales declined during the control period, but in 1993 prevalence of cysts was 13%. Prevalence of E granulosus infestation was zero in the control area in 1993, but it was 2.4% in Powys dogs outside the control area in 1989 and 9.2% in dogs in Gwent in 1991. Conclusions-Human hydatid disease has been successfully controlled in south Powys but cystic echinococcosis is still endemic in sheep in mid-Wales, and there is a focus of infection in humans, sheep, and dogs in the bordering areas of Gwent and mid-Glamorgan. There is considerable potential for an upsurge in human cases if control measures are relaxed.	UNIV SALFORD,DEPT BIOL SCI,SALFORD M5 4WT,LANCS,ENGLAND; HLTH PROMOT UNIT,POWYS HLTH PROMOT,BRECON LD3 0LS,POWYS,WALES	University of Salford	Palmer, SR (corresponding author), CTR COMMUNICABLE DIS SURVEILLANCE,WELSH UNIT,PUBL HLTH LAB SERV,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.							ALLAN JC, 1992, PARASITOLOGY, V104, P347, DOI 10.1017/S0031182000061801; BARONET D, 1994, ANN TROP MED PARASIT, V88, P482; CRAIG PS, 1995, VET PARASITOL, V56, P293, DOI 10.1016/0304-4017(94)00680-B; FRNACIS B, 1993, GLIM SYSTEM RELEASE; GEMMELL MA, 1981, FAO UNEP WHO GUIDELI; LLOYD S, 1991, VET REC, V129, P73, DOI 10.1136/vr.129.4.73; PALMER SR, 1987, EPIDEMIOL INFECT, V99, P693, DOI 10.1017/S0950268800066553; SWAN AV, 1991, OXFORD TXB PUBLIC HL, V2; THOMAS TDL, 1966, THESIS LIVERPOOL U; WALTERS TMH, 1986, J SMALL ANIM PRACT, V27, P693, DOI 10.1111/j.1748-5827.1986.tb03769.x; WALTERS TMH, 1992, VET REC, V131, P39, DOI 10.1136/vr.131.2.39; WALTERS TMH, 1978, VET REC, V102, P257, DOI 10.1136/vr.102.12.257; WALTERS TMH, 1980, VET PARASITOL, V7, P185, DOI 10.1016/0304-4017(80)90022-9	13	32	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					674	675						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597734	Green Published			2022-12-01	WOS:A1996UB11000024
J	Campbell, KHS; McWhir, J; Ritchie, WA; Wilmut, I				Campbell, KHS; McWhir, J; Ritchie, WA; Wilmut, I			Sheep cloned by nuclear transfer from a cultured cell line	NATURE			English	Article							EMBRYOS; TRANSPLANTATION	Nuclear transfer has been used in mammals as both a valuable tool in embryological studies(1) and as a method for the multiplication of 'elite' embryos(2-4). Offspring have only been reported when early embryos, or embryo-derived cells during primary culture, were used as nuclear donors(5,6). Here we provide the first report, to our knowledge, of live mammalian offspring following nuclear transfer from an established cell line. Lambs were born after cells derived from sheep embryos, which had been cultured for 6 to 13 passages, were induced to quiesce by serum starvation before transfer of their nuclei into enucleated oocytes. Induction of quiescence in the donor cells may modify the donor chromatin structure to help nuclear reprogramming and allow development. This approach will provide the same powerful opportunities for analysis and modification of gene function in livestock species that are available in the mouse through the use of embryonic stem cells(7).			Campbell, KHS (corresponding author), ROSLIN INST EDINBURGH, ROSLIN EH25 9PS, MIDLOTHIAN, SCOTLAND.							BONDIOLI KR, 1990, THERIOGENOLOGY, V33, P165, DOI 10.1016/0093-691X(90)90607-U; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BUCHANAN FC, 1994, ANIM GENET, V25, P60, DOI 10.1111/j.1365-2052.1994.tb00069.x; CAMPBELL KHS, 1994, BIOL REPROD, V50, P1385, DOI 10.1095/biolreprod50.6.1385; CAMPBELL KHS, 1993, BIOL REPROD, V49, P933, DOI 10.1095/biolreprod49.5.933; CHESNE P, 1993, CR ACAD SCI III-VIE, V316, P487; COLLAS P, 1994, MOL REPROD DEV, V38, P264, DOI 10.1002/mrd.1080380306; Galli C., 1994, Zygote, V2, P385; Gerfen RW, 1995, ANIM BIOTECHNOL, V6, P1, DOI 10.1080/10495399509525828; HOOPER ML, 1992, EMBRYONAL STEM CELLS; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; PIEDRAHITA JA, 1990, THERIOGENOLOGY, V34, P879, DOI 10.1016/0093-691X(90)90559-C; PRATHER RS, 1990, INT REV CYTOL, V120, P169; SIMS M, 1994, P NATL ACAD SCI USA, V91, P6143, DOI 10.1073/pnas.91.13.6143; SZOLLOSI D, 1988, J CELL SCI, V91, P603; WHITFIELD JF, 1985, CONTROL ANIMAL CELL, V1, P331; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0	18	1251	1462	4	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					64	66		10.1038/380064a0	http://dx.doi.org/10.1038/380064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598906				2022-12-01	WOS:A1996TY87700056
J	Feher, MD; Simms, JP; Lant, AF				Feher, MD; Simms, JP; Lant, AF			History of chickenpox and steroid cards: A new warning?	BRITISH MEDICAL JOURNAL			English	Article									CHELSEA & WESTMINSTER HOSP,DEPT PHARM,LONDON SW10 9NH,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT PHARM,LONDON SW3 6LX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Feher, MD (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,LONDON SW10 9NH,ENGLAND.							*COMM SAF MED, 1994, CURR PROBL PHARM, V20; *DEP HLTH, 1994, CORT VAR ZOST VIR CM; DOWELL SF, 1993, PEDIATRICS, V92, P223; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					542	543		10.1136/bmj.312.7030.542	http://dx.doi.org/10.1136/bmj.312.7030.542			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595283	Green Published			2022-12-01	WOS:A1996TY88500023
J	Jewitt, D; Senay, M; Matthews, H				Jewitt, D; Senay, M; Matthews, H			Observations of carbon monoxide in comet Hale-Bopp	SCIENCE			English	Article							P/HALLEY	The recently discovered comet Hale-Bopp (C/1995 O1) sports a bright dust coma even though it is still far from the sun (presently 6 astronomical units). This feature has attracted considerable interest in the public and scientific arenas. The comet is headed toward perihelion at 0.92 astronomical unit in April 1997 and is widely expected to then become a spectacular naked-eye comet. With millimeter-wave observations, carbon monoxide (CO) has been identified as the driver for the early activity observed in Hale-Bopp.	JOINT ASTRON CTR,HILO,HI 96720; NATL RES COUNCIL CANADA,HERZBERG INST ASTROPHYS,OTTAWA,ON K1A 0R6,CANADA	National Research Council Canada	Jewitt, D (corresponding author), UNIV HAWAII,INST ASTRON,2680 WOODLAWN DR,HONOLULU,HI 96822, USA.							AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; BAILEY M, UNPUB; BOICE DC, 1993, P DISTANT COMET ACTI, P134; Brown G. N.  Jr., 1980, Advances in Cryogenic Engineering. Vol.25. Proceedings of the 1979 Cryogenic Engineering Conference, P662; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; CROVISIER J, 1995, 27 ANN M AM ASTR SOC; CROVISIER J, 1983, ASTRON ASTROPHYS, V1223, P61; DAVIES J, 1995, 6225 INT ASTR UN; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; HICKS M, 1995, 6200 INT ASTR UN; HUEBNER WF, 1992, SOLAR PHOTO RATES PL, P273; Jewitt D., 1990, Astrophysical Journal, V351, P277, DOI 10.1086/168463; JEWITT DC, 1991, COMETS POST HALLEY E, P19; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; LUU JX, 1990, ASTRON J, V100, P913, DOI 10.1086/115571; MATTHEWS H, 1995, 6234 INT ASTR UN; MCNAUGHT RH, 1995, 6198 INT ASTR UN; PRIALNIK D, 1989, ADV SPACE RES, V9, P25; RAUER H, 1995, 6236 INT ASTR UN; SAMARASINHA NH, 1994, ICARUS, V108, P103, DOI 10.1006/icar.1994.1044; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P469; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WHIPPLE FL, 1950, ASTROPHYS J, V111, P375, DOI 10.1086/145272; WOMACK M, 1995, 6276 INT ASTRON UNIO	24	61	61	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1110	1113		10.1126/science.271.5252.1110	http://dx.doi.org/10.1126/science.271.5252.1110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599086				2022-12-01	WOS:A1996TW70100036
J	Endress, M; Zinner, E; Bischoff, A				Endress, M; Zinner, E; Bischoff, A			Early aqueous activity on primitive meteorite parent bodies	NATURE			English	Article							EARLY SOLAR-SYSTEM; INTERSTELLAR GRAINS; ISOTOPE SYSTEMATICS	THE interstellar material from which the Solar System formed has been modified by many processes(1): evaporation and condensation in the solar nebula, accretion into protoplanetary bodies and post-accretion processes within these bodies, Meteorites provide a record of these events and their chronology(2), Carbonaceous CI chondrites are among the most primitive, undifferentiated meteorites(3-6), but nevertheless show evidence of post-accretion alteration(7); they contain carbonates that are believed to have formed by reactions between anhydrous CI precursor materials and circulating fluids in the meteorite parent body (or bodies), yet little is known about the nature of these reactions or the timescale on which they occurred, Here we report measurements of excess Cr-53-formed by the decay of short-lived Mn-53-in five carbonate fragments from the CI chondrites Orgueil and Ivuna. Our results show that aqueous alteration on small protoplanetary bodies must have begun less than 20 Myr after the time of formation of the oldest known solar-nebula condensates(2) (Allende refractory inclusions). This upper limit is much shorter than that of 50 Myr inferred from previous studies(8), and clearly establishes aqueous alteration as one of the earliest processes in the chemical evolution of the Solar System.	WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,ST LOUIS,MO 63130; UNIV MUNSTER,INST PLANETOL,D-48149 MUNSTER,GERMANY	Washington University (WUSTL); University of Munster								ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; ENDRESS M, 1994, METEORITICS, V29, P463; Endress M, 1996, GEOCHIM COSMOCHIM AC, V60, P489, DOI 10.1016/0016-7037(95)00399-1; FREDRIKSSON K, 1988, METEORITICS, V23, P35, DOI 10.1111/j.1945-5100.1988.tb00894.x; Kerridge JF., 1988, METEORITES EARLY SOL; Lugmair G. W., 1992, LUNAR PLANET SCI, VXXIII, P823; LUGMAIR GW, 1994, LPS, V25, P813; MACDOUGALL JD, 1984, NATURE, V307, P249, DOI 10.1038/307249a0; MACDOUGALL JD, 1989, METEORITICS, V24, P297; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MANHES G, 1988, COMPTES RENDUS ATP P, P323; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; Richardson S. M., 1978, Meteoritics, V13, P141, DOI 10.1111/j.1945-5100.1978.tb00803.x; SCATENAWACHEL DE, 1984, LUNAR PLANET SCI, V15, P718; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; Tilton G. G., 1988, METEORITES EARLY SOL, P259; Zinner E., 1988, METEORITES EARLY SOL; [No title captured]; [No title captured]	21	128	132	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					701	703		10.1038/379701a0	http://dx.doi.org/10.1038/379701a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602215				2022-12-01	WOS:A1996TW56700043
J	Koo, D; Maloney, K; Tauxe, R				Koo, D; Maloney, K; Tauxe, R			Epidemiology of diarrheal disease outbreaks on cruise ships, 1986 through 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHIGELLOSIS; ABOARD	Objective.-To describe the epidemiology of cruise-associated diarrheal disease outbreaks from 1986 through 1993, to determine if the incidence had changed since 1985, and to determine the preventability of outbreaks that continue to occur. Design.-The numerator data were collated from Centers for Disease Control and Prevention (CDC) outbreak investigation reports from 1986 through 1993. The denominator data were summations of cruise ship data on the number of passengers and length of cruises collected during routine diarrheal illness surveillance, available only for the period 1989 through 1993. Setting.-Cruise ships with outbreaks of diarrheal disease. Participants.-Cruise ship passengers and crew or staff who participated in the original investigations. Main Outcome Measures.-The incidence of outbreaks during the study period, pathogens isolated, and vehicles of transmission implicated in investigations. Results.-Among cruises of 3 to 15 days, CDC staff investigated 1.4 outbreaks per 1000 cruises, or 2.3 outbreaks per 10 million passenger-days. An etiologic agent was implicated in 21 (68%) of 31 investigated outbreaks: bacterial in 12, viral in nine. A specific vehicle of transmission was identified in 16. The most common vehicles of transmission were undercooked scallops (three outbreaks caused by enterotoxigenic Escherichia coli), eggs (two outbreaks caused by Salmonella serotype Enteritidis, one by Norwalk-like virus), and food items provided by caterers during onshore excursions (three outbreaks, one caused by Shigella sonnei). Conclusions.-Observance of two simple precautions could have prevented almost one third (5/16, or 31%) of the investigated outbreaks on cruise ships. Cruise lines have been reminded to cook seafoods thoroughly and to use pasteurized eggs for menu items calling for pooled eggs. Preventing food handlers from working while ill and riot using onshore caterers for offship excursions might have prevented at least an additional one third (5/16) of these outbreaks.	CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ADDISS DG, 1989, EPIDEMIOL INFECT, V103, P63, DOI 10.1017/S0950268800030363; DAVIES JW, 1977, CAN MED ASSOC J, V106, P877; LEW JF, 1991, AM J EPIDEMIOL, V134, P413, DOI 10.1093/oxfordjournals.aje.a116103; MERSON MH, 1975, JAMA-J AM MED ASSOC, V231, P723, DOI 10.1001/jama.231.7.723; MERSON MH, 1976, J MILK FOOD TECHNOL, V39, P285, DOI 10.4315/0022-2747-39.4.285; MERSON MH, 1975, AM J EPIDEMIOL, V101, P165, DOI 10.1093/oxfordjournals.aje.a112081; 1980, VESSEL SANITATION PR	7	45	47	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					545	547		10.1001/jama.275.7.545	http://dx.doi.org/10.1001/jama.275.7.545			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606476				2022-12-01	WOS:A1996TV56900032
J	Hurtley, SM				Hurtley, SM			Lysosomal degradation of ubiquitin-tagged receptors	SCIENCE			English	Editorial Material																		GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	4	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					617	617		10.1126/science.271.5249.617	http://dx.doi.org/10.1126/science.271.5249.617			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571124				2022-12-01	WOS:A1996TT87000035
J	Hiss, RG; Greenfield, S				Hiss, RG; Greenfield, S			Forum three: Changes in the US health care system that would facilitate improved care for non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				At the conclusion of the conference detailed in this supplement, conference attendees participated in one of three fora to discuss an assigned topic and incorporate conference presentations into the discussion. Forum Three, the results of which are reported here, addressed the challenging question of what changes in the U.S. health care system would facilitate improved care for patients with non-insulin-dependent diabetes mellitus (NIDDM). Using the nominal group process-a discussion technique designed to obtain a rank-ordered list of responses to the challenge question from a group of informed persons-forum Three made the following priority recommendations: 1) Establish universal access to the comprehensive preventive services necessary to optimally manage the estimated 16 million Americans with NIDDM; 2) create a system of co-management between primary and specialty care services; and 3) modify the current health care system to include a program for increased patient and public awareness of the seriousness of NIDDM, special training for primary care residents and practicing physicians in this area, development of standards of care, creation of a central coordinating agency for all aspects of diabetes care, and development of outcome-based goals for patients and providers.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI USA	Tufts Medical Center; University of Michigan System; University of Michigan				Greenfield, Sheldon/0000-0003-4628-1998				BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; DELBECQ AL, 1971, J APPL BEHAV SCI, V7, P466, DOI 10.1177/002188637100700404; FISHER EB, 1994, NIH943773 NAT I DIAB, P101; GREENFIELD S, 1995, MED CARE, V33, pAS47; GREENFIELD S, IN PRESS JAMA; HISS RG, 1994, DIABETES REV, V2, P310; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; 1989, NIH892925 US DEP HLT; 1976, DHEW781086 NAT HEART; 1976, DHEW761018 US DEP HL; 1995, DIABETES CARE S1, V18, P1	11	14	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				180	183		10.7326/0003-4819-124-1_Part_2-199601011-00021	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554216				2022-12-01	WOS:A1996TL94400021
J	Barker, FG; Jannetta, PJ; Bissonette, DJ; Larkins, MV; Jho, HD				Barker, FG; Jannetta, PJ; Bissonette, DJ; Larkins, MV; Jho, HD			The long-term outcome of microvascular decompression for trigeminal neuralgia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETROGASSERIAN GLYCEROL RHIZOTOMY; PARTIAL SENSORY RHIZOTOMY; HEMIFACIAL SPASM; MANAGEMENT; EXPERIENCE; INJECTION; GANGLION	Background. Several surgical procedures to treat trigeminal neuralgia (tic douloureux) are available, but most reports provide only short-term follow-up information. Methods. We describe the long-term results of surgery in 1185 patients who underwent microvascular decompression of the trigeminal nerve for medically intractable trigeminal neuralgia, The outcome of the procedure was assessed prospectively with annual questionnaires. Results. Of the 1185 patients who underwent microvascular decompression during the 20-year study period, 1155 were followed for 1 year or more after the operation, The median follow-up period was 6.2 years, Most postoperative recurrences of tic took place in the first two years after surgery, Thirty percent of the patients had recurrences of tie during the study period, and 11 percent underwent second operations for the recurrences. Ten years after surgery, 70 percent of the patients (as determined by Kaplan-Meier analysis) had excellent final results - that is, they were free of pain without medication for tie. An additional 4 percent had occasional pain that did not require long-term medication, Ten years after the procedure, the annual rate of the recurrence of tic was less than 1 percent, Female sex, symptoms lasting more than eight years, venous compression of the trigeminal-root entry zone, and the lack of immediate postoperative cessation of tic were significant predictors of eventual recurrence, Having undergone a previous ablative procedure did not lessen a patient's likelihood of having a cessation of tic after microvascular decompression, but the rates of burning and aching facial pain, as reported on the last follow-up questionnaire, were higher if a trigeminal-ganglion lesion had been created with radiofrequency current before microvascular decompression. Major complications included two deaths shortly after the operation (0.2 percent) and one brain-stem infarction (0.1 percent), Sixteen patients (1 percent) had ipsilateral hearing loss. Conclusions. Microvascular decompression is a safe and effective treatment for trigeminal neuralgia, with a high rate of long-term success. (C) 1996, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, NEUROL SERV, BOSTON, MA 02114 USA; UNIV PITTSBURGH, DEPT NEUROL SURG, PITTSBURGH, PA 15260 USA; SW OHIO NEUROSURG, PIQUA, OH USA	Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Apfelbaum R I, 1983, Clin Neurosurg, V31, P351; BARBA D, 1984, J NEUROSURG, V60, P104, DOI 10.3171/jns.1984.60.1.0104; BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201; BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359; BERGENHEIM AT, 1991, ACTA NEUROCHIR, V111, P114, DOI 10.1007/BF01400498; BRISMAN R, 1987, J NEUROSURG, V67, P44, DOI 10.3171/jns.1987.67.1.0044; BROGGI G, 1990, NEUROSURGERY, V26, P783, DOI 10.1227/00006123-199005000-00008; BURCHIEL KJ, 1988, J NEUROSURG, V69, P35, DOI 10.3171/jns.1988.69.1.0035; BURCHIEL KJ, 1988, J NEUROSURG, V69, P361, DOI 10.3171/jns.1988.69.3.0361; CUTBUSH K, 1964, AUST N Z J SURG, V64, P173; FUJIMAKI T, 1990, J NEUROSURG, V73, P212, DOI 10.3171/jns.1990.73.2.0212; GEHAN EA, 1969, J CHRON DIS, V21, P629, DOI 10.1016/0021-9681(69)90035-6; HAKANSON S, 1981, NEUROSURGERY, V9, P638, DOI 10.1227/00006123-198112000-00005; HAMLYN PJ, 1992, J NEUROSURG, V76, P948, DOI 10.3171/jns.1992.76.6.0948; Jannetta P J, 1979, Clin Neurosurg, V26, P607; JANNETTA PJ, 1977, NEUROCHIRURGIA, V20, P145; JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159; Jannetta PJ, 1990, TRIGEMINAL NEURALGIA, P201; KATUSIC S, 1990, ANN NEUROL, V27, P89, DOI 10.1002/ana.410270114; KLUN B, 1992, NEUROSURGERY, V30, P49, DOI 10.1227/00006123-199201000-00009; KOLLURI S, 1984, SURG NEUROL, V22, P235, DOI 10.1016/0090-3019(84)90005-3; Lee E.T., 1992, STATISTICAL METHODS; LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001; MENDOZA N, 1995, BRIT J NEUROSURG, V9, P13, DOI 10.1080/02688699550041692; MULLAN S, 1983, J NEUROSURG, V59, P1007, DOI 10.3171/jns.1983.59.6.1007; *NAT CTR HLTH STAT, 1989, VIT STAT US, V2; PIATT JH, 1984, NEUROSURGERY, V14, P462, DOI 10.1227/00006123-198404000-00012; POLLACK IF, 1988, J NEUROSURG, V68, P559, DOI 10.3171/jns.1988.68.4.0559; PUCA A, 1993, ACTA NEUROCHIR, P165; SLETTEBO H, 1993, ACTA NEUROCHIR, V122, P231, DOI 10.1007/BF01405534; SUN T, 1994, ACTA NEUROCHIR, V126, P144, DOI 10.1007/BF01476425; SWEET WH, 1974, J NEUROSURG, V40, P143, DOI 10.3171/jns.1974.40.2.0143; Sweet WH, 1993, BRAIN SURG COMPLICAT, V2, P2053; SZAPIRO J, 1985, NEUROSURGERY, V17, P920, DOI 10.1227/00006123-198512000-00009; TAARNHOJ P, 1952, J NEUROSURG, V9, P288, DOI 10.3171/jns.1952.9.3.0288; TAHA JM, 1995, J NEUROSURG, V83, P989, DOI 10.3171/jns.1995.83.6.0989; TAYLOR JC, 1981, POSTGRAD MED J, V57, P16, DOI 10.1136/pgmj.57.663.16; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; ZAKRZEWSKA JM, 1993, ACTA NEUROCHIR, V122, P225, DOI 10.1007/BF01405533	39	910	967	3	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1077	1083		10.1056/NEJM199604253341701	http://dx.doi.org/10.1056/NEJM199604253341701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598865				2022-12-01	WOS:A1996UG45700001
J	Gong, SC; Nussenzweig, MC				Gong, SC; Nussenzweig, MC			Regulation of an early developmental checkpoint in the B cell pathway by Ig beta	SCIENCE			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; ANTIGEN RECEPTOR; ALLELIC EXCLUSION; TRANSGENIC MICE; LYMPHOCYTES-B; BONE-MARROW; LIGHT-CHAIN; PRE-B; HEAVY; MU	Many of the cell fate decisions in precursor B cells and more mature B cells are controlled by membrane immunoglobulin (Ig) M heavy chain (m mu) and the Ig alpha-Ig beta signal transducers. The role of Ig beta in regulating early B cell development was examined in mice that lack Ig beta (Ig beta(-/-)). These mice had a complete block in B cell development at the immature CD43(+)B220(+) stage. Immunoglobulin heavy chain diversity (D-H) and joining (J(H)) segments rearranged, but variable (V-H) to DJ(H) recombination and Immunoglobulin messenger RNA expression were compromised. These experiments define an unexpected, early requirement for Ig beta to produce B cells that can complete VDJ(H) recombination.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019					ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; LOFFERT D, 1994, IMMUNOL REV, V137, P135, DOI 10.1111/j.1600-065X.1994.tb00662.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; PAPAVASILIOU F, 1995, J EXP MED, V182, P1389, DOI 10.1084/jem.182.5.1389; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; PETRIE HT, 1995, J EXP MED, V182, P121, DOI 10.1084/jem.182.1.121; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	47	233	237	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					411	414		10.1126/science.272.5260.411	http://dx.doi.org/10.1126/science.272.5260.411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602530				2022-12-01	WOS:A1996UG25200047
J	Yu, CE; Oshima, J; Fu, YH; Wijsman, EM; Hisama, F; Alisch, R; Matthews, S; Nakura, J; Miki, T; Ouais, S; Martin, GM; Mulligan, J; Schellenberg, GD				Yu, CE; Oshima, J; Fu, YH; Wijsman, EM; Hisama, F; Alisch, R; Matthews, S; Nakura, J; Miki, T; Ouais, S; Martin, GM; Mulligan, J; Schellenberg, GD			Positional cloning of the Warner's syndrome gene	SCIENCE			English	Article							VARIEGATED TRANSLOCATION MOSAICISM; WERNERS SYNDROME; XERODERMA-PIGMENTOSUM; FIBROBLAST-CULTURES; PUTATIVE HELICASES; DNA HELICASE; REPAIR; RECOMBINATION; CHROMOSOME-8; LYMPHOCYTES	Werner's syndrome (WS) is an inherited disease with clinical symptoms resembling premature aging. Early susceptibility to a number of major age-related diseases is a key feature of this disorder. The gene responsible for WS (known as WRN) was identified by positional cloning. The predicted protein is 1432 amino acids in length and shows significant similarity to DNA helicases. Four mutations in WS patients were identified. Two of the mutations are splice-junction mutations, with the predicted result being the exclusion of exons from the final messenger RNA. One of these mutations, which results in a frameshift and a predicted truncated protein, was found in the homozygous state in 60 percent of Japanese WS patients examined. The other two mutations are nonsense mutations. The identification of a mutated putative helicase as the gene product of the WS gene suggests that defective DNA metabolism is involved in the complex process of aging in WS patients.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT NEUROL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DIV MED GENET, DEPT MED, SEATTLE, WA 98195 USA; DARWIN MOLEC CORP, BOTHELL, WA 98021 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06510 USA; DAMASCUS CITY HOSP, ENDOCRINOL SECT, DAMASCUS, SYRIA; OSAKA UNIV, SCH MED, DEPT GERIATR MED, SUITA, OSAKA 565, JAPAN	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University; Osaka University			Hisama, Fuki M./I-7323-2019	Hisama, Fuki M./0000-0001-7772-7855	NATIONAL INSTITUTE ON AGING [P01AG001751, T32AG000057, R01AG012019] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG00057, R01 AG12019, P01 AG01751] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CERIMELE D, 1982, HUM GENET, V62, P25, DOI 10.1007/BF00295600; CHANG M, 1994, AM J PATHOL, V144, P1; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FREJTER WL, 1992, P NATL ACAD SCI USA, V89, P261; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUKUCHI K, 1985, SOMAT CELL MOLEC GEN, V11, P303, DOI 10.1007/BF01534688; FUKUCHI K, 1990, HUM GENET, V84, P249; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GODDARD KAB, IN PRESS AM J HUM GE; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTO M, 1978, J AM GERIATR SOC, V26, P341, DOI 10.1111/j.1532-5415.1978.tb03681.x; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GOTO M, 1981, CLIN GENET, V19, P8; HOEHN H, 1975, CYTOGENET CELL GENET, V15, P282, DOI 10.1159/000130526; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KIHARA K, 1994, JPN J HUM GENET, V39, P403, DOI 10.1007/BF01892385; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; MULLIGAN J, UNPUB; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; NAKURA J, 1994, GENOMICS, V23, P600, DOI 10.1006/geno.1994.1548; NAKURA J, 1993, GERONTOLOGY, V39, P11; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; SCHELLENBERG GD, 1992, LANCET, V339, P1002, DOI 10.1016/0140-6736(92)91590-5; SCHULZ VP, IN PRESS HUM GENET; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THANNHAUSER SJ, 1945, ANN INTERN MED, V23, P559, DOI 10.7326/0003-4819-23-4-559; TOLLEFSBOL TO, 1984, AGE, V7, P75, DOI 10.1007/BF02432205; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WANG JC, 1991, J BIOL CHEM, V266, P6659; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINSTON W, 1993, GENOMICS, V16, P685; YE L, 1995, GENOMICS, V28, P566, DOI 10.1006/geno.1995.1189; YU CE, 1994, AM J HUM GENET, V55, P356; YU CH, UNPUB	58	1385	1438	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					258	262		10.1126/science.272.5259.258	http://dx.doi.org/10.1126/science.272.5259.258			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602509				2022-12-01	WOS:A1996UE72900039
J	Stone, PH; Thompson, B; Anderson, V; Kronenberg, MW; Gibson, RS; Rogers, WJ; Diver, DJ; Theroux, P; Warnica, JW; Nasmith, JB; Kells, C; Kleiman, N; McCabe, CH; Schactman, M; Knatterud, GL; Braunwald, E				Stone, PH; Thompson, B; Anderson, V; Kronenberg, MW; Gibson, RS; Rogers, WJ; Diver, DJ; Theroux, P; Warnica, JW; Nasmith, JB; Kells, C; Kleiman, N; McCabe, CH; Schactman, M; Knatterud, GL; Braunwald, E			Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction - The TIMI III Registry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BYPASS-SURGERY; HEART-DISEASE; INTERVENTION-REGISTRY; ADVERSE PROGNOSIS; MORTALITY-RATES; WOMEN; GENDER; PATTERNS; BLACK	Objective.-To investigate the natural history and response to treatment of patients with unstable angina or non-Q-wave myocardial infarction (MI). Design.-Inception cohort. Setting.-Patients in general community, primary care, or referral hospitals. Patients.-All patients with an episode of unstable exertional chest pain or chest pain at rest presumed to be ischemic in origin lasting 5 minutes or more but without persisting ST-segment elevation greater than 30 minutes or the development of Q-waves were identified and enumerated in 18 participating hospitals. A subset of enumerated patients was selected to be followed prospectively using specific sampling strategies that would provide adequate numbers of black, women, and elderly (aged greater than or equal to 75 years) patients for comparison with their respective counterparts. Main Outcome Measures.-The primary analysis compared the incidence of death or MI at 42 days after entry into the prospective study according to race, sex, and age. Other outcomes considered were recurrent ischemia and the combined outcomes of death, MI, or recurrent ischemia by 42 days after entry. Results.-A total of 8676 admissions with unstable angina or non-Q-wave MI were enumerated and, of these, 3318 patients were selected for the prospective study. The direct adjusted mean age of the 3318 patients was 63.8 years. There were 943 blacks and 2375 nonblacks. Compared with nonblacks, blacks were less likely to be treated with intensive anti-ischemic therapy for their qualifying anginal episode and less likely to undergo invasive procedures (risk ratio [RR], 0.65; 95% confidence interval [CI], 0.58 to 0.72; P<.001). However, of those who underwent angiography (45% of blacks and 61% of nonblacks), blacks had less extensive and severe coronary stenoses than nonblacks. The incidence of death and MI was similar for blacks and nonblacks, but blacks had a lower incidence of recurrent ischemia. There were 1678 men and 1640 women. Women were less likely than men to receive intensive anti-ischemic therapy and less likely to undergo coronary angiography (RR, 0.71; 95% CI, 0.65 to 0.78; P<.001). Women had less severe and extensive coronary disease and were less likely to undergo revascularization, yet had a similar risk of experiencing an adverse cardiac event by 6 weeks. There were 2490 patients aged 75 years or less and 828 patients aged more than 75 years. Elderly patients received less aggressive anti-ischemic therapy and were less likely to undergo coronary angiography than their younger counterparts. Elderly patients had more severe and extensive coronary disease but fewer revascularization procedures than younger patients and experienced a much higher incidence of adverse cardiac events both in hospital and by 6 weeks. Conclusions.-Among patients presenting with acute ischemic chest pain without persistent ST-segment elevation, blacks appeared to have less severe coronary disease, received revascularization less frequently, and had less recurrent ischemia compared with nonblacks. Women also were found to have less severe coronary disease and were treated less intensely than men, but experienced similar outcomes. Elderly patients had more severe coronary disease than younger patients on coronary angiography, but were more likely to be treated medically, and they experienced far more adverse outcomes. These data suggest that more aggressive strategies should be directed to those patients with the greatest likelihood of adverse outcomes.	MARYLAND MED RES INST, TIMI III REGISTRY DATA COORDINATING CTR, BALTIMORE, MD 21210 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, TIMI III REGISTRY STUDY CHAIRMANS OFF, BOSTON, MA 02115 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; HARVARD UNIV, BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HOP SACRE COEUR, DEPT MED, MONTREAL, PQ H4J 1C5, CANADA; INST CARDIOL, DEPT MED, MONTREAL, PQ, CANADA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV CALGARY, FOOTHILLS PROV GEN HOSP, DEPT MED, CALGARY, AB, CANADA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, HOUSTON, TX USA; UNIV TEXAS, MED BRANCH, DEPT MED, GALVESTON, TX 77550 USA; UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA USA; VICTORIA GEN HOSP, DEPT MED, HALIFAX, NS B3H 2Y9, CANADA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Baylor College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; Universite de Montreal; Universite de Montreal; Institut de Cardiologie de Montreal; University of Alabama System; University of Alabama Birmingham; University of Calgary; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Medical Branch Galveston; University of Virginia; Dalhousie University; University of Victoria					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042428, R01HL042311] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42428, R01-HL-42311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY MJ, 1985, CIRCULATION, V71, P90; DIVER DJ, 1994, AM J CARDIOL, V74, P531, DOI 10.1016/0002-9149(94)90739-0; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GRAYBILL FA, 1976, THEORY APPLICATION L; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.268.11.1417; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; Scheffe H, 1999, ANAL VARIANCE, V72; SHRYOCK HS, 1975, METHODS MAT DEMOGRAP, P419; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; Snedecor GW, 1967, STATISTICAL METHODS, P199; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; TAYLOR HA, 1993, CIRCULATION, V88, P1484, DOI 10.1161/01.CIR.88.4.1484; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1988, AM J CARDIOL, V62, P860, DOI 10.1016/0002-9149(88)90882-X; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557	42	285	298	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1104	1112		10.1001/jama.275.14.1104	http://dx.doi.org/10.1001/jama.275.14.1104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601930				2022-12-01	WOS:A1996UD02700027
J	Guerette, PA; Ginzinger, DG; Weber, BHF; Gosline, JM				Guerette, PA; Ginzinger, DG; Weber, BHF; Gosline, JM			Silk properties determined by gland-specific expression of a spider fibroin gene family	SCIENCE			English	Article								Spiders produce a variety of silks that range from Lycra-like elastic fibers to Kevlar-like superfibers. A gene family from the spider Araneus diadematus was found to encode silk-forming proteins (fibroins) with different proportions of amorphous glycine-rich domains and crystal domains built from poly(alanine) and poly(glycine-alanine) repeat motifs. Spiders produce silks of different composition by gland-specific expression of this gene family, which allows for a range of mechanical properties according to the crystal-forming potential of the constituent fibroins. These principles of fiber property control may be important in the development of genetically engineered structural proteins.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER,BC V6T 1Z4,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z4,CANADA	University of British Columbia; University of British Columbia				Weber, Bernhard H.F./0000-0002-8808-7723				ANDERSEN SO, 1970, COMP BIOCHEM PHYSIOL, V35, P705, DOI 10.1016/0010-406X(70)90988-6; BECKWITT R, 1994, J BIOL CHEM, V269, P6661; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNY M, 1980, MECHANICAL PROPERTIE, P475; FRASER RDB, 1972, CONFORMATION FIBROUS; GOSLINE J, 1995, BIOMIMETICS DESIGN P, P237; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; GOSLINE JM, 1994, MAT SCI BIOTECHNOLOG, P328; HINMAN MB, 1994, MAT SCI BIOTECHNOLOG, P222; JACKSON C, 1995, MACROMOLECULES, V28, P5975, DOI 10.1021/ma00121a042; KERKAM K, 1991, NATURE, V349, P596, DOI 10.1038/349596a0; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSE JR, 1993, FASEB J, V7, pA1208, DOI 10.1096/fasebj.7.13.8405806; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; VOLLRATH F, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0392-70	16	343	387	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					112	115		10.1126/science.272.5258.112	http://dx.doi.org/10.1126/science.272.5258.112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600519				2022-12-01	WOS:A1996UD59700051
J	Ferrara, N; CarverMoore, K; Chen, H; Dowd, M; Lu, L; OShea, KS; PowellBraxton, L; Hillan, KJ; Moore, MW				Ferrara, N; CarverMoore, K; Chen, H; Dowd, M; Lu, L; OShea, KS; PowellBraxton, L; Hillan, KJ; Moore, MW			Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ES CELLS; ANGIOGENESIS; DIFFERENTIATION; EXPRESSION; RECEPTOR; VASCULOGENESIS; DISRUPTION; SUGGESTS; ONCOGENE	ANGIOGENESIS is required for a wide variety of physiological and pathological processes(1). The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF)(2,3) is a major mediator of pathological angiogenesis(4-6). Also, the expression of VEGF and its two receptors, Flt-1 and Flk-1/KDR, is related to the formation of blood vessels in mouse and rat embryos(7-10). Mice homozygous for mutations that inactivate either receptor die in utero between days 8.5 and 9.5 (refs 11,12). However, ligand(s) other than VEGF might activate such receptors(13,14). To assess the role of VEGF directly, we disrupted the VEGF gene in embryonic stem cells. Here we report the unexpected finding that loss of a single VEGF allele is lethal in the mouse embryo between days 11 and 12. Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	Roche Holding; Genentech; Roche Holding; Genentech; University of Michigan System; University of Michigan	Ferrara, N (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,4600 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BREIER G, 1992, DEVELOPMENT, V114, P521; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HILBERG F, 1992, ONCOGENE, V7, P2371; Hogan B., 2014, MANIPULATING MOUSE E; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LU LH, 1994, CELL VISION, V1, P169; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBRIDE WG, 1961, LANCET, V2, P1358; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Pugh RCB, 1976, PATHOLOGY TESTIS; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Sambrook J., 1989, MOL CLONING LAB MANU; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; THEILER K, 1989, HOUSE MOUSE; Tisher E, 1991, J BIOL CHEM, V266, P11947; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640	30	2789	2926	5	89	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					439	442		10.1038/380439a0	http://dx.doi.org/10.1038/380439a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602242	Green Submitted			2022-12-01	WOS:A1996UD59000062
J	Moore, RD; Chaisson, RE				Moore, RD; Chaisson, RE			Natural history of opportunistic disease in an HIV-infected urban clinical cohort	ANNALS OF INTERNAL MEDICINE			English	Article						AIDS-related opportunistic infections; human immunodeficiency virus infection; urban health services; pneumonia, Pneumocystis carinii; acquired immunodeficiency syndrome	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; SAN-FRANCISCO; TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; CONTROLLED TRIAL; UNITED-STATES; AIDS; PROPHYLAXIS	Objective: To determine the effect of contemporary clinical care on the natural history of opportunistic disease in an urban population infected with the human immunodeficiency virus (HIV). Setting: Urban university HIV clinic. Design: Retrospective and prospective observational study. Patients: 1246 HIV-infected patients with CD4(+) counts of 300 cells/mm(3) or less. Measurements: Incidence rates and Kaplan-Meier estimates of the probability of developing opportunistic disease with time, distribution of the CD4(+) counts at which opportunistic disease develops, survival after the development of opportunistic disease, and the association between preventive drug therapies and the occurrence of opportunistic infection. Results: The most common opportunistic disease was Candida esophagitis, which had an incidence of 13.3 events per 100 person-years and a 3-year Kaplan-Meier probability of 0.30. Pneumocystis carinii pneumonia, Mycobacterium avium complex bacteremia, cytomegalovirus, and the acquired immunodeficiency syndrome dementia complex occurred at rates of 5 to 9 events per 100 person-years and 3-year Kaplan-Meier probabilities of 0.15 to 0.22. Toxoplasmosis, cryptococcal meningitis, herpes zoster, the wasting syndrome, and Kaposi sarcoma occurred at rates of about 2 to 4 events per 100 person-years and with 3-year Kaplan-Meier probabilities of 0.05 to 0.10. Non-Hodgkin lymphoma, M. tuberculosis infection, progressive multifocal leukoencephalopathy, and cryptosporidiosis were the least common disorders, with an incidence of about 1 to 2 events per 100 person-years and a 3-year Kaplan-Meier probability less than 0.05. Only the incidences of cryptococcal meningitis, secondary P. carinii pneumonia, and herpes tester decreased (P < 0.05) between 1989-1992 and 1993-1995. Fluconazole use was associated with a decreased relative rate of 0.49 (P = 0.06) for cryptococcal meningitis and a decreased relative rate of 0.61 (P = 0.005) for esophageal candidiasis. Rifabutin use was associated with a decreased relative rate of 0.37 (P = 0.002) for M. avium complex bacteremia, and trimethoprim-sulfamethoxazole use was associated with decreased relative rates of 0.33 (P = 0.02) for secondary P. carinii pneumonia and 0.55 (P = 0.08) for primary P. carinii pneumonia. Candidiasis, herpes tester, and M. tuberculosis infection first occurred at a median CD4(+) count greater than 100 cells/mm(3), but all other opportunistic diseases first occurred at a median CD4(+) count less than 50 cells/mm(3). Median survival after diagnosis varied from 35 days for non-Hodgkin lymphoma to 680 days for herpes zoster. Conclusions: In the patients studied, the-incidences of secondary P. carinii pneumonia, cryptococcal meningitis, and herpes tester have declined in the past 5 years. The incidences of primary P. carinii pneumonia and Kaposi sarcoma appear to be declining compared with historical estimates. However, although these and other opportunistic diseases continue to be relatively frequent complications of HIV infection, they are first occurring at more advanced immunosuppression than in the past. Continued efforts are needed to develop effective strategies for preventing opportunistic disease in very advanced HIV infection.			Moore, RD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, 1830 E MONUMENT ST, ROOM 8059, BALTIMORE, MD 21205 USA.				AHRQ HHS [R01 HS07809] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BARTLETT JG, 1994, MED MANAGEMENT HIV I; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P507; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; COX DR, 1972, J R STAT SOC B, V34, P187; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GALLANT JE, 1994, ARCH INTERN MED, V154, P566, DOI 10.1001/archinte.154.5.566; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GILLESPIE SM, 1991, ANN NEUROL, V30, P597, DOI 10.1002/ana.410300413; GLESBY MJ, 1995, CLIN INFECT DIS, V21, P370, DOI 10.1093/clinids/21.2.370; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HOLMBERG SD, 1995, AM J EPIDEMIOL, V141, P395, DOI 10.1093/oxfordjournals.aje.a117441; JAFFE HW, 1983, J INFECT DIS, V148, P339, DOI 10.1093/infdis/148.2.339; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P336; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1992, AIDS, V6, P671, DOI 10.1097/00002030-199207000-00009; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RUTHERFORD GW, 1989, J INFECT DIS, V159, P569, DOI 10.1093/infdis/159.3.569; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELIK RM, 1984, AM J MED, V76, P493, DOI 10.1016/0002-9343(84)90669-7; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; SPECTOR SA, 1995, 2 NAT C HUM RETR WAS; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T; 1994, MMWR-MORBID MORTAL W, V43, P644; 1994, NEW ENGL J MED, V44, P81	50	229	239	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					633	+		10.7326/0003-4819-124-7-199604010-00003	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607591				2022-12-01	WOS:A1996UB51300003
J	Bevec, D; Jaksche, H; Oft, M; Wohl, T; Himmelspach, M; Pacher, A; Schebesta, M; Koettnitz, K; Dobrovnik, M; Csonga, R; Lottspeich, F; Hauber, J				Bevec, D; Jaksche, H; Oft, M; Wohl, T; Himmelspach, M; Pacher, A; Schebesta, M; Koettnitz, K; Dobrovnik, M; Csonga, R; Lottspeich, F; Hauber, J			Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EUKARYOTIC INITIATION FACTOR-5A; GENE-EXPRESSION REQUIRES; HUMAN T-CELLS; TRANS-ACTIVATOR; RESPONSIVE ELEMENT; REGULATORY GENES; CARBOXY-TERMINUS; TARGET SEQUENCE; MESSENGER-RNA	Eukaryotic initiation factor 5A (eIF-5A) is a cellular cofactor required for the function of the human immunodeficiency virus type-1 (HIV-1) Rev trans-activator protein. The majority of a set of eIF-5A mutants did not support growth of yeast cells having an inactivated genomic copy of eIF-5A, indicating that the introduced mutation eliminated eIF-5A activity. Two nonfunctional mutants, eIF-5AM13 and eIF-5AM14, retained their binding capacity for the HIV-1 Rev response element:Rev complex. Both mutants were constitutively expressed in human T cells. When these T cells were infected with replication-competent HIV-1, virus replication was inhibited. The eIF-5AM13 and eIF-5AM14 proteins blocked Rev trans-activation and Rev-mediated nuclear export.	SANDOZ GMBH,RES INST,DEPT IMMUNODERMATOL,A-1235 VIENNA,AUSTRIA; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Novartis; Sandoz; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society			Schebesta, Michael/B-5891-2008					ANSORGE W, 1982, EXP CELL RES, V140, P31, DOI 10.1016/0014-4827(82)90152-5; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870; BEVEC D, 1994, HUM GENE THER, V5, P193, DOI 10.1089/hum.1994.5.2-193; BEVEC D, UNPUB; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028; DOBROVNIK M, UNPUB; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KANG HA, 1994, J BIOL CHEM, V269, P3934; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MAGDOLEN V, 1994, MOL GEN GENET, V244, P646, DOI 10.1007/BF00282755; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; Pacher A, UNPUB; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOHL T, 1993, MOL GEN GENET, V241, P305; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	45	174	185	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1858	1860		10.1126/science.271.5257.1858	http://dx.doi.org/10.1126/science.271.5257.1858			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596953				2022-12-01	WOS:A1996UC77800044
J	Reuss, ML; Paneth, N; PintoMartin, JA; Lorenz, JM; Susser, M				Reuss, ML; Paneth, N; PintoMartin, JA; Lorenz, JM; Susser, M			The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; WEIGHT PREMATURE-INFANTS; THYROID-FUNCTION; BIRTH-WEIGHT; TRIIODOTHYRONINE CONCENTRATIONS; FREE-THYROXINE; THYROTROPIN; REPLACEMENT; DEFICIENCY; LESS	Background. Transient hypothyroxinemia, a common finding in premature infants, is not thought to have long-term sequelae or to require treatment. We investigated whether hypothyroxinemia in premature infants is a cause of subsequent motor and cognitive abnormalities. Methods. In this historical cohort study, we retrieved blood thyroxine values, obtained on routine screening in the first week of life, from state screening records of children who weighed 2000 g or less at birth, who were born at 33 weeks' gestation or earlier, and who were enrolled in a population-based study of the late sequelae of neonatal brain hemorrhage. We investigated the relation of these values to the odds for disabling cerebral palsy among 463 subjects for whom data were available and to the mental-development score on the Bayley Scales of Infant Development or the Stanford-Binet Intelligence Scales for Children at the age of two years in 400 subjects. The effects of severe hypothyroxinemia, defined as a blood thyroxine value more than 2.6 SD below the mean for New Jersey newborns, were assessed before and after adjustment for gestational age and potentially confounding variables. Results. In analyses adjusted for gestational age, infants with severe hypothyroxinemia had a risk of disabling cerebral palsy that was nearly 11 times that of infants without hypothyroxinemia (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 39.3) and a mean mental-development score at the age of two that was 15.4 points lower (95 percent confidence interval, 8.1 to 22.6 points) than the mean score of children with normal neonatal blood thyroxine concentrations. After adjustment for gestational age and multiple prenatal, perinatal, and early and late neonatal variables, severe hypothyroxinemia was still associated with an increased risk of disabling cerebral palsy (odds ratio, 4.4; 95 percent confidence interval, 1.0 to 18.6) and a reduction of nearly 7 points (95 percent confidence interval, 0.3 to 13.2 points) in the mental-development score. Conclusions. Severe hypothyroxinemia in preterm infants may be an important cause of problems in neurologic and mental development detected at the age of two years. (C) 1996, Massachusetts Medical Society.	COLUMBIA UNIV, SERGIEVSKY CTR, NEW YORK, NY USA; COLUMBIA UNIV, DEPT OBSTET & GYNECOL, NEW YORK, NY USA; MICHIGAN STATE UNIV, COLL HUMAN MED, PROGRAM EPIDEMIOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, COLL HUMAN MED, DEPT PEDIAT & HUMAN GENET, E LANSING, MI 48824 USA; UNIV PENN, SCH NURSING, PHILADELPHIA, PA 19104 USA	Columbia University; Columbia University; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine; University of Pennsylvania			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X	NICHD NIH HHS [HD-30278] Funding Source: Medline; NINDS NIH HHS [NS-20713] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020713] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATO M, 1989, HORM RES, V32, P213, DOI 10.1159/000181292; Bayley N., 1969, BAYLEY SCALES INFANT; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; CHOWDHRY P, 1984, PEDIATRICS, V73, P301; CUESTAS RA, 1979, J PEDIATR-US, V94, P643, DOI 10.1016/S0022-3476(79)80042-6; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DESCORBAR GM, 1987, HORM RES, V26, P12; EGGERMONT E, 1984, HELV PAEDIATR ACTA, V39, P209; ETLING N, 1984, HELV PAEDIATR ACTA, V39, P223; FABRIS N, 1987, J CLIN ENDOCR METAB, V65, P247, DOI 10.1210/jcem-65-2-247; FISHER DA, 1990, PEDIATR CLIN N AM, V37, P1297; FISHER DA, 1981, P SERONO S, V40, P225; FRANKLIN RC, 1986, ARCH DIS CHILD, V61, P589, DOI 10.1136/adc.61.6.589; FUSE Y, 1990, J DEV PHYSIOL, V14, P17; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HADEED AJ, 1981, PEDIATRICS, V68, P494; Harkavy K L, 1991, J Perinatol, V11, P117; HENNEMANN G, 1988, Acta Medica Austriaca, V15, P42; HETZEL BS, 1989, J NUTR, V119, P145, DOI 10.1093/jn/119.2.145; JOHN R, 1987, ANN CLIN BIOCHEM, V24, P461, DOI 10.1177/000456328702400506; KARNA P, 1991, AM J PERINAT, V8, P288, DOI 10.1055/s-2007-999399; KLEIN AH, 1979, PEDIATRICS, V63, P380; KOK JH, 1995, PEDIATR RES, V37, pA218; KOOISTRA L, 1994, J PEDIATR-US, V124, P903, DOI 10.1016/S0022-3476(05)83178-6; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LUCAS A, 1988, ARCH DIS CHILD, V63, P1201, DOI 10.1136/adc.63.10.1201; MEIJER WJ, 1992, ARCH DIS CHILD, V67, P944, DOI 10.1136/adc.67.7.944; MERCADO M, 1987, CLIN PEDIATR, V26, P343, DOI 10.1177/000992288702600704; MERCADO M, 1988, EARLY HUM DEV, V16, P131, DOI 10.1016/0378-3782(88)90093-X; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; OUDEN ALD, 1996, PEDIATR RES, V39, P142; PHAROAH P, 1981, DEV MED CHILD NEUROL, V23, P76; Pinto-Martin J, 1992, Paediatr Perinat Epidemiol, V6, P273, DOI 10.1111/j.1365-3016.1992.tb00767.x; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; ROBERTSON CMT, 1992, PEDIATRICS, V90, P750; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; SCHONBERGER W, 1981, EUR J PEDIATR, V135, P245, DOI 10.1007/BF00442098; STEIN SA, 1991, ADV EXP MED BIOL, V299, P47; TERM LM, 1972, STANFORD BINET INTEL; TILLOTSON SL, 1994, BRIT MED J, V309, P440, DOI 10.1136/bmj.309.6952.440; VANWASSENAER AG, 1993, ACTA ENDOCRINOL-COP, V129, P139, DOI 10.1530/acta.0.1290139; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5	43	276	285	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					821	827		10.1056/NEJM199603283341303	http://dx.doi.org/10.1056/NEJM199603283341303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596548	Bronze			2022-12-01	WOS:A1996UB95000003
J	Macgregor, SH; Hamley, JG; Dunbar, JA; Dodd, TRP; Cromarty, JA				Macgregor, SH; Hamley, JG; Dunbar, JA; Dodd, TRP; Cromarty, JA			Evaluation of a primary care anticoagulant clinic managed by a pharmacist	BRITISH MEDICAL JOURNAL			English	Article									TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND; ROBERT GORDON UNIV,ABERDEEN AB1 1FR,SCOTLAND	Robert Gordon University	Macgregor, SH (corresponding author), DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND.		Dunbar, James A/G-3034-2012					HALL J, 1994, PHARM J, V252, P230; JENNINGS I, 1991, J CLIN PATHOL, V44, P950, DOI 10.1136/jcp.44.11.950; RADLEY AS, 1995, J CLIN PATHOL, V48, P545, DOI 10.1136/jcp.48.6.545; RADLEY AS, 1994, PHARM J, V252, P91; 1990, J CLIN PATHOL, V43, P177	5	29	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					560	560		10.1136/bmj.312.7030.560	http://dx.doi.org/10.1136/bmj.312.7030.560			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595288	Green Published			2022-12-01	WOS:A1996TY88500031
J	Monaghan, G; Ryan, M; Seddon, R; Hume, R; Burchell, B				Monaghan, G; Ryan, M; Seddon, R; Hume, R; Burchell, B			Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome	LANCET			English	Article							CRIGLER-NAJJAR SYNDROME; DRUG-METABOLISM; GLUCURONIDATION; POPULATION; TYPE-2; LIVER	Background The genetic basis of Gilbert's syndrome is ill-defined. This common mild hyperbilirubinaemia sometimes presents as an intermittent jaundice, A reduced hepatic bilirubin UDP-glucuronosyltransferase (UGT) is associated with this syndrome, We have examined variation in the gene encoding the UGT1*1 enzyme and serum bilirubin levels in a Scottish population. Methods Blood was collected from 12 patients with confirmed or suspected Gilbert's syndrome, from 6 members of a family with 4 Gilbert members, and from 77 non-smoking, alcohol-free, drug-free volunteers recruited from the staff of a teaching hospital in Dundee. Polymerase chain reaction amplification was used to examine sequence variation of the promoter upstream of the UGT1*1 exon I, Genotypes were assigned as follows: 6/6 (homozygous for a common allele bearing the sequence [TA](6)TAA), 7/7 (homozygous for a rarer allele with the sequence [TA](7)TAA), and 6/7 (heterozygous with one of each allele). Findings Individuals in the population with the 7/7 genotype had significantly higher bilirubin concentrations than those who had the 6/7 or 6/6 genotype, 14 volunteers underwent a 24 h fasting test to see if they had Gilbert's syndrome, and all four positives had the 7/7 genotype. One confirmed Gilbert's patient, two recurrent jaundice patients (with suspected Gilbert's syndrome), and nine clinically diagnosed cases had the 7/7 genotype. Segregation of the 7/7 genotype with the Gilbert phenotype was also demonstrated in the family with four affected members. The frequency of the 7/7 genotype in this eastern Scottish population was 10-13%. Interpretation In a healthy population there was an association between;variation in bilirubin concentration and a mutation within the gene encoding the enzyme bilirubin UGT, This and other findings suggest the existence of a mild and a more severe form of Gilbert's syndrome, depending on whether the gene defect lies in the promoter sequence upstream of UGT1*I exon I, as here (mild), or in the coding sequence (severe) of the gene.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH & OBSTET & GYNAECOL, DUNDEE DD1 9SY, SCOTLAND; N DEVON DIST HOSP, DEPT CHEM PATHOL, BARNSTAPLE, DEVON, ENGLAND	University of Dundee	Monaghan, G (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT BIOCHEM MED, DUNDEE DD1 9SY, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AONO S, 1995, LANCET, V345, P958, DOI 10.1016/S0140-6736(95)90702-5; BAILEY A, 1977, LANCET, V1, P931; BOSMA P, 1994, HEPATOLOGY       OCT, pA226; CARULLI N, 1976, GUT, V17, P581, DOI 10.1136/gut.17.8.581; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; EBNER T, 1993, MOL PHARMACOL, V43, P649; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; FEVERY J, 1981, EUR J CLIN INVEST, V11, P417, DOI 10.1111/j.1365-2362.1981.tb02006.x; GOLLAN JL, 1975, GASTROENTEROLOGY, V68, P1543; IDEO G, 1971, EXPERIENTIA, V27, P24, DOI 10.1007/BF02137719; KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183; LASCELLES PT, 1989, DIAGNOSTIC FUNCTION, P24; MACKLON AF, 1979, CLIN PHARMACOKINET, V4, P223, DOI 10.2165/00003088-197904030-00004; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOHRABI NN, 1994, THESIS U DUNDEE; OWENS D, 1973, BRIT MED J, V3, P559, DOI 10.1136/bmj.3.5880.559; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; REAVEN GM, 1994, J INTERN MED, V236, P13; ROSMA PJ, 1995, NEW ENGL J MED, V333, P1171; SUTHERLAND L, 1993, BIOCHEM PHARMACOL, V45, P295, DOI 10.1016/0006-2952(93)90064-4; Thompson R.P.H., 1981, FAMILIAL HYPERBILIRU, P91; WATSON KJR, 1989, BAILLIERE CLIN GASTR, V3, P337, DOI 10.1016/0950-3528(89)90004-3	22	507	528	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1996	347	9001					578	581		10.1016/S0140-6736(96)91273-8	http://dx.doi.org/10.1016/S0140-6736(96)91273-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596320				2022-12-01	WOS:A1996TX69400011
J	Kimura, T; Yokoi, H; Nakagawa, Y; Tamura, T; Kaburagi, S; Sawada, Y; Sato, Y; Yokoi, H; Hamasaki, N; Nosaka, H; Nobuyoshi, M				Kimura, T; Yokoi, H; Nakagawa, Y; Tamura, T; Kaburagi, S; Sawada, Y; Sato, Y; Yokoi, H; Hamasaki, N; Nosaka, H; Nobuyoshi, M			Three-year follow-up after implantation of metallic coronary-artery stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; RESTENOSIS; EXPERIENCE; MULTICENTER; OCCLUSION	Background. Coronary-artery stents are known to reduce rates of restenosis after coronary angioplasty, but it is uncertain how long this benefit is maintained. Methods. We evaluated clinical and angiographic follow-up information for up to three years after the implantation of Palmaz-Schatz metallic coronary-artery stents in 143 patients with 147 lesions of native coronary arteries. Results, The rate of survival free of myocardial infarction, bypass surgery, and repeated coronary angioplasty for stented lesions was 74.6 percent at three years. After 14 months, revascularization of the stented lesion was necessary in only three patients (2.1 percent), In contrast, coronary angioplasty for a new lesion was required in 11 patients (7.7 percent), Follow-up coronary angiography of 137 lesions at six months, 114 lesions at one year, and 72 lesions at three years revealed a decrease in minimal luminal diameter from 2.54+/-0.44 mm immediately after stent implantation to 1.87+/-0.56 mm at six months, but no further decrease in diameter at one year (in patients with paired angiograms, 1.95+/-0.49 mm at both six months and one year), Significant late improvement in luminal diameter was observed at three years (in patients with paired angiograms, 1.94+/-0.48 mm at six months and 2.09+/-0.48 mm at three years; P<0.001). Conclusions. Clinical and angiographic outcomes up to three years after coronary-artery stenting were favorable, with a low rate of revascularization of the stented lesions. Late improvement in luminal diameter appears to occur between six months and three years.	KOKURA MEM HOSP,DEPT CARDIOL,KOKURAKITA KU,KITAKYUSHU,FUKUOKA 802,JAPAN	Kokura Memorial Hospital								CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1992, CIRCULATION, V86, P1836, DOI 10.1161/01.CIR.86.6.1836; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GORDON PC, 1994, AM J CARDIOL, V74, P26, DOI 10.1016/0002-9149(94)90486-3; HERNANDEZ RA, 1992, J AM COLL CARDIOL, V19, P1402, DOI 10.1016/0735-1097(92)90594-D; HERRMANN HC, 1992, CIRCULATION, V86, P812, DOI 10.1161/01.CIR.86.3.812; KASTRATI A, 1993, CIRCULATION, V87, P1498, DOI 10.1161/01.CIR.87.5.1498; KIMURA T, 1993, J AM COLL CARDIOL, V21, P1557, DOI 10.1016/0735-1097(93)90368-B; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; MATTHEWS DE, 1988, USING UNDERSTANDING; MINTZ GS, 1995, J AM COLL CARDIOL, V25, pA36; NAKAMURA S, 1994, CIRCULATION, V89, P2026, DOI 10.1161/01.CIR.89.5.2026; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; PAINTER JA, 1994, CIRCULATION, V90, P163; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHATZ RA, 1987, CIRCULATION, V76, P450, DOI 10.1161/01.CIR.76.2.450; SCHOMIG A, 1994, CIRCULATION, V90, P2716, DOI 10.1161/01.CIR.90.6.2716; Serruys P.W., 1994, QUANTITATIVE CORONAR; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; WHITE CJ, 1992, J AM COLL CARDIOL, V19, P870, DOI 10.1016/0735-1097(92)90534-T; 1985, NEW ENGL J MED, V312, P932	29	431	445	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					561	566		10.1056/NEJM199602293340903	http://dx.doi.org/10.1056/NEJM199602293340903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569823				2022-12-01	WOS:A1996TW69600003
J	Stiell, IG; Greenberg, GH; Wells, GA; McDowell, I; Cwinn, AA; Smith, NA; Cacciotti, TF; Sivilotti, MLA				Stiell, IG; Greenberg, GH; Wells, GA; McDowell, I; Cwinn, AA; Smith, NA; Cacciotti, TF; Sivilotti, MLA			Prospective validation of a decision rule for the use of radiography in acute knee injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ANKLE INJURIES; RECURSIVE PARTITION; PREDICTION RULES; SURVIVAL-DATA; EMERGENCY; FRACTURE; AVULSION; PROGRAM	Objective. - To validate a previously derived decision rule for the use of radiography in patients with acute knee injury. Design. - Prospectively administered survey. Setting. - Emergency departments of two university hospitals serving adults. Patients. - Convenience sample of 1096 of 1251 eligible adults with acute knee injuries; 124 patients were examined by two physicians. Main Outcome Measures. - Attending emergency physicians assessed each patient for standardized clinical variables and determined the need for radiography according to the decision rule. Patients who did not have radiography underwent a structured telephone interview at day 14 to determine the possibility of a fracture. The rule was assessed for ability to correctly identify the criterion standard, fracture of the knee, An attempt was made to refine the rule by means of univariate and recursive partitioning analyses. Results. - The decision rule had a sensitivity of 1.0 (95% confidence interval [CI], 0.94 to 1.0) for identifying 63 clinically important fractures. Physicians correctly interpreted the rule in 96% of cases, and the kappa value for interpretation was 0.77 (95% CI, 0.65 to 0.89). The potential relative reduction in use of radiography was estimated to be 28%, The probability of fracture, if the decision rule were ''negative, is estimated to be 0% (95% CI, 0% to 0.4%). Attempts to refine the rule led to a model with improved specificity but with an unacceptable loss of sensitivity. Conclusion. - Prospective validation has shown this decision rule to be 100% sensitive for identifying fractures of the knee, to be reliable and acceptable, and to have the potential to allow physicians to reduce the use of radiography in patients with acute knee injury.	UNIV OTTAWA,FAC MED,DEPT EMERGENCY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,CLIN EPIDEMIOL UNIT,OTTAWA,ON,CANADA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa			Sivilotti, Marco L.A./AAR-8892-2020	Sivilotti, Marco L.A./0000-0001-6641-1118; Stiell, Ian/0000-0002-2583-6408				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; ANIS AH, 1995, ANN EMERG MED, V26, P422, DOI 10.1016/S0196-0644(95)70108-7; Bauer Steven J., 1995, Journal of Emergency Medicine, V13, P611, DOI 10.1016/0736-4679(95)00064-H; Baugher W H, 1984, Emerg Med Clin North Am, V2, P347; CALLAHAM ML, 1987, CURRENT THERAPY EMER; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; CIAMPI A, 1986, COMPUT STAT DATA AN, V4, P185, DOI 10.1016/0167-9473(86)90033-2; CIAMPI A, 1987, TIME SERIES ECONOMET, V5, P23; DIAMOND GA, 1989, AM J CARDIOL, V63, P99, DOI 10.1016/0002-9149(89)91084-9; DIETZ GW, 1986, RADIOLOGY, V159, P467, DOI 10.1148/radiology.159.2.3961179; FAIRCLOUGH JA, 1988, INJURY, V19, P79, DOI 10.1016/0020-1383(88)90077-0; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR., 1987, CLINIMETRICS; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FRIEDMAN JH, 1977, IEEE T COMPUT, V16, P404; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GOLDMAN AB, 1988, AM J ROENTGENOL, V151, P1163, DOI 10.2214/ajr.151.6.1163; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARWOODNUSS A, 1991, CLIN PRACTICE EMERGE; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MATTHEWS MG, 1986, BRIT MED J, V293, P959; McCaig L F, 1994, Adv Data, P1; MCCONNOCHIE KM, 1990, PEDIATRICS, V86, P45; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; ROSEN P, 1992, EMERGENCY MED CONCEP; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SAXENA AC, 1992, ANN EMERG MED, V21, P658; SEABERG DC, 1994, AM J EMERG MED, V12, P541, DOI 10.1016/0735-6757(94)90274-7; SIMON RR, 1995, EMERGENCY ORTHOPEDIC; Sox HC, 1988, MED DECISION MAKING; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; SVENSON J, 1988, LANCET, V1, P244; TINTINALLI JE, 1992, EMERGENCY MED COMPRE; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEBER JE, 1995, ANN EMERG MED, V26, P429, DOI 10.1016/S0196-0644(95)70109-5; 1994, NATL HOSPITAL AMBULA; 1992, 1991 92 ONT MIN HLTH	50	167	167	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					611	615		10.1001/jama.275.8.611	http://dx.doi.org/10.1001/jama.275.8.611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594242				2022-12-01	WOS:A1996TW62700021
J	Bujan, L; Mansat, A; Pontonnier, F; Mieusset, R				Bujan, L; Mansat, A; Pontonnier, F; Mieusset, R			Time series analysis of sperm concentration in fertile men in Toulouse, France between 1977 and 1992	BRITISH MEDICAL JOURNAL			English	Article							SEMEN CHARACTERISTICS	Objectives-To investigate whether sperm production has changed during the past 16 years in the Toulouse area of France. Design-Time series analysis of sperm donors' specimens between 1977 and 1992. Setting-Sperm bank of university hospital in Toulouse, France. Subjects-302 healthy fertile men candidate sperm donors more than 20 and up to 45 years old and without any infertile brothers. Main outcome measure-Spermatozoa concentration. Results-Donors' mean age at time of donation was 34.05 (SD 5.13), but this increased significantly (P<0.001) during the study, from 32.4 in 1977 to 36 in 1992. Mean sperm count of samples was 83.12 x 10(6)/ml (SD 68.42 x 10(6)/ml). Sperm concentration was positively linked to the year of donation (Pearson's coefficient r = 0.12, P < 0.05), but this correlation disappeared after adjustment for age of donors (r = 0.09, P > 0.05). Conclusion-Sperm concentration has not changed with time in the Toulouse area.	CHU LA GRAVE,CTR STERILITE MASCULINE,F-31052 TOULOUSE,FRANCE; CHU LA GRAVE,CECOS MIDI PYRENEES,F-31052 TOULOUSE,FRANCE	CHU de Toulouse; CHU de Toulouse				Bujan, Louis/0000-0003-1540-0536; Mieusset, Roger/0000-0001-9057-630X				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; [Anonymous], 1992, ARCH DIS CHILD, V67, P892; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COUZET P, 1994, ENV FRANCE EDITION 1, P9; DELAMASSA JP, 1994, DG 13 TELECOMMUNICAT, P5; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; JOUANNET P, 1981, INT J ANDROL, V4, P440, DOI 10.1111/j.1365-2605.1981.tb00728.x; LAVOUX T, 1994, ENV FRANCE EDITION 1, P216; MICHAL F, 1993, ENVIRON HEALTH PERSP, V101, P159, DOI 10.2307/3431390; MIEUSSET R, 1987, FERTIL STERIL, V48, P1006; MIEUSSET R, 1995, INT J ANDROL, V18, P169, DOI 10.1111/j.1365-2605.1995.tb00408.x; MOLLER H, 1993, EUR UROL, V23, P8; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; STEENO OP, 1984, ANDROLOGIA, V16, P5; TOPPARI J, 1995, MALE REPROD HLTH ENV	17	183	192	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					471	472		10.1136/bmj.312.7029.471	http://dx.doi.org/10.1136/bmj.312.7029.471			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597677	Green Published			2022-12-01	WOS:A1996TX38300021
J	Kim, SS; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, SS; Dallmann, HG; McHenry, CS; Marians, KJ			Coupling of a replicative polymerase and helicase: A tau-DnaB interaction mediates rapid replication fork movement	CELL			English	Article							COORDINATED LEADING-STRAND; ESCHERICHIA-COLI; III HOLOENZYME; PROTEIN; PURIFICATION; IDENTIFICATION; MECHANISM; SUBUNITS; TEMPLATE; SIZE	The E. coli replication fork synthesizes DNA at the rate of nearly 1000 nt/s. We show here that an interaction between the tau subunit of the replicative polymerase (the DNA polymerase III holoenzyme) and the replication fork DNA helicase (DnaB) is required to mediate this high rate of replication fork movement. In the absence of this interaction, the polymerase follows behind the helicase at a rate equal to the slow (similar to 35 nt/s) unwinding rate of the helicase alone, whereas upon establishing a tau-DnaB contact, DnaB becomes a more effective helicase, increasing its translocation rate by more than 10-fold. This finding establishes the existence of both a physical and communications link between the two major replication machines in the replisome: the DNA polymerase and the primosome.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, SS (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM036255, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, GM36255] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kim S, 1996, J BIOL CHEM, V271, P4315; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	35	291	292	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					643	650		10.1016/S0092-8674(00)81039-9	http://dx.doi.org/10.1016/S0092-8674(00)81039-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598050	hybrid			2022-12-01	WOS:A1996TX17600016
J	Needleman, HL; Riess, JA; Tobin, MJ; Biesecker, GE; Greenhouse, JB				Needleman, HL; Riess, JA; Tobin, MJ; Biesecker, GE; Greenhouse, JB			Bone lead levels and delinquent behavior	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE	Objective.-To evaluate the association between body lead burden and social adjustment. Design.-Retrospective cohort study. Setting.-Public school community. Participants.-From a population of 850 boys in the first grade at public schools, 503 were selected on the basis of a risk scale for antisocial behavior. All of the 850 boys who scored in the upper 30th percentile of the distribution on a self-reported antisocial behavior scale were matched with an equal number drawn by lot from the lower 70% of the distribution. From this sample, 301 students accepted the invitation to participate. Exposure Measure.-K x-ray fluorescence spectroscopy of tibia at subjects' age of 12 years. Main Outcome Measures.-Child Behavior Checklist (CBCL), teachers' and parents' reports, and subjects' self-report of antisocial behavior and delinquency at 7 and 11 years of age. Results.-Subjects, teachers, and parents were blind to the bone lead measurements. At 7 years of age, borderline associations between teachers' aggression, delinquency, and externalizing scores and lead levels were observed after adjustment for covariates. At 11 years of age, parents reported a significant lead-related association with the following CBCL cluster scores: somatic complaints and delinquent, aggressive, internalizing, and externalizing behavior. Teachers reported significant associations of lead with somatic complaints, anxious/depressed behavior, social problems, attention problems, and delinquent, aggressive, internalizing, and externalizing behavior. High-lead subjects reported; higher scores in subjects' self-reports of delinquency at 11 years. High-lead subjects were more likely to obtain worse scores on all items of the CBCL during the 4-year period of observation. High bone lead levels were associated with an increased risk of exceeding the clinical score (T>70) for attention, aggression, and delinquency. Conclusion.-Lead exposure is associated with increased risk for antisocial and delinquent behavior, and the effect follows a developmental course.	UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,PITTSBURGH,PA; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University			Klishevych, Nataliia/ABB-2500-2021; Greenhouse, Joel/W-2132-2019	Greenhouse, Joel/0000-0001-5087-9648	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005015] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 05015-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACHENBACH TM, 1995, J AM ACAD CHILD PSY, V34, P488, DOI 10.1097/00004583-199504000-00016; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; [Anonymous], 1988, NATURE EXTENT LEAD P; BELLINGER D, 1994, ENVIRON RES, V66, P12, DOI 10.1006/enrs.1994.1041; Byers RK, 1943, AM J DIS CHILD, V66, P471; DENNO DW, 1990, BIOL VIOLENCE; FARRINGTON DP, 1991, DEV TREATMENT CHILDH, P189; FERGUSSON DM, 1993, J CHILD PSYCHOL PSYC, V34, P215, DOI 10.1111/j.1469-7610.1993.tb00980.x; GOLDSTEIN GW, 1992, HUMAN LEAD EXPOSURE; HATZAKIS A, 1987, INT C HEAVY METALS E, P204; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; LANSDOWN R, 1983, LEAD VERSUS HLTH; LANTHONY P, 1987, J FR OPHTALMOL, V10, P579; LAUGHLIN NK, 1991, NEUROTOXICOL TERATOL, V13, P429, DOI 10.1016/0892-0362(91)90092-B; Letz R, 1988, NES2 NEUROBEHAVIORAL; LOEBER R, 1991, J CRIM LAW CRIM, V82, P36; LOEBER R, 1983, PSYCHOL BULL, V94, P68, DOI 10.1037/0033-2909.94.1.68; LOEBER R, 1989, CROSS NATIONAL RES S; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MOFFITT TE, 1990, CRIME JUSTICE, V12, P99, DOI 10.1086/449165; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; OFFORD DR, 1979, J NERV MENT DIS, V167, P734, DOI 10.1097/00005053-197912000-00003; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; Raven JC, 1988, MANUAL RAVENS PROGR; REYNOLDS CR, 1990, HDB PSYCHOL ED ASSES, P370; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; SATTERFIELD JH, 1987, CAUSES CRIME; SCIARILLO WG, 1992, AM J PUBLIC HEALTH, V82, P1356, DOI 10.2105/AJPH.82.10.1356; TAYLOR D, 1978, J PHARMACOL EXP THER, V206, P371; THOMSON GOB, 1989, J CHILD PSYCHOL PSYC, V30, P515, DOI 10.1111/j.1469-7610.1989.tb00265.x; TODD AC, 1991, ENVIRON RES, V57, P117; Tonry ML, 1991, HUMAN DEV CRIMINAL B, DOI DOI 10.1007/978-1-4613-9055-8; WATKINS CE, 1986, PROF PSYCHOL-RES PR, V17, P36; Wilson James, 1986, CRIME HUMAN NATURE	35	443	458	0	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					363	369		10.1001/jama.275.5.363	http://dx.doi.org/10.1001/jama.275.5.363			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT303	8569015				2022-12-01	WOS:A1996TT30300029
J	Dacey, DM; Lee, BB; Stafford, DK; Pokorny, J; Smith, VC				Dacey, DM; Lee, BB; Stafford, DK; Pokorny, J; Smith, VC			Horizontal cells of the primate retina: Cone specificity without spectral opponency	SCIENCE			English	Article							MACAQUE GANGLION-CELLS; MONKEY RETINA; PHOTORECEPTORS; SENSITIVITY; CONNECTIONS; RESPONSES	The chromatic dimensions of human color vision have a neural basis in the retina. Ganglion cells, the output neurons of the retina, exhibit spectral opponency; they are excited by some wavelengths and inhibited by others. The hypothesis that the opponent circuitry emerges from selective connections between horizontal cell interneurons and cone photoreceptors sensitive to long, middle, and short wavelengths (L-, M-, and S-cones) was tested by physiologically and anatomically characterizing cone connections of horizontal cell mosaics in macaque monkeys. H1 horizontal cells received input only from L- and M-cones, whereas H2 horizontal cells received a strong input from S-cones and a weaker input from L- and M-cones. All cone inputs were the same sign, and both horizontal cell types lacked opponency. Despite cone type selectivity, the horizontal cell cannot be the locus of an opponent transformation in primates, including humans.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY; UNIV CHICAGO,CTR VISUAL SCI,CHICAGO,IL 60637	Max Planck Society; University of Chicago	Dacey, DM (corresponding author), UNIV WASHINGTON,DEPT BIOL STRUCT,BOX 357420,SEATTLE,WA 98195, USA.			Dacey, Dennis/0000-0001-8476-5585				AHNELT P, 1994, J COMP NEUROL, V343, P406, DOI 10.1002/cne.903430306; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; BURKHARDT DA, 1993, VISUAL NEUROSCI, V10, P981, DOI 10.1017/S0952523800010087; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DACHEUX RF, 1990, PROC R SOC SER B-BIO, V239, P213, DOI 10.1098/rspb.1990.0014; DEVALOIS RL, 1964, SCIENCE, V146, P1184, DOI 10.1126/science.146.3648.1184; DEVALOIS RL, 1958, SCIENCE, V127, P238, DOI 10.1126/science.127.3292.238; Goodchild A. K., 1995, Society for Neuroscience Abstracts, V21, P1645; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; KAMERMANS M, 1995, PROG RETIN EYE RES, V14, P313, DOI 10.1016/1350-9462(94)00003-2; KOLB H, 1980, J COMP NEUROL, V189, P31; LEE BB, 1995, COLOR VISION DEFICIE, V11, P177; Lennie P., 1991, COMPUTATIONAL MODELS, P71, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; MANGEL SC, 1991, J PHYSIOL-LONDON, V442, P211, DOI 10.1113/jphysiol.1991.sp018790; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SCHNEEWEIS DM, 1995, SCIENCE, V268, P1053, DOI 10.1126/science.7754386; SMITH RG, 1995, VISUAL NEUROSCI, V12, P545, DOI 10.1017/S0952523800008440; SMITH VC, 1975, VISION RES, V15, P161, DOI 10.1016/0042-6989(75)90203-5; SMITH VC, 1992, J PHYSIOL-LONDON, V458, P191, DOI 10.1113/jphysiol.1992.sp019413; SMITH VC, 1995, J OPT SOC AM A, V12, P241, DOI 10.1364/JOSAA.12.000241; SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992; VALBERG A, 1992, J PHYSIOL-LONDON, V458, P579, DOI 10.1113/jphysiol.1992.sp019435; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; Wyszecki Gunter, 1982, COLOR SCI, V8	28	184	187	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					656	659		10.1126/science.271.5249.656	http://dx.doi.org/10.1126/science.271.5249.656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571130				2022-12-01	WOS:A1996TT87000049
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ			Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							ELDERLY PATIENTS; MORTALITY; PROGNOSIS; OUTCOMES; WOMEN; CARE	Objective: To examine recent trends in the use of thrombolytic therapy in elderly patients who have had acute myocardial infarction and to determine whether failure to meet time-to-hospital presentation and electrocardiographic criteria might explain age-related differences in the use of thrombolytic therapy. Design: A national registry of patients who have had acute myocardial infarction. Setting: 1249 U.S. hospitals. Patients: 350 755 patients who had an acute myocardial infarction from 1 July 1990 to 30 September 1994. Measurements: Trends in the proportions of patients who received thrombolytic therapy were examined according to age and sex. The association between age and treatment with a thrombolytic agent was determined by crude and multivariable-adjusted analyses. Results: Use of a thrombolytic agent was inversely related to patient age: Almost 51% of patients younger than age 55 years received a thrombolytic agent during hospitalization for acute myocardial infarction; this proportion decreased to 43.6% for patients aged 55 to 64 years, 33.0% for those aged 65 to 74 years, 19.0% for those aged 75 to 84 years, and 7.4% for those aged 85 years or older. However, relative increases in the use of thrombolytic therapy over time were greatest for patients in the oldest age groups. Between 1 July 1990 and 30 June 1991, 16.0% of patients aged 75 to 84 years received a thrombolytic agent compared with 21.4% between 1 June 1993 and 30 September 1994 (a 33.8% relative increase in use). Among persons aged 85 years or older, the proportion of treated patients increased from 5.3% to 9.1% over this same period (a 71.7% relative increase in use). Increases in thrombolytic use were most prominent for older women. After adjustment for sex, diagnosis by initial electrocardiogram, electrocardiogram-based infarction description, time from symptom onset to hospital presentation, and period of the acute myocardial infarction, the odds of receiving a thrombolytic agent were significantly reduced for patients in the older age groups compared with the odds for patients younger than age 55 years (for patients aged 75 to 84 years, the adjusted odds ratio was 0.27 [95% CI, 0.26 to 0.28]; for patients aged 85 years or older, the odds ratio was 0.09 [CI, 0.08 to 0.10]). Conclusions: Although older patients who have had acute myocardial infarction less commonly receive a thrombolytic agent, use of thrombolytic therapy in this population is expanding. However, substantial differences across age groups persist in the likelihood of receiving treatment, even after adjustment for potentially confounding factors. Age-related differences in thrombolytic use may not be completely explained by the degree to which older patients do not meet conventional eligibility criteria for thrombolytic therapy.	UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CLINTRIALS RES INC, LEXINGTON, KY 40504 USA; JOHNS HOPKINS UNIV, BAYVIEW MED CTR, DIV CARDIOL, BALTIMORE, MD 21224 USA; UNIV ALABAMA, MED CTR, BIRMINGHAM, AL 35294 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Gurwitz, JH (corresponding author), BRIGHAM & WOMENS HOSP, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, SUITE 341, BOSTON, MA 02115 USA.				NIA NIH HHS [K08 AG00510] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; CHAMBERLAIN DA, 1988, LANCET, V1, P545; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.268.11.1417; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; GURWITZ JH, 1993, INCLUSION ELDERLY IN, P205; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROGERS WJ, 1995, AM J MED, V99, P195, DOI 10.1016/S0002-9343(99)80140-5; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.1093/biomet/54.1-2.167; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILCOX RG, 1988, LANCET, V2, P525; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4; 1992, CARDIOLOGY, V21, P5	37	118	121	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					283	+		10.7326/0003-4819-124-3-199602010-00001	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554222				2022-12-01	WOS:A1996TR59600001
J	Sabin, CA; Phillips, AN; Lee, CA				Sabin, CA; Phillips, AN; Lee, CA			Arguments contradict the ''foreign protein-zidovudine'' hypothesis - Response	BRITISH MEDICAL JOURNAL			English	Editorial Material									ROYAL FREE HOSP,HAEMOPHILIA CTR,DEPT HAEMATOL,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,HAEMOSTASIS UNIT,DEPT HAEMATOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Sabin, CA (corresponding author), ROYAL FREE HOSP,SCH MED,HIV RES UNIT,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DUESBERG P, 1996, BMJ, V312; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; MONTORO JB, 1995, BLOOD, V86, P2213, DOI 10.1182/blood.V86.6.2213.bloodjournal8662213; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; 1994, HIV AIDS SURVEILLANC, V6, P1	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					211	212						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563584				2022-12-01	WOS:A1996TT48600023
J	Siniossoglou, S; Wimmer, C; Rieger, M; Doye, V; Tekotte, H; Weise, C; Emig, S; Segref, A; Hurt, EC				Siniossoglou, S; Wimmer, C; Rieger, M; Doye, V; Tekotte, H; Weise, C; Emig, S; Segref, A; Hurt, EC			A novel complex of nucleoporins, which includes Sec13p and a Sec13p homolog, is essential for normal nuclear pores	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; RECONSTITUTION; PROTEINS; INVITRO; MUTANT; NSP1	In a genetic screen for nucleoporin-interacting components, a novel nuclear pore protein Nup84p, which exhibits homology to mammalian Nup107p, was isolated. Nup84p forms a complex with five proteins, of which Nup120p, Nup85p, Sec13p, and a Sec13p homolog were identified. Upon isolation of Sec13p-ProtA, nucleoporins were still associated, but the major copurifying band was a 150 kDa protein, showing that Sec13p occurs in two complexes. Disruption of any of the genes encoding Nup84p, Nup85p, or Nup120p caused defects in nuclear membrane and nuclear pore complex organization, as well as in poly(A)(+) RNA transport. Thus, the Nup84p complex in conjunction with Sec13-type proteins is required for correct nuclear pore biogenesis.	EUROPEAN MOLEC BIOL LAB, D-69115 HEIDELBERG, GERMANY; FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; INST CURIE, CNRS UMR 144, SECT RECH, F-75231 PARIS, FRANCE	European Molecular Biology Laboratory (EMBL); Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Ed Hurt, Dr./AAE-8874-2019; Segref, Alexandra/C-8325-2011	Ed Hurt, Dr./0000-0002-4535-8255; Segref, Alexandra/0000-0001-8095-4469; Tekotte, Hille/0000-0003-2164-7412				AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; JORDAN EG, 1977, EXP CELL RES, V104, P446, DOI 10.1016/0014-4827(77)90114-8; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; LI O, 1995, MOL BIOL CELL, V6, P401, DOI 10.1091/mbc.6.4.401; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1994, J BIOL CHEM, V269, P17600; RASMUSSEN SW, 1994, YEAST, V10, pS63, DOI 10.1002/yea.320100008; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMOS G, 1995, FEBS LETT, V369, P107, DOI 10.1016/0014-5793(95)00674-X; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083	33	267	277	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					265	275		10.1016/S0092-8674(00)80981-2	http://dx.doi.org/10.1016/S0092-8674(00)80981-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565072	Bronze			2022-12-01	WOS:A1996TR59500013
J	Plouffe, JF; Breiman, RF; Facklam, RR				Plouffe, JF; Breiman, RF; Facklam, RR			Bacteremia with Streptococcus pneumoniae - Implications for therapy and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL BACTEREMIA; INFECTIONS; RESISTANCE; COUNTY	Objective.-To determine the incidence and mortality rates of patients with bacteremic infections with Streptococcus pneumoniae, and to determine the serotypes and antimicrobial susceptibilities of the pneumococcal isolates. Design.-Prospective case ascertainment and procurement of S pneumoniae isolates between January 1991 and April 1994, Setting.-Ten adult care hospitals in Franklin County, Ohio. Patients.-Patients (N=590) in whom S pneumoniae was isolated from blood cultures. Measurements.-Demographic data from patients with pneumococcal bacteremia were obtained by chart review. Pneumococcal serotyping and antimicrobial susceptibility testing were performed on 499 bacteremic isolates. Results.-Among residents of Franklin County, the annual incidence of pneumococcal bacteremia was higher in patients at least 65 years old (83.0 per 100 000 population) compared with younger adults (9.6 per 100 000 population) (odds ratio [OR], 8.74; 95% confidence interval [CI], 7.19 to 10.62) and more common among African Americans than whites (OR, 1.36; 954;, CI, 1.05 to 1.75), The relative risk of pneumococcal bacteremia among persons infected with the human immunodeficiency virus was 41.8 times (CI, 19.0 to 92.0) that of county residents 18 to 64 years of age. The overall mortality rate was 19% and was age-dependent, reaching 38% in patients at least 85 years old, The distribution of pneumococcal serotypes causing bacteremia was remarkably consistent over time. The incidence of drug-resistant strains increased during the study period; by 1994 14% were resistant to penicillin, 12% to ceftazidime, and 24% to trimethoprim-sulfamethoxazole. The resistant strains included several serotypes of S pneumoniae. Most serotypes (89.8%) of S pneumoniae causing bacteremia are contained in the pneumococcal vaccine. Conclusions.-Increased use of pneumococcal vaccine and recognition of antimicrobial resistance patterns may assist physicians in treating patients with S pneumoniae bacteremia. Educational programs to discourage unnecessary antimicrobial drug use should be developed for patients and physicians.	CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	Plouffe, JF (corresponding author), OHIO STATE UNIV,MED CTR,DEPT INTERNAL MED,N-1135 DOAN HALL,COLUMBUS,OH 43210, USA.							APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROOME CV, 1981, REV INFECT DIS, V3, P277; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; DOUGLAS RM, 1975, MED J AUSTRALIA, V1, P82, DOI 10.5694/j.1326-5377.1975.tb111243.x; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JORGENSEN JH, 1991, J INFECT DIS, V163, P644, DOI 10.1093/infdis/163.3.644; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; MARSTON BJ, 1993, LEGIONELLA, P36; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; PLOUFFE JF, 1994, J CLIN MICROBIOL, V32, P1606, DOI 10.1128/JCM.32.6.1606-1607.1994; PLOUFFE JF, 1994, 94TH GEN M AM SOC MI; SCHAPPERT SM, 1992, ADV DATA US DEP HLTH, V214; WOODHEAD MA, 1987, LANCET, V1, P671; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P216; 1994, M7A3 NAT COMM LAB ST; 1989, MMWR-MORBID MORTAL W, V38, P64; 1993, MMWR-MORBID MORTAL W, V44, P33; 1984, MMWR-MORBID MORTAL W, V33, P281; 1987, Q J MED, V62, P195; 1995, MMWR-MORBID MORTAL W, V44, P24; 1994, MMWR-MORBID MORTAL W, V43, P23; 1984, MMWR-MORBID MORTAL W, V33, P273; 1993, AM REV RESPIR DIS, V148, P1418; 1994, MMWR-MORBID MORTAL W, V43, P223	35	244	249	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					194	198		10.1001/jama.275.3.194	http://dx.doi.org/10.1001/jama.275.3.194			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604171				2022-12-01	WOS:A1996TP28200026
J	Desenclos, JC; Bouvet, P; BenzLemoine, E; Grimont, F; Desqueyroux, H; Rebiere, I; Grimont, PA				Desenclos, JC; Bouvet, P; BenzLemoine, E; Grimont, F; Desqueyroux, H; Rebiere, I; Grimont, PA			Large outbreak of Salmonella enterica serotype paratyphi B infection caused by a goats' milk cheese, France, 1993: A case finding and epidemiological study	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER ENTERITIS	Objective-To assess the magnitude of a nationwide outbreak of infection with Salmonella enterica serotype paratyphi B and identify the vehicle and source of infection. Design - A case finding study of S paratyphi B infection between 15 August and 30 November 1993; a pair matched case-control study; an environmental investigation at a processing plant that produced a raw goats' milk cheese incriminated in the outbreak; phage typing and genotyping of food and human Sparatyphi B isolates. Setting - France, 15 August to 30 November 1993. Subjects - 273 patients with S paratyphi B infection; 59 pairs of cases and controls matched for age, sex, and city of residence. Main outcome measures - Numbers of cases and incidence rates by region of residence and age; matched odds ratios for dairy food preferences. Results - Among the 273 cases there was one death; 203 (78%) strains belonged to phage type 1 var 3. The incidence of infection was greatest in the region where goats) milk cheese is commonly produced. Comparison of cases and controls showed a 12-fold greater risk of illness (95% confidence interval 1.6 to 92.3) from eating brand A unpasteurised goats' milk cheese. Sparatyphi B isolates of phage type 1 var 3 were recovered from cheese A, goats' milk at the plant processing cheese A, and goats' milk supplied to the plant by a single farm. Genotypic IS 200 typing of food and human 1 var 3 phage type isolates showed a common IS 200 pattern. Conclusion - This outbreak emphasises the potential health hazards of widely distributed unpasteurised milk products in France and the need for their close bacterial monitoring.	INST PASTEUR, CTR NATL REFERENCE SALMONELLA SHIGELLA, PARIS, FRANCE; DIRECT DEPT AFFAIRES SANIT & SOCIALES DEUX SEVRES, NIORT, FRANCE; INST PASTEUR, CTR NATL REFERENCE TYPAGE MOLEC ENTER, PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Desenclos, JC (corresponding author), RESEAU NATL SANTE PUBL, F-94415 ST MAURICE, FRANCE.							Benenson AS, 1990, CONTROL COMMUNICABLE, V15th; BILLE J, 1990, T IND MICR, P71; CAZENAVE DJC, 1993, B EPIDEMIOLOGIQUE HE, V48, P222; CHAUVIN P, 1993, B EPIDEMIOLOGIQUE HE, V21, P93; EZQUERRA E, 1993, J GEN MICROBIOL, V139, P2409, DOI 10.1099/00221287-139-10-2409; FELIX A, 1951, LANCET, V2, P10; GRIMONT PAD, 1991, B EPIDEMIOLOGIQUE HE, V25, P102; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; POTELON JL, 1989, B EPIDEMIOLOGIQUE HE, V24, P98; ROBINSON DA, 1981, BRIT MED J, V282, P1374, DOI 10.1136/bmj.282.6273.1374; ROBINSON DA, 1979, BRIT MED J, V1, P1171, DOI 10.1136/bmj.1.6172.1171; Schlesselman J.J., 1982, CASE CONTROL STUDIES; Talbot J C, 1967, Public Health, V81, P191, DOI 10.1016/S0033-3506(67)80185-9; WRIGHT EP, 1983, J HYG-CAMBRIDGE, V91, P227, DOI 10.1017/S002217240006023X; 1993, GUIDELINES APPLICATI; 1991, RECENSEMENT GENERRAL	16	57	59	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					91	94						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555937	Green Published			2022-12-01	WOS:A1996TQ16800024
J	Klein, R; Klein, BEK; Moss, SE				Klein, R; Klein, BEK; Moss, SE			Relation of glycemic control to diabetic microvascular complications in diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			STAGE RENAL-DISEASE; GROSS PROTEINURIA; METABOLIC CONTROL; 4-YEAR INCIDENCE; PLASMA-GLUCOSE; BLOOD-PRESSURE; PIMA-INDIANS; RETINOPATHY; NEPHROPATHY; POPULATION	Objective: To describe the relation between glycated hemoglobin and the incidence or progression, or both, of diabetic microvascular complications in persons with insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). Design: Population-based cohort study. Setting: An 11-county area in southern Wisconsin. Patients: All persons with IDDM diagnosed before age 30 and taking insulin (n = 996) and a probability sample (based on duration of disease) of persons diagnosed with diabetes at age 30 or older who were either taking insulin (n = 674) or not taking insulin (n = 696) and who participated in a baseline examination from 1980 to 1982. Survivors of the cohort were re-examined again in 1984 to 1986 and 1990 to 1992. Measurements: The incidence and progression of diabetic retinopathy was determined by masked grading of stereoscopic color fundus photographs using the modified Early Treatment Diabetic Retinopathy Study severity scale. Gross proteinuria was determined using a dipstick. Ten-year incidence of renal dialysis or transplantation or loss of tactile sensation or of temperature sensitivity was based on self-reported history. Results: The glycated hemoglobin level at baseline was strongly related to the incidence or progression, or both, of diabetic retinopathy, the incidence of gross proteinuria, and the incidence of loss of tactile sensation or temperature sensitivity in persons with either IDDM or NIDDM. Conclusions: These prospective epidemiologic data suggest that glycemic control is similarly related to the incidence and progression of diabetic microvascular complications in both IDDM and NIDDM. However, further evidence from clinical trials in persons with NIDDM is necessary to assess the risks and benefits of such treatment in preventing these complications.			Klein, R (corresponding author), UNIV WISCONSIN, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 610 N WALNUT ST, 460 WARF, MADISON, WI 53705 USA.				NEI NIH HHS [EYO-3083] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DYCK PJ, 1985, ADV EXP MED BIOL, V189, P305; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; FABRE J, 1982, KIDNEY INT, V21, P730, DOI 10.1038/ki.1982.90; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; HASSLACHER C, 1985, DIABETOLOGIA, V28, P6, DOI 10.1007/BF00276992; HASSLACHER C, 1989, NEPHROL DIAL TRANSPL, V4, P859, DOI 10.1093/ndt/4.10.859; Hosmer D, 2013, APPL LOGISTIC REGRES; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KLEIN R, 1993, DIABETES, V42, P381, DOI 10.2337/diabetes.42.3.381; KLEIN R, 1987, DIABETES CARE, V10, P633, DOI 10.2337/diacare.10.5.633; KLEIN R, 1991, ARCH INTERN MED, V151, P1344, DOI 10.1001/archinte.151.7.1344; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1985, ADV EXP MED BIOL, V189, P321; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; KOHNER EM, 1987, PRACT CARDIOL, V13, P70; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LEE ET, 1992, DIABETES CARE, V15, P1620, DOI 10.2337/diacare.15.11.1620; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAUER SM, 1985, ADV EXP MED BIOL, V189, P299; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; ORCHARD TJ, 1994, DIABETES CARE, V17, P326, DOI 10.2337/diacare.17.4.326; PETTITT DJ, 1980, LANCET, V2, P1050; PUGH JA, 1993, DIABETOLOGIA, V36, P1094, DOI 10.1007/BF02374504; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TEUSCHER A, 1988, DIABETES CARE, V11, P246, DOI 10.2337/diacare.11.3.246; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; 1976, PREV MED, V5, P207; 1981, INVEST OPHTH VIS SCI, V21, P210; 1981, FAST HEMOGLOBIN TEST, P1; PB85223006AS	43	197	211	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				90	96		10.7326/0003-4819-124-1_Part_2-199601011-00003	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554220				2022-12-01	WOS:A1996TL94400003
J	Amarenco, P; Heinzlef, O; Lucas, C; Touboul, PJ; Gerard, JL; Adrai, V; Rougemont, D; Bousser, MG; Chauvel, C; Benhalima, B; Albo, C; Abergel, E; Besson, G; Vercueil, L; Bertrand, B; Chavot, D; Tatu, L; Bernard, Y; Rondepierre, P; Goulard, L; Deklunder, G; Chamas, E; Falcon, S; Wolf, JE; Giroud, M; Tzourio, C				Amarenco, P; Heinzlef, O; Lucas, C; Touboul, PJ; Gerard, JL; Adrai, V; Rougemont, D; Bousser, MG; Chauvel, C; Benhalima, B; Albo, C; Abergel, E; Besson, G; Vercueil, L; Bertrand, B; Chavot, D; Tatu, L; Bernard, Y; Rondepierre, P; Goulard, L; Deklunder, G; Chamas, E; Falcon, S; Wolf, JE; Giroud, M; Tzourio, C			Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; CARDIOPULMONARY BYPASS; SYSTEMIC EMBOLIZATION; CEREBRAL INFARCTION; COMPLICATION; ATHEROMAS; PLAQUE	Background. Atherosclerotic disease of the aortic arch is found in 60 percent of patients 60 years of age or older who have had brain infarction. The aim of this study was to determine whether atherosclerotic plaques in the aortic arch are a risk factor for recurrent brain infarction and for vascular events in general (i.e., brain infarction, myocardial infarction, peripheral embolism, and death from vascular causes). Methods. For a period of two to four years, we followed a cohort of 331 patients 60 years of age or older who were consecutively admitted to the hospital with brain infarction (a total of 788 person-years of follow-up). All patients underwent transesophageal echocardiography to determine whether atherosclerotic plaques were present in the aortic arch proximal to the ostium of the left subclavian artery. The patients were divided into three groups according to the thickness of the wall of the aortic arch (<1 mm, 1 to 3.9 mm, and greater than or equal to 4 mm). Results. The incidence of recurrent brain infarction was 11.9 per 100 person-years in patients with an aortic-wall thickness of greater than or equal to 4 mm, as compared with 3.5 per 100 person-years in patients with a wall thickness of 1 to 3.9 mm and 2.8 per 100 person-years in patients with a wall thickness of <1 mm (P<0.001). The overall incidence of vascular events was 26.0, 9.1, and 5.9 per 100 person-years of follow-up in the respective groups (P<0.001). After adjustment for the presence of carotid stenosis, atrial fibrillation, peripheral arterial disease, and other risk factors, aortic plaques greater than or equal to 4 mm thick (including the thickness of the aortic wall) were found to be independent predictors of recurrent brain infarction (relative risk, 3.8; 95 percent confidence interval, 1.8 to 7.8; P=0.0012) and of all vascular events (relative risk, 3.5; 95 percent confidence interval, 2.1 to 5.9; P<0.001). Conclusions. Atherosclerotic plaques greater than or equal to 4 mm thick in the aortic arch are significant predictors of recurrent brain infarction and other vascular events. (C) 1996, Massachusetts Medical Society.			Amarenco, P (corresponding author), HOP ST ANTOINE, SERV NEUROL, 184 RUE FAUBOURG ST ANTOINE, F-75571 PARIS 12, FRANCE.		Tzourio, christophe/B-4015-2009; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/L-6344-2019; VERCUEIL, Laurent/AAN-2941-2021	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; VERCUEIL, Laurent/0000-0003-3323-0091				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CASTLEMA B, 1967, NEW ENGL J MED, V276, P1368, DOI 10.1056/NEJM196706152762410; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; DAVILAROMAN VG, 1994, STROKE, V25, P2010, DOI 10.1161/01.STR.25.10.2010; DIXON WJ, 1992, BMDP STATISTICAL SOF; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; JONES EF, 1995, STROKE, V26, P218; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; *SAS I, 1989, SAS US GUID, V1; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1994, J AM COLL CARDIOL, V23, P1085, DOI 10.1016/0735-1097(94)90595-9; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WINTER WJ, 1957, ARCH PATHOL, V64, P137; 1993, LANCET, V342, P1255; 1994, BRIT MED J, V308, P1540; 1972, NEW ENGL J MED, V286, P1146	36	458	467	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1216	1221						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606716				2022-12-01	WOS:A1996UJ05400002
J	Hubbard, R; Lewontin, RC				Hubbard, R; Lewontin, RC			Pitfalls of genetic testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ATTITUDES				Hubbard, R (corresponding author), HARVARD UNIV,CAMBRIDGE,MA 02138, USA.							BABUL R, 1993, JAMA-J AM MED ASSOC, V270, P2321, DOI 10.1001/jama.270.19.2321; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; GIANNELLI F, 1990, NUCLEIC ACIDS RES, V18, P4053, DOI 10.1093/nar/18.14.4053; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KOLATA G, 1996, NY TIMES        0401, pA15; KOLATA G, 1996, NY TIMES        0617, pA1; PAPERMASTER DS, 1995, NAT MED, V1, P874, DOI 10.1038/nm0995-874; Seachrist Lisa, 1995, Sci News, V148, P394, DOI 10.2307/4018302; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P93; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P50; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P74; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P104; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P64; WERTZ DC, 1992, AM J HUM GENET, V50, P1077; 1993, NEW ENGL J MED, V329, P1308	17	84	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1192	1194		10.1056/NEJM199605023341812	http://dx.doi.org/10.1056/NEJM199605023341812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602190				2022-12-01	WOS:A1996UG83100012
J	Kushi, LH; Folsom, AR; Prineas, RJ; Mink, PJ; Wu, Y; Bostick, RM				Kushi, LH; Folsom, AR; Prineas, RJ; Mink, PJ; Wu, Y; Bostick, RM			Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; E CONSUMPTION; ATHEROSCLEROSIS; RISK; QUESTIONNAIRE; PROGRESSION; POPULATION; RABBIT; MEN	Background. The role of dietary antioxidant vitamins in preventing coronary heart disease has aroused considerable interest because of the knowledge that oxidative modification of low-density lipoprotein may promote atherosclerosis. Methods. We studied 34,486 postmenopausal women with no cardiovascular disease who in early 1986 completed a questionnaire that assessed, among other factors, their intake of vitamins A, E, and C from food sources and supplements. During approximately seven years of follow-up (ending December 31, 1992), 242 of the women died of coronary heart disease. Results. In analyses adjusted for age and dietary energy intake, vitamin E consumption appeared to be inversely associated with the risk of death from coronary heart disease, This association was particularly striking in the subgroup of 21,809 women who did not consume vitamin supplements (relative risks from lowest to highest quintile of vitamin E intake, 1.0, 0.68, 0.71, 0.42, and 0.42; P for trend=0.008), After adjustment for possible confounding variables, this inverse association remained (relative risks from lowest to highest quintile, 1.0, 0.70, 0.76, 0.32, and 0.38; P for trend=0.004). There was little evidence that the intake of vitamin E from supplements was associated with a decreased risk of death from coronary heart disease, but the effects of high-dose supplementation and the duration of supplement use could not be definitively addressed, Intake of vitamins A and C did not appear to be associated with the risk of death from coronary heart disease. Conclusions. These results suggest that in postmenopausal women the intake of vitamin E from food is inversely associated with the risk of death from coronary heart disease and that such women can lower their risk without using vitamin supplements. By contrast, the intake of vitamins A and C was not associated with lower risks of dying from coronary disease. (C) 1996, Massachusetis Medical Society.	UNIV MIAMI, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33152 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA	University of Miami; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; Wake Forest Baptist Medical Center	Kushi, LH (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Kushi, Lawrence/0000-0001-9136-1175	NCI NIH HHS [CA-39742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; BEATON GH, 1994, AM J CLIN NUTR, V59, p253S, DOI 10.1093/ajcn/59.1.253S; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MEYER F, 1994, CIRCULATION, V89, P932; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; Prineas R J, 1993, Ann Epidemiol, V3, P35, DOI 10.1016/1047-2797(93)90007-Q; PRINEAS RJ, 1993, NEW ENGL J MED, V329, P359; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WHITE AD, IN PRESS J CLIN EPID; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	30	697	721	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1156	1162		10.1056/NEJM199605023341803	http://dx.doi.org/10.1056/NEJM199605023341803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602181				2022-12-01	WOS:A1996UG83100003
J	Pisacane, A; deLuca, U; Criscuolo, L; Vaccaro, F; Valiante, A; Inglese, A; Caracciolo, G; Pinto, L				Pisacane, A; deLuca, U; Criscuolo, L; Vaccaro, F; Valiante, A; Inglese, A; Caracciolo, G; Pinto, L			Breast feeding and hypertrophic pyloric stenosis: Population based case-control study	BRITISH MEDICAL JOURNAL			English	Article									SANTOBONO PAEDIAT HOSP,NAPLES,ITALY		Pisacane, A (corresponding author), UNIV NAPLES,DEPT PAEDIAT,I-80131 NAPLES,ITALY.							DODGE JA, 1975, ARCH DIS CHILD, V50, P171, DOI 10.1136/adc.50.3.171; JEDD MB, 1986, AM J DIS CHILD, V142, P334; MARCHINI G, 1994, ACTA PAEDIATR, V83, P374, DOI 10.1111/j.1651-2227.1994.tb18122.x; SPENCE MA, 1978, GENETIC EPIDEMIOLOGY, P331; WEBB AR, 1983, ARCH DIS CHILD, V58, P586, DOI 10.1136/adc.58.8.586	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					745	746						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605461	Green Published			2022-12-01	WOS:A1996UC16600027
J	Fukasawa, K; Choi, T; Kuriyama, R; Rulong, S; VandeVoude, GF				Fukasawa, K; Choi, T; Kuriyama, R; Rulong, S; VandeVoude, GF			Abnormal centrosome amplification in the absence of p53	SCIENCE			English	Article							WILD-TYPE P53; HAMSTER OVARY CELLS; GENE AMPLIFICATION; FRIEND-VIRUS; CYCLE; EXPRESSION; TRANSCRIPTION; PROTEIN; BINDING; CANCER	The centrosome plays a vital role in mitotic fidelity, ensuring establishment of bipolar spindles and balanced chromosome segregation. Centrosome duplication occurs only once during the cell cycle and is therefore highly regulated. Here, it is shown that in mouse embryonic fibroblasts (MEFs) lacking the p53 tumor suppressor protein, multiple copies of functionally competent centrosomes are generated during a single cell cycle. In contrast, MEFs prepared from normal mice or mice deficient in the retinoblastoma tumor suppressor gene product do not display these abnormalities. The abnormally amplified centrosomes profoundly affect mitotic fidelity, resulting in unequal segregation of chromosomes. These observations implicate p53 in the regulation of centrosome duplication and suggest one possible mechanism by which the loss of p53 may cause genetic instability.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System; University of Minnesota Twin Cities								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLAIRZAJDEL ME, 1988, ONCOGENE, V2, P579; BOMENS M, 1992, CENTROSOME, P1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; CALARCO PD, 1983, J CELL BIOL, V101, P319; CARDER P, 1993, ONCOGENE, V8, P1397; CLAYTON L, 1985, CELL, V35, P621; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUKASAWA K, UNPUB; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KURIYAMA R, 1986, CELL MOTIL CYTOSKEL, V6, P355, DOI 10.1002/cm.970060402; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROBBINS E, 1968, J CELL BIOL, V36, P329, DOI 10.1083/jcb.36.2.329; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	57	722	743	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1744	1747		10.1126/science.271.5256.1744	http://dx.doi.org/10.1126/science.271.5256.1744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596939	Green Submitted			2022-12-01	WOS:A1996UB15100052
J	Leach, DR; Krummel, MF; Allison, JP				Leach, DR; Krummel, MF; Allison, JP			Enhancement of antitumor immunity by CTLA-4 blockade	SCIENCE			English	Article							RECEPTOR; CELLS; CD28; MOLECULES; MOUSE; COSTIMULATION; EXPRESSION; REJECTION; ANTIGEN	One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [R37CA040041, T32CA009179, R01CA040041, R01CA057986] Funding Source: NIH RePORTER; NCI NIH HHS [CA57986, CA09179, CA40041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1995, CURR OPIN IMMUNOL, V7, P682, DOI 10.1016/0952-7915(95)80077-8; ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BASKAR S, 1995, J EXP MED, V181, P619, DOI 10.1084/jem.181.2.619; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GROSS JA, 1992, J IMMUNOL, V149, P380; HARPER K, 1991, J IMMUNOL, V147, P1037; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; KEARNEY ER, 1995, J IMMUNOL, V155, P1033; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; KRUMMEL MF, IN PRESS INT IMMUNOL; LEACH DR, 1995, J IMMUNOL, V154, P738; LEACH DRF, UNPUB; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TOWNSEND SE, 1994, CANCER RES, V54, P6477; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	33	2488	2677	22	392	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1734	1736		10.1126/science.271.5256.1734	http://dx.doi.org/10.1126/science.271.5256.1734			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596936				2022-12-01	WOS:A1996UB15100049
J	Gilks, CF; Ojoo, SA; Ojoo, JC; Brindle, RJ; Paul, J; Batchelor, BIF; Kimari, JN; Newnham, R; Bwayo, J; Plummer, FA; Warrell, DA				Gilks, CF; Ojoo, SA; Ojoo, JC; Brindle, RJ; Paul, J; Batchelor, BIF; Kimari, JN; Newnham, R; Bwayo, J; Plummer, FA; Warrell, DA			Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya	LANCET			English	Article							BACTEREMIA; DIAGNOSIS; PNEUMONIA; SINUSITIS; ADULTS	Background HIV infection is a major risk factor for pneumococcal disease in industrialised countries. Although both are common infections in sub-Saharan Africa, few studies have investigated the importance of this interaction. We have followed up a cohort of female sex-workers in Nairobi and report here on the extent of invasive pneumococcal disease. Methods A well-established cohort of low-class female sex-workers, based around a community clinic, was followed up from October, 1989, to September, 1992. 587 participants were HIV positive and 132 remained HIV negative. Set protocols were used to investigate common presentations. Cases were identified clinically and radiographically. and other pathogens were identified clinically and radiographically. Streptococcus pneumoniae and other pathogens were diagnosed by culture. Findings Seventy-nine episodes of invasive pneumococcal disease were seen in the 587 HIV-positive women compared with one episode in the 132 seronegative women (relative risk 17.8, 95% CI 2.5 to 126.5). In seropositive women the incidence rate was 42.5 per 1000 person-years and the recurrence rate was 264 per 1000 person-years. By serotyping, most recurrent events were re-infection. A wide spectrum of HIV-related pneumococcal disease was seen: only 56% of cases were pneumonia; sinusitis was seen in 30% of cases, and occult bacteraemia, a novel adult presentation, in 11%. Despite forty-two bacteraemic episodes, no deaths were attributable to Strep pneumoniae. At first presentation the mean CD4 cell count was 302/mu L (SD 191) and was 171/mu L (105) for recurrent episodes. During acute Strep pneumoniae infection the CD4 cell count was reversibly suppressed (mean fall in sixteen episodes, 105/mu L [123]). The neutrophil response to acute infection was blunted and was correlated with CD4 count (r=0.50, 95% CI 0.29 to 0.66). Strep pneumoniae caused more disease, at an earlier stage of HIV immunosuppression, than Mycobacterium tuberculosis or non-typhi salmonellae. Interpretation Our study highlights the importance of the pneumococcus as an early but readily treatable complication of HIV infection in sub-Saharan Africa.	KENYA GOVT MED RES CTR,CLIN RES CTR,NAIROBI,KENYA; KENYA GOVT MED RES CTR,CTR MICROBIOL RES,NAIROBI,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; UNIV WINNIPEG,WINNIPEG,MB R3B 2E9,CANADA; UNIV OXFORD,CTR TROP MED,OXFORD,ENGLAND	Kenya Medical Research Institute; Kenya Medical Research Institute; University of Nairobi; University of Winnipeg; University of Oxford			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADERAYE G, 1994, TUBERCLE LUNG DIS, V75, P308, DOI 10.1016/0962-8479(94)90138-4; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AUSTRIAN R, 1986, SA MED J, V77, P46; BARNES DJ, 1988, AUST NZ J MED, V18, P754, DOI 10.1111/j.1445-5994.1988.tb00174.x; BARRETTC.E, 1971, AM REV RESPIR DIS, V103, P845; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GILKS C, 1993, 9 INT C AIDS BERL; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GODOFSKY EW, 1992, AM J MED, V93, P163, DOI 10.1016/0002-9343(92)90046-E; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JORDENS JZ, 1995, J INFECT DIS, V172, P983, DOI 10.1093/infdis/172.4.983; KELL CM, 1993, INFECT IMMUN, V61, P4382, DOI 10.1128/IAI.61.10.4382-4391.1993; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; MIENTJES GHC, 1993, BRIT MED J, V306, P371, DOI 10.1136/bmj.306.6874.371; NUNN P, 1993, TUBERC LUND DIS, V7, P273; PALLANGYO K, 1992, AIDS, V6, P971, DOI 10.1097/00002030-199209000-00010; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; SIMANI P, 1992, 8 INT C AIDS AMST; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; SPITALNY KC, 1982, JOHNS HOPKINS MED J, V150, P35; TAELMAN H, 1990, 5 INT C AIDS AFR KIN; TAELMAN H, 1992, 8 INT C AIDS AMST; TEKLU B, 1984, PRINCIPLES MED AFRIC, P761; VONREYN CF, 1993, J CLIN MICROBIOL, V31, P3247; WALLACE JM, 1993, AM REV RESPIR DIS, V148, P1523, DOI 10.1164/ajrccm/148.6_Pt_1.1523; *WHO, 1994, WHOGPATCOSEF944; 1987, MMWR-MORBID M      S, V36, pS1; 1992, MMWR-MORBID MORTAL W, V41, P1	31	163	163	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					718	723		10.1016/S0140-6736(96)90076-8	http://dx.doi.org/10.1016/S0140-6736(96)90076-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602001				2022-12-01	WOS:A1996TZ98200009
J	Dietrich, WF; Miller, J; Steen, R; Merchant, MA; DamronBoles, D; Husain, Z; Dredge, R; Daly, MJ; Ingalls, KA; OConnor, TJ; Evans, CA; DeAngelis, MM; Levinson, DM; Kruglyak, L; Goodman, N; Copeland, NG; Jenkins, NA; Hawkins, TL; Stein, L; Page, DC; Lander, ES				Dietrich, WF; Miller, J; Steen, R; Merchant, MA; DamronBoles, D; Husain, Z; Dredge, R; Daly, MJ; Ingalls, KA; OConnor, TJ; Evans, CA; DeAngelis, MM; Levinson, DM; Kruglyak, L; Goodman, N; Copeland, NG; Jenkins, NA; Hawkins, TL; Stein, L; Page, DC; Lander, ES			A comprehensive genetic map of the mouse genome	NATURE			English	Article							LINKAGE MAP	The availability of dense genetic linkage maps of mammalian genomes makes feasible a wide range of studies, including positional cloning of monogenic traits, genetic dissection of polygenic traits, construction of genome-wide physical maps, rapid marker-assisted construction of congenic strains, and evolutionary comparisons(1,2). We have been engaged for the past five years in a concerted effort to produce a dense genetic map of the laboratory mouse(3-6). Here we present the final report of this project. The map contains 7,377 genetic markers, consisting of 6,580 highly informative simple sequence length polymorphisms integrated with 797 restriction fragment length polymorphisms in mouse genes. The average spacing between markers is about 0.2 centimorgans or 400 kilobases.	WHITEHEAD INST BIOMED RES, WHITEHEAD MIT CTR GENOME RES, CAMBRIDGE, MA 02142 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			DeAngelis, e/J-7863-2015; Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752; Merchant, Mark/0000-0003-0690-8581				BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; BUCHBERG AM, 1989, GENETICS, V122, P153; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DIETRICH WF, 1992, GENETIC MAPS 1992; EVANS E, 1994, GENETIC VARIANTS STR; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2; MILLER JC, 1994, GENETIC VARIANTS STR; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	19	738	778	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	1996	380	6570					149	152		10.1038/380149a0	http://dx.doi.org/10.1038/380149a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600386				2022-12-01	WOS:A1996TZ97800047
J	Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA				Bindels, PJE; Krol, A; vanAmeijden, E; MulderFolkerts, DKF; vandenHoek, JAR; vanGriensven, GPJ; Coutinho, RA			Euthanasia and physician-assisted suicide in homosexual men with AIDS	LANCET			English	Article							IMMUNODEFICIENCY-SYNDROME AIDS; LONGITUDINAL DATA-ANALYSIS; RESPONSIVENESS; SURVIVAL	Background In the Netherlands a nationwide study has shown that, in 38% of deaths, there have been medical decisions concerning the end of life (MDEL); 2.1% of all deaths were brought about by euthanasia or physician-assisted suicide (PAS). We investigated the incidence of MDEL in homosexual men with AIDS, suspecting that it might be higher, and studied the effect of euthanasia/PAS on survival time. Methods The patients were 131 male homosexual participants in a cohort study in Amsterdam, diagnosed between 1985 and 1992 as having AIDS; all had died before Jan 1, 1995. Clinical and laboratory data and information on mode of death were obtained from their physicians and by review of hospital records. Those who died by euthanasia/PAS or in whom there had been other MDEL were then compared with those who died naturally. Findings 29 men (22%) had died by euthanasia/PAS and in 17 (13%) another MDEL had been made; thus, more than one-third of these men had made medical decisions concerning the end of life. The greatest difference between the groups was in age at time of diagnosis-72% aged 40 or more in the euthanasia/PAS group compared with 38% in the natural death group. The likelihood (relative risk) of euthanasia/PAS increased with duration of survival after AIDS diagnosis. Comparison of the groups in terms of three laboratory markers (CD4+ and CD8+ cells and phytohaemagglutinin responses) in the two years before death, and estimates of these markers at the time of death, did not indicate any substantial shortening of life by euthanasia/PAS; in the judgment of the physicians, most of these patients would have died naturally within one month. Interpretation A possible reason for the high incidence of MDEL in this cohort was a good knowledge of the characteristics of AIDS acquired through long-term awareness of HIV infection. The higher rate of euthanasia in those with long survival from AIDS diagnosis could reflect either additional suffering or the greater opportunity to discuss this option with friends and physicians. Our findings indicate that euthanasia and other MDEL did little to shorten life; rather, they were an extreme form of palliation, applied in the terminal phase of a lethal disease.			Bindels, PJE (corresponding author), DEPT PUBL HLTH,MUNICIPAL HLTH SERV,NIEUWE ACHTERGRACHT 100,POB 20244,1000 HE AMSTERDAM,NETHERLANDS.							Anderson P.K., 1993, STAT MODELS BASED CO; BINDELS PJE, 1995, J INFECT DIS, V172, P97, DOI 10.1093/infdis/172.1.97; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; FAHEY JL, 1989, NEW ENGL J MED, V321, P673; GRIENSVEN GP, 1987, AM J EPIDEMIOL, V125, P1048; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; PIJNENBORG L, 1995, END LIFE DECISIONS M; SCHELLEKENS PTA, 1990, J CLIN IMMUNOL, V10, P121, DOI 10.1007/BF00918194; SEAGE GR, 1993, AM J PUBLIC HEALTH, V83, P72, DOI 10.2105/AJPH.83.1.72; SORGDRAGER W, 1995, MED CONTACT, V50, P381; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1991, MED CONTACT, V46, P174; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR-MORBID M      S, V36, pS1	21	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					499	504		10.1016/S0140-6736(96)91138-1	http://dx.doi.org/10.1016/S0140-6736(96)91138-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW697	8596267				2022-12-01	WOS:A1996TW69700009
J	Little, P; Smith, L; Cantrell, T; Chapman, J; Langridge, J; Pickering, R				Little, P; Smith, L; Cantrell, T; Chapman, J; Langridge, J; Pickering, R			General practitioners' management of acute back pain: A survey of reported practice compared with clinical guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPINAL MANIPULATION; CONTROLLED TRIAL; EXERCISE; PHYSIOTHERAPY; THERAPY; REST	Objective-To compare general practitioners' reported management of acute back pain with ''evidence based'' guidelines for its management. Design-Confidential postal questionnaire. Setting-One health district in the South and West region. Subjects-236 general practitioners; 166 (70%) responded. Outcome measures-Examination routinely performed, ''danger'' symptoms and signs warranting urgent referral, advice given, and satisfaction with management. Results-A minority of general practitioners do not examine reflexes routinely (27%, 95% confidence interval 20% to 34%), and a majority do not examine routinely for muscle weakness or sensation. Although most would refer patients with danger signs, some would not seek urgent advice for saddle anaesthesia (6%, 3% to 11%), extensor plantar response (45%, 37% to 53%), or neurological signs at multiple levels (15%, 10% to 21%). A minority do not give advice about back exercises (42%, 34% to 49%), fitness (34%, 26% to 41%), or everyday activities. A minority performed manipulation (20%) or acupuncture (6%). One third rated their satisfaction with management of back pain as 4 out of 10 or less. Conclusions-The management of back pain by general practitioners does not match the guidelines, but there is little evidence from general practice for many of the recommendations, including routine examination, activity modification, educational advice, and back exercises. General practitioners need to be more aware of danger symptoms and of the benefits of early mobilisation and possibly of manipulation for persisting symptoms. Guidelines should reference each recommendation and discuss study methodology and the setting of evidence.	SOUTHAMPTON HOSP, NHS TRUST, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SOUTHAMPTON, SCH OCCUPAT THERAPY & PHYSIOTHERAPY, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND; UNIV SOUTHAMPTON, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton; University of Southampton	Little, P (corresponding author), UNIV SOUTHAMPTON, FAC MED HLTH & BIOL SCI, SOUTHAMPTON SO16 5ST, HANTS, ENGLAND.			Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S1, V70, P1; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; CHOLER U, 1985, ONT RUGGEN FORSCH ME; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; FAAS A, 1995, SPINE, V20, P941, DOI 10.1097/00007632-199504150-00012; FAAS A, 1993, SPINE, V18, P1388; FEDER G, 1994, BRIT MED J, V309, P1457, DOI 10.1136/bmj.309.6967.1457; FRANK A, 1993, BMJ-BRIT MED J, V306, P901, DOI 10.1136/bmj.306.6882.901; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GARDNER SB, 1989, CIA CONFIDENCE INTER; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUNDEWALL B, 1993, SPINE, V18, P587, DOI 10.1097/00007632-199304000-00011; JONES SL, 1988, SPINE, V13, P553, DOI 10.1097/00007632-198805000-00020; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1995, SPINE, V20, P228, DOI 10.1097/00007632-199501150-00021; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Management of cancer pain, 1994, AGENCY HLTH CARE POL; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MEADE TW, 1992, BRIT MED J, V304, P1310, DOI 10.1136/bmj.304.6837.1310; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; ROLAND M, 1989, J ROY COLL GEN PRACT, V39, P244; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; ROLAND MO, 1983, PRACTITIONER, V227, P1119; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; STUBBS DA, 1983, ERGONOMICS, V26, P767, DOI 10.1080/00140138308963398; VALAT JP, 1994, RHEUMATOLOGY EUROPE, V23, P55; WADDELL G, 1993, ANN RHEUM DIS, V52, P317, DOI 10.1136/ard.52.5.317; WADDELL G, 1992, BAILLIERE CLIN RHEUM, V6, P523, DOI 10.1016/S0950-3579(05)80126-8; WADSWORTH MEJ, 1971, HLTH SICKNESS CHOICE; 1994, MANAGEMENT GUIDELINE; 1994, EFFECTIVE HLTH CARE, P8; 1987, SPINE, V12, pS9; 1993, BETTER LIVING BETTER; 1994, GUIDE MANAGEMENT LOW	42	61	61	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					485	488		10.1136/bmj.312.7029.485	http://dx.doi.org/10.1136/bmj.312.7029.485			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597683	Green Published			2022-12-01	WOS:A1996TX38300028
J	Kelner, KL				Kelner, KL			Ion channels: Opening the gate	SCIENCE			English	Editorial Material							SODIUM											ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; LARSSON HP, IN PRESS NEURON; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	5	2	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					615	615		10.1126/science.271.5249.615	http://dx.doi.org/10.1126/science.271.5249.615			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571122				2022-12-01	WOS:A1996TT87000033
J	Chandrasekharan, UM; Sanker, S; Glynias, MJ; Karnik, SS; Husain, A				Chandrasekharan, UM; Sanker, S; Glynias, MJ; Karnik, SS; Husain, A			Angiotensin II-forming activity in a reconstructed ancestral chymase	SCIENCE			English	Article							SUBSTRATE-SPECIFICITY; SUBSTANCE-P; HUMAN HEART; MAST-CELLS; PEPTIDE; ENZYME; GENE; RAT	The current model of serine protease diversity theorizes that the earliest protease molecules were simple digestive enzymes that gained complex regulatory functions and restricted substrate specificities through evolution. Among the chymase group of serine proteases are enzymes that convert angiotensin I to angiotensin II, as well as others that simply degrade angiotensins. An ancestral chymase reconstructed with the use of phylogenetic inference, total gene synthesis, and protein expression had efficient and specific angiotensin II-forming activity (turnover number, about 700 per second). Thus, angiotensin II-forming activity is the more primitive state for chymases, and the loss of such activity occurred later in the evolution of some of these serine proteases.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012; Karnik, Sadashiva/Y-2477-2019	Husain, Ahsan/0000-0003-3426-3469; Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [HL44201, R01 HL057470, HL33713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713, R01HL044201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; ERDOS EG, 1985, BIOCHEM SOC T, V13, P42, DOI 10.1042/bst0130042; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HAKANSON R, 1986, HISTOCHEMISTRY, V86, P5, DOI 10.1007/BF00492340; HENDERSON IW, 1981, ADV ANIMAL COMP PHYS, P355; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; HOIT BD, 1995, J CLIN INVEST, V95, P1519, DOI 10.1172/JCI117824; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; PASTOR LM, 1988, J SUBMICR CYTOL PATH, V20, P25; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REMMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097; SWOFFORD DL, 1992, PAUP PHYLOGENETIC AN; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0	20	166	170	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					502	505		10.1126/science.271.5248.502	http://dx.doi.org/10.1126/science.271.5248.502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560264				2022-12-01	WOS:A1996TR32200041
J	Colas, P; Cohen, B; Jessen, T; Grishina, I; McCoy, J; Brent, R				Colas, P; Cohen, B; Jessen, T; Grishina, I; McCoy, J; Brent, R			Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2	NATURE			English	Article							BINDING; LIBRARY; LIGANDS	A NETWORK of interacting proteins controls the activity of cyclin-dependent kinase 2 (Cdk2) (refs 1, 2) and governs the entry of higher eukaryotic cells into S phase. Analysis of this and other genetic regulatory networks would be facilitated by intracellular reagents that recognize specific targets and inhibit specific network connections. We report here the expression of a combinatorial library of constrained 20-residue peptides displayed by the active-site loop of Escherichia coli thioredoxin, and the use of a two-hybrid system to select those that bind human Cdk2. These peptide aptamers were designed to mimic the recognition function of the complementarity-determining regions of immunoglobulins. The aptamers recognized different epitopes on the Cdk2 surface with equilibrium dissociation constant in the nanomolar range; those tested inhibited Cdk2 activity. Our results show that peptide aptamers bear some analogies with monoclonal antibodies, with the advantages that they are isolated together with their coding genes, that their small sizes should allow their structures to be solved, and that they are designated to function inside cells.	MASSACHUSETTS GEN HOSP, DEPT BIOL MOLEC, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; GENET INST INC, CAMBRIDGE, MA 02142 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Colas, Pierre/0000-0001-7436-3718				Ausubel F.M., 1994, CURRENT PROTOCOLS MO; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KATO J, 1993, GENE DEV, V7, P331; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MCCONNELL SJ, 1994, GENE, V151, P115, DOI 10.1016/0378-1119(94)90640-8; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; REYMOND A, 1995, ONCOGENE, V11, P1173; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Scott Jamie K., 1994, Current Opinion in Biotechnology, V5, P40, DOI 10.1016/S0958-1669(05)80068-0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	26	336	408	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					548	550		10.1038/380548a0	http://dx.doi.org/10.1038/380548a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606778				2022-12-01	WOS:A1996UE66300056
J	Goldman, M				Goldman, M			Cancer risk of low-level exposure	SCIENCE			English	Editorial Material											Goldman, M (corresponding author), UNIV CALIF DAVIS,DEPT SURG & RADIOL SCI,DAVIS,CA 95616, USA.							AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; [Anonymous], 1994, SOURC EFF ION RAD, P16; COHEN BL, 1995, HEALTH PHYS, V68, P157, DOI 10.1097/00004032-199502000-00002; EVANS R, 1974, HEALTH PHYS, V17, P497; GOLDMAN M, 1971, RADIAT RES, V47, P305; KITCHIN KT, 1994, TOXICOLOGY, V88, P31, DOI 10.1016/0300-483X(94)90109-0; Kondo S., 1993, HLTH EFFECTS LOW LEV; LEWIS EB, 1957, SCIENCE, V125, P965, DOI 10.1126/science.125.3255.965; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; *NATL RES COUNC, 1990, HLTH EFF EXP LOW LEV; ROSENBLATT LS, 1971, HEALTH PHYS, V21, P869; WOLFF S, 1988, INT J RADIAT BIOL, V53, P39, DOI 10.1080/09553008814550401	12	56	59	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1821	1822		10.1126/science.271.5257.1821	http://dx.doi.org/10.1126/science.271.5257.1821			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596947				2022-12-01	WOS:A1996UC77800031
J	Reddy, MM; Quinton, PM; Haws, C; Wine, JJ; Grygorczyk, R; Tabcharani, JA; Hanrahan, JW; Gunderson, KL; Kopito, RR				Reddy, MM; Quinton, PM; Haws, C; Wine, JJ; Grygorczyk, R; Tabcharani, JA; Hanrahan, JW; Gunderson, KL; Kopito, RR			Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP	SCIENCE			English	Article							GENE; CFTR; IDENTIFICATION; SELECTIVITY; CHANNEL; CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride ion channel regulated by protein kinase A and adenosine triphosphate (ATP). Loss of CFTR-mediated chloride ion conductance from the apical plasma membrane of epithelial cells is a primary physiological lesion in cystic fibrosis. CFTR has also been suggested to function as an ATP channel, although the size of the ATP anion is much larger than the estimated size of the CFTR pore. ATP was not conducted through CFTR in intact organs, polarized human lung cell lines, stably transfected mammalian cell lines, or planar lipid bilayers reconstituted with CFTR protein. These findings suggest that ATP permeation through the CFTR is unlikely to contribute to the normal function of CFTR or to the pathogenesis of cystic fibrosis.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA; STANFORD UNIV, DEPT PSYCHOL, CYST FIBROSIS RES LAB, STANFORD, CA 94305 USA; MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA	Stanford University; University of California System; University of California Riverside; Stanford University; McGill University			Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039; Grygorczyk, Ryszard/0000-0002-9798-7651	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045913, R01DK043994] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK45913, DK43994] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BULL HB, 1972, INTRO PHYSICAL BIOCH; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P30, DOI 10.1007/BF00582707; GRYGORCZYK R, IN PRESS J MEMBR BIO; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; GUNDERSON KL, UNPUB; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanrahan John W., 1993, P93; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; NEHER E, 1992, METHOD ENZYMOL, V207, P123; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1982, FLUID ELECTROLYTE AB, P53; REDDY MM, 1994, AM J PHYSIOL-CELL PH, V267, pC1136, DOI 10.1152/ajpcell.1994.267.4.C1136; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698	25	165	166	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1876	1879		10.1126/science.271.5257.1876	http://dx.doi.org/10.1126/science.271.5257.1876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596959				2022-12-01	WOS:A1996UC77800050
J	Duchosal, MA; Rothermel, AL; McConahey, PJ; Dixon, FJ; Altieri, DC				Duchosal, MA; Rothermel, AL; McConahey, PJ; Dixon, FJ; Altieri, DC			In vivo immunosuppression by targeting a novel protease receptor	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; B-CELL LYMPHOMAS; PBL-SCID MICE; LYMPHOPROLIFERATIVE DISEASE; T-CELLS; ACTIVATION; PATHOGENESIS; GENERATION; MECHANISM	MEMBRANE receptors for blood proteases govern the clotting(1) and fibrinolytic(2) cascades, regulate signal transduction(3,4), and control the growth of mesenchymal cells(5,6). Despite their importance in the development of vascular injury(7), it is unclear whether these mechanisms participate in the generation of an immune response. Here we report that targeting a factor Xa receptor, designated effector cell protease receptor-1 (EPR-1), with antisense oligonucleotide or with a monoclonal antibody (mAb 2E1)(8) inhibited CD3/T-cell receptor-dependent lymphocyte proliferation. Immunosuppression was mediated by abolishing cytokine production and down-modulating membrane expression of the interleukin (IL)-2 receptor. In vivo administration of mAb 2E1 to severe-combined-immunodeficient mice injected with human peripheral blood leukocytes suppressed production of human immunoglobulin, abolished graft-versus-host disease, and protected these xenochimaeric mice from Epstein-Barr-virus-induced human lymphoproliferative disease. These observations indicate a new role for protease receptors in the regulation of the immune response, and identify a potential target for therapeutic immunosuppression in humans.	RW JOHNSON PHARMACEUT RES INST, RARITAN, NJ 08869 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; YALE UNIV, BOYER CTR MOLEC MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Yale University	Duchosal, MA (corresponding author), CHU VAUDOIS, DEPT INTERNAL MED, DIV HAEMATOL, CH-1011 LAUSANNE, SWITZERLAND.							ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; DUCHOSAL MA, 1992, AM J PATHOL, V141, P1097; DUCHOSAL MA, 1992, NATURE, V355, P258, DOI 10.1038/355258a0; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; JANEWAY CA, 1993, CURR OPIN IMMUNOL, V5, P313, DOI 10.1016/0952-7915(93)90048-W; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1991, NATURE, V353, P509, DOI 10.1038/353509c0; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; OKANO M, 1990, AM J PATHOL, V137, P517; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PICCHIO GR, 1992, CANCER RES, V52, P2468; PIRRUCCELLO SJ, 1992, AM J PATHOL, V140, P1187; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN BL, 1991, J IMMUNOL, V147, P2493; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VERONESE ML, 1992, J EXP MED, V176, P1763, DOI 10.1084/jem.176.6.1763; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER C, 1987, EUR J IMMUNOL, V17, P873, DOI 10.1002/eji.1830170622	28	26	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1996	380	6572					352	356		10.1038/380352a0	http://dx.doi.org/10.1038/380352a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598931				2022-12-01	WOS:A1996UC37900062
J	Mengaud, J; Ohayon, H; Gounon, P; Mege, RM; Cossart, P				Mengaud, J; Ohayon, H; Gounon, P; Mege, RM; Cossart, P			E-cadherin is the receptor for internalin, a surface protein required for entry of L-monocytogenes into epithelial cells	CELL			English	Article							CULTURED MAMMALIAN-CELLS; GRAM-POSITIVE COCCI; ADHESION MOLECULES; LISTERIA-MONOCYTOGENES; MEDIATED-IMMUNITY; INVASIN PROTEIN; IDENTIFICATION; UVOMORULIN; BACTERIA; DOMAIN	We report the first identification of a cellular receptor mediating entry of a gram-positive bacterium into nonphagocytotic cells. By an affinity chromatography approach, we identified E-cadherin as the ligand for internalin, an L. monocytogenes protein essential for entry into epithelial cells. Expression of the chicken homolog of E-cadherin (L-CAM) in transfected fibroblasts dramatically increases entry of L. monocytogenes and promotes that of a recombinant L. innocua strain expressing internalin but does not promote entry of the wild-type noninvasive L. innocua or that of an internalin-deficient mutant of L. monocytogenes. Furthermore, L-CAM-specific antibodies block internalin-mediated entry. In contrast to Salmonella, Listeria enters cells by a mechanism of induced phagocytosis occurring without membrane ruffling. This work reveals a novel type of heterophilic interactions for E-cadherin.	INST PASTEUR, UNITE INTERACT BACTERIES CELLULES, F-75724 PARIS 15, FRANCE; INST PASTEUR, STN CENT MICROSCOPIE ELECT, F-75724 PARIS 15, FRANCE; INSERM, U440, F-75005 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)			Mege, Rene Marc/M-9569-2013	Mege, Rene-Marc/0000-0001-8128-5543				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; BRAY DF, 1993, MICROSC RES TECHNIQ, V26, P489, DOI 10.1002/jemt.1070260603; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; DRAMSI S, 1993, MOL MICROBIOL, V9, P931, DOI 10.1111/j.1365-2958.1993.tb01223.x; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cellbio.8.1.333; Finlay B B, 1994, Curr Top Microbiol Immunol, V192, P163; FINLAY BB, 1991, J CELL SCI, V99, P283; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1985, J EXP MED, V161, P1384, DOI 10.1084/jem.161.6.1384; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GAILLARD JL, 1994, METHOD ENZYMOL, V236, P551; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEPAY DA, 1985, J EXP MED, V161, P1503, DOI 10.1084/jem.161.6.1503; MACDONALD TT, 1980, INFECT IMMUN, V28, P516; MARCO AJ, 1992, J COMP PATHOL, V107, P1, DOI 10.1016/0021-9975(92)90090-H; MASON I, 1994, CURR BIOL, V4, P1158, DOI 10.1016/S0960-9822(00)00263-3; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILLER VL, 1994, INVASION GENES YERSI, P213; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Parsot C, 1994, Curr Top Microbiol Immunol, V192, P217; RACZ P, 1972, LAB INVEST, V26, P694; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; TEMMGROVE CJ, 1994, J CELL SCI, V107, P2951; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WILLEMS J, 1995, FEBS LETT, V363, P289, DOI 10.1016/0014-5793(95)00334-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	63	667	687	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					923	932		10.1016/S0092-8674(00)81070-3	http://dx.doi.org/10.1016/S0092-8674(00)81070-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601315	Bronze			2022-12-01	WOS:A1996UC38100013
J	Fagon, JY; Chastre, J; Vuagnat, A; Trouillet, JL; Novara, A; Gibert, C				Fagon, JY; Chastre, J; Vuagnat, A; Trouillet, JL; Novara, A; Gibert, C			Nosocomial pneumonia and mortality among patients in intensive care units	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUOUS MECHANICAL VENTILATION; PROTECTED SPECIMEN BRUSH; ATTRIBUTABLE MORTALITY; INFECTION; RISK; FATALITY; FAILURE; DEATHS; SYSTEM; STAY	Objective.-To evaluate the role that nosocomial pneumonia plays in the outcome of intensive care unit (ICU) patients. Design.-Cohort study. Setting.-Medical ICU, Hospital Bichat, Paris, France, an academic tertiary care center. Patients.-A total of 1978 consecutive patients admitted to the ICU for at least 48 hours. Main Outcome Measures.-Various parameters known to be strongly associated with death of ICU patients were recorded: age, location before admission to the ICU, diagnostic categories, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Simplified Acute Physiologic Score, McCabe score, number and type of dysfunctional organs, and the development of nosocomial bacteremia and nosocomial urinary tract infection. These variables and the presence or absence of nosocomial pneumonia were compared between survivors and nonsurvivors and entered into a stepwise logistic regression model to evaluate their independent prognostic roles. Results.-Nosocomial pneumonia developed in 328 patients (16.6%) whose mortality rate was 52.4% compared with 22.4% for patients without ICU-acquired pneumonia (P<.001). APACHE II score (odds ratio [OR]=1.08; 95% confidence interval [CI], 1.06 to 1.10; P<.001), number of dysfunctional organs (OR=1.54; 95% CI, 1.36 to 1.74; P<.001), nosocomial pneumonia (OR=2.08; 95% CI, 1.55 to 2.80; P<.001), nosocomial bacteremia (OR=2.51; 95% CI, 1.78 to 3.55; P<.001), ultimately or rapidly fatal underlying disease (OR=1.76; 95% CI, 1.38 to 2.25; P<.001), and admission from another ICU (OR=1.30; 95% CI, 1.01 to 1.68; P=.04) were significantly associated with mortality. Conclusion.-These data suggest that, in addition to the severity of underlying medical conditions and nosocomial bacteremia, nosocomial pneumonia independently contributes to ICU patient mortality.			Fagon, JY (corresponding author), HOP BICHAT,SERV REANIMAT MED,46 RUE HENRI HUCHARD,F-75877 PARIS 18,FRANCE.							BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; CHASTRE J, 1988, AM J MED, V85, P499; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GROSS PA, 1983, AM J MED, V75, P658, DOI 10.1016/0002-9343(83)90453-9; GROSS PA, 1980, AM J MED, V68, P219, DOI 10.1016/0002-9343(80)90357-5; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; SPILKER B, 1991, GUIDE CLIN TRIALS, P134; TEASDALE G, 1974, LANCET, V2, P81; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	28	333	349	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					866	869		10.1001/jama.275.11.866	http://dx.doi.org/10.1001/jama.275.11.866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596225				2022-12-01	WOS:A1996TZ97100030
J	Schieber, RA; Switzer, DW				Schieber, RA; Switzer, DW			Injuries from propane gas grills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									US CONSUMER PROD SAFETY COMMISS,BETHESDA,MD		Schieber, RA (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.							*US CONS PROD SAF, 1992, NEISS SAMPL DES IMPL	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					886	886		10.1001/jama.275.11.886	http://dx.doi.org/10.1001/jama.275.11.886			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596229				2022-12-01	WOS:A1996TZ97100035
J	Crossley, PH; Martinez, S; Martin, GR				Crossley, PH; Martinez, S; Martin, GR			Midbrain development induced by FGF8 in the chick embryo	NATURE			English	Article							EXPRESSION PATTERNS; INT-1 PROTOONCOGENE; MOUSE-BRAIN; HOMEO BOX; EN-2; PHENOTYPE; REGION; WNT-1; GENES	Vertebrate midbrain development depends on an organizing centre located at the isthmus, a constriction in the embryonic mid/hindbrain region-(1-3,28). Isthmic tissue grafts transform chick caudal forebrain into an ectopic midbrain that is the mirror image of the normal midbrain(4). Here we report that FGF8 protein has the same midbrain-inducing and polarizing effect as isthmic tissue. Moreover, FGF8 induces ectopic expression in the forebrain of genes normally expressed in the isthmus, suggesting that the ectopic midbrain forms under the influence of signals from a new 'isthmus-like' organizing centre induced in the forebrain. Because Fgf8 itself is expressed in the isthmus, our results identify FGF8 as an important signalling molecule in normal midbrain development.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV ALICANTE,INST NEUROSCI,ALACANT,SPAIN; UNIV MURCIA,FAC MED,DEPT MORPHOL SCI,E-30001 MURCIA,SPAIN	University of California System; University of California San Francisco; Universitat d'Alacant; University of Murcia	Crossley, PH (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926				ANG SL, 1993, DEVELOPMENT, V118, P139; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BALLYCUIF L, 1994, DEVELOPMENT, V120, P3379; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; GARDNER CA, 1992, DEV DYNAM, V193, P370, DOI 10.1002/aja.1001930410; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; RUBENSTEIN J, 1995, SCIENCE, V266, P578; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WILKINSON D, 1992, IN SITU HYBRIDISATIO; WURST W, 1994, DEVELOPMENT, V120, P2065	28	597	604	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					66	68		10.1038/380066a0	http://dx.doi.org/10.1038/380066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598907				2022-12-01	WOS:A1996TY87700057
J	Tappero, JW; Khan, AS; Pinner, RW; Wenger, JD; Graber, JM; Armstrong, LR; Holman, RC; Ksiazek, TG; Khabbaz, RF				Tappero, JW; Khan, AS; Pinner, RW; Wenger, JD; Graber, JM; Armstrong, LR; Holman, RC; Ksiazek, TG; Khabbaz, RF			Utility of emergency, telephone-based national surveillance for Hantavirus pulmonary syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On May 27, 1993, in response to the outbreak investigation of newly recognized Hantavirus pulmonary syndrome (HPS) in the Four Corners states (New Mexico, Arizona, Utah, and Colorado), the Centers for Disease Control and Prevention established a national surveillance case definition for severe, unexplained respiratory disease to determine the extent of HPS throughout the United States, A toll-free telephone hotline number was instituted to provide updated information about unexplained respiratory illness and to serve as a passive mechanism for reporting suspected cases. Clinical information was obtained from callers reporting suspected cases, and diagnostic specimens and medical record reviews were requested from health care providers, From June 3 through December 31, 1993, the hotline received 21 443 telephone inquiries; callers identified 280 suspected cases living outside the Four Comers states with at least one specimen available for diagnostic testing. By December 31, 1993, 21 confirmed cases (age range, 14 to 58 years) residing in 11 states outside the Four Corners region had been identified, This passive surveillance system was successful in rapidly identifying the widespread sporadic geographic distribution for HPS cases throughout the United States and could serve as a model for similar emergencies, Expanding and coordinating surveillance systems for the early detection, tracking, and evaluation of emerging infections is a critical component of disease prevention.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,BIOMETR ACTIV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Berkelman RL, 1996, JAMA-J AM MED ASSOC, V275, P315, DOI 10.1001/jama.275.4.315; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; Carleton M.D., 1989, P7; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHAPMAN LE, 1994, INFECT AGENT DIS, V3, P234; CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; ELLIOTT LH, 1994, AM J TROP MED HYG, V51, P102, DOI 10.4269/ajtmh.1994.51.102; FELDMANN H, 1993, VIRUS RES, V30, P351, DOI 10.1016/0168-1702(93)90101-R; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; KHAN AS, IN PRESS J INFECT DI; KSAIZEK TG, 1995, AM J TROP MED HYG, V52, P117; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; ROLLIN PE, 1995, J MED VIROL, V46, P35, DOI 10.1002/jmv.1890460108; SHEFER AM, 1994, CLIN INFECT DIS, V19, P1105, DOI 10.1093/clinids/19.6.1105; SPIROPOULOU CF, 1994, VIROLOGY, V200, P715, DOI 10.1006/viro.1994.1235; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; THACKER SB, 1983, JAMA-J AM MED ASSOC, V249, P1181; ZAKI SR, 1995, AM J PATHOL, V146, P552; ZAKI SR, IN PRESS ARCH PATHOL; ZEITZ PS, 1995, J INFECT DIS, V171, P864, DOI 10.1093/infdis/171.4.864; 1993, MMWR-MORBID MORTAL W, V42, P612; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V43, P99; 1993, MMWR-MORBID MORTAL W, V42, P441; 1993, MMWR-MORBID MORTAL W, V42, P421; 1994, MMWR-MORBID MORTAL W, V43, P105; 1993, MMWR-MORBID MORTAL W, V42, P816; 1994, MMWR-MORBID MORTAL W, V43, P45	32	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					398	400		10.1001/jama.275.5.398	http://dx.doi.org/10.1001/jama.275.5.398			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569020				2022-12-01	WOS:A1996TT30300034
J	Zahn, R; Perrett, S; Stenberg, G; Fersht, AR				Zahn, R; Perrett, S; Stenberg, G; Fersht, AR			Catalysis of amide proton exchange by the molecular chaperones GroEL and SecB	SCIENCE			English	Article							HYDROGEN-EXCHANGE; ESCHERICHIA-COLI; PROTEIN; BARNASE; STABILITY; BINDING; SURFACE; PATHWAY	Hydrogen-deuterium exchange of 39 amide protons of Bacillus amyloliquefaciens ribonuclease (barnase) was analyzed by two-dimensional nuclear magnetic resonance in the presence of micromolar concentrations of the molecular chaperones GroEL and SecB. Both chaperones bound to native barnase under physiological conditions and catalyzed exchange of deeply buried amide protons with solvent. Such exchange required complete unfolding of barnase, which occurred in the complex with the chaperones. Subsequent collapse of unfolded barnase to the exchange-protected folding intermediate was markedly slowed in the presence of GroEL or SecB. Thus, both chaperones have the potential to correct misfolding in proteins by annealing.	UNIV CAMBRIDGE,MRC,UNIT PROT FUNCT & DESIGN,DEPT CHEM,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge			Perrett, Sarah/AAS-9483-2020; Fersht, Alan R/B-2189-2008	Perrett, Sarah/0000-0003-0137-0997; 				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CLARKE J, 1993, P NATL ACAD SCI USA, V90, P9837, DOI 10.1073/pnas.90.21.9837; CORRALES F, UNPUB; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PERRETT S, 1995, BIOCHEMISTRY-US, V34, P9288, DOI 10.1021/bi00029a003; PERRETT S, UNPUB; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; RODER H, 1985, BIOCHEMISTRY-US, V24, P7396, DOI 10.1021/bi00346a055; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; STENBERG G, UNPUB; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOPPING TB, 1994, PROTEIN SCI, V3, P760; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZAHN R, 1994, THESIS U MUNICH	46	134	135	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					642	645		10.1126/science.271.5249.642	http://dx.doi.org/10.1126/science.271.5249.642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571125				2022-12-01	WOS:A1996TT87000044
J	Michallet, M; Archimbaud, E; Bandini, G; Rowlings, PA; Deeg, HJ; Gahrton, G; Montserrat, E; Rozman, C; Gratwohl, A; Gale, RP				Michallet, M; Archimbaud, E; Bandini, G; Rowlings, PA; Deeg, HJ; Gahrton, G; Montserrat, E; Rozman, C; Gratwohl, A; Gale, RP			HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIVARIATE SURVIVAL ANALYSIS; PROGNOSIS; FLUDARABINE; ADULTS	Objective: To characterize in detail the outcomes of HLA-identical sibling bone marrow transplantation for chronic lymphocytic leukemia (CLL) in patients Lounger than 60 years of age. Design: Retrospective cohort study. Setting: 30 centers for bone marrow transplantation worldwide, which reported data on outcome of HLA-identical sibling bone marrow transplantation for CLL to the European Group for Blood and Marrow Transplantation or the International Bone Marrow Transplant Registry between 1984 and 1992. Patients: 54 patients diagnosed with CLL (median age, 41 years; range, 21 to 58 years). The median interval from diagnosis to transplantation was 37 months (range, 5 to 130 months). At the time of transplantation, 3 patients were at Rai stage 0; 10 were at stage 1; 10 were at stage 2; 7 were at stage 3; and 22 were at stage 4. Intervention: Transplant regimens varied. Most patients received high-dose cyclophosphamide and total body irradiation, followed by infusion of bone marrow from an HLA-identical sibling. After transplantation, immune suppression with cyclosporine or methotrexate or both was generally used to prevent graft-versus-host disease. Measurements: The primary outcome was survival. We also studied hematologic remission, defined as normalization of the leukocyte count, hemoglobin level, and platelet count, and absence of lymphadenopathy and splenomegaly. Results: 38 patients (70%) achieved hematologic remission. Twenty-four (44%) remain alive a median of 27 months (range, 5 to 80 months) after transplantation. Three-year survival probability was 46% (95% CI, 32% to 60%). Three patients who received transplants at Rai stage 0 remain alive 21, 32, and 45 months after transplantation. Three-year survival probabilities were as follows: 68% (CI, 38% to 98%) in 10 patients who received transplants at Rai stage 1, 30% (CI, 2% to 58%) in 10 patients who received transplants at Rai stage 2, 57% (CI, 21% to 93%) in 7 patients who received transplants at Rai stage 3, and 34% (CI, 12% to 56%) in 22 patients who received transplants at Rai stage 4 CLL. Five patients (9%) died of progressive leukemia and 25 (46%) of treatment-related complications. Conclusions: Bone marrow transplants from HLA-identical siblings can result in hematologic remission and survival in persons with CLL, but it is uncertain how these results compare with those of conventional therapies.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, HLTH POLICY INST, MILWAUKEE, WI 53226 USA; SAN ORSOLA HOSP, BOLOGNA, ITALY; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; KAROLINSKA INST, HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN; KAROLINSKA INST, HUDDINGE, SWEDEN; SALICK HLTH CARE INC, LOS ANGELES, CA USA; HOP EDOUARD HERRIOT, HOP LYON, F-69437 LYON 03, FRANCE; HOP EDOUARD HERRIOT, SERV HEMATOL, F-69437 LYON 03, FRANCE; HUDDINGE HOSP, KAROLINSKA INST, DEPT MED, S-14186 HUDDINGE, SWEDEN; ST VINCENTS HOSP, DEPT HEMATOL, SYDNEY, NSW, AUSTRALIA; ROYAL POSTGRAD MED SCH, DEPT HEMATOL, LONDON, ENGLAND; CLAUDE HURIEZ HOSP, DEPT HEMATOL, LILLE, FRANCE; LONG ISL JEWISH MED CTR, NEW HYDE PK, NY 11042 USA; UNIV HOSP, DIV HEMATOL, DEPT INTERNAL MED, BASEL, SWITZERLAND; HOSP CLIN BARCELONA, BARCELONA, SPAIN	Medical College of Wisconsin; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Fred Hutchinson Cancer Center; Karolinska Institutet; Karolinska Institutet; CHU Lyon; CHU Lyon; Karolinska Institutet; St Vincents Hospital Sydney; Imperial College London; Universite de Lille - ISITE; CHU Lille; Northwell Health; University of Barcelona; Hospital Clinic de Barcelona					NCI NIH HHS [P01-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDINI G, 1991, BONE MARROW TRANSPL, V7, P251; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; GAJEWSKI JL, 1996, IN PRESS J CLIN ONCO; GALE RP, 1993, BAILLIERE CLIN HAEM, V6, P879, DOI 10.1016/S0950-3536(05)80181-7; GALE RP, 1996, IN PRESS LEUKEMIA; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; JULIUSSON G, 1993, CHRONIC LYMPHOCYTIC, P83; KEATING MJ, 1993, BLOOD, V81, P2878; KHOURI IF, 1994, J CLIN ONCOL, V12, P748, DOI 10.1200/JCO.1994.12.4.748; LEE JS, 1987, BLOOD, V69, P929; MICHALLET M, 1991, BONE MARROW TRANSPL, V7, P275; MONTSERRAT E, 1989, ANN INTERN MED, V110, P236; MONTSERRAT E, 1991, BLOOD, V78, P1545; MONTSERRAT E, 1986, BRIT J HAEMATOL, V62, P567, DOI 10.1111/j.1365-2141.1986.tb02969.x; RABINOWE SN, 1993, BLOOD, V82, P1366; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; ROZMAN C, 1984, BLOOD, V64, P642	20	204	207	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					311	315		10.7326/0003-4819-124-3-199602010-00005	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554226				2022-12-01	WOS:A1996TR59600005
J	Savage, B; Saldivar, E; Ruggeri, ZM				Savage, B; Saldivar, E; Ruggeri, ZM			Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor	CELL			English	Article							VONWILLEBRAND-FACTOR-BINDING; CORONARY-ARTERY THROMBOSIS; MEMBRANE GLYCOPROTEIN-IB; IIB-IIIA COMPLEX; SHEAR-STRESS; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; DOMAIN; AGGREGATION; DISEASE	We have identified two distinct mechanisms initiating the adhesion of flowing platelets to thrombogenic surfaces. The integrin alpha(IIb)beta(3) promotes immediate arrest onto fibrinogen but is fully efficient only at wall shear rates below 600-900 s(-1), perhaps because of a relatively slow rate of bond formation or low resistance to tensile stress. In contrast, glycoprotein Ib alpha binding to immobilized von Willebrand factor (vWF) appears to have fast association and dissociation rates as well as high resistance to tensile stress, supporting slow movement of platelets in continuous contact with the surface even at shear rates in excess of 6000 s(-1). This eventually allows activated alpha(IIb)beta(3) to arrest platelets onto vWF under conditions not permissive of direct binding to fibrinogen. The coupling of these different functions may be crucial for thrombogenesis.	SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Savage, B (corresponding author), SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.		Pieper, Maja/AAN-8539-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042846, P01HL048728, R01HL042846, P01HL031950] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48728, HL-31950, HL-42846] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU BR, 1993, BLOOD, V81, P1263; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; COLLER BS, 1980, BLOOD, V55, P169; DISE CA, 1982, J BIOL CHEM, V257, P4701; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FUJIMURA Y, 1991, BLOOD, V77, P113; Fung YC., 1981, BIOMECHANICS; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GIBSON CM, 1993, ARTERIOSCLER THROMB, V13, P310, DOI 10.1161/01.ATV.13.2.310; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOGSTAD GO, 1982, BLOOD, V60, P663; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HANDA M, 1986, J BIOL CHEM, V261, P2579; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MOAKE JL, 1988, BLOOD, V71, P1366; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MUSTARD JF, 1978, BLOOD, V52, P453; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NICHOLS TC, 1991, CIRCULATION, V83, P56; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SAVAGE B, 1995, J BIOL CHEM, V270, P28812, DOI 10.1074/jbc.270.48.28812; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SIXMA JJ, 1977, SEMIN HEMATOL, V14, P265; STRONY J, 1990, CIRCULATION, V81, P1106, DOI 10.1161/01.CIR.81.3.1106; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; TOZEREN A, 1992, BIOPHYS J, V63, P700, DOI 10.1016/S0006-3495(92)81660-0; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1971, NEW ENGL J MED, V285, P369, DOI 10.1056/NEJM197108122850703; WEISS HJ, 1993, J LAB CLIN MED, V122, P324; Whitmore R. L., 1968, RHEOLOGY CIRCULATION	57	943	973	3	65	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					289	297		10.1016/S0092-8674(00)80983-6	http://dx.doi.org/10.1016/S0092-8674(00)80983-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565074	Bronze			2022-12-01	WOS:A1996TR59500015
J	Fine, KD				Fine, KD			The prevalence of occult gastrointestinal bleeding in celiac sprue	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUTEN-FREE DIET; IRON-DEFICIENCY; REFRACTORY SPRUE; DISEASE; DIARRHEA; CHILDREN; ANEMIA	Background. Iron deficiency complicating celiac sprue is usually attributed to the malabsorption of dietary iron or the loss of iron from the intestinal mucosa, There has been little investigation of the role of intestinal loss of blood in patients with this condition, The purpose of this study was to determine the prevalence of occult gastrointestinal bleeding in patients with celiac sprue. Methods. We tested one 48- or 72-hour stool collection from each of 8 patients with partial villous atrophy and 28 patients with total villous atrophy using a guaiac-impregnated card (Hemoccult). Serving as controls were 18 normal subjects, each studied before and during laxative-induced diarrhea; 17 patients with idiopathic chronic diarrhea; 63 patients with microscopic colitis; 23 patients with pancreatic steatorrhea; and 7 patients with treated celiac sprue who had normal intestinal histologic features, All the patients underwent a diagnostic workup that included esophagogastroduodenoscopy, colonoscopy, and barium radiography of the small bower. Results. Positive Hemoccult tests were infrequent in each of the control groups, occurring in 0 to 8 percent of the subjects, whereas 2 of the 8 patients with partial villous atrophy (25 percent) and 15 of the 28 patients with total villous atrophy (54 percent) had positive tests, When the patients with total villous atrophy were classified according to their subsequent responses to a gluten-free diet, 7 of the 17 who were responsive to gluten withdrawal (41 percent) were Hemoccult-positive, as compared with 8 of the 11 who did not respond to the diet (73 percent). Conclusions. Occult gastrointestinal bleeding can be detected in about half of patients with celiac sprue and should be added to the list of factors that can contribute to iron deficiency in patients with this disorder. (C) 1996, Massachusetts Medical Society.			Fine, KD (corresponding author), BAYLOR UNIV, MED CTR, DEPT GASTROINTESTINAL RES, 3500 GASTON AVE, DALLAS, TX 75246 USA.				NIDDK NIH HHS [5-R01-DK37172-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; BADENOCH J, 1954, BLOOD, V9, P123, DOI 10.1182/blood.V9.2.123.123; BADENOCH J, 1960, LANCET, V1, P192; BONAMICO M, 1987, J PEDIATR GASTR NUTR, V6, P702, DOI 10.1097/00005176-198709000-00007; BRADY CE, 1994, J CLIN GASTROENTEROL, V18, P130, DOI 10.1097/00004836-199403000-00010; COOKE WT, 1984, COELIAC DISEASE, P128; COOPER BT, 1987, Q J MED, V63, P269; DEPLA ACTM, 1990, HEPATO-GASTROENTEROL, V37, P90; DUBOIS RN, 1989, JAMA-J AM MED ASSOC, V262, P935, DOI 10.1001/jama.262.7.935; GIULIANI ER, 1961, J NUCL MED, V2, P297; GOSTOUT CJ, 1993, GASTROINTEST ENDOSC, V39, P76, DOI 10.1016/S0016-5107(93)70018-8; HOFFBRAND AV, 1974, CLIN GASTROENTEROL, V3, P71; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOLMES GKT, 1992, DYN NUTR R, V2, P105; KAGNOFF MF, 1991, TXB GASTROENTEROLOGY, P1503; KILPATRICK ZM, 1969, J AMER MED ASSOC, V208, P999, DOI 10.1001/jama.208.6.999; KOSNAI I, 1979, ARCH DIS CHILD, V54, P375, DOI 10.1136/adc.54.5.375; MARSH MN, 1993, EUR J GASTROEN HEPAT, V5, P784; MCGUIGAN JE, 1964, GASTROENTEROLOGY, V47, P636; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STEVENS D, 1979, ARCH DIS CHILD, V54, P648, DOI 10.1136/adc.54.8.648; SUTTON DR, 1970, LANCET, V2, P387; SYLWESTROWICZ T, 1989, AM J GASTROENTEROL, V84, P763; TRIER JS, 1978, GASTROENTEROLOGY, V75, P307; WEBB MGT, 1967, BMJ-BRIT MED J, V2, P151, DOI 10.1136/bmj.2.5545.151; WHITEHEAD R, 1965, J CLIN PATHOL, V18, P110, DOI 10.1136/jcp.18.1.110	26	100	104	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1163	1167		10.1056/NEJM199605023341804	http://dx.doi.org/10.1056/NEJM199605023341804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602182				2022-12-01	WOS:A1996UG83100004
J	Senard, JM; Montastruc, P; Herxheimer, A				Senard, JM; Montastruc, P; Herxheimer, A			Early warnings about drugs - From the stock market	LANCET			English	Editorial Material											Senard, JM (corresponding author), FAC MED TOULOUSE,SERV PHARMACOL MED & CLIN,TOULOUSE,FRANCE.			Senard, Jean-Michel/0000-0001-7679-1281				COSNARD D, 1993, ECHOS           1026, P12; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; NODELANGLOIS F, 1995, LIBERATION      0729, P20; 1995, SCRIP, V2048, P16; 1993, INVESTIR, V1032, P18; 1994, ECHOS           0817, P7; 1995, INVESTIR, V1095, P14	7	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					987	988		10.1016/S0140-6736(96)90141-5	http://dx.doi.org/10.1016/S0140-6736(96)90141-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606610				2022-12-01	WOS:A1996UF38000006
J	Rothwell, PM; Wroe, SJ; Slattery, J; Warlow, CP				Rothwell, PM; Wroe, SJ; Slattery, J; Warlow, CP			Is stroke incidence related to season or temperature?	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; RATES	Background A winter excess of ischaemic stroke has been found in mortality and hospital-based studies. It is often assumed that this is due to seasonal variation in stroke incidence and several pathophysiological explanations have been proposed. We studied the incidence of stroke in relation to season and outside temperature. Methods The data came from a community-based study of first ever in a lifetime stroke in a defined population of about 105 000. 675 such strokes were registered over four years and the month of onset was analysed separately for cerebral infarction, primary intracerebral haemorrhage, and subarachnoid haemorrhage. Findings There was no significant seasonal variation. The incidence of primary intracerebral haemorrhage was increased at low temperatures, but there was no significant relation between the incidence of ischaemic stroke or subarachnoid haemorrhage and temperature. Interpretation The widely reported winter excess of ischaemic strokes may be an artifact due to referral bias in hospital-based studies and increased case fatality during the winter in mortality studies.	IPSWICH HOSP,DEPT NEUROL,IPSWICH,SUFFOLK,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital	Rothwell, PM (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLEN CMC, 1983, Q J MED, V52, P515; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; HABERMAN S, 1981, J NEUROL SCI, V52, P25, DOI 10.1016/0022-510X(81)90131-3; KELLYHAYES M, 1995, STROKE, V26, P1343, DOI 10.1161/01.STR.26.8.1343; PAN WH, 1995, LANCET, V345, P353, DOI 10.1016/S0140-6736(95)90341-0; RICCI S, 1992, NEUROEPIDEMIOLOGY, V11, P59, DOI 10.1159/000110913; ROTHWELL PM, 1994, LANCET, V344, P1161, DOI 10.1016/S0140-6736(94)90671-8; SOBEL E, 1987, STROKE, V18, P38, DOI 10.1161/01.STR.18.1.38; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; WALTER SD, 1975, BRIT J PREV SOC MED, V29, P18; *WHO, 1977, WHO MAN MORT AN, P212; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	14	126	129	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					934	936		10.1016/S0140-6736(96)91415-4	http://dx.doi.org/10.1016/S0140-6736(96)91415-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598757				2022-12-01	WOS:A1996UD59100010
J	Camins, BC; Bock, N; Watkins, DL; Blumberg, HM				Camins, BC; Bock, N; Watkins, DL; Blumberg, HM			Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL TRANSMISSION; EPIDEMIOLOGY; INFECTION; OUTBREAK	Objective.-To examine health care workers' (HCWs') acceptance of and adherence to isoniazid preventive therapy in the setting of a comprehensive tuberculin skin-testing program. Design.-Descriptive case series. Setting.-University-affiliated inner-city public hospital in Atlanta, Ga. Participants.-A total of 125 HCWs (91 hospital employees and 34 house staff or medical students [the physician group]) who had a positive tuberculin skin test between July 1992 and January 1994 and were offered isoniazid preventive therapy. Interventions.-Health care workers with a recent tuberculin skin test conversion were required to have a chest x-ray performed and see a physician and were encouraged but not required to undergo preventive therapy. Main Outcome Measures.-Acceptance and initiation of preventive therapy with isoniazid by HCWs, completion of at least 6 months of preventive therapy, and differences between the employee and physician groups. Results.-All 125 HCWs with a recent positive tuberculin skin test had a chest radiograph performed, 123 (98.4%) saw a physician, and 105 (84%) initiated preventive therapy. Sixty-nine (66%) of the 105 HCWs who initiated preventive therapy (55% of the 125 total) completed at least 6 months of isoniazid therapy. More of the physician group than of the employee group completed preventive therapy (25 of 34 [74%] vs 44 of 91 [48%], respectively; P<.01). Of the 36 HCWs who started but did not complete preventive therapy, 12 discontinued therapy because of an adverse drug effect and 24 were nonadherent. Conclusions.-Acceptance of tuberculosis preventive therapy by HCWs was high in the setting of a comprehensive tuberculin skin-testing program, and completion of therapy was much higher in the physician group than in previously reported series.	EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30303; GRADY MEM HOSP,ATLANTA,GA	Emory University			Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443	NHLBI NIH HHS [K07 HL03078-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CATANZARO A, 1995, LANCET, V345, P204, DOI 10.1016/S0140-6736(95)90216-3; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; GIESELER PJ, 1987, AM REV RESPIR DIS, V135, P3; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; MCGOWAN JE, 1995, CLIN INFECT DIS, V21, P489, DOI 10.1093/clinids/21.3.489; SALPETER S, 1992, WESTERN J MED, V157, P421; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; ZAZA S, 1995, J INFECT DIS, V172, P1542, DOI 10.1093/infdis/172.6.1542; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, AM J RESP CRIT CARE, V149, P1359	19	26	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1013	1015						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596233				2022-12-01	WOS:A1996UC12300029
J	Sengupta, P; Chou, JH; Bargmann, CI				Sengupta, P; Chou, JH; Bargmann, CI			odr-10 encodes a seven transmembrane domain olfactory receptor required for responses to the odorant diacetyl	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SENSITIVE ADENYLATE-CYCLASE; C-ELEGANS; PROTEIN; EXPRESSION; EPITHELIUM; SEQUENCE; GENOME; SYSTEM; TRANSDUCTION	Olfactory signaling is initiated by interactions between odorants and olfactory receptors. We show that the C. elegans odr-10 gene is likely to encode a receptor for the odorant diacetyl. odr-10 mutants have a specific defect in chemotaxis to diacetyl, one of several odorants detected by the AWA olfactory neurons. odr-10 encodes a predicted seven transmembrane domain receptor; a green fluorescent protein-tagged Odr-10 protein is localized to the AWA sensory cilia. odr-10 expression is regulated by odr-7, a transcription factor implicated in AWA sensory specification. Expression of odr-10 from a heterologous promoter directs behavioral responses to diacetyl, but not to another odorant detected by the AWA neurons. These results provide functional evidence for a specific interaction between an olfactory receptor protein and its odorant ligand.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,GENET PROGRAM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526; Chou, Joseph/0000-0002-3138-0777; Bargmann, Cornelia/0000-0002-8484-0618				AATSINKI JT, 1994, BIOTECHNIQUES, V16, P282; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOEKHOFF I, 1994, J NEUROSCI, V14, P3304; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; IVANOVA TT, 1993, J GEN PHYSIOL, V102, P1085, DOI 10.1085/jgp.102.6.1085; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KANG JS, 1995, J NEUROPHYSIOL, V73, P172, DOI 10.1152/jn.1995.73.1.172; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J., 1989, MOL CLONING LAB MANU; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; SIDDIQI O, 1987, TRENDS GENET, V3, P137, DOI 10.1016/0168-9525(87)90204-6; SINGER MS, 1995, NATURE, V377, P19, DOI 10.1038/377019b0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	55	397	418	4	70	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					899	909		10.1016/S0092-8674(00)81068-5	http://dx.doi.org/10.1016/S0092-8674(00)81068-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601313	Bronze			2022-12-01	WOS:A1996UC38100011
J	Khachigian, LM; Lindner, V; Williams, AJ; Collins, T				Khachigian, LM; Lindner, V; Williams, AJ; Collins, T			Egr-1-induced endothelial gene expression: A common theme in vascular injury	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; HUMAN ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE; TRANSCRIPTION FACTOR; ARTERIAL INJURY; BINDING; PROMOTER; EGR-1; SITE; ANGIOPLASTY	A number of pathophysiologically relevant genes, including platelet-derived growth factor B-chain (PDGF-B), are induced in the vasculature after acute mechanical injury. In rat aorta, the activated expression of these genes was preceded by a marked increase in the amount of the early-growth-response gene product Egr-1 at the endothelial wound edge. Egr-1 interacts with a novel element in the proximal PDGF-B promoter, as well as with consensus elements in the promoters of other genes induced by endothelial injury. This interaction is crucial for injury-induced PDGF-B promoter-dependent expression. Sp1, whose binding site in the PDGF-B promoter overlaps that of Egr-1, occupies this element in unstimulated cells and is displaced by increasing amounts of Egr-1. These findings implicate Egr-1 in the up-regulated expression of PDGF-B and other potent mediators in mechanically injured arterial endothelial cells.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington Seattle			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P755; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, UNPUB; KIM SJ, 1989, J BIOL CHEM, V264, P402; LINDNER V, 1995, AM J PATHOL, V146, P1488; Lindner V, 1996, AM J PATHOL, V148, P427; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MATTSSON E, 1995, TRENDS CARDIOVAS MED, V5, P200, DOI 10.1016/1050-1738(95)00075-K; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; REED MJ, 1995, AM J PATHOL, V147, P1068; REKHTER MD, 1994, CIRC RES, V75, P410, DOI 10.1161/01.RES.75.3.410; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671	35	476	491	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1427	1431		10.1126/science.271.5254.1427	http://dx.doi.org/10.1126/science.271.5254.1427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596917				2022-12-01	WOS:A1996TY96100049
J	Nelson, KB; Dambrosia, JM; Ting, TY; Grether, JK				Nelson, KB; Dambrosia, JM; Ting, TY; Grether, JK			Uncertain value of electronic fetal monitoring in predicting cerebral palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WESTERN-AUSTRALIA; ANTECEDENTS; RISK	Background. Electronic monitoring of the fetal heart rate is commonly performed, in part to detect hypoxia during delivery that may result in brain injury: It is not known whether specific abnormalities on electronic fetal monitoring are related to the risk of cerebral palsy. Methods. Among 155,636 children born from 1983 through 1985 in four California counties, we identified singleton infants with birth weights of at least 2500 g who survived to three years of age and had moderate or severe cerebral palsy. The children with cerebral palsy were compared with randomly selected control children with respect to characteristics noted in the birth records. Results. Seventy-eight of 95 children with cerebral palsy and 300 of 378 controls underwent intrapartum fetal monitoring. Characteristics found to be associated with an increased risk of cerebral palsy were multiple late decelerations in the heart rate, commonly defined as slowing of the heart rate well after the onset of uterine contractions (odds ratio, 3.9; 95 percent confidence interval, 1.7 to 9.3), and decreased beat-to-beat variability of the heart rate (odds ratio, 2.7; 95 percent confidence interval, 1.1 to 5.8); there was no association between the highest or lowest fetal heart rate recorded for each child and the risk of cerebral palsy. Even after adjustment for other risk factors, the association of abnormalities on fetal monitoring with an increased risk of cerebral palsy persisted (adjusted odds ratio, 2.7; 95 percent confidence interval, 1.4 to 5.4). The 21 children with cerebral palsy who had multiple late decelerations or decreased variability in heart rate on fetal monitoring represented only 0.19 percent of singleton infants with birth weights of 2500 g or more who had these fetal-monitoring findings, for a false positive rate of 99.8 percent. Conclusions. Specific abnormal findings on electronic monitoring of the fetal heart rate were associated with an increased risk of cerebral palsy. However, the false positive rate was extremely high. Since cesarean section is often performed when such abnormalities are noted and is associated with risk to the mother, our findings arouse concern that, if these indications were widely used, many cesarean sections would be performed without benefit and with the potential for harm. (C) 1996, Massachusetts Medical Society.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892; NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892; HOWARD HUGHES MED INST,BETHESDA,MD 20817; UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; CALIF DEPT HLTH SERV,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA 94608	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Howard Hughes Medical Institute; University of Pennsylvania; California Department of Health Care Services								BADER TJ, 1995, OBSTET GYNECOL, V85, P643; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; Cohen A B, 1982, Med Decis Making, V2, P79, DOI 10.1177/0272989X8200200111; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; CUNNINGHAM GC, 1979, INTRAUTERINE GROWTH; GRANT A, 1989, EFFECTIVE CARE PREGN, V2, P846; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; KRAGELOHMANN I, 1995, DEV MED CHILD NEUROL, V37, P191; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; Lumley J, 1988, Paediatr Perinat Epidemiol, V2, P299, DOI 10.1111/j.1365-3016.1988.tb00223.x; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MACGILLIVRAY I, 1995, PAEDIATR PERINAT EP, V9, P146, DOI 10.1111/j.1365-3016.1995.tb00130.x; NAULTY CM, 1994, AM J PERINAT, V11, P377, DOI 10.1055/s-2007-994601; NEILSON JP, 1994, BIRTH-ISS PERINAT C, V21, P101, DOI 10.1111/j.1523-536X.1994.tb00242.x; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; NIELSEN TF, 1984, ACTA OBSTET GYN SCAN, V63, P103, DOI 10.3109/00016348409154643; NIELSEN TF, 1995, REPRODUCTIVE HLTH CA, P279; PANETH N, 1993, CLIN INVEST MED, V16, P159; Paul R H, 1994, J Perinatol, V14, P393; ROSTOW VP, 1989, NEW ENGL J MED, V321, P1057, DOI 10.1056/NEJM198910123211526; SCHELLER JM, 1994, OBSTET GYNECOL, V83, P624, DOI 10.1097/00006250-199404000-00025; SHY KK, 1987, ANNU REV PUBL HEALTH, V8, P165, DOI 10.1146/annurev.publhealth.8.1.165; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; THACKER SB, 1995, OBSTET GYNECOL, V86, P613, DOI 10.1016/0029-7844(95)00232-G; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; VINTZILEOS AM, 1995, OBSTET GYNECOL, V85, P149, DOI 10.1016/0029-7844(94)00320-D; YUDKIN PL, 1995, PAEDIATR PERINAT EP, V9, P156, DOI 10.1111/j.1365-3016.1995.tb00131.x	31	299	305	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					613	618		10.1056/NEJM199603073341001	http://dx.doi.org/10.1056/NEJM199603073341001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592523				2022-12-01	WOS:A1996TX69300001
J	[Anonymous]				[Anonymous]			Infected blood in Japan	NATURE			English	Editorial Material																		1996, NATURE, V379, P663; 1996, NATURE, V379, P760	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598891				2022-12-01	WOS:A1996TY87700002
J	King, GE; Markowitz, LE; Heath, J; Redd, SC; Coleman, S; Bellini, WJ; Sievert, A				King, GE; Markowitz, LE; Heath, J; Redd, SC; Coleman, S; Bellini, WJ; Sievert, A			Antibody response to measles mumps rubella vaccine of children with mild illness at the time of vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENZYME IMMUNOASSAYS; OPPORTUNITIES; INFANTS	Objective.-To examine the response to measles-mumps-rubella (MMR) vaccine among children with and without mild illness. Design.-Prospective cohort. Participants.-A total of 386 children aged 15 to 23 months. Main Outcome Measures.-Seroconversion rates to measles, mumps, and rubella in ill and well children. Setting.-Six public health immunization clinics in two counties in the greater metropolitan Atlanta, Ga, area from February 1992 to April 1993. Results.-Acute upper respiratory tract infection, otitis media, and diarrhea were observed in 128 (33%), 41 (11%), and 13 (3%) of the children (groups are not mutually exclusive); 157 children had one of these mild illnesses and 229 were well. Overall seroconversion rates were 98% for measles, 83% for mumps, and 98% for rubella antigens, Measles seroconversion rates for ill children compared with well children, respectively, were as follows: upper respiratory tract infection, 99% vs 97%; mild fever, 98% vs 97%; otitis media, 98% vs 98%; diarrhea, 100% vs 98%; and any mild illness, 99% vs 97%. Estimates of the magnitude of antibody response to measles, mumps, and rubella antigens were the same for children with and without mild illness. There was no association of mild illness with increased rates and severity of adverse events reported in the 2 weeks after vaccination. Conclusions.-Vaccinating children who present with mild illnesses with MMR vaccine is a safe and efficacious practice. These results support recommendations of the Advisory Committee on Immunization Practices and the American Academy of Pediatrics.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30333; DEKALB CTY BOARD HLTH,DECATUR,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ATKINSON WL, 1992, 32 INT C ANT AG CHEM; DENNEHY PH, 1994, PEDIATRICS, V94, P514; FARIZO KM, 1992, PEDIATRICS, V89, P589; FORGHANI B, 1979, J CLIN MICROBIOL, V9, P657; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HUMMEL KB, 1992, J CLIN MICROBIOL, V30, P2874, DOI 10.1128/JCM.30.11.2874-2880.1992; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; NDIKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448, DOI 10.1093/ije/17.2.448; PETER G, 1994, REPORT COMMITTEE INF, P35; Ratman S, 1995, J PEDIATR, V127, P432; 1987, MMWR-MORBID MORTAL W, V36, P45; 1994, MMWR-MORBID MORTAL W, V43, P57; 1994, MMWR-MORBID MORTAL W, V43, P26; 1993, MMWR-MORBID MORTAL W, V42, P5; 1989, MMWR-MORBID MORTAL W, V38, P9	18	16	17	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					704	707		10.1001/jama.275.9.704	http://dx.doi.org/10.1001/jama.275.9.704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594268				2022-12-01	WOS:A1996TX17400026
J	Bourke, GJ				Bourke, GJ			Airbags and fatal injuries to children	LANCET			English	Editorial Material											Bourke, GJ (corresponding author), UNIV COLL DUBLIN,DEPT EPIDEMIOL & PUBL HLTH MED,DUBLIN,IRELAND.							HERBERT D C, 1964, Med J Aust, V1, P61; NORMAN LG, 1962, 12 WHO PUBL HLTH PAP; 1995, H9517 NAT TRANSP SAF; 1995, MMWR-MORBID MORTAL W, V44, P845; 1993, MMWR-MORBID MORTAL W, V42, P280; 1995, TRAFFIC SAFETY FACTS	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					560	560		10.1016/S0140-6736(96)91269-6	http://dx.doi.org/10.1016/S0140-6736(96)91269-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596316				2022-12-01	WOS:A1996TX69400007
J	Nightingale, SL				Nightingale, SL			New tuberculosis test approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-01	WOS:A1996TW62700005
J	Hubbard, R; Lewis, S; Richards, K; Johnston, I; Britton, J				Hubbard, R; Lewis, S; Richards, K; Johnston, I; Britton, J			Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis	LANCET			English	Article							PULMONARY FIBROSIS; RESPIRATORY-TRACT; WORKERS; DISEASES; LUNG; POLISHER	Background We have previously suggested that cryptogenic fibrosing alveolitis (CFA) may be caused by occupational exposures, particularly to metal or wood dust. We have specifically investigated this hypothesis in a case-control study of patients with CFA. Methods We obtained lifetime occupational histories by postal questionnaire from 218 patients with CFA and 569 controls matched for age, sex, and community, living in the Trent region of the UK. Information was subsequently verified by telephone interview in 165 cases and 408 controls. Serum IgE, rheumatoid factor, and antinuclear antibodies and skin sensitivity to common allergens were measured in cases and in one matched control for each. Findings The relative risk of CFA, after adjustment for smoking, was significantly increased in relation to questionnaire-reported exposure to metal dust (odds ratio 1.68 [95% CI 1.07-2.65], p=0.024) or to wood dust (1.71 [1.01-2.92], p=0.048). Similar results were obtained with the telephone interview data. Significant exposure-response effects were found for both metal-dust and wood-dust exposure. CFA was also associated with the presence of rheumatoid factor or antinuclear antibodies, but not with positive allergen skin tests or raised IgE concentrations. There was no evidence of interaction between the effects of rheumatoid factor, antinuclear antibodies, positive shin allergen tests, or IgE concentrations and exposure to metal or wood dust. The combined aetiological fraction attributable to exposure to metal or wood dust was of the order of 20%. Interpretation Occupational exposures to metal or wood dust are independent risk factors for CFA. Avoidance or limitation of these exposures may provide an opportunity to prevent the disease.	UNIV NOTTINGHAM, CITY HOSP, DIV RESP MED, NOTTINGHAM NG5 1PB, ENGLAND; QUEENS MED CTR, QUEENS RESP UNIT, NOTTINGHAM NG7 2UH, ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham			Britton, John R/G-9705-2011					[Anonymous], 1994, Respir Med, V88, P165; BARTTER T, 1991, ARCH INTERN MED, V151, P1197, DOI 10.1001/archinte.151.6.1197; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; CAROSSO A, 1987, BRIT J IND MED, V44, P53; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CUGELL DW, 1992, CLIN CHEST MED, V13, P269; DEVUYST P, 1986, EUR J RESPIR DIS, V68, P131; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; JEDERLINIC PJ, 1990, AM REV RESPIR DIS, V142, P1179, DOI 10.1164/ajrccm/142.5.1179; JOHNSTON I, 1990, BRIT MED J, V301, P1017, DOI 10.1136/bmj.301.6759.1017; JOHNSTON IDA, 1993, EUR RESPIR J, V6, P891; LILIS R, 1985, CHEST, V88, P306, DOI 10.1378/chest.88.2.306; MARSH P, 1994, RESP MED, V88, P369, DOI 10.1016/0954-6111(94)90043-4; NEMERY B, 1990, AM REV RESPIR DIS, V141, P1373, DOI 10.1164/ajrccm/141.5_Pt_1.1373; NEMERY B, 1990, EUR RESPIR J, V3, P202; RAMAGE JE, 1988, AM REV RESPIR DIS, V137, P1229, DOI 10.1164/ajrccm/137.5.1229; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; TOWNSHEND RH, 1982, BRIT J IND MED, V39, P411; Turner-Warwick M, 1971, Clin Allergy, V1, P83; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; TURNERWARWICK M, 1970, BMJ-BRIT MED J, V3, P492, DOI 10.1136/bmj.3.5721.492; VALLYATHAN V, 1982, CHEST, V81, P372, DOI 10.1378/chest.81.3.372; VANASSENDELFT AH, 1985, CHEST, V87, P394, DOI 10.1378/chest.87.3.394; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; WALDRON HA, 1994, OCCUPATIONAL LUNG DI, P593	29	241	248	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	1996	347	8997					284	289		10.1016/S0140-6736(96)90465-1	http://dx.doi.org/10.1016/S0140-6736(96)90465-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569361				2022-12-01	WOS:A1996TT48500008
J	vanDijk, MR; Janse, CJ; Waters, AP				vanDijk, MR; Janse, CJ; Waters, AP			Expression of a Plasmodium gene introduced into subtelomeric regions of Plasmodium berghei chromosomes	SCIENCE			English	Article							SIZE POLYMORPHISM; FALCIPARUM; BREAKAGE; DNA	Targeted integration of exogenous DNA into the genome of malaria parasites will allow their phenotype to be modulated by means of gene disruption or the stable expression of foreign and mutated genes. Described here is the site-specific integration through reciprocal exchange, and subsequent expression, of a selectable marker gene into the genome of the pathogenic, bloodstage forms of the rodent malaria parasite Plasmodium berghei. Stable integration of a single copy of the marker gene (retained for more than 70 generations in the absence of drug pressure) into a nontranscribed subtelomeric repeat array of different chromosomes was observed. Expression of the gene within the subtelomeres indicated that the previously recorded absence of transcription in these regions could be due to a corresponding absence of genes rather than active silencing mechanisms.	LEIDEN UNIV, DEPT PARASITOL, 2300 AL LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205				BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; DORE E, 1990, MOL CELL BIOL, V10, P2423, DOI 10.1128/MCB.10.5.2423; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; JANSE CJ, 1992, NUCLEIC ACIDS RES, V20, P581, DOI 10.1093/nar/20.3.581; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LANZER M, 1996, MOL BIOCHEM PARASIT, V70, P1; PACE T, 1990, MOL CELL BIOL, V10, P6759, DOI 10.1128/MCB.10.12.6759; POLOGE LG, 1990, MOL CELL BIOL, V10, P3243, DOI 10.1128/MCB.10.6.3243; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; PONZI M, 1992, NUCLEIC ACIDS RES, V20, P4491, DOI 10.1093/nar/20.17.4491; PONZI M, 1990, MOL BIOCHEM PARASIT, V41, P73, DOI 10.1016/0166-6851(90)90098-7; SCHERF A, 1992, EMBO J, V11, P2293, DOI 10.1002/j.1460-2075.1992.tb05288.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; VANDIJK MR, 1994, MOL BIOCHEM PARASIT, V68, P167, DOI 10.1016/0166-6851(94)00163-4; VANDIJK MR, UNPUB; WU Y, IN PRESS P NATL ACAD; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	18	76	76	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					662	665		10.1126/science.271.5249.662	http://dx.doi.org/10.1126/science.271.5249.662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571132				2022-12-01	WOS:A1996TT87000051
J	Dai, G; Levy, O; Carrasco, N				Dai, G; Levy, O; Carrasco, N			Cloning and characterization of the thyroid iodide transporter	NATURE			English	Article							EXPRESSION; PROTEIN	IODIDE (I-) is an essential constituent of the thyroid hormones T-3 and T-4, and is accumulated by the thyroid. The transport of iodide, the first step in thyroid hormogenesis, is catalysed by the Na+/I- symporter, an intrinsic membrane protein that is crucial for the evaluation, diagnosis and treatment of thyroid disorders. Although several other important thyroid proteins involved in hormogenesis have been characterized, the Na+/I- symporter has not. Here we report the isolation of a complementary DNA clone that encodes this symporter, as a result of functional screening of a cDNA library from a rat thyroid derived cell line (FRTL-5) in Xenopus laevis oocytes. Oocyte microinjection of an RNA transcript made in vitro from this cDNA clone elicited a more than 700-fold increase in perchlorate-sensitive Na+/I- symport activity over background. To our knowledge, this is the first iodide-transporting molecule to have its cDNA cloned, providing a missing link in the thyroid hormone biosynthetic pathway.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162				CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAI G, 1996, IN PRESS HDB BIOL PH, V2; DEGROOT LJ, 1995, ENDOCRINOLOGY, P507; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Surratt C K, 1993, Curr Opin Nephrol Hypertens, V2, P744; VILIJN F, 1989, J BIOL CHEM, V264, P11901; VULSMA T, 1991, ACTA ENDOCRINOL-COP, V124, P405, DOI 10.1530/acta.0.1240405; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; WERNER SC, 1991, THYROID FUNDAMENTAL, P1; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	19	870	932	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					458	460		10.1038/379458a0	http://dx.doi.org/10.1038/379458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559252				2022-12-01	WOS:A1996TT30400062
J	Hicke, L; Riezman, H				Hicke, L; Riezman, H			Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis	CELL			English	Article							PHEROMONE RECEPTOR; INSULIN-RECEPTOR; ALPHA-FACTOR; PROTEIN; DEGRADATION; INTERNALIZATION; VACUOLE; GENE; CEREVISIAE; SUBUNIT	Binding of alpha factor to Ste2p, a G protein-coupled plasma membrane receptor, activates a signal transduction pathway and stimulates endocytosis of the receptor-ligand complex. Ligand binding also induces ubiquitination of the Ste2p cytoplasmic tail. Protein ubiquitination is required for stimulated endocytosis of Steep, as internalization is 5- to 15-fold slower in ubc mutants that lack multiple ubiquitin-conjugating enzymes. In a C-terminal truncated form of Ste2p that is rapidly ubiquitinated and endocytosed in response to ligand binding, a single lysine to arginine substitution in its cytoplasmic tail eliminates both ubiquitination and internalization. Thus, ubiquitination of Ste2p itself is required for ligand-stimulated endocytosis. We propose that ubiquitination mediates degradation of receptor-ligand complexes, not via the proteasome, but by acting as a signal for endocytosis leading to subsequent degradation in the lysosome/vacuole.			Hicke, L (corresponding author), UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	52	642	656	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					277	287		10.1016/S0092-8674(00)80982-4	http://dx.doi.org/10.1016/S0092-8674(00)80982-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565073	Bronze			2022-12-01	WOS:A1996TR59500014
J	GALLAGHER, EJ; LOMBARDI, G; GENNIS, P				GALLAGHER, EJ; LOMBARDI, G; GENNIS, P			EFFECTIVENESS OF BYSTANDER CARDIOPULMONARY-RESUSCITATION AND SURVIVAL FOLLOWING OUT-OF-HOSPITAL CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIENCE; SYSTEM; CPR	Objective.-To examine the independent relationship between effectiveness of bystander cardiopulmonary resuscitation (CPR) and survival following out-of-hospital cardiac arrest. Design.-Prospective observational cohort. Setting.-New York City. Participants.-A total of 2071 consecutive out-of-hospital cardiac arrests meeting Utstein criteria. Intervention.-Trained prehospital personnel assessed the quality of bystander CPR on arrival at the scene. Satisfactory execution of CPR required performance of both adequate compressions and ventilations in conformity with current American Heart Association guidelines. Main Outcome Measure.-Adjusted association between CPR effectiveness and survival. Survival was defined as discharge from hospital to home. Results.-Outcome was determined on all members of the inception cohort-none were lost to follow-up. When the association between bystander CPR and survival was adjusted for effectiveness of CPR in the parent data set (N=2071), only effective CPR was retained in the logistic model (adjusted odds ratio [OR]=5.7; 95% confidence interval [CI], 2.7 to 12.2; P<.001). Of the subset of 662 individuals (32%) who received bystander CPR, 305 (46%) had it performed effectively. Of these, 4.6% (14/305) survived vs 1.4% (5/357) of those with ineffective CPR (OR=3.4; 95% CI, 1.1 to 12.1; P<.02). After adjustment for witness status, initial rhythm, interval from collapse to CPR, and interval from collapse to advanced life support, effective CPR remained independently associated with improved survival (adjusted OR=3.9; 95% CI, 1.1 to 14.0; P<.04). Conclusion.-The association between bystander CPR and survival in out-of-hospital cardiac arrest appears to be confounded by CPR quality. Effective CPR is independently associated with a quantitatively and statistically significant improvement in survival.	ALBERT EINSTEIN COLL MED,DEPT EMERGENCY MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; YALE UNIV,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,NEW HAVEN,CT	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University								BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BOSSAERT L, 1989, RESUSCITATION, V17, pS55, DOI 10.1016/0300-9572(89)90091-9; CHANDRA NC, 1992, CURR EMERG CARDIAC C, V3, P5; COBB LA, 1980, ANNU REV MED, V31, P454; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; GENNIS P, 1994, ANN EMERG MED, V24, P194, DOI 10.1016/S0196-0644(94)70130-X; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; LUND I, 1976, LANCET, V2, P702; NEWMAN MM, 1994, CURR EMERG CARDIAC C, V17, P11; STUEVEN H, 1986, ANN EMERG MED, V15, P707, DOI 10.1016/S0196-0644(86)80430-9; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WHITE BC, 1985, JAMA-J AM MED ASSOC, V254, P3308; 1994, ADV CARDIAC LIFE SUP; 1992, JAMA-J AM MED ASSOC, V268, P2184	22	379	383	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1922	1925		10.1001/jama.274.24.1922	http://dx.doi.org/10.1001/jama.274.24.1922			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568985				2022-12-01	WOS:A1995TL16900033
J	CastroAlamancos, MA; Connors, BW				CastroAlamancos, MA; Connors, BW			Short-term plasticity of a thalamocortical pathway dynamically modulated by behavioral state	SCIENCE			English	Article							AUGMENTING RESPONSES; NEURONS; CAT; RAT; NEOCORTEX; CORTEX; NOREPINEPHRINE; POTENTIALS	The neocortex receives information about the environment and the rest of the brain through pathways from the thalamus. These pathways have frequency-dependent properties that can strongly influence their effect on the neocortex. In 1943 Morison and Dempsey described "augmenting responses," a form of short-term plasticity in some thalamocortical pathways that is triggered by 8- to 15-hertz activation. Results from anesthetized rats showed that the augmenting response is initiated by pyramidal cells in layer V. The augmenting response was also observed in awake, unrestrained animals and was found to be dynamically modulated by their behavioral state.			CastroAlamancos, MA (corresponding author), BROWN UNIV, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.		Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157; Castro-Alamancos, Manuel/0000-0002-2916-9585	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025983] Funding Source: NIH RePORTER; NIMH NIH HHS [MH19118] Funding Source: Medline; NINDS NIH HHS [NS25983] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGMON A, 1992, J NEUROSCI, V12, P319; ASTONJONES G, 1981, J NEUROSCI, V1, P876; CASTROALAMANCOS MA, 1993, NEUROSCIENCE, V52, P637, DOI 10.1016/0306-4522(93)90412-9; CastroAlamancos MA, 1996, J NEUROSCI, V16, P2767; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; Cooper J.R., 1991, BIOCH BASIS NEUROPHA; Dempsey EW, 1943, AM J PHYSIOL, V138, P0283, DOI 10.1152/ajplegacy.1943.138.2.283; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P217, DOI 10.1113/jphysiol.1985.sp015821; GLENN LL, 1982, NEUROSCIENCE, V7, P1861, DOI 10.1016/0306-4522(82)90003-3; HERKENHAM M, 1980, SCIENCE, V207, P532, DOI 10.1126/science.7352263; Herkenham M., 1986, CEREB CORTEX, V5, P403; JONES EG, 1986, CEREBRAL CORTEX, V5; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; MORIN D, 1981, BRAIN RES, V205, P49, DOI 10.1016/0006-8993(81)90719-8; Morison RS, 1943, AM J PHYSIOL, V138, P0297, DOI 10.1152/ajplegacy.1943.138.2.297; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th; PURPURA DP, 1964, J NEUROPHYSIOL, V27, P117, DOI 10.1152/jn.1964.27.2.117; SASAKI K, 1970, Experimental Neurology, V26, P369, DOI 10.1016/0014-4886(70)90133-0; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; SOMOGYI P, 1990, NEURAL MECHANISMS VI, P35; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P26, DOI 10.1152/jn.1961.24.1.26; STERIADE M, 1969, J NEUROPHYSIOL, V32, P251, DOI 10.1152/jn.1969.32.2.251; STERIADE M, 1981, BRAIN RES, V205, P67, DOI 10.1016/0006-8993(81)90720-4; Steriade M, 1990, THALAMIC OSCILLATION; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; WANG Z, 1993, J NEUROSCI, V13, P2199; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	31	81	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					274	277		10.1126/science.272.5259.274	http://dx.doi.org/10.1126/science.272.5259.274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602513				2022-12-01	WOS:A1996UE72900043
J	Despres, JP; Lamarche, B; Mauriege, P; Cantin, B; Dagenais, GR; Moorjani, S; Lupien, PJ				Despres, JP; Lamarche, B; Mauriege, P; Cantin, B; Dagenais, GR; Moorjani, S; Lupien, PJ			Hyperinsulinemia as an independent risk factor for ischemic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADIPOSE-TISSUE DISTRIBUTION; HIGH-DENSITY LIPOPROTEIN; INSULIN RESISTANCE; GLUCOSE-TOLERANCE; PLASMA-INSULIN; FOLLOW-UP; ABDOMINAL FAT; OBESE WOMEN; BODY-FAT; CORONARY	Background. Prospective studies suggest that hyperinsulinemia may be an important risk factor for ischemic heart disease. However, it has not been determined whether plasma insulin levels are independently related to ischemic heart disease after adjustment for other risk factors, including plasma lipoprotein levels. Methods. In 1985 we collected blood samples from 2103 men from suburbs of Quebec City, Canada, who were 45 to 75 years of age and who did not have ischemic heart disease. A first ischemic event (angina pectoris, acute myocardial infarction, or death from coronary heart disease) occurred in 114 men (case patients) between 1985 and 1990. Each case patient was matched for age, body-mass index, smoking habits, and alcohol consumption with a control selected from among the 1989 men who remained free of ischemic heart disease during follow-up. After excluding men with diabetes, we compared fasting plasma insulin and lipoprotein concentrations at base line in 91 case patients and 105 controls. Results. Pasting insulin concentrations at base line were 18 percent higher in the case patients than in the controls (P<0.001). Logistic-regression analysis showed that the insulin concentration remained associated with ischemic heart disease (odds ratio for ischemic heart disease with each increase of 1 SD in the insulin concentration, 1.7; 95 percent confidence interval, 1.3 to 2.4) after adjustment for systolic blood pressure, use of medications, and family history of ischemic heart disease. Further adjustment by multivariate analysis for plasma triglyceride, apolipoprotein B, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol concentrations did not significantly diminish the association between the insulin concentration and the risk of ischemic heart disease (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3). Conclusions. High fasting insulin concentrations appear to be an independent predictor of ischemic heart disease in men. (C) 1996, Massachusetts Medical Society.	UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal	Despres, JP (corresponding author), CHU LAVAL,RES CTR,LIPID RES CTR,2705 LAURIER BLVD,ST FOY,PQ G1V 4G2,CANADA.		Lamarche, Benoit/ABA-4785-2021	Lamarche, Benoit/0000-0002-4443-5378				ALBERS JJ, 1978, CLIN CHEM, V24, P853; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; CASASSUS P, 1992, ARTERIOSCLER THROMB, V12, P1387, DOI 10.1161/01.ATV.12.12.1387; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; DESPRES JP, 1989, ARTERIOSCLEROSIS, V9, P203, DOI 10.1161/01.ATV.9.2.203; DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304; DESPRES JP, 1994, BAILLIERE CLIN ENDOC, V8, P629, DOI 10.1016/S0950-351X(05)80289-7; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FONTBONNE A, 1994, DIABETOLOGIA, V37, P953, DOI 10.1007/BF00400954; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAFFNER SM, 1993, DIABETES, V42, P1297, DOI 10.2337/diabetes.42.9.1297; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; LAURELL CB, 1972, SCAND J CLIN LAB INV, V29, P21, DOI 10.3109/00365517209102748; LAWS A, 1992, J INTERN MED, V231, P25, DOI 10.1111/j.1365-2796.1992.tb00494.x; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MOORJANI S, 1987, METABOLISM, V36, P244, DOI 10.1016/0026-0495(87)90183-1; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; YARNELL JWG, 1994, BRIT HEART J, V171, P293; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	33	1400	1452	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					952	957		10.1056/NEJM199604113341504	http://dx.doi.org/10.1056/NEJM199604113341504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596596				2022-12-01	WOS:A1996UD59600004
J	Carmeliet, P; Ferreira, V; Breier, G; Pollefeyt, S; Kieckens, L; Gertsenstein, M; Fahrig, M; Vandenhoeck, A; Harpal, K; Eberhardt, C; Declercq, C; Pawling, J; Moons, L; Collen, D; Risau, W; Nagy, A				Carmeliet, P; Ferreira, V; Breier, G; Pollefeyt, S; Kieckens, L; Gertsenstein, M; Fahrig, M; Vandenhoeck, A; Harpal, K; Eberhardt, C; Declercq, C; Pawling, J; Moons, L; Collen, D; Risau, W; Nagy, A			Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; STEM-CELLS; MICE; ANGIOGENESIS; EXPRESSION; GENE; VASCULOGENESIS; RECEPTOR	THE endothelial cell-specific vascular endothelial growth factor (VEGF)(1-5) and its cellular receptors Flt-1 (refs 6,7) and Flk-1 (refs 8,9) have been implicated in the formation of the embryonic vasculature. This is suggested by their colocalized expression during embryogenesis(10,11) and the impaired vessel formation in Flk-1 (ref. 12) and Flt-1 (ref. 13) deficient embryos. However, because Flt-1 also binds placental growth factor(14,15), a VEGF homologue, the precise role of VEGF was unknown. Here we report that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF(+/-)) embryos, generated by aggregation of embryonic stem (ES) cells with tetraploid embryos (T-ES)(16,17), and more impaired in homozygous VEGF-deficient (VEGF(-/-)) T-ES embryos, resulting in death at mid-gestation. Similar phenotypes were observed in F-1-VEGF(+/-) embryos, generated by germline transmission. We believe that this heterozygous lethal phenotype, which differs from the homozygous lethality in VEGF-receptor-deficient embryos, is unprecedented for a targeted autosomal gene inactivation, and is indicative of a tight dose-dependent regulation of embryonic vessel development by VEGF.	MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, ABT MOL ZELLBIOL, BAD NAUHEIM, GERMANY; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1A1, CANADA	Max Planck Society; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Carmeliet, P (corresponding author), CATHOLIC UNIV LEUVEN VIB, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM.		Nagy, Andras/G-6465-2013; Breier, Georg/E-3580-2016; Carmeliet, Peter/AAQ-5140-2020	Nagy, Andras/0000-0003-4311-0413; Breier, Georg/0000-0002-9467-780X; Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9276; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAGY A, 1994, GENE TARGETING PRACT, P147; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	28	3149	3323	2	147	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					435	439		10.1038/380435a0	http://dx.doi.org/10.1038/380435a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602241				2022-12-01	WOS:A1996UD59000061
J	Sawatari, A; Callaway, EM				Sawatari, A; Callaway, EM			Convergence of magno- and parvocellular pathways in layer 4B of macaque primary visual cortex	NATURE			English	Article							SLICES; PARALLEL	EARLY visual processing is characterized by two independent parallel pathways: the magnocellular stream, which carries information useful for motion analysis, and the parvocellular stream, which carries information useful for analyses of shape and colour(1-3). Although increasing anatomical and physiological evidence indicates some degree of convergence of the two streams, the pathway through layer 4B of primary visual cortex (V1) and on to higher cortical areas is usually considered to carry only magnocellular input(1-3). This is inferred from anatomical descriptions of local circuitry in V1, and functional studies of area MT, which receives input from layer 4B(4-7). We have directly measured the sources of local functional input to individual layer 4B neurons by combining intracellular recording and biocytin labelling with laser-scanning photostimulations(8-10). We found that most layer 4B neurons receive strong input from both magnocellular-stream-recipient layer 4C alpha neurons and parvocellular-stream-recipient layer 4C beta neurons. Thus higher cortical areas that receive input either directly or indirectly from layer 4B are likely to be more strongly influenced by the parvocellular pathway than previously believed.			Sawatari, A (corresponding author), SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Callaway, Edward/D-4336-2011	Callaway, Edward/0000-0002-6366-5267				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; LACHICA EA, 1992, P NATL ACAD SCI USA, V89, P3566, DOI 10.1073/pnas.89.8.3566; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; Van Essen D. C., 1994, COGNITIVE NEUROSCIEN; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; YOSHIOKA T, 1994, VISUAL NEUROSCI, V11, P467, DOI 10.1017/S0952523800002406	15	129	133	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					442	446		10.1038/380442a0	http://dx.doi.org/10.1038/380442a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602243				2022-12-01	WOS:A1996UD59000063
J	Vale, RD; Funatsu, T; Pierce, DW; Romberg, L; Harada, Y; Yanagida, T				Vale, RD; Funatsu, T; Pierce, DW; Romberg, L; Harada, Y; Yanagida, T			Direct observation of single kinesin molecules moving along microtubules	NATURE			English	Article							HEAVY-CHAIN; MOVEMENT; DOMAIN; MOTOR; EXPRESSION	KINESIN is a two-headed motor protein that powers organelle transport along microtubules(1). Many ATP molecules are hydrolysed by kinesin for each diffusional encounter with the microtubule(2,3). Here we report the development of a new assay in which the processive movement of individual fluorescently labelled kinesin molecules along a microtubule can be visualized directly; this observation is achieved by low-background total internal reflection fluorescence microscopy(4) in the absence of attachment of the motor to a cargo (for example, an organelle or bead). The average distance travelled after a binding encounter with a microtubule is 600 nm, which reflects a similar to 1% probability of detachment per mechanical cycle, Surprisingly, processive movement could still be observed at salt concentrations as high as 0.3 M NaCl. Truncated kinesin molecules having only a single motor domain do not show detectable processive movement, which is consistent with a model in which kinesin's two force-generating heads operate by a hand-over-hand mechanism.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; OSAKA UNIV,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Osaka University	Vale, RD (corresponding author), RES DEV CORP JAPAN,ERATO,YANAGIDA BIOMOTRON PROJECT,SENBA HIGASHI 2-4-14,MINO,OSAKA 562,JAPAN.		Yanagida, Toshio/D-1919-2009; Funatsu, Takashi/Q-1404-2015	Funatsu, Takashi/0000-0002-9656-8308	Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [P01 AR042895-040005, P01 AR042895] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1994, MOTOR PROTEINS, V1; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1994, J BIOL CHEM, V269, P23769; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	24	579	617	1	108	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					451	453		10.1038/380451a0	http://dx.doi.org/10.1038/380451a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602245	Green Accepted			2022-12-01	WOS:A1996UD59000065
J	Bhatia, S; Robison, LL; Oberlin, O; Greenberg, M; Bunin, G; FossatiBellani, F; Meadows, AT				Bhatia, S; Robison, LL; Oberlin, O; Greenberg, M; Bunin, G; FossatiBellani, F; Meadows, AT			Breast cancer and other second neoplasms after childhood Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							2ND MALIGNANT NEOPLASMS; FOLLOW-UP; ALKYLATING-AGENTS; ACUTE-LEUKEMIA; INCREASED RISK; THERAPY; CHEMOTHERAPY; SPLENECTOMY; RADIOTHERAPY; IRRADIATION	Background. Patients who survive Hodgkin's disease are at increased risk for second neoplasms, As survival times increase, solid tumors are emerging as a serious long-term complication. Methods. The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to deter mine the incidence of second neoplasms and the risk factors associated with them. Results. In this cohort, there were 88 second neoplasms as compared with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidence interval, 14.3 to 22.3), The estimated actuarial incidence of any second neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent); the incidence of solid tumors was 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent), Breast cancer was the most common solid tumor (standardized incidence ratio, 75.3; 95 percent confidence interval, 44.9 to 118.4), with an estimated actuarial incidence in women that approached 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) by 40 years of age, Older age (10 to 16 vs, <10 years) at the time of radiation treatment (relative risk, 1.9) and a higher dose (2000 to 4000 vs, <2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer, The estimated actuarial incidence of leukemia reached a plateau of 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent) 14 years after diagnosis. Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia. Conclusions. The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. Systematic screening for breast cancer could be important in the health care of such women. (C) 1996, Massachusetts Medical Society.	UNIV MINNESOTA, DEPT PEDIAT, DIV PEDIAT EPIDEMIOL & CLIN RES, MINNEAPOLIS, MN 55455 USA; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; NATL TUMOR INST, MILAN, ITALY	University of Minnesota System; University of Minnesota Twin Cities; UNICANCER; Gustave Roussy; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Robison, Leslie/N-8122-2018					ABRAHAMSEN JF, 1993, J CLIN ONCOL, V11, P255, DOI 10.1200/JCO.1993.11.2.255; ANDRIEU JM, 1990, J CLIN ONCOL, V8, P1148, DOI 10.1200/JCO.1990.8.7.1148; ARSENEAU JC, 1972, NEW ENGL J MED, V287, P1119, DOI 10.1056/NEJM197211302872204; BARAL E, 1977, CANCER, V40, P2905, DOI 10.1002/1097-0142(197712)40:6<2905::AID-CNCR2820400621>3.0.CO;2-Y; BEATY O, 1995, J CLIN ONCOL, V13, P603, DOI 10.1200/JCO.1995.13.3.603; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOICE JD, 1979, RADIOLOGY, V131, P589, DOI 10.1148/131.3.589; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; BOIVIN JF, 1984, JNCI-J NATL CANCER I, V72, P233; CANELLOS GP, 1975, LANCET, V1, P947; CIMINO G, 1991, J CLIN ONCOL, V9, P432, DOI 10.1200/JCO.1991.9.3.432; Coleman C. N., 1982, CANCER SURV, V1, P733; COLTMAN CA, 1982, CANCER TREAT REP, V66, P1023; CURTIS RE, 1988, NEW ENGL J MED, V319, P244; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; GREENE MH, 1985, 852714 NIH PUBL, P191; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; HORNING SJ, 1981, NEW ENGL J MED, V304, P1377, DOI 10.1056/NEJM198106043042301; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOLETSKY AJ, 1986, J CLIN ONCOL, V4, P311, DOI 10.1200/JCO.1986.4.3.311; MACKENZI.I, 1965, BRIT J CANCER, V19, P1, DOI 10.1038/bjc.1965.1; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MILLER BA, 1993, 932789 NIH PUBL; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; RODRIGUEZ MA, 1993, ANN ONCOL, V4, P125, DOI 10.1093/oxfordjournals.annonc.a058414; ROSENBERG SA, 1985, INT J RADIAT ONCOL, V11, P5, DOI 10.1016/0360-3016(85)90357-8; SHERINS RJ, 1973, ANN INTERN MED, V79, P216, DOI 10.7326/0003-4819-79-2-216; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STORM HH, 1985, 852714 NIH PUBL, P389; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TURA S, 1993, J CLIN ONCOL, V11, P925, DOI 10.1200/JCO.1993.11.5.925; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERVELDEN JW, 1988, INT J CANCER, V42, P252, DOI 10.1002/ijc.2910420218; VANLEEUWEN FE, 1987, LANCET, V2, P210; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312	44	673	684	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					745	751		10.1056/NEJM199603213341201	http://dx.doi.org/10.1056/NEJM199603213341201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592547				2022-12-01	WOS:A1996TZ97900001
J	Buchdahl, R; Parker, A; Stebbings, T; Babiker, A				Buchdahl, R; Parker, A; Stebbings, T; Babiker, A			Association between air pollution and acute childhood wheezy episodes: Prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							LUNG-FUNCTION; ASTHMA; OZONE; CHILDREN; REGRESSION; EXPOSURES; BACTERIA; VIRUSES; VISITS	Objective-To examine the association between the air pollutants ozone, sulphur dioxide, and nitrogen dioxide and the incidence of acute childhood wheezy episodes. Design-Prospective observational study over one year. Setting-District general hospital. Subjects-1025 children attending the accident and emergency department with acute wheezy episodes; 4285 children with other conditions as the control group. Main outcome measures-Daily incidence of acute wheezy episodes. Results-After seasonal adjustment, day to day variations in daily average concentrations of ozone and sulphur dioxide were found to have significant associations with the incidence of acute wheezy episodes. The strongest association was with ozone, for which a non-linear U shaped relation was seen. In terms of the incidence rate ratio (1 at a mean 24 hour ozone concentration of 40 Alpha mu g/m(3) (SD=19.1)), children were more likely to attend when the concentration was two standard deviations below the mean (incidence rate ratio=3.01; 95% confidence interval 2.17 to 4.18) or two standard deviations above the mean (1.34; 1.09 to 1.66). Sulphur dioxide had a weaker log-linear relation with incidence (1.12; 1.05 to 1.19 for each standard deviation (14.1) increase in sulphur dioxide concentration). Further adjustment for temperature and wind speed did not significantly alter these associations. Conclusions-Independent of season, temperature, and wind speed, fluctuations in concentrations of atmospheric ozone and sulphur dioxide are strongly associated with patterns of attendance at accident and emergency departments for acute childhood wheezy episodes. A critical ozone concentration seems to exist in the atmosphere above or below which children are more likely to develop symptoms.	LONDON BOROUGH HILLINGDON, ENVIRONM PROTECT UNIT, UXBRIDGE UB8 1UN, MIDDX, ENGLAND; UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND	Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School	Buchdahl, R (corresponding author), HILLINGDON HOSP, UXBRIDGE UB8 3NN, MIDDX, ENGLAND.							ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BRIDGMAN HA, 1990, GLOBAL AIR POLLUTION; BURLESON GR, 1975, APPL MICROBIOL, V29, P340, DOI 10.1128/AEM.29.3.340-344.1975; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; COX CS, 1989, SCI PROG, V73, P469; *DEP HLTH ADV GROU, 1991, 1 DEP HLTH ADV GROUP; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GODLEE F, 1991, BRIT MED J, V303, P1539, DOI 10.1136/bmj.303.6816.1539; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PARTRIDGE RH, 1995, QU109 NAT PHYS LAB; PHELAN PD, 1994, BRIT MED J, V308, P1584, DOI 10.1136/bmj.308.6944.1584; READ C, 1991, AIR POLLUTION CHILD; RICHARDS W, 1981, ANN ALLERGY, V47, P348; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SOUKUP J, 1993, ENVIRON RES, V60, P178, DOI 10.1006/enrs.1993.1025; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; *STAT CORP, 1993, STAT REF MAN 3 1; TSENG RYM, 1990, ANN ALLERGY, V65, P379; VONZIEMSSEN H, 1875, CYCLOPAEDIA PRACTICE, V2; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133	32	49	49	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					661	665						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597731				2022-12-01	WOS:A1996UB11000021
J	Nantel, F; Monaco, L; Foulkes, NS; Masquilier, D; LeMeur, M; Henriksen, K; Dierich, A; Parvinen, M; SassoneCorsi, P				Nantel, F; Monaco, L; Foulkes, NS; Masquilier, D; LeMeur, M; Henriksen, K; Dierich, A; Parvinen, M; SassoneCorsi, P			Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; MOUSE PROTAMINE-1; PROTEIN; SPERMATOGENESIS; TRANSCRIPTION; EXPRESSION; ACTIVATOR; DIRECTS; SWITCH; GENES	Spermiogenesis is a complex process by which postmeiotic male germ cells differentiate into mature spermatozoa. This process involves remarkable structural and biochemical changes including nuclear DNA compaction and acrosome formation(1,2). Transcriptional activator CREM (cyclic AMP-responsive element modulator) is highly expressed in postmeiotic cells(3-5), and CREM may be responsible for the activation of several haploid germ cell-specific genes involved in the structuring of the spermatozoon(5-7). The specific role of CREM in spermiogenesis was addressed using CREM-mutant mice generated by homologous recombination. Analysis of the seminiferous epithelium in mutant male mice reveals postmeiotic arrest at the first step of spermiogenesis. Late spermatids are completely absent, and there is a significant increase in apoptotic germ cells. We show that CREM deficiency results in the lack of postmeiotic cell-specific gene expression. The complete lack of spermatozoa in the mutant mice is reminiscent of cases of human infertility.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; TURKU UNIV,DEPT ANAT,SF-20520 TURKU,FINLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Turku			Monaco, Lucia/A-4031-2010; Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				BABA T, 1994, J BIOL CHEM, V269, P10133; CHAGANTI RSK, 1979, AM J HUM GENET, V31, P634; CHEVRIER P, 1988, EMBO J, V7, P29; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; HENRIKSEN K, 1995, INT J ANDROL, V18, P256, DOI 10.1111/ijan.1995.18.5.256; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KISTLER MK, 1994, BIOL REPROD, V51, P1322, DOI 10.1095/biolreprod51.6.1322; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; LALLI E, 1994, J BIOL CHEM, V269, P17356; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MICIC M, 1992, HUM REPROD, V7, P1118, DOI 10.1093/oxfordjournals.humrep.a137804; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; PARVINEN M, 1981, HISTOCHEMISTRY, V71, P567, DOI 10.1007/BF00508382; PARVINEN M, 1982, ENDOCR REV, V3, P404, DOI 10.1210/edrv-3-4-404; PEREY B, 1961, AM J ANAT, V108, P47, DOI 10.1002/aja.1001080105; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Rubin M R, 1991, DNA Seq, V1, P329, DOI 10.3109/10425179109020787; Santen R. J., 1987, ENDOCRINOL METAB, P821; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418	30	477	494	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					159	162		10.1038/380159a0	http://dx.doi.org/10.1038/380159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600390				2022-12-01	WOS:A1996TZ97800051
J	Northridge, D				Northridge, D			Frusemide or nitrates for acute heart failure?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; FUROSEMIDE; RESPONSES; THERAPY; VOLUME				Northridge, D (corresponding author), WESTERN GEN HOSP,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAYLISS J, 1987, BRIT HEART J, V57, P17; BIAGI RW, 1967, LANCET, V1, P849; BRAUNWALD E, 1994, AM HEART J, V72, pS68; CHATTERJEE K, 1973, CIRCULATION, V48, P1183, DOI 10.1161/01.CIR.48.6.1183; DIKSHIT K, 1973, NEW ENGL J MED, V288, P1087, DOI 10.1056/NEJM197305242882102; FRANCIOSA JA, 1982, CLIN PHARMACOL THER, V32, P62, DOI 10.1038/clpt.1982.127; FRANCIS GS, 1985, ANN INTERN MED, V103, P1, DOI 10.7326/0003-4819-103-1-1; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; Hampton J. R., 1994, British Heart Journal, V72, pS68; IKRAM H, 1980, CLIN SCI, V59, P443, DOI 10.1042/cs0590443; JOHNSTON GD, 1983, CIRC RES, V53, P630, DOI 10.1161/01.RES.53.5.630; KIELY J, 1973, CIRCULATION, V48, P581, DOI 10.1161/01.CIR.48.3.581; Kruck F, 1991, Drugs, V41 Suppl 3, P60; LAL S, 1969, BRIT HEART J, V31, P711; LARSEN FF, 1988, EUR HEART J, V9, P125, DOI 10.1093/oxfordjournals.eurheartj.a062465; MOND H, 1974, BRIT HEART J, V36, P44; NELSON GIC, 1983, LANCET, V1, P730; NELSON GIC, 1983, EUR HEART J, V4, P706, DOI 10.1093/oxfordjournals.eurheartj.a061382; NISHIMURA M, 1981, CRIT CARE MED, V9, P829; VALETTE H, 1983, EUR J CLIN PHARMACOL, V24, P163, DOI 10.1007/BF00613811; VERMA SP, 1987, BRIT J CLIN PHARMACO, V24, P21, DOI 10.1111/j.1365-2125.1987.tb03131.x	21	25	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					667	668		10.1016/S0140-6736(96)91209-X	http://dx.doi.org/10.1016/S0140-6736(96)91209-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596385				2022-12-01	WOS:A1996TZ28500017
J	Stensvold, I; Tverdal, A; Jacobsen, BK				Stensvold, I; Tverdal, A; Jacobsen, BK			Cohort study of coffee intake and death from coronary heart disease over 12 years	BRITISH MEDICAL JOURNAL			English	Article							BOILED COFFEE		UNIV TROMSO,INST COMMUNITY MED,TROMSO,NORWAY	UiT The Arctic University of Tromso	Stensvold, I (corresponding author), NATL HLTH SCREENING SERV,POB 8155,N-0033 OSLO,NORWAY.			Tverdal, Aage/0000-0002-2909-5678				AHOLA I, 1991, J INTERN MED, V230, P293, DOI 10.1111/j.1365-2796.1991.tb00447.x; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; KAWACHI I, 1994, BRIT HEART J, V72, P269; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q	5	28	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					544	545		10.1136/bmj.312.7030.544	http://dx.doi.org/10.1136/bmj.312.7030.544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595285	Green Published			2022-12-01	WOS:A1996TY88500025
J	Bradley, D; Carpenter, R; Copsey, L; Vincent, C; Rothstein, S; Coen, E				Bradley, D; Carpenter, R; Copsey, L; Vincent, C; Rothstein, S; Coen, E			Control of inflorescence architecture in Antirrhinum	NATURE			English	Article							FLOWER DEVELOPMENT; SACCHAROMYCES-CEREVISIAE; GENE; MAJUS; TRANSPOSON; MUTATIONS; MERISTEM; CLONING; LOCUS	Flowering plants exhibit two types of inflorescence architecture: determinate and indeterminate. The centroradialis mutation causes the normally indeterminate inflorescence of Antirrhinum to terminate in a flower. We show that centroradialis is expressed in the inflorescence apex a few days after floral induction, and interacts with the floral-meristemidentity gene floricaula to regulate flower position and morphology. The protein CEN is similar to animal proteins that associate with lipids and GTP-binding proteins. We propose a model for how different inflorescence structures may arise through the action and evolution of centroradialis.			Bradley, D (corresponding author), JOHN INNES CTR,DEPT GENET,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Rothstein, Steven J/A-4947-2013	Rothstein, Steven J/0000-0003-0737-1878				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRADLEY D, IN PRESS DEVELOPMENT; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN EA, 1991, REV PL PHYSL PL MOL, V42, P241; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COEN ES, 1994, DEVELOPMENT, P107; COEN ES, 1989, MOBILE DNA, P413; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Hammer K., 1990, Kulturpflanze, V38, P91; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Keeble F, 1910, NEW PHYTOL, V9, P68, DOI DOI 10.1111/J.1469-8137.1910.TB05554.X; KUCKUCK H, 1930, INDUKT ABSTANIM VERE, V51, P51; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; Stebbins G.L., 1974, FLOWERING PLANTS EVO; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TRIPP ML, 1989, MOL MICROBIOL, V3, P1319, DOI 10.1111/j.1365-2958.1989.tb00113.x; Weberling F., 1989, MORPHOLOGY FLOWERS I; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	34	320	355	4	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					791	797		10.1038/379791a0	http://dx.doi.org/10.1038/379791a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587601				2022-12-01	WOS:A1996TX50100048
J	Nightingale, SL				Nightingale, SL			New Reporting requirements for device user facilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5611 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-01	WOS:A1996TW62700030
J	Desai, CJ; Gindhart, JG; Goldstein, LSB; Zinn, K				Desai, CJ; Gindhart, JG; Goldstein, LSB; Zinn, K			Receptor tyrosine phosphatases are required for motor axon guidance in the Drosophila embryo	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; P ELEMENTS; KINASE; TRANSPOSITION; CLONING; NEURONS; SUBSET; GENES; CNS	The receptor tyrosine phosphatases DPTP69D and DPTP99A are expressed on motor axons in Drosophila embryos. In mutant embryos lacking DPTP69D protein, motor neuron growth cones stop growing before reaching their muscle targets, or follow incorrect pathways that bypass these muscles. Mutant embryos lacking DPTP99A are indistinguishable from wild type. Motor axon defects in dptp69D dptp99A double mutant embryos, however, are much more severe than in embryos lacking only DPTP69D. Our results demonstrate that DPTP69D and DPTP99A are required for motor axon guidance and that they have partially redundant functions during development of the neuromuscular system.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DIV CELLULAR & MOLEC MED,DEPT PHARMACOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	Desai, CJ (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.				NIGMS NIH HHS [GM35252] Funding Source: Medline; NINDS NIH HHS [NS28182] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028182] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; DALBY B, 1995, GENETICS, V139, P757; DESAI CJ, 1994, J NEUROSCI, V14, P7272; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FITZPATRICK KA, 1995, MECH DEVELOP, V53, P171, DOI 10.1016/0925-4773(95)00432-Z; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HAMILTON BA, 1995, ROUX ARCH DEV BIOL, V204, P187, DOI 10.1007/BF00241271; HAMILTON BA, 1994, DROSOPHILA MELANOGAS, P81; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KRUEGER NX, 1996, CELL, V84; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LITTLETON JT, 1993, CELL, V74, P1124; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATEL NH, 1994, DROSOPHILA MELANOGAS, P446; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STOKER AW, 1995, DEVELOPMENT, V121, P1833; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOWER J, 1993, GENETICS, V133, P347; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	36	252	255	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					599	609		10.1016/S0092-8674(00)81035-1	http://dx.doi.org/10.1016/S0092-8674(00)81035-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598046	Bronze			2022-12-01	WOS:A1996TX17600012
J	NobenTrauth, N; Kropf, P; Muller, I				NobenTrauth, N; Kropf, P; Muller, I			Susceptibility to Leishmania major infection in interleukin-4-deficient mice	SCIENCE			English	Article							MURINE LEISHMANIASIS; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY; BALB/C MOUSE; IFN-GAMMA; T-CELLS; IL-4; TH2; GROWTH; INTERLEUKIN-10	Interleukin-4 (IL-4), a pleiotropic cytokine, is a major regulator of the immune system and is considered crucial for the development of T helper cell type 2 (T(H)2) responses. The susceptibility of BALB/c mice to infection with Leishmania major has been associated with a polarized T(H)2 response and an inability to down-modulate IL-4 production. The role of IL-4 in vivo was examined directly by disrupting the IL-4 gene in BALB/c embryonic stem cells. Despite the absence of IL-4, the genetically pure BALB/c mutant mice remained susceptible to L. major infection, Showed no signs of lesion healing or parasite clearance, and did not switch to a T(H)1 phenotype.	JACKSON LAB, BAR HARBOR, ME 04609 USA	Jackson Laboratory	NobenTrauth, N (corresponding author), UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA.				NIAID NIH HHS [1R29 AI37636-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037636] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARTER KC, 1989, EUR J IMMUNOL, V19, P779, DOI 10.1002/eji.1830190432; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DING A, 1990, J IMMUNOL, V145, P940; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GERLING IC, 1994, MAMM GENOME, V5, P318, DOI 10.1007/BF00389549; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HJULSTROM S, 1995, EUR J IMMUNOL, V25, P1469, DOI 10.1002/eji.1830250552; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEZAMADAVILA CM, 1992, PARASITE IMMUNOL, V14, P37, DOI 10.1111/j.1365-3024.1992.tb00004.x; LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2; LIEW FY, 1993, ADV PARASIT, V32, P162; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MOCK B, 1993, EUR J IMMUNOGENET, V20, P335, DOI 10.1111/j.1744-313X.1993.tb00153.x; MORAWETZ RA, 1994, SCIENCE, V265, P264, DOI 10.1126/science.8023146; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; NABORS GS, 1994, INFECT IMMUN, V62, P5498, DOI 10.1128/IAI.62.12.5498-5504.1994; NACY CA, 1991, RES IMMUNOL, V142, P573, DOI 10.1016/0923-2494(91)90105-R; NOBENTRAUTH N, IN PRESS TRANSGENIC; NOBENTRAUTH N, UNPUB; OSWALD IP, 1992, J IMMUNOL, V148, P3578; POWRIE F, 1993, EUR J IMMUNOL, V23, P2223, DOI 10.1002/eji.1830230926; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; SADICK MD, 1991, INFECT IMMUN, V59, P4710, DOI 10.1128/IAI.59.12.4710-4714.1991; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1989, EXP PARASITOL, V68, P369, DOI 10.1016/0014-4894(89)90120-3; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SLADE SJ, 1989, IMMUNOBIOLOGY, V179, P353, DOI 10.1016/S0171-2985(89)80041-5; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0	44	258	260	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					987	990		10.1126/science.271.5251.987	http://dx.doi.org/10.1126/science.271.5251.987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584936				2022-12-01	WOS:A1996TV70400049
J	Johnson, AE; Gordon, C; Hobbs, FDR; Bacon, PA				Johnson, AE; Gordon, C; Hobbs, FDR; Bacon, PA			Undiagnosed systemic lupus erythematosus in the community	LANCET			English	Article							POPULATION	Background Systemic lupus erythematosus (SLE) produces a wide range of symptoms, some of them mild; therefore it may be underdiagnosed. In a pilot study we tested the ability of a screening questionnaire to identify undiagnosed cases in the community. Methods A 10-item questionnaire was mailed to 3500 women aged 18-65 randomly selected from a general practice list in Birmingham, UK. A random sample of 300 non-respondents were sent two further mailings, Women returning the questionnaire with three positive answers were to attend for an antinuclear antibody (ANA) test; and those testing positive were to be referred to a rheumatologist for standard clinical assessment. Findings 1153 (30%) of the women responded, and 307 of these gave three or more positive answers on the questionnaire, The survey disclosed three women with previously undiagnosed SLE; and, in addition, it picked up all four of the women whose SLE had been diagnosed previously. Interpretation The prevalence of SLE revealed by this survey in Birmingham women is 200/100 000 (95% confidence interval 80 to 412), whereas the prevalence of diagnosed SLE in this age group is 54/100 000 (95% CI 47-62). Thus, a substantial number of undiagnosed cases exist, and further work needs to focus on the prevalence in different ethnic groups and the benefits of early diagnosis and treatment.	UNIV BIRMINGHAM,FAC MED & DENT,DEPT RHEUMATOL,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,FAC MED & DENT,DEPT GEN PRACTICE,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham				Gordon, Caroline/0000-0002-1244-6443; hobbs, richard/0000-0001-7976-7172				Balarajan R, 1991, Health Trends, V23, P90; CHANG NC, 1983, J RHEUMATOL, V10, P41; CHOU CT, 1986, J RHEUMATOL, V13, P806; HAYNES RB, 1988, CAN MED ASSOC J, V124, P703; HOCHBERG MC, 1983, CLIN EXP RHEUMATOL, V1, P67; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; JOHNSON AE, 1993, BRIT J RHEUMATOL, V32, P30; LIANG MH, 1980, ARTHRITIS RHEUM-US, V23, P153, DOI 10.1002/art.1780230204; MCINNES PM, 1994, ARTHRITIS RHEUM, V37, P1000, DOI 10.1002/art.1780370704; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	10	45	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					367	369		10.1016/S0140-6736(96)90539-5	http://dx.doi.org/10.1016/S0140-6736(96)90539-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598703				2022-12-01	WOS:A1996TU69500011
J	Grotzfeld, RM; Branda, N; Rebek, J				Grotzfeld, RM; Branda, N; Rebek, J			Reversible encapsulation of disc-shaped guests by a synthetic, self-assembled host	SCIENCE			English	Article							COMPLEX	Here, the synthesis of a bowl-shaped molecule is described and evidence of its reversible dimerization by means of hydrogen bonds is presented. The dimer features a flattened spherical cavity of peculiar symmetry and acts as a host for the encapsulation of guest molecules of complementary shape. Encapsulation of aromatic guests in chloroform solution and of cyclohexane in p-xylene solution was demonstrated by nuclear magnetic resonance experiments. The passage of guests into and out of the cavity is slow and occurs on a time scale of hours. The system was used to explore the effects of size, shape, and solvation on molecular recognition coupled with assembly.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BARTLE KD, 1965, TETRAHEDRON, V21, P3289, DOI 10.1016/S0040-4020(01)96950-9; BAXTER P, 1993, ANGEW CHEM INT EDIT, V32, P69, DOI 10.1002/anie.199300691; BONARLAW RP, 1993, TETRAHEDRON LETT, V34, P1677, DOI 10.1016/0040-4039(93)85039-Y; BRANDA N, 1994, SCIENCE, V263, P1267, DOI 10.1126/science.8122107; BRANDA N, 1995, J AM CHEM SOC, V117, P85, DOI 10.1021/ja00106a010; CHAPMAN KT, 1989, J AM CHEM SOC, V111, P3075, DOI 10.1021/ja00190a058; CHAPMAN RG, 1995, J AM CHEM SOC, V117, P9081, DOI 10.1021/ja00140a031; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4316, DOI 10.1021/ja00089a021; MATHIAS JP, 1994, J AM CHEM SOC, V116, P1725, DOI 10.1021/ja00084a013; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; QUAN MLC, 1991, J AM CHEM SOC, V113, P2754, DOI 10.1021/ja00007a060; SETO CT, 1991, J AM CHEM SOC, V113, P712, DOI 10.1021/ja00002a071; SIMARD M, 1991, J AM CHEM SOC, V113, P4696, DOI 10.1021/ja00012a057; VALDES C, 1995, ANGEW CHEM INT EDIT, V34, P1885, DOI 10.1002/anie.199518851; VOGEL AI, 1989, VOGELS TXB PRACTICAL, P939; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991; YANG J, 1993, J AM CHEM SOC, V115, P5314, DOI 10.1021/ja00065a061	19	102	102	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					487	489		10.1126/science.271.5248.487	http://dx.doi.org/10.1126/science.271.5248.487			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560261				2022-12-01	WOS:A1996TR32200035
J	OBrien, JP				OBrien, JP			Controversies in management - Should backache be treated with spinal fusion? Spinal fusion is the only treatment for discogenic pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUMBAR SPINE; POSTERIOR											FARFAN HF, 1981, CLIN ORTHOP RELAT R, P198; Hibbs, 1911, NY MED J, V93, P1013, DOI 10.1097/BLO.0b013e3180686b30; HODGSON AR, 1956, BRIT J SURG, V44, P266, DOI 10.1002/bjs.18004418508; KUSLICH SD, 1991, ORTHOP CLIN N AM, V22, P181; MCCALL IW, 1979, SPINE, V4, P441, DOI 10.1097/00007632-197909000-00009; PARK WM, 1979, BRIT J RADIOL, V52, P382, DOI 10.1259/0007-1285-52-617-382; WEATHERLEY CR, 1986, J BONE JOINT SURG BR, V68, P142, DOI 10.1302/0301-620X.68B1.2934399; WILTSE LL, 1977, CLIN ORTHOP RELAT R, V129, P22; YOSHIZAWA H, 1980, J PATHOL, V132, P95, DOI 10.1002/path.1711320202; 1972, BLAKISTONS GOULD MED, P137	10	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					38	39		10.1136/bmj.312.7022.38	http://dx.doi.org/10.1136/bmj.312.7022.38			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555861	Green Published			2022-12-01	WOS:A1996TP20900027
J	Hurt, RD; Offord, KP; Croghan, IT; GomezDahl, L; Kottke, TE; Morse, RM; Melton, LJ				Hurt, RD; Offord, KP; Croghan, IT; GomezDahl, L; Kottke, TE; Morse, RM; Melton, LJ			Mortality following inpatient addictions treatment - Role of tobacco use in a community-based cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING; ALCOHOLICS; ABUSE; DEPENDENCE; DRINKING; SUICIDE	Objective.-To determine the impact of tobacco- and alcohol-related deaths on overall mortality following inpatient treatment for alcoholism and other nonnicotine drugs of dependence. Design.-Population-based retrospective cohort study. Setting.-Olmsted County, Minnesota (the Rochester Epidemiology Project), and the Inpatient Addiction Program (IAP) at Mayo Clinic, Rochester. Patients.-All 845 Olmsted County residents admitted to an inpatient addiction program for treatment of alcoholism and other nonnicotine drugs of dependence during the period 1972 through 1983. Methods.-Patients were followed up through the medical record linkage system of the Rochester Epidemiology Project through December 1994 to obtain vital status, and death certificates were obtained for those who died. The underlying cause of death was classified as alcohol related, tobacco related, both, or neither based on the classification from the Centers for Disease Control and Prevention. The observed number of deaths by underlying cause was compared with the expected number using cause-specific 1987 death rates for the white population of the United States. All-cause mortality was also compared with that expected for persons in the West North Central Region of the United States of like age, sex, and year of birth. Univariate and multivariate assessments were made to identify predictors of all-cause mortality from baseline demographic information. Results.-At admission, the mean (SD) age of the 845 patients was 41.4 (14.5) years, and 35% were women. Altogether, 78% had alcohol as their only nonnicotine drug of dependence and 18% had alcohol and other nonnicotine drugs of dependence, while 4% were classified as having a nonalcohol, nonnicotine drug dependence alone. At admission, 75% were current and 8% former cigarette smokers, 3% were current cigar or pipe smokers, and 2% were current users of smokeless tobacco. Follow-up after the index IAP admission totaled 8913 person-years (mean [SD] of 10.5 [5.6] years per patient). Death certificates were obtained for 96% (214) of the 222 patients who died. Of these 214 deaths, 50.9% (109) had a tobacco-related and 34.1% (73) had an alcohol-related underlying cause (P<.001). The cumulative mortality significantly exceeded that expected (P<.001); at 20 years, the observed mortality was 48.1% vs an expected 18.5%. Multivariate predictors of mortality, even after adjusting for expected mortality, were older age at admission (P<.001) and male sex (P<.001). Conclusions.-Patients previously treated for alcoholism and/or other nonnicotine drug dependence had an increased cumulative mortality that was due more to tobacco-related than to alcohol-related causes. Nicotine dependence treatment is imperative in such high-risk patients.	MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PSYCHIAT & PSYCHOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Hurt, RD (corresponding author), MAYO CLIN & MAYO FDN, NICOTINE DEPENDENCE CTR, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008039] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline; NIDA NIH HHS [DA 08039] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], [No title captured]; BARR HC, 1994, J STUD ALCOHOL, V45, P440; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; Bergstralh E, 1986, TECHNICAL REPORT SER, V31; BERGSTRALH EJ, 1988, TECHNICAL SUPPORT SE, V37; BULLOCK KD, 1992, JAMA-J AM MED ASSOC, V267, P668, DOI 10.1001/jama.267.5.668; BURLING TA, 1988, ADDICT BEHAV, V13, P185, DOI 10.1016/0306-4603(88)90010-X; COX DR, 1972, J R STAT SOC B, V34, P187; CRAIG TJ, 1977, J STUD ALCOHOL, V38, P1434, DOI 10.15288/jsa.1977.38.1434; Delaney G O, 1988, N J Med, V85, P131; DIETVORST TF, 1978, J CLIN PSYCHOL, V34, P244, DOI 10.1002/1097-4679(197801)34:1<244::AID-JCLP2270340150>3.0.CO;2-V; DIFRANZA JR, 1990, J STUD ALCOHOL, V51, P130, DOI 10.15288/jsa.1990.51.130; DORPAT TL, 1960, COMPR PSYCHIAT, V1, P349, DOI 10.1016/S0010-440X(60)80058-2; EDWARDS G, 1983, LANCET, V2, P269; FEUERLEIN W, 1994, ADDICTION, V89, P841, DOI 10.1111/j.1360-0443.1994.tb00987.x; FINNEY JW, 1992, J STUD ALCOHOL, V53, P142, DOI 10.15288/jsa.1992.53.142; FISHMAN ML, 1993, J SUBST ABUSE TREAT, V10, P133, DOI 10.1016/0740-5472(93)90037-3; FLEMING TR, 1981, COMMUN STAT A-THEOR, V10, P763, DOI 10.1080/03610928108828073; GILLIS L S, 1969, South African Medical Journal, V43, P230; GOLDSMITH JR, 1991, J ADDICT DIS, V11, P67; HOFFMAN AL, 1993, J SUBST ABUSE TREAT, V10, P153, DOI 10.1016/0740-5472(93)90040-9; HURT RD, 1994, ALCOHOL CLIN EXP RES, V18, P867, DOI 10.1111/j.1530-0277.1994.tb00052.x; JOSEPH AM, 1990, JAMA-J AM MED ASSOC, V263, P3043; KARAN LD, 1993, J SUBST ABUSE TREAT, V10, P101, DOI 10.1016/0740-5472(93)90032-W; KOZLOWSKI LT, 1989, ADDICT BEHAV, V14, P273, DOI 10.1016/0306-4603(89)90058-0; KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LAMBIE DG, 1982, NZ MED J, V96, P199; LEWIS CE, 1995, ALCOHOL CLIN EXP RES, V19, P984, DOI 10.1111/j.1530-0277.1995.tb00978.x; MALETZKY BM, 1974, AM J PSYCHIAT, V131, P445; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARSHALL EJ, 1994, ADDICTION, V89, P1293, DOI 10.1111/j.1360-0443.1994.tb03308.x; MCALPINE DE, 1990, MAYO CLIN PROC, V65, P13, DOI 10.1016/S0025-6196(12)62105-3; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MOOS RH, 1994, ALCOHOL CLIN EXP RES, V18, P187, DOI 10.1111/j.1530-0277.1994.tb00902.x; MORSE RM, 1991, PROFESSIONAL COU AUG, P33; National Center for Health Statistics, 1993, DHHS PUBL, V41; OCONNOR A, 1985, BRIT J PSYCHIAT, V146, P645, DOI 10.1192/bjp.146.6.645; OHARA K, 1989, BRIT J ADDICT, V84, P287; ORLEANS CT, 1993, J SUBST ABUSE TREAT, V10, P197, DOI 10.1016/0740-5472(93)90045-4; PUCKET CD, 1994, ED ANNOTATION ICD9CM; RAVENHOLT RT, 1984, POPUL DEV REV, V10, P697, DOI 10.2307/1973289; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROSENGREN A, 1988, ACTA MED SCAND, V223, P111; SCHMIDT W, 1981, CANCER-AM CANCER SOC, V47, P1031, DOI 10.1002/1097-0142(19810301)47:5<1031::AID-CNCR2820470534>3.0.CO;2-C; TAYLOR JR, 1983, J STUD ALCOHOL, V44, P17, DOI 10.15288/jsa.1983.44.17; VAILLANT GE, 1991, J GEN INTERN MED, V6, P299, DOI 10.1007/BF02597425; 1995, MINN CANC SURVEI MAR, P2; 1993, MMWR-MORBID MORTAL W, V42, P645; 1990, MMWR-MORBID MORTAL W, V11, P172	51	514	517	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1097	1103		10.1001/jama.275.14.1097	http://dx.doi.org/10.1001/jama.275.14.1097			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD027	8601929				2022-12-01	WOS:A1996UD02700026
J	Nagar, B; Overduin, M; Ikura, M; Rini, JM				Nagar, B; Overduin, M; Ikura, M; Rini, JM			Structural basis of calcium-induced E-cadherin rigidification and dimerization	NATURE			English	Article							CELL-ADHESION; PROTEIN	THE cadherins mediate cell adhesion and play a fundamental role in normal development(1). They participate in the maintenance of proper cell-cell contacts: for example, reduced levels of epithelial cadherin (E-cadherin) correlate with increased invasiveness in many human tumour cell types(2,3). The cadherins typically consist of five tandemly repeated extracellular domains, a single membrane-spanning segment and a cytoplasmic region(4-6). The N-terminal extracellular domains mediate cell-cell contact(7) while the cytoplasmic region interacts with the cytoskeleton through the catenins(8). Cadherins depend on calcium for their function: removal of calcium abolishes adhesive activity, renders cadherins vulnerable to proteases (reviewed in ref, 4) and, in E-cadherin, induces a dramatic reversible conformational change in the entire extracellular region(9). We report here the X-ray crystal structure at 2.0 Angstrom resolution of the two N-terminal extracellular domains of E-cadherin in the presence of calcium. The structure reveals a two-fold symmetric dimer, each molecule of which binds a contiguous array of three bridged calcium ions. Not only do the bound calcium ions linearize and rigidify the molecule, they promote dimerization. Although the N-terminal domain of each molecule in the dimer is aligned in a parallel orientation, the interactions between them differ significantly from those found in the neural cadherin (N-cadherin) N-terminal domain (NCD1) structure(10). The E-cadherin dual-domain structure reported here defines the role played by calcium in the cadherin-mediated formation and maintenance of solid tissues.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Tsukuba; University of Tsukuba			Nagar, Bhushan/C-1297-2010; Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Ikura, Mitsuhiko/0000-0002-9524-1303				BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; Blaschuk O W, 1994, Can J Oncol, V4, P291; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; BRUNGER AT, 1992, XPLOR V 3 1 SYSTEM X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, IN PRESS METH ENZYM; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAREEL M, 1994, MOL BIOL REP, V19, P45, DOI 10.1007/BF00987321; NOSE A, 1990, CELL, V61, P17; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OVERDUIN M, IN PRESS J BIOMOL NM; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RINGWALD M, 1987, EMBO J, V6, P3547; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TESMER JJG, 1994, PROTEINS, V18, P394, DOI 10.1002/prot.340180410; TONG KI, 1994, FEBS LETT, V352, P318; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832	28	546	560	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					360	364		10.1038/380360a0	http://dx.doi.org/10.1038/380360a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598933				2022-12-01	WOS:A1996UC37900064
J	Ernster, VL; Barclay, J; Kerlikowske, K; Grady, D; Henderson, IC				Ernster, VL; Barclay, J; Kerlikowske, K; Grady, D; Henderson, IC			Incidence of and treatment for ductal carcinoma in situ of the breast	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRADUCTAL CARCINOMA; SCREENING MAMMOGRAPHY; FEMALE BREAST; INSITU; CANCER; WOMEN; LESIONS; DCIS; PREVALENCE; MANAGEMENT	Objective.-To describe trends in incidence and treatment for ductal carcinoma in situ (DCIS) of the breast in the United States between 1973 and 1992 and to estimate total numbers of in situ cases diagnosed and numbers treated by mastectomy since 1983, when screening mammography for breast cancer began to become widespread. Design.-Analysis of population-based breast cancer incidence data collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program since 1973 and treatment data collected by the SEER program since 1983. Study Population.-All women in the geographic areas of the United States included in the SEER program. Main Outcome Measures.-Annual age-adjusted and age-specific incidence rates for DCIS; time trends in distribution of cases by type of treatment; percentage of cases treated by mastectomy by geographic area; and estimated numbers for the entire United States of DCIS cases, mastectomies for DCIS, and cases attributable to mammography. Results.-There was a marked increase in DCIS incidence beginning in the early 1980s. Average annual increases in rates between 1973 and 1983 and between 1983 and 1992 changed from 0.3% to 12.0% among women aged 30 to 39 years, from 0.4% to 17.4% among women aged 40 to 49 years, and from 5.2% to 18.1% among women aged 50 years or older. The total estimated number of DCIS cases in the United States in 1992 (23 368) was 200% higher than expected based on 1983 rates and trends between 1973 and 1983, Between 1983 and 1992, there was a marked decline in the proportion of DCIS cases treated by mastectomy (from 71% to 43.8%) and an increase in those treated by lumpectomy (from 25.6% to 53.3%). In 1992, 23.3% of cases were treated by lumpectomy and radiation, 30.2% by lumpectomy alone, and 2.6% with no surgery, Treatment patterns varied substantially by geographic area, with 57.7% of cases in New Mexico treated by mastectomy in 1992 compared with 28.8% in Connecticut, Despite the decline in the proportion of cases treated by mastectomy, the increased DCIS incidence rates resulted in an increase in the absolute number of cases treated by mastectomy until 1990 (n=10 657); in 1992, there were an estimated 10 242 DCIS cases treated by mastectomy. Conclusions-Incidence rates of DCIS of the breast have increased dramatically since 1983. This increase correlates with the widespread adoption of modern mammographic screening. While early detection of invasive breast cancer is beneficial, the value of DCIS detection is currently unknown. There is cause for concern about the large number of DCIS cases that are being diagnosed as a consequence of screening mammography, most of which are treated; by some form of surgery. In addition, the proportion of cases treated by mastectomy may be inappropriately high, particularly in some areas of the United States.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; VET ADM MED CTR,GEN INTERNAL MED SECT,SAN FRANCISCO,CA 94121; SEQUUS PHARMACEUT INC,MENLO PK,CA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ernster, VL (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOSTAT & EPIDEMIOL,BOX 0560,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [U01 CA 63740, CA 58207-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, U01CA063740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTH A, 1995, WESTERN J MED, V163, P360; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; BASSETT LW, 1992, RADIOL CLIN N AM, V30, P93; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BERG JW, 1995, CANCER, V75, P257, DOI 10.1002/1097-0142(19950101)75:1+<257::AID-CNCR2820751311>3.0.CO;2-Y; BHATHAL PS, 1985, BRIT J CANCER, V51, P271, DOI 10.1038/bjc.1985.39; BROWN ML, 1990, ANN INTERN MED, V113, P547, DOI 10.7326/0003-4819-113-7-547; CARPENTER R, 1989, BRIT J SURG, V76, P564, DOI 10.1002/bjs.1800760612; COLEMAN EA, 1992, AM J SURG, V164, P74, DOI 10.1016/S0002-9610(05)80652-X; FAGGIANO F, 1994, J EPIDEMIOL COMMUN H, V48, P447, DOI 10.1136/jech.48.5.447; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER ER, 1991, J SURG ONCOL, V47, P139, DOI 10.1002/jso.2930470302; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; GUMP FE, 1987, SURGERY, V102, P790; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LYNDE JL, 1993, SOUTHERN MED J, V86, P338, DOI 10.1097/00007611-199303000-00018; MILLIKAN R, 1995, BREAST CANCER RES TR, V35, P65, DOI 10.1007/BF00694747; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; *NCI, 1995, SURV EP END RES SEER; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; OSTEEN RT, 1994, CANCER, V73, P1994, DOI 10.1002/1097-0142(19940401)73:7<1994::AID-CNCR2820730735>3.0.CO;2-O; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Page DL, 1987, DIAGNOSTIC HISTOPATH, P157; POPE TL, 1988, RADIOLOGY, V168, P63, DOI 10.1148/radiology.168.1.3380984; REBNER M, 1994, RADIOLOGY, V190, P623, DOI 10.1148/radiology.190.3.8115600; Ries L, 1994, NIH PUBLICATION, V94-2789; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P630, DOI 10.1016/S0959-8049(05)80114-5; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; SONNENFIELD M, 1991, RADIOLOGY, V181, P623; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; VANDONGEN JA, 1992, EUR J CANCER, V28A, P626, DOI 10.1016/S0959-8049(05)80113-3; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208; 1990, MMWR-MORBID MORTAL W, V39, P621; 1990, MMWR-MORBID MORTAL W, V39, P627	48	440	452	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					913	918		10.1001/jama.275.12.913	http://dx.doi.org/10.1001/jama.275.12.913			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598618				2022-12-01	WOS:A1996UA56300030
J	Yu, SF; Baldwin, DN; Gwynn, SR; Yendapalli, S; Linial, ML				Yu, SF; Baldwin, DN; Gwynn, SR; Yendapalli, S; Linial, ML			Human foamy virus replication: A pathway distinct from that of retroviruses and hepadnaviruses	SCIENCE			English	Article							HUMAN SPUMARETROVIRUS; HUMAN-IMMUNODEFICIENCY; GENE-PRODUCTS; GAG PROTEINS; IDENTIFICATION; EXPRESSION; VIRIONS; BINDING; GENOME; BEL	Human foamy virus (HFV) is the prototype of the Spumavirus genus of Retroviridae. In all other retroviruses, the pol gene products, including reverse transcriptase, are synthesized as Gag-Pol fusion proteins and are cleaved to functional enzymes during viral budding or release, In contrast, the Pol protein of HFV is translated from a spliced messenger RNA and lacks Gag domains, Infectious HFV particles contain double-stranded DNA similar in size to full-length provirus, suggesting that reverse transcription has taken place in viral particles before new rounds of infection, reminiscent of hepadnaviruses. These data suggest that foamy viruses possess a replication pathway containing features of both retroviruses and hepadnaviruses but distinct from both.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,INTERDISCIPLINARY PROGRAM MOLEC & CELLULAR BIOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA18282, F32 CA60357] Funding Source: Medline; NHLBI NIH HHS [HL53762] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018282, F32CA060357] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN D, UNPUB; BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BARTHOLOMA A, 1992, VIRUS RES, V23, P27, DOI 10.1016/0168-1702(92)90065-H; Coffin J. M., 1990, VIROLOGY, P1437; FELSENSTEIN KM, 1988, J VIROL, V62, P2179, DOI 10.1128/JVI.62.6.2179-2182.1988; GANEM D, 1994, INFECT AGENT DIS, V3, P85; HAHN H, 1994, J GEN VIROL, V75, P2635, DOI 10.1099/0022-1317-75-10-2635; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; KOGEL D, 1995, VIROLOGY, V213, P97, DOI 10.1006/viro.1995.1550; KONVALINKA J, 1995, J VIROL, V69, P7264, DOI 10.1128/JVI.69.11.7264-7268.1995; LOCHELT M, 1991, VIROLOGY, V184, P43, DOI 10.1016/0042-6822(91)90820-2; Lochelt M, 1996, J VIROL, V70, P1033; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MAURER B, 1988, J VIROL, V62, P1590, DOI 10.1128/JVI.62.5.1590-1597.1988; MURANYI W, 1991, J VIROL, V65, P727, DOI 10.1128/JVI.65.2.727-735.1991; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; NETZER KO, 1990, J GEN VIROL, V71, P1237, DOI 10.1099/0022-1317-71-5-1237; NETZER KO, 1993, VIROLOGY, V192, P336, DOI 10.1006/viro.1993.1039; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; RETHWILM A, 1991, P NATL ACAD SCI USA, V88, P941, DOI 10.1073/pnas.88.3.941; SCHLIEPHAKE AW, 1994, J VIROL, V68, P4946, DOI 10.1128/JVI.68.8.4946-4954.1994; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; Vogt P. K., 1990, CURR TOP MICROBIOL, V157, P93; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yu SF, 1996, J VIROL, V70, P1250, DOI 10.1128/JVI.70.2.1250-1254.1996; YU SF, 1993, J VIROL, V67, P6618, DOI 10.1128/JVI.67.11.6618-6624.1993; [No title captured]	31	230	238	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1579	1582		10.1126/science.271.5255.1579	http://dx.doi.org/10.1126/science.271.5255.1579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599113				2022-12-01	WOS:A1996TZ98300040
J	Davey, PG; Bax, RP; Newey, J; Reeves, D; Rutherford, D; Slack, R; Warren, RE; Watt, B; Wilson, J				Davey, PG; Bax, RP; Newey, J; Reeves, D; Rutherford, D; Slack, R; Warren, RE; Watt, B; Wilson, J			Growth in the use of antibiotics in the community in England and Scotland in 1980-93	BRITISH MEDICAL JOURNAL			English	Article									SMITHKLINE BEECHAM PHARMACEUT,HARLOW CM19 5AW,ESSEX,ENGLAND; HALLWOOD HLTH CTR,WEAVER VALE WA7 2OT,CHESHIRE,ENGLAND; SOUTHMEAD HOSP,DEPT MED MICROBIOL,BRISTOL BS10 5NB,AVON,ENGLAND; PIPELANDS HLTH CTR,ST ANDREWS KY16 8JZ,FIFE,SCOTLAND; PUBL HLTH LAB SERV LAB,NOTTINGHAM NG7 2UH,ENGLAND; PUBL HLTH LAB,SHREWSBURY SY3 8XQ,ENGLAND; CITY HOSP EDINBURGH,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; NOTTINGHAMSHIRE FAMILY HLTH SERV AUTHOR,NOTTINGHAM NG1 5EP,ENGLAND	GlaxoSmithKline; Southmead Hospital	Davey, PG (corresponding author), NINEWELLS HOSP,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.							BORDER P, 1994, DIS FIGHTING BACK GR, P1; Davey P G, 1992, Pharmacoeconomics, V1, P409; MCGAVOCK H, 1993, BRIT MED J, V307, P1118, DOI 10.1136/bmj.307.6912.1118; TABOULET F, 1990, J EC MED, V8, P37	4	68	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					613	613						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595337	Green Published			2022-12-01	WOS:A1996TZ84000027
J	McGrath, AM; Jackson, GA				McGrath, AM; Jackson, GA			Survey of neuroleptic prescribing in residents of nursing homes in Glasgow	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USE		PARKHEAD HOSP,GLASGOW G31 5BA,LANARK,SCOTLAND; KNIGHTSWOOD HOSP,GLASGOW G13 2XF,LANARK,SCOTLAND					jackson, graham/0000-0002-0526-7084				BROWN JW, 1993, J NERV MENT DIS, V181, P695, DOI 10.1097/00005053-199311000-00008; JENCKS SF, 1991, JAMA-J AM MED ASSOC, V265, P502; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SENLA TP, 1994, J AM GERIATR SOC, V42, P648	5	105	105	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					611	612						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ840	8595335				2022-12-01	WOS:A1996TZ84000025
J	Pantel, K; Izbicki, J; Passlick, B; Angstwurm, M; Haussinger, K; Thetter, O; Riethmuller, G				Pantel, K; Izbicki, J; Passlick, B; Angstwurm, M; Haussinger, K; Thetter, O; Riethmuller, G			Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases	LANCET			English	Article							MICROMETASTATIC CARCINOMA-CELLS; MONOCLONAL-ANTIBODIES; EXPRESSION; TISSUES; CYTOKERATIN; EPITHELIA; GENE	Background Metastasis is generally looked on as a late event in the natural history of epithelial tumours. However, the poor prognosis of patients with apparently localised lung cancer indicates that micrometastases occur often before diagnosis of the primary tumour. Methods At primary surgery, disseminated tumour cells were detected immunocytochemically in bone marrow of 139 patients with non-small-cell lung carcinomas without evidence of distant metastases (pT(1-4)pN(1-2)M(0)). Tumour cells in bone-marrow aspirates were detected with monoclonal antibody CK2 against cytokeratin polypeptide 18. Patients were followed up for a median of 39 months (range 14-52) after surgery. 215 patients without epithelial cancer (ie, with benign epithelial tumours, nonepithelial neoplasms, or inflammatory diseases) acted as controls. Findings In 83 of 139 (59.7%) patients cytokeratin-positive cells were detected at frequencies of 1 in 100 000 to 1 in 1 000 000. Even without histopathological involvement of lymph nodes (pN(0)), tumour cells were found in 38 of 70 (54.3%) patients. 1 positive cell was found in each of 6 out of 215 controls. Surgical manipulation during primary tumour resection did not affect the frequency of these cells. In Cox's regression analyses, the presence of such cells was a significant and independent predictor for a later clinical relapse in node-negative patients (p=0.028). Interpretation Early dissemination of isolated tumour cells is a frequent and intrinsic characteristic of non-small-cell lung carcinomas. The finding of these cells may help to decide whether adjuvant systemic therapy is required for the individual patient.	UNIV MUNICH, CHIRURG KLINIKUM INNENSTADT, D-80336 MUNICH, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, KLIN ALLGEMEINCHIRURG, HAMBURG, GERMANY; ZENT KRANKENHAUS GAUTING, ABT THORAXCHIRURG, GAUTING, GERMANY; ZENT KRANKENHAUS GAUTING, ABT PULMONOL, GAUTING, GERMANY	University of Munich; University of Hamburg	Pantel, K (corresponding author), UNIV MUNICH, INST IMMUNOL, D-80336 MUNICH, GERMANY.							BOS JL, 1989, CANCER RES, V49, P4682; BURKHARDT R, 1980, B CANCER, V67, P291; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DATTA YH, 1994, J CLIN ONCOL, V12, P475, DOI 10.1200/JCO.1994.12.3.475; DEBUS E, 1982, EMBO J, V1, P1641, DOI 10.1002/j.1460-2075.1982.tb01367.x; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; GRUNOW N, 1991, PATHOLOGE, V12, P270; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARRISON WJ, 1962, J CLIN PATHOL, V15, P254, DOI 10.1136/jcp.15.3.254; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; IMMERMAN SC, 1981, ANN THORAC SURG, V32, P23, DOI 10.1016/S0003-4975(10)61368-9; KRISMANN M, 1995, J CLIN ONCOL, V13, P2769, DOI 10.1200/JCO.1995.13.11.2769; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOMBURG F, 1987, CANCER RES, V47, P2883; PAGE A, 1987, CAN J SURG, V30, P96; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PANTEL K, 1991, CANCER RES, V51, P4712; PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162; PANTEL K, 1993, CANCER RES, V53, P1027; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; TRAWEEK ST, 1993, AM J PATHOL, V142, P1111; WOOD DP, 1994, J UROLOGY, V151, P303	28	336	346	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					649	653		10.1016/S0140-6736(96)91203-9	http://dx.doi.org/10.1016/S0140-6736(96)91203-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596379				2022-12-01	WOS:A1996TZ28500011
J	Lee, N				Lee, N			South Africa's AIDS play provokes controversy	LANCET			English	News Item																			0	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					610	610		10.1016/S0140-6736(96)91306-9	http://dx.doi.org/10.1016/S0140-6736(96)91306-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596329				2022-12-01	WOS:A1996TX69400041
J	TalarWilliams, C; Hijazi, YM; Walther, MM; Linehan, WM; Hallahan, CW; Lubensky, L; Kerr, CS; Hoffman, GS; Fauci, AS; Sneller, MC				TalarWilliams, C; Hijazi, YM; Walther, MM; Linehan, WM; Hallahan, CW; Lubensky, L; Kerr, CS; Hoffman, GS; Fauci, AS; Sneller, MC			Cyclophosphamide-induced cystitis and bladder cancer in patients with wegener granulomatosis	ANNALS OF INTERNAL MEDICINE			English	Article							ULCERATIVE-COLITIS; RHEUMATOID-ARTHRITIS; TOXICITY	Objective: To describe the incidence of, clinical manifestations of, and risk factors for cyclophosphamide-induced urinary bladder toxicity in patients treated for nonmalignant disease. Design: Retrospective analysis of patients followed at the National Institutes of Allergy and Infectious Diseases from 1967 to 1993. Setting: The Warren G. Magnuson Clinical Center of the National Institutes of Health (NIH). Patients: 145 patients who received cyclophosphamide for the treatment of Wegener granulomatosis and were followed for 0.5 to 27 years (median, 8.5 years), for a total of 1333 patient-years. Measurements: Clinical characteristics, cystoscopic findings, results of cytologic examination of urine, surgical pathology. and total dose and duration of cyclophosphamide therapy were recorded and analyzed using a computer-based information retrieval system. Results: Nonglomerular hematuria occurred in 73 of 145 patients treated with cyclophosphamide (50%). Sixty of the 73 patients with nonglomerular hematuria (82%) had cystoscopy at the NIH. Forty-two of the 60 patients (70%) who had cystoscopy had macroscopic changes consistent with cyclophosphamide-induced bladder injury. Seven patients (5%) developed transitional-cell carcinoma of the urinary bladder. In 6 of these 7 patients, the total cumulative cyclophosphamide dose exceeded 100 g, and the cumulative duration of cyclophosphamide therapy exceeded 2.7 years. Before they were given a diagnosis of bladder cancer, all 7 patients had had one or more episodes of microscopic or gross nonglomerular hematuria. In contrast, none of the 72 patients who had never had nonglomerular hematuria developed bladder cancer. Cox proportional hazards regression analysis showed that only microscopic nonglomerular hematuria was a significant risk factor for the development of bladder cancer (P < 0.01). Conclusion: Long-term oral cyclophosphamide therapy is associated with substantial urotoxicity, including the development of transitional-cell carcinoma of the urinary bladder. In this cohort of patients, the estimated incidence of bladder cancer after the first exposure to cyclophosphamide was 5% at 10 years and 16% at 15 years. Nonglomerular hematuria was a frequent manifestation of cyclophosphamide-induced cystitis, and it identified a subgroup of patients at high risk for the development of bladder cancer.	NIAID,NIH,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BAKER GL, 1987, AM J MED, V83, P1, DOI 10.1016/0002-9343(87)90490-6; COLEMAN DV, 1975, ACTA CYTOL, V19, P93; COX DR, 1972, J R STAT SOC B, V34, P187; COX PJ, 1979, BIOCHEM PHARMACOL, V28, P2045, DOI 10.1016/0006-2952(79)90222-3; CROWLEY J, 1977, J AM STAT ASSOC, V72, P27, DOI 10.2307/2286902; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FORNI AM, 1964, CANCER, V17, P1348, DOI 10.1002/1097-0142(196410)17:10<1348::AID-CNCR2820171017>3.0.CO;2-0; FRAISER LH, 1991, DRUGS, V42, P781, DOI 10.2165/00003495-199142050-00005; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; JEWELL DP, 1993, GASTROINTESTINAL DIS, P105; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORELITZ BI, 1995, BOCKUS GASTROENTEROL, P1364; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LOFBERG R, 1990, GASTROENTEROLOGY, V99, P1021; PEDERSENBJERGAARD J, 1988, NEW ENGL J MED, V318, P1028, DOI 10.1056/NEJM198804213181604; PLOTZ PH, 1979, ANN INTERN MED, V91, P221, DOI 10.7326/0003-4819-91-2-221; REZA MJ, 1975, ARTHRITIS RHEUM, V18, P501, DOI 10.1002/art.1780180513; RIES LAG, 1994, NIH942789 PUB; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; STILLWELL TJ, 1988, ARTHRITIS RHEUM, V31, P465, DOI 10.1002/art.1780310402; WEISS MA, 1989, PATHOLOGY URINARY BL, P245	24	379	393	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					477	&		10.7326/0003-4819-124-5-199603010-00003	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602705				2022-12-01	WOS:A1996TW77300003
J	Tamai, H; Sudo, T; Kimura, A; Mukuta, T; Matsubayashi, S; Kuma, K; Nagataki, S; Sasazuki, T				Tamai, H; Sudo, T; Kimura, A; Mukuta, T; Matsubayashi, S; Kuma, K; Nagataki, S; Sasazuki, T			Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with graves disease	ANNALS OF INTERNAL MEDICINE			English	Article							PROPYLTHIOURACIL-INDUCED AGRANULOCYTOSIS; INSULIN AUTOIMMUNE SYNDROME; COLONY-STIMULATING FACTOR; LUPUS-LIKE SYNDROME; MHC CLASS-II; ANTITHYROID DRUGS; IMMUNE-RESPONSE; HLA; SUSCEPTIBILITY; GENES	Objective: To determine the association between HLA class II genes and methimazole-induced agranulocytosis in patients with Graves disease. Design: Case-control study. Setting: Kuma Hospital, which specializes in thyroid diseases, in Kobe, Japan. Subjects: 24 patients with Graves disease who had methimazole-induced agranulocytosis diagnosed by peripheral granulocyte counts of less than 0.5 x 10(9)/L, and 68 patients with Graves disease treated with methimazole, who were free from agranulocytosis. Controls were 525 healthy, unrelated Japanese student volunteers at Kyushu University in Japan. Measurements: All HLA class II genes were analyzed for polymorphisms at the DNA level by using the polymerase chain reaction sequence-specific oligonucleotide probes method. The allele frequencies in the agranulocytotic Graves disease group were compared with those in the nonagranulocytotic Graves disease and control groups. Results: A strong positive association was seen in DRB1*08032 between the agranulocytotic group and both the control and nonagranulocytotic Graves disease groups. Conclusion: The HLA DRB1*08032 allele was strongly associated with susceptibility to methimazole-induced agranulocytosis, suggesting that cellular autoimmunity may be involved in its development.	KYUSHU UNIV, MED INST BIOREGULAT, DEPT GENET, HIGASHI KU, FUKUOKA 812, JAPAN; TOKYO MED & DENT UNIV, MED RES INST,DEPT TISSUE PHYSIOL,DIV ADULT DIS, CHIYODA KU, TOKYO 101, JAPAN; KUMA HOSP, CHUOU KU, KOBE, HYOGO 650, JAPAN; NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, NAGASAKI 852, JAPAN	Kyushu University; Tokyo Medical & Dental University (TMDU); Kuma Hospital; Nagasaki University	Tamai, H (corresponding author), KYUSHU UNIV, FAC MED, DEPT PSYCHOSOMAT MED, HIGASHI KU, 3-1-1 MAIDASHI, FUKUOKA 812, JAPAN.			nagataki, shigenobu/0000-0002-9974-3554				AMRHEIN JA, 1970, J PEDIATR-US, V76, P54, DOI 10.1016/S0022-3476(70)80130-5; BERKMAN EM, 1983, TRANSFUSION, V23, P135, DOI 10.1046/j.1537-2995.1983.23283172851.x; BILEZIKIAN SB, 1976, JOHNS HOPKINS MED J, V138, P124; BODMER JG, 1995, TISSUE ANTIGENS, V46, P1; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; COOPER DS, 1983, ANN INTERN MED, V98, P26, DOI 10.7326/0003-4819-98-1-26; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; DONG RP, 1992, HUM IMMUNOL, V35, P165, DOI 10.1016/0198-8859(92)90101-R; FIBBE WE, 1986, BRIT J HAEMATOL, V64, P363, DOI 10.1111/j.1365-2141.1986.tb04130.x; FU XT, 1995, J EXP MED, V181, P915, DOI 10.1084/jem.181.3.915; GEORGE AJT, 1995, IMMUNOL TODAY, V16, P209, DOI 10.1016/0167-5699(95)80158-8; GUFFY MM, 1984, ARCH INTERN MED, V144, P1687, DOI 10.1001/archinte.144.8.1687; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HEINRICH B, 1989, ANN INTERN MED, V111, P621, DOI 10.7326/0003-4819-111-7-621_2; Imanish T, 1992, HLA 1991, V1, P1065; KIMURA A, 1992, TISSUE ANTIGENS, V40, P5, DOI 10.1111/j.1399-0039.1992.tb01951.x; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; MARSHALL KW, 1994, J IMMUNOL, V152, P4946; MATSUSHITA S, 1994, J EXP MED, V180, P873, DOI 10.1084/jem.180.3.873; MCDEVITT HO, 1980, NEW ENGL J MED, V303, P1514, DOI 10.1056/NEJM198012253032606; MCGAVACK TH, 1954, AM J MED, V17, P36, DOI 10.1016/0002-9343(54)90141-2; McIntyre P A, 1971, Trans Assoc Am Physicians, V84, P217; MOORE FD, 1946, JAMA-J AM MED ASSOC, V130, P315, DOI 10.1001/jama.1946.02870060001001; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RENOUX G, 1980, DRUGS, V20, P89, DOI 10.2165/00003495-198020020-00001; ROSOVE MH, 1977, WESTERN J MED, V126, P339; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; SATO K, 1985, J ENDOCRINOL INVEST, V8, P551, DOI 10.1007/BF03348560; TAKAYAMAHASUMI S, 1990, DIABETES RES CLIN PR, V10, P211, DOI 10.1016/0168-8227(90)90063-Y; TAMAI H, 1994, J CLIN ENDOCR METAB, V78, P94, DOI 10.1210/jc.78.1.94; TAMAI H, 1989, CLIN ENDOCRINOL, V30, P525, DOI 10.1111/j.1365-2265.1989.tb01424.x; TAMAI H, 1993, J CLIN ENDOCR METAB, V77, P1356, DOI 10.1210/jc.77.5.1356; TIWARI JL, HLA DISEASE ASS, P214; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TOTH EL, 1988, AM J MED, V85, P725; TROTTER W. R., 1962, JOUR NEW DRUGS, V2, P333, DOI 10.1177/009127006200200603; UCHIGATA Y, 1992, LANCET, V340, P1467, DOI 10.1016/0140-6736(92)92654-X; UNO H, 1981, NATURE, V292, P768, DOI 10.1038/292768a0; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; WALL JR, 1984, J CLIN ENDOCR METAB, V58, P868, DOI 10.1210/jcem-58-5-868; WALZER RA, 1963, JAMA-J AM MED ASSOC, V184, P743, DOI 10.1001/jama.1963.03700230043006; WEITZMAN SA, 1978, LANCET, V1, P1068	44	53	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					490	494		10.7326/0003-4819-124-5-199603010-00005	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602707				2022-12-01	WOS:A1996TW77300005
J	Esteban, JI; Gomez, J; Martell, M; Cabot, B; Quer, J; Camps, J; Gonzalez, A; Otero, T; Moya, A; Esteban, R; Guardia, J				Esteban, JI; Gomez, J; Martell, M; Cabot, B; Quer, J; Camps, J; Gonzalez, A; Otero, T; Moya, A; Esteban, R; Guardia, J			Transmission of hepatitis C virus by a cardiac surgeon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTTRANSFUSION HEPATITIS; NEEDLESTICK INJURY; DENTAL PRACTICE; INFECTION; RNA; HCV; ANTIBODIES; REGIONS; ASSAY	Background. In the course of a study conducted from 1992 through 1994 of the efficacy of screening blood donors for antibodies to hepatitis C virus (HCV), we found that two patients had acquired hepatitis C after cardiac surgery, with the transmission apparently unrelated to blood transfusions, Because their surgeon had chronic hepatitis C, we sought to determine whether he was transmitting the virus to his patients. Methods. Of 222 of the surgeon's patients who participated in studies of post-transfusion hepatitis between 1988 and 1994, 6 contracted postoperative hepatitis C, despite the use of only seronegative blood for transfusions, All six patients had undergone valve-replacement surgery, Analyses were performed to compare nucleotide sequences encompassing the hypervariable region at the junction between the coding regions for envelope glycoproteins E1 and E2 in the surgeon, the patients, and 10 controls infected with the same HCV genotype. Results. The surgeon and five of the six patients with hepatitis C unrelated to transfusion were infected with HCV genotype 3; the sixth patient had genotype 1 and was considered to have been infected from another source, Thirteen other patients of the surgeon had transfusion associated hepatitis C and were also infected with genotype 1. The average net genetic distance between the sequences from the five patients with HCV genotype 3 and those from the surgeon was 2.1 percent (range, 1.1 to 2.5 percent; P<0,001), as compared with an average distance of 7.6 percent (range, 6.1 to 8.3 percent) between the sequences from the patients and those from the controls, The results of a phylogenetic-tree analysis indicated a common epidemiologic origin of the viruses from the surgeon and the five patients. Conclusions. Our findings provide evidence that a cardiac surgeon with chronic hepatitis C may have transmitted HCV to five of his patients during open-heart surgery.	UNIV AUTONOMA BARCELONA,HOSP GEN VALLE HEBRON,LIVER UNIT,DEPT MED,E-08035 BARCELONA,SPAIN; UNIV VALENCIA,DEPT GENET,VALENCIA,SPAIN	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; University of Valencia			Quer, Josep/A-6741-2012; Moya, Andrés/A-8190-2008; Martell, Maria/J-8191-2013; Jordi, Gómez/L-6112-2015	Quer, Josep/0000-0003-0014-084X; Moya, Andrés/0000-0002-2867-1119; Martell, Maria/0000-0002-0935-0029; esteban, rafael/0000-0001-5280-392X; Gomez, Jordi/0000-0002-7806-1503				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; [Anonymous], VIRAL HEPATITIS LIVE; Brown AJL, 1994, EVOLUTIONARY BIOL VI, P75; CARIANI E, 1991, LANCET, V337, P850, DOI 10.1016/0140-6736(91)92555-G; CHUNG HT, 1993, HEPATOLOGY, V18, P1045; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GONZALEZ A, 1995, HEPATOLOGY, V22, P439, DOI 10.1016/0270-9139(95)90563-4; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HOSIE KB, 1988, LANCET, V2, P1500; HUANG YY, 1994, TRANSFUSION, V34, P661, DOI 10.1046/j.1537-2995.1994.34894353459.x; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; NEI M, 1989, MOL BIOL EVOL, V6, P290; NELSON KE, 1992, NEW ENGL J MED, V327, P1601; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; VILADOMIU L, 1992, HEPATOLOGY, V15, P767, DOI 10.1002/hep.1840150504; WANG YJ, 1994, VOX SANG, V67, P187, DOI 10.1111/j.1423-0410.1994.tb01657.x; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, LANCET, V338, P1040	37	296	302	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					555	560		10.1056/NEJM199602293340902	http://dx.doi.org/10.1056/NEJM199602293340902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569822				2022-12-01	WOS:A1996TW69600002
J	Nightingale, SL				Nightingale, SL			Fat substitute Olestra approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-01	WOS:A1996TW62700031
J	Gittoes, NJL; Miller, MR; Daykin, J; Sheppard, MC; Franklyn, JA				Gittoes, NJL; Miller, MR; Daykin, J; Sheppard, MC; Franklyn, JA			Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								Committee on Research into Chronic Bronchitis, 1966, QUESTIONNAIRE RESP S; COOPER JC, 1991, ANN ROY COLL SURG, V73, P32; EMPEY DW, 1972, BRIT MED J, V3, P503, DOI 10.1136/bmj.3.5825.503; MILLER MR, 1990, Q J MED, V74, P177; MILLER MR, 1988, THORAX, V43, P265, DOI 10.1136/thx.43.4.265	5	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					484	484		10.1136/bmj.312.7029.484	http://dx.doi.org/10.1136/bmj.312.7029.484			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597682	Green Published			2022-12-01	WOS:A1996TX38300027
J	Krueger, NX; VanVactor, D; Wan, HI; Gelbart, WM; Goodman, CS; Saito, H				Krueger, NX; VanVactor, D; Wan, HI; Gelbart, WM; Goodman, CS; Saito, H			The transmembrane tyrosine phosphatase DLAR controls motor axon guidance in Drosophila	CELL			English	Article							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; NERVOUS-SYSTEM AXONS; IMMUNOGLOBULIN SUPERFAMILY; CYTOPLASMIC REGION; GENETIC-ANALYSIS; FASCICLIN-II; C-ELEGANS; RECEPTOR; PROTEIN	DLAR is a receptor-like, transmembrane protein-tyrosine phosphatase in Drosophila that is expressed almost exclusively by developing neurons. Analysis of Dlar loss-of-function mutations shows that DLAR plays a key role during motoneuron growth cone guidance. Segmental nerve b (SNb) motor axons normally exit the common motor pathway, enter the ventral target region, and then synapse on specific ventral muscles. In Dlar mutant embryos, SNb axons bypass their normal target region and instead continue to extend along the common pathway. SNd motor axons also make pathfinding errors, while SNa and SNc axons appear normal. Thus, DLAR controls the ability of certain motor axons to navigate specific choice points in the developing Drosophila nervous system.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DIV NEUROBIOL,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Harvard University			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Van Vactor, Jr., David L./0000-0001-8156-9482	NIGMS NIH HHS [GM53415] Funding Source: Medline; PHS HHS [AL26598] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DESAI CJ, 1996, CELL, V84; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1996, IN PRESS ANN REV NEU, V19; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIN DM, 1995, NEURON, V14, P707, DOI 10.1016/0896-6273(95)90215-5; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Maness P F, 1990, Adv Exp Med Biol, V265, P117; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; OGRADY P, 1994, J BIOL CHEM, V269, P25193; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAN MG, 1993, J BIOL CHEM, V268, P19284; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER T, 1995, NEURON, V15, P259, DOI 10.1016/0896-6273(95)90032-2; Schultz Leonard D., 1993, Cell, V73, P1445; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; STOKER AW, 1995, DEVELOPMENT, V121, P1833; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YAN H, 1993, J BIOL CHEM, V268, P24880; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	62	293	297	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					611	622		10.1016/S0092-8674(00)81036-3	http://dx.doi.org/10.1016/S0092-8674(00)81036-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598047	Bronze			2022-12-01	WOS:A1996TX17600013
J	Cheng, EHY; Levine, B; Boise, LH; Thompson, CB; Hardwick, JM				Cheng, EHY; Levine, B; Boise, LH; Thompson, CB; Hardwick, JM			Bax-independent inhibition of apoptosis by Bcl-x(L)	NATURE			English	Article							SINDBIS VIRUS; MICE	THE Bcl-2-related protein, Bcl-x(L), has been shown to block apoptosis induced by a variety of stimuli(1-5) and to be a stronger protector against apoptosis than Bcl-2 under certain circumstances(2,5). Using site-specific mutagenesis, we show here that the amino-acid residues critical for protection of cells by Bcl-x(L) against Sindbis virus-induced apoptosis are clustered within the Bcl-2-homology regions 1 and 2 (BH1 and BH2 regions). The residues necessary for Bcl-x(L) function are not identical to those required for Bcl-2 function(6), Although it has been suggested that heterodimerization between Bcl-x(L) and Bax is essential for the anti death activity of Bcl-x(L) (refs 7, 8), our results suggest that the interaction with Bax is not required for Bcl-x(L) to exert its death-repressing activity, Specific mutations that disrupt the ability of Bcl-x(L) to interact with Bax or Bak still preserve 70-80% of the anti-death activity of wild-type Bcl-x(L).	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Columbia University; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Cheng, EHY (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,DEPT NEUROL,NEUROVIROL LABS,MEYER 6-181,BALTIMORE,MD 21287, USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815				BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOLSE LH, 1993, CELL, V74, P597; Bomer C, 1994, J CELL BIOL, V126, P1059; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DOLE MG, 1995, CANCER RES, V55, P2576; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GOTTSCHALK AR, IN PRESS CELL DEATH; HERTZ JM, 1992, J VIROL, V66, P857, DOI 10.1128/JVI.66.2.857-864.1992; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAMADA S, 1995, CANCER RES, V55, P354; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; TANAKA S, 1993, J BIOL CHEM, V268, P10920; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	29	432	461	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					554	556		10.1038/379554a0	http://dx.doi.org/10.1038/379554a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596636				2022-12-01	WOS:A1996TU69300054
J	Rozenberg, P; Goffinet, F; Philippe, HJ; Nisand, I				Rozenberg, P; Goffinet, F; Philippe, HJ; Nisand, I			Ultrasonographic measurement of lower uterine segment to assess risk of defects of scarred uterus	LANCET			English	Article							PREVIOUS CESAREAN-SECTION; X-RAY PELVIMETRY; VAGINAL DELIVERY; RUPTURE; DEHISCENCE; PREGNANCY; DIAGNOSIS; BIRTH	Background Ultrasonography has been used to examine the scarred uterus in women who have had previous caesarean sections in an attempt to assess the risk of rupture of the scar during subsequent labour. The predictive value of such measurements has not been adequately assessed, however. We aimed to evaluate the usefulness of sonographic measurement of the lower uterine segment before labour in predicting the risk of intrapartum uterine rupture. Methods In this prospective observational study, the obstetricians were not told the ultrasonographic findings and did not use them to make decisions about type of delivery. Eligible patients were those with previous caesarean sections booked for delivery at our hospital. 642 patients underwent ultrasound examination at 36-38 weeks' gestation, and were allocated to four groups according to the thickness of the lower uterine segment. Ultrasonographic findings were compared with those of physical examination at delivery. Findings The overall frequency of defective scars was 4.0% (15 ruptures, 10 dehiscences). The frequency of defects rose as the thickness of the lower uterine segment decreased: there were no defects among 278 women with measurements greater than 4.5 mm, three (2%) among 177 women with values of 3.6-4.5 mm, 14 (10%) among 136 women with values of 2.6-3.5 mm, and eight (16%) among 51 women with values of 1.6-2.5 mm. With a cutoff value of 3.5 mm, the sensitivity of ultrasonographic measurement was 88.0%, the specificity 73.2%, positive predictive value 11.8%, and negative predictive value 99.3%. Interpretation Our results show that the risk of a defective scar is directly related to the degree of thinning of the lower uterine segment at around 37 weeks of pregnancy. The high negative predictive value of the method may encourage obstetricians in hospitals where routine repeat elective caesarean is the norm to offer a trial of labour to patients with a thickness value of 3.5 mm or greater.			Rozenberg, P (corresponding author), CTR HOSP INTERCOMMUNAL,DEPT OBSTET & GYNAECOL,LEON TOUHLADJIAN,F-78303 POISSY,FRANCE.			GOFFINET, Francois/0000-0001-9643-0299				ACTON CM, 1978, AUSTRALAS RADIOL, V22, P254, DOI 10.1111/j.1440-1673.1978.tb02068.x; ARAKI T, 1982, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V34, P738; AVRECH OM, 1994, ULTRASOUND OBST GYN, V4, P151, DOI 10.1046/j.1469-0705.1994.04020151.x; BEDI DG, 1986, J CLIN ULTRASOUND, V14, P529, DOI 10.1002/jcu.1870140706; BROWN JE, 1986, AM J OBSTET GYNECOL, V155, P4; CHAPMAN K, 1994, BRIT J OBSTET GYNAEC, V101, P549, DOI 10.1111/j.1471-0528.1994.tb13163.x; CHAZOTTE C, 1990, AM J OBSTET GYNECOL, V163, P738, DOI 10.1016/0002-9378(90)91059-L; COWAN RK, 1994, OBSTET GYNECOL, V83, P933, DOI 10.1097/00006250-199406000-00006; FLAMM BL, 1988, AM J OBSTET GYNECOL, V158, P1079, DOI 10.1016/0002-9378(88)90224-4; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; GALE JT, 1986, J ULTRAS MED, V5, P713; KRISHNAMURTHY S, 1991, BRIT J OBSTET GYNAEC, V98, P716, DOI 10.1111/j.1471-0528.1991.tb13462.x; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; LEUNG AS, 1993, AM J OBSTET GYNECOL, V169, P945, DOI 10.1016/0002-9378(93)90032-E; MEEHAN FP, 1990, INT J GYNECOL OBSTET, V31, P249, DOI 10.1016/0020-7292(90)91019-M; MICHAELS WH, 1988, OBSTET GYNECOL, V71, P112; NIELSEN TF, 1989, AM J OBSTET GYNECOL, V160, P569, DOI 10.1016/S0002-9378(89)80029-8; OSMERS R, 1988, INT J GYNECOL OBSTET, V26, P279, DOI 10.1016/0020-7292(88)90274-3; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; THUBISI M, 1993, BRIT J OBSTET GYNAEC, V100, P421, DOI 10.1111/j.1471-0528.1993.tb15265.x; 1981, NIH8220967 PUBL	21	175	194	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					281	284		10.1016/S0140-6736(96)90464-X	http://dx.doi.org/10.1016/S0140-6736(96)90464-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569360				2022-12-01	WOS:A1996TT48500007
J	Sawle, G				Sawle, G			Visual vertigo	LANCET			English	Editorial Material											Sawle, G (corresponding author), QUEENS MED CTR,DIV CLIN NEUROL,NOTTINGHAM,ENGLAND.							BRONSTEIN AM, 1995, J NEUROL NEUROSUR PS, V59, P472, DOI 10.1136/jnnp.59.5.472; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P510; RUDGE P, 1995, J NEUROL NEUROSUR PS, V59, P568, DOI 10.1136/jnnp.59.6.568	3	2	2	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					986	987		10.1016/S0140-6736(96)90140-3	http://dx.doi.org/10.1016/S0140-6736(96)90140-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606609				2022-12-01	WOS:A1996UF38000005
J	McGovern, PG; Pankow, JS; Shahar, E; Doliszny, KM; Folsom, AR; Blackburn, H; Luepker, RV				McGovern, PG; Pankow, JS; Shahar, E; Doliszny, KM; Folsom, AR; Blackburn, H; Luepker, RV			Recent trends in acute coronary heart disease - Mortality, morbidity, medical care, and risk factors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; SURVIVAL; RATES; CHOLESTEROL; DECLINE; DEATH	Background. Mortality from coronary heart disease (CHD) has declined in the United States since the late 1960s. To understand the reasons for the decline during the period from 1985 to 1990, we examined trends in mortality and morbidity due to CHD, medical care, and risk factors for CHD in a large metropolitan population, Methods. We identified all deaths from CHD in residents of the Minneapolis-St. Paul, Minnesota, metropolitan area who were 30 to 74 years old and classified the deaths according to whether they occurred in or out of the hospital, For 1985 and 1990, we obtained lists of patients in this age range who were discharged with a diagnosis of acute CHD from all area hospitals, and we selected the medical records of 50 percent of these patients for abstraction. Definite myocardial infarctions were identified with a standardized diagnostic algorithm, The 1985 and 1990 cohorts of patients hospitalized for myocardial infarction were followed for at least three years to identify those who died from any cause. Trends in risk factors for CHD were investigated through surveys of 25-to-74-year-olds that were conducted in 1985 through 1987 and 1990 through 1992. Results. Between 1985 and 1990, mortality from CHD fell by 25 percent for both men and women, and the decline in in-hospital mortality (41 percent) exceeded the decline in out-of-hospital mortality (17 percent) among men, The rates of hospitalization for acute myocardial infarction declined slightly, by 5 to 10 percent, between 1985 and 1990. Survival among patients hospitalized for acute myocardial infarction increased substantially during that period. After adjustment for age and previous myocardial infarction, the relative risk of dying within three years of hospitalization for a myocardial infarction (for the 1990 cohort as compared with the 1985 cohort) was 0.76 for men (95 percent confidence interval, 0.65 to 0.89) and 0.84 for women (95 percent confidence interval, 0.71 to 1.00). Substantial increases in the use of thrombolytic therapy, heparin, aspirin, and coronary angioplasty paralleled the survival trends, In general, the risk-factor profile of the area population with respect to CHD also improved considerably during that time, Conclusions. The recent decline in mortality due to CHD in the Minneapolis-St. Paul metropolitan area can be explained by both the declining incidence of myocardial infarction in the population and the improved survival of patients with myocardial infarction.			McGovern, PG (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Pankow, James/0000-0001-7076-483X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727, T32HL007036] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07036, R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; BURKE GL, 1989, INT J EPIDEMIOL, V18, pS73; BURNAND B, 1992, J CLIN EPIDEMIOL, V45, P929, DOI 10.1016/0895-4356(92)90109-Z; BUTTS WC, 1974, CLIN CHEM, V20, P1344; DELLBORG M, 1994, EUR HEART J, V15, P5, DOI 10.1093/oxfordjournals.eurheartj.a060379; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; EDLAVITCH SA, 1990, J CLIN EPIDEMIOL, V43, P93, DOI 10.1016/0895-4356(90)90061-S; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; *NAT CTR HLTH STAT, 1990, VITAL HLTH STATISTIC, V13; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; PANKOW JS, 1994, J CLIN EPIDEMIOL, V47, P1051, DOI 10.1016/0895-4356(94)90121-X; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; RAPAPORT E, 1988, TRENDS CORONARY HEAR, P221; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TARONE RE, 1981, J CHRON DIS, V34, P463, DOI 10.1016/0021-9681(81)90006-0; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; THOM TJ, 1988, TRENDS CORONARY HEAR, P7; WEISFELDT ML, 1988, TRENDS CORONARY HEAR, P171; World Health Organization, 1980, INT CLASSIFICATION D; 1990, MON VITAL STAT REP S, V41	34	568	587	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1996	334	14					884	890		10.1056/NEJM199604043341403	http://dx.doi.org/10.1056/NEJM199604043341403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD374	8596571				2022-12-01	WOS:A1996UD37400003
J	Spitz, AM; Velebil, P; Koonin, LM; Strauss, LT; Goodman, KA; Wingo, P; Wilson, JB; Morris, L; Marks, JS				Spitz, AM; Velebil, P; Koonin, LM; Strauss, LT; Goodman, KA; Wingo, P; Wilson, JB; Morris, L; Marks, JS			Pregnancy, abortion, and birth rates among US adolescents - 1980, 1985, and 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To analyze pregnancy, abortion, and birth rates among US adolescent girls in 1980, 1985, and 1990. Design.-Retrospective analysis of trends in data on pregnancies, abortions, and births. Population.-US adolescent girls aged 13 to 19 years. Main Outcome Measures.-Pregnancy, abortion, and birth rates (with and without adjustment for sexual experience) among teenaged girls aged 15 to 19 years and girls under 15 years. Results.-Although pregnancy rates among all teenaged girls 15 to 19 years old remained fairly stable from 1980 to 1985, they increased by 9% during the last half of the decade, totaling 95.9 pregnancies per 1000 teenaged girls 15 to 19 years old by 1990. Because rates of sexual experience increased even faster, pregnancy rates among sexually experienced teens aged 15 to 19 actually declined between 1980 and 1990 by approximately 8%. Abortion rates among these teens remained stable during the 1980s, with 35.8 and 36.0 abortions per 1000 in 1980 and 1990, respectively. As with overall pregnancy rates, abortion rates among these sexually experienced teenaged girls declined during the 1980s. Between 1980 and 1985, birth rates among teenaged girls aged 15 to 19 years declined by 4%, but they increased by 18% during the latter half of the decade, totaling 59.9 births per 1000 in 1980. Among these sexually experienced teenagers, birth rates also declined between 1980 and 1985 and then increased over the next 5 years. In 1990, pregnancies and abortions among girls younger than 15 years accounted for only 3% of all adolescent pregnancies and abortions. However, the number of births among these younger adolescents increased by 15% over the decade. In that age group, trends in pregnancy, abortion, and birth rates over the decade were similar to those for older teens, However, during the late 1980s, the abortion rate declined and the pregnancy rate remained stable, resulting in a 26% increase in the birth rate. Conclusions.-Despite efforts to reduce adolescent pregnancy in the United States, pregnancy and birth rates for that group continue to be the highest among developed countries. Considering that 95% of adolescent pregnancies are unintended, increased efforts to prevent these pregnancies are warranted.	NATL CTR HLTH STAT, DIV VITAL STAT, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Spitz, AM (corresponding author), CTR DIS CONTROL & PREVENT, DIV REPROD HLTH, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA 30341 USA.							*A GUTTM I, 1994, SEX AM TEEN; ATRASH HK, 1990, CONT OB GYN, V35, P58; Brown S., 1995, BEST INTENTIONS; Burt M R, 1990, Adv Adolesc Mental Health, V4, P265; *CDC, 1983, AB SURV 1979 1980; DICLEMENTE RJ, 1992, PEDIATRICS, V89, P197; FRASER AM, 1995, NEW ENGL J MED, V332, P1113, DOI 10.1056/NEJM199504273321701; FROST JJ, 1995, FAM PLANN PERSPECT, V27, P188, DOI 10.2307/2136274; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; HENSHAW SK, 1992, US TEENAGE PREGNANCY; HENSHAW SK, 1988, INS OUTSJ HLTH POPUL, P46; Hofferth S. L., 1987, RISKING FUTURE ADOLE, V2, P123; HOLLMAN FW, 1993, CURRENT POPULATION R; JAY MS, 1988, ADOLESCENT PEDIAT G, V1, P83, DOI 10.1016/S0932-8610(88)80029-X; Jones E.M., 1986, TEENAGE PREGNANCY IN; KOCHANEK KD, 1991, MONTHLY VITAL STAT S, V39, P1; Koonin L M, 1993, MMWR CDC Surveill Summ, V42, P29; Lawson H W, 1989, MMWR CDC Surveill Summ, V38, P11; MACIAK BJ, 1987, JAMA-J AM MED ASSOC, V258, P2069; MCANARNEY ER, 1989, JAMA-J AM MED ASSOC, V262, P74, DOI 10.1001/jama.262.1.74; MOORE KA, 1995, ADOLESCENT PREGNANCY; MOSHER WD, 1991, FAM PLANN PERSPECT, V23, P108, DOI 10.2307/2135822; ORR DP, 1988, J ADOLESCENT HEALTH, V9, P273, DOI 10.1016/0197-0070(88)90249-5; Peterson L., 1995, ADV DATA VITAL HLTH; PICCININO LJ, IN PRESS ADV DATA VI; PITTMAN K, 1988, TEENAGE PREGNANCY AD; *PUBL HLTH SERV, 1986, 1990 HLTH OBJ NAT MI; Spitz A M, 1993, MMWR CDC Surveill Summ, V42, P1; SPITZ AM, 1987, MMWR-MORBID MORTAL W, V36, P1; *US DEP HHS, 1991, US DHHS PUBL; VENTURA SJ, 1992, MONTHLY VITAL STAT S, V41, P1; ZUCKERMAN BS, 1994, J PEDIATR, V105, P857; 1995, MMWR-MORBID MORTAL W, V44, P131; 1992, TEENAGE PREGNANCY TO; 1993, MONTHLY VITAL STAT S, V42, P1; 1990, MONTHLY VITAL STAT S, V41, P1	36	47	49	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					989	994		10.1001/jama.275.13.989	http://dx.doi.org/10.1001/jama.275.13.989			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596256				2022-12-01	WOS:A1996UC12300025
J	Goonasekera, CDA; Shah, V; Wade, AM; Barratt, TM; Dillon, MJ				Goonasekera, CDA; Shah, V; Wade, AM; Barratt, TM; Dillon, MJ			15-year follow-up of renin and blood pressure in reflux nephropathy	LANCET			English	Article							VESICOURETERIC REFLUX; CHILDREN; PLASMA; HYPERTENSION	Background Beginning in 1978 a cohort of patients with reflux nephropathy first seen at a London Children's hospital have had 5-yearly follow-ups. This is the fourth (15-year) report from that series. Methods Of the original 100 normotensive children with reflux nephropathy 78 were traced for the 15-year study in 1994. Five patients were excluded because of nephrectomy, ten for other reasons, and eight refused to take part, leaving 55. 26 were on oral contraceptives. Supine blood pressure and plasma renin activity (PRA) were measured, and daily sodium excretion was assessed on a sample of overnight urine. Findings Of the 55 patients (15 male, 40 female, median age 27 years, range 20-31), five had systolic and two had diastolic hypertension. Compared with the 10-year (1988) follow-up there was no change in blood pressure standard deviation scores (SDS) in this cohort. PRA showed an increasing dissociation from controls after 15 years of age and was significantly above that of controls by age 25. Exclusion of the patients on oral contraceptives did not significantly alter the results. The PRA values in 1988 were not individually predictive of the development of hypertension over the ensuing 5 years. Interpretation Previously, in the long-term study of reflux nephropathy, blood pressure SDS had progressively increased with age. By 15 years blood pressure had levelled out and the PRA, though raised, did not predict the development of hypertension. Oral contraceptive use did not significantly modify the results.	INST CHILD HLTH, DIV CLIN SCI, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DIV BIOCHEM & GENET, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DIV EPIDEMIOL, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, BIOSTAT UNIT, LONDON WC1N 1EH, ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST, RENAL UNIT, LONDON, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Goonasekera, Chulananda/G-9327-2016	Goonasekera, Chulananda/0000-0002-9754-6477				[Anonymous], 1987, PEDIATRICS, V79, P1; BAILEY RR, 1984, CONTRIBUTIONS NEPRHO, P146; BRAREN V, 1988, UROLOGY, V32, P228, DOI 10.1016/0090-4295(88)90390-1; DERKX FHM, 1986, J CLIN ENDOCR METAB, V63, P1008, DOI 10.1210/jcem-63-4-1008; DILLON MJ, 1975, J CLIN PATHOL, V28, P625, DOI 10.1136/jcp.28.8.625; DILLON MJ, 1987, PEDIATR NEPHROL, V1, P59, DOI 10.1007/BF00866886; DILLON MJ, 1984, CONTRIBUTIONS NEPHRO, P68; GILL DG, 1976, ARCH DIS CHILD, V51, P951, DOI 10.1136/adc.51.12.951; Graystone JE, 1968, HUMAN GROWTH, P182; GUSMANO R, 1988, CONTRIB NEPHROL, V61, P201; JARDIM H, 1991, ARCH DIS CHILD, V66, P1213, DOI 10.1136/adc.66.10.1213; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; SAVAGE JM, 1987, ARCH DIS CHILD, V62, P678, DOI 10.1136/adc.62.7.678; SAVAGE JM, 1978, LANCET, V2, P441; SMELLIE JM, 1989, URINARY TRACT INFECT, P39; SMELLIE JM, 1979, REFLUX NEPHROPATHY, P14; STILL JL, 1967, ARCH DIS CHILD, V42, P34, DOI 10.1136/adc.42.221.34; The WHO multicentre trial of the vasopressor effects of combined oral contraceptives, 1989, CONTRACEPTION, V40, P129; WALLACE DMA, 1978, BRIT J UROL, V50, P479, DOI 10.1111/j.1464-410X.1978.tb06195.x; WOLFISH NM, 1993, J PEDIATR-US, V123, P559, DOI 10.1016/S0022-3476(05)80950-3	20	50	51	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					640	643		10.1016/S0140-6736(96)91201-5	http://dx.doi.org/10.1016/S0140-6736(96)91201-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596377				2022-12-01	WOS:A1996TZ28500009
J	Multhaup, G; Schlicksupp, A; Hesse, L; Beher, D; Ruppert, T; Masters, CL; Beyreuther, K				Multhaup, G; Schlicksupp, A; Hesse, L; Beher, D; Ruppert, T; Masters, CL; Beyreuther, K			The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)	SCIENCE			English	Article							CEREBROSPINAL-FLUID; WILSON DISEASE; MENKES DISEASE; CANDIDATE GENE; CEREBRAL-HEMORRHAGE; TRANSPORTING ATPASE; SENILE PLAQUES; GROWTH-FACTOR; BETA-PROTEIN; MUTATION	The transition metal ion copper(II) has a critical role in chronic neurologic diseases. The amyloid precursor protein (APP) of Alzheimer's disease or a synthetic peptide representing its copper-binding site reduced bound copper(II) to copper(I). This copper ion-mediated redox reaction led to disulfide bond formation in APP, which indicated that free sulfhydryl groups of APP were involved. Neither superoxide nor hydrogen peroxide had an effect on the kinetics of copper(II) reduction. The reduction of copper(II) to copper(I) by APP involves an electron-transfer reaction and could enhance the production of hydroxyl radicals, which could then attack nearby sires. Thus, copper-mediated toxicity may contribute to neurodegeneration in Alzheimer's disease.	UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; MENTAL HLTH RES INST VICTORIA,NEUROPATHOL LAB,PARKVILLE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; University of Melbourne	Multhaup, G (corresponding author), UNIV HEIDELBERG,ZMBH CTR MOLEC BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.		Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266; Beher, Dirk/0000-0001-8005-5359				BASUN H, 1991, J NEURAL TRANSM, V4, P231; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORK LC, 1990, AM J PATHOL, V137, P1383; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FITZGERALD DJ, 1995, SCIENCE, V268, P1920, DOI 10.1126/science.7604269; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARTMANN HA, 1992, MED HYPOTHESES, V38, P75, DOI 10.1016/0306-9877(92)90162-6; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JOSELOW M, 1951, J BIOL CHEM, V191, P11; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LU HS, 1992, J BIOL CHEM, V267, P8770; LYNCH SM, 1993, J LIPID RES, V34, P1745; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; NULTHAUP G, 1994, FEBS LETT, V355, P151; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PICKART L, 1987, METHOD ENZYMOL, V147, P314; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; ROCH JM, 1992, J BIOL CHEM, V267, P2214; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMONS M, 1995, J NEUROSCI RES, V41, P121, DOI 10.1002/jnr.490410114; SMALL DH, 1994, J NEUROSCI, V14, P2117; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WANG D, 1995, J NEUROPATH EXP NEUR, V54, P548, DOI 10.1097/00005072-199507000-00009; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431	57	609	619	0	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1406	1409		10.1126/science.271.5254.1406	http://dx.doi.org/10.1126/science.271.5254.1406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596911				2022-12-01	WOS:A1996TY96100043
J	Reichhardt, T				Reichhardt, T			Regulators face questioning on particulate rules	NATURE			English	Editorial Material																			0	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					11	12						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598893				2022-12-01	WOS:A1996TY87700017
J	vonBartheld, CS; Byers, MR; Williams, R; Bothwell, M				vonBartheld, CS; Byers, MR; Williams, R; Bothwell, M			Anterograde transport of neurotrophins and axodendritic transfer in the developing visual system	NATURE			English	Article							NERVE GROWTH-FACTOR; RETROGRADE TRANSPORT; AXONAL-TRANSPORT; RECEPTORS; BRAIN; INTERNALIZATION; EXPRESSION; SYNAPSES; NEURONS; DEATH	Neurotrophic factors support the differentiation and survival of neurons(1,2) and influence properties of synaptic transmission(3,4). The neurotrophic hypothesis postulates a retrograde action of trophic factors: their production and release by target cells and their uptake by innervating axons(5). Besides the retrograde route of trophic messengers, the survival of neurons and the development of synapses is thought to be also regulated by anterograde, afferent trophic signals(6-10). We now show that exogenous neurotrophins are transported in the anterograde direction, from cell bodies to the axon terminals, and that the intact neurotrophin is released after anterograde transport, taken up and utilized by second-order visual neurons in the developing chick brain. These results suggest that anterogradely transported neurotrophins may play a role in synaptic plasticity and may have effects at more than one synapse beyond the initial release site.	UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195; KAROLINSKA INST,DEPT DEV BIOL,S-17177 STOCKHOLM,SWEDEN	University of Washington; University of Washington Seattle; Karolinska Institutet	vonBartheld, CS (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							[Anonymous], [No title captured]; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BYERS MR, 1974, BRAIN RES, V75, P97, DOI 10.1016/0006-8993(74)90773-2; CATSICAS M, 1992, J NEUROSCI, V12, P4642; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; CLAUDE P, 1982, J NEUROSCI, V2, P431; Cowan W. M., 1970, CONT RES METHODS NEU, P217, DOI 10.1007/978-3-642-85986-1_11; EMFORS P, 1990, NEURON, V5, P511; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; HAMMERSCHLAG R, 1982, TRENDS NEUROSCI, V5, P12, DOI 10.1016/0166-2236(82)90009-1; HERZOG KH, 1994, DEVELOPMENT, V120, P1643; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; NIETOBONA MP, 1993, J NEUROSCI RES, V36, P520, DOI 10.1002/jnr.490360504; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; RICHARDSON PM, 1986, J NEUROSCI, V6, P2312; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SMITH RS, 1994, J NEUROCHEM, V62, P1698; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; VONBARTHELD CS, 1991, J COMP NEUROL, V310, P103, DOI 10.1002/cne.903100110; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; WAYNE DB, 1990, DEV BIOL, V138, P484, DOI 10.1016/0012-1606(90)90214-4; WILLIAMS R, 1995, EUR J NEUROSCI, V7, P116, DOI 10.1111/j.1460-9568.1995.tb01026.x; ZHOU XF, IN PRESS NEUROSCIENC	31	255	255	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					830	833		10.1038/379830a0	http://dx.doi.org/10.1038/379830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587607				2022-12-01	WOS:A1996TX50100060
J	Irvine, S; Cawood, E; Richardson, D; MacDonald, E; Aitken, J				Irvine, S; Cawood, E; Richardson, D; MacDonald, E; Aitken, J			Evidence of deteriorating semen quality in the United Kingdom: Birth cohort study in 577 men in Scotland over 11 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALE-FERTILITY; CHANGING PARAMETERS; TESTICULAR CANCER; SPERM COUNTS; EPIDEMIOLOGY; INFERTILITY; TERMS	Objective-To determine whether the quality of semen has changed in a group of over 500 Scottish men born between 1951 and 1973. Design-Retrospective review of data on semen quality collected in a single laboratory over 11 years and according to World Health Organisation guidelines. Setting-Programme of gamete biology research funded by Medical Research Council. Subjects-577 volunteer semen donors. Of these, 171 were born before 1959, 120 were born in 1960-4, 171 in 1965-9, and 115 in 1970-4. Main outcome measures-Conventional criteria of semen quality including semen volume (ml), sperm concentration (10(6)/ml), overall motility (% motile), total number of sperm in the ejaculate (10(6)), and total number of motile sperm in the ejaculate (10(6)). Results-When the four birth cohort groups were compared a later year of birth was associated with a lower sperm concentration, a lower total number of sperm in the ejaculate, and a lower number of motile sperm in the ejaculate. The median sperm concentration fell from 98 x 10(6)/ml among donors born before 1959 to 78 x 10(6)/ml among donors born after 1970 (P = 0.002). The total number of sperm in the ejaculate fell from 301 x 10(6) to 214 x 10(6) (P = 0.0005), and the total number of motile sperm in the ejaculate fell from 169.7 x 10(6) to 129.0 x 10(6) (P = 0.0065). Conclusion-This study provides direct evidence that semen quality is deteriorating, with a later year of birth being significantly associated with a reduced number of sperm in adult life.	UNIV EDINBURGH, CTR REPROD BIOL, REPROD MED LABS, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Irvine, S (corresponding author), MRC, CTR REPROD BIOL, REPROD BIOL UNIT, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND.			Aitken, Robert John/0000-0002-9152-156X				AITKEN RJ, 1982, FERTIL STERIL, V38, P68; AITKEN RJ, 1991, AM J OBSTET GYNECOL, V164, P542, DOI 10.1016/S0002-9378(11)80017-7; [Anonymous], 1987, WHO LAB MANUAL EXAMI; [Anonymous], 1992, WHO LAB MANUAL EXAMI; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Barratt C. L. R., 1993, Human Reproduction (Oxford), V8, P1521; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BOYLE P, 1985, LANCET, V1, P1311; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; IRVINE DS, 1995, HUM REPROD, V10, P2752, DOI 10.1093/oxfordjournals.humrep.a135786; IRVINE DS, 1994, ENDOCRIN METAB CLIN, V23, P725, DOI 10.1016/S0889-8529(18)30064-1; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; JOHNSON L, 1986, J ANDROL, V7, P331; LETO S, 1981, FERTIL STERIL, V36, P766; MACLEOD J, 1979, FERTIL STERIL, V31, P103; MACLEOD J, 1951, J UROLOGY, V66, P436, DOI 10.1016/S0022-5347(17)74358-3; MENKVELD R, 1986, ARCH ANDROLOGY, V17, P143, DOI 10.3109/01485018608990186; MORTIMER D, 1982, ARCH ANDROLOGY, V8, P251, DOI 10.3109/01485018208990205; NELSON CMK, 1974, FERTIL STERIL, V25, P503; OSSER S, 1984, ARCH ANDROLOGY, V12, P113, DOI 10.3109/01485018409161159; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHARPE RM, 1995, ENV HLTH PERSPECT, V103, P2; SHERINS RJ, 1995, NEW ENGL J MED, V332, P327, DOI 10.1056/NEJM199502023320510; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; 1980, LAB MANUAL EXAMINATI; 1995, IEH ASSESSMENT ENV O; 1995, MALE REPROD HLTH ENV	32	336	352	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 24	1996	312	7029					467	471		10.1136/bmj.312.7029.467	http://dx.doi.org/10.1136/bmj.312.7029.467			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597676	Green Published			2022-12-01	WOS:A1996TX38300020
J	Todorov, P; Cariuk, P; McDevitt, T; Coles, B; Fearon, K; Tisdale, M				Todorov, P; Cariuk, P; McDevitt, T; Coles, B; Fearon, K; Tisdale, M			Characterization of a cancer cachectic factor	NATURE			English	Article							LEUKEMIA-INHIBITORY FACTOR; TUMOR NECROSIS FACTOR; CACHEXIA; MICE; MECHANISM; MUSCLE; CELLS; MODEL	CANCER cachexia is a syndrome of progressive wasting which has been suggested to be mediated by tumour-necrosis factor-alpha (ref. 1), interleukins 1 and 6 (ref. 2), interferon-gamma (ref. 3) and leukaemia-inhibitory factor(4). It has proved difficult to correlate levels of tumour-necrosis factor-alpha and interleukin-6 with cancer cachexia(5,6), and the weight loss induced by leukaemia-inhibitory factor may be due to toxicity(7). In the murine adenocarcinoma MAC16, cachexia is mediated by circulatory catabolic factors(8,9), which we have now isolated using an antibody cloned from splenocytes of mice transplanted with the MAC16 tumour, with a delayed cachexia(10). The material is a proteoglycan of relative molecular mass 24K which produces cachexia in vivo by inducing catabolism of skeletal muscle. The 24K material was also present in urine of cachectic cancer patients, but was absent from normal subjects, patients with weight loss due to trauma, and cancer patients with little or no weight loss. This suggests that cachexia in mice and humans may be produced by the same material.	UNIV ASTON,INST PHARMACEUT SCI,CRC,NUTR BIOCHEM RES GRP,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT BIOCHEM,CRC,MOLEC TOXICOL GRP,LONDON W1P 6D8,ENGLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Aston University; University of Birmingham; University of London; University College London; Royal Infirmary of Edinburgh; University of Edinburgh								BECK SA, 1987, CANCER RES, V47, P5919; BECK SA, 1991, CANCER RES, V51, P6089; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BIBBY MC, 1987, J NATL CANCER I, V78, P539; GARCIAMARTINEZ C, 1994, CANCER LETT, V76, P1, DOI 10.1016/0304-3835(94)90126-0; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; MCDEVITT TM, 1992, BRIT J CANCER, V66, P815, DOI 10.1038/bjc.1992.366; MCDEVITT TM, 1995, J CANCER RES, V55, P1458; METCALF D, 1990, BLOOD, V76, P50; MORI M, 1991, CANCER RES, V51, P6656; PLUMB JA, 1991, CLIN NUTR, V10, P23, DOI 10.1016/0261-5614(91)90077-P; SMITH KL, 1993, BRIT J CANCER, V68, P314, DOI 10.1038/bjc.1993.334; SOCHER SH, 1988, J NATL CANCER I, V80, P595, DOI 10.1093/jnci/80.8.595; SODA K, 1994, JPN J CANCER RES, V85, P1124, DOI 10.1111/j.1349-7006.1994.tb02917.x; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; YOSHIZAWA N, 1992, J IMMUNOL, V148, P3110	17	340	361	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					739	742		10.1038/379739a0	http://dx.doi.org/10.1038/379739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602222				2022-12-01	WOS:A1996TW56700056
J	Smith, S; Robinson, J; Hollyer, J; Bhatt, R; Ash, S; Shaunak, S				Smith, S; Robinson, J; Hollyer, J; Bhatt, R; Ash, S; Shaunak, S			Combining specialist and primary health care teams for HIV positive patients: Retrospective and prospective studies	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; FUNDING POLICIES; HOSPITAL DOCTORS; AIDS; COMMUNICATION; INFECTION	Objective-To develop and evaluate a model of health care for HIV positive patients involving specialist, hospital based teams and primary health care teams. Design-One year retrospective and 2 1/2 year prospective study. Setting-Two hospitals in west London and 88 general practitioners in 72 general practices. Subjects-209 adults with HIV infection. Intervention-General practitioners enrolled in the project were fared structured outpatient clinic summaries. When hospital inpatients were discharged, a brief discharge summary was fared. General practitioners had access to consultant physicians skilled in HIV medicine through a 24 hour mobile telephone service. An HIV/AIDS management and treatment guide containing relevant local information was produced. Quarterly discussion forums for general practitioners were held, and a regular newsletter was produced. Main outcome measures-Hospital attendance and general practitioner consultations; perceived benefits and problems of patients and general practitioners. Results-The average length of a hospital inpatient stay was halved for those patients who had participated in the project for two years, and the average number of visits to the outpatient clinic per month fell for patients with AIDS. There was a substantial increase in the number of visits to general practitioners by patients with AIDS and symptomatic HIV infection. Patients and general practitioners both felt that the standard of health care provided had improved. Conclusions-This model of health care efficiently and effectively utilised existing teams of hospital and primary health care professionals to provide care for HIV positive patients. Simple, prompt, and regular communication systems which provided information relevant to the needs of general practitioners were central to its success.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,MED STAT UNIT,LONDON W12 0NN,ENGLAND; GROVE MED PRACTICE,NORTHOLT,MIDDX,ENGLAND; EALING GEN HOSP,CAMERON CTR,LONDON,ENGLAND	Imperial College London; Imperial College London; Imperial College London								Butters E, 1991, Health Trends, V23, P59; COULTER A, 1995, BRIT MED J, V311, P1447, DOI 10.1136/bmj.311.7018.1447; COYLE A, 1995, BRIT MED J, V310, P1636, DOI 10.1136/bmj.310.6995.1636; GRUN L, 1994, BRIT MED J, V308, P538; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; HICKMAN M, 1994, J PUBLIC HEALTH MED, V16, P447, DOI 10.1093/oxfordjournals.pubmed.a043026; HOCHULI V, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-b; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247; Main J, 1993, Qual Health Care, V2, P53, DOI 10.1136/qshc.2.1.53; MANSFIELD S, 1993, LANCET, V342, P726; MCCARTHY M, 1993, BRIT MED J, V307, P367, DOI 10.1136/bmj.307.6900.367; MORLEY V, 1993, BMJ-BRIT MED J, V306, P112, DOI 10.1136/bmj.306.6870.112; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; RAWAL J, 1993, BRIT MED J, V307, P1044, DOI 10.1136/bmj.307.6911.1044; REGNARD C, 1994, BRIT MED J, V308, P655, DOI 10.1136/bmj.308.6929.655d; SCHRODER F, 1995, BRIT MED J, V310, P142; SINGH S, 1994, BRIT MED J, V308, P539; SMITH S, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-c; SMITS A, 1990, BRIT MED J, V300, P241, DOI 10.1136/bmj.300.6719.241; VANDAMME R, 1994, BRIT J GEN PRACT, V44, P9; WADSWORTH E, 1992, BRIT J GEN PRACT, V42, P107; WILLIAMS H, 1993, BRIT MED J, V307, P802, DOI 10.1136/bmj.307.6907.802; 1994, BRIT MED J, V308, P559; 1994, BRIT MED J, V308, P1208	25	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					416	420						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601114	Green Published			2022-12-01	WOS:A1996TW56400024
J	Chopra, I; Hodgson, J; Metcalf, B; Poste, G				Chopra, I; Hodgson, J; Metcalf, B; Poste, G			New approaches to the control of infections caused by antibiotic-resistant bacteria - An industry perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,EPSOM KT18 5X0,SURREY,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,UPPER MERION,PA	GlaxoSmithKline; GlaxoSmithKline								ALLEN NE, 1985, ANNU REP MED CHEM, V20, P155; CASADEVALL A, 1994, ANTIMICROB AGENTS CH, V38, P1695, DOI 10.1128/AAC.38.8.1695; DALE DC, 1994, CLIN INFECT DIS   S2, V18, P180; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DeMarsh PL, 1996, J INFECT DIS, V173, P203, DOI 10.1093/infdis/173.1.203; DOUGAN G, 1994, MICROBIOL-SGM, V140, P215, DOI 10.1099/13500872-140-2-215; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Garrett Laurie, 1994, COMING PLAGUE NEWLY; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; JACOB L, 1994, CIBA F SYMP, V186, P197; LAMBERT HP, 1984, BRIT MED BULL, V40, P102, DOI 10.1093/oxfordjournals.bmb.a071938; Levy SB, 1992, ANTIBIOTIC PARADOX M; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEUHAUS FC, 1992, EMERGING TARGETS ANT, P205; Podzorski Raymond P., 1993, Clinical Microbiology Newsletter, V15, P137, DOI 10.1016/0196-4399(93)90042-L; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Russell A.D., 1990, UNDERSTANDING ANTIBA; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377; SPARLING PF, 1994, P NATL ACAD SCI USA, V91, P2456, DOI 10.1073/pnas.91.7.2456; STAGER CE, 1992, CLIN MICROBIOL REV, V5, P302, DOI 10.1128/CMR.5.3.302-327.1992; SUTCLIFFE JA, 1988, ANNU REP MED CHEM, V23, P141; TALLY FT, 1995, J ANTIMICROB CHEMOTH, V35, P449, DOI 10.1093/jac/35.4.449; UTT EA, 1995, CAN J MICROBIOL, V41, P152, DOI 10.1139/m95-020	25	53	53	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					401	403		10.1001/jama.275.5.401	http://dx.doi.org/10.1001/jama.275.5.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569021				2022-12-01	WOS:A1996TT30300035
J	Bonn, D				Bonn, D			What prospects for hormonal contraceptives for men?	LANCET			English	News Item																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					316	316		10.1016/S0140-6736(96)90482-1	http://dx.doi.org/10.1016/S0140-6736(96)90482-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569371				2022-12-01	WOS:A1996TT48500023
J	Buckwalter, JA				Buckwalter, JA			Joint distraction for osteoarthritis	LANCET			English	Editorial Material											Buckwalter, JA (corresponding author), UNIV IOWA HOSP & CLIN,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242, USA.							ABDO RV, 1992, FOOT ANKLE, V13, P307, DOI 10.1177/107110079201300602; BUCKWALTER JA, 1994, J BONE JOINT SURG AM, V76A, P1405, DOI 10.2106/00004623-199409000-00019; KITAOKA HB, 1994, J BONE JOINT SURG AM, V76A, P974, DOI 10.2106/00004623-199407000-00003; OGILVIEHARRIS DJ, 1993, J BONE JOINT SURG AM, V75A, P1167, DOI 10.2106/00004623-199308000-00006; TAKAKURA Y, 1995, J BONE JOINT SURG BR, V77B, P50, DOI 10.1302/0301-620X.77B1.7822395; VANVALBURG AA, 1995, J BONE JOINT SURG BR, V77, P720, DOI 10.1302/0301-620X.77B5.7559696	6	20	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					279	280		10.1016/S0140-6736(96)90463-8	http://dx.doi.org/10.1016/S0140-6736(96)90463-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569359				2022-12-01	WOS:A1996TT48500006
J	Sheng, ZH; Rettig, J; Cook, T; Catterall, WA				Sheng, ZH; Rettig, J; Cook, T; Catterall, WA			Calcium-dependent interaction of N-type calcium channels with the synaptic core complex	NATURE			English	Article							TRANSMITTER RELEASE; MEMBRANE-PROTEIN; ACTIVE ZONES; SYNAPTOTAGMIN; SYNTAXIN; VESICLES; DOCKING	NEUROTRANSMITTER release is initiated by influx of Ca2+ through voltage-gated Ca2+ channels(1,2), within 200 mu s of the action potential arriving at the synaptic terminal(3), as the Ca2+ concentration increases from 100 nM to >200 mu M(4). Exocytosis requires high Ca2+ concentration, with a threshold of 20-50 mu M and half-maximal activation at 190 mu M(5,6). The synaptic membrane syntaxin(7,8), 25K synaptosome-associated protein (SNAP25)9, and vesicle-associated membrane protein (VAMP)/synaptobrevin(10-12), are thought to form a synaptic core complex which mediates vesicle docking and membrane fusion(13-19) Synaptotagmin may be the low-affinity Ca2+-sensor(20-24), but other Ca2+-sensors are involved(25-27) as residual neurotransmission persists in synaptotagmin-null mutants. Syntaxin binds to N-type Ca2+ channels(7,8,28,29) at a site in the intracellular loop connecting domains II and III30. Here we describe Ca2+ dependent interaction of this site with syntaxin and SNAP25 which has a biphasic dependence on Ca2+, with maximal binding at 20 mu M free Ca2+, near the threshold for transmitter release. Ca2+-dependent interaction of Ca2+ channels with the synaptic core complex may be important for Ca2+-dependent docking and fusion of synaptic vesicles.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Rettig, Jens/K-5103-2013	Rettig, Jens/0000-0001-6160-3954				BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6309; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHENG ZH, 1994, NEURON, V13, P1301; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	30	300	307	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					451	454		10.1038/379451a0	http://dx.doi.org/10.1038/379451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559250				2022-12-01	WOS:A1996TT30400060
J	Feldman, DE; Brainard, MS; Knudsen, EI				Feldman, DE; Brainard, MS; Knudsen, EI			Newly learned auditory responses mediated by NMDA receptors in the owl inferior colliculus	SCIENCE			English	Article							LONG-TERM POTENTIATION; OPTIC TECTUM; BARN OWL; VISUAL RESPONSES; SPACE; MAPS; NEURONS; CORTEX; ANTAGONIST; PLASTICITY	Alignment of auditory and visual receptive fields in the optic tectum of the barn owl (Tyto alba) is maintained through experience-dependent modification of auditory responses in the external nucleus of the inferior colliculus (ICX), which provides auditory input to the tectum. Newly learned tectal auditory responses, induced by altered visual experience, were found to be pharmacologically distinct from normal responses expressed at the same tectal sites. N-methyl-D-aspartate (NMDA) receptor antagonists administered systemically or applied locally in the ICX reduced learned responses more than normal responses. This differential blockade was not observed with non-NMDA or broad-spectrum antagonists. Thus, NMDA receptors preferentially mediate the expression of novel neuronal responses induced by experience during development.			Feldman, DE (corresponding author), STANFORD UNIV, SCH MED, DEPT NEUROBIOL, FAIRCHILD SCI BLDG, STANFORD, CA 94305 USA.			Brainard, Michael/0000-0002-9425-9907	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC00155-14] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BEAR MF, 1990, J NEUROSCI, V10, P909; BRAINARD MS, 1995, J NEUROPHYSIOL, V73, P595, DOI 10.1152/jn.1995.73.2.595; BRAINARD MS, 1993, J NEUROSCI, V13, P4589; BRAINARD MS, 1993, INT CONGR SER, V1036, P113; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAW NW, 1993, ANNU REV NEUROSCI, V16, P207, DOI 10.1146/annurev.ne.16.030193.001231; DUNIA R, 1989, HEARING RES, V37, P241, DOI 10.1016/0378-5955(89)90025-7; Feldman D. P., UNPUB; FELDMAN DE, 1994, J NEUROSCI, V14, P5939; FOX K, 1989, J NEUROSCI, V9, P2443; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GOZLAN H, 1994, J NEUROPHYSIOL, V72, P3017, DOI 10.1152/jn.1994.72.6.3017; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KNUDSEN EI, 1983, J COMP NEUROL, V218, P187, DOI 10.1002/cne.902180206; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; KNUDSEN EI, 1991, J NEUROSCI, V11, P1727; KNUDSEN EI, 1991, SCIENCE, V253, P85, DOI 10.1126/science.2063209; KOHR G, 1993, J NEUROSCI, V13, P3612; KWON YH, 1991, J NEUROPHYSIOL, V66, P414, DOI 10.1152/jn.1991.66.2.414; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOONEY R, 1992, J NEUROSCI, V12, P2464; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; NETER J, 1990, APPLIED LINEAR STATI; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; OLSEN JF, 1989, J NEUROSCI, V9, P2591; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SILLAR KT, 1991, BRAIN RES, V545, P24, DOI 10.1016/0006-8993(91)91265-3; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	36	72	72	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					525	528		10.1126/science.271.5248.525	http://dx.doi.org/10.1126/science.271.5248.525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560271				2022-12-01	WOS:A1996TR32200048
J	Visa, N; AlzhanovaEricsson, AT; Sun, X; Kiseleva, E; Bjorkroth, B; Wurtz, T; Daneholt, B				Visa, N; AlzhanovaEricsson, AT; Sun, X; Kiseleva, E; Bjorkroth, B; Wurtz, T; Daneholt, B			A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes	CELL			English	Article							PREMESSENGER RIBONUCLEOPROTEIN PARTICLE; ELECTRON-MICROSCOPE TOMOGRAPHY; SALIVARY-GLAND CELLS; CHIRONOMUS-TENTANS; DROSOPHILA-MELANOGASTER; HNRNP PROTEINS; HEAT-SHOCK; COMPLEXES; INVIVO; VISUALIZATION	In the larval salivary glands of C. tentans, it is possible to visualize by electron microscopy how Balbiani ring (BR) pre-mRNA associates with proteins to form pre-mRNP particles, how these particles move to and through the nuclear pore, and how the BR RNA is engaged in the formation of giant polysomes in the cytoplasm. Here, we study C. tentans hrp36, an abundant protein in the BR particles, and establish that it is similar to the mammalian hnRNP A1. By immunoelectron microscopy it is demonstrated that hrp36 is added to BR RNA concomitant with transcription, remains in nucleoplasmic BR particles, and is translocated through the nuclear pore still associated with BR RNA. It appears in the giant BR RNA-containing polysomes, where it remains as an abundant protein in spite of ongoing translation.			Visa, N (corresponding author), KAROLINSKA INST, MED NOBEL INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN.		Visa, Neus/C-9459-2016; Visa, Neus/R-8037-2019	Visa, Neus/0000-0003-3145-3953; Visa, Neus/0000-0003-3145-3953; Kiseleva, Elena/0000-0001-6949-182X				AMERO SA, 1991, GENE DEV, V5, P188, DOI 10.1101/gad.5.2.188; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEYER AL, 1990, EUKARYOTIC NUCLEUS, V2, P431; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CASE ST, 1978, J MOL BIOL, V124, P223, DOI 10.1016/0022-2836(78)90157-2; DANEHOLT B, 1977, J CELL BIOL, V73, P149, DOI 10.1083/jcb.73.1.149; Daneholt B., 1982, P382; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE D, 1969, J CELL BIOL, V40, P61, DOI 10.1083/jcb.40.1.61; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EDSTROM JE, 1978, CHROMOSOMA, V66, P33, DOI 10.1007/BF00285814; FRANCKE C, 1982, EMBO J, V1, P59, DOI 10.1002/j.1460-2075.1982.tb01124.x; GREENBERG JR, 1981, P NATL ACAD SCI-BIOL, V78, P2923, DOI 10.1073/pnas.78.5.2923; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; JONES RE, 1980, J CELL BIOL, V86, P235, DOI 10.1083/jcb.86.1.235; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KISELEVA EV, 1989, FEBS LETT, V257, P251, DOI 10.1016/0014-5793(89)81545-5; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR A, 1975, J MOL BIOL, V96, P353, DOI 10.1016/0022-2836(75)90165-5; LEZZI M, 1981, CHROMOSOMA, V83, P327, DOI 10.1007/BF00327356; LONNROTH A, 1992, EXP CELL RES, V199, P292, DOI 10.1016/0014-4827(92)90437-D; MARTIN TE, 1980, CELL BIOL COMPREHENS, P137; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; MINIKH V B, 1985, Biokhimiya, V50, P604; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAYCHAUDHURI G, 1992, MOL CELL BIOL, V12, P847, DOI 10.1128/MCB.12.2.847; RICE CM, 1993, NUCLEIC ACIDS RES, V21, P2967, DOI 10.1093/nar/21.13.2967; RISAU W, 1983, CELL, V33, P529, DOI 10.1016/0092-8674(83)90434-8; SHEN J, 1995, P NATL ACAD SCI USA, V92, P1822, DOI 10.1073/pnas.92.6.1822; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SPIRIN AS, 1985, TRENDS BIOCHEM SCI, V10, P162, DOI 10.1016/0968-0004(85)90158-6; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; THOMAS JO, 1983, J MOL BIOL, V171, P439, DOI 10.1016/0022-2836(83)90039-6; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WIESLANDER L, 1994, PROG NUCLEIC ACID RE, V48, P275, DOI 10.1016/S0079-6603(08)60858-2; WURTZ T, 1990, P NATL ACAD SCI USA, V87, P831, DOI 10.1073/pnas.87.2.831; WURTZ T, 1996, IN PRESS MOL CELL BI; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5	60	208	214	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					253	264		10.1016/S0092-8674(00)80980-0	http://dx.doi.org/10.1016/S0092-8674(00)80980-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565071	Bronze			2022-12-01	WOS:A1996TR59500012
J	Li, JM; Nagpal, P; Vitart, V; McMorris, TC; Chory, J				Li, JM; Nagpal, P; Vitart, V; McMorris, TC; Chory, J			A role for brassinosteroids in light-dependent development of Arabidopsis	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; PLANT-GROWTH; GENE	Although steroid hormones are important for animal development, the physiological role of plant steroids is unknown. The Arabidopsis DET2 gene encodes a protein that shares significant sequence identity with mammalian steroid 5 alpha-reductases. A mutation of glutamate 204, which is absolutely required for the activity of human steroid reductase, abolishes the in vivo activity of DET2 and leads to defects in light-regulated development that can be ameliorated by application of a plant steroid, brassinolide. Thus, DET2 may encode a reductase in the brassinolide biosynthetic pathway, and brassinosteroids may constitute a distinct dass of phytohormones with an important role in light-regulated development of higher plants.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92037 USA	Salk Institute; University of California System; University of California San Diego			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778; Vitart, Veronique/0000-0002-4991-3797; Nagpal, Punita/0000-0003-2257-9183				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arteca Richard N., 1995, P206; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; Davies Peter J., 1995, P1; DEGREEF JA, 1983, PHOTOMORPHOGENESIS, P401; Dellaporta S.L., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; GEUNS JMC, 1978, PHYTOCHEMISTRY, V17, P1, DOI 10.1016/S0031-9422(00)89671-5; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Li J. P. H., UNPUB; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.pp.39.060188.000323; MCNELLIS TW, 1995, PLANT CELL, V7, P1749, DOI 10.1105/tpc.7.11.1749; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577	27	671	722	13	143	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1996	272	5260					398	401		10.1126/science.272.5260.398	http://dx.doi.org/10.1126/science.272.5260.398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602526				2022-12-01	WOS:A1996UG25200043
J	Tobler, I; Gaus, SE; Deboer, T; Achermann, P; Fischer, M; Rulicke, T; Moser, M; Oesch, B; McBride, PA; Manson, JC				Tobler, I; Gaus, SE; Deboer, T; Achermann, P; Fischer, M; Rulicke, T; Moser, M; Oesch, B; McBride, PA; Manson, JC			Altered circadian activity rhythms and sleep in mice devoid of prion protein	NATURE			English	Article							FATAL FAMILIAL INSOMNIA; GENE; SCRAPIE; NUCLEI; RATS; EEG	There is a wealth of data supporting a central role for the prion protein (PrP) in the neurodegenerative prion diseases of both humans and other species(1), yet the normal function of PrP, which is expressed at the cell surface of neurons and glial cells(2,3), is unknown. It has been speculated that neuropathology may be due to loss of normal function of PrP (ref. 4). Here we show that in mice devoid of PrP there is an alteration in both circadian activity rhythms and sleep patterns. To our knowledge, this is the first null mutation that has been shown to affect sleep regulation and our results indicate that the pathology of at least one of the inherited prion diseases, fatal familial insomnia(5), where there is a profound alteration in sleep and the daily rhythms of many hormones(6-10), may be related to the normal function of the prion protein.	UNIV ZURICH,DEPT 1,INST MOLEC BIOL,CH-8093 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,CENT BIOL LAB,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND; BBSRC,INST ANIM HLTH,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND; MRC,NEUROPATHOGENESIS UNIT,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND	University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Roslin Institute; University of Edinburgh	Tobler, I (corresponding author), UNIV ZURICH,INST PHARMACOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.		Achermann, Peter/N-1215-2014	Achermann, Peter/0000-0002-0208-3511				Borbely AA, 1994, PRINCIPLES PRACTICE, P309; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BULT A, 1993, BRAIN RES BULL, V32, P623, DOI 10.1016/0361-9230(93)90164-7; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEBOER T, 1994, J COMP PHYSIOL A, V174, P145; DEBOER T, 1995, BRAIN RES, V670, P153, DOI 10.1016/0006-8993(94)01299-W; FISCHER M, IN PRESS EMBO J; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198, DOI 10.1152/ajpregu.1991.261.1.R198; FRIEDMAN.JK, 1974, PHYSIOL BEHAV, V12, P169, DOI 10.1016/0031-9384(74)90169-3; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; Manson J., 1992, Neurodegeneration, V1, P45; MANSON JC, 1995, NEURODEGENERATION, V4, P113; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONTAGNA P, 1995, ADV NEUROIMMUNOL, V5, P13, DOI 10.1016/0960-5428(94)00042-M; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; PORTALUPPI F, 1994, J CLIN ENDOCR METAB, V78, P1075, DOI 10.1210/jc.78.5.1075; POSSIDENTE B, 1988, BEHAV GENET, V18, P109, DOI 10.1007/BF01067080; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; TOBLER I, 1986, ELECTROEN CLIN NEURO, V64, P74, DOI 10.1016/0013-4694(86)90044-1; VALATX JL, 1974, BRAIN RES, V69, P315, DOI 10.1016/0006-8993(74)90009-2; VALATX JL, 1972, NATURE, V238, P226, DOI 10.1038/238226a0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WESTAWAY D, 1986, NUCLEIC ACIDS RES, V14, P2035, DOI 10.1093/nar/14.5.2035; YAMADA N, 1988, PHYSIOL BEHAV, V42, P87, DOI 10.1016/0031-9384(88)90265-X	28	508	523	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					639	642		10.1038/380639a0	http://dx.doi.org/10.1038/380639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602267				2022-12-01	WOS:A1996UF74100050
J	Doerner, P; Jorgensen, JE; You, R; Steppuhn, J; Lamb, C				Doerner, P; Jorgensen, JE; You, R; Steppuhn, J; Lamb, C			Control of root growth and development by cyclin expression	NATURE			English	Article							ARABIDOPSIS-THALIANA; CELL-PROLIFERATION; GENE; FIBROBLASTS; ONCOGENE; G(1)	ROOT development is plastic, with post-embryonic organogenesis being mediated by meristems(1), Although cell division is intrinsic to meristem initiation, maintenance and proliferative growth, the role of the cell cycle in regulating growth and development is unclear, To address this question, we examined the expression of cdc2 and eye genes, which encode the catalytic and regulatory subunits, respectively, of cyclin-dependent protein kinases that control progression through the cell cycle(2). Unlike cdc2, which is expressed not only in apical meristems but also before lateral root initiation(3) in quiescent, pericycle cells arrested in the G2 phase of the cell cycle(4), cyc1At transcripts accumulate specifically in dividing cells immediately before cytokinesis. Ectopic expression of cyc1At under the control of the cdc2aAt promoter in Arabidopsis plants markedly accelerates growth without altering the pattern of lateral root development or inducing neoplasia. Thus cyclin expression is a limiting factor for growth, which in turn drives indeterminate development of the root system.			Doerner, P (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Doerner, Peter/0000-0001-7218-8469				Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BLAKELY LM, 1979, PLANT SCI LETT, V14, P79, DOI 10.1016/0304-4211(79)90158-5; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; DOLAN L, 1993, DEVELOPMENT, V119, P71; DREW MC, 1975, NEW PHYTOL, V75, P479, DOI 10.1111/j.1469-8137.1975.tb01409.x; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FERREIRA PCG, 1994, PLANT CELL, V6, P1763, DOI 10.1105/tpc.6.12.1763; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEMERLY A, 1992, P NATL ACAD SCI USA, V89, P3295, DOI 10.1073/pnas.89.8.3295; HEMERLY A, 1995, EMBO J, V14, P3295; HEMERLY AS, 1993, PLANT CELL, V5, P1711, DOI 10.1105/tpc.5.12.1711; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURRAY A, 1993, CELL CYCLE; NORRIS SR, 1993, PLANT MOL BIOL, V21, P895, DOI 10.1007/BF00027120; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEEVES TA, 1989, PATTERNS PLANT DEV, P1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846	30	308	335	2	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					520	523		10.1038/380520a0	http://dx.doi.org/10.1038/380520a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606769				2022-12-01	WOS:A1996UE66300047
J	Shan, SO; Loh, S; Herschlag, D				Shan, SO; Loh, S; Herschlag, D			The energetics of hydrogen bonds in model systems: Implications for enzymatic catalysis	SCIENCE			English	Article							DIMETHYL-SULFOXIDE SOLUTION; PROTON-TRANSFER REACTIONS; GENERAL ACID CATALYSIS; CARBON ACIDS; GAS-PHASE; EQUILIBRIUM ACIDITIES; EXCHANGE EQUILIBRIA; ION SOLVATION; ANIONS; SOLVENT	Low-barrier or short, strong hydrogen bonds have been proposed to contribute 10 to 20 kilocalories per mole to transition-state stabilization in enzymatic catalysis. The proposal invokes a large increase in hydrogen bond energy when the pK(a) values of the donor and acceptor (where K-a is the acid constant) become matched in the transition state (Delta pK(a) = 0). This hypothesis was tested by investigating the energetics of hydrogen bonds as a function of Delta pK(a) for homologous series of compounds under nonaqueous conditions that are conducive to the formation of low-barrier hydrogen bonds. In all cases, there was a linear correlation between the increase in hydrogen-bond energy and the decrease in Delta pK(a), as expected from simple electrostatic effects. However, no additional energetic contribution to the hydrogen bond was observed at Delta pK(a) = 0. These results and those of other model studies suggest alternative mechanisms by which hydrogen bonds can contribute to enzymatic catalysis, in accord with conventional electrcstatic considerations.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ALBRECHT G, 1984, Z NATURFORSCH A, V39, P986; ALBRECHT G, 1983, J CHEM SOC F1, V80, P553; ALLERHAND A, 1963, J AM CHEM SOC, V85, P371, DOI 10.1021/ja00887a001; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P8264, DOI 10.1021/ja00494a040; BARTL H, 1980, Z KRISTALLOGR, V152, P161, DOI 10.1524/zkri.1980.152.3-4.161; BEESON C, 1993, J AM CHEM SOC, V115, P10275, DOI 10.1021/ja00075a049; BIAGINICINGI M, 1977, ACTA CRYSTALLOGR B, V33, P3772; BORDWELL FG, 1988, ACCOUNTS CHEM RES, V21, P456, DOI 10.1021/ar00156a004; BORDWELL FG, 1984, J ORG CHEM, V49, P1424, DOI 10.1021/jo00182a020; BORDWELL FG, 1980, J ORG CHEM, V45, P3305, DOI 10.1021/jo01304a034; BORS DA, 1985, J AM CHEM SOC, V107, P6975, DOI 10.1021/ja00310a038; CALDWELL G, 1984, J AM CHEM SOC, V106, P4660, DOI 10.1021/ja00329a002; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DIXON HP, 1972, J CHEM PHYS, V57, P4388, DOI 10.1063/1.1678079; EXNER O, 1988, CORRELATION ANAL CHE, P439; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FUNDERBURK LH, 1978, J AM CHEM SOC, V100, P6708, DOI 10.1021/ja00489a026; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; GILSON MK, 1989, P NATL ACAD SCI USA, V86, P1524, DOI 10.1073/pnas.86.5.1524; GORDON JE, 1961, J ORG CHEM, V26, P738, DOI 10.1021/jo01062a024; GUNNARSSON G, 1976, CHEM PHYS LETT, V38, P96, DOI 10.1016/0009-2614(76)80264-3; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; Hibbert Frank., 1990, ADV PHYS ORG CHEM, V26, P255; HINE J, 1972, J AM CHEM SOC, V94, P5766, DOI 10.1021/ja00771a038; HINE J, 1962, PHYSICAL ORGANIC CHE, pCH4; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, pCH6; KASENDE O, 1984, J PHYS CHEM-US, V88, P2636, DOI 10.1021/j150656a042; KOLTHOFF IM, 1971, J AM CHEM SOC, V93, P3843, DOI 10.1021/ja00745a001; Kortum G., 1961, DISSOCIATION CONSTAN; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KRYGOWSKI TM, 1975, J AM CHEM SOC, V97, P2143, DOI 10.1021/ja00841a026; LARSON JW, 1983, J AM CHEM SOC, V105, P2944, DOI 10.1021/ja00348a003; MATTHEWS WS, 1975, J AM CHEM SOC, V97, P7006, DOI 10.1021/ja00857a010; MEOTNER M, 1984, J AM CHEM SOC, V106, P1257, DOI 10.1021/ja00317a015; MEOTNER M, 1986, J PHYS CHEM-US, V90, P6687, DOI 10.1021/j100283a019; MEOTNER M, 1986, J AM CHEM SOC, V108, P7525, DOI 10.1021/ja00284a014; MIHALICK JE, UNPUB; NADLER EB, 1989, J AM CHEM SOC, V111, P213, DOI 10.1021/ja00183a033; PAWLAK Z, 1984, ELECTROCHIM ACTA, V29, P391, DOI 10.1016/0013-4686(84)87080-2; PERRIN CL, 1989, J AM CHEM SOC, V111, P8010, DOI 10.1021/ja00202a050; PERRIN CL, 1992, J AM CHEM SOC, V114, P8559, DOI 10.1021/ja00048a031; PERRIN CL, 1994, SCIENCE, V266, P1665, DOI 10.1126/science.266.5191.1665; RAO SN, 1987, NATURE, V328, P551, DOI 10.1038/328551a0; ROTHENBERG ME, 1985, J AM CHEM SOC, V107, P1340, DOI 10.1021/ja00291a038; RUBIN J, 1965, J PHYS CHEM-US, V69, P3089, DOI 10.1021/j100893a045; SAUNDERS M, 1984, J AM CHEM SOC, V106, P3098, DOI 10.1021/ja00323a005; SCHEINER S, 1995, J AM CHEM SOC, V117, P6970, DOI 10.1021/ja00131a020; SCHMIDEDER H, 1987, J MOL STRUCT, V161, P87, DOI 10.1016/0022-2860(87)85064-0; SCHWARTZ B, 1995, J AM CHEM SOC, V117, P11902, DOI 10.1021/ja00153a011; SCHWARTZ B, 1995, BIOCHEMISTRY-US, V34, P15459, DOI 10.1021/bi00047a010; SHAN S, UNPUB; SHERRY AD, 1970, J PHYS CHEM-US, V74, P3535, DOI 10.1021/j100713a017; STAHL N, 1986, J AM CHEM SOC, V108, P4196, DOI 10.1021/ja00274a058; TAFT RW, 1969, J AM CHEM SOC, V91, P4801, DOI 10.1021/ja01045a038; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; USHER KC, 1994, BIOCHEMISTRY-US, V33, P7753, DOI 10.1021/bi00191a002; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WARSHEL A, 1981, BIOCHEMISTRY-US, V20, P3167, DOI 10.1021/bi00514a028; WILCOX CS, 1995, TETRAHEDRON, V51, P621, DOI 10.1016/0040-4020(94)00921-G; YAMDAGNI R, 1971, J AM CHEM SOC, V93, P7139, DOI 10.1021/ja00755a003	67	251	253	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					97	101		10.1126/science.272.5258.97	http://dx.doi.org/10.1126/science.272.5258.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600542				2022-12-01	WOS:A1996UD59700046
J	Polson, AG; Bass, BL; Casey, JL				Polson, AG; Bass, BL; Casey, JL			RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase	NATURE			English	Article							UNWINDING ACTIVITY; MAMMALIAN-CELLS; GENOME; REPLICATION; EXPRESSION; MECHANISM	HEPATITIS delta virus (HDV) is a subviral human pathogen that requires hepatitis B virus (HBV) for packaging(1,2). Concurrent infection by HBV and HDV increases the risk of severe liver disease compared to infection with HBV alone(3). The HDV genome is a closed circular RNA of about 1,700 bases which is replicated through an RNA intermediate, the antigenome(4). Both RNAs cars be folded into highly base-paired, rod-shaped structures, similar to the plant viroid RNAs(5). Two forms of the sole HDV protein, hepatitis delta antigen, are derived from a single open reading frame by RNA editing; the enzymes responsible for the editing have not been characterized, Here we report that the purified enzyme dsRAD (for double-stranded-RNA-adenosine deaminase) can edit HDV antigenomic RNA in vitro. Most important, we observe that mutations in critical sequences of the antigenome have identical effects on in vitro and in vivo editing, suggesting that dsRAD, or a closely related enzyme, is responsible for editing HDV RNA in vivo.	UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; GEORGETOWN UNIV,MED CTR,DIV MOL VIROL & IMMUNOL,ROCKVILLE,MD 20852	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Georgetown University	Polson, AG (corresponding author), UNIV UTAH,DEPT BIOCHEM,6110A EIHG,BLDG 533,SALT LAKE CITY,UT 84112, USA.			Casey, John/0000-0003-0396-9856				BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CASEY JL, 1992, P NATL ACAD SCI USA, V89, P7149, DOI 10.1073/pnas.89.15.7149; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hurst SR, 1995, RNA, V1, P1051; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NETTER HJ, 1995, J VIROL, V69, P1687, DOI 10.1128/JVI.69.3.1687-1692.1995; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; TANG JR, 1994, J MED VIROL, V42, P1, DOI 10.1002/jmv.1890420102; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU JC, 1991, J VIROL, V65, P1099, DOI 10.1128/JVI.65.3.1099-1104.1991; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; ZHENG HQ, 1992, J VIROL, V66, P4693, DOI 10.1128/JVI.66.8.4693-4697.1992	27	256	264	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					454	456						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602246				2022-12-01	WOS:A1996UD59000066
J	Reiman, EM; Caselli, RJ; Yun, LS; Chen, KW; Bandy, D; Minoshima, S; Thibodeau, SN; Osborne, D				Reiman, EM; Caselli, RJ; Yun, LS; Chen, KW; Bandy, D; Minoshima, S; Thibodeau, SN; Osborne, D			Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; AMYLOID-BETA-PEPTIDE; TYPE-4 ALLELE; RISK; METABOLISM; BINDING; BRAIN	Background. Variants of the apolipoprotein pared regional rates of glucose metabolism in the two groups. E allele appear to account for most cases of late-onset Alzheimer's disease, and persons with two copies of the epsilon 4 allele appear to have an especially high risk of dementia. Positron-emission tomography (PET) has identified specific regions of the brain In which the rate of glucose metabolism declines progressively in patients with probable Alzheimer's disease, We used PET to investigate whether these same regions of the brain are affected in subjects homozygous for the epsilon 4 allele before the onset of cognitive impairment. Methods. Apolipoprotein E genotypes were established in 235 volunteers 50 to 65 years of age who reported a family history of probable Alzheimer's disease, Neurologic and psychiatric evaluations, a battery of neuropsychological tests, magnetic resonance imaging, and PET were performed in 11 E4 homozygotes and 22 controls without the epsilon 4 allele who were matched for sex, age, and level of education. An automated method was used to generate an aggregate surface-projection map that compared regional rates of glucose metabolism in the two groups. Results. The epsilon 4 homozygotes were cognitively normal, They had significantly reduced rates of glucose metabolism In the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease, They also had reduced rates of glucose metabolism in additional prefrontal regions, which may be preferentially affected during normal aging. Conclusions. In late middle age, cognitively normal subjects who are homozygous for the epsilon 4 allele for apolipoprotein E have reduced glucose metabolism in the same regions of the brain as in patients with probable Alzheimer's disease, These findings provide preclinical evidence that the presence of the epsilon 4 allele is a risk factor for Alzheimer's disease, PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease. (C) 1996, Massachusetts Medical Society.	UNIV ARIZONA, DEPT PSYCHIAT, TUCSON, AZ USA; UNIV ARIZONA, DEPT RADIOL, TUCSON, AZ 85724 USA; MAYO CLIN, DEPT NEUROL, SCOTTSDALE, AZ USA; MAYO CLIN, DEPT PSYCHOL, SCOTTSDALE, AZ USA; ARIZONA STATE UNIV, DEPT COMP SCI, TEMPE, AZ 85287 USA; UNIV MICHIGAN, DIV NUCL MED, ANN ARBOR, MI 48109 USA; MAYO CLIN, DEPT LAB MED & PATHOL, ROCHESTER, MN USA	University of Arizona; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Arizona State University; Arizona State University-Tempe; University of Michigan System; University of Michigan; Mayo Clinic	Reiman, EM (corresponding author), GOOD SAMARITAN REG MED CTR, POSITRON EMISS TOMOG CTR, 1111 E MCDOWELL RD, PHOENIX, AZ 85006 USA.		Chen, Kewei/P-6304-2015	Chen, Kewei/0000-0001-8497-3069				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1983, NEUROPSYCHOLOGICAL A; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRUN A, 1976, ARCH PSYCHIAT NERVEN, V223, P15, DOI 10.1007/BF00367450; CASELLI RJ, 1995, ARCH NEUROL-CHICAGO, V52, P1004, DOI 10.1001/archneur.1995.00540340096018; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; COFFEY CE, 1992, NEUROLOGY, V42, P527, DOI 10.1212/WNL.42.3.527; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; First M.B., 1990, USERS GUIDE STRUCTUR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAFTON ST, 1992, ARCH NEUROL-CHICAGO, V49, P1161, DOI 10.1001/archneur.1992.00530350075022; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HIXSON JE, 1990, J LIPID RES, V31, P545; KAPLITT MG, 1995, ABSTR SOC NEUROSCI, V21, P1008; KENNEDY AM, 1995, NEUROSCI LETT, V186, P17, DOI 10.1016/0304-3940(95)11270-7; KUHL DE, 1982, J CEREBR BLOOD F MET, V2, P163, DOI 10.1038/jcbfm.1982.15; LOESSNER A, 1995, J NUCL MED, V36, P1141; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCGEER EG, 1990, CAN J NEUROL SCI, V17, P1; MIELKE R, 1994, DEMENTIA, V5, P36, DOI 10.1159/000106692; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; MINOSHIMA S, 1995, J COMPUT ASSIST TOMO, V19, P541, DOI 10.1097/00004728-199507000-00006; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PIETRINI P, 1993, DEMENTIA, V4, P94, DOI 10.1159/000107349; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; RIGGS JE, 1994, ARCH NEUROL-CHICAGO, V51, P750, DOI 10.1001/archneur.1994.00540200024011; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SALMON E, 1991, ACTA NEUROL BELG, V91, P288; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHWARTZ WJ, 1979, SCIENCE, V205, P723, DOI 10.1126/science.462184; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; SMITH GS, 1992, ARCH NEUROL-CHICAGO, V49, P1142, DOI 10.1001/archneur.1992.00530350056020; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; [No title captured]	50	1084	1111	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					752	758		10.1056/NEJM199603213341202	http://dx.doi.org/10.1056/NEJM199603213341202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592548	Bronze			2022-12-01	WOS:A1996TZ97900002
J	Lanker, S; Valdivieso, MH; Wittenberg, C				Lanker, S; Valdivieso, MH; Wittenberg, C			Rapid degradation of the G(1) cyclin Cln2 induced by CDK-dependent phosphorylation	SCIENCE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; G1 CYCLINS; GENE; CDC28; ASSOCIATION; ACTIVATOR; DIVISION; COMPLEX	Cyclins regulate the major cell cycle transitions in eukaryotes through association with cyclin-dependent protein kinases (CDKs). In yeast, G(1) cyclins are essential, rate-limiting activators of cell cycle initiation. G(1)-specific accumulation of one G(1) cyclin, Cln2, results from periodic gene expression coupled with rapid protein turnover. Site-directed mutagenesis of CLN2 revealed that its phosphorylation provides a signal that promotes rapid degradation. Cln2 phosphorylation is dependent on the Cdc28 protein kinase, the CDK that it activates, These findings suggest that Cln2 is rendered self-limiting by virtue of its ability to activate its cognate CDK subunit.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; EDIFICIO DEPT MICROBIOL BIOL, E-37007 SALAMANCA, SPAIN	Scripps Research Institute; Scripps Research Institute			Valdivieso, M.-Henar/B-5199-2017	Valdivieso, M.-Henar/0000-0002-6857-7493	NIGMS NIH HHS [GM43487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; LANKER S, UNPUB; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LITTLEFIELD R, UNPUB; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VALDIVIESO M, UNPUB; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, UNPUB; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	32	195	196	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1597	1601		10.1126/science.271.5255.1597	http://dx.doi.org/10.1126/science.271.5255.1597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599119				2022-12-01	WOS:A1996TZ98300046
J	Hirsch, E; Iglesias, A; Potocnik, AJ; Hartmann, U; Fassler, R				Hirsch, E; Iglesias, A; Potocnik, AJ; Hartmann, U; Fassler, R			Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta(1) integrins	NATURE			English	Article							GENE REARRANGEMENT; FETAL LIVER; ADHESION; HEMATOPOIESIS; TRANSCRIPTION; PRECURSORS; ACTIVATION; RECEPTOR; CHAIN	Adhesive interactions mediated by integrins of the beta(1) subfamily(1) are thought to be critical in controlling differentiation and migration of blood cell precursors(2-7). Here we report that chimaeric mice generated with beta(1)-integrin-deficient embryonic stem (ES) cells(8,9) lack beta(1)(-/-) cells in blood and in haematopoietic organs such as spleen, thymus and bone marrow. Chimaeric embryos contain beta(1)-null haematopoietic cells in the yolk sac and in fetal blood but not in fetal liver. We show that such beta(1)(-/-) haematopoietic stem cells derived from yolk sac of 10.5-day-old chimaeric embryos readily generate erythroid and myeloid colonies and that beta(1)(-/-) ES cells can differentiate into mature B lymphocytes in vitro. Our results indicate that haematopoietic stem cells lacking beta(1) integrins can form and differentiate into different lineages but cannot colonize the fetal liver.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY	Max Planck Society; Max Planck Society; Max Planck Society			Hirsch, Emilio/F-4848-2013	Hirsch, Emilio/0000-0002-9073-6024; Potocnik, Alexandre/0000-0002-4730-8593				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; GIANCOTTI FG, 1986, J CELL BIOL, V103, P429, DOI 10.1083/jcb.103.2.429; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGLESIAS A, 1992, EUR J IMMUNOL, V22, P335, DOI 10.1002/eji.1830220208; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEPTIN M, 1984, EUR J IMMUNOL, V14, P534, DOI 10.1002/eji.1830140610; Moore K. A., 1993, Gene targeting: a practical approach., P63; PAPAYANNOPOULOU T, 1992, BLOOD, V79, P1686; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PEVNY L, 1995, DEVELOPMENT, V121, P163; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; RUIZ P, 1995, EUR J IMMUNOL, V25, P2034, DOI 10.1002/eji.1830250735; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUBRAMANIAM M, 1995, J EXP MED, V181, P2277, DOI 10.1084/jem.181.6.2277; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WILT FH, 1965, SCIENCE, V147, P1588, DOI 10.1126/science.147.3665.1588; YANG JT, 1995, DEVELOPMENT, V121, P549	28	290	300	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					171	175		10.1038/380171a0	http://dx.doi.org/10.1038/380171a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600394				2022-12-01	WOS:A1996TZ97800055
J	Davidson, AC; Emberlin, J; Cook, AD; Venables, KM; Wallis, DN; Webb, J; Brooke, D; Brookes, B; Brown, R; Findlay, A; Harris, M; Hulbert, D; Little, G; Nonoo, C; ODonnell, C; Park, G; Soorma, A				Davidson, AC; Emberlin, J; Cook, AD; Venables, KM; Wallis, DN; Webb, J; Brooke, D; Brookes, B; Brown, R; Findlay, A; Harris, M; Hulbert, D; Little, G; Nonoo, C; ODonnell, C; Park, G; Soorma, A			A major outbreak of asthma associated with a thunderstorm: Experience of accident and emergency departments and patients' characteristics	BRITISH MEDICAL JOURNAL			English	Article							GRASS-POLLEN; MECHANISM	Objective-To investigate the time course of an epidemic of asthma after a thunderstorm, characteristics of patients affected, and the demand on emergency medical resources. Design-study of registers and records in accident and emergency departments and questionnaire to staff. Setting-London area. Subjects-All patients presenting at 12 accident and emergency departments with asthma or other airways disease. Main outcome measures-Numbers of patients, clinical features, information on shortage of resources-equipment, drugs, and staff. Results-The epidemic had a sudden onset on 24 June 1994; 640 patients with asthma or other airways disease attended during 30 hours from 1800 on 24 June, nearly 10 times the expected number. Over half (365) the patients were aged 21 to 40 years. A history of hay fever was recorded in 403 patients; for 283 patients this was the first known attack of asthma; a history of chronic obstructive airways disease was recorded in 12 patients. In all, 104 patients were admitted (including five to an intensive care unit). Several departments ran out of equipment or drugs, called in additional doctors, or both. Conclusions-This study supports the view that this epidemic was larger than previously reported epidemics and the hypothesis that ''thunderstorm associated asthma'' is related to aeroallergens. Demands on resources were considerable; a larger proportion of patients needing intensive care would have caused greater problems.	NEWHAM GEN HOSP,DEPT ACCID & EMERGENCY,LONDON E13 8RU,ENGLAND; POLLEN RES UNIT,WORCESTER WR2 6AJ,ENGLAND; NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON SW3 6LR,ENGLAND	University of Worcester; Imperial College London								Alderman P M, 1986, Arch Emerg Med, V3, P260; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; CAMPBELLHEWSON G, 1994, BRIT MED J, V309, P1086, DOI 10.1136/bmj.309.6961.1086a; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1983, LANCET, V2, P253; *DEP HLTH ADV GROU, 1995, 4 DEP HLTH ADV GROUP; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HIGHAM JH, 1994, BRIT MED J, V309, P604; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; MURRAY V, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131c; Norris-Hill J, 1993, AEROBIOLOGIA, V9, P27, DOI DOI 10.1007/BF02311367; PACKE GE, 1985, LANCET, V2, P199; PACKE GE, 1986, LANCET, V1, P850; PREMARATNE UN, IN PRESS RESPIR MED; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; 1985, LANCET, V1, P1079	18	94	95	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					601	604						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595332				2022-12-01	WOS:A1996TZ84000022
J	Dias, R; Robbins, TW; Roberts, AC				Dias, R; Robbins, TW; Roberts, AC			Dissociation in prefrontal cortex of affective and attentional shifts	NATURE			English	Article							FRONTAL-CORTEX; LOBE	The prefrontal cortex is implicated in such human characteristics as volition, planning, abstract reasoning and affect(1-6). Frontal-lobe damage can cause disinhibition such that the behaviour of a subject is guided by previously acquired responses that are inappropriate to the current situation(7-9). Here we demonstrate that disinhibition, or a loss of inhibitory control, can be selective for particular cognitive functions and that different regions of the prefrontal cortex provide inhibitory control in different aspects of cognitive processing. Thus, whereas damage to the lateral prefrontal cortex (Brodmann's area 9) in monkeys causes a loss of inhibitory control in attentional selection, damage to the orbito-frontal cortex in monkeys causes a loss of inhibitory control in 'affective' processing, thereby impairing the ability to alter behaviour in response to fluctuations in the emotional significance of stimuli. These findings not only support the view that the prefrontal cortex has multiple functions, but also provide evidence for the distribution of different cognitive functions within specific regions of prefrontal cortex.	UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Cambridge			Roberts, Angela C/C-1313-2012; Robbins, Trevor W/A-7551-2008	Roberts, Angela C/0000-0003-2873-157X; Robbins, Trevor/0000-0003-0642-5977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARAL DG, 1993, AMYGDALA NEUROBIOLOG, P1; Brodmann K., 1909, VERGLEICHENDE LOKALI; Damasio AR., 2006, DESCARTES ERROR EMOT; Fuster J, 1989, PREFRONTAL CORTEX; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Mishkin M., 1964, FRONTAL GRANULAR COR, P219; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PREUSS TM, 1991, J COMP NEUROL, V310, P429, DOI 10.1002/cne.903100402; ROBERTS AC, 1994, J NEUROSCI, V14, P2531; ROBERTS AC, 1988, Q J EXP PSYCHOL-B, V40, P321; Shallice T, 1988, NEUROPSYCHOLOGY MENT, P328; SUTHERLAND NS, 1971, MECHANISMS ANIMAL DI; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	18	1196	1209	0	99	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					69	72		10.1038/380069a0	http://dx.doi.org/10.1038/380069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598908				2022-12-01	WOS:A1996TY87700058
J	Klingelhutz, AJ; Foster, SA; McDougall, JK				Klingelhutz, AJ; Foster, SA; McDougall, JK			Telomerase activation by the E6 gene product of human papillomavirus type 16	NATURE			English	Article							TERMINAL TRANSFERASE; HUMAN FIBROBLASTS; RIBONUCLEOPROTEIN; ONCOPROTEIN; REPEATS; ENZYME; CELLS; P53	Activation of telomerase, a ribonucleoprotein complex that synthesizes telomere repeat sequences(1-4), is linked to cell immortalization and is characteristic of most cell lines and tumours(4,5-8) Here we show that expression of the human papillomavirus type 16 (HPV-16) E6 protein activates telomerase in early-passage human keratinocytes and mammary epithelial cells. This activation was observed in cells pre-crisis, that is, before they became immortal, and occurred within one passage of retroviral infection with vectors expressing HPV-16 E6. Studies using HPV-16 E6 mutants showed that there was no correlation between the ability of the mutants to activate telomerase and their ability to target p53 for degradation, suggesting that telomerase activation by HPV-16 E6 is p53 independent. Keratinocytes expressing wild-type HPV-16 E6 have an extended lifespan, but do not become immortal(9), indicating that telomerase activation and E6-mediated degradation of p53 are insufficient for their immortalization. These results show that telomerase activation is an intrinsic, but insufficient, component of transformation by HPV.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Klingelhutz, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM CANC BIOL,SEATTLE,WA 98104, USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; MILLER AD, 1988, J VIROL, V62, P4337, DOI 10.1128/JVI.62.11.4337-4345.1988; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	21	649	677	1	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					79	82		10.1038/380079a0	http://dx.doi.org/10.1038/380079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598912				2022-12-01	WOS:A1996TY87700061
J	Belmont, LD; Mitchison, TJ				Belmont, LD; Mitchison, TJ			Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules	CELL			English	Article							DYNAMIC INSTABILITY; TRANSITION FREQUENCIES; CYTOPLASMIC EXTRACTS; XENOPUS; KINASE; STATHMIN; CELLS; PHOSPHORYLATION; INTERPHASE; LEUKEMIA	Using a polymerization inhibition assay, we have purified a small, heat stable protein that physically interacts with tubulin dimers and increases the catastrophe rate of microtubules. Sequence analysis identified this protein as oncoprotein 18 (Op18)/stathmin, a conserved phosphoprotein that is highly expressed in leukemia cells. Immunodepletion experiments in Xenopus egg extracts showed that Op18/stathmin is involved in physiological regulation of mitotic microtubule dynamics. Op18/stathmin is a microtubule regulator that preferentially interacts with unpolymerized subunits. It is a candidate for increasing the microtubule catastrophe rate in mitosis and might also regulate microtubule dynamics in response to external signals.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Belmont, LD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565, R37GM039565] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39565-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; ROWLANDS DC, 1995, LAB INVEST, V72, P100; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; SAWIN KE, 1992, J CELL SCI, V101, P303; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; SOBEL A, 1989, J BIOL CHEM, V264, P3765; VANDRE DD, 1991, J CELL SCI, V98, P577; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1	37	572	589	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					623	631		10.1016/S0092-8674(00)81037-5	http://dx.doi.org/10.1016/S0092-8674(00)81037-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598048	Bronze			2022-12-01	WOS:A1996TX17600014
J	RiveraPomar, R; Niessing, D; SchmidtOtt, U; Gehring, WJ; Jackle, H				RiveraPomar, R; Niessing, D; SchmidtOtt, U; Gehring, WJ; Jackle, H			RNA binding and translational suppression by bicoid	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYOS; BODY PATTERN; GRADIENT; PROTEIN; TRANSCRIPTION; EXPRESSION; KRUPPEL; LOCALIZATION; ANTERIOR	THE anterior determinant bicoid (bcd) of Drosophila is a homeodomain protein. It forms an anterior-to-posterior gradient in the embryo and activates, in a concentration-dependent manner, several zygotic segmentation genes during blastoderm formation(1-4). Its posterior counterpart, the homeodomain transcription factor caudal (cad)(5-7), forms a concentration gradient in the opposite direction, emanating from evenly distributed messenger RNA in the egg. In embryos lacking bcd activity as a result of mutation, the cad gradient fails to form and cad becomes evenly distributed throughout the embryo(8). This suggests that bcd may act in the region-specific control of cad mRNA translation. Here we report that bcd binds through its homeodomain to cad mRNA in vitro, and exerts translational control through a bcd-binding region of cad mRNA.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel	RiveraPomar, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM,ABT MOLEK ENTWICKLUNGSBIOL,FASSBERG,D-37077 GOTTINGEN,GERMANY.		Niessing, Dierk/M-4619-2014; Niessing, Dierk/AAE-4936-2022	Niessing, Dierk/0000-0002-5589-369X; Niessing, Dierk/0000-0002-5589-369X				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1989, THESIS EBERHARD KARL; HESS MA, 1994, J BIOL CHEM, V269, P10913; HUISKAMP M, 1988, NATURE, V338, P629; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1987, DEVELOPMENT, V101, P421; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Pankratz Michael J., 1993, P467; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; RUDEN DM, 1995, DEVELOPMENT, V121, P63; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STJOHNSTON RD, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	29	250	254	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					746	749		10.1038/379746a0	http://dx.doi.org/10.1038/379746a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602224				2022-12-01	WOS:A1996TW56700058
J	Utz, JP; Swensen, SJ; Gertz, MA				Utz, JP; Swensen, SJ; Gertz, MA			Pulmonary amyloidosis - The Mayo Clinic experience from 1980 to 1993	ANNALS OF INTERNAL MEDICINE			English	Article						amyloidosis; biopsy; bronchoscopy; amyloid; respiratory tract diseases	LOWER RESPIRATORY-TRACT; TRANS-BRONCHIAL BIOPSY; TRACHEOBRONCHOPATHIA OSTEOPLASTICA; LOCALIZED AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; HILAR ADENOPATHY; PLEURAL DISEASE; NEEDLE-BIOPSY; MANIFESTATIONS; DIAGNOSIS	Objective: To define the prognosis for and radiographic presentation of patients with pulmonary amyloidosis. Design: Retrospective review of the Mayo Clinic experience with biopsy-proven pulmonary amyloidosis from 1980 to 1993. Setting: Tertiary care center. Patients: Patients with pulmonary biopsy specimens showing amyloid deposition. Measurements: Medical records were reviewed, and pertinent information was recorded, including demographic data, type of pulmonary biopsy, results of biopsies of nonpulmonary sites and of immunoelectrophoresis, and other clinical, radiographic, and laboratory information necessary for distinguishing localized pulmonary amyloidosis, primary systemic amyloidosis, secondary amyloidosis, and familial amyloidosis. Results: 35 of 55 patients with pulmonary amyloidosis had primary systemic amyloidosis that presented radiographically as an interstitial or reticulonodular pattern with or without pleural effusion. The median survival after diagnosis was 16 months. Nodular pulmonary ''amyloidomas'' (nodular amyloid lesions) were not associated with systemic disease and were associated with a benign prognosis. Three of 4 patients with localized tracheobronchial amyloidosis required Nd:YAC (neodymium:yttrium-aluminum-garnet) laser therapy for obstructive symptoms. ''Senile'' amyloid deposition was an incidental finding in some patients at autopsy. Conclusions: Localized amyloidomas are characterized by a benign course and are not associated with systemic amyloidosis. Despite its localized nature, tracheobronchial amyloid deposition may be asymptomatic or may result in significant morbidity due to obstructive phenomena. Pulmonary amyloidosis associated with primary systemic amyloidosis generally presents as a diffuse interstitial pattern with or without pleural effusion. Complete survival data indicate that long-term outcome is poor after diagnosis. We describe the largest series of patients diagnosed by bronchoscopic lung biopsy. Despite reports to the contrary, we have found bronchoscopic lung biopsy to be a safe and effective diagnostic technique.	MAYO MED CTR, ROCHESTER, MN USA	Mayo Clinic	Utz, JP (corresponding author), MAYO CLIN & MAYO FDN, MAYO MED SCH, 200 1ST ST SW, E-18, ROCHESTER, MN 55905 USA.		Gertz, Morie/K-2873-2019					ALROY GG, 1972, CHEST, V61, P465, DOI 10.1378/chest.61.5.465; BIERNY JP, 1978, AM J ROENTGENOL, V131, P1082; BREUER R, 1985, THORAX, V40, P870, DOI 10.1136/thx.40.11.870; BUXBAUM JN, 1988, CECIL TXB MED, P1198; CANDEIRA SR, 1991, CHEST, V100, P292, DOI 10.1378/chest.100.1.292-a; CELLI BR, 1978, CHEST, V74, P543, DOI 10.1378/chest.74.5.543; CORDIER JF, 1986, CHEST, V90, P827, DOI 10.1378/chest.90.6.827; DAHLGREN SE, 1970, ACTA PATH MICRO IM A, VA 78, P1; DAHLIN DC, 1950, MED CLIN N AM, P1107; DAIL DH, 1988, PULMONARY PATHOLOGY, P535; DESAI RA, 1979, CHEST, V76, P170, DOI 10.1378/chest.76.2.170; FLEMMING AFS, 1980, BRIT J DIS CHEST, V74, P183, DOI 10.1016/0007-0971(80)90032-7; GALLEGO FG, 1974, NEW ENGL J MED, V291, P531; GERTZ MA, 1989, MAYO CLIN PROC, V64, P1505, DOI 10.1016/S0025-6196(12)65706-1; GOTTLIEB LS, 1972, AM REV RESPIR DIS, V105, P425; GROSS BH, 1981, RADIOLOGY, V138, P11, DOI 10.1148/radiology.138.1.7455070; HOLMES S, 1988, BRIT J DIS CHEST, V82, P414, DOI 10.1016/0007-0971(88)90097-6; HUI AN, 1986, ARCH PATHOL LAB MED, V110, P212; JONES AW, 1977, BRIT J DIS CHEST, V71, P268, DOI 10.1016/0007-0971(77)90124-3; KAMBERG S, 1962, NEW ENGL J MED, V266, P587, DOI 10.1056/NEJM196203222661204; KAVURU MS, 1990, CHEST, V98, P20, DOI 10.1378/chest.98.1.20; KAW YT, 1991, DIAGN CYTOPATHOL, V7, P628, DOI 10.1002/dc.2840070617; KHAN JA, 1996, CLIN PULM MED, V2, P66; KIDD CR, 1974, NEW ENGL J MED, V290, P972; KIM C H, 1990, Korean Journal of Internal Medicine, V5, P63; KLINE LR, 1985, AM REV RESPIR DIS, V132, P191; KNAPP MJ, 1988, ARCH PATHOL LAB MED, V112, P57; KUNZE WP, 1979, PATHOL RES PRACT, V164, P413, DOI 10.1016/S0344-0338(79)80058-8; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; LEWINSOHN G, 1976, CHEST, V69, P682, DOI 10.1378/chest.69.5.682; MARTIN CJ, 1974, ARCH OTOLARYNGOL, V100, P290; NIENHUIS DM, 1990, ANN OTO RHINOL LARYN, V99, P689, DOI 10.1177/000348949009900903; OSNOSS KL, 1980, CHEST, V78, P786, DOI 10.1378/chest.78.5.786; PETERMANN W, 1987, EUR J RESPIR DIS, V71, P210; PITKANEN P, 1984, AM J PATHOL, V117, P391; POH SC, 1975, THORAX, V30, P186, DOI 10.1136/thx.30.2.186; RUBINOW A, 1978, AM REV RESPIR DIS, V118, P603; SAKULA A, 1968, THORAX, V23, P105, DOI 10.1136/thx.23.1.105; SHINOI K, 1962, DIS CHEST, V42, P442, DOI 10.1378/chest.42.4.442; SIONGCHUAN L, 1975, THORAX, V30, P178; SMITH RRL, 1979, AM J MED, V66, P96, DOI 10.1016/0002-9343(79)90488-1; STRANGE C, 1987, CHEST, V92, P367, DOI 10.1378/chest.92.2.367; THOMPSON PJ, 1983, THORAX, V38, P84, DOI 10.1136/thx.38.2.84; TOMASHEFSKI JF, 1980, ACTA CYTOL, V24, P224; WEISMANN RE, 1947, J THORAC SURG, V16, P269; WEISS L, 1960, AM J CLIN PATHOL, V33, P318; WILSON SR, 1976, RADIOLOGY, V120, P283, DOI 10.1148/120.2.283; YOOD RA, 1983, JAMA-J AM MED ASSOC, V249, P1322, DOI 10.1001/jama.249.10.1322	48	240	257	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					407	+		10.7326/0003-4819-124-4-199602150-00004	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554249				2022-12-01	WOS:A1996TV22000004
J	Daub, H; Weiss, FU; Wallasch, C; Ullrich, A				Daub, H; Weiss, FU; Wallasch, C; Ullrich, A			Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors	NATURE			English	Article							SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; KINASE; GROWTH; FIBROBLASTS; ACTIVATION; TRANSDUCTION; MECHANISM; STIMULATE	TRANSDUCTION of a mitogenic signal from the cell membrane to the nucleus involves the adapter proteins SHC and Grb2, which mediate activation of the Ras/mitogen-activated protein (MAP) kinase pathway(1-5). In contrast to receptor tyrosine kinases (RTKs), the signalling steps leading to Ras/MAP kinase activation by G-protein-coupled receptors (GPCRs) are still poorly characterized but appear to include beta gamma subunits of heterotrimeric G-proteins and as-yet unidentified tyrosine kinases(6-8). We report here that the epidermal growth factor receptor (EGFR) and the neu oncoprotein become rapidly tyrosine-phosphorylated upon stimulation of Rat-1 cells with the GPCR agonists endothelin-1, lysophosphatic acid and thrombin, suggesting that there is an intracellular mechanism for transactivation. Specific inhibition of EGFR function by either the selective tyrphostin AG1478 or a dominant-negative EGFR mutant suppressed MAP kinase activation and strongly inhibited induction of fos gene expression and DNA synthesis, Our results demonstrate a role for RTKs as downstream mediators in GPCR mitogenic signalling and suggest a ligand-independent mechanism of RTK activation through intracellular signal crosstalk.			Daub, H (corresponding author), MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,AM KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Weiss, Frank Ulrich/A-6386-2009	Weiss, Frank Ulrich/0000-0003-3369-6369				AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1994, REV CELL BIOL, V10, P251; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	29	1268	1297	2	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					557	560		10.1038/379557a0	http://dx.doi.org/10.1038/379557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596637				2022-12-01	WOS:A1996TU69300055
J	Licht, S; Gerfen, GJ; Stubbe, JA				Licht, S; Gerfen, GJ; Stubbe, JA			Thiyl radicals in ribonucleotide reductases	SCIENCE			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; REDUCTION; ELECTRON; COENZYME-B12; MECHANISM; COBAMIDES; STATE; DNA	The ribonucleoside triphosphate reductase (RTPR) from Lactobacillus leichmannii catalyzes adenosylcobalamin (AdoCbl)-dependent nucleotide reduction, as well as exchange of the 5' hydrogens of AdoCbl with solvent. A protein-based thiyl radical is proposed as an intermediate in both of these processes. In the presence of RTPR containing specifically deuterated cysteine residues, the electron paramagnetic resonance (EPR) spectrum of an intermediate in the exchange reaction and the reduction reaction, trapped by rapid freeze quench techniques, exhibits narrowed hyperfine features relative to the corresponding unlabeled RTPR. The spectrum was interpreted to represent a thiyl radical coupled to cob(II)alamin. Another proposed intermediate, 5'-deoxyadenosine, was detected by rapid acid quench techniques, Similarities in mechanism between RTPR and the Escherichia coli ribonucleotide reductase suggest that both enzymes require a thiyl radical for catalysis.	MIT, FRANCIS BITTER MAGNET LAB, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Licht, S (corresponding author), MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029595, R37GM029595] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00317] Funding Source: Medline; NIGMS NIH HHS [GM 29595] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1967, J BIOL CHEM, V242, P3589; ASHLEY GW, 1986, J BIOL CHEM, V261, P3958; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; CHENG H, 1995, ARCH BIOCHEM BIOPHYS, V316, P619, DOI 10.1006/abbi.1995.1082; GERFEN GJ, UNPUB; HAMILTON JA, 1971, BIOCHEMISTRY-US, V10, P347, DOI 10.1021/bi00778a023; HIBLER DW, 1989, METHOD ENZYMOL, V177, P74; HOGANSON CW, 1994, MET IONS BIOL SYST, V30, P77; HOGENKAMP HP, 1968, J BIOL CHEM, V243, P799; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; MAWHINNEY TP, 1986, J CHROMATOGR, V358, P231, DOI 10.1016/S0021-9673(01)90333-4; NSLLOU FP, 1970, SNSL VHRM, V46, P1248; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SANDO GN, 1975, J BIOL CHEM, V250, P8774; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; THELANDER L, 1974, J BIOL CHEM, V249, P4858; TSAI AL, 1995, J BIOL CHEM, V250, P1053; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WERTZ JE, 1986, ELECT SPIN RESONANCE, P498; WILLING A, 1988, EUR J BIOCHEM, V175, P167, DOI 10.1111/j.1432-1033.1988.tb14179.x	30	270	274	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					477	481		10.1126/science.271.5248.477	http://dx.doi.org/10.1126/science.271.5248.477			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560260				2022-12-01	WOS:A1996TR32200032
J	Pfaff, SL; Mendelsohn, M; Stewart, CL; Edlund, T; Jessell, TM				Pfaff, SL; Mendelsohn, M; Stewart, CL; Edlund, T; Jessell, TM			Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation	CELL			English	Article							LARVAL FROG RETINA; CELL PATTERN; SPINAL-CORD; FLOOR PLATE; HOMEODOMAIN; EXPRESSION; NOTOCHORD; ELEGANS; LINEAGE; MOUSE	Motor neuron differentiation is accompanied by the expression of a LIM homeodomain transcription factor, Islet1 (ISL1). To assess the involvement of ISL1 in the generation of motor neurons, we analyzed cell differentiation in the neural tube of embryos in which ISL1 expression has been eliminated by gene targeting. Motor neurons are not generated without ISL1, although many other aspects of cell differentiation in the neural tube occur normally. A population of interneurons that express Engrailed1 (EN1), however, also fails to differentiate in Isl1 mutant embryos. The differentiation of EN1(+) interneurons can be induced in both wild-type and mutant neural tissue by regions of the neural tube that contain motor neurons. These results show that ISL1 is required for the generation of motor neurons and suggest that motor neuron generation is required for the subsequent differentiation of certain interneurons.	ROCHE INST MOLEC BIOL,DEPT CELL & DEV BIOL,NUTLEY,NJ 07110; UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University	Pfaff, SL (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.							[Anonymous], 1977, HDB PHYSL NERVOUS SY; Appel B, 1995, DEVELOPMENT, V121, P4117; BARTH KA, 1995, DEVELOPMENT, V121, P1755; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Brown AG, 1981, ORG SPINAL CORD; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; HAMBURGER V, 1948, J COMP NEUROL, V88, P221, DOI 10.1002/cne.900880204; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; NEGISHI K, 1982, SCIENCE, V216, P747, DOI 10.1126/science.7079736; NOMES WO, 1978, BRAIN RES, V159, P1; REH TA, 1987, J NEUROSCI, V7, P3317; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHENG H, 1996, IN PRESS SCIENCE; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TOKUMOTO M, 1995, DEV BIOL, V171, P578, DOI 10.1006/dbio.1995.1306; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	38	633	651	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					309	320		10.1016/S0092-8674(00)80985-X	http://dx.doi.org/10.1016/S0092-8674(00)80985-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565076	hybrid			2022-12-01	WOS:A1996TR59500017
J	Forrester, TE; Wilks, RJ; Bennett, FI; Simeon, D; Osmond, C; Allen, M; Chung, AP; Scott, P				Forrester, TE; Wilks, RJ; Bennett, FI; Simeon, D; Osmond, C; Allen, M; Chung, AP; Scott, P			Fetal growth and cardiovascular risk factors in Jamaican schoolchildren	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ADULT LIFE; SERUM-CHOLESTEROL; CHILDHOOD; LIPOPROTEINS; CHILDREN; DISEASE; LIPIDS; HYPERTENSION; ADOLESCENCE	Objective-To determine relation between schoolchildren's blood pressure, glycated haemoglobin level, and cholesterol concentration and their anthropometry, socioeconomic status, and birth measurements. Design-Retrospective cohort study. Setting-27 schools closest to University Hospital of the West Indies, Kingston, Jamaica. Subjects-2337 children aged 6-16 years who were born at university hospital were recruited, and their birth records were recovered: 1610 had suitable records, 659 had records including birth length, and 610 of these were prepubertal. Main outcome measures-Blood pressure, haemoglobin level, serum cholesterol concentration, anthropometry at birth, current anthropometry, and socioeconomic status. Results-Multiple regression analysis showed that children's systolic blood pressure was inversely related to their birth weight (P < 0.0001) and directly related to their current weight. Glycated haemoglobin level was higher in children with thicker triceps skinfolds (P < 0.001) and who had been shorter at birth (P = 0.003). Serum cholesterol concentration was inversely related to current height (P = 0.001) and to length at birth (P = 0.09) and was directly related to triceps skinfold thickness and higher socioeconomic status (P < 0.001). Conclusions-Blood pressure in childhood was inversely related to birth weight and directly to current weight. Glycaemic control and serum cholesterol were related to short length at birth, height deficit in childhood, and childhood obesity.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton	Forrester, TE (corresponding author), UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA.			SIMEON, DONALD/0000-0002-6197-9369; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON AJ, 1988, ARTERIOSCLEROSIS, V8, P88, DOI 10.1161/01.ATV.8.1.88; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ANTIA AU, 1990, W INDIAN MED J, V24, P110; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1994, FETAL MATERNAL MED R, V6, P71, DOI DOI 10.1017/S0965539500001005; BEAGLEHOLE R, 1977, AM J EPIDEMIOL, V105, P87, DOI 10.1093/oxfordjournals.aje.a112359; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BURNS TL, 1989, AM J EPIDEMIOL, V129, P973, DOI 10.1093/oxfordjournals.aje.a115229; CAMPOS H, 1991, ARTERIOSCLER THROMB, V11, P1077, DOI 10.1161/01.ATV.11.4.1077; CLARKE WR, 1978, CIRCULATION, V58, P626, DOI 10.1161/01.CIR.58.4.626; FREEDMAN DS, 1987, PEDIATRICS, V80, P789; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALL PM, 1983, ANN CLIN BIOCHEM, V20, P129, DOI 10.1177/000456328302000301; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LAUER RM, 1984, CIRCULATION, V69, P242, DOI 10.1161/01.CIR.69.2.242; LAUER RM, 1991, HYPERTENSION, V18, P74, DOI 10.1161/01.HYP.18.3_Suppl.I74; LAUER RM, 1988, PEDIATRICS, V75, P1081; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW CM, IN PRESS DIABET MED; LIU K, 1989, HYPERTENSION, V14, P218, DOI 10.1161/01.HYP.14.2.218; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MARGETTS BM, 1991, INT J EPIDEMIOL, V20, P938, DOI 10.1093/ije/20.4.938; Martorell R, 1989, ANTHROPOMETRIC STAND; MILLER GJ, 1976, CLIN SCI MOL MED, V51, P475, DOI 10.1042/cs0510475; MUELLER WH, 1984, AM J PHYS ANTHROPOL, V64, P389, DOI 10.1002/ajpa.1330640404; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; STERN MP, 1986, ARTERIOSCLEROSIS, V6, P123, DOI 10.1161/01.ATV.6.2.123; WARD R, 1990, HYPERTENSION PATHOPH, P81; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1992, J EPIDEMIOL COMMUNIT, V46, P1640; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	39	175	176	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					156	160						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563535				2022-12-01	WOS:A1996TR32500023
J	Javitt, JC; Aiello, LP				Javitt, JC; Aiello, LP			Cost-effectiveness of detecting and treating diabetic retinopathy	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			4-YEAR INCIDENCE; MELLITUS; DIAGNOSIS; AGE; PHOTOCOAGULATION; PROGRESSION; GUIDELINES; PREVALENCE; MORTALITY; SEVERITY	Objective: To determine, from the health insurer's perspective, the cost of preventing vision loss in patients with diabetes mellitus through ophthalmologic screening and treatment and to calculate the cost-effectiveness of these interventions as compared with that of other medical interventions. Design: Computer modeling, incorporating data from population-based epidemiologic studies and multicenter clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings. Results: Screening and treatment of eye disease in patients with diabetes mellitus costs $3190 per quality-adjusted life-year (QALY) saved. This average cost is a weighted average (based on prevalence of disease) of the cost-effectiveness of detecting and treating diabetic eye disease in those with insulin-dependent diabetes mellitus ($1996 per QALY), those with non-insulin-dependent diabetes mellitus (NIDDM) who use insulin for glycemic control ($2933 per QALY), and those with NIDDM who do not use insulin for glycemic control ($3530 per QALY). Conclusions: Our analysis indicates that prevention programs aimed at improving eye care for diabetic persons not only result in substantial federal budgetary savings but are highly cost-effective health investments for society. Ophthalmologic screening for diabetic persons is more cost-effective than many routinely provided health interventions. Because diabetic eye disease is the leading cause of new cases of blindness among working-age Americans, these results support the widespread use of screening and treatment for diabetic eye disease.	JOSLIN DIABET CTR, BEETHAM EYE INST, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Javitt, JC (corresponding author), GEORGETOWN UNIV, MED CTR, CTR SIGHT, 3800 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609	NEI NIH HHS [R21-EY07744, R01-EYO8805] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY007744, R01EY008805] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1979, Arch Ophthalmol, V97, P654; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], DIABETIC RETINOPATHY; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BRADFORD DF, 1983, PUBLIC EXPENDITURE P, P129; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499; CANNER JK, 1992, WIN P SIM C, V25, P1041; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; Davis M D, 1979, Trans Am Ophthalmol Soc, V77, P144; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; DRUMMOND M, 1987, CNSULTANT REPORT NAT; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; EVERHART J, 1985, NIH851468 US DEP HLT, P1; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; Johannesson M, 1992, Int J Technol Assess Health Care, V8, P359; Kenny S.J., 1995, NIH PUBLICATION, P47; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KLEIN HA, 1970, US DHEW73427; KLEIN R, 1985, DIABETES CARE, V8, P71, DOI 10.2337/diacare.8.1.S71; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1987, OPHTHALMOLOGY, V94, P747; KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1984, NIH851468 PUBLICATIO, P1; KNATTERUD GL, 1983, ISRAEL J MED SCI, V19, P424; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MARTIN DB, 1985, NIH851468 PHS US DEP, pR24; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; RING A, 1991, CLIN DIABETES MELLIT, P728; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; VANDER JF, 1991, OPHTHALMOLOGY, V98, P1575; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; 1993, MMWR-MORBID MORTAL W, V42, P191; 1989, DIABETES 2000 ELIMIN; 1992, LANCET, V340, P148; 1987, VITAL STATISTICS US, V2; ANAL EARLY TREATMENT; 1980, VISION PROBLEMS US S; 1988, VITAL STATISTICS US, V1, P17; 1990, AVERAGE MEDICARE ALL	54	270	274	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				164	169		10.7326/0003-4819-124-1_Part_2-199601011-00017	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554212				2022-12-01	WOS:A1996TL94400017
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ON THE INTERNET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-01	WOS:A1995TL16900011
J	GAN, SS; AMASINO, RM				GAN, SS; AMASINO, RM			INHIBITION OF LEAF SENESCENCE BY AUTOREGULATED PRODUCTION OF CYTOKININ	SCIENCE			English	Article							TOBACCO PLANTS	Controlling expression of IPT, a gene encoding isopentenyl transferase (the enzyme that catalyzes the rate-limiting step in cytokinin biosynthesis), with a senescence-specific promoter results in the suppression of leaf senescence. Transgenic tobacco plants expressing this chimeric gene do not exhibit the developmental abnormalities usually associated with IPT expression because the system is autoregulatory. Because sufficient cytokinin is produced to retard senescence, the activity of the senescence-specific promoter is attenuated. Senescence-retarded leaves exhibit a prolonged, photosynthetically active life-span. This result demonstrates that endogenously produced cytokinin can regulate senescence and provides a system to specifically manipulate the senescence program.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								Duvick D. N., 1984, Genetic contributions to yield gains of five major crop plants. Proceedings of a symposium sponsored by Division C-1 of the Crop Science Society of America, 2 December 1981, in Atlanta, Georgia, P15; GAN S, UNPUB; GARNER RJ, 1988, GRAFTERS HDB; HEWELT A, 1994, PLANT J, V6, P879, DOI 10.1046/j.1365-313X.1994.6060879.x; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; LI Y, 1992, DEV BIOL, V153, P386, DOI 10.1016/0012-1606(92)90123-X; LOHMAN KN, 1994, PHYSIOL PLANTARUM, V92, P322, DOI 10.1111/j.1399-3054.1994.tb05343.x; MARTINEAU B, 1994, PLANT J, V5, P11, DOI 10.1046/j.1365-313X.1994.5010011.x; NOODEN LD, 1979, SCIENCE, V206, P841, DOI 10.1126/science.206.4420.841; NOODEN LD, 1978, PHYTOHORMONES RELATE, V2, P329; RICHMOND AE, 1957, SCIENCE, V125, P650, DOI 10.1126/science.125.3249.650-a; SINGH S, 1992, PHYSIOL PLANTARUM, V86, P388, DOI 10.1111/j.1399-3054.1992.tb01334.x; SMART CM, 1991, PLANT CELL, V3, P647, DOI 10.1105/tpc.3.7.647; THOMAS H, 1980, ANNU REV PLANT PHYS, V31, P83, DOI 10.1146/annurev.pp.31.060180.000503	14	772	974	8	230	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1986	1988		10.1126/science.270.5244.1986	http://dx.doi.org/10.1126/science.270.5244.1986			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8592746				2022-12-01	WOS:A1995TL42000040
J	Weiss, EJ; Bray, PF; Tayback, M; Schulman, SP; Kickler, TS; Becker, LC; Weiss, JL; Gerstenblith, G; GoldschmidtClermont, PJ				Weiss, EJ; Bray, PF; Tayback, M; Schulman, SP; Kickler, TS; Becker, LC; Weiss, JL; Gerstenblith, G; GoldschmidtClermont, PJ			A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE ASPIRIN; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; GPIIB-IIIA; TRIAL; REINFARCTION; PREVENTION; DISEASE; THERAPY; PECTORIS	Background. Platelet glycoprotein IIb/IIIa is a membrane receptor for fibrinogen and von Willebrand factor, and it has an important role in platelet aggregation, It is known to be involved in the pathogenesis of acute coronary syndromes, Previously, we found a high frequency of a particular polymorphism, Pl(A2), of the gene encoding glycoprotein IIIa in kindreds with a high prevalence of premature myocardial infarction. Methods. To investigate the relation between the Pl(A2) polymorphism and acute coronary syndromes, we conducted a case-control study of 71 case patients with myocardial infarction or unstable angina and 68 inpatient controls without known heart disease, The groups were matched for age, race, and sex, We used two methods to determine the Pl(A2) genotype, reverse dot blot hybridization and allele-specific restriction digestion. Results. The prevalence of Pl(A2) was 2.1 times higher among the case patients than among the controls (39.4 percent vs, 19.1 percent, P=0.01), In a subgroup of patients whose disease began before the age of 60 years, the prevalence of Pl(A2) was 50 percent, a value that was 3.6 times that among control subjects under 60 years of age (13.9 percent, P=0.002), Among subjects with the Pl(A2) polymorphism, the odds ratio for having a coronary event was 2.8 (95 percent confidence interval, 1.2 to 6.4). In the patients less than 60 years of age at the onset of disease, the odds ratio was 6.2 (95 percent confidence interval, 1.8 to 22.4). Conclusions. We observed a strong association between the Pl(A2) polymorphism of the glycoprotein IIIa gene and acute coronary thrombosis, and this association was strongest in patients who had had coronary events before the age of 60 years. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BERNARD LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV HEMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR002241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49762] Funding Source: Medline; NINR NIH HHS [NR02241] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1980, CIRCULATION, V62, P449; BORNE AEGV, 1990, TRANSFUSION, V30, P477, DOI 10.1046/j.1537-2995.1990.30590296385.x; BRAY PF, 1994, BLOOD, V84, P4361, DOI 10.1182/blood.V84.12.4361.bloodjournal84124361; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Chandler A B, 1974, Am J Cardiol, V34, P823; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GOLD HK, 1990, J CLIN INVEST, V86, P651, DOI 10.1172/JCI114757; HOFFMAN W, 1991, PROSTAG LEUKOTR ESS, V44, P159, DOI 10.1016/0952-3278(91)90051-6; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; JIN Y, 1993, BLOOD, V82, P2281; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KICKLER TS, 1994, SCI BASIS TRANSFUSIO, P304; KIM HO, 1995, TRANSFUSION, V35, P863, DOI 10.1046/j.1537-2995.1995.351096026369.x; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KUNICKI TJ, 1979, MOL IMMUNOL, V16, P353, DOI 10.1016/0161-5890(79)90100-7; LAM JYT, 1986, J AM COLL CARDIOL, V8, P1380, DOI 10.1016/S0735-1097(86)80311-4; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MICKELSON JK, 1989, J MOL CELL CARDIOL, V21, P393, DOI 10.1016/0022-2828(89)90650-0; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1994, THROMBOSIS HEMORRHAG, P529; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RAMSEY G, 1986, TRANSFUSION, V26, P531, DOI 10.1046/j.1537-2995.1986.26687043619.x; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RIDKER PM, 1991, CIRCULATION, V84, P708, DOI 10.1161/01.CIR.84.2.708; SHULMAN NR, 1961, J CLIN INVEST, V40, P1597, DOI 10.1172/JCI104383; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VAN LOGHEM JJ J, 1959, Vox Sang, V4, P161; VERHEUGT FWA, 1990, AM J CARDIOL, V66, P267, DOI 10.1016/0002-9149(90)90833-M; WALLENTIN L, 1990, LANCET, V336, P827; Weiss EJ, 1995, TISSUE ANTIGENS, V46, P374, DOI 10.1111/j.1399-0039.1995.tb03129.x; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	41	624	650	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1090	1094		10.1056/NEJM199604253341703	http://dx.doi.org/10.1056/NEJM199604253341703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598867	Green Published			2022-12-01	WOS:A1996UG45700003
J	Lindpaintner, K; Lee, MA; Larson, MG; Rao, VS; Pfeffer, MA; Ordovas, JM; Schaefer, EJ; Wilson, AF; Wilson, PWF; Vasan, RS; Myers, RH; Levy, D				Lindpaintner, K; Lee, MA; Larson, MG; Rao, VS; Pfeffer, MA; Ordovas, JM; Schaefer, EJ; Wilson, AF; Wilson, PWF; Vasan, RS; Myers, RH; Levy, D			Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-FAILURE; HYPERTROPHY; TWINS; CELLS; CAPTOPRIL; RATS; POLYMORPHISM; HYPERTENSION; DYSFUNCTION; EXPRESSION	Background. Homozygous carriers of the D allele of the angiotensin-converting-enzyme (ACE) gene have been reported to be at increased risk for various cardiovascular disorders, including left ventricular hypertrophy. We investigated the potential role of the ACE gene in influencing left ventricular mass. Methods. Quantitative echocardiographic data and DNA samples were available for 2439 subjects from the Framingham Heart Study. ACE genotypes were determined by an assay based on the polymerase chain reaction. (The D allele of the ACE gene contains a deletion, whereas the I [insertion] allele does not.) Left ventricular mass and the prevalence of left ventricular hypertrophy, adjusted for clinical covariates, were analyzed according to genotype, Genetic linkage between the ACE locus and left ventricular mass was evaluated by quantitative analysis of pairs of siblings. Results. The ACE genotype was associated neither with left ventricular mass nor with the prevalence of left ventricular hypertrophy. Mean (+/-SE) left ventricular mass (adjusted for sex) among subjects carrying the DD, DI, and II genotypes was 165+/-1.6, 165+/-1.3, and 166+/-2.0 g, respectively (P=0.90). The prevalence of left ventricular hypertrophy among the three genotype groups was 15.6 percent, 13.6 percent, and 15.6 percent, respectively (P=0.36), and the adjusted relative risk of left ventricular hypertrophy associated with the DD genotype was 1.10 (95 percent confidence interval, 0.86 to 1.19). Linkage analysis in 759 pairs of siblings using both the ACE D/I marker and a microsatellite polymorphism at the neighboring locus for the human growth hormone gene failed to support any role of ACE in influencing left ventricular mass. Conclusions. The ACE genotype showed no association with echocardiographically determined left ventricular mass, nor did it confer an increased risk of left ventricular hypertrophy. We found no appreciable role of the ACE gene in influencing left ventricular mass.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV CARDIOL, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02118 USA; TUFTS UNIV, SCH MED,HUMAN NUTR RES CTR AGING,USDA, LIPID METAB LAB, BOSTON, MA USA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOMETRY & GENET, NEW ORLEANS, LA 70112 USA; NHLBI, BETHESDA, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Boston University; Boston University; Tufts University; United States Department of Agriculture (USDA); Framingham Heart Study; Louisiana State University System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lindpaintner, K (corresponding author), HARVARD UNIV, DIV CARDIOVASC DIS,DEPT MED,BRIGHAM & WOMENS HOSP, SCH MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Ramachandran, Vasan/Y-2527-2019; Wilson, Peter W.F./J-2455-2016; Levy, Daniel/ABF-6873-2021; Lee-Kirsch, Min Ae/C-5769-2018; Wilson, Alexander F./Q-6910-2019; Wilson, Alexander/C-2320-2009; Levy, Daniel/ABB-2752-2021; Ordovas, Jose/B-8727-2013	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Ordovas, Jose/0000-0002-7581-5680; Myers, Richard/0000-0002-8365-2674; Larson, Martin/0000-0002-9631-1254	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003138] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03655] Funding Source: Medline; NHLBI NIH HHS [K04-HL03138-01] Funding Source: Medline; PHS HHS [N01-38038] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; AMOS CI, 1989, GENET EPIDEMIOL, V6, P435, DOI 10.1002/gepi.1370060306; AMOS CL, 1989, GENET EPIDEMIOL, V6, P727; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BIELEN E, 1990, EUR HEART J, V11, P7, DOI 10.1093/oxfordjournals.eurheartj.a059595; BOEHNKE M, 1991, AM J HUM GENET, V48, P22; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; FABRIS B, 1990, CLIN EXP PHARMACOL P, V17, P309, DOI 10.1111/j.1440-1681.1990.tb01326.x; FAGARD R, 1987, AM J CARDIOL, V60, P1362, DOI 10.1016/0002-9149(87)90620-5; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HARSHFIELD GA, 1990, AM J HYPERTENS, V3, P538, DOI 10.1093/ajh/3.7.538; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; IWAI N, 1994, CIRCULATION, V90, P2622, DOI 10.1161/01.CIR.90.6.2622; IWAI N, 1992, J HYPERTENS, V10, P1155, DOI 10.1097/00004872-199210000-00007; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; JULIEN J, 1990, J AM COLL CARDIOL, V16, P137, DOI 10.1016/0735-1097(90)90470-A; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KUPARI M, 1994, AM J PHYSIOL, V267, pH1107, DOI 10.1152/ajpheart.1994.267.3.H1107; LANDRY F, 1985, JAMA-J AM MED ASSOC, V254, P77, DOI 10.1001/jama.254.1.77; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LAUER MS, 1994, AM J CARDIOL, V74, P487, DOI 10.1016/0002-9149(94)90909-1; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; *LOU STAT U CTR, 1991, SAGE STAT AN GEN EP; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POST WS, IN PRESS J AM COLL C; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; *SAS I, 1979, SAS STAT US GUID VER, P891; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SHURTLEFF D, 1974, NIH PUBLICATION; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; TIRET L, 1992, AM J HUM GENET, V51, P197; VERHAAREN HA, 1991, AM J CARDIOL, V68, P661, DOI 10.1016/0002-9149(91)90361-N; 1992, NEW ENGL J MED, V327, P1768	52	228	234	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1023	1028		10.1056/NEJM199604183341604	http://dx.doi.org/10.1056/NEJM199604183341604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598840				2022-12-01	WOS:A1996UE73300004
J	Sablin, EP; Kull, FJ; Cooke, R; Vale, RD; Fletterick, RJ				Sablin, EP; Kull, FJ; Cooke, R; Vale, RD; Fletterick, RJ			Crystal structure of the motor domain of the kinesin-related motor ncd	NATURE			English	Article							PROTEIN; DROSOPHILA; MOVEMENT	MICROTUBULE-BASED ATPases of the kinesin superfamily(1,2) provide the motile force for many animated features of living cells. Kinesin motors differ in their direction of movement along microtubules. Kinesin(3) and ncd(4,5), a kinesin-related motor involved in formation and maintenance of mitotic and meiotic spindles, move in opposite directions along microtubules, even though their motor domains are 40% identical in amino-acid sequence. Here we report the crystal structure of the MgADP complex of the Drosophila ncd motor domain determined to 2.5 Angstrom by X-ray crystallography, and compare it to the kinesin structure. The ncd and kinesin motor domains are remarkably similar in structure, and the locations of conserved surface amino acids suggest these motors share a common microtubule-binding site, Moreover, structural and functional comparisons of ncd, kinesin, myosin and G proteins indicate that these NTPases may have a similar strategy of changing conformation between NTP and NDP states. We propose a general model for converting a common gamma-phosphate-sensing mechanism into opposite polarities of movement for kinesin and ncd.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BOUME HR, 1990, NATURE, V348, P125; BOUME HR, 1991, NATURE, V349, P117; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hoenger A., 1995, Molecular Biology of the Cell, V6, p157A; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NABER N, 1995, PROTEIN SCI, V4, P1824, DOI 10.1002/pro.5560040917; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SABLIN EP, 1995, PROTEINS, V21, P68, DOI 10.1002/prot.340210108; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	28	318	324	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					555	559		10.1038/380555a0	http://dx.doi.org/10.1038/380555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606780				2022-12-01	WOS:A1996UE66300058
J	Shaw, GM; Velie, EM; Schaffer, D				Shaw, GM; Velie, EM; Schaffer, D			Risk of neural tube defect-affected pregnancies among obese women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALPHA-FETOPROTEIN LEVELS; MATERNAL WEIGHT	Objective.-To investigate the risk for neural tube defect (NTD)-affected pregnancies among obese women (ie, women with a body mass index [BMI] >29 kg/m(2)) compared with women of average prepregnancy weight. Design.-Population-based case-control study. Setting.-All hospitals in 55 of 58 counties in California. Participants.-In-person interviews were conducted with mothers of 538 (88% of eligible) NTD cases (including fetuses and infants electively terminated, stillborn, or born alive) and with mothers of 539 nonmalformed controls (88%) within an average of 5 months from the term delivery date. Main Outcome Measures.-The risk of an NTD-affected pregnancy among obese women. Results.-Compared with women whose BMI was less than or equal to 29 kg/m(2), an increased risk for NTD-affected pregnancy was observed among obese women (odds ratio, 1.9; 95% confidence interval, 1.3 to 2.9). The increased risk was not attributable to maternal nonuse of a vitamin containing folic acid, diabetes, use of diet pills, lower dietary folate intake, or an NTD-pregnancy history. Adjustment for maternal age, education, gravidity, use of vitamins, and use of alcohol did not change the odds ratio. The risk associated with maternal obesity was greater for spina bifida and for other less prevalent NTDs than for anencephaly. Conclusion.-Because as many as 10% of women maybe obese periconceptionally, the observed twofold increased risk is relevant to the population burden of NTDs.	KAISER PERMANENTE,DIV RES,OAKLAND,CA	Kaiser Permanente	Shaw, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,1900 POWELL ST,SUITE 1050,EMERYVILLE,CA 94608, USA.		Velie, Ellen/AAF-3493-2020	Shaw, Gary/0000-0001-7438-4914				BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; CAVDAR AO, 1980, TERATOLOGY, V22, P141, DOI 10.1002/tera.1420220116; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; EANDERSON WJF, 1958, LANCET, V1, P1305; Elwood JM, 1992, EPIDEMIOLOGY CONTROL, P521; FRIEL JK, 1995, AM J MED GENET, V55, P195, DOI 10.1002/ajmg.1320550209; HADDOW JE, 1982, BRIT J OBSTET GYNAEC, V89, P93, DOI 10.1111/j.1471-0528.1982.tb04646.x; JOHNSON AM, 1990, AM J OBSTET GYNECOL, V163, P9, DOI 10.1016/S0002-9378(11)90655-3; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MARTIN L, 1988, LANCET, V1, P640; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; *NAT AC SCI, 1990, NUTR PREGN, P5; PERRY GS, 1995, EPIDEMIOLOGY, V6, P61, DOI 10.1097/00001648-199501000-00012; RICHARDS ID, 1969, BRIT J PREV SOC MED, V23, P218; ROBERT E, 1995, REPROD TOXICOL, V9, P57, DOI 10.1016/0890-6238(94)00056-3; Ruge S, 1985, Obstet Gynecol Surv, V40, P57, DOI 10.1097/00006254-198502000-00001; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; *STAT EP RES CORP, 1991, EGRET VERS 0256; WALD N, 1981, BRIT J OBSTET GYNAEC, V88, P1094, DOI 10.1111/j.1471-0528.1981.tb01759.x; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; WALLER DK, 1995, AM J OBSTET GYNECOL, V172, P246, DOI 10.1016/0002-9378(95)90140-X; WATKINS M, 1994, AM J EPIDEMIOL, V139, pS11; WOLFE HM, 1990, OBSTET GYNECOL, V76, P339	23	273	274	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1093	1096		10.1001/jama.275.14.1093	http://dx.doi.org/10.1001/jama.275.14.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601928				2022-12-01	WOS:A1996UD02700025
J	Szarewski, A; Jarvis, MJ; Sasieni, P; Anderson, M; Edwards, R; Steele, SJ; Guillebaud, J; Cuzick, J				Szarewski, A; Jarvis, MJ; Sasieni, P; Anderson, M; Edwards, R; Steele, SJ; Guillebaud, J; Cuzick, J			Effect of smoking cessation on cervical lesion size	LANCET			English	Article							COTININE; NONSMOKERS; NICOTINE; SMOKERS; NEOPLASIA; CANCER; FLUIDS; MUCUS	Background Cigarette smoking has been postulated as a cofactor in the aetiology of cervical cancer, but a causal role is difficult to establish because of potential confounding by sexual behaviour. We have investigated the effect of cessation or reduction in cigarette smoking on the course of minor-grade cervical lesions. Methods In this intervention study 82 women volunteers with minor-grade lesions on colposcopy (cervical intraepithelial neoplasia grade 1 or less) attempted to give up smoking for 6 months. Smoking histories were taken at 3-monthly clinic visits and verified by measurement of salivary cotinine concentrations. At each clinic visit, a photograph of the cervix was taken; the image was digitised and computer-aided image analysis was used to assess lesion size, by investigators unaware of smoking status. Findings Of the 82 women, 17 stopped smoking completely for at least 6 months and 11 others reduced their smoking consumption by more than 75%. Of these 28 women, 23 (82%) showed a reduction in lesion size of at least 20% or 4 mm(2) compared with 13 (28%) of the 47 non-quitters (odds ratio 12.0 [95% CI 3.9-32.7]). The remaining seven women had unconfirmed smoking histories. There was a significant correlation between the extent of smoking reduction and the change in lesion size (chi(2) for trend=31.55, p<0.0001). Adjustment for social class, method of contraception, and stage of menstrual cycle did not affect the results. Interpretation Our findings support a link between smoking and cervical disease and suggest that smoking cessation could have a beneficial effect on early cervical abnormalities.	IMPERIAL CANC RES FUND, HLTH BEHAV UNIT, LONDON WC2A 3PX, ENGLAND; UNIV HOSP, DEPT HISTOPATHOL, NOTTINGHAM, ENGLAND; UCL HOSP TRUST, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND; MARGARET PYKE CTR RES & TRAINING FAMILY PLANNING, LONDON, ENGLAND	Cancer Research UK; Nottingham University Hospital NHS Trust; University of Nottingham; University College London Hospitals NHS Foundation Trust; University of London; University College London	Szarewski, A (corresponding author), IMPERIAL CANC RES FUND, DEPT MATH STAT & EPIDEMIOL, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Ruiz, Emilia Sanchez/K-3013-2013; Jarvis, Martin J/B-1034-2008	Ruiz, Emilia Sanchez/0000-0003-0522-8007; Jarvis, Martin J/0000-0001-9238-8038; Sasieni, Peter/0000-0003-1509-8744				BARTON SE, 1988, LANCET, V2, P652; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; FAIRLEY CK, 1995, AUST NZ J OBSTET GYN, V35, P181, DOI 10.1111/j.1479-828X.1995.tb01865.x; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; IARC, 1995, IARC MON EV CARC RIS, P64; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; LUESLEY D, 1994, BRIT J OBSTET GYNAEC, V101, P49, DOI 10.1111/j.1471-0528.1994.tb13009.x; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; POPPE WAJ, 1995, GYNECOL OBSTET INVES, V39, P34, DOI 10.1159/000292372; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SHAFI MI, 1994, BRIT J OBSTET GYNAEC, V101, P234, DOI 10.1111/j.1471-0528.1994.tb13116.x; STAFL A, 1981, AM J OBSTET GYNECOL, V139, P815, DOI 10.1016/0002-9378(81)90549-4; TERRY G, 1994, LANCET, V344, P1096, DOI 10.1016/S0140-6736(94)91757-4; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V106, P257, DOI 10.1093/oxfordjournals.aje.a112460; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9	20	80	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					941	943		10.1016/S0140-6736(96)91417-8	http://dx.doi.org/10.1016/S0140-6736(96)91417-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598759				2022-12-01	WOS:A1996UD59100012
J	Hoffmann, A; Chiang, CM; Oelgeschlager, T; Xie, XL; Burley, SK; Nakatani, Y; Roeder, RG				Hoffmann, A; Chiang, CM; Oelgeschlager, T; Xie, XL; Burley, SK; Nakatani, Y; Roeder, RG			A histone octamer-like structure within TFIID	NATURE			English	Article							IMMEDIATE EARLY PROTEIN; RNA POLYMERASE-II; TATA BOX; PROMOTER INTERACTIONS; PREINITIATION COMPLEX; TRANSCRIPTION FACTOR; INITIATION; BINDING	THE general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding(1,2), commits promoters within chromatin to transcription(3), and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment(4-7) or conformational changes in TFIID-promoter complexes(8,9). Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP)(2), TBP-associated factors (TAFs) that interact with and mediate the function of activators(2,7,10,11) and intersubunit interactions(2) but have yielded relatively little insight into the structural organization of the complete or the actual mechanism of transcriptional activation. Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15. Together with analyses of native TFIID complexes and accompanying crystallographic studies(12), the results suggest that there is a histone octamer-like TAF complex within TFIID.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,LABS MOL BIOPHYS,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NINCDS,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Oelgeschlager, Thomas/0000-0002-4086-719X; Burley, Stephen/0000-0002-2487-9713				ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BURLEY SK, IN PRESS REV BIOCH; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRUSS D, 1995, BIOESSAYS, V17, P1; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	30	159	162	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					356	359		10.1038/380356a0	http://dx.doi.org/10.1038/380356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598932				2022-12-01	WOS:A1996UC37900063
J	Eccles, M; Clapp, Z; Grimshaw, J; Adams, PC; Higgins, B; Purves, I; Russell, I				Eccles, M; Clapp, Z; Grimshaw, J; Adams, PC; Higgins, B; Purves, I; Russell, I			North of England evidence based guidelines development project: Methods of guideline development .1.	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUPUNCTURE; METAANALYSIS; TRIALS; PAIN		UNIV ABERDEEN, HLTH SERV RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND; ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; FREEMAN RD HOSP, NEWCASTLE UPON TYNE NE7 7DN, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT PRIMARY HLTH CARE, SOWERBY UNIT PRIMARY CARE INFORMAT, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV YORK, DEPT HLTH SCI & CLIN EVALUAT, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Aberdeen; Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), UNIV NEWCASTLE UPON TYNE, CTR HLTH SERV RES, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND.		Eccles, Martin P/AAD-4029-2020; Russell, Ian T/H-1181-2012; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				[Anonymous], 1993, THORAX, V48, pS1; [Anonymous], 1979, J CANADIAN MED ASS, V121, P1193; *CLIN RES AUD GROU, 1993, CLIN GUID REP WORK P; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Institute of Medicine, 1992, GUID CLIN PRACT DEV; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; *N ENGL STAB ANG G, IN PRESS BMJ; *ROYAL COLL GEN PR, 1995, 26 ROYAL COLL GEN PR; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; *U LEEDS, 1994, B U LEEDS, V8; 1996, BRIT MED J, V312, P762	20	129	144	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	1996	312	7033					760	762						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605466				2022-12-01	WOS:A1996UC16600040
J	denHeijer, M; Koster, T; Blom, HJ; Bos, GMJ; Briet, E; Reitsma, PH; Vandenbroucke, JP; Rosendaal, FR				denHeijer, M; Koster, T; Blom, HJ; Bos, GMJ; Briet, E; Reitsma, PH; Vandenbroucke, JP; Rosendaal, FR			Hyperhomocysteinemia as a risk factor for deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA HOMOCYSTEINE; PROTEIN-C; HOMOCYSTINURIA; DEFICIENCY; ARTERIAL; DISEASE	Background. Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis, To assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels In patients with a first episode of deep-vein thrombosis and in normal control subjects. Methods. We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed episode of deep-vein thrombosis and in 269 healthy controls matched to the patients according to age and sex, Hyperhomocysteinemia was defined as a plasma homocysteine level above the 95th percentile in the control group (18.5 mu mol per liter). Results. Of the 269 patients, 28 (10 percent) had plasma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2), The association between elevated homocysteine levels and venous thrombosis was stronger among women than among men and increased with age, The exclusion of subjects with other established risk factors for thrombosis (e.g., a deficiency of protein C, protein S, or antithrombin; resistance to activated protein C; pregnancy or recent childbirth; or oral-contraceptive use) did not materially affect the risk estimates. Conclusions. High plasma homocysteine levels are a risk factor for deep-vein thrombosis in the general population. (C) 1996, Massachusetts Medical Society.	LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS; UNIV NIJMEGEN HOSP,LAB PEDIAT & NEUROL,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Radboud University Nijmegen	denHeijer, M (corresponding author), MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,POB 40551,2504 LN THE HAGUE,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017; Martinelli, ida/J-2287-2015; Vandenbroucke, Jan/AAM-3928-2020	Rosendaal, Frits/0000-0003-2558-7496; Martinelli, ida/0000-0001-9218-3622; Vandenbroucke, Jan/0000-0001-5668-6716; Blom, Henk/0000-0001-5202-9241				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BIENVENU T, 1991, PRESSE MED, V20, P985; BLOM HJ, 1994, FIBRINOLYSIS, V8, P86, DOI 10.1016/0268-9499(94)90257-7; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DENHEIJER M, 1994, FIBRINOLYSIS S2, V8, P291; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; MUDD SH, 1985, AM J HUM GENET, V37, P1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1990, BLOOD, V75, P895; RODGERS GM, 1988, J CLIN INVEST, V81, P1911, DOI 10.1172/JCI113538; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Te Poele-Pothoff M. T. W. B., 1995, Annals of Clinical Biochemistry, V32, P218; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	25	881	894	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					759	762		10.1056/NEJM199603213341203	http://dx.doi.org/10.1056/NEJM199603213341203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592549	Green Published			2022-12-01	WOS:A1996TZ97900003
J	Haas, GG				Haas, GG			Antisperm antibodies in infertile men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SPERM-ASSOCIATED IMMUNOGLOBULINS; PENETRATION; BINDING; PLACEBO				Haas, GG (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT OBSTET & GYNECOL,SECT REPROD ENDOCRINOL INFERTIL,OKLAHOMA CITY,OK 73190, USA.							ACOSTA AA, 1994, FERTIL STERIL, V62, P826; ADEGHE AJH, 1989, INT J ANDROL, V12, P281, DOI 10.1111/j.1365-2605.1989.tb01315.x; ASCH RH, 1977, FERTIL STERIL, V28, P671; BRONSON RA, 1987, FERTIL STERIL, V48, P505; HAAS GG, 1987, FERTIL STERIL, V47, P295; HAAS GG, 1985, AM J REPROD IM MIC, V7, P109; HAAS GG, 1988, J ANDROL, V9, P190; HAAS GG, 1986, FERTIL STERIL, V46, P334; HAMILTON F, 1989, J IN VITRO FERTIL EM, V6, P342, DOI 10.1007/BF01138774; HENDRY WF, 1990, LANCET, V335, P85, DOI 10.1016/0140-6736(90)90548-J; LANSFORD B, 1990, J ANDROL, V11, P532; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P287, DOI 10.1016/0165-0378(91)90041-N	12	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					885	886		10.1001/jama.275.11.885	http://dx.doi.org/10.1001/jama.275.11.885			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596228				2022-12-01	WOS:A1996TZ97100034
J	Zwicker, J; Liu, NS; Engeland, K; Lucibello, FC; Muller, R				Zwicker, J; Liu, NS; Engeland, K; Lucibello, FC; Muller, R			Cell cycle regulation of E2F site occupation in vivo	SCIENCE			English	Article							TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE; BINDING PROTEIN; EXPRESSION; PRODUCT; CDNA; CLONING	DNA-binding E2F complexes have been identified throughout the mammalian cell cycle, including the transcriptionally inactive complexes with pocket proteins, which occur early in the prereplicative G(1) phase of the cycle, and the transactivating free E2F, which increases in late G(1). Here, a regulatory B-myb promoter site was shown to bind with high affinity to free E2F and to E2F-pocket protein complexes in an indistinguishable way in vitro. In contrast, in vivo footprinting with NIH 3T3 cells demonstrated E2F site occupation specifically in early G(1), when the B-myb promoter is inactive. These observations indicate that a novel mechanism governs E2F-DNA interactions during the cell cycle and emphasize the relevance of E2F site-directed transcriptional repression.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35033 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016; Engeland, Kurt/AAW-9965-2020	Müller, Rolf/0000-0003-3339-4248; Engeland, Kurt/0000-0003-3525-0440				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; ENGELAND K, UNPUB; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIU N, UNPUB; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, UNPUB	29	149	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1595	1597		10.1126/science.271.5255.1595	http://dx.doi.org/10.1126/science.271.5255.1595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599118				2022-12-01	WOS:A1996TZ98300045
J	Ferradini, L; Gu, H; DeSmet, A; Rajewsky, K; Reynaud, CA; Weill, JC				Ferradini, L; Gu, H; DeSmet, A; Rajewsky, K; Reynaud, CA; Weill, JC			Rearrangement-enhancing element upstream of the mouse immunoglobulin kappa chain J cluster	SCIENCE			English	Article							REGION GENE SEGMENTS; B-CELL; V(D)J RECOMBINATION; INTRON ENHANCER; TRANSCRIPTION; MICE; EXPRESSION; HEAVY; LOCUS; DISRUPTION	Transcriptional regulatory elements have been shown to be necessary but not sufficient for the developmental regulation of immunoglobulin gene rearrangement in mouse precursor B cells. In the chicken lambda light chain locus, additional elements in the V-J intervening sequence are involved in negative and positive regulation of rearrangement. Here, mutation of the mouse homolog of a chicken element, located in the V-kappa-J(kappa) intervening sequence upstream of the J(kappa) duster, was shown to significantly decrease rearrangement. This cis-acting recombination-enhancing element affects the rearrangement process without being involved in regulating transcription.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne	Ferradini, L (corresponding author), UNIV PARIS 05, FAC MED NECKER ENFANT MALAD,INST NECKER,INSERM, U373, 156 RUE VAUGIRARD, F-75730 PARIS 05, FRANCE.			Rajewsky, Klaus/0000-0002-6633-6370				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BUCCHINI D, 1987, NATURE, V326, P409, DOI 10.1038/326409a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; Ferradini L, 1994, Semin Immunol, V6, P165, DOI 10.1006/smim.1994.1022; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LECLERCQ L, 1989, NUCLEIC ACIDS RES, V17, P6809, DOI 10.1093/nar/17.17.6809; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; MEDINA CA, 1993, J EXP MED, V177, P1317, DOI 10.1084/jem.177.5.1317; NELSON KJ, 1984, NUCLEIC ACIDS RES, V12, P1911, DOI 10.1093/nar/12.4.1911; NISHI M, 1985, P NATL ACAD SCI USA, V82, P6399, DOI 10.1073/pnas.82.19.6399; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; RETH M, 1981, THESIS U COLOGNE COL; SAUER B, 1990, New Biologist, V2, P441; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; WEAVER D, 1987, P NATL ACAD SCI USA, V84, P1516, DOI 10.1073/pnas.84.6.1516; WOOD DL, 1984, P NATL ACAD SCI-BIOL, V81, P4756, DOI 10.1073/pnas.81.15.4756; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	41	64	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1996	271	5254					1416	1420		10.1126/science.271.5254.1416	http://dx.doi.org/10.1126/science.271.5254.1416			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596914				2022-12-01	WOS:A1996TY96100046
J	Eastman, QM; Leu, TMJ; Schatz, DG				Eastman, QM; Leu, TMJ; Schatz, DG			Initiation of V(D)J recombination in vitro obeying the 12/23 rule	NATURE			English	Article							MOUSE THYMOCYTES; DNA-SYNTHESIS; SIGNALS; INVITRO; BREAKS	V(D)J recombination the process that assembles antigen-receptor genes, is directed by signal sequences flanking the DNA segments to be joined. Signals consist of a conserved heptamer and nonamer separated by a spacer of either 12 or 23 base pairs. Recombination occurs almost exclusively between two signals with spacers of different lengths. This restriction, called the '12/ 23 rule', governs the organization and pattern of rearrangement of antigen-receptor loci(1,2). In vitro work demonstrating the direct roles of the Rag proteins in the initiation of V(D)J recombination did not recreate the 12/23 rule(3,4). Instead, double-strand breaks were formed efficiently at isolated signals. Here we show that extracts made from a lymphoid cell line that expresses truncated forms of the Rag1 and Rag2 proteins have a signal-cutting activity that obeys the 12/23 rule. Cleavage at the two signals is concerted and requires their synapsis, and mutations of one signal prevent cleavage at both.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; UNIV ZURICH IRCHEL,CH-8057 ZURICH,SWITZERLAND	Howard Hughes Medical Institute; Yale University; Yale University; University of Zurich			Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; HANIFORD D, 1994, EMBO J, V13, P3401, DOI 10.1002/j.1460-2075.1994.tb06643.x; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P5644; SHEEHAN KM, 1993, MOL CELL BIOL, V13, P1363, DOI 10.1128/MCB.13.3.1363; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	20	202	204	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					85	88		10.1038/380085a0	http://dx.doi.org/10.1038/380085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598914				2022-12-01	WOS:A1996TY87700063
J	Sewry, CA; Philpot, J; Sorokin, LM; Wilson, LA; Naom, I; Goodwin, F; DAlessandro, M; Dubowitz, V; Muntoni, F				Sewry, CA; Philpot, J; Sorokin, LM; Wilson, LA; Naom, I; Goodwin, F; DAlessandro, M; Dubowitz, V; Muntoni, F			Diagnosis of merosin (laminin-2) deficient congenital muscular dystrophy by skin biopsy	LANCET			English	Article								Background The alpha 2 chain of laminin-2 (merosin), encoded by a gene on chromosome 6q22, is deficient in about half the cases of congenital muscular dystrophy. Diagnosis of this condition has relied on immunocytochemical analysis of the alpha 2 chain in muscle biopsy specimens. We have observed that normal skin also expresses laminin alpha 2 in the basement membrane at the junction of the dermis and epidermis. Here we have investigated laminin alpha 2 deficiency in skin biopsy specimens from two patients with congenital muscular dystrophy. Participants Two patients with severe congenital muscular dystrophy gave informed consent to a shin biopsy. The girl was aged 10 and the boy was aged 7. The specimens were labelled with a commercially available mouse monoclonal antibody and a rat monoclonal antibody (4H8-2), which recognise an 80 and a 380 kDa fragment of the alpha 2 chain, respectively. The antibodies were visualised by standard methods. A muscle biopsy specimen was available for each case, and was processed with the skin biopsy samples (from the girl a few months previously, from the boy at age 14 days). Skin biopsies were done on four controls with normal expression of laminin alpha 2 on their skeletal muscle fibres. Findings We did not detect laminin alpha 2 in skin specimens from either case, although the controls were positive. The muscle biopsy specimens from the girl showed a few fibres, with traces of laminin alpha 2; those from the boy showed no laminin alpha 2. Interpretation Skin biopsy specimens will provide a useful alternative to muscle biopsy samples for the assessment of laminin-2 (merosin) status in congenital muscular dystrophy.	ROYAL POSTGRAD MED SCH,MUSCLE CELL BIOL GRP,MRC,CTR CLIN SCI,LONDON W12 0NN,ENGLAND; UNIV ERLANGEN NURNBERG,INST EXPT MED,W-8520 ERLANGEN,GERMANY	Imperial College London; University of Erlangen Nuremberg	Sewry, CA (corresponding author), ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,NEUROMUSCULAR UNIT,LONDON W12 0NN,ENGLAND.			Sorokin, Lydia/0000-0001-7704-7921				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; Dubowitz V., 1995, MUSCLE DISORDERS CHI; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; HELBLINGLECLERC, 1995, CR ACAD SCI PARIS LI, V318, P1245; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HILLAIRE D, 1994, HUM MOL GENET, V3, P1657, DOI 10.1093/hmg/3.9.1657; MERCURI E, 1995, NEUROPEDIATRICS, V26, P156, DOI 10.1055/s-2007-979746; MERCURI E, 1995, NEUROPEDIATRICS, V26, P3, DOI 10.1055/s-2007-979711; MUNTONI F, 1995, LANCET, V345, P591, DOI 10.1016/S0140-6736(95)90504-9; PHILPOT J, 1995, NEUROMUSCULAR DISORD, V5, P301, DOI 10.1016/0960-8966(94)00069-L; SCHULER F, 1995, J CELL SCI, V108, P3795; SEWRY CA, 1995, NEUROMUSCULAR DISORD, V5, P307, DOI 10.1016/0960-8966(94)00072-H; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351	16	72	74	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					582	584		10.1016/S0140-6736(96)91274-X	http://dx.doi.org/10.1016/S0140-6736(96)91274-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596321				2022-12-01	WOS:A1996TX69400012
J	Altman, RB; Merino, JE				Altman, RB; Merino, JE			Knotted umbilical cord	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Altman, RB (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.								0	2	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					573	573		10.1056/NEJM199602293340905	http://dx.doi.org/10.1056/NEJM199602293340905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569825				2022-12-01	WOS:A1996TW69600005
J	Cao, ZD; Henzel, WJ; Gao, XO				Cao, ZD; Henzel, WJ; Gao, XO			IRAK: A kinase associated with the interleukin-1 receptor	SCIENCE			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; DROSOPHILA EMBRYO; TRANSMEMBRANE PROTEIN; DORSOVENTRAL POLARITY; ARABIDOPSIS-THALIANA; GENE; TOLL; ACTIVATION	The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI). When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B). A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned. When human embryonic kidney cells (cell line 293) overexpressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated. The primary amino acid sequence of IRAK shares similarity with that of Pelle, a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.	GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech	Cao, ZD (corresponding author), TULARIK INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ING YL, 1994, ONCOGENE, V9, P1745; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MORAN TV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P9, DOI 10.1016/0167-4781(93)90031-8; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; STJOHNSTON D, 1992, CELL, V68, P201; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5	33	757	826	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1128	1131		10.1126/science.271.5252.1128	http://dx.doi.org/10.1126/science.271.5252.1128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599092				2022-12-01	WOS:A1996TW70100042
J	Pontoglio, M; Barra, J; Hadchouel, M; Doyen, A; Kress, C; Bach, JP; Babinet, C; Yaniv, M				Pontoglio, M; Barra, J; Hadchouel, M; Doyen, A; Kress, C; Bach, JP; Babinet, C; Yaniv, M			Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome	CELL			English	Article							ENRICHED TRANSCRIPTION FACTOR; DNA-BINDING; ALBUMIN GENE; EXPRESSION; PROTEIN; MOUSE; CELLS; HOMEODOMAIN; DOMAIN; HOMEOPROTEINS	HNF1 is a transcriptional activator of many hepatic genes including albumin, alpha 1-antitrypsin, and alpha- and beta-fibrinogen. It is related to the homeobox gene family and is predominantly expressed in liver and kidney. Mice lacking HNF1 fail to thrive and die around weaning after a progressive wasting syndrome with a marked liver enlargement. The transcription rate of genes like albumin and alpha 1-antitrypsin is reduced, while the gene coding for phenylalanine hydroxylase is totally silent, giving rise to phenylketonuria. Mutant mice also suffer from severe Fanconi syndrome caused by renal proximal tubular dysfunction. The resulting massive urinary glucose loss leads to energy and water wasting. HNF1-deficient mice may provide a model for human renal Fanconi syndrome.	INST PASTEUR,CTR NATL RECH SCI,URA 1960,UNITE BIOL DEV,F-75724 PARIS 15,FRANCE; HOP KREMLIN BICETRE,INSERM,U347,F-94276 LE KREMLIN BICETR,FRANCE; HOP KREMLIN BICETRE,BIOCHIM LAB,F-94276 LE KREMLIN BICETR,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Pontoglio, M (corresponding author), INST PASTEUR,DEPT BIOTECHNOL,CTR NATL RECH SCI,URA 1644,UNITE VIRUS ONCOGENES,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BESMOND C, 1983, BIOCHEM BIOPH RES CO, V117, P601, DOI 10.1016/0006-291X(83)91243-3; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BRADLEY A, 1987, TETATOCARCINOMAS EMB; BRENNER BM, 1991, KIDNEY; CAMPOS JR, 1991, EMBO J, V10, P1445; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P120; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KESNER L, 1975, CLIN CHEM, V21, P353; KOEPSELL H, 1990, J MEMBRANE BIOL, V114, P113, DOI 10.1007/BF01869093; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LAZZARO D, 1992, DEVELOPMENT, V114, P469; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONALD JD, 1988, J NEUROCHEM, V50, P655, DOI 10.1111/j.1471-4159.1988.tb02961.x; MCDONALD JD, 1990, P NATL ACAD SCI USA, V87, P1965, DOI 10.1073/pnas.87.5.1965; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROYER P, 1983, MOL CLONING; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG YB, 1994, J BIOL CHEM, V269, P9137; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; [No title captured]	44	480	496	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					575	585		10.1016/S0092-8674(00)81033-8	http://dx.doi.org/10.1016/S0092-8674(00)81033-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598044	Bronze			2022-12-01	WOS:A1996TX17600010
J	Dubnau, J; Struhl, G				Dubnau, J; Struhl, G			RNA recognition and translational regulation by a homeodomain protein	NATURE			English	Article							HOMEOTIC GENE ANTENNAPEDIA; DROSOPHILA EMBRYO; BICOID PROTEIN; MESSENGER-RNA; ANTERIOR PATTERN; POLY(A) TAIL; BINDING-SITE; MAJOR GROOVE; FUSHI-TARAZU; EXPRESSION	In Drosophila, the primary determinant of anterior pattern is the gradient morphogen bicoid (bcd), a homeodomain protein that binds DNA and transcriptionally activates target genes at different threshold concentrations. Here we present evidence that bcd also binds RNA and acts as a translational repressor to generate an opposing gradient of the homeodomain protein caudal (cad). RNA binding by bcd seems to involve direct interactions between the bcd homeodomain and discrete target sequences within the 3' untranslated region of the cad messenger RNA and to block the initiation of cad translation.			Dubnau, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,701 W 168 ST,NEW YORK,NY 10032, USA.			Dubnau, Josh/0000-0002-9285-7444				ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUBNAU J, 1995, THESIS COLUMBIA U; FISCHER JA, 1985, NUCLEIC ACIDS RES, V13, P6899, DOI 10.1093/nar/13.19.6899; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	42	286	290	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					694	699		10.1038/379694a0	http://dx.doi.org/10.1038/379694a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602214				2022-12-01	WOS:A1996TW56700042
J	Lois, C; GarciaVerdugo, JM; AlvarezBuylla, A				Lois, C; GarciaVerdugo, JM; AlvarezBuylla, A			Chain migration of neuronal precursors	SCIENCE			English	Article							DEVELOPING CEREBRAL-CORTEX; FIBRILLARY ACIDIC PROTEIN; RADIAL GLIAL FIBERS; RAT OLFACTORY-BULB; ADULT AVIAN BRAIN; CELL-MIGRATION; MONOCLONAL-ANTIBODY; SUBEPENDYMAL LAYER; GRANULE CELLS; OPTIC TECTUM	In the brain of adult mice, cells that divide in the subventricular zone of the lateral ventricle migrate up to 5 millimeters to the olfactory bulb where they differentiate into neurons. These migrating cells were found to move as chains through a well-defined pathway, the rostral migratory stream. Electron microscopic analysis of serial sections showed that these chains contained only closely apposed, elongated neuroblasts connected by membrane specializations. A second cell type, which contained glial fibrillary acidic protein, ensheathed the chains of migrating neuroblasts. Thus, during chain migration, neural precursors moved associated with each other and were not guided by radial glial or axonal fibers.	ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV VALENCIA,FAC BIOL,E-46100 VALENCIA,SPAIN	Rockefeller University; University of Valencia			García-Verdugo, José Manuel/L-8421-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; Alvarez-Buylla, Arturo/0000-0003-4426-8925	NICHD NIH HHS [HD32116] Funding Source: Medline; NINDS NIH HHS [NS28478] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028478, R37NS028478, R01NS028478] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; BONFANTI L, 1994, NEUROSCIENCE, V62, P291, DOI 10.1016/0306-4522(94)90333-6; BOURRAT F, 1990, J COMP NEUROL, V294, P1, DOI 10.1002/cne.902940102; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CULICAN SM, 1990, J NEUROSCI, V10, P684; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; GADISSEUX JF, 1992, J COMP NEUROL, V322, P246, DOI 10.1002/cne.903220210; GARCIAVERDUGO JM, 1986, J MORPHOL, V189, P189, DOI 10.1002/jmor.1051890209; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Herrup Karl, 1994, Current Opinion in Neurobiology, V4, P108, DOI 10.1016/0959-4388(94)90039-6; Jacobson M., 1991, DEV NEUROBIOLOGY; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KISHI K, 1990, ARCH HISTOL CYTOL, V53, P219, DOI 10.1679/aohc.53.219; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOPEZGARCIA C, 1988, DEV BRAIN RES, V43, P167, DOI 10.1016/0165-3806(88)90096-X; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; ONO K, 1990, ANAT EMBRYOL, V182, P11; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; PUELLES L, 1977, ANAT EMBRYOL, V150, P187, DOI 10.1007/BF00316650; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAYMOND PA, 1983, J NEUROSCI, V3, P1077; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; STAHELIN LA, 1974, INT REV CYTOL, V39, P191; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; 1970, ANAT REC, V166, P257	48	1030	1073	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					978	981		10.1126/science.271.5251.978	http://dx.doi.org/10.1126/science.271.5251.978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584933				2022-12-01	WOS:A1996TV70400046
J	Beare, S; Steward, WP				Beare, S; Steward, WP			Plasma free iron and chemotherapy toxicity	LANCET			English	Editorial Material							DEFEROXAMINE				Beare, S (corresponding author), QUEENS UNIV,NATL CANC INST CANADA,CLIN TRIALS GRP,KINGSTON,ON,CANADA.							AISEN P, 1992, ANN NEUROL, V32, pS62, DOI 10.1002/ana.410320711; BUSS JL, 1993, AGENTS ACTIONS, V40, P86, DOI 10.1007/BF01976756; CARMINE TC, 1995, CANCER LETT, V94, P219, DOI 10.1016/0304-3835(95)03852-N; DONFRANCESCO A, 1992, AM J CLIN ONCOL-CANC, V15, P319, DOI 10.1097/00000421-199208000-00009; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; GORDEUK VR, 1992, FEBS LETT, V308, P4, DOI 10.1016/0014-5793(92)81037-M; HAY J, 1991, ARCH TOXICOL, V65, P81, DOI 10.1007/BF02034932; KONTOGHIORGHES GJ, 1995, ANALYST, V120, P845, DOI 10.1039/an9952000845; MALISZA KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P680, DOI 10.1006/abbi.1995.1091; MARCIANI MG, 1991, HAEMATOLOGICA, V76, P131; SOBEL MM, 1991, MOL PHARMACOL, V41, P8; SPEYER JL, 1992, J CLIN ONCOL, V10, P117, DOI 10.1200/JCO.1992.10.1.117	12	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					342	343		10.1016/S0140-6736(96)90530-9	http://dx.doi.org/10.1016/S0140-6736(96)90530-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598694				2022-12-01	WOS:A1996TU69500002
J	Bolland, S; Kleckner, N				Bolland, S; Kleckner, N			The three chemical steps of Tn10/IS10 transposition involve repeated utilization of a single active site	CELL			English	Article							DNA STRAND TRANSFER; TN10 TRANSPOSITION; TN7 TRANSPOSITION; INVITRO PROCEEDS; TARGET SITE; MU-DNA; MECHANISM; RECOMBINATION; INTERMEDIATE; CATALYSIS	Nonreplicative transposition by Tn10/IS10 involves three chemical steps at each transposon end: cleavage of the two strands plus joining of one strand to target DNA. These steps occur within a synaptic complex comprising two transposon ends and monomers of IS10 transposase. We report four transposase mutations that individually abolish each of the three chemical steps without affecting the synaptic complex. We conclude that a single constellation of residues, the ''active site,'' directly catalyzes each of the three steps. Analyses of reactions containing mixtures of wild-type and catalysis-defective transposases indicate that a single transposase monomer at each end catalyzes the cleavage of two strands and that strand transfer is carried out by the same monomers that previously catalyzed cleavage. These and other data suggest that one active site unit carries out all three reactions in succession at one transposon end.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [R01 GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7314; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COEN ES, 1989, MOBILE DNA, P227; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; HUISMAN O, 1987, GENETICS, V116, P185; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWON D, 1995, P NATL ACAD SCI USA, V92, P8234, DOI 10.1073/pnas.92.18.8234; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596	38	85	86	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					223	233		10.1016/S0092-8674(00)80977-0	http://dx.doi.org/10.1016/S0092-8674(00)80977-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565068	Bronze			2022-12-01	WOS:A1996TR59500009
J	Gillis, CR; Hole, DJ				Gillis, CR; Hole, DJ			Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare survival outcome for patients with breast cancer cared for by specialist and non-specialist surgeons in a geographically defined area. Design-Retrospective study of all female patients aged under 75 years in the area treated between 1980 and June 1988 (before breast screening began). Patients were identified from the cancer registry and from pathology records of all hospitals in the area. Specialist surgeons were identified by one author. All other surgeons caring for patients from the area were considered non-specialists. Setting-A geographically defined population in urban west of Scotland. Subjects-3786 patients with histologically verified breast cancer operated on between 1 January 1980 and 30 June 1988 and followed to 31 December 1993. Main outcome measures-Five and 10 year survival rates for specialists and non-specialists; relative hazard ratios derived from Cox's proportional hazards model adjusted for prognostic factors-age, socioeconomic status, tumour size, and nodal involvement. Results-The five year survival rate was 9% higher and the 10 year survival 8% higher for patients cared for by specialist surgeons. A reduction in risk of dying of 16% (95% confidence interval 6% to 25%) was found after adjustment for age, tumour size, socioeconomic status, and nodal involvement. The benefit of specialist care was apparent for all age groups, for small and large tumours, and for tumours that did and did not affect the nodes and was consistent across all socioeconomic categories. Conclusions-Survival differences of the magnitude demonstrated have implications for the provision of services for the treatment of women with breast cancer. There is a need to improve equity in the treatment of breast cancer.			Gillis, CR (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND.							BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; CARSTAIRS V, 1988, DEPRIVATION HLTH SCO; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; HARDING MJ, 1993, LANCET, V341, P999, DOI 10.1016/0140-6736(93)91082-W; JUNOR EJ, 1994, BRIT J CANCER, V70, P363, DOI 10.1038/bjc.1994.307; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; OLIVOTTO IA, 1994, NEW ENGL J MED, V330, P805, DOI 10.1056/NEJM199403243301201; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SHARP L, 1993, CANCER REGISTRATION; 1992, LANCET, V339, P71; 1986, BRIT MED J, V293, P946	15	254	257	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					145	148		10.1136/bmj.312.7024.145	http://dx.doi.org/10.1136/bmj.312.7024.145			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563532	Green Published			2022-12-01	WOS:A1996TR32500019
J	Hu, DJ; Dondero, TJ; Rayfield, MA; George, JR; Schochetman, G; Jaffe, HW; Luo, CC; Kalish, ML; Weniger, BG; Pau, CP; Schable, CA; Curran, JW				Hu, DJ; Dondero, TJ; Rayfield, MA; George, JR; Schochetman, G; Jaffe, HW; Luo, CC; Kalish, ML; Weniger, BG; Pau, CP; Schable, CA; Curran, JW			The emerging genetic diversity of HIV - The importance of global surveillance for diagnostics, research, and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE PROTEIN; ZIDOVUDINE AZT; INFECTION; TYPE-1; AIDS; TRANSMISSION; SEQUENCE; RISK; RETROVIRUS	The discovery of highly divergent strains of human immunodeficiency virus (HIV) not reliably detected by a number of commonly used diagnostic tests has underscored the need for effective surveillance to track HIV variants and to direct research and prevention activities. Pathogens such as HIV that mutate extensively present significant challenges to effective monitoring of pathogens and to disease control, To date, relatively few systematic large-scale attempts have been made to characterize and sequence HIV isolates. For most of the world, including the United States, information an the distribution of HIV strains among different population groups Is limited. We describe herein the implications resulting from the rapid evolution of HIV and the need for systematic surveillance integrated with laboratory science and applied research. General surveillance guidelines are provided to assist in Identifying population groups for screening, in applying descriptive epidemiology and systematic sampling, and in developing and evaluating efficient laboratory testing algorithms. Timely reporting and dissemination of data is also an important element of surveillance efforts, Ultimately, the success of a global surveillance network depends on collaboration and on coordination of clinical laboratory, and epidemiologic efforts.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV AIDS STD & TB LAB RES, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	Hu, DJ (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HIV STD & TB PREVENT, DIV HIV AIDS PREVENT, MAILSTOP E-50, ATLANTA, GA 30333 USA.			Hu, Dale/0000-0002-0519-1032; Weniger, Bruce/0000-0002-5450-5464				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; ARTENSTEIN AW, 1995, LANCET, V346, P1197, DOI 10.1016/S0140-6736(95)92900-2; ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; ASHTON LJ, 1994, LANCET, V344, P718, DOI 10.1016/S0140-6736(94)92210-1; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOBKOV A, 1994, AIDS, V8, P1649, DOI 10.1097/00002030-199412000-00002; BOBKOV A, 1994, AIDS, V8, P619, DOI 10.1097/00002030-199405000-00007; BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CHEINGSONGPOPOV R, 1994, AIDS RES HUM RETROV, V10, P1379, DOI 10.1089/aid.1994.10.1379; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COURPOTIN C, 1994, PEDIATR INFECT DIS J, V13, P502; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DELAPORTE E, 1988, AIDS, V2, P136, DOI 10.1097/00002030-198804000-00013; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DOOLITTLE RF, 1989, NATURE, V339, P338, DOI 10.1038/339338a0; DUMITRESCU O, 1994, J INFECT DIS, V169, P281, DOI 10.1093/infdis/169.2.281; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ESSEX M, 1995, 3RD INT C AIDS AS PA; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FENYO EM, 1988, J VIROL, V62, P4414; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; GAO F, 1994, AIDS RES HUM RETROV, V10, P625, DOI 10.1089/aid.1994.10.625; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GURTLER LG, 1994, J VIROL, V68, P1581; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLMES EC, 1995, J INFECT DIS, V171, P45, DOI 10.1093/infdis/171.1.45; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KALISH ML, 1994, AIDS RES HUM RETROV, V10, P1573, DOI 10.1089/aid.1994.10.1573; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; KOSTRIKIS LG, 1995, J VIROL, V69, P6122, DOI 10.1128/JVI.69.10.6122-6130.1995; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUIKEN CL, 1993, P NATL ACAD SCI USA, V90, P9061, DOI 10.1073/pnas.90.19.9061; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; Lederberg J., 1992, EMERGING INFECT MICR; LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421; LI WH, 1988, MOL BIOL EVOL, V5, P313; LI WH, 1989, MOL BIOL EVOL, V6, P424; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561; LOUWAGIE J, 1992, AIDS RES HUM RETROV, V8, P1467, DOI 10.1089/aid.1992.8.1467; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; LUKASHOV VV, 1995, AIDS, V9, P435, DOI 10.1097/00002030-199509050-00004; LUO CC, 1995, LANCET, V345, P1051, DOI 10.1016/S0140-6736(95)90792-0; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; Myers G, 1994, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; OBRIEN TR, 1991, AIDS, V5, P85, DOI 10.1097/00002030-199101000-00012; OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PIENIAZEK D, 1995, EMERG INFECT DIS, V1, P86, DOI 10.3201/eid0103.950303; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; RUBSAMENWAIGMANN H, 1994, AIDS RES HUM RETROV, V10, P1401, DOI 10.1089/aid.1994.10.1401; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Schochetman G., 1994, AIDS TESTING COMPREH; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Sharp P.M., 1994, AIDS S1, V8, pS27; SHPAER EG, 1993, J MOL EVOL, V37, P57; SIEGRIST CA, 1994, LANCET, V344, P1771, DOI 10.1016/S0140-6736(94)92911-4; SMITH JD, 1994, AIDS RES HUM RETROV, V10, P577, DOI 10.1089/aid.1994.10.577; TSUCHIE H, 1995, INT J STD AIDS, V6, P117, DOI 10.1177/095646249500600211; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENIGER BG, 1994, AIDS, V8, pS13; WENIGER BG, 1994, 10TH INT C AIDS YOK; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015; WIKE CM, 1992, AIDS RES HUM RETROV, V8, P1297, DOI 10.1089/aid.1992.8.1297; WILLIAMSON C, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91543-5; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZEKENG L, 1994, AIDS, V8, P1626, DOI 10.1097/00002030-199411000-00020; ZHONG P, 1995, AIDS RES HUM RETROV, V11, P239, DOI 10.1089/aid.1995.11.239; 1993, MMWR-MORBID MORTAL W, V42, P948; 1995, MMWR-MORBID MORTAL W, V44, P603; 1981, MMWR-MORBID MORTAL W, V30, P305; 1993, MMWR-MORBID MORTAL W, V42, P329; 1990, MMWR-MORBID MORTAL W, V39, P489	119	224	227	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					210	216		10.1001/jama.275.3.210	http://dx.doi.org/10.1001/jama.275.3.210			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604174				2022-12-01	WOS:A1996TP28200029
J	May, EW; Craig, NL				May, EW; Craig, NL			Switching from cut-and-paste to replicative Tn7 transposition	SCIENCE			English	Article							BACTERIOPHAGE-MU; MICROSCOPIC ANALYSIS; MECHANISM; DNA; RECOMBINATION; INTERMEDIATE; INSERTION; PROTEIN; COINTEGRATION; PURIFICATION	The bacterial transposon Tn7 usually moves through a cut-and-paste mechanism whereby the transposon is excised from a donor site and joined to a target site io form a simple insertion. The transposon was converted to a replicative element that generated plasmid fusions in vitro and cointegrate products in vivo. This switch was a consequence of the separation of 5'- and 3'-end processing reactions of Tn7 transposition as demonstrated by the consequences of a single amino acid alteration in an element-encoded protein essential for normal cut-and-paste transposition. The mutation specifically blocked cleavage of the 5' strand at each transposon end without disturbing the breakage and joining or! the 3' strand, producing a fusion (the Shapiro Intermediate) that resulted in replicative transposition. The ability of Tn7 recombination products to serve as substrates for both the limited gap repair required to complete cut-and-paste transposition and the extensive DNA replication involved in cointegrate formation suggests a remarkable plasticity in Tn7's recruitment of host repair and replication functions.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								ARCISZEWSKA LK, 1991, J BIOL CHEM, V266, P21736; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; Berg D. E., 1989, MOBILE DNA; BIEL SW, 1984, GENETICS, V108, P319; BIERY M, UNPUB; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; CRAIG NL, 1989, MOBILE DNA, P211; CRAIG NL, 1995, CURR TOP MICROBIOL I, V204, P27; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; DERBYSHIRE KM, 1986, CELL, V47, P325, DOI 10.1016/0092-8674(86)90586-6; Galas D, 1989, MOBILE DNA, P109; GARY P, IN PRESS J MOL BIOL; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; KUBO KM, 1990, J BACTERIOL, V172, P2774, DOI 10.1128/jb.172.5.2774-2778.1990; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; MAY E, UNPUB; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; OHTSUBO E, 1980, COLD SPRING HARB SYM, V45, P283, DOI 10.1101/SQB.1981.045.01.041; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; Sambrook J., 1989, MOL CLONING LAB MANU; SARNOVSKY R, UNPUB; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHARPE PL, 1992, NUCLEIC ACIDS RES, V20, P2525; SHERRATT D, 1989, MOBILE DNA, P163; STELLWAGEN A, UNPUB; SURETTE MG, 1987, CELL, V49, P254; TANG Y, 1991, NUCLEIC ACIDS RES, V19, P3395, DOI 10.1093/nar/19.12.3395; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; WEINERT TA, 1983, SCIENCE, V222, P755, DOI 10.1126/science.6314502	39	84	87	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					401	404		10.1126/science.272.5260.401	http://dx.doi.org/10.1126/science.272.5260.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602527				2022-12-01	WOS:A1996UG25200044
J	Taylor, IK; Hill, AA; Hayes, M; Rhodes, CG; OShaughnessy, KM; OConnor, BJ; Jones, HA; Hughes, JMB; Jones, T; Pride, NB; Fuller, RW				Taylor, IK; Hill, AA; Hayes, M; Rhodes, CG; OShaughnessy, KM; OConnor, BJ; Jones, HA; Hughes, JMB; Jones, T; Pride, NB; Fuller, RW			Imaging allergen-invoked airway inflammation in atopic asthma with [F-18]-fluorodeoxyglucose and positron emission tomography	LANCET			English	Article							BRONCHOALVEOLAR LAVAGE; GLUCOSE-UTILIZATION; LOBAR PNEUMONIA; CHALLENGE; LUNG; METABOLISM; DENSITY; HUMANS	Background Airway inflammation is a feature of asthma and can be quantified invasively with bronchial lavage and endobronchial histology. Inflammatory foci can be imaged non-invasively with positron emission tomography (PET) and [F-18]-fluorodeoxyglucose ((18)FDG) to quantify glucose uptake in activated granulocytes. We used this technique to study airway inflammation in asthma. Methods Nine men with mild atopic asthma were studied. In five, we studied the effect of bronchoscopic segmental allergen challenge on (18)FDG uptake. Allergen was instilled into the posterior segment of the right upper lobe; a similar volume (20 mL) of isotonic saline was instilled into the posterior segment of the left upper lobe. At 1-32 h after instillation, PET with (18)FDG was done. In the other four patients, we administered aerosolised allergen. Findings (18)FDG uptake was increased four-fold in the right compared with the left upper lobe (geometric mean of ratios 4.30, 95% Cl 2.39-7.72, p=0.002). Aerosolised administration of allergen did not significantly increase (18)FDG uptake. Interpretation These data show that local allergen-invoked airway inflammation can be visualised with (18)FDG and PET in asthma. The cellular localisation of the (18)FDG signal remains to be determined.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RESP MED,LONDON W12,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,LONDON W12,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CYCLOTRON UNIT,LONDON W12,ENGLAND; GLAXO RES & DEV,GREENFORD,MIDDX,ENGLAND	Imperial College London; Imperial College London; Imperial College London; GlaxoSmithKline				Hill, Anthony/0000-0002-7605-9274				BRUDIN LH, 1994, EUR J NUCL MED, V21, P297, DOI 10.1007/BF00947964; DECHATELET LR, 1977, BLOOD, V50, P525; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; HASLETT C, 1989, AM REV RESPIR DIS, V140, P756, DOI 10.1164/ajrccm/140.3.756; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JONES HA, 1994, AM J RESP CRIT CARE, V149, P1635, DOI 10.1164/ajrccm.149.6.7516252; JONES HA, 1995, AM J RESP CRIT CARE, V151, pA343; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; NOLOP KB, 1987, CANCER, V60, P2682, DOI 10.1002/1097-0142(19871201)60:11<2682::AID-CNCR2820601118>3.0.CO;2-H; PANTIN CF, 1988, AM REV RESPIR DIS, V138, P1234, DOI 10.1164/ajrccm/138.5.1234; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; REISS M, 1978, J CLIN INVEST, V61, P480, DOI 10.1172/JCI108959; RHODES CG, 1981, J COMPUT ASSIST TOMO, V5, P783, DOI 10.1097/00004728-198112000-00001; ROBB R A, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P9; SAVERYMUTTU SH, 1985, THORAX, V40, P925, DOI 10.1136/thx.40.12.925; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; UEKI J, 1993, J APPL PHYSIOL, V75, P559, DOI 10.1152/jappl.1993.75.2.559; WASHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797; WOLLMER P, 1982, LANCET, V2, P1361	23	59	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					937	940		10.1016/S0140-6736(96)91416-6	http://dx.doi.org/10.1016/S0140-6736(96)91416-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598758				2022-12-01	WOS:A1996UD59100011
J	Scanziani, M; Malenka, RC; Nicoll, RA				Scanziani, M; Malenka, RC; Nicoll, RA			Role of intercellular interactions in heterosynaptic long-term depression	NATURE			English	Article							SYNAPTIC PLASTICITY; AREA CA1; HIPPOCAMPUS; POTENTIATION; RECEPTORS; INDUCTION; RAT; STIMULATION	BIDIRECTIONAL control of synaptic strength is thought to be important for the development of neuronal circuits and information storage. The demonstration of homosynaptic long-term depression(1) greatly enhances the usefulness of the synapse as a mnemonic device, but theoreticians have also seen the need for heterosynaptic decreases in synaptic efficacy, both in neuronal development(2-4) and information storage(5). Indeed, induction of long-term potentiation in one population of synapses can be associated with a modest depression at neighbouring inactive synapses in the same population of cells(6-10). Here we report that in the CA1 region of the hippocampus this heterosynaptic long-term depression has the property that its sites of induction and expression occur in different populations of cells and thus requires the spread of a signal between neurons. Such a mechanism ensures a widespread distribution of this form of plasticity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scanziani, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143, USA.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHRISTIE BR, 1994, HIPPOCAMPUS, V4, P127, DOI 10.1002/hipo.450040203; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DESMOND NL, 1991, BRAIN RES, V552, P93, DOI 10.1016/0006-8993(91)90664-H; GROVER LM, 1993, NEUROSCI LETT, V154, P39, DOI 10.1016/0304-3940(93)90166-I; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MANZONI OJ, 1994, SCIENCE, V265, P2098, DOI 10.1126/science.7916485; MARTIN KAC, 1988, Q J EXP PHYSIOL CMS, V73, P637, DOI 10.1113/expphysiol.1988.sp003190; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHREURS BG, 1993, BRAIN RES, V631, P235, DOI 10.1016/0006-8993(93)91540-9; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WICKENS JR, 1991, NEUROSCI LETT, V130, P128, DOI 10.1016/0304-3940(91)90244-N; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	27	89	90	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					446	450		10.1038/380446a0	http://dx.doi.org/10.1038/380446a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602244				2022-12-01	WOS:A1996UD59000064
J	Busettini, C; Masson, GS; Miles, FA				Busettini, C; Masson, GS; Miles, FA			A role for stereoscopic depth cues in the rapid visual stabilization of the eyes	NATURE			English	Article							OCULAR-FOLLOWING RESPONSES; DEPENDENCE	PRIMATES have visual tracking systems that help stabilize the eyes on the surroundings by responding to retinal image motion at ultra-short latencies(1,2). However, as the observer moves through the environment, the image motion on the retina depends on the three-dimensional structure of the scene(3,4). We report here that the very earliest of these tracking responses is elicited only by objects moving in the immediate vicinity of the plane of fixation: objects nearer or farther are ignored. This selectivity is achieved by means of a stereoscopic depth mechanism which uses the fact that the two eyes have differing viewpoints, so only objects in the plane of fixation have images that occupy corresponding positions on the two retinae. Such behaviour is readily explained by the known binocular properties of some motion-selective neurons in the visual cortex(5). Some (stereoanomalous) subjects showed highly specific tracking deficits as though lacking one subtype of these neurons.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				BUSETTINI C, 1991, J NEUROPHYSIOL, V66, P865, DOI 10.1152/jn.1991.66.3.865; BUSETTINI C, 1994, CONTEMPORARY OCULAR MOTOR AND VESTIBULAR RESEARCH: A TRIBUTE TO DAVID A. ROBINSON, P312; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GELLMAN RS, 1990, VISUAL NEUROSCI, V5, P107, DOI 10.1017/S0952523800000158; Gibson J.J., 1950, PERCEPTION VISUAL WO, DOI DOI 10.2307/1419017; HOWARD IP, 1989, EXP BRAIN RES, V78, P309; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; MILES FA, 1992, HEAD NECK SENSORY MO, P471; MILES FA, 1991, REPRESENTATIONS VISI, P185; MORGAN MJ, 1995, NATURE, V378, P380, DOI 10.1038/378380a0; POGGIO GF, 1995, CEREB CORTEX, V5, P193, DOI 10.1093/cercor/5.3.193	11	46	46	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					342	345		10.1038/380342a0	http://dx.doi.org/10.1038/380342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598928				2022-12-01	WOS:A1996UC37900059
J	Hein, HO; Suadicani, P; Gyntelberg, F				Hein, HO; Suadicani, P; Gyntelberg, F			Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: Six year follow up in the Copenhagen male study	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; MEN	Objectives-To investigate the interplay between use of alcohol, concentration of low density lipoprotein cholesterol, and risk of ischaemic heart disease. Design-Prospective study with controlling for several relevant confounders, including concentrations of other lipid fractions. Setting-Copenhagen male study, Denmark. Subjects-2826 men aged 53-74 years without overt ischaemic heart disease. Main outcome measure-Incidence of ischaemic heart disease during a six year follow up period. Results-172 men (6.1%) had a first ischaemic heart disease event. There was an overall inverse association between alcohol intake and risk of ischaemic heart disease. The association was highly dependent on concentration of low density lipoprotein cholesterol. In men with a high concentration (greater than or equal to 5.25 mmol/l) cumulative incidence rates of ischaemic heart disease were 16.4% for abstainers, 8.7% for those who drank 1-21 beverages a week, and 4.4% for those who drank 22 or more beverages a week. With abstainers as reference and after adjust ment for confounders, corresponding relative risks (95% confidence interval) were 0.4 (0.2 to 1.0; P<0.05) and 0.2 (0.1 to 0.8; P<0.01). In men with a concentration <3.63 mmol/l use of alcohol was not associated with risk. The attributable risk (95% confidence interval) of ischaemic heart disease among men with concentrations greater than or equal to 3.63 mmol/l who abstained from drinking alcohol was 43% (10% to 64%). Conclusions-In middle aged and elderly men the inverse association between alcohol consumption and risk of ischaemic heart disease is highly dependent on the concentration of low density lipoprotein cholesterol. These results support the suggestion that use of alcohol may in part explain the French paradox.			Hein, HO (corresponding author), STATE UNIV HOSP,RIGSHOSP 7122,EPIDEMIOL RES UNIT,DK-2200 COPENHAGEN N,DENMARK.							[Anonymous], 1982, EPIDEMIOLOGIC RES; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTELLI WP, 1977, LANCET, V2, P153; CASTELLI WP, 1984, AM J MED, V76, P2; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; FOLSOM AR, 1955, EUR HEART J SA, V16, P21; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; GYNTELBERG F, 1975, DAN MED BULL, V22, P81; HEIN HO, 1992, J INTERN MED, V232, P481, DOI 10.1111/j.1365-2796.1992.tb00620.x; HEIN HO, 1993, LANCET, V341, P392, DOI 10.1016/0140-6736(93)92987-5; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; NORUSIS MJ, 1988, SPSS PC PLUS BASE MA; NORUSIS MJ, 1988, SPSS PC PLUS ADV STA; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Rose G.A., 1982, CARDIOVASCULAR SURVE; ROSE GA, 1964, LANCET, V1, P296; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; Stahler F, 1977, Med Lab (Stuttg), V30, P29; SUADICANI P, 1994, INT J EPIDEMIOL, V23, P293, DOI 10.1093/ije/23.2.293; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; Svalastoga Kaare, 1959, PRESTIGE CLASS MOBIL; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1960, BRIT MED J, V2, P1665	34	98	99	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					736	741						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605458	Green Published			2022-12-01	WOS:A1996UC16600024
J	vanderSchouw, YT; vanderGraaf, Y; Steyerberg, EW; Eijkemans, MJC; Banga, JD				vanderSchouw, YT; vanderGraaf, Y; Steyerberg, EW; Eijkemans, MJC; Banga, JD			Age at menopause as a risk factor for cardiovascular mortality	LANCET			English	Article							CORONARY HEART-DISEASE; WOMEN; ESTROGEN	Background Although an association of occurrence of menopause and subsequent oestrogen deficiency with increased cardiovascular disease has been postulated, studies on this association have not shown convincing results. We investigated whether age at menopause is associated with cardiovascular mortality risk. Methods We studied a cohort of 12 115 postmenopausal women living in Utrecht, Netherlands, aged 50-65 years at enrolment in a breast cancer screening project. During follow-up of up to 20 years the women attended screening rounds at which we asked questions on menopausal status, age at menopause, medication use, cardiovascular risk factors, and ovarian function. Deaths were ascertained from the patient's family physicians. Life-table analysis and Cox regression analysis were used to investigate the association between age at menopause and cardiovascular mortality. All analyses were adjusted for biological age. Findings 824 women died of cardiovascular causes. 1459 women had left the study area. The risk of cardiovascular mortality was higher for women with early menopauses than for those with late menopauses. The age-adjusted hazard ratio of age at menopause was 0.982 (95% CI 0.968-0.996, p=0.01)-ie, for each year's delay in the menopause the cardiovascular mortality risk decreased by 2%. The extra risk of early menopause seemed to decrease with biological age (p for interaction 0.07); at biological age 60 the reduction of the annual hazard was 3%, but at age 80 there was no reduction. Adjustment for known cardiovascular risk factors and indicators of ovarian function did not significantly alter the risk estimate. Interpretation These results support the hypothesis that longer exposure to endogenous oestrogens protects against cardiovascular diseases. The effect of an early menopause may be more important at younger biological ages.	ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, CTR CLIN DECIS SCI, ROTTERDAM, NETHERLANDS; ACAD HOSP, DEPT INTERNAL MED, UTRECHT, NETHERLANDS	Erasmus University Rotterdam	vanderSchouw, YT (corresponding author), UNIV UTRECHT, DEPT EPIDEMIOL, POB 80035, 3508 TA UTRECHT, NETHERLANDS.		Eijkemans, Marinus J/D-8214-2013; van der Schouw, Yvonne T./F-8327-2014; Steyerberg, Ewout/C-1509-2018	van der Schouw, Yvonne T./0000-0002-4605-435X; Steyerberg, Ewout/0000-0002-7787-0122				BARRETTCONNOR E, 1995, BRIT MED J, V311, P1193, DOI 10.1136/bmj.311.7014.1193; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BEARD CM, 1984, AM J EPIDEMIOL, V120, P108, DOI 10.1093/oxfordjournals.aje.a113859; BENGTSSON C, 1973, ACTA MED SCAND S, V89, P75; BRAMBILLA DJ, 1989, J CLIN EPIDEMIOL, V42, P1031, DOI 10.1016/0895-4356(89)90044-9; BRESLOW NE, 1987, STAT METHODS CANCER, V2, P195; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; CORRAO JM, 1990, CARDIOLOGY, V77, P8, DOI 10.1159/000174649; DENTONKELAAR I, 1994, BRIT J CANCER, V69, P352, DOI 10.1038/bjc.1994.64; DEWAARD F, 1984, J CHRON DIS, V47, P41; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; LUOTO R, 1994, AM J EPIDEMIOL, V139, P64, DOI 10.1093/oxfordjournals.aje.a116936; Midgette A S, 1990, Epidemiology, V1, P474, DOI 10.1097/00001648-199011000-00010; PARRISH HM, 1967, AM J OBSTET GYNECOL, V99, P155; RIVIN AU, 1954, CIRCULATION, V9, P533, DOI 10.1161/01.CIR.9.4.533; ROBINSON RW, 1959, ARCH INTERN MED, V104, P908, DOI 10.1001/archinte.1959.00270120064010; ROSENBERG L, 1981, AM J OBSTET GYNECOL, V139, P47, DOI 10.1016/0002-9378(81)90410-5; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANFORD JL, 1987, J CHRON DIS, V40, P995, DOI 10.1016/0021-9681(87)90113-5; TRACY RE, 1966, J CHRON DIS, V19, P1245, DOI 10.1016/0021-9681(66)90022-1; WINKELSTEIN W Jr, 1958, J Chronic Dis, V7, P273, DOI 10.1016/0021-9681(58)90085-7; WUEST JH, 1953, CIRCULATION, V7, P801, DOI 10.1161/01.CIR.7.6.801	27	481	486	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	1996	347	9003					714	718		10.1016/S0140-6736(96)90075-6	http://dx.doi.org/10.1016/S0140-6736(96)90075-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602000	Green Submitted			2022-12-01	WOS:A1996TZ98200008
J	Perelson, AS; Neumann, AU; Markowitz, M; Leonard, JM; Ho, DD				Perelson, AS; Neumann, AU; Markowitz, M; Leonard, JM; Ho, DD			HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1	A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t(1/2) = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t(1/2) = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time-defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles-is 2.6 days, These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.	AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	United States Department of Energy (DOE); Los Alamos National Laboratory; Abbott Laboratories			Yang, Chen/G-1379-2010; Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [N01 AI45218, AI27742] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, N01AI045218] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; NATHANSON N, 1966, AM J EPIDEMIOL, V85, P494; NOWAK MA, 1995, NATURE, V375, P193, DOI 10.1038/375193a0; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Winslow D L, 1995, AIDS, V9 Suppl A, pS183	15	2623	2719	6	210	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1582	1586		10.1126/science.271.5255.1582	http://dx.doi.org/10.1126/science.271.5255.1582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599114				2022-12-01	WOS:A1996TZ98300041
J	Mok, A; Nelson, EAS				Mok, A; Nelson, EAS			Children on hunger strike: Child abuse or legitimate protest?	BRITISH MEDICAL JOURNAL			English	Article								The issue of children on hunger strike (voluntary total fasting) has not been reported before. The World Medical Association Declaration of Tokyo 1975 and the Declaration of Malta 1991 (revised 1992) provide clinicians with guidelines for the management of adult patients on hunger strike(12) but do not mention children. We report the management of 14 Vietnamese children, aged 1 to 12 years, who took part in a hunger strike at a refugee detention centre in Hong Kong.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PAEDIAT,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital			Nelson, E Anthony S/ABF-4238-2020	Nelson, E Anthony S/0000-0002-2521-3403				[Anonymous], 1989, CONV RIGHTS CHILD 20; DEVEREUX JA, 1993, BRIT MED J, V306, P1459, DOI 10.1136/bmj.306.6890.1459; KALK WJ, 1991, LANCET, V337, P660, DOI 10.1016/0140-6736(91)92465-E; SHIELD JP, 1994, BRIT MED J, V308, P1182, DOI 10.1136/bmj.308.6938.1182; 1994, S CHINA MORNING 0914; 1975, WORLD MED J, V22, P87; 1992, 44 WORLD MED ASS MAR; 1991, 43 WORLD MED ASS MAL	8	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					501	502		10.1136/bmj.312.7029.501	http://dx.doi.org/10.1136/bmj.312.7029.501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597690	Green Published			2022-12-01	WOS:A1996TX38300037
J	VanDaele, PLA; Seibel, MJ; Burger, H; Hofman, A; Grobbee, DE; VanLeeuwen, JPTM; Birkenhager, JC; Pols, HAP				VanDaele, PLA; Seibel, MJ; Burger, H; Hofman, A; Grobbee, DE; VanLeeuwen, JPTM; Birkenhager, JC; Pols, HAP			Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; UNIV HEIDELBERG,DEPT ENDOCRINOL & METAB,HEIDELBERG,GERMANY	Erasmus University Rotterdam; Erasmus University Rotterdam; Ruprecht Karls University Heidelberg			Grobbee, Diederick/C-7651-2014; van Leeuwen, Johannes/D-5015-2014	Grobbee, Diederick/0000-0003-4472-4468; van Leeuwen, Johannes/0000-0002-2282-4006; Seibel, Markus J/0000-0002-2701-378X				CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; JOHNSTON CC, 1994, OSTEOPOROSIS INT, V4, P43; LIPS P, 1990, BONE MINER, V9, P49, DOI 10.1016/0169-6009(90)90099-2; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107	5	154	156	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					482	483		10.1136/bmj.312.7029.482	http://dx.doi.org/10.1136/bmj.312.7029.482			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597681	Green Submitted, Green Published			2022-12-01	WOS:A1996TX38300025
J	Wang, TW; Danielson, PD; Li, BY; Shah, PC; Kim, SD; Donahoe, PK				Wang, TW; Danielson, PD; Li, BY; Shah, PC; Kim, SD; Donahoe, PK			The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PROTEIN FARNESYLTRANSFERASE; II RECEPTOR; P21RAS; CLONING; RECOGNITION; EXPRESSION; ACTIVATION	The alpha subunit of p21(RAS) farnesyltransferase (FNTA), which is also shared by geranylgeranyltransferase, was isolated as a specific cytoplasmic interactor of the transforming growth factor-beta (TGF-beta) and activin type I receptors with the use of the yeast two-hybrid system. FNTA interacts specifically with ligand-free TGF-beta type I receptor but is phosphorylated and released upon ligand binding. Furthermore, the release is dependent on the kinase activity of the TGF-beta type II receptor. Thus, the growth inhibitory and differentiative pathways activated by TGF-beta and activin involve novel mechanisms of serine-threonine receptor phosphorylation-dependent release of cytoplasmic interactors and regulation of the activation of small G proteins, such as p21(RAS).			Wang, TW (corresponding author), MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114, USA.				NICHD NIH HHS [R01 HD3081, R01 HD32112, HD28138] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112, P30HD028138] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES DA, 1993, GENOMICS, V18, P105, DOI 10.1006/geno.1993.1432; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WANG TW, UNPUB; WARANA JL, 1994, MOL CELL BIOL, V14, P944; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	34	109	111	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1120	1122		10.1126/science.271.5252.1120	http://dx.doi.org/10.1126/science.271.5252.1120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599089				2022-12-01	WOS:A1996TW70100039
J	Daltry, JC; Wuster, W; Thorpe, RS				Daltry, JC; Wuster, W; Thorpe, RS			Diet and snake venom evolution	NATURE			English	Article							RATTLESNAKE VENOM; RUSSELL VIPER; ISLAND; PREY	VENOM composition within snake species can show considerable geographical variation(1), an important consideration because bites by conspecific populations may differ in symptomatology and require different treatments(2-5). The underlying causes of this phenomenon have never been explained, Here we present evidence that the variation in the venom of the pitviper Calloselasma rhodostoma (Serpentes: Viperidae) is closely associated with its diet, We also evaluated other possible causes of geographic variation in venom using partial Mantel tests(6-10) and independent contrasts(11), but rejected both contemporary gene flow (estimated from geographical proximity) and the phylogenetic relationships (assessed by analysis of mitochondrial DNA) among populations as important influences upon venom evolution, As the primary function of viperid venom is to immobilize and digest prey(12-14) and prey animals vary in their susceptibility to venom(15,16), we suggest that geographical variation in venom composition reflects natural selection for feeding on local prey.	UNIV COLL N WALES, SCH BIOL SCI, BANGOR LL57 2UW, GWYNEDD, WALES	Bangor University			Wuster, Wolfgang/B-2879-2008	Wuster, Wolfgang/0000-0002-4890-4311; Daltry, Jennifer C./0000-0003-0364-9465				BARRIO AVELINO, 1951, ACTA PHYSIOL LATINOAMER, V1, P291; BOCHE J, 1981, B SOC PATHOL EXOT, V74, P356; BROWN RP, 1991, NATURE, V352, P60, DOI 10.1038/352060a0; CASTELLANO S, 1994, BIOL J LINN SOC, V52, P365, DOI 10.1006/bijl.1994.1057; CHEN YC, 1984, TOXICON, V22, P53, DOI 10.1016/0041-0101(84)90138-7; CHIPPAUX JP, 1991, TOXICON, V29, P1279, DOI 10.1016/0041-0101(91)90116-9; ELLIOTT WB, 1978, BIOL REPTILIA, V8, P163; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FELSENSTEIN J, 1990, PHYLIP VERSION 3 3; FOOTE R, 1977, COMP BIOCHEM PHYS B, V57, P235, DOI 10.1016/0305-0491(77)90150-X; GREGORYDWYER VM, 1986, TOXICON, V24, P995, DOI 10.1016/0041-0101(86)90005-X; HAYES WK, 1991, TOXICON, V29, P867, DOI 10.1016/0041-0101(91)90223-E; JAYANTHI GP, 1988, TOXICON, V26, P257, DOI 10.1016/0041-0101(88)90216-4; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; MACKESSY SP, 1988, COPEIA, P92, DOI 10.2307/1445927; MCELROY D, 1992, RESTRICTION ENZYME A; Minton S. A., 1969, VENOMOUS REPTILES; MORITZ C, 1992, SYST BIOL, V41, P273, DOI 10.2307/2992567; POUGH FH, 1983, AM ZOOL, V23, P443; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Tan N.-H., 1991, Tropical Biomedicine, V8, P91; THOMAS RG, 1979, TOXICON, V17, P221, DOI 10.1016/0041-0101(79)90211-3; Thorpe R.S., 1994, Linnean Society Symposium Series, V17, P189; THORPE RS, 1995, PHILOS T ROY SOC B, V349, P61, DOI 10.1098/rstb.1995.0091; THORPE RS, 1993, BIOL J LINN SOC, V48, P75, DOI 10.1111/j.1095-8312.1993.tb00878.x; TU AT, 1978, J HERPETOL, V12, P105, DOI 10.2307/1563515; TU AT, 1968, NATURE, V217, P761; WARRELL DA, 1986, NATURAL TOXINS ANIMA, P00025; WUSTER W, 1992, BIOL J LINN SOC, V47, P97, DOI 10.1111/j.1095-8312.1992.tb00658.x	29	486	497	1	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					537	540		10.1038/379537a0	http://dx.doi.org/10.1038/379537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596631				2022-12-01	WOS:A1996TU69300049
J	Pisetsky, DS				Pisetsky, DS			The breakthrough	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Pisetsky, DS (corresponding author), DUKE UNIV, MED CTR,VET AFFAIRS MED CTR,BOX 151G,ROOM E-1008, 508 FULTON ST, DURHAM, NC 27705 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					345	347		10.7326/0003-4819-124-3-199602010-00013	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554234				2022-12-01	WOS:A1996TR59600013
J	Acton, S; Rigotti, A; Landschulz, KT; Xu, SZ; Hobbs, HH; Krieger, M				Acton, S; Rigotti, A; Landschulz, KT; Xu, SZ; Hobbs, HH; Krieger, M			Identification of scavenger receptor SR-BI as a high density lipoprotein receptor	SCIENCE			English	Article							CHOLESTERYL LINOLEYL ETHER; APOPROTEIN-A-I; SELECTIVE UPTAKE; MEDIATED ENDOCYTOSIS; HEPATOMA-CELLS; ADRENAL-GLAND; RAT; ESTERS; METABOLISM; HEPATOCYTES	High density lipoprotein (HDL) and low density lipoprotein (LDL) are cholesterol transport particles whose plasma concentrations are directly (LDL) and inversely (HDL) correlated with risk for atherosclerosis. LDL catabolism involves cellular uptake and degradation of the entire particle by a well-characterized receptor. HDL, in contrast, selectively delivers its cholesterol, but not protein, to cells by unknown receptors. Here it is shown that the class B scavenger receptor SR-BI is an HDL receptor. SR-BI binds HDL with high affinity, is expressed primarily in liver and nonplacental steroidogenic tissues, and mediates selective cholesterol uptake by a mechanism distinct from the classic LDL receptor pathway.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Girelli, Domenico/B-1183-2008; Eckhardt, Erik/G-1567-2010	Girelli, Domenico/0000-0001-9684-1899; 	NHLBI NIH HHS [HL09047, HL41484, HL52212] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, F32HL009047, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSEN JM, 1981, J BIOL CHEM, V256, P7362; ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; ASSRNAN G, 1995, METABOLIC MOL BASES, P2053; BABITT J, UNPUB; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; Brown M S, 1979, Recent Prog Horm Res, V35, P215; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Converse CA, 1992, LIPOPROTEIN ANAL PRA; DELAMATRE JG, 1991, J CELL PHYSIOL, V146, P18, DOI 10.1002/jcp.1041460104; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; MACKINNON M, 1986, J BIOL CHEM, V261, P2548; MURPHY BD, 1985, ENDOCRINOLOGY, V116, P1587, DOI 10.1210/endo-116-4-1587; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WISHART R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P375, DOI 10.1016/0005-2760(90)90083-A	43	1932	2047	1	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					518	520		10.1126/science.271.5248.518	http://dx.doi.org/10.1126/science.271.5248.518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560269				2022-12-01	WOS:A1996TR32200046
J	Patz, JA; Epstein, PR; Burke, TA; Balbus, JM				Patz, JA; Epstein, PR; Burke, TA; Balbus, JM			Global climate change and emerging infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AEDES-AEGYPTI DIPTERA; SUB-SAHARAN AFRICA; CONTACT HYPERSENSITIVITY; SCHISTOSOMA-HAEMATOBIUM; ULTRAVIOLET-IRRADIATION; IMMUNE-SYSTEM; UV-RADIATION; SEA-LEVEL; TEMPERATURE; SUPPRESSION	Climatic factors influence the emergence and reemergence of infectious diseases, in addition to multiple human, biological, and ecological determinants. Climatologists have identified upward trends in global temperatures and now estimate an unprecedented rise of 2.0 degrees C by the year 2100. Of major concern is that these changes can affect the introduction and dissemination of many serious infectious diseases. The incidence of mosquito-borne diseases, including malaria, dengue, and viral encephalitides, are among those diseases most sensitive to climate. Climate change would directly affect disease transmission by shifting the vector's geographic range and increasing reproductive and biting rates and by shortening the pathogen incubation period. Climate-related increases in sea surface temperature and sea level can lead to higher incidence of water-borne infectious and toxin-related illnesses, such as cholera and shellfish poisoning. Human migration and damage to health infrastructures from the projected increase in climate variability could indirectly contribute to disease transmission. Human susceptibility to infections might be further compounded by malnutrition due to climate stress on agriculture and potential alterations in the human immune system caused by increased flux of ultraviolet radiation. Analyzing the role of climate in the emergence of human infectious diseases will require interdisciplinary cooperation among physicians, climatologists, biologists, and social scientists. Increased disease surveillance; integrated modeling, and use of geographically based data systems wilt afford more anticipatory measures by the medical community. Understanding the linkages between climatological and ecological change as determinants of disease emergence and redistribution will ultimately help optimize preventive strategies.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DIV ENVIRONM & OCCUPAT MED,WASHINGTON,DC 20052	Johns Hopkins University; Harvard University; Harvard Medical School; George Washington University	Patz, JA (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA.							ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; ANDERSON DM, 1992, HARMFUL ALGAE NEWS, V2, P4; [Anonymous], 1992, IARC MONOGRAPHS EVAL, V55; BAADSGAARD O, 1991, ARCH DERMATOL, V127, P99, DOI 10.1001/archderm.127.1.99; BARNOLA JM, 1994, TRENDS 93 COMPENDIUM, V65; Benenson AS, 1990, CONTROL COMMUNICABLE, V15th; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; BOWEN SG, 1980, ST LOUIS ENCEPHALITI; Brown A. W. A., 1983, Integrated mosquito control methodologies. Volume 1. Experience and components from conventional chemical control, P161; BRUCE JP, 1994, B AM METEOROL SOC, V75, P1831, DOI 10.1175/1520-0477(1994)075<1831:NDRAGC>2.0.CO;2; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CESTARI TF, 1995, J INVEST DERMATOL, V105, P8, DOI 10.1111/1523-1747.ep12312309; CHANDLER AC, 1945, AM J TROP MED, V25, P145; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; CRUZ PD, 1988, PHOTODERMATOLOGY, V5, P151; DAYNES RA, 1990, GLOBAL ATMOSPHERIC C; DEFABO EC, 1983, J EXP MED, V157, P84; DOBSON A, 1993, LANCET, V342, P1096, DOI 10.1016/0140-6736(93)92069-6; DOBSON A, 1992, GLOBAL WARMING BIOL; EPSTEIN PR, 1995, AM J PUBLIC HEALTH, V85, P168, DOI 10.2105/AJPH.85.2.168; EPSTEIN PR, 1994, DIS EVOLUTION GLOBAL, P423; Figueroa M, 1982, Bull Pan Am Health Organ, V16, P130; FLAVIN C, 1994, WORLD WATCH, V7, P10; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; GIANNINI MS, 1990, GLOBAL ATMOSPHERIC C; Gilles HM., 1993, BRUCE CHWATTS ESSENT, V3rd ed.; GILLETT JD, 1974, EFFECTS METEOROLOGIC, P79; Glantz M.H., 1991, TELECONNECTIONS LINK; GLASS GE, 1993, APPLICATIONS GIS TEC; GREENWOOD BM, 1984, LANCET, V1, P1339; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; Haile D.G., 1989, POTENTIAL EFFECTS GL; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; HALSTEAD SB, 1988, HDB VIRAL RICKETTSIA, P85; Halstead Scott B., 1993, Tropical Medicine, V35, P137; HARDY JL, 1988, ARBOVIRUSES EPIDEMIO, V1; HERRERABASTO E, 1992, AM J TROP MED HYG, V46, P649, DOI 10.4269/ajtmh.1992.46.649; HERSEY P, 1983, J IMMUNOL, V31, P171; Houghton J.T., 1990, CLIMATE CHANGE IPCC; Houghton J.T., 1992, CLIMATE CHANGE 1992; HUQ A, 1990, APPL ENVIRON MICROB, V56, P2370, DOI 10.1128/AEM.56.8.2370-2373.1990; JEEVAN A, 1990, CELL IMMUNOL, V130, P32, DOI 10.1016/0008-8749(90)90159-O; JETTEN TH, 1994, CHANGE, V18, P10; KARL TR, 1993, B AM METEOROL SOC, V74, P1007, DOI 10.1175/1520-0477(1993)074<1007:ANPORG>2.0.CO;2; KARL TR, 1995, NATURE, V377, P217, DOI 10.1038/377217a0; Karl TR, 1995, CONSEQUENCES, V1, P3; KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032; Kiladis GN, 1989, J CLIMATE, V2, P1069, DOI 10.1175/1520-0442(1989)002<1069:GCAAWE>2.0.CO;2; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; KRIPKE ML, 1986, J INVEST DERMATOL, V86, P543, DOI 10.1111/1523-1747.ep12355000; KRIPKE ML, 1992, EFFECTS HUMAN HLTH U; LARCOM LL, 1990, J NATL CANCER I, V82, P1361, DOI 10.1093/jnci/82.16.1361; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Lederberg J., 1992, EMERGING INFECT MICR; Lembeye G., 1992, HARMFUL ALGAE NEWS, V2, P1; LEVINS R, 1994, AM SCI, V82, P52; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MACDONALD G, 1954, TROPICAL DIS B, V50, P871; MACDONALD W W, 1956, Ann Trop Med Parasitol, V50, P399; MARTENS WJM, 1995, ENVIRON HEALTH PERSP, V103, P458, DOI 10.2307/3432584; MARTENS WJM, 1994, GLOBAL DYNAMICS SUST, V3; MARTENS WJM, 1995, GLOBO REPORT SERIES, V10; MASKELL K, 1993, LANCET, V342, P1027, DOI 10.1016/0140-6736(93)92883-U; Matsuoka Y., 1995, J GLOBAL ENV ENG, V1, P43; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; McMichael AJ., 1995, ECOSYST HEALLTH, V1, P23; MEARNS LO, 1993, DROUGHT ASSESSMENT M, P109; Mills D., 1995, PUBLICATIONS CLIMATO, V48, P1; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; MONATH TP, 1987, AM J TROP MED HYG, V37, pS40, DOI 10.4269/ajtmh.1987.37.40S; MONATH TP, 1990, PRINCIPLES PRACTICE; MOORE PS, 1992, CLIN INFECT DIS, V14, P515, DOI 10.1093/clinids/14.2.515; MORISON WL, 1989, PHOTOCHEM PHOTOBIOL, V50, P515, DOI 10.1111/j.1751-1097.1989.tb05557.x; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; Nicholls N., 1991, TELECONNECTIONS LINK, P493; NODEN BH, IN PRESS PARASITOLOG; NOONAN FP, 1981, PHOTOCHEM PHOTOBIOL, V34, P683, DOI 10.1111/j.1751-1097.1981.tb09064.x; Oaks SC, 1991, MALARIA OBSTACLES OP; PANT CP, 1973, J MED ENTOMOL, V10, P219, DOI 10.1093/jmedent/10.2.219; PARRILLA G, 1994, NATURE, V369, P204; PARRY ML, 1993, LANCET, V342, P1345, DOI 10.1016/0140-6736(93)92251-N; PATZ JA, 1995, WORLD RESOURCE REV, V7, P104; PATZ JA, IN PRESS CLIMATE RES; RAPER SCB, 1995, RISING SEA LEVEL SUB; REEVES WC, 1994, J MED ENTOMOL, V31, P323, DOI 10.1093/jmedent/31.3.323; REISEN WK, 1993, J MED ENTOMOL, V30, P151, DOI 10.1093/jmedent/30.1.151; REITER P, 1988, ARBOVIRUSES EPIDEMIO, P245; ROGERS DJ, 1991, NATURE, V351, P739, DOI 10.1038/351739a0; ROGERS DJ, 1993, LANCET, V342, P1282, DOI 10.1016/0140-6736(93)92367-3; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; RUEDA LM, 1990, J MED ENTOMOL, V27, P892, DOI 10.1093/jmedent/27.5.892; Schneider S.H., 1990, GLOBAL WARMING ARE W; SCOTT TW, 1993, J MED ENTOMOL, V30, P922, DOI 10.1093/jmedent/30.5.922; SHIFF CJ, 1979, T ROY SOC TROP MED H, V73, P375, DOI 10.1016/0035-9203(79)90157-3; SHIFF CJ, 1975, INT J PARASITOL, V5, P119; SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227; Shope R.E., 1990, GLOBAL ATMOSPHERIC C; SHOPE RE, 1980, YALE J BIOL MED, V53, P93; STONE R, 1993, SCIENCE, V262, P833, DOI 10.1126/science.8235603; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; TAYLOR P, 1986, T ROY SOC TROP MED H, V80, P12, DOI 10.1016/0035-9203(86)90185-9; TESTER P, 1991, HLTH ENV DIGEST, V5, P4; Titus J. G., 1995, PROBABILITY SEA LEVE; TRENT DW, 1983, VIROLOGY, V128, P271, DOI 10.1016/0042-6822(83)90255-6; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; VANDERLEUN JC, 1991, ENV EFFECTS OZONE DE; WASHINO RK, 1994, AM J TROP MED HYG, V50, P134, DOI 10.4269/ajtmh.1994.50.134; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; WENZEL RP, 1994, NEW ENGL J MED, V330, P1004, DOI 10.1056/NEJM199404073301410; WHETTON PH, 1993, CLIMATIC CHANGE, V25, P289, DOI 10.1007/BF01098378; WIGLEY TML, 1992, NATURE, V357, P293, DOI 10.1038/357293a0; WJMcG Tegart, 1990, CLIMATE CHANGE IPCC, DOI Australian Government Publishing Service; WOLFF K, 1983, J INVEST DERMATOL, V80, pS17, DOI 10.1111/1523-1747.ep12536750; ZULUETA J, 1980, T R SOC TROP MED HYG, V74, P624; 1985, 10 YEARS ONCHOCERCIA; 1992, 9404 SCRIPPS I OC RE; 1989, MMWR-MORBID MORTAL W, V38, P440; 1994, RAD FORCING CLIMATE; 1990, POTENTIAL HLTH EFFEC; 1994, DENGUE DENGUE HEMORR, P98; IN PRESS CLIMATE CHA; 1991, 1991 ENSO CLIM CHANG	128	420	450	8	327	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					217	223		10.1001/jama.275.3.217	http://dx.doi.org/10.1001/jama.275.3.217			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604175				2022-12-01	WOS:A1996TP28200030
J	Mortier, E; Pouchot, J; Girard, L; Boussougant, Y; Vinceneux, P				Mortier, E; Pouchot, J; Girard, L; Boussougant, Y; Vinceneux, P			Assessment of urine analysis for the diagnosis of tuberculosis	BRITISH MEDICAL JOURNAL			English	Article									UNIV PARIS 07,HOP LOUIS MOURIER,DEPT MICROBIOL,F-92700 COLOMBES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite	Mortier, E (corresponding author), UNIV PARIS 07,HOP LOUIS MOURIER,DEPT INTERNAL MED,F-92700 COLOMBES,FRANCE.							BARBEZAT C, 1981, SCHWEIZ RUNDSCH MED, V70, P241; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BENTZ RR, 1975, AM REV RESPIR DIS, V111, P647; FAVEZ G, 1972, SCHWEIZ MED WSCHR, V102, P877; GARCIARODRIGUEZ JA, 1994, CLIN INFECT DIS, V18, P557, DOI 10.1093/clinids/18.4.557	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					27	28		10.1136/bmj.312.7022.27	http://dx.doi.org/10.1136/bmj.312.7022.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555854	Green Published			2022-12-01	WOS:A1996TP20900020
J	Torgerson, DJ; Spencer, A				Torgerson, DJ; Spencer, A			Marginal costs and benefits	BRITISH MEDICAL JOURNAL			English	Article								Decision makers are interested in measuring the costs and benefits of various interventions, and sometimes they are presented with the average costs and benefits of alternative interventions and asked to compare these. Usually a newer intervention is being compared with an existing one, and the most appropriate comparison is not of average costs (and benefits) but of the extra-or marginal-costs (and benefits) of the new intervention. Reanalysis of the cost effectiveness ratio of biochemical screening of all women for Down's syndrome compared with age based screening shows that the marginal cost effectiveness of biochemical screening is pound 47 786, compared with an average cost effectiveness of pound 37 591. It may sometimes be difficult or costly to calculate marginal costs and benefits, but this should be done whenever possible.	UNIV YORK,DEPT ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	Torgerson, DJ (corresponding author), UNIV YORK,CTR HLTH ECON,NATL PRIMARY CARE RES & DEV,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Spencer, Anne/0000-0002-8163-3103				HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; MCGHEE SM, 1994, BRIT J GEN PRACT, V44, P441; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; Piggott M, 1994, J Med Screen, V1, P45; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WHYNES DK, 1995, HEALTH ECON, V4, P31, DOI 10.1002/hec.4730040104; WILLIAMS A, 1974, BRIT MED BULL, V30, P252, DOI 10.1093/oxfordjournals.bmb.a071211	7	37	37	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					35	36		10.1136/bmj.312.7022.35	http://dx.doi.org/10.1136/bmj.312.7022.35			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555859	Green Published			2022-12-01	WOS:A1996TP20900025
J	Condos, R; McClune, A; Rom, WN; Schluger, NW				Condos, R; McClune, A; Rom, WN; Schluger, NW			Peripheral-blood-based PCR assay to identify patients with active pulmonary tuberculosis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; DIAGNOSIS; STRAINS	Background There is a need for rapid diagnosis of pulmonary tuberculosis. We have previously used a PCR to detect circulating Mycobacterium tuberculosis DNA in blood samples from patients (mostly HIV-infected) with pulmonary tuberculosis. We have now prospectively investigated the role of this blood-based PCR assay for diagnosis of this disease in a clinical setting. Methods Our PCR assay is specific for the IS6110 insertion element of the M tuberculosis complex of organisms. We used it to test peripheral blood from 88 consecutive patients admitted to a chest ward with suspected pulmonary tuberculosis. Personnel who carried out the assay did not know the results of any clinical investigations and ultimate diagnosis, and clinicians did not know the PCR results. Results of the PCR assay were compared with the final clinical diagnosis. A subgroup of 15 patients had blood samples assayed serially to track the PCR signal over time. Findings 41 patients had a final clinical diagnosis of tuberculosis, and the cases were typical of those seen at our hospital: HIV infection was common, and most cases were not sputum-smear positive for acid-fast bacilli. The PCR assay correctly identified 39 of 41 patients with proven pulmonary tuberculosis, 26 (63%) of whom were sputum-smear negative. There were five patients in whom a positive PCR result did not accord with the final clinical diagnosis, and two of the 44 negative PCR results were classified as false negatives. The overall sensitivity and specificity of the PCR assay for a diagnosis of tuberculosis was 95% and 89%, respectively. In 15 patients with pulmonary tuberculosis and a positive blood assay, the PCR result remained positive after 1 month of therapy, but had reverted to negative in 13 of the 15 by 4 months of therapy. Interpretation We conclude that peripheral-blood-based PCR detection for the diagnosis of tuberculosis is a technically feasible approach that has a potentially important role in the diagnosis of pulmonary tuberculosis.	NYU,MED CTR & SCH MED,BELLEVUE CHEST SERV,NEW YORK,NY; NYU,MED CTR & SCH MED,DIV PULM & CRIT CARE MED,NEW YORK,NY	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003030] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03030] Funding Source: Medline; PHS HHS [M01 00096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALUOCH JA, 1985, TUBERCLE, V66, P237, DOI 10.1016/0041-3879(85)90061-3; BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496; CHIN DP, 1995, AM J RESP CRIT CARE, V151, P1872, DOI 10.1164/ajrccm.151.6.7767534; GODFREYFAUSSETT P, 1995, THORAX, V50, P709, DOI 10.1136/thx.50.7.709; GORDIN FM, 1983, AM REV RESPIR DIS, V139, P1090; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; KENNEDY N, 1994, J INFECT DIS, V170, P713, DOI 10.1093/infdis/170.3.713; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1; SCHLUGER NW, 1994, LANCET, V344, P232, DOI 10.1016/S0140-6736(94)92999-8; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SCHLUGER NW, 1994, AM J RESP CRIT CARE, V149, P264, DOI 10.1164/ajrccm.149.1.8111591; SCHLUGERNW, 1995, AM J RESP CRIT CARE, V152, P11; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SMITH E, 1992, SCAND J INFECT DIS, V24, P109, DOI 10.3109/00365549209048409; WILSON SM, 1993, T ROY SOC TROP MED H, V87, P177, DOI 10.1016/0035-9203(93)90478-9; YAJKO DM, 1994, CLIN INFECT DIS, V19, P334, DOI 10.1093/clinids/19.2.334; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615, DOI 10.1128/JCM.31.6.1615-1618.1993	20	80	83	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1082	1085		10.1016/S0140-6736(96)90281-0	http://dx.doi.org/10.1016/S0140-6736(96)90281-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602060	hybrid			2022-12-01	WOS:A1996UG04200014
J	Zheng, C; Heintz, N; Hatten, ME				Zheng, C; Heintz, N; Hatten, ME			CNS gene encoding astrotactin, which supports neuronal migration along glial fibers	SCIENCE			English	Article							FETAL MONKEY NEOCORTEX; CEREBELLAR CORTEX; CELL MIGRATION; DIFFERENTIATION; SYSTEM; TIME	Vertebrate central nervous system (CNS) histogenesis depends on glia-guided migration of postmitotic neurons to form neuronal laminae. Previous studies have established that the neuronal protein astrotactin functions in murine cerebellar granule cell migration in vitro. The gene encoding astrotactin predicts a protein with three epidermal growth factor repeats and two fibronectin type III repeats. Astrotactin messenger RNA is expressed in postmitotic neuronal precursors in the cerebellum, hippocampus, cerebrum, and olfactory bulb, where migration establishes laminar structures. Fab fragments of antibodies to a recombinant astrotactin peptide blocked migration of cerebellar granule neurons in vitro along astroglial fibers. Transfection of astrotactin complementary DNA into 3T3 cells indicated that astrotactin acts as a ligand for neuron-glia binding during neuronal migration.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University					NINDS NIH HHS [NS15429] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015429] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1994, CURRENT PROTOCOL S27, V2; Cajal S.R., 1911, HISTOLOGIE SYSTEME N; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FISHELL G, 1991, DEVELOPMENT, V113, P755; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1993, SCIENCE, V260, P367, DOI 10.1126/science.8469990; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KUHAR S, 1993, DEVELOPMENT, V112, P97; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5	19	192	195	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					417	419		10.1126/science.272.5260.417	http://dx.doi.org/10.1126/science.272.5260.417			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602532				2022-12-01	WOS:A1996UG25200049
J	Arrow, KJ; Cropper, ML; Eads, GC; Hahn, RW; Lave, LB; Noll, RG; Portney, PR; Russell, M; Schmalensee, R; Smith, VK; Stavins, RN				Arrow, KJ; Cropper, ML; Eads, GC; Hahn, RW; Lave, LB; Noll, RG; Portney, PR; Russell, M; Schmalensee, R; Smith, VK; Stavins, RN			Is there a role for benefit-cost analysis in environmental, health, and safety regulation?	SCIENCE			English	Editorial Material									WORLD BANK,WASHINGTON,DC 20433; CHARLES RIVER ASSOCIATES INC,WASHINGTON,DC 20004; AMER ENTERPRISE INST PUBL POLICY RES,WASHINGTON,DC 20036; CARNEGIE MELLON UNIV,GRAD SCH IND ORG,PITTSBURGH,PA 15213; RESOURCES FUTURE INC,WASHINGTON,DC 20036; UNIV TENNESSEE,DEPT ECON,KNOXVILLE,TN 37996; MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; DUKE UNIV,DURHAM,NC 27708; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	The World Bank; Charles River Associates; American Enterprise Institute for Public Policy Research; Carnegie Mellon University; Resources for the Future; University of Tennessee System; University of Tennessee Knoxville; Massachusetts Institute of Technology (MIT); Duke University; Harvard University	Arrow, KJ (corresponding author), STANFORD UNIV,DEPT ECON,STANFORD,CA 94305, USA.							Arrow KJ, 1996, BENEFIT COST ANAL EN; CHRISTIANSEN GB, 1985, HDB NATURAL RESOURCE, V1, P345; CROPPER ML, 1992, J ECON LIT, V30, P675; FRAAS A, 1991, LAW CONTEMP PROBL, V54, P113, DOI 10.2307/1191875; Freeman A. M., 1993, MEASUREMENT ENV RESO; Grubb W.Norton., 1984, ENV POLICY REAGANS E, P121; HAHN RW, IN PRESS RISKS COSTS; Hopkins T. D., 1992, COST REGULATION FILL; JAFFE AB, 1995, J ECON LIT, V33, P132; MORRALL JF, 1986, REGULATION, V10, P25; *OFF MAN BUDG, 1993, REG PROGR US GOV APR; *OFF MAN BUDG, 1995, BUDG US GOV FISC YEA; Schmalensee R, 1994, BALANCING EC GROWTH, P55	13	324	328	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					221	222		10.1126/science.272.5259.221	http://dx.doi.org/10.1126/science.272.5259.221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UE729	8602504				2022-12-01	WOS:A1996UE72900028
J	Rose, C; Vargas, F; Facchinetti, P; Bourgeat, P; Bambal, RB; Bishop, PB; Chan, SMT; Moore, ANJ; Ganellin, CR; Schwartz, JC				Rose, C; Vargas, F; Facchinetti, P; Bourgeat, P; Bambal, RB; Bishop, PB; Chan, SMT; Moore, ANJ; Ganellin, CR; Schwartz, JC			Characterization and Inhibition of a cholecystokinin-inactivating serine peptidase	NATURE			English	Article							SYNAPTIC-MEMBRANES; BRAIN-SLICES; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENDOGENOUS CHOLECYSTOKININ; TETRAPEPTIDE DEGRADATION; ENKEPHALINASE INHIBITOR; SUBSTRATE-SPECIFICITY; OCTAPEPTIDE CCK-8; PROTEINS; AMINOPEPTIDASE	A cholecystokinin (CCK)-inactivating peptidase was purified and identified as a membrane-bound isoform of tripeptidyl peptidase II (EC 3.4. 14. 10), a cytosolic subtilisin-like peptidase of previously unknown functions. The peptidase was found in neurons responding to cholecystokinin, as well as in non-neuronal cells. Butabindide, a potent and specific inhibitor, was designed and shown to protect endogenous cholecystokinin from inactivation and to display pro-satiating effects mediated by the CCKA receptor.	UNIV LONDON UNIV COLL, CHRISTOPHER INGOLD LABS, DEPT CHEM, LONDON WC1H 0AJ, ENGLAND; UNIV PARIS 05, FAC PHARM, F-75006 PARIS, FRANCE	University of London; University College London; UDICE-French Research Universities; Universite Paris Cite	Rose, C (corresponding author), CTR PAUL BROCA, INSERM, U109, UNITE NEUROBIOL & PHARMACOL, 2TER RUE ALESIA, F-75014 PARIS, FRANCE.							BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BAUMER P, 1992, GUT, V33, P753, DOI 10.1136/gut.33.6.753; CAMUS A, 1989, NEUROSCIENCE, V29, P595, DOI 10.1016/0306-4522(89)90133-4; CHARIOT J, 1990, AM J PHYSIOL, V259, pG198, DOI 10.1152/ajpgi.1990.259.2.G198; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIELSEN EM, 1977, BIOCHIM BIOPHYS ACTA, V494, P332, DOI 10.1016/0005-2795(77)90163-5; DESCHODTLANCKMAN M, 1984, PEPTIDES, V5, P649, DOI 10.1016/0196-9781(84)90098-6; DESCHODTLANCKMAN M, 1983, PEPTIDES, V4, P71, DOI 10.1016/0196-9781(83)90169-9; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; Dockray GJ, 1990, GASTROINTEST ENDOSC, P321; DURIEUX C, 1986, NEUROPEPTIDES, V7, P1, DOI 10.1016/0143-4179(86)90072-7; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GIROS B, 1987, J PHARMACOL EXP THER, V243, P666; HOKFELT T, 1980, NATURE, V285, P476, DOI 10.1038/285476a0; HUGHES J, 1990, P NATL ACAD SCI USA, V87, P6728, DOI 10.1073/pnas.87.17.6728; HUGHES J, 1989, NEUROPEPTIDE CHOLECY; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLORENS C, 1980, BIOCHEM BIOPH RES CO, V96, P1710, DOI 10.1016/0006-291X(80)91371-6; LLORENSCORTES C, 1986, P NATL ACAD SCI USA, V83, P6226, DOI 10.1073/pnas.83.16.6226; LOTTI VJ, 1987, J PHARMACOL EXP THER, V241, P103; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATSAS R, 1984, FEBS LETT, V175, P124, DOI 10.1016/0014-5793(84)80583-9; MCDERMOTT JR, 1983, NEUROCHEM INT, V5, P641, DOI 10.1016/0197-0186(83)90058-X; PATEY G, 1981, SCIENCE, V212, P113, DOI 10.1126/science.7015510; PERSSON H, 1989, P NATL ACAD SCI USA, V86, P6166, DOI 10.1073/pnas.86.16.6166; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; ROSE C, 1988, P NATL ACAD SCI USA, V85, P8326, DOI 10.1073/pnas.85.21.8326; ROSE C, 1989, NEUROSCIENCE, V29, P583, DOI 10.1016/0306-4522(89)90132-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHWARTZ JC, 1981, LIFE SCI, V29, P1715, DOI 10.1016/0024-3205(81)90182-X; SMITH GP, 1994, ANN NY ACAD SCI, V713, P236, DOI 10.1111/j.1749-6632.1994.tb44071.x; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEARDO L, 1985, J NEUROCHEM, V45, P784, DOI 10.1111/j.1471-4159.1985.tb04061.x; TARR GE, 1986, MICROCHARACTERIZATIO, P155; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; VANDERHAEGEN JJ, 1984, ANN NY ACAD SCI, V448, P1; Vanderhaeghen J.J., 1985, Handbook of Chemical Neuroanatomy, V4, P406; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; WHITTAKE.VP, 1966, ANN NY ACAD SCI, V137, P982, DOI 10.1111/j.1749-6632.1966.tb50211.x; WILSON C, 1993, NEUROCHEM RES, V18, P743, DOI 10.1007/BF00966768; WOODRUFF G, 1991, REV PHARM, V31, P469; ZUZEL KA, 1985, NEUROSCIENCE, V15, P149, DOI 10.1016/0306-4522(85)90129-0	50	141	147	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1996	380	6573					403	409		10.1038/380403a0	http://dx.doi.org/10.1038/380403a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602240				2022-12-01	WOS:A1996UD59000051
J	Riddington, DW; Venkatesh, B; Boivin, CM; Bonser, RS; Elliot, TSJ; Marshall, T; Mountford, PJ; Bion, JF				Riddington, DW; Venkatesh, B; Boivin, CM; Bonser, RS; Elliot, TSJ; Marshall, T; Mountford, PJ; Bion, JF			Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR NECROSIS FACTOR; GASTROINTESTINAL COMPLICATIONS; CARDIAC OPERATIONS; INTRAMURAL PH; LUNG INJURY; MULTIPLE; ISCHEMIA; HYPOPERFUSION; ABSORPTION	Objective.-To examine the relationship between gastric intramucosal pH, intestinal permeability, endotoxemia, and oxygen delivery in patients undergoing cardiopulmonary bypass (CPB). Design.-Prospective, observational study. Setting.-Tertiary care center. Patients.-Fifty patients undergoing elective cardiac surgery and 10 patients awaiting elective cardiac surgery. Interventions.-Patients received chromium 51-labeled ethylenediaminetetraacetic acid (Cr-51-EDTA) as a marker of intestinal permeability; insertion of a nasogastric tonometer to measure intramucosal pH (pHi); insertion of a pulmonary artery catheter to measure systemic oxygen delivery and consumption variables; arterial blood sampling for plasma endotoxin by the Limulus amebocyte lysate assay; and blood and urine sampling for measurement of Cr-51-EDTA. Main Outcome Measures.-Systemic oxygen delivery, duration of gastric mucosal acidosis, absorption of Cr-51-EDTA, appearance of systemic endotoxemia, renal dysfunction, and duration of hospital stay. Results.-Median (range) 24-hour urinary recovery of Cr-51-EDTA in patients was 10.6% (2.1% to 40.2%) while that in controls was 1.2% (0.7% to 2.0%, P<.001). Intestinal permeability increased during CPB. The median (range) for the lowest pHi after bypass was 6.98 (6.74 to 7.17). The pHi did not decline until CPB was discontinued and the heart took over the load of the circulation. Endotoxin was detectable (>0.2 endotoxin unit per milliliter) in the plasma of 21 patients (42%) during the study, most of whom were endotoxemic by the end of CPB. There was no evident relationship between the degree of gut permeability, endotoxemia, gut ischemia, or systemic oxygen dynamics. Conclusions.-Cardiopulmonary bypass is associated with increases in gut permeability, which precede gut mucosal ischemia. In cardiac surgical patients, a low pHi is not necessarily indicative of an adverse clinical outcome. Endotoxemia as measured by the Limulus amebocyte lysate assay is common. The increased intestinal absorption of Cr-51-EDTA and gastric mucosal acidosis occur as independent phenomena and are not related in severity or time of onset.	UNIV BIRMINGHAM, DEPT ANAESTHESIA & INTENS CARE MED, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, DEPT NUCL MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, DEPT MED MICROBIOL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; QUEEN ELIZABETH HOSP, CARDIOTHORAC SURG UNIT, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham			Venkatesh, Bala/F-4700-2010	Venkatesh, Bala/0000-0002-3234-5244; Bion, Julian/0000-0003-0344-5403				AABAKKEN L, 1989, SCAND J GASTROENTERO, V24, P351, DOI 10.3109/00365528909093059; Altman DG, 1991, PRACTICAL STAT MED R, P426; ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BERTHIAUME F, 1994, CRIT CARE MED, V22, P455, DOI 10.1097/00003246-199403000-00016; BION JF, 1994, CRIT CARE MED, V22, P40, DOI 10.1097/00003246-199401000-00011; BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; DEITCH EA, 1990, ARCH SURG-CHICAGO, V125, P403; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; ELIA M, 1987, CLIN SCI, V73, P197, DOI 10.1042/cs0730197; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FIDDIANGREEN RG, 1986, ARCH SURG-CHICAGO, V121, P654; FINE J, 1967, GASTROENTEROLOGY, V52, P454; FINK MP, 1991, ARCH SURG-CHICAGO, V126, P211; FONG YM, 1989, J IMMUNOL, V142, P2321; GIRAUD GD, 1984, J PHARMACOL EXP THER, V230, P214; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HOWDEN CW, 1991, AM J GASTROENTEROL, V86, P1445; KOIKE K, 1992, SURGERY, V112, P173; MARIK PE, 1993, CHEST, V104, P225, DOI 10.1378/chest.104.1.225; MARTINEZPELLUS AE, 1993, CRIT CARE MED, V21, P1684, DOI 10.1097/00003246-199311000-00017; METCHNIKOFF E, 1908, STUDIES OPPORTUNISTI, P309; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MONETA GL, 1985, AM J SURG, V149, P648, DOI 10.1016/S0002-9610(85)80148-3; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; OHRI SK, 1991, ANN THORAC SURG, V52, P826, DOI 10.1016/0003-4975(91)91219-L; OHRI SK, 1994, GASTROENTEROLOGY, V106, P318, DOI 10.1016/0016-5085(94)90588-6; PAPA M, 1983, J SURG RES, V35, P264, DOI 10.1016/S0022-4804(83)80013-4; PARSONNET V, 1989, CIRCULATION, V79, P3; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; RIDDINGTON D, 1994, CRIT CARE MED, V22, P96, DOI 10.1097/00003246-199401000-00019; RIDDINGTON D, 1992, LANCET, V340, P547, DOI 10.1016/0140-6736(92)91742-Q; RIDDINGTON DW, 1994, NUCL MED COMMUN, V15, P257; SOONG CV, 1995, BRIT J SURG, V82, P912, DOI 10.1002/bjs.1800820718; STJOHN RC, 1993, J APPL PHYSIOL, V74, P1994, DOI 10.1152/jappl.1993.74.4.1994; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WELLING RE, 1986, ARCH SURG-CHICAGO, V121, P1178; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H	40	197	203	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1996	275	13					1007	1012		10.1001/jama.275.13.1007	http://dx.doi.org/10.1001/jama.275.13.1007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC123	8596232				2022-12-01	WOS:A1996UC12300028
J	Skaggs, WE; McNaughton, BL				Skaggs, WE; McNaughton, BL			Replay of neuronal firing sequences in rat hippocampus during sleep following spatial experience	SCIENCE			English	Article							LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; COMPLEX-SPIKE CELLS; FREELY-MOVING RAT; LASTING POTENTIATION; SYNAPTIC TRANSMISSION; PERFORANT PATH; UNIT-ACTIVITY; THETA-RHYTHM; DENTATE GYRUS	The correlated activity of rat hippocampal pyramidal cells during sleep reflects the activity of those cells during earlier spatial exploration. Now the patterns of activity during sleep have also been found to reflect the order in which the cells fired during spatial exploration. this relation was reliably stronger for sleep after the behavioral session than before it; thus, the activity during sleep reflects changes produced by experience, This memory for temporal order of neuronal firing could be produced by an interaction between the temporal integration properties of long-term potentiation and the phase shifting of spike activity with respect to the hippocampal theta rhythm.			Skaggs, WE (corresponding author), UNIV ARIZONA, ARIZONA RES LABS, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA.				NIA NIH HHS [AG12609] Funding Source: Medline; NIMH NIH HHS [MH46823] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046823, R37MH046823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012609, R37AG012609] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1991, LONG TERM POTENTIATI, P357; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Cohen, 1993, MEMORY AMNESIA HIPPO, DOI 10.1136/jnnp.58.1.128-a; COLINO A, 1992, J NEUROSCI, V12, P180; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DOUGLAS RM, 1975, BRAIN RES, V86, P205, DOI 10.1016/0006-8993(75)90697-6; FOX SE, 1981, EXP BRAIN RES, V41, P399; GREENSTEIN YJ, 1988, BRAIN RES, V438, P331, DOI 10.1016/0006-8993(88)91358-3; GUSTAFSSON B, 1986, J NEUROSCI, V6, P1575; LARSON J, 1989, BRAIN RES, V489, P49, DOI 10.1016/0006-8993(89)90007-3; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MULLER RU, 1987, J NEUROSCI, V7, P1935; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1979, PROG NEUROBIOL, V13, P419, DOI 10.1016/0301-0082(79)90005-4; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OLTON DS, 1978, EXP NEUROL, V58, P387, DOI 10.1016/0014-4886(78)90096-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SKAGGS WE, IN PRESS HIPPOCAMPUS; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI SS, 1987, ELECTROENCEPHALOGR C, V69, P541; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; YLINEN A, 1995, J NEUROSCI, V15, P30	43	707	713	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1870	1873		10.1126/science.271.5257.1870	http://dx.doi.org/10.1126/science.271.5257.1870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596957				2022-12-01	WOS:A1996UC77800048
J	Levin, JE; Miller, JP				Levin, JE; Miller, JP			Broadband neural encoding in the cricket cercal sensory system enhanced by stochastic resonance	NATURE			English	Article							PRIMARY INTERNEURONS; INFORMATION; REPRESENTATION	Sensory systems are often required to detect a small amplitude signal embedded in broadband background noise. Traditionally, ambient noise is regarded as detrimental to encoding accuracy. Recently, however, a phenomenon known as stochastic resonance has been described in which, for systems with a nonlinear threshold, increasing the input noise level can actually improve the output signal-to-noise ratio over a limited range of signal and noise strengths. Previous theoretical and experimental studies of stochastic resonance in physica(1-7) and biological(6-10) systems have dealt exclusively with single-frequency sine stimuli embedded in a broadband noise background. In the past year it has been shown in a theoretical and modelling study that stochastic resonance can be observed with broadband signals(11,12). Here we demonstrate that broadband stochastic resonance is manifest in the peripheral layers of neural processing in a simple sensory system, and that it plays a role over a wide range of biologically relevant stimulus parameters. Further, we quantify the functional significance of the phenomenon within the context of signal processing, using information theory.			Levin, JE (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BIALEK W, 1993, PHYSICA A, V200, P581, DOI 10.1016/0378-4371(93)90563-J; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; CAMHI JM, 1978, J COMP PHYSIOL, V128, P203, DOI 10.1007/BF00656853; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; COLLINS JJ, 1995, PHYS REV E, V52, pR3321, DOI 10.1103/PhysRevE.52.R3321; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; FAUUVE S, 1993, J POHYS LETT A, V97, P5; GNATZY W, 1990, J COMP PHYSIOL A, V167, P551, DOI 10.1007/BF00190826; KANOU M, 1984, J COMP PHYSIOL, V154, P357, DOI 10.1007/BF00605235; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; Shannon CE, 1949, MATH THEORY COMMUNIC, P64; THEUNISSEN FE, 1991, J NEUROPHYSIOL, V66, P1690, DOI 10.1152/jn.1991.66.5.1690; THEUNISSEN FE, IN OPRESS J NEUROPHY; THEUNISSEN FE, 1993, THESIS U CALIFORNIA; TOBIAS M, 1979, J COMP PHYSIOL, V129, P51, DOI 10.1007/BF00679911; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; ZHOU T, 1990, PHYS REV A, V41, P4255, DOI 10.1103/PhysRevA.41.4255	23	599	615	1	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					165	168		10.1038/380165a0	http://dx.doi.org/10.1038/380165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600392				2022-12-01	WOS:A1996TZ97800053
J	DeRobertis, EM; Sasai, Y				DeRobertis, EM; Sasai, Y			A common plan for dorsoventral patterning in Bilateria	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; XENOPUS MESODERM; MELANOGASTER; INDUCTION; NOGGIN; STAGE	Functional studies seem now to confirm, as first suggested by E. Geoffroy Saint-Hilaire in 1822, that there was an inversion of the dorsoventral axis during animal evolution. A conserved system of extracellular signals provides positional information for the allocation of embryonic cells to specific tissue types both in Drosophila and vertebrates; the ventral region of Drosophila is homologous to the dorsal side of the vertebrate. Developmental studies are now revealing some of the characteristics of the ancestral animal that gave rise to the arthropod and mammalian lineages, for which we propose the name Urbilateria.			DeRobertis, EM (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.			De Robertis, Edward/0000-0002-7843-1869				Appel Toby, 1987, CUVIER GEOFFROY DEBA; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CLEMENT JH, 1995, MECH DEVELOP, V52, P357, DOI 10.1016/0925-4773(95)00413-U; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DALE L, 1992, DEVELOPMENT, V115, P573; De Robertis E.M., 1994, P11; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Geoffroy Saint-Hilaire uU., 1822, MEM MUS HIST NAT, V9, P89; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Haeckel E, 1874, Q J MICROSC SCI, V14, P142; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAWLEY SHB, 1995, GENE DEV, V9, P2913; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HOGEN BLM, 1995, NATURE, V376, P210; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JEFFERIES RPS, 1995, NATURE, V374, P22, DOI 10.1038/374022a0; JONES CM, 1995, CURR BIOL, V5, P574, DOI 10.1016/S0960-9822(95)00112-6; JONES CM, 1992, DEVELOPMENT, V115, P639; LACALLI TC, 1995, NATURE, V373, P110, DOI 10.1038/373110c0; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUBLERJUNG K, 1994, ROUX ARCH DEV BIOL, V203, P357, DOI 10.1007/BF00188683; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PETERSON KJ, 1995, NATURE, V373, P111, DOI 10.1038/373111a0; PHILIPPE H, 1994, DEVELOPMENT, P15; PREOBRAZHENSKII AA, 1985, DOKL AKAD NAUK SSSR+, V284, P1489; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SCHIMDT JE, 1995, DEV BIOL, V169, P37; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; SUZUKI A, 1995, GROWTH DIFFERENT, V35, P581; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WILLMER CH, 1990, INVERTEBRATE RELATIO; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; YAMADA, 1995, J CELL BIOL, V130, P217; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	57	553	566	4	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					37	40		10.1038/380037a0	http://dx.doi.org/10.1038/380037a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598900				2022-12-01	WOS:A1996TY87700047
J	Ramachandran, VS; Tyler, CW; Gregory, RL; RogersRamachandran, D; Duensing, S; Pillsbury, C; Ramachandran, C				Ramachandran, VS; Tyler, CW; Gregory, RL; RogersRamachandran, D; Duensing, S; Pillsbury, C; Ramachandran, C			Rapid adaptive camouflage in tropical flounders	NATURE			English	Article								Despite the commonly held view that flatfish can change their surface markings to match their background pattern(1), there have been few systematic studies(2,3) and it has recently been claimed(4) that their capacity for such adaptive changes is minimal. Here we show that the tropical flatfish Bothus ocellatus can achieve pattern-matching with surprising fidelity. By adjusting the contrast of different sets of 'splotches' of different grain size (or spatial frequency) on the skin, the fish can blend into a wide range of background textures in just 2-8 seconds.			Ramachandran, VS (corresponding author), UNIV CALIF SAN DIEGO,BRAIN & PERCEPT LAB,0109,,LA JOLLA,CA 92093, USA.							BOMFORD L, 1992, CAMOUFLAGE COLOR; Mast S. O., 1916, Bulletin of the Bureau of Fisheries Washington, V34; PACKARD A, 1995, CEPHALOPOD NEUROBIOL, P231; SAIDEL WM, 1988, SENSORY BIOL AQUATIC; SAIDEL WM, 1977, THESIS MIT CAMBRIDGE; Sumner F. B., 1911, Journal of Experimental Zoology Philadelphia, V10, DOI 10.1002/jez.1400100405	6	89	98	3	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					815	818		10.1038/379815a0	http://dx.doi.org/10.1038/379815a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587602				2022-12-01	WOS:A1996TX50100055
J	Clark, DA				Clark, DA			Red-cell antibodies in pregnancy: Evidence overturned	LANCET			English	Editorial Material							NEWBORN; PATIENT				Clark, DA (corresponding author), MCMASTER UNIV,HAMILTON,ON,CANADA.							Dickersin K, 1993, ANN NY ACAD SCI, V703, P145; ENGELFRIET CP, 1994, TRANSFUSION, V34, P627; FROEHLICH P, 1995, LANCET, V346, P1039, DOI 10.1016/S0140-6736(95)91722-5; HADLEY AG, 1992, VOX SANG, V63, P291, DOI 10.1111/j.1423-0410.1992.tb01242.x; JUDD WJ, 1990, TRANSFUSION, V30, P175, DOI 10.1046/j.1537-2995.1990.30290162907.x; SOCOL ML, 1992, PRINCIPLES PRACTICE, P1046; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VANDIJK BA, 1995, TRANSFUSION MED, V4, P199; 1992, JAMA-J AM MED ASSOC, V268, P2420; 1994, AM J REPROD IMMUNOL, V32, P55	10	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					485	486		10.1016/S0140-6736(96)91133-2	http://dx.doi.org/10.1016/S0140-6736(96)91133-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596262				2022-12-01	WOS:A1996TW69700004
J	Griffiths, C; Naish, J; Sturdy, P; Pereira, F				Griffiths, C; Naish, J; Sturdy, P; Pereira, F			Prescribing and hospital admissions for asthma in east London	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT EPIDEMIOL & MED STAT,LONDON,ENGLAND	University of London; Queen Mary University London	Griffiths, C (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL M, 1995, BRIT MED J, V310, P1069, DOI 10.1136/bmj.310.6986.1069b; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; 1994, HLTH E ANN PUBLIC HL	5	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					481	482		10.1136/bmj.312.7029.481	http://dx.doi.org/10.1136/bmj.312.7029.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597680	Green Published			2022-12-01	WOS:A1996TX38300024
J	Fowler, JS; Volkow, ND; Wang, GJ; Pappas, N; Logan, J; MacGregor, R; Alexoff, D; Shea, C; Schlyer, D; Wolf, AP; Warner, D; Zezulkova, I; Cilento, R				Fowler, JS; Volkow, ND; Wang, GJ; Pappas, N; Logan, J; MacGregor, R; Alexoff, D; Shea, C; Schlyer, D; Wolf, AP; Warner, D; Zezulkova, I; Cilento, R			Inhibition of monoamine oxidase B in the brains of smokers	NATURE			English	Article							L-DEPRENYL; PARKINSONS-DISEASE; CIGARETTE SMOKERS; TOBACCO-SMOKE; NEUROTOXICITY; STRIATUM; RATS	THE massive health problem associated with cigarette smoking is exacerbated by the addictive properties of tobacco smoke and the limited success of current approaches to cessation of smoking(1). Yet little is known about the neuropharmacological actions of cigarette smoke that contribute to smoking behaviour, or why smoking is so prevalent in psychiatric disorders(2) and is associated with a decreased risk of Parkinson's disease(3), Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers. MAO B is involved in the breakdown of dopamine, a neurotransmitter implicated in reinforcing and motivating behaviours as well as movement. MAO B inhibition is therefore associated with enhanced activity of dopamine(4), as well as with decreased production of hydrogen peroxide, a source of reactive oxygen species 5, We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking.	SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Fowler, JS (corresponding author), BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973, USA.							BERLIN I, 1995, CLIN PHARMACOL THER, V58, P444, DOI 10.1016/0009-9236(95)90058-6; BERRY MD, 1994, PROG NEUROBIOL, V42, P375, DOI 10.1016/0301-0082(94)90081-7; BOULTON AA, 1988, LANCET, V1, P114; CARR LA, 1991, LIFE SCI, V48, P1173, DOI 10.1016/0024-3205(91)90455-K; CARR LA, 1990, NEUROPHARMACOLOGY, V29, P311, DOI 10.1016/0028-3908(90)90019-N; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DLUZEN DE, 1991, J NEURAL TRANSM-GEN, V85, P145, DOI 10.1007/BF01244706; Dougherty E., 1992, INTRO MORPHOLOGICAL; FOWLER JS, 1994, SYNAPSE, V18, P86, DOI 10.1002/syn.890180203; FOWLER JS, 1995, J NUCL MED, V36, P1255; FOWLER JS, 1988, J NEUROCHEM, V51, P1524, DOI 10.1111/j.1471-4159.1988.tb01121.x; Henningfield Jack E., 1995, P1715; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JOSSAN SS, 1987, BIOGENIC AMINES, V4, P371; KNOLL J, 1994, LIFE SCI, V54, P1047, DOI 10.1016/0024-3205(94)00415-3; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; NORMAN TR, 1987, PSYCHIAT RES, V20, P199, DOI 10.1016/0165-1781(87)90079-5; ORELAND L, 1981, LIFE SCI, V29, P2511, DOI 10.1016/0024-3205(81)90706-2; PATERSON IA, 1991, J PHARMACOL EXP THER, V258, P1019; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pavlin R, 1993, FARM VESTN, V44, P185; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RIEDERER P, 1986, J NEUROCHEM, V46, P1359, DOI 10.1111/j.1471-4159.1986.tb01747.x; STAPLETON JM, 1993, NIDA RES MONOGR, V132, P106; TARIOT PN, 1987, PSYCHOPHARMACOLOGY, V91, P489, DOI 10.1007/BF00216016; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; WANG GJ, 1994, J NUCL MED, V35, P1457; YAMASHITA K, 1988, GERONTOLOGY, V34, P199, DOI 10.1159/000212953; YONG VW, 1986, J NEUROL SCI, V72, P265, DOI 10.1016/0022-510X(86)90014-6; YU PH, 1987, LIFE SCI, V41, P675, DOI 10.1016/0024-3205(87)90446-2	31	519	538	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					733	736		10.1038/379733a0	http://dx.doi.org/10.1038/379733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602220				2022-12-01	WOS:A1996TW56700054
J	Baukrowitz, T; Yellen, G				Baukrowitz, T; Yellen, G			Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K+ channel	SCIENCE			English	Article							POTASSIUM CHANNELS; MOLECULAR MECHANISMS; LOCAL-ANESTHETICS; CALCIUM CHANNELS; INACTIVATION	Quaternary ammonium blockers inhibit many voltage-activated potassium (K+) channels from the intracellular side. When applied to Drosophila Shaker potassium channels expressed in mammalian cells, these rapidly reversible blockers produced use-dependent inhibition through an unusual mechanism-they promoted an intrinsic conformational change known as C-type inactivation, from which recovery is slow. The blockers did so by cutting off potassium ion flow to a site in the pore, which then emptied at a rate of 10(5) ions per second. This slow rate probably reflected the departure of the last ion from the multi-ion pore: Permeation of ions (at 10(7) per second) occurs rapidly because of ion-ion repulsion, but the last ion to leave would experience no such repulsion.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School				Baukrowitz, Thomas/0000-0003-4562-0505; Yellen, Gary/0000-0003-4228-7866	NINDS NIH HHS [R01 NS029693, NS29693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; BAUKROWITZ T, UNPUB; BIGGER JT, 1985, PHARM BASIS THERAPEU, pCH31; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLATSKY TJ, 1990, CIRCULATION, V82, P2235, DOI 10.1161/01.CIR.82.6.2235; Crank J., 1979, MATH DIFFUSION; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HILLE B, 1992, IONIC CHANNELS EXCIT, pCH11; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HONDEGHEM LM, 1990, CIRCULATION, V81, P686, DOI 10.1161/01.CIR.81.2.686; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; LABARCA P, 1992, Biophysical Journal, V61, pA378; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MACDONALD RL, 1989, EPILEPSIA, V30, pS19, DOI 10.1111/j.1528-1157.1989.tb05810.x; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; YELLEN G, 1984, J GEN PHYSIOL, V84, P187, DOI 10.1085/jgp.84.2.187; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	28	194	195	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					653	656		10.1126/science.271.5249.653	http://dx.doi.org/10.1126/science.271.5249.653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571129				2022-12-01	WOS:A1996TT87000048
J	Hotamisligil, GS; Peraldi, P; Budavari, A; Ellis, R; White, MF; Spiegelman, BM				Hotamisligil, GS; Peraldi, P; Budavari, A; Ellis, R; White, MF; Spiegelman, BM			IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; CELLS; IRS-1	Tumor necrosis factor-alpha (TNF-alpha) is an important mediator of insulin resistance in obesity and diabetes through its ability to decrease the tyrosine kinase activity of the insulin receptor (IR). Treatment of cultured murine adipocytes with TNF-alpha was shown to induce serine phosphorylation of insulin receptor substrate 1 (IRS-1) and convert IRS-1 into an inhibitor of the IR tyrosine kinase activity in vitro. Myeloid 32D cells, which lack endogenous IRS-1, were resistant to TNF-alpha-mediated inhibition of IR signaling, whereas transfected 32D cells that express IRS-1 were very sensitive to this effect of TNF-alpha. An inhibitory form of IRS-1 was observed in muscle and fat tissues from obese rats. These results indicate that TNF-alpha induces insulin resistance through an unexpected action of IRS-1 to attenuate insulin receptor signaling.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MOLEC & CELLULAR BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Robles-Sardin, Alma E/M-7714-2015; Peraldi, Pascal/O-4592-2016	Robles-Sardin, Alma E/0000-0003-2044-7793; Peraldi, Pascal/0000-0003-0205-9252	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEGUM N, 1995, DIABETES, V44, pA140; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DOUGLAS RG, 1991, AM J PHYSIOL, V261, pE606, DOI 10.1152/ajpendo.1991.261.5.E606; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOTAMISLIGIL GS, UNPUB; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRODER G, 1995, DIABETES, V44, pA264; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Moller DE, 1993, INSULIN RESISTANCE; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1	27	2023	2109	6	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					665	668		10.1126/science.271.5249.665	http://dx.doi.org/10.1126/science.271.5249.665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571133				2022-12-01	WOS:A1996TT87000052
J	Klein, MG; Cheng, H; Santana, LF; Jiang, YH; Lederer, WJ; Schneider, MF				Klein, MG; Cheng, H; Santana, LF; Jiang, YH; Lederer, WJ; Schneider, MF			Two mechanisms of quantized calcium release in skeletal muscle	NATURE			English	Article							FROG TWITCH FIBERS; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; ANTIPYRYLAZO-III; CHARGE MOVEMENT; CHANNEL; PURIFICATION; SIGNALS	SKELETAL muscle uses voltage sensors in the transverse tubular membrane(1-3) that are linked by protein-protein interactions(4-6) to intracellular ryanodine receptors(7-10), which gate the release of calcium from the sarcoplasmic reticulum. Here we show, by using voltage-clamped single fibres and confocal imaging, that sto chastic calcium-release events, visualized as Ca2+ sparks, occur in skeletal muscle and originate at the tried. Unitary triadic Ca2+-release events are initiated by the voltage sensor in a steeply voltage-dependent manner, or occur spontaneously by a mechanism independent of the voltage sensor. Large amplitude events also occur during depolarization and consist of two or more unitary events. We propose a 'dual-control' model for discrete Ca2+ release events from the sacroplasmic reticulum that unifies diverse observations about Ca2+-signalling in frog skeletal muscle, and that may be applicable to other excitable cells.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Heping, Cheng/AAE-2680-2019; Santana, Luis/AAF-9298-2019; Lederer, William/B-1285-2010	Heping, Cheng/0000-0002-9604-6702; Santana, Luis/0000-0002-4297-8029; 				BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ENDO M, 1966, J PHYSIOL-LONDON, V185, P224, DOI 10.1113/jphysiol.1966.sp007983; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIAMSTRON.C, 1994, REV PHYSL, V56, P509; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; HUXLEY AF, 1958, J PHYSIOL-LONDON, V144, P426, DOI 10.1113/jphysiol.1958.sp006111; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; IRVING M, 1987, J GEN PHYSIOL, V89, P1, DOI 10.1085/jgp.89.1.1; KLEIN MG, 1990, J PHYSIOL-LONDON, V425, P599, DOI 10.1113/jphysiol.1990.sp018120; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MAYLIE J, 1987, J GEN PHYSIOL, V89, P83, DOI 10.1085/jgp.89.1.83; MAYLIE J, 1991, J PHYSIOL-LONDON, V442, P551, DOI 10.1113/jphysiol.1991.sp018808; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MINTA A, 1989, J BIOL CHEM, V264, P8171; PIZARRO G, 1991, J GEN PHYSIOL, V97, P913, DOI 10.1085/jgp.97.5.913; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P747; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; STEM MD, 1992, BIOPHYS J, V63, P497; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901	31	273	282	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					455	458		10.1038/379455a0	http://dx.doi.org/10.1038/379455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559251				2022-12-01	WOS:A1996TT30400061
J	Mirenowicz, J; Schultz, W				Mirenowicz, J; Schultz, W			Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli	NATURE			English	Article							NUCLEUS-ACCUMBENS; VENTRAL STRIATUM; MONKEY; RESPONSES; REWARD; INVIVO; MICRODIALYSIS; AMYGDALA; PRIMATE; COMPLEX	MIDBRAIN dopamine systems are crucially involved in motivational processes underlying the learning and execution of goal-directed behaviour(1-5). Dopamine neurons in monkeys are uniformly activated by unpredicted appetitive stimuli such as food and liquid rewards and conditioned, reward-predicting stimuli. By contrast, fully predicted stimuli are ineffective(6-8), and the omission of predicted reward depresses their activity(9). These characteristics follow associative-learning rules(10,11), suggesting that dopamine responses report an error in reward prediction(12). Accordingly, neural network models are efficiently trained using a dopamine-like reinforcement signal(13,14). However, it is unknown whether the responses to environmental stimuli concern specific motivational attributes or reflect more general stimulus salience(4,15). To resolve this, we have compared dopamine impulse responses to motivationally opposing appetitive and aversive stimuli. In contrast to appetitive events, primary and conditioned non-noxious aversive stimuli either failed to activate dopamine neurons or, in cases of close resemblance with appetitive stimuli, induced weaker responses than appetitive stimuli. Thus, dopamine neurons preferentially report environmental stimuli with appetitive rather than aversive motivational value.	UNIV FRIBOURG,INST PHYSIOL,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg								ABERCROMBIE ED, 1989, J NEUROCHEM, V52, P1655, DOI 10.1111/j.1471-4159.1989.tb09224.x; [Anonymous], 1992, SEMIN NEUROSCI; BENINGER RJ, 1983, SCIENCE, V220, P1304, DOI 10.1126/science.6857251; CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0; CHERGUI K, 1994, NEUROSCIENCE, V62, P641, DOI 10.1016/0306-4522(94)90465-0; CHURCH WH, 1987, BRAIN RES, V412, P397, DOI 10.1016/0006-8993(87)91150-4; DELONG MR, 1983, J NEUROSCI, V3, P1599; Dickinson A., 1980, CONT ANIMAL LEARNING; FREUND TF, 1984, NEUROSCIENCE, V13, P1189, DOI 10.1016/0306-4522(84)90294-X; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GAFFAN D, 1987, J NEUROSCI, V7, P2285; GARRIS PA, 1994, NEUROSCIENCE, V59, P417, DOI 10.1016/0306-4522(94)90606-8; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LOUILOT A, 1986, BRAIN RES, V397, P395, DOI 10.1016/0006-8993(86)90646-3; MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024, DOI 10.1152/jn.1994.72.2.1024; NISHIJO H, 1988, J NEUROSCI, V8, P3570; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI [10.1177/0269881120954052, DOI 10.1177/0269881120954052, DOI 10.1101/GR.110528.110]; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SCHULTZ W, 1987, J NEUROPHYSIOL, V57, P201, DOI 10.1152/jn.1987.57.1.201; Schultz W., 1995, MODELS INFORM PROCES, P233; SCHULTZ W, 1983, EXP BRAIN RES S, V7, P171; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; YOUNG AMJ, 1992, NEUROSCIENCE, V48, P871, DOI 10.1016/0306-4522(92)90275-7; YUNG KKL, 1995, NEUROSCIENCE, V65, P709, DOI 10.1016/0306-4522(94)00536-E; [No title captured]	30	619	629	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					449	451		10.1038/379449a0	http://dx.doi.org/10.1038/379449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559249				2022-12-01	WOS:A1996TT30400059
J	HELZLSOUER, KJ; ALBERG, AJ; GORDON, GB; LONGCOPE, C; BUSH, TL; HOFFMAN, SC; COMSTOCK, GW				HELZLSOUER, KJ; ALBERG, AJ; GORDON, GB; LONGCOPE, C; BUSH, TL; HOFFMAN, SC; COMSTOCK, GW			SERUM GONADOTROPINS AND STEROID-HORMONES AND THE DEVELOPMENT OF OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEHYDROEPIANDROSTERONE SULFATE; POSTMENOPAUSAL WOMEN; BREAST-CANCER; ANDROGEN; GROWTH; RISK; DIETARY	Objective.-To prospectively examine the association between endogenous hormones and development of ovarian cancer. Design.-Nested case-control study. Setting.-A population-based serum bank in Washington County, Maryland. Participants.-Serum samples were collected in 1974 from 20 305 county residents and stored at - 70 degrees C. From 1975 through 1989, a total of 31 cases of ovarian cancer were identified in women who were not taking hormones at the time of blood collection. These cases were matched to 62 controls on age, menopausal status, and, for premenopausal women, number of days from the beginning of the last menstrual period. Main Outcome Measure.-Prediagnostic endogenous hormone levels of cases and controls were compared. Results.-Mean follicle-stimulating hormone levels were lower among cases (43.3 IU/L) compared with controls (54.4 IU/L) (P=.04), and increasing levels were associated with significantly lower risk (P for trend=.01), particularly among postmenopausal women. Luteinizing hormone levels were 9% lower among cases than controls, but the difference was not statistically significant (P=.39). Compared with controls, cases had higher androstenedione levels (4.5 nmol/L vs 3.3 nmol; P=.03) and higher dehydroepiandrosterone (DHEA) levels (15.9 nmol/L vs 9.7 nmol/L; P=.02). The risk of ovarian cancer increased with higher levels of androstenedione and DHEA sulfate (P for trend=.008 and .11, respectively). These associations were not materially different between premenopausal and postmenopausal women. Conclusion.-The results suggest that women with low serum gonadotropin levels or high androgen levels have an increased risk of ovarian cancer. These findings do not support the hypothesis that pituitary gonadotropins increase the risk of ovarian cancer. Replication of the study in other populations is highly desirable.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; UNIV MASSACHUSETTS, MED CTR, DEPT OBSTET & GYNECOL, WORCESTER, MA USA	Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	HELZLSOUER, KJ (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.				NCI NIH HHS [CA47503, CA36390, CA01522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036390, R55CA036390, R01CA047503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breslow N, 1980, STAT METHODS CANC RE, P248; BYERS T, 1983, JNCI-J NATL CANCER I, V71, P681; CARLSTROM K, 1985, ACTA OBSTET GYN SCAN, V64, P267, DOI 10.3109/00016348509155126; CRAMER DW, 1984, OBSTET GYNECOL, V63, P833; CUZICK J, 1983, INT J CANCER, V32, P723, DOI 10.1002/ijc.2910320611; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; GARDNER WU, 1961, J NATL CANCER I, V26, P829; GODWIN AK, 1992, HEMATOL ONCOL CLIN N, V6, P829; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; HEINONEN PK, 1986, GYNECOL ONCOL, V25, P1, DOI 10.1016/0090-8258(86)90058-2; HELZLSOUER KJ, 1992, CANCER RES, V52, P1; HSING AW, 1989, CLIN CHEM, V35, P2145; LONGCOPE C, 1986, MATURITAS, V8, P189, DOI 10.1016/0378-5122(86)90025-3; LUCISANO A, 1986, MATURITAS, V8, P57, DOI 10.1016/0378-5122(86)90008-3; MAHLCK CG, 1986, ACTA OBSTET GYN SCAN, P1; MANGO D, 1985, J ENDOCRINOL INVEST, V8, P359, DOI 10.1007/BF03348514; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; SAWADA M, 1990, INT J CANCER, V45, P359, DOI 10.1002/ijc.2910450225; SIMON WE, 1983, J NATL CANCER I, V70, P839; SLOTMAN BJ, 1989, CANCER LETT, V45, P213, DOI 10.1016/0304-3835(89)90080-3; SPICER DV, 1993, CONTRACEPTION, V47, P427, DOI 10.1016/0010-7824(93)90095-O; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; 1988, NCI NIH882789 PUBL H	26	210	224	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1926	1930		10.1001/jama.274.24.1926	http://dx.doi.org/10.1001/jama.274.24.1926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568986				2022-12-01	WOS:A1995TL16900034
J	Watura, R; Lloyd, DCF; Chawda, S				Watura, R; Lloyd, DCF; Chawda, S			Magnetic resonance imaging of the knee: Direct access for general practitioners	BRITISH MEDICAL JOURNAL			English	Article									CARDIFF ROYAL INFIRM,DEPT RADIOL,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								BOEREE NR, 1991, INJURY, V22, P291, DOI 10.1016/0020-1383(91)90008-3; MAIR WJ, 1974, BMJ-BRIT MED J, V3, P732, DOI 10.1136/bmj.3.5933.732; POLLY DW, 1988, J BONE JOINT SURG AM, V70A, P192, DOI 10.2106/00004623-198870020-00005; Smith G L, 1979, J R Coll Gen Pract, V29, P539; WRIGHT HJ, 1979, J ROY SOC MED, V72, P88	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1614	1614		10.1136/bmj.311.7020.1614	http://dx.doi.org/10.1136/bmj.311.7020.1614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555806	Green Published			2022-12-01	WOS:A1995TL42200025
J	Pahor, M; Guralnik, JM; Furberg, CD; Carbonin, P; Havlik, RJ				Pahor, M; Guralnik, JM; Furberg, CD; Carbonin, P; Havlik, RJ			Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old	LANCET			English	Article							PLATELET-AGGREGATION; CLINICAL-TRIAL; DIHYDROPYRIDINES; HEMORRHAGE	Background Calcium antagonists are used frequently in management of hypertension, In addition to their cardiovascular effects, these drugs inhibit platelet aggregation. Therefore we examined whether the use of calcium antagonists was associated with an increased risk of gastrointestinal haemorrhage (GIH). Methods A prospective cohort study was conducted from 1985 through 1992 on 1636 hypertensive persons aged greater than or equal to 68 years living in three communities. The participants were taking beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, or calcium antagonists; those taking combinations of these drugs were excluded, The incidence of GIH was assessed by surveying hospital discharge deaths. Age, gender, disability, arterial pressure, other drugs, and comorbid conditions were examined as confounders. Findings Compared with beta-blockers (4819 person-years, 65 events), after adjustment for confounders the relative risk for GIH associated with ACE inhibitors (772 person-years, 13 events) was 1 . 23 (95% CI 0 . 66-2 . 28) and with calcium antagonists (1510 person-years, 42 events) it was 1 . 86 (1 . 22-2 . 82). The risks for verapamil, diltiazem, and nifedipine did not differ significantly. The results were unchanged when the analyses were restricted to severe events (GIH in conjunction with blood transfusion or death). Interpretation Calcium antagonists were associated with an increased risk of GIH in this population. Therefore caution is needed in prescription of these agents to old patients who have other risk factors for gastrointestinal bleeding.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Wake Forest University; Wake Forest Baptist Medical Center	Pahor, M (corresponding author), UNIV CATTOLICA SACRO CUORE,IST MED INTERNA & GERIATRIA,LARGO F VITO 1,I-00168 ROME,ITALY.							BERKELS R, 1994, THROMB HAEMOSTASIS, V72, P309; BLACHE D, 1992, PHARMACOLOGY, V45, P250, DOI 10.1159/000139008; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAVIS BR, IN PRESS AM J HYPERT; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, pS8; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HUDSON N, 1995, GUT, V37, P177, DOI 10.1136/gut.37.2.177; KARIO K, 1995, J HUM HYPERTENS, V9, P206; Katz S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI DOI 10.1001/JAMA.1963.03060120024016; KONRADDALHOFF I, 1991, EUR J CLIN PHARMACOL, V41, P313, DOI 10.1007/BF00314958; LANDRY JA, 1988, GERONTOLOGIST, V28, P672, DOI 10.1093/geront/28.5.672; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; PAHOR M, 1994, J AM GERIATR SOC, V42, P816, DOI 10.1111/j.1532-5415.1994.tb06552.x; PAHOR M, 1994, JAMA-J AM MED ASSOC, V272, P595, DOI 10.1001/jama.272.8.595; PALES J, 1991, BIOCHIM BIOPHYS ACTA, V1064, P169, DOI 10.1016/0005-2736(91)90298-M; *PHS HLTH CAR FIN, 1980, INT CLASS DIS; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; *SPSS, 1993, SPSS ADV STAT REF GU; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; WALLEN NH, 1995, AM J CARDIOL, V75, P1, DOI 10.1016/S0002-9149(99)80516-5; ZUCKER ML, 1993, THROMB HAEMOSTASIS, V70, P332; 1977, JAMA-J AM MED ASSOC, V237, P2385	30	215	217	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1061	1065		10.1016/S0140-6736(96)90276-7	http://dx.doi.org/10.1016/S0140-6736(96)90276-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602055				2022-12-01	WOS:A1996UG04200009
J	Kenyon, TA; Valway, SE; Ihle, WW; Onorato, IM; Castro, KG				Kenyon, TA; Valway, SE; Ihle, WW; Onorato, IM; Castro, KG			Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. In April 1994, a passenger with infectious multidrug-resistant tuberculosis traveled on commercial-airline flights from Honolulu to Chicago and from Chicago to Baltimore and returned one month later, We sought to determine whether she had infected any of her contacts on this extensive trip. Methods. Passengers and crew were identified from airline records and were notified of their exposure, asked to complete a questionnaire, and screened by tuberculin skin tests. Results. Of the 925 people on the airplanes, 802 (86.7 percent) responded. All 11 contacts with positive tuberculin skin tests who were on the April flights and 2 of 3 contacts with positive tests who were on the Baltimore-to-Chicago flight in May had other risk factors for tuberculosis, More contacts on the final, 8.75-hour flight from Chicago to Honolulu had positive skin tests than those on the other three flights (6 percent, as compared with 2.3, 3.8, and 2.8 percent). Of 15 contacts with positive tests on the May flight from Chicago to Honolulu, 6 (4 with skin-test conversions) had no other risk factors; all 6 had sat in the same section of the plane as the index patient (P = 0.001). Passengers seated within two rows of the index patient were more likely to have positive tuberculin skin tests than those in the rest of the section (4 of 13, or 30.8 percent, vs. 2 of 55, or 3.6 percent; rate ratio, 8.5; 95 percent confidence interval, 7.7 to 41.3; P = 0.01). Conclusions. The transmission of Mycobacterium tuberculosis that we describe aboard a commercial aircraft involved a highly infectious passenger, a long flight, and close proximity of contacts to the index patient. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; *CDC, 1987, DHHS PUBL, P95; Dean A.G., 1994, EPI INFO VERSION 6 W; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; *IMM NAT SERV, 1994, STAT YB IMM NAT SERV; MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003; MILLER MA, 1993, M AM PUBL HLTH ASS E; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; *PHS, 1991, TECHN INSTR MED EX A; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RITZINGER FR, 1965, AEROMED REV, V4, P1; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; WILSON RA, 1994, TRANSPORTATION AM ST; 1995, MMWR-MORBID MORTAL W, V44, P387; 1992, AM REV RESPIR DIS, V146, P1623; 1995, MMWR-MORBID MORTAL W, V44, P137; 1992, MMWR-MORBID MORTAL W, V41, P59	23	263	271	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					933	938		10.1056/NEJM199604113341501	http://dx.doi.org/10.1056/NEJM199604113341501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596593				2022-12-01	WOS:A1996UD59600001
J	Strick, TR; Allemand, JF; Bensimon, D; Bensimon, A; Croquette, V				Strick, TR; Allemand, JF; Bensimon, D; Bensimon, A; Croquette, V			The elasticity of a single supercoiled DNA molecule	SCIENCE			English	Article							TORSIONAL RIGIDITY; DEPOLARIZATION; MACROMOLECULES; FLUORESCENCE; ENERGETICS; DYNAMICS	Single linear DNA molecules were bound at multiple sites at one extremity to a treated glass cover slip and at the other to a magnetic bead. The DNA was therefore torsionally constrained, A magnetic field was used to rotate the beads and thus to coil and pull the DNA. The stretching force was determined by analysis of the Brownian fluctuations of the bead. Here, the elastic behavior of individual lambda DNA molecules over- and underwound by up to 500 turns was studied, A sharp transition was discovered from a low to a high extension state at a force of similar to 0.45 piconewtons for underwound molecules and at a force of similar to 3 piconewtons for overwound ones. These transitions, probably reflecting the formation of alternative structures in stretched coiled DNA molecules, might be relevant for DNA transcription and replication.	UNIV PARIS 07,ENS,PHYS STAT LAB,F-75231 PARIS 05,FRANCE; INST PASTEUR,ADN,BIOPHYS LAB,F-75015 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Strick, TR (corresponding author), UNIV PARIS 06,ENS,PHYS STAT LAB,24 RUE LHOMOND,F-75231 PARIS 05,FRANCE.		Bensimon, David/E-7768-2015; Strick, Terence R/J-1886-2012	Bensimon, David/0000-0003-1971-9907; Allemand, Jean - Francois/0000-0001-7496-0977; Croquette, Vincent/0000-0003-1400-0039; Strick, Terence/0000-0003-1744-3679				ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ALLISON SA, 1979, CHEM PHYS, V41, P35, DOI 10.1016/0301-0104(79)80131-7; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KLENIN KV, 1995, BIOPHYS J, V68, P81, DOI 10.1016/S0006-3495(95)80161-X; Kornberg A., 1992, DNA REPLICATION; LANGOWSKI J, 1994, BIOPOLYMERS, V34, P639, DOI 10.1002/bip.360340506; MARKO JF, 1994, SCIENCE, V265, P506, DOI 10.1126/science.8036491; MARKO JF, 1995, PHYS REV E, V52, P2912, DOI 10.1103/PhysRevE.52.2912; MARKO JF, COMMUNICATION; MCCLELLAN JA, 1991, J MOL BIOL, V219, P145, DOI 10.1016/0022-2836(91)90555-K; MORSE RH, 1988, CELL, V54, P285, DOI 10.1016/0092-8674(88)90190-0; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SELVIN PR, 1992, SCIENCE, V255, P82, DOI 10.1126/science.1553534; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SIMON A, 1995, P INSTRUMENTATION PH, P93; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; VINOGRAD J, 1965, P NATL ACAD SCI USA, V53, P1104, DOI 10.1073/pnas.53.5.1104; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	34	998	1027	4	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1835	1837		10.1126/science.271.5257.1835	http://dx.doi.org/10.1126/science.271.5257.1835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596951				2022-12-01	WOS:A1996UC77800037
J	Hall, SL; Padgett, RA				Hall, SL; Padgett, RA			Requirement of U12 snRNA for in vivo splicing of a minor class of eukaryotic nuclear pre-mRNA introns	SCIENCE			English	Article							COMPENSATORY BASE CHANGE; MESSENGER-RNA; SITE SELECTION; U6 SNRNA; PAIRING INTERACTION; U2 SNRNP; YEAST; RIBONUCLEOPROTEINS; INVITRO; SPLICEOSOME	A conserved sequence element in a minor class of eukaryotic pre-messenger RNA (pre-mRNA) introns was previously proposed to base pair with a complementary sequence in the U12 small nuclear RNA (snRNA) in a manner analogous to the pairing of U2 snRNA with the branch site sequence of the major class of introns. Here, mutations generated in this conserved sequence element block the splicing of a member of this minor intron class in vivo. This block was relieved by coexpression of a U12 snRNA containing compensatory mutations that restore the proposed base pairing interaction, These results show that this minor class of pre-mRNA introns is a distinct class existing alongside the major class of introns in animal genomes, and these results also establish an in vivo function for U12 snRNA.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045371] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM45371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baserga S., 1993, RNA WORLD, P359; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RUSKIN B, 1985, CELL, V41, P833, DOI 10.1016/S0092-8674(85)80064-7; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TARN WY, 1995, RNA, V1, P644; TARN WY, IN PRESS CELL; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	29	169	170	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1716	1718		10.1126/science.271.5256.1716	http://dx.doi.org/10.1126/science.271.5256.1716			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596930				2022-12-01	WOS:A1996UB15100043
J	Mebatsion, T; Konig, M; Conzelmann, KK				Mebatsion, T; Konig, M; Conzelmann, KK			Budding of rabies virus particles in the absence of the spike glycoprotein	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; MATRIX PROTEIN; INSECT CELLS; MEMBRANE; GENE; PRECURSOR; SEQUENCES; RNA	Budding of enveloped viruses from cellular membranes is believed to depend on the presence of transmembrane spike proteins interacting with cytoplasmic virus components. To address the mechanism of rhabdovirus budding, we generated rabies virus mutants deficient for the glycoprotein G or the G cytoplasmic tail. We found that spikeless rhabdovirus particles were released from cells infected with the G-deficient mutant, demonstrating that a viral surface protein is not required to drive the budding process. However, particle production is enhanced approximately B-fold and 30-fold in the presence of tailless G or G, respectively. This reveals that G also possesses an intrinsic and independent exocytosis activity. We propose a model according to which efficient budding of rhabdoviruses is achieved by a concerted action of both core and spike proteins.	UNIV GIESSEN,INST VIROL,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen	Mebatsion, T (corresponding author), FED RES CTR VIRUS DIS ANIM,INST CLIN VIROL,PAUL EHRLICH STR 28,D-72076 TUBINGEN,GERMANY.		Conzelmann, Karl-Klaus/L-7239-2013	Conzelmann, Karl-Klaus/0000-0002-8614-3656				ANILIONIS A, 1981, NATURE, V294, P275, DOI 10.1038/294275a0; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHONG LD, 1994, J VIROL, V68, P441, DOI 10.1128/JVI.68.1.441-447.1994; CHONG LD, 1993, J VIROL, V67, P407, DOI 10.1128/JVI.67.1.407-414.1993; CONZELMANN KK, 1991, VIROLOGY, V184, P655, DOI 10.1016/0042-6822(91)90435-E; CONZELMANN KK, 1994, J VIROL, V68, P713, DOI 10.1128/JVI.68.2.713-719.1994; CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R; DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUDIN Y, 1991, VIROLOGY, V184, P441, DOI 10.1016/0042-6822(91)90866-A; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; JIN H, 1994, EMBO J, V13, P5504, DOI 10.1002/j.1460-2075.1994.tb06885.x; JUSTICE PA, 1995, J VIROL, V69, P3156, DOI 10.1128/JVI.69.5.3156-3160.1995; Kessler S W, 1981, Methods Enzymol, V73, P442; LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477; LI Y, 1993, J VIROL, V67, P4415, DOI 10.1128/JVI.67.7.4415-4420.1993; MEBATSION T, 1995, J VIROL, V69, P1444, DOI 10.1128/JVI.69.3.1444-1451.1995; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; OWENS RJ, 1993, J VIROL, V67, P360, DOI 10.1128/JVI.67.1.360-365.1993; RHEE SS, 1990, J VIROL, V64, P3844, DOI 10.1128/JVI.64.8.3844-3852.1990; ROLLS MM, 1994, CELL, V79, P497, DOI 10.1016/0092-8674(94)90258-5; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SCHNEIDER LG, 1981, REPLICATION NEGATIVE, P947; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; SOKOL F, 1968, J VIROL, V2, P836, DOI 10.1128/JVI.2.8.836-849.1968; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WUNNER WH, 1985, ANN INST PASTEUR VIR, V136E, P353, DOI 10.1016/S0769-2617(85)80127-1; ZAVADA J, 1982, J GEN VIROL, V63, P15, DOI 10.1099/0022-1317-63-1-15; ZHAO HX, 1994, EMBO J, V13, P4204, DOI 10.1002/j.1460-2075.1994.tb06740.x	37	215	248	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					941	951		10.1016/S0092-8674(00)81072-7	http://dx.doi.org/10.1016/S0092-8674(00)81072-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601317	Bronze			2022-12-01	WOS:A1996UC38100015
J	Self, DW; Barnhart, WJ; Lehman, DA; Nestler, EJ				Self, DW; Barnhart, WJ; Lehman, DA; Nestler, EJ			Opposite modulation of cocaine-seeking behavior by D-1- and D-2-like dopamine receptor agonists	SCIENCE			English	Article							SELF-ADMINISTRATION BEHAVIOR; VENTRAL TEGMENTAL AREA; RHESUS-MONKEYS; RAT; REINSTATEMENT; BROMOCRIPTINE; HEROIN; AMPHETAMINE; INVOLVEMENT; INJECTIONS	Activation of the mesolimbic dopamine system is known to trigger relapse in animal models of cocaine-seeking behavior. We found that this ''priming'' effect was selectively induced by D-2-like, and not by D-1-like, dopamine receptor agonists in rats. Moreover, D-1-like receptor agonists prevented cocaine-seeking behavior induced by cocaine itself, whereas D-1-like receptor agonists enhanced this behavior, These results demonstrate an important dissociation between D-1- and D-2-like receptor processes in cocaine-seeking behavior and support further evaluation of D-1-like receptor agonists as a possible pharmacotherapy for cocaine addiction.	YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PHARMACOL, NEW HAVEN, CT 06508 USA	Yale University	Self, DW (corresponding author), YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, LAB MOLEC PSYCHIAT, NEW HAVEN, CT 06508 USA.							ANDERSEN PH, 1990, EUR J PHARM-MOLEC PH, V188, P335, DOI 10.1016/0922-4106(90)90194-3; BELMAKER RH, 1977, BRIT J PSYCHIAT, V131, P222, DOI 10.1192/bjp.131.2.222b; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; CHILDRESS AR, 1988, NIDA RES MONOGR, P137; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266; FREEDMAN JE, 1995, TRENDS PHARMACOL SCI, V272, pR1; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HUBNER CB, 1990, NEUROPSYCHOPHARMACOL, V3, P101; JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414; JOHANSON C, 1995, PSYCHOPHARMACOLOGY 4; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KLEVEN MS, 1990, PSYCHOPHARMACOLOGY, V101, P208, DOI 10.1007/BF02244128; LARGE CH, 1994, TRENDS PHARMACOL SCI, V15, P46, DOI 10.1016/0165-6147(94)90108-2; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MISERENDINO MJD, 1993, MOL CELL NEUROSCI, V4, P440, DOI 10.1006/mcne.1993.1055; PRESTON KL, 1992, J PHARMACOL EXP THER, V262, P279; ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3; ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5; SATEL S, 1992, CLIN GUIDE COCAINE A, P172; SELF DW, 1995, SYNAPSE, V21, P312, DOI 10.1002/syn.890210405; SELF DW, 1992, BRAIN RES, V582, P349, DOI 10.1016/0006-8993(92)90155-3; SHIPPENBERG TS, 1991, PSYCHOPHARMACOLOGY, V103, P209, DOI 10.1007/BF02244205; SHIPPENBERG TS, 1987, BRAIN RES, V436; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIRIS SG, 1991, SCHIZOPHRENIA BULL, V17, P75, DOI 10.1093/schbul/17.1.75; SNYDER SH, 1981, P NATL ACAD SCI-BIOL, V78, P3260, DOI 10.1073/pnas.78.5.3260; SPEALMAN RD, 1991, J PHARMACOL EXP THER, V258, P945; STEWART J, 1988, BRAIN RES, V457, P287, DOI 10.1016/0006-8993(88)90698-1; STEWART J, 1984, PHARMACOL BIOCHEM BE, V20, P917, DOI 10.1016/0091-3057(84)90017-0; TSURUTA K, 1981, NATURE, V292, P463, DOI 10.1038/292463a0; WEED MR, 1993, PSYCHOPHARMACOLOGY, V113, P51, DOI 10.1007/BF02244333; WISE RA, 1990, PSYCHOPHARMACOLOGY, V100, P355, DOI 10.1007/BF02244606; WITKIN JM, 1991, J PHARMACOL EXP THER, V257, P706	37	418	424	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1586	1589		10.1126/science.271.5255.1586	http://dx.doi.org/10.1126/science.271.5255.1586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599115				2022-12-01	WOS:A1996TZ98300042
J	Sherertz, RJ; Reagan, DR; Hampton, KD; Robertson, KL; Streed, SA; Hoen, HM; Thomas, R; Gwaltney, JM				Sherertz, RJ; Reagan, DR; Hampton, KD; Robertson, KL; Streed, SA; Hoen, HM; Thomas, R; Gwaltney, JM			A cloud adult: The Staphylococcus aureus - Virus interaction revisited	ANNALS OF INTERNAL MEDICINE			English	Article							NEWBORN NURSERY; MOLECULAR EPIDEMIOLOGY; BACTERIAL ADHERENCE; GEL-ELECTROPHORESIS; NASAL CARRIAGE; CARE UNIT; OUTBREAK; INFECTION; SPREAD; COLDS	Background: Nasal carriage of Staphylococcus aureus is common among health care workers, but outbreaks caused by such carriers are relatively uncommon. We previously reported outbreaks of S. aureus skin infections that affected newborn infants and were attributed to an S. aureus nasa I carrier who had had an associated upper respiratory tract infection (URI) during the outbreak period. Objective: To investigate the contribution of a nasal methicillin-resistant S. aureus (MRSA) carrier (physician 4) who contracted a URI to an outbreak of MRSA infections that involved 8 of 43 patients in a surgical intensive care unit during a 3-week period. Design: An epidemiologic study of an outbreak of MRSA infections and a quantitative investigation of airborne dispersal of S. aureus associated with an experimentally induced rhinoviral Infection. Setting: A university hospital. Participants: 43 patients in a surgical intensive care unit and 1 physician. Measurements: Molecular typing was done, and risk factors for MRSA colonization were analyzed. Agar settle plates and volumetric air cultures were used to evaluate the airborne dispersal of S. aureus by physician 4 before and after a rhinoviral infection and with or without a surgical mask. Results: A search for nasal carriers of MRSA identified a single physician (physician 4); molecular typing showed that the MRSA strain from physician 4 and those from the patients were identical. Multivariate logistic regression analysis identified exposure to physician 4 and duration of ventilation as independent risk factors for colonization with MRSA (P less than or equal to 0.008). Air cultures showed that physician 4 dispersed little S. aureus in the absence of a URI. After experimental induction of a rhinovirus URI, physician 4's airborne dispersal of S. aureus without a surgical mask increased 40-fold; dispersal was significantly reduced when physician 4 wore a mask (P less than or equal to 0.015). Conclusions: Physician 4 became a ''cloud adult,'' analogous to the ''cloud babies'' described by Eichenwald and coworkers who shed S. aureus into the air in association with viral URIs. Airborne dispersal of S. aureus in association with a URI may be an important mechanism of transmission of S. aureus.	E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, JOHNSON CITY, TN 37614 USA; N CAROLINA BAPTIST HOSP INC, WINSTON SALEM, NC USA; UNIV VIRGINIA, SCH MED, CHARLOTTESVILLE, VA USA	East Tennessee State University; Wake Forest University; Wake Forest Baptist Medical Center; University of Virginia	Sherertz, RJ (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.							BACK NA, 1993, JAMA-J AM MED ASSOC, V270, P1329, DOI 10.1001/jama.270.11.1329; BARRY AL, 1991, AM SOC MICROBIOLOGY, V11, P17; BELANI A, 1986, INFECT CONT HOSP EP, V7, P487, DOI 10.1017/S0195941700065097; BETHUNE DW, 1965, LANCET, V1, P480; BIBEL DJ, 1982, J INVEST DERMATOL, V79, P250, DOI 10.1111/1523-1747.ep12500072; BOYCE JM, 1993, CLIN INFECT DIS, V17, P496, DOI 10.1093/clinids/17.3.496; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; CHOWDHURY MNH, 1992, J HOSP INFECT, V22, P299, DOI 10.1016/0195-6701(92)90015-E; COOVADIA YM, 1989, J HOSP INFECT, V14, P303, DOI 10.1016/0195-6701(89)90070-4; DANCER SJ, 1988, J INFECTION, V16, P87, DOI 10.1016/S0163-4453(88)96249-4; DANCER SJ, 1990, J INFECTION, V20, P73, DOI 10.1016/S0163-4453(90)92434-M; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; EICHENWALD HF, 1960, AM J DIS CHILD, V100, P161, DOI 10.1001/archpedi.1960.04020040163003; Fa W., 1995, PRINCIPLES PRACTICES, V4, P1754; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GAYNES R, 1991, J INFECT DIS, V163, P117, DOI 10.1093/infdis/163.1.117; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62; GWALTNEY JM, 1982, UPPER AIRWAY PHYSL A, P399; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HAMRE D, 1966, AM J EPIDEMIOL, V83, P238, DOI 10.1093/oxfordjournals.aje.a120579; HARE R, 1956, BMJ-BRIT MED J, V2, P840, DOI 10.1136/bmj.2.4997.840; HEDBERG K, 1990, PEDIATR INFECT DIS J, V9, P268, DOI 10.1097/00006454-199004000-00009; HOEGER PH, 1988, PEDIATR INFECT DIS J, V7, P340, DOI 10.1097/00006454-198805000-00010; HUIJSMANSEVERS AGM, 1978, ARCH CHIR NEERL, V30, P141; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KINSMAN OS, 1983, J MED MICROBIOL, V16, P215, DOI 10.1099/00222615-16-2-215; KNIGHT V, 1964, PROG MED VIROL, V6, P1; LIANOU P, 1989, ACTA DERM-VENEREOL, V69, P330; LIPSKY BA, 1987, DIABETES CARE, V10, P483, DOI 10.2337/diacare.10.4.483; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; NAHMIAS AJ, 1960, JAMA-J AM MED ASSOC, V174, P1269, DOI 10.1001/jama.1960.03030100037009; NAKASHIMA AK, 1984, INFECT CONT HOSP EP, V5, P326, DOI 10.1017/S0195941700060513; NICHOL KP, 1967, NEW ENGL J MED, V277, P667, DOI 10.1056/NEJM196709282771301; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; RICHARDSON JF, 1990, J HOSP INFECT, V16, P109, DOI 10.1016/0195-6701(90)90055-S; Sahm D.H., 1991, MANUAL CLIN MICROBIO; SANFORD BA, 1987, P SOC EXP BIOL MED, V185, P120; SINGH G, 1978, DERMATOLOGICA, V157, P21, DOI 10.1159/000250804; STONE AA, 1992, BEHAV MED, V18, P115, DOI 10.1080/08964289.1992.9936961; TANNER EI, 1980, J HYG-CAMBRIDGE, V85, P219, DOI 10.1017/S0022172400063257; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; WHITE A, 1961, J LAB CLIN MED, V58, P273; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; WINKLER J, 1990, J INFECT DIS, V162, P1400, DOI 10.1093/infdis/162.6.1400	49	148	158	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					539	+		10.7326/0003-4819-124-6-199603150-00001	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597316				2022-12-01	WOS:A1996TZ52900001
J	Dib, C; Faure, S; Fizames, C; Samson, D; Drouot, N; Vignal, A; Millasseau, P; Marc, S; Hazan, J; Seboun, E; Lathrop, M; Gyapay, G; Morissette, J; Weissenbach, J				Dib, C; Faure, S; Fizames, C; Samson, D; Drouot, N; Vignal, A; Millasseau, P; Marc, S; Hazan, J; Seboun, E; Lathrop, M; Gyapay, G; Morissette, J; Weissenbach, J			A comprehensive genetic map of the human genome based on 5,264 microsatellites	NATURE			English	Article								The great increase in successful linkage studies in a number of higher eukaryotes during recent years has essentially resulted from major improvements in reference genetic linkage maps(1-6), which at present consist of short tandem repeat polymorphisms of simple sequences or microsatellites(7,8). We report here the last version of the Genethon human linkage map(6). This map consists of 5,264 short tandem (AC/TG)(n) repeat polymorphisms with a mean heterozygosity of 70%. The map spans a sex-averaged genetic distance of 3,699 cM and comprises 2,335 positions, of which 2,032 could be ordered with an odds ratio of at least 1,000:1 against alternative orders. The average interval size is 1.6 cM; 59% of the map is covered by intervals of 2 cM at most and 1% remains in intervals above 10 cM.	GENETHON SA,F-91000 EVRY,FRANCE; CNRS,URA 1922,F-91000 EVRY,FRANCE; HOP ST LOUIS,INSERM,U358,PARIS,FRANCE; CHU LAVAL,CTR RECH,QUEBEC CITY,PQ G1V 4G2,CANADA	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Laval University			Vignal, Alain/I-6253-2017	Vignal, Alain/0000-0002-6797-2125; Fizames, Cecile/0000-0002-0551-8250; Steinbach, Delphine/0000-0001-7144-7908; Hazan, Jamile/0000-0001-8119-0325				BARENDSE W, 1994, NAT GENET, V6, P227, DOI 10.1038/ng0394-227; CHUMAKOV IM, 1995, NATURE, V377, P175; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ELSNER TI, 1995, AM J HUM GENET, V56, P500; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; PLAETKE R, 1995, AM J HUM GENET, V56, P508; Spurr N. K., 1994, European Journal of Human Genetics, V2, P193; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; 1995, AM J HUM GENET, V57, P619	21	2675	2781	0	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					152	154		10.1038/380152a0	http://dx.doi.org/10.1038/380152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600387				2022-12-01	WOS:A1996TZ97800048
J	vanderWal, G; OnwuteakaPhilipsen, BD				vanderWal, G; OnwuteakaPhilipsen, BD			Cases of euthanasia and assisted suicide reported to the public prosecutor in North Holland over 10 years	BRITISH MEDICAL JOURNAL			English	Article									VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,1081 BT AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam								VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; VANDERWAL G, 1992, EUTHANASIA ASSISTED	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1996	312	7031					612	613						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595336				2022-12-01	WOS:A1996TZ84000026
J	Tishkoff, SA; Dietzsch, E; Speed, W; Pakstis, AJ; Kidd, JR; Cheung, K; BonneTamir, B; SantachiaraBenerecetti, AS; Moral, P; Krings, M; Paabo, S; Watson, E; Risch, N; Jenkins, T; Kidd, KK				Tishkoff, SA; Dietzsch, E; Speed, W; Pakstis, AJ; Kidd, JR; Cheung, K; BonneTamir, B; SantachiaraBenerecetti, AS; Moral, P; Krings, M; Paabo, S; Watson, E; Risch, N; Jenkins, T; Kidd, KK			Global patterns of linkage disequilibrium at the CD4 locus and modern human origins	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; STEPWISE MUTATION MODEL; HUMAN-EVOLUTION; HUMAN-POPULATIONS; TRANSGENIC MICE; CONTROL REGION; SEQUENCES; POLYMORPHISMS; EXPRESSION; SCALE	Haplotypes consisting of alleles at a short tandem repeat polymorphism (STRP) and an Alu deletion polymorphism at the CD4 locus on chromosome 12 were analyzed in more than 1600 individuals sampled from 42 geographically dispersed populations (13 African, 2 Middle Eastern, 7 European, 9 Asian, 3 Pacific, and 8 Amerindian). Sub-Saharan African populations had more haplotypes and exhibited more variability in frequencies of haplotypes than the Northeast African or non-African populations. The Alu deletion was nearly always associated with a single STRP allele in non-African and Northeast African populations but was associated with a wide range of STRP alleles in the sub-Saharan African populations. This global pattern of haplotype variation and linkage disequilibrium suggests a common and recent African origin for all non-African human populations.	S AFRICAN INST MED RES,SCH PATHOL,DEPT HUMAN GENET,JOHANNESBURG 2000,SOUTH AFRICA; UNIV WITWATERSRAND,JOHANNESBURG 2000,SOUTH AFRICA; TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL; UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAVERSO,I-27100 PAVIA,ITALY; UNIV BARCELONA,DEPT ANIM BIOL,E-08028 BARCELONA,SPAIN; UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY; MASSEY UNIV,SCH BIOL SCI,PALMERSTON NORTH,NEW ZEALAND; UNIV MUNICH,INST ZOOL,D-80333 MUNICH 2,GERMANY; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	University of Witwatersrand; Tel Aviv University; Sackler Faculty of Medicine; University of Pavia; University of Barcelona; University of Munich; Massey University; University of Munich; Stanford University	Tishkoff, SA (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Moral, Pedro/K-9587-2014; Klein, Richard G/B-5910-2009	Moral, Pedro/0000-0001-5072-5892; 	NHGRI NIH HHS [HG00348] Funding Source: Medline; NIAAA NIH HHS [AA09379] Funding Source: Medline; NIMH NIH HHS [MH39239] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039239, R01MH039239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009379] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288; BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; Bowcock A M, 1991, Gene Geogr, V5, P151; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CASTIGLIONE CM, 1995, AM J HUM GENET, V57, P1445; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DEKA R, 1995, AM J HUM GENET, V56, P461; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EDWARDS MC, 1991, NUCLEIC ACIDS RES, V19, P4791, DOI 10.1093/nar/19.17.4791-a; EDWARDS MC, 1992, GENOMICS, V14, P590, DOI 10.1016/S0888-7543(05)80156-9; GILLESPIE FP, 1993, MOL CELL BIOL, V13, P2952, DOI 10.1128/MCB.13.5.2952; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GOLDSTEIN DB, 1995, GENETICS, V139, P463; GOODFELLOW PN, 1995, NATURE, V378, P379; HAKIM I, 1990, PLURIDISCIPLINARY AP, P43; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HARPENDING HC, 1993, CURR ANTHROPOL, V34, P483, DOI 10.1086/204195; HASEGAWA M, 1993, J MOL EVOL, V37, P347, DOI 10.1007/BF00178865; HAWLEY ME, 1995, J HERED, V86, P409, DOI 10.1093/oxfordjournals.jhered.a111613; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; Hill A., 1994, INTEGRATIVE PATHS PA, P123; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; JONES JS, 1986, NATURE, V319, P449, DOI 10.1038/319449b0; JORDE LB, 1995, AM J HUM GENET, V57, P523; KIDD KK, IN PRESS ALCOHOLISM; LAHR MM, 1995, EVOL ANTHR, V3, P48; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; MAHTANI MM, 1993, HUM MOL GENET, V2, P431, DOI 10.1093/hmg/2.4.431; MARTINSON JJ, 1995, AM J HUM GENET, V57, P1186; MCNEMAR Q, 1969, PSYCHOL STATISTICS; MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807; MICHALATOSBELOI.S, UNPUB; NEI M, 1989, HUM HERED, V39, P276, DOI 10.1159/000153872; NEI M, 1993, MOL BIOL EVOL, V10, P927; Nei M., 1987, MOL EVOLUTIONARY GEN; PENNY D, 1995, MOL BIOL EVOL, V12, P863; REYNOLDS J, 1983, GENETICS, V105, P767; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; RITTE U, 1993, HUM BIOL, V65, P359; ROGERS AR, 1995, HUM BIOL, V67, P1; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; SATTA Y, 1994, P NATL ACAD SCI USA, V91, P7184, DOI 10.1073/pnas.91.15.7184; SHEBA C, 1962, AM J PHYS ANTHROPOL, V20, P167, DOI 10.1002/ajpa.1330200218; SHRIVER MD, 1993, GENETICS, V134, P983; SLATKIN M, 1995, MOL BIOL EVOL, V12, P473; SLATKIN M, 1995, GENETICS, V139, P457; SLATKIN M, 1994, GENETICS, V137, P331; STRINGER CB, 1993, ORIGIN AND EVOLUTION OF HUMANS AND HUMANNESS, P75; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; STRINGER CB, 1992, HOMO SAPIENS EVOLUTI, P9; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; Tishkoff S. A., 1995, American Journal of Human Genetics, V57, pA42; TISHKOFF SA, 1995, AM J PHYS ANTHR S, V20, P211; VALDES AM, 1993, GENETICS, V133, P737; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WILSON AC, 1969, P NATL ACAD SCI USA, V63, P1088, DOI 10.1073/pnas.63.4.1088; WOLPOFF M, 1989, HUMAN REVOLUTION BEH, V1, P62; WOLPOFF MH, 1992, HOMO SAPIENS EVOLUTI, P25; WORKMAN PL, 1970, AM J HUM GENET, V22, P24; ZISCHLER H, 1995, NATURE, V378, P489, DOI 10.1038/378489a0; ZOOSSMANNDISKIN A, 1991, ISRAEL J MED SCI, V27, P245	74	483	489	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1996	271	5254					1380	1387		10.1126/science.271.5254.1380	http://dx.doi.org/10.1126/science.271.5254.1380			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY961	8596909				2022-12-01	WOS:A1996TY96100036
J	Nakai, J; Dirksen, RT; Nguyen, HT; Pessah, IN; Beam, KG; Allen, PD				Nakai, J; Dirksen, RT; Nguyen, HT; Pessah, IN; Beam, KG; Allen, PD			Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor	NATURE			English	Article							DYSGENIC SKELETAL-MUSCLE; STEM-CELL LINES; COMPLEMENTARY-DNA; RELEASE CHANNEL; CALCIUM CURRENT; PERCHLORATE; EXPRESSION	Excitation-contraction coupling in skeletal muscle involves a voltage sensor in the plasma membrane which, in response to depolarization, causes an intracellular calcium-release channel to open. The skeletal isoform of the ryanodine receptor (RyR-1) functions as the Ca2+-release channel(1-3) and the dihydropyridine receptor (DHPR) functions as the voltage sensor and also as an L-type Ca2+ channel(4,5). Here we examine the possibility that there is a retrograde signal from RyR-1 to the DHPR, using myotubes from mice homozygous for a disrupted RyR-1 gene (dyspedic mice)(3). As expected, we find that there is no excitation-contraction coupling in dyspedic myotubes, but we also find that they have a roughly 30-fold reduction in L-type Ca2+-current density. Injection of dyspedic myotubes with RyR-1 complementary DNA restores excitation-contraction coupling and causes the density of L-type Ca2+ current to rise towards normal. Despite the differences in Ca2+-current magnitude, measurements of charge movement indicate that the density of DHPRs is similar in dyspedic and RyR-1-expressing myotubes. Our results support the possibility of a retrograde signal hy which RyR-1 enhances the function of DHPRs as Ca2+ channels.	CHILDRENS HOSP,DEPT CARDIOL,MOLEC CARDIOL LAB,BOSTON,MA 02115; KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 60601,JAPAN; COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523; UNIV CALIF DAVIS,SCH VET MED,DEPT MOLEC BIOSCI,DAVIS,CA 95616; BRIGHAM & WOMENS HOSP,DEPT ANESTHESIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Kyoto University; Colorado State University; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital			Pessah, Isaac N/K-7985-2017; Tuluc, Petronel/C-2527-2011; Nakai, Junichi/GQZ-6415-2022	Pessah, Isaac N/0000-0002-8149-588X; 				ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; BUCK R, 1992, J BIOL CHEM, V287, P23560; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; DIRKSEN RT, 1995, J GEN PHYSIOL, V105, P227, DOI 10.1085/jgp.105.2.227; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FELDMEYER D, 1993, PFLUG ARCH EUR J PHY, V425, P54, DOI 10.1007/BF00374503; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P373, DOI 10.1085/jgp.102.3.373; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; MA J, 1991, Biophysical Journal, V59, p201A; MA JJ, 1988, BIOPHYS J, V53, P387, DOI 10.1016/S0006-3495(88)83115-1; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEJIAALVAREZ R, 1991, J GEN PHYSIOL, V97, P393, DOI 10.1085/jgp.97.2.393; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TAKEKURA H, 1994, BIOPHYS J, V67, P793, DOI 10.1016/S0006-3495(94)80539-9; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WINGER DB, 1990, J PHYSIOL-LONDON, V425, P563; YATANI A, 1988, J BIOL CHEM, V263, P9887	30	386	389	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					72	75		10.1038/380072a0	http://dx.doi.org/10.1038/380072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598910				2022-12-01	WOS:A1996TY87700059
J	Quinn, J; Fyrberg, AM; Ganster, RW; Schmidt, MC; Peterson, CL				Quinn, J; Fyrberg, AM; Ganster, RW; Schmidt, MC; Peterson, CL			DNA-binding properties of the yeast SWI/SNF complex	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATOR; CRUCIFORM DNA; PROTEIN; GENES; ENHANCERS; HMG1	The SWI/SNF complex is required for the enhancement of transcription by many transcriptional activators in yeast(1,2) Genetic and biochemical studies indicate that the complex facilitates activator function by antagonizing chromatin-mediated transcriptional repression(3-6). The absence of known DNA-binding motifs in several SWI/SNF subunits and the failure to identify SWI/SNF-dependent DNA-binding activities in crude yeast extracts have led to the belief that the complex does not bind DNA(7,8). Here we show that the SWI/SNF complex has a high affinity for DNA and that its DNA-binding properties are similar to those of proteins containing HMG-box domains(9). The complex interacts with the minor groove of the DNA helix, binds synthetic four-way junction DNA, and introduces positive supercoils into relaxed plasmid DNA. These properties are likely to be important in the remodelling of chromatin structure by the SWI/SNF complex.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Quinn, Janet/AAR-9957-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049650, R01GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049650, R37 GM049650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; CAIMS BR, 1994, P NATL ACAD SCI USA, V91, P1950; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; FISHER RP, 1992, J BIOL CHEM, V267, P3358; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HIRSCHHORN JN, 1992, GENE DEV, V6, P228; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; PETERSON CL, 1988, MOL CELL BIOL, V8, P4972, DOI 10.1128/MCB.8.11.4972; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TREICH I, 1995, MOL CELL BIOL, V15, P4240; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WEMER MH, 1995, CELL, V81, P705; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S	27	176	177	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					844	847		10.1038/379844a0	http://dx.doi.org/10.1038/379844a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587611				2022-12-01	WOS:A1996TX50100064
J	Whynes, DK; Baines, DL; Tolley, KH				Whynes, DK; Baines, DL; Tolley, KH			Explaining variations in general practice prescribing costs per ASTRO-PU (age, sex, and temporary resident originated prescribing unit)	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,SCH MED,SCH PUBL HLTH,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Whynes, DK (corresponding author), UNIV NOTTINGHAM,DEPT ECON,NOTTINGHAM NG7 2RD,ENGLAND.		Baines, Darrin/ABI-5893-2020	Baines, Darrin/0000-0001-9502-4678				BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1994, PRESCRIPTION IMPROVE; 1994, EL942 NHS MAN EX DEP	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					488	489		10.1136/bmj.312.7029.488	http://dx.doi.org/10.1136/bmj.312.7029.488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597684	Green Published			2022-12-01	WOS:A1996TX38300029
J	Zimmerman, SC; Zeng, FW; Reichert, DEC; Kolotuchin, SV				Zimmerman, SC; Zeng, FW; Reichert, DEC; Kolotuchin, SV			Self-assembling dendrimers	SCIENCE			English	Article							CASCADE	Hydrogen bond-mediated self-assembly is a powerful strategy for generating large structures from smaller subunits. The synthesis of molecules containing two isophthalic acid units covalently attached to a rigid aromatic spacer is described. By normal pairing of carboxylic acids into hydrogen-bonded dimers, these molecules self-assemble in organic solvents to form either a series of linear aggregates or a cyclic hexamer. These molecules were linked to the core of a family of polyether dendrimers, which caused the hexamer to be formed preferentially. The stability of the hexamer depended on the generation number of the dendrimer. The largest of these hydrogen-bonded macromolecular assemblies is roughly disk-shaped with a 9-nanometer diameter and a 2-nanometer thickness. Its size and molecular mass (34,000 daltons) are comparable to that of small proteins.			Zimmerman, SC (corresponding author), UNIV ILLINOIS,DEPT CHEM,600 S MATHEWS AVE,URBANA,IL 61801, USA.		Reichert, David/AAS-4442-2020; Zimmerman, Steven C. C/E-4244-2010; Reichert, David/B-3281-2009	Reichert, David/0000-0003-3432-8998; Zimmerman, Steven C. C/0000-0002-5333-3437; Reichert, David/0000-0003-3432-8998	NIGMS NIH HHS [GM39782] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039782] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONSEN MW, 1994, CARBOHYD POLYM, V25, P13, DOI 10.1016/0144-8617(94)90157-0; BARTH HG, 1994, ANAL CHEM, V66, pR595, DOI 10.1021/ac00084a022; CHAPMAN TM, 1994, J AM CHEM SOC, V116, P11195, DOI 10.1021/ja00103a060; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; HAWKER CJ, 1993, J CHEM SOC PERK T 1, P1287, DOI 10.1039/p19930001287; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; LEHN JM, 1994, PURE APPL CHEM, V66, P1961, DOI 10.1351/pac199466101961; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; MATHIAS JP, 1994, J AM CHEM SOC, V116, P1725, DOI 10.1021/ja00084a013; MHATRE R, 1994, CHROMATOGRAPHIA, V38, P349, DOI 10.1007/BF02269779; NEWKOME GR, 1993, J ORG CHEM, V58, P3123, DOI 10.1021/jo00063a036; NEWKOME GR, 1995, POLYM PREPRINTS, V36, P609; NEWKOME GR, 1992, ALDRICHIM ACTA, V25, P31; ROGER P, 1993, CARBOHYD POLYM, V21, P83, DOI 10.1016/0144-8617(93)90002-L; TOMALIA DA, 1993, TOP CURR CHEM, V165, P193; VANHEST JCM, 1995, SCIENCE, V268, P1592, DOI 10.1126/science.268.5217.1592; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; XU ZF, 1994, ADV DENDR MACROMOL, V1, P69; ZERKOWSKI JA, 1992, J AM CHEM SOC, V114, P5473, DOI 10.1021/ja00039a096; ZIMMERMAN SC, 1993, P NATL ACAD SCI USA, V90, P1190, DOI 10.1073/pnas.90.4.1190	20	567	591	1	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1095	1098		10.1126/science.271.5252.1095	http://dx.doi.org/10.1126/science.271.5252.1095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599085				2022-12-01	WOS:A1996TW70100031
J	Hinchey, J; Chaves, C; Appignani, B; Breen, J; Pao, L; Wang, A; Pessin, MS; Lamy, C; Mas, JL; Caplan, LR				Hinchey, J; Chaves, C; Appignani, B; Breen, J; Pao, L; Wang, A; Pessin, MS; Lamy, C; Mas, JL; Caplan, LR			A reversible posterior leukoencephalopathy syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NERVOUS-SYSTEM TOXICITY; BONE-MARROW TRANSPLANTATION; HUMAN-ENDOTHELIAL-CELLS; WHITE-MATTER LESIONS; HYPERTENSIVE ENCEPHALOPATHY; LIVER-TRANSPLANTATION; CORTICAL BLINDNESS; RENAL ARTERIOPATHY; CYCLOSPORINE; ECLAMPSIA	Background and Methods. In some patients who are hospitalized for acute illness, we have noted a reversible syndrome of headache, altered mental functioning, seizures, and loss of vision associated with findings indicating predominantly posterior leukoencephalopathy on imaging studies, To elucidate this syndrome, we searched the log books listing computed tomographic (CT) and magnetic resonance imaging (MRI) studies performed at the New England Medical Center in Boston and Hopital Sainte Anne in Paris; we found 15 such patients who were evaluated from 1988 through 1994. Results. Of the 15 patients, 7 were receiving immunosuppressive therapy after transplantation or as treatment for aplastic anemia, 1 was receiving interferon for melanoma, 3 had eclampsia, and 4 had acute hypertensive encephalopathy associated with renal disease (2 with lupus nephritis, 1 with acute glomerulonephritis, and 1 with acetaminophen-induced hepatorenal failure), Altogether, 12 patients had abrupt increases in blood pressure, and 8 had some impairment of renal function. The clinical findings included headaches, vomiting, confusion, seizures, cortical blindness and other visual abnormalities, and motor signs, CT and MRI studies showed extensive bilateral white-matter abnormalities suggestive of edema in the posterior regions of the cerebral hemispheres, but the changes often involved other cerebral areas, the brain stem, or the cerebellum. The patients were treated with antihypertensive medications, and immunosuppressive therapy was withdrawn or the dose was reduced, In all 15 patients, the neurologic deficits resolved within two weeks. Conclusions. Reversible, predominantly posterior leukoencephalopathy may develop in patients who have renal insufficiency or hypertension or who are immunosuppressed, The findings on neuroimaging are characteristic of subcortical edema without infarction. (C) 1996, Massachusetts Medical Society.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT NEUROL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HOP ST ANNE, SERV NEUROL, F-75674 PARIS, FRANCE	Tufts Medical Center; Tufts University; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite								ABUELMAGD KM, 1991, TRANSPLANT P, V23, P3190; ANTONOVYCH TT, 1988, TRANSPL P, V20, P951; BENIGNI A, 1992, TRANSPLANTATION, V54, P775, DOI 10.1097/00007890-199211000-00002; BHATT BD, 1988, NEW ENGL J MED, V318, P788; BROWN Z, 1987, TRANSPLANT P, V19, P1178; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; BYROM FB, 1954, LANCET, V2, P201; CAPLAN LR, 1980, NEUROLOGY, V30, P72, DOI 10.1212/WNL.30.1.72; COHEN RB, 1993, ANN INTERN MED, V118, P114, DOI 10.7326/0003-4819-118-2-199301150-00007; DAHMUS MA, 1992, AM J OBSTET GYNECOL, V167, P935, DOI 10.1016/S0002-9378(12)80015-9; DEGROEN PC, 1988, NEW ENGL J MED, V318, P789; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; DEKLIPPEL N, 1992, LANCET, V339, P1114, DOI 10.1016/0140-6736(92)90707-A; DIGRE KB, 1993, ARCH NEUROL-CHICAGO, V50, P399, DOI 10.1001/archneur.1993.00540040055015; DINSDALE HB, 1971, EUR NEUROL, V6, P29, DOI 10.1159/000114461; DINSDALE HB, 1974, ARCH NEUROL-CHICAGO, V31, P80, DOI 10.1001/archneur.1974.00490380028002; DONALDSON JO, 1993, LANCET, V342, P504; DONALDSON JO, 1993, LANCET, V341, P1447; DUNCAN R, 1989, J NEUROL NEUROSUR PS, V52, P899, DOI 10.1136/jnnp.52.7.899; EIDELMAN BH, 1991, TRANSPLANT P, V23, P3175; FISHER M, 1985, ANN NEUROL, V18, P268, DOI 10.1002/ana.410180219; FOGO A, 1990, TRANSPLANTATION, V49, P1190, DOI 10.1097/00007890-199006000-00038; FREISE CE, 1991, TRANSPLANT P, V23, P3173; GOTTRAND F, 1991, NEW ENGL J MED, V324, P1744; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; HERZOG TJ, 1990, OBSTET GYNECOL, V76, P980; HOLLER E, 1989, BLOOD, V73, P2018; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; HUMPHREYS TR, 1993, J AM ACAD DERMATOL, V29, P490, DOI 10.1016/S0190-9622(08)82005-1; IGARASHI T, 1994, ANN RHEUM DIS, V53, P350, DOI 10.1136/ard.53.5.350; JACOBS BC, 1992, MAGNETIC RESONANCE I, P636; JOHANSSON BB, 1983, ACTA MED SCAND, P107; KUPFERSCHMIDT H, 1995, ANN INTERN MED, V123, P598, DOI 10.7326/0003-4819-123-8-199510150-00006; MERIMSKY O, 1992, ANTI-CANCER DRUG, V3, P567, DOI 10.1097/00001813-199212000-00002; MOUTABARRIK A, 1991, TRANSPLANT P, V23, P3137; MUELLER AR, 1994, TRANSPLANTATION, V58, P155, DOI 10.1097/00007890-199405820-00006; RAPS EC, 1993, ANN NEUROL, V33, P222, DOI 10.1002/ana.410330215; RAROQUE HG, 1990, NEUROLOGY, V40, P167, DOI 10.1212/WNL.40.1.167; REMUZZI G, 1989, AM J KIDNEY DIS, V13, P261, DOI 10.1016/S0272-6386(89)80032-0; ROBERTSON DM, 1970, AM J PATHOL, V59, P115; RUBIN AM, 1987, NEUROLOGY, V37, P1072, DOI 10.1212/WNL.37.6.1072; SANDERS TG, 1991, RADIOLOGY, V180, P475, DOI 10.1148/radiology.180.2.2068315; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P379, DOI 10.2214/ajr.159.2.1632361; Sheth RD, 1996, EUR NEUROL, V36, P25, DOI 10.1159/000117195; SHUTTER LA, 1993, NEUROLOGY, V43, P2417, DOI 10.1212/WNL.43.11.2417; SIBAI BM, 1980, OBSTET GYNECOL, V55, P74; SLOANE JP, 1985, LANCET, V2, P280; SOMMER BG, 1986, TRANSPLANT P, V18, P151; SOMMER BG, 1985, AM J SURG, V149, P756, DOI 10.1016/S0002-9610(85)80181-1; STEIN DP, 1992, ANN NEUROL, V31, P644, DOI 10.1002/ana.410310612; TOLLEMAR J, 1988, NEW ENGL J MED, V318, P788; TROMMER BL, 1988, STROKE, V19, P326, DOI 10.1161/01.STR.19.3.326; TRUWIT CL, 1991, AM J NEURORADIOL, V12, P651; VAUGHN DJ, 1993, AM J NEURORADIOL, V14, P1014; VERBEKE M, 1994, CARDIOVASC RES, V28, P1152, DOI 10.1093/cvr/28.8.1152; WEINGARTEN K, 1994, AM J ROENTGENOL, V162, P665, DOI 10.2214/ajr.162.3.8109519; WIJDICKS EFM, 1994, ANN NEUROL, V35, P498, DOI 10.1002/ana.410350422; WILL AD, 1987, NEUROLOGY, V37, P1555, DOI 10.1212/WNL.37.9.1555; ZOJA C, 1986, LAB INVEST, V55, P455	60	2255	2432	2	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					494	500		10.1056/NEJM199602223340803	http://dx.doi.org/10.1056/NEJM199602223340803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559202				2022-12-01	WOS:A1996TV68600003
J	Neuenschwander, S; Singer, W				Neuenschwander, S; Singer, W			Long-range synchronization of oscillatory light responses in the cat retina and lateral geniculate nucleus	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; GANGLION-CELLS; VISUAL-CORTEX; DISCHARGE; NEURONS	VISUAL responses in the retina and the lateral geniculate nucleus (LGN) exhibit oscillatory patterning within a broad range of frequencies(1-9). Oscillatory activity is often associated with the synchronization of spatially distributed responses(10). Here we demonstrate, with simultaneous multi-electrode recordings from the retina and the LGN, that stationary and moving light stimuli evoke in retinal ganglion cells oscillatory responses in the frequency range of 61 to 114 Hz that become synchronized over distances larger than 20 degrees of visual angle across the nasal and temporal halves of the retina. This temporal patterning of retinal responses is transmitted reliably by LGN neurons, such that stimuli crossing the vertical meridian evoke synchronous responses in the LGNs of both hemispheres. The oscillatory responses are not phase-locked to the stimulus onset, indicating that synchronization results from horizontal interactions in the retina, The occurrence of synchronization depends on global stimulus properties such as size and continuity, suggesting that temporal correlation among responses of spatially segregated ganglion cells can be exploited to convey information relevant for perceptual grouping.	MAX PLANCK INST HIRNFORSCH, D-60528 FRANKFURT, GERMANY	Max Planck Society			Singer, Wolf/D-6874-2012	NEUENSCHWANDER, Sergio/0000-0001-7493-121X				ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812; ARNETT DW, 1978, EXP BRAIN RES, V32, P49; ARNETT DW, 1975, EXP BRAIN RES, V24, P111; BISHOP PO, 1964, J PHYSIOL-LONDON, V170, P598, DOI 10.1113/jphysiol.1964.sp007352; COOK JE, 1995, MICROSC RES TECHNIQ, V31, P408, DOI 10.1002/jemt.1070310510; DEVRIES SH, 1993, CELL S, V10, P1390; DOTY RW, 1963, J PHYSIOL-LONDON, V168, P205, DOI 10.1113/jphysiol.1963.sp007187; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; GERSTEIN GL, 1972, BIOPHYS J, V12, P453, DOI 10.1016/S0006-3495(72)86097-1; GHOSE GM, 1992, J NEUROPHYSIOL, V68, P1558, DOI 10.1152/jn.1992.68.5.1558; ITO H, 1994, SOC NEUR ABSTR, V20; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; MASTRONARDE DN, 1989, TRENDS NEUROSCI, V12, P75, DOI 10.1016/0166-2236(89)90140-9; NUNEZ A, 1992, NEUROSCIENCE, V51, P269, DOI 10.1016/0306-4522(92)90314-R; PEICHL L, 1979, J PHYSIOL-LONDON, V291, P117, DOI 10.1113/jphysiol.1979.sp012803; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; ROBSON JG, 1987, J OPT SOC AM A, V4, P2301, DOI 10.1364/JOSAA.4.002301; RODIECK RW, 1967, J NEUROPHYSIOL, V30, P1043, DOI 10.1152/jn.1967.30.5.1043; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; STEVENS JK, 1976, J NEUROPHYSIOL, V39, P239, DOI 10.1152/jn.1976.39.2.239; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WORGOTTER F, 1995, VISUAL NEUROSCI, V12, P469, DOI 10.1017/S0952523800008373	26	240	246	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					728	733		10.1038/379728a0	http://dx.doi.org/10.1038/379728a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602219				2022-12-01	WOS:A1996TW56700053
J	Wilm, M; Shevchenko, A; Houthaeve, T; Breit, S; Schweigerer, L; Fotsis, T; Mann, M				Wilm, M; Shevchenko, A; Houthaeve, T; Breit, S; Schweigerer, L; Fotsis, T; Mann, M			Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry	NATURE			English	Article							PEPTIDES	MOLECULAR analysis of complex biological structures and processes increasingly requires sensitive methods far protein sequencing. Electrospray mass spectrometry(1) has been applied to the high-sensitivity sequencing of short peptides(2), but technical difficulties have prevented similar success with gel-isolated proteins. Here we report a simple and robust technique for the sequencing of proteins isolated by polyacrylamide gel electrophoresis, using nano-electrospray(3,4) tandem mass spectrometry(5,6). As little as 5 ng protein starting material on Coomassie- or silver-stained gels can be sequenced. Multiple-sequence stretches of up to 16 amino acids are obtained, which identify the protein unambiguously if already present in databases or provide information to clone the corresponding gene. We have applied this method to the sequencing and cloning of a protein which inhibits the proliferation of capillary endothelial cells in vitro and thus may have potential antiangiogenic effects on solid tumours.	EUROPEAN MOLEC BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CHILDRENS HOSP,DIV ONCOL & HAEMATOL,D-69120 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; HUNKAPILLER M, 1984, NATURE, V310, P105, DOI 10.1038/310105a0; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JENO P, 1995, ANAL BIOCHEM, V224, P451; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	16	1465	1530	2	176	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					466	469		10.1038/379466a0	http://dx.doi.org/10.1038/379466a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559255				2022-12-01	WOS:A1996TT30400065
J	Omran, M; Russell, G				Omran, M; Russell, G			Continuing increase in respiratory symptoms and atopy Aberdeen schoolchildren	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen								ANDERSON PG, 1993, CARDIOVASC PATHOL, V2, P6; AUSTIN JB, 1994, ARCH DIS CHILD, V71, P211, DOI 10.1136/adc.71.3.211; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171	5	117	118	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					34	34		10.1136/bmj.312.7022.34	http://dx.doi.org/10.1136/bmj.312.7022.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555858	Green Published			2022-12-01	WOS:A1996TP20900024
J	Garner, DW				Garner, DW			Banning tobacco billboards - The case for municipal action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1994, Baltimore, Md, became the first city to generally prohibit billboards from displaying alcohol and tobacco advertisements. The owner of most of Baltimore's billboards, Penn Advertising, sued, but the federal district court rejected the billboard company's complaint and ruled that the First Amendment had not been violated and that the federal cigarette labeling acts had not preempted the ability of Baltimore to regulate and prohibit billboard cigarette advertising. In the fall of 1995, the federal district court's judgment was unanimously affirmed by the Fourth Circuit Court of Appeals in Richmond, Va. This article analyzes the constitutional and preemption issues and concludes that states and municipalities are on firm legal ground when they restrict the location or placement of publicly visible cigarette advertisements without attempting to regulate the advertisement's content or message. States and municipalities command broad authority to protect children and to shield the public from intrusive forms of advertisement that inflict their messages on a captive audience. A billboard ban thus offers local communities a legal avenue to help curb the rising tide of juvenile smoking without raising taxes, creating bureaucracy, or angering smokers.			Garner, DW (corresponding author), SO ILLINOIS UNIV,SCH LAW,CARBONDALE,IL 62901, USA.							AGUS C, 1990, NEWSDAY         0613, P4; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; KIRBY J, 1990, NEWSDAY         0304, P4; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; ROEMER R, 1986, UNPUB NATL LEGISLATI, P66; RONSON J, 1992, WORLD SMOKING HLTH, V2, P25; RONSON J, 1992, WORLD SMOKING HLTH, V2, P24; ROTHSTEIN L, 1995, HLTH LAW NEWS    SEP, P4; *SMOK CONTR ADV RE, 1994, ISS STUD CORR ADV IN; *US DEPT HHS, 1989, HLTH CONS SMOK NIC A, P9; *US DEPT HHS, 1994, PREV TOB US YOUNG PE, P192; 1995, TOBOCCO FREE YOU FAL, P17; 1965, PUB L, V8992; 1994, MILFORD DAILY N 1118, P1; 1993, FED REGISTER, V58, P45156; 1995, FED REGISTER, V60, P41314; 1993, SCENIC AM, P16; 1995, FED REGISTER, V60, P41315; 1970, 91222 PUB L; 1993, FED REGISTER, V58, P45158	21	6	6	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1263	1269						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601959				2022-12-01	WOS:A1996UF47800031
J	Choi, OH; Kim, JH; Kinet, JP				Choi, OH; Kim, JH; Kinet, JP			Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor	NATURE			English	Article							CELL; TRANSDUCTION; PLATELETS	Calcium mobilization through antigen receptors, including high-affinity IgE receptors (Fc epsilon RI), is thought to be mediated by inositol-1,4,5-trisphosphate production (InsP(3))(1-4). Here we show that antigen clustering of Fc epsilon RI on the rat mast-cell line (RBC 2H3) activates a sphingosine kinase (SK) and produces sphingosine-l-phosphate (S1P), an alternative second messenger for intracellular calcium mobilization, The sphingosine analogue, D-L-threo-dihydrosphingosine (DHS), inhibits the SK enzyme competitively with a dissociation constant, K-i, of 5 to 18 mu M. This inhibition substantially suppresses the Fc epsilon RI-mediated calcium signal, but leaves intact the syk tyrosine kinase activation and the small InsP(3) production. The entire InsP(3)-dependent pathway activated by a transfected G-protein coupled receptor, used here as a positive control, also remained intact. Thus Fc epsilon RI principally utilizes a SK pathway to mobilize calcium.	BETH ISRAEL HOSP,LAB ALLERGY & IMMUNOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Choi, OH (corresponding author), NIAID,LAB ALLERG DIS,NIH,ROCKVILLE,MD 20852, USA.							BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CHOI OH, 1993, J IMMUNOL, V151, P5586; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; MATTIE M, 1994, J BIOL CHEM, V269, P3181; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x	17	371	384	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					634	636						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602265				2022-12-01	WOS:A1996UF74100048
J	Shimoda, K; vanDeursen, J; Sangster, MY; Sarawar, SR; Carson, RT; Tripp, RA; Chu, C; Quelle, FW; Nosaka, T; Vignali, DAA; Doherty, PC; Grosveld, G; Paul, WE; Ihle, JN				Shimoda, K; vanDeursen, J; Sangster, MY; Sarawar, SR; Carson, RT; Tripp, RA; Chu, C; Quelle, FW; Nosaka, T; Vignali, DAA; Doherty, PC; Grosveld, G; Paul, WE; Ihle, JN			Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene	NATURE			English	Article							IL-4; GENERATION; INVIVO; CELLS	Signal transducers and activators of transcription (Stats) are activated by tyrosine phosphorylation in response to cytokines, and are thought to mediate many of their functional responses(1-4) Stat6 is activated in response to interleukin (IL)-4 (refs 5,6) and may contribute to various functions including mitogenesis, T-helper cell differentiation and immunoglobulin isotype switching(7). To evaluate the role of Stat6, we generated Stat6-null mice (Stat6(-/-)) by gene disruption in embryonic stem cells. The mice were viable, indicating the lack of a non-redundant function in normal development. Although naive lymphoid cell development was normal, Stat6(-/-) mice were deficient in IL-4-mediated functions including Th2 helper T-cell differentiation, expression of cell surface markers, and immunoglobulin class switching to IgE. In contrast, IL-4-mediated proliferation was only partly affected.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; NIAID, IMMUNOL LAB, NIH, BETHESDA, MD 20892 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Tripp, Ralph A./F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph A./0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489; Quelle, Frederick/0000-0002-1184-6170; Sangster, Mark/0000-0002-1599-5894				COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COVFFMAN RL, 1996, J IMMUNOL, V136, P4538; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; HOUR J, 1994, SCIENCE, V265, P1701; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KATONA IM, 1991, J IMMUNOL, V146, P4215; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRETSOVALI A, 1995, NUCLEIC ACIDS RES, V23, P2919, DOI 10.1093/nar/23.15.2919; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RICHARDSML, 1994, J IMMUNOL, V22, P3453; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; SNAPPER CM, 1988, P NATL ACAD SCI USA, V85, P6107, DOI 10.1073/pnas.85.16.6107; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7	29	1071	1095	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	1996	380	6575					630	633		10.1038/380630a0	http://dx.doi.org/10.1038/380630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602264				2022-12-01	WOS:A1996UF74100047
J	Sugita, Y				Sugita, Y			Global plasticity in adult visual cortex following reversal of visual input	NATURE			English	Article							CONNECTIONS; MOTION	THE reversal or displacement of the retinal image by prism spectacles leads to extreme disruption of visually guided behaviour, but after an extended period of visual transformation normal behaviour is gradually restored. It is unclear whether this adaptation involves a change in visual perception(1-5), the learning of new motor responses(6), a modification of the sensorimotor control system(7) or a proprioceptive change in the perceived positions of the body parts(8). Here I describe the effects of visual field reversal on neuronal activity in the monkey visual cortex After a few months of wearing reversing spectacles, some cells in the primary visual cortex began to respond to stimuli presented not only in the contralateral visual field but also in the ipsilateral field. These cells were not selective for orientation or direction of motion, but responded well to a light flash. This result suggests that adaptation to visual field reversal is mediated, at least in part, by a large-scale functional reorganization at an early stage the visual processing pathway.			Sugita, Y (corresponding author), TOYOHASHI UNIV TECHNOL,LAB NEURAL SYST,TOYOHASHI,AICHI 441,JAPAN.							BISHOP PO, 1962, J PHYSIOL-LONDON, V163, P466, DOI 10.1113/jphysiol.1962.sp006990; CUSICK CG, 1984, J COMP NEUROL, V230, P311, DOI 10.1002/cne.902300302; DAY RH, 1967, PSYCHOL BULL, V67, P307, DOI 10.1037/h0024482; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HARRIS CS, 1963, SCIENCE, V140, P812, DOI 10.1126/science.140.3568.812; HELD R, 1963, SCIENCE, V142, P455, DOI 10.1126/science.142.3591.455; Kohler I, 1964, PSYCHOL ISSUES, V3, P1; SHIMOJO S, 1981, PERCEPTION, V10, P391, DOI 10.1068/p100391; SPATZ WB, 1984, NEUROSCI LETT, V48, P49, DOI 10.1016/0304-3940(84)90287-8; Stratton G. M., 1897, PSYCHOL REV, V4, P463, DOI [10.1037/h0075482, DOI 10.1037/H0071173]; Stratton G.M., 1897, PSYCHOL REV, V4, P341, DOI [DOI 10.1037/H0075482, 10.1037/h0075482]; SUGITA Y, 1994, PERCEPT MOTOR SKILL, V79, P1047, DOI 10.2466/pms.1994.79.2.1047; SUGITA Y, 1991, NEUROREPORT, V2, P751, DOI 10.1097/00001756-199112000-00005; TANAKA K, 1993, J NEUROPHYSIOL, V69, P128, DOI 10.1152/jn.1993.69.1.128; Taylor J. g., 1962, BEHAV BASIS PERCEPTI; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4	16	60	60	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					523	526		10.1038/380523a0	http://dx.doi.org/10.1038/380523a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UE663	8606770				2022-12-01	WOS:A1996UE66300048
J	Gerstein, HC; Yusuf, S				Gerstein, HC; Yusuf, S			Dysglycaemia and risk of cardiovascular disease	LANCET			English	Article							CORONARY-HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; MORTALITY; HYPERGLYCEMIA; ASSOCIATION; WHITEHALL; NIDDM; DEATH; MEN		MCMASTER UNIV, CHEDOKE MCMASTER HOSP, DEPT MED, DIABET CARE & RES CTR, HAMILTON, ON L8N 3Z5, CANADA; HAMILTON CIV HOSP, RES CTR, PREVENT CARDIOL & THERAPEUT PROGRAMME, HAMILTON, ON, CANADA	McMaster University; McMaster University			Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836; Yusuf, Salim/0000-0003-4776-5601				BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BURCHFIEL CM, 1994, STROKE, V25, P951, DOI 10.1161/01.STR.25.5.951; CURB JD, 1995, CIRCULATION, V91, P2591, DOI 10.1161/01.CIR.91.10.2591; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; DONAHUE RP, 1992, DIABETES CARE, V15, P1141, DOI 10.2337/diacare.15.9.1141; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; FULLER JH, 1980, LANCET, V1, P1373; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HERMAN JB, 1977, DIABETOLOGIA, V13, P229, DOI 10.1007/BF01219704; JARRETT RJ, 1984, DIABETOLOGIA, V26, P99; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; Kenny S.J., 1995, NIH PUBLICATION, P47; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LEONETTI F, 1993, J ENDOCRINOL INVEST, V16, P875, DOI 10.1007/BF03348949; MALBERG K, 1995, J AM COLL CARDIOL, V26, P57; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; REWERS M, 1995, NIH PUBLICATION, P179; SCHEIDTNAVE C, 1991, AM J EPIDEMIOL, V133, P565, DOI 10.1093/oxfordjournals.aje.a115928; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; VIBERTI G, 1995, NEW ENGL J MED, V332, P1293, DOI 10.1056/NEJM199505113321909; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; 1992, JAMA-J AM MED ASSOC, V266, P1292	29	138	143	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					949	950		10.1016/S0140-6736(96)91420-8	http://dx.doi.org/10.1016/S0140-6736(96)91420-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598762				2022-12-01	WOS:A1996UD59100015
J	Francino, MP; Chao, L; Riley, MA; Ochman, H				Francino, MP; Chao, L; Riley, MA; Ochman, H			Asymmetries generated by transcription-coupled repair in enterobacterial genes	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTATION-RATES; DNA-REPLICATION; LAGGING-STRAND; CODON USAGE; POPULATIONS; DEAMINATION; SALMONELLA; REGION; OPERON	Although certain replication errors occur at different frequencies on each of the complementary strands of DNA, it remains unclear whether this bias is prevalent enough during chromosome replication to affect sequence evolution. Here, nucleotide substitutions in enteric bacteria were examined, and no difference in mutation rates was detected between the leading and lagging strands, but in comparing the coding and noncoding strands, an excess of C-->T changes was observed on the coding strand. This asymmetry is best explained by transcription-coupled repair on the noncoding strand. Although the vast majority of mutations are thought to arise from spontaneous errors during replication, this result implicates DNA damage as a substantial source of mutations in the wild.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; UNIV MARYLAND, DEPT ZOOL, COLLEGE PK, MD 20742 USA; YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA	University of Rochester; University System of Maryland; University of Maryland College Park; Yale University			Francino, M.Pilar/H-9090-2015; Riley, Margaret Ann/AAB-9743-2022	Francino, M.Pilar/0000-0002-4510-5653; 				BERG OG, 1995, J MOL EVOL, V41, P449, DOI 10.1007/BF00160316; BOYD EF, 1994, P NATL ACAD SCI USA, V91, P1280, DOI 10.1073/pnas.91.4.1280; BULMER M, 1991, J MOL EVOL, V33, P305, DOI 10.1007/BF02102861; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DOWNES CS, 1993, BIOESSAYS, V15, P209, DOI 10.1002/bies.950150311; DUBOSE RF, 1988, P NATL ACAD SCI USA, V85, P7036, DOI 10.1073/pnas.85.18.7036; EYREWALKER A, 1995, GENETICS, V140, P1407; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; HALL BG, 1992, MOL BIOL EVOL, V9, P654; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; Kornberg A., 1992, DNA REPLICATION; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MADDISON WP, 1992, MACCLADE V 3 0 ANAL; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NELSON K, 1994, P NATL ACAD SCI USA, V91, P10227, DOI 10.1073/pnas.91.21.10227; NELSON K, 1991, P NATL ACAD SCI USA, V88, P6667, DOI 10.1073/pnas.88.15.6667; NELSON K, 1992, J BACTERIOL, V174, P6886, DOI 10.1128/JB.174.21.6886-6895.1992; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; PHILLIPS GJ, 1987, NUCLEIC ACIDS RES, V15, P2611, DOI 10.1093/nar/15.6.2611; ROBERTS JD, 1994, J BIOL CHEM, V269, P1711; SELANDER RK, 1994, FEMS SYMP, P17; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SKANDALIS A, 1994, MUTAT RES, V314, P21, DOI 10.1016/0921-8777(94)90057-4; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; WU CI, 1991, NATURE, V352, P114, DOI 10.1038/352114b0; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0; [No title captured]	31	109	113	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					107	109		10.1126/science.272.5258.107	http://dx.doi.org/10.1126/science.272.5258.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600517				2022-12-01	WOS:A1996UD59700049
J	Nehrbass, U; Blobel, G				Nehrbass, U; Blobel, G			Role of the nuclear transport factor p10 in nuclear import	SCIENCE			English	Article							PROTEIN RAN/TC4	The nuclear import factor p10 was cloned from Saccharomyces cerevisiae and found to be essential. The protein p10 can bind directly to several peptide repeat-containing nucleoporins. It also binds to the guanosine triphosphatase (GTPase) Ran in its guanosine diphosphate (GDP)-bound form and to karyopherin beta. Assembly of the karyopherin heterodimer on immobilized nucleoporin yielded cooperative binding of p10 and Ran-GDP. Addition of GTP to this pentameric complex led to dissociation of karyopherin alpha, presumably via in situ formation of Ran-GTP from Ran-GDP. Thus, p10 appears to coordinate the Ran-dependent association and dissociation reactions underlying nuclear import.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University				Vallar, Laurent/0000-0002-4404-1010; Nehrbass, Ulf/0000-0002-7028-8076				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DECASTILLIA CS, 1995, J CELL BIOL, V131, P19; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385	27	155	157	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					120	122		10.1126/science.272.5258.120	http://dx.doi.org/10.1126/science.272.5258.120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600522				2022-12-01	WOS:A1996UD59700054
J	Nowak, MA; Bangham, CRM				Nowak, MA; Bangham, CRM			Population dynamics of immune responses to persistent viruses	SCIENCE			English	Review							CYTOTOXIC LYMPHOCYTES-T; CENTRAL-NERVOUS-SYSTEM; EPSTEIN-BARR-VIRUS; GENETIC-VARIATION; CELL RECOGNITION; HIV-INFECTION; TYPE-1; INVIVO; INFLUENZA; CLEARANCE	Mathematical models, which are based on a firm understanding of biological interactions, can provide nonintuitive insights into the dynamics of host responses to infectious agents and can suggest new avenues for experimentation. Here, a simple mathematical approach is developed to explore the relation between antiviral immune responses, virus load, and virus diversity. The model results are compared to data on cytotoxic Tell responses and viral diversity in infections with the human T cell leukemia virus (HTLV-1) and the human immunodeficiency virus (HIV-1).	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, LONDON W2 1PG, ENGLAND	Imperial College London	Nowak, MA (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008	Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUR Z, 1991, EXP HEMATOL, V19, P364; ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; ANDERSON R M, 1991; ANDERSON RM, 1994, SCIENCE, V264, P1884, DOI 10.1126/science.8009218; ANDERSON RM, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P335; Antia R, 1996, P NATL ACAD SCI USA, V93, P985, DOI 10.1073/pnas.93.3.985; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; ASJO B, 1990, AIDS RES HUM RETROV, V6, P1177, DOI 10.1089/aid.1990.6.1177; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Bangham C R, 1993, Curr Opin Neurobiol, V3, P773, DOI 10.1016/0959-4388(93)90152-O; Bangham CRM, 1996, SEMIN VIROL, V7, P41, DOI 10.1006/smvy.1996.0006; BERTOLETTI A, 1994, J EXP MED, V180, P933, DOI 10.1084/jem.180.3.933; BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0; BONHOEFFER S, 1995, IMMUNOL TODAY, V16, P131, DOI 10.1016/0167-5699(95)80129-4; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BUREAU JF, 1993, NAT GENET, V5, P87, DOI 10.1038/ng0993-87; BURK RD, 1994, J INFECT DIS, V170, P1418, DOI 10.1093/infdis/170.6.1418; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CANNON MJ, 1987, IMMUNOLOGY, V62, P133; CHEYNIER R, 1995, ADV EXP MED BIOL, V374, P173; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Daenke S, 1996, VIROLOGY, V217, P139, DOI 10.1006/viro.1996.0101; DEBOER RJ, 1994, P NATL ACAD SCI USA, V91, P544, DOI 10.1073/pnas.91.2.544; DEBOER RJ, 1995, J THEOR BIOL, V175, P567, DOI 10.1006/jtbi.1995.0165; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DIEHL LJ, 1995, J VIROL, V69, P2328, DOI 10.1128/JVI.69.4.2328-2332.1995; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; Ferrari C, 1996, SEMIN VIROL, V7, P23, DOI 10.1006/smvy.1996.0004; FONG TL, 1994, J MED VIROL, V43, P155, DOI 10.1002/jmv.1890430210; FOX JC, 1995, J GEN VIROL, V76, P309, DOI 10.1099/0022-1317-76-2-309; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HERZ AVM, IN PRESS P NATL ACAD; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; KHANNA R, 1993, J IMMUNOL, V150, P5154; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCELRATH MJ, 1994, J VIROL, V68, P5074, DOI 10.1128/JVI.68.8.5074-5083.1994; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MCLEAN AR, 1992, J THEOR BIOL, V155, P69, DOI 10.1016/S0022-5193(05)80549-1; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MITTLER JE, J ACQUIRED IMMUNE DE; MOSKOPHIDIS D, 1994, J IMMUNOL, V152, P4976; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; NIEWIESK S, 1994, J VIROL, V68, P6778, DOI 10.1128/JVI.68.10.6778-6781.1994; NIEWIESK S, IN PRESS J MOL EVOL; NOWAK MA, 1995, J THEOR BIOL, V175, P325, DOI 10.1006/jtbi.1995.0146; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, NATURE, V375, P193, DOI 10.1038/375193a0; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; NOWAK MA, IN PRESS P NATL ACAD; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATAK M, 1993, SCIENCE, V259, P1749; REDDEHASE MJ, 1994, J EXP MED, V179, P185, DOI 10.1084/jem.179.1.185; REHERMANN B, 1995, J CLIN INVEST, V96, P1527, DOI 10.1172/JCI118191; RICKINSON AB, 1986, EPSTEINBARR VIRUS RE, P75; RIDDELL SR, 1992, SCIENCE, V257, P238; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SASAKI A, 1994, J THEOR BIOL, V168, P291, DOI 10.1006/jtbi.1994.1110; SHANLEY JD, 1993, J INFECT DIS, V167, P264, DOI 10.1093/infdis/167.2.264; STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	102	887	934	7	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					74	79		10.1126/science.272.5258.74	http://dx.doi.org/10.1126/science.272.5258.74			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600540				2022-12-01	WOS:A1996UD59700039
J	Pasqualini, R; Ruoslahti, E				Pasqualini, R; Ruoslahti, E			Organ targeting in vivo using phage display peptide libraries	NATURE			English	Article							RECEPTOR; PROTEINS	PREFERENTIAL homing of tumour cells(1,2) and leukocytes(3,4) to specific organs indicates that tissues carry unique marker molecules accessible to circulating cells. Organ-selective address molecules on endothelial surfaces have been identified for lymphocyte homing to various lymphoid organs and to tissues undergoing inflammation(5-8), and an endothelial marker responsible for tumour homing to the lungs has also been identified(9). Here we report a new approach to studying organ-selective targeting based on in vivo screening of random peptide sequences. Peptides capable of mediating selective localization of phage to brain and kidney blood vessels were identified, and showed up to 13-fold selectivity for these organs. One of the peptides displayed by the brain-localizing phage mas synthesized and shown to specifically inhibit the localization of the homologous phage into the brain. When coated onto glutaraldehyde-fixed red blood cells, the peptide caused selective localization of intravenously injected cells into the brain, These peptide sequences represent the first step towards identifying selective endothelial markers, which may be useful in targeting cells, drugs and genes into selected tissues.	LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SALMI M, 1992, P NATL ACAD SCI USA, V89, P11436, DOI 10.1073/pnas.89.23.11436; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	15	972	1156	5	169	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					364	366		10.1038/380364a0	http://dx.doi.org/10.1038/380364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598934				2022-12-01	WOS:A1996UC37900065
J	Dowswell, T; Thornton, JG; Hewison, J; Lilford, RJL				Dowswell, T; Thornton, JG; Hewison, J; Lilford, RJL			Should there be a trial of home versus hospital delivery in the United Kingdom? Measuring outcomes other than safety is feasible	BRITISH MEDICAL JOURNAL			English	Article											Dowswell, T (corresponding author), UNIV LEEDS,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				CAMPBELL R, 1986, BRIT J OBSTET GYNAEC, V93, P675, DOI 10.1111/j.1471-0528.1986.tb07965.x; CUNNINGHAM JD, 1993, SOC SCI MED, V36, P475, DOI 10.1016/0277-9536(93)90409-W; *DEP HLTH EXP MAT, 1993, REP 1; *HOUS COMM HLTH CO, 1992, WINT REP; *ROY COLL OBST GYN, 1992, RESP REP HOUS COMM H	5	38	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					753	753						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605464				2022-12-01	WOS:A1996UC16600032
J	Brownell, JE; Zhou, JX; Ranalli, T; Kobayashi, R; Edmondson, DG; Roth, SY; Allis, CD				Brownell, JE; Zhou, JX; Ranalli, T; Kobayashi, R; Edmondson, DG; Roth, SY; Allis, CD			Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation	CELL			English	Article							TRANSCRIPTION; NUCLEOSOME; DNA; CHROMATIN; SNF2/SWI2; PROTEINS; SNF5; SWI1	We report the cloning of a transcription-associated histone acetyltransferase type A (HAT A). This Tetrahymena enzyme is strikingly homologous to the yeast protein Gcn5, a putative transcriptional adaptor, and we demonstrate that recombinant Gcn5p possesses HAT activity. Both the ciliate enzyme and Gcn5p contain potential active site residues found in other acetyltransferases and a highly conserved bromodomain. The presence of this domain in nuclear A-type HATs, but not in cytoplasmic B-type HATs, suggests a mechanism whereby HAT A is directed to chromatin to facilitate transcriptional activation. These findings shed light on the biochemical function of the evolutionarily conserved Gcn5p-Ada complex, directly linking histone acetylation to gene activation, and indicate that histone acetylation is a targeted phenomenon.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Rochester; Cold Spring Harbor Laboratory; University of Texas System; UTMD Anderson Cancer Center				Edmondson, Diane/0000-0003-3702-9715; Dent, Sharon/0000-0002-4824-3269	NCI NIH HHS [F32CA65098] Funding Source: Medline; NIGMS NIH HHS [GM51189, GM53512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053512, R01GM053512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, MOL CELL BIOL, V16, P593; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; JOHNSON LM, 1990, P NATL ACAD SCI USA, V369, P245; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KURIHARA T, 1992, EUR J BIOCHEM, V210, P999, DOI 10.1111/j.1432-1033.1992.tb17505.x; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1994, CHROMOSOMA, V103, P441; MADIREDDI MT, 1994, DEV BIOL, V165, P418, DOI 10.1006/dbio.1994.1264; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.bb.20.060191.002051; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAVERNARAKIS N, 1995, MOL GEN GENET, V247, P571, DOI 10.1007/BF00290348; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/0092-8674(93)90673-E; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; VAVRA KJ, 1982, J BIOL CHEM, V257, P2591; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P337; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	59	1246	1302	8	102	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					843	851		10.1016/S0092-8674(00)81063-6	http://dx.doi.org/10.1016/S0092-8674(00)81063-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601308	hybrid			2022-12-01	WOS:A1996UC38100006
J	Lansdown, ABG				Lansdown, ABG			Zinc in the healing wound	LANCET			English	Editorial Material							VENOUS LEG ULCERS; TISSUE				Lansdown, ABG (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT COMPARAT BIOL,LONDON,ENGLAND.							AGREN MS, 1993, BRIT J DERMATOL, V129, P221, DOI 10.1111/j.1365-2133.1993.tb03533.x; BARCIA PJ, 1970, ANN SURG, V172, P1048, DOI 10.1097/00000658-197012000-00019; ERIKSSON G, 1986, BRIT J DERMATOL, V114, P227, DOI 10.1111/j.1365-2133.1986.tb02801.x; HALLBOOK T, 1972, LANCET, V2, P780; HENG MK, 1993, BRIT J DERMATOL, V129, P280, DOI 10.1111/j.1365-2133.1993.tb11847.x; HENZEL JH, 1970, ARCH SURG-CHICAGO, V100, P349; Lansdown A. B. G., 1993, International Journal of Cosmetic Science, V15, P83, DOI 10.1111/j.1467-2494.1993.tb00072.x; LANSDOWN ABG, 1995, CRC CRIT R TOXICOL, V12, P397; OCCLESTON NL, 1995, 5 ANN M EUR TISS REP; PARISI AF, 1969, AM J CLIN NUTR, V22, P1222; PORIES WJ, 1967, ANN SURG, V165, P432; Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93	12	64	65	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					706	707		10.1016/S0140-6736(96)90072-0	http://dx.doi.org/10.1016/S0140-6736(96)90072-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601997	Bronze			2022-12-01	WOS:A1996TZ98200005
J	Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA				Berlowitz, DR; Ash, AS; Brandeis, GH; Brand, HK; Halpern, JL; Moskowitz, MA			Rating long-term care facilities on pressure ulcer development: Importance of case-mix adjustment	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOMES; QUALITY; MORTALITY; SORES; RISK	Objective: To determine the importance of case-mix adjustment in interpreting differences in rates of pressure ulcer development in Department of Veterans Affairs long-term care facilities. Design: A sample assembled from the Patient Assessment File, a Veterans Affairs administrative database, was used to derive predictors of pressure ulcer development; the resulting model was validated in a separate sample. Facility-level rates of pressure ulcer development, both unadjusted long-term care and adjusted for case mix using the predictive model, were compared. Setting: Department of Veterans Affairs long-term care facilities. Patients: The derivation sample consisted of 31 150 intermediate medicine and nursing home residents who were initially free of pressure ulcers and were institutionalized between October 1991 and April 1993. The validation sample consisted of 17 946 residents institutionalized from April 1993 to October 1993. Measurement: Development of a stage 2 or greater pressure ulcer. Results: 11 factors predicted pressure ulcer development. Validated performance properties of the resulting model were good. Model-predicted rates of pressure ulcer development at individual long-term care facilities varied from 1.9% to 6.3%, and observed rates ranged from 0% to 10.9%. Case-mix-adjusted rates and ranks of facilities differed considerably from unadjusted ratings. For example, among five facilities that were identified as high outliers on the basis of unadjusted rates, two remained as outliers after adjustment for case mix. Conclusions: Gong-term care facilities differ in case mix. Adjustments for case mix result in different judgments about facility performance and should be used when facility incidence rates are compared.	BOSTON UNIV, MED CTR, GEN INTERNAL MED SECT, BOSTON, MA 02118 USA; DEPT VET AFFAIRS, WASHINGTON, DC USA	Boston University	Berlowitz, DR (corresponding author), VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, 200 SPRINGS RD, BEDFORD, MA 01730 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Berlowitz, Dan/0000-0002-8783-5611				ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BERLOWITZ DR, 1993, IMPROVING CARE NURSI; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; GERON SM, 1991, GERONTOLOGIST, V31, P292, DOI 10.1093/geront/31.3.292; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HOSMER EW, 1989, APPL LOGISTIC REGRES; Institute of Medicine (US) Committee on Nursing Home Regulation, 1986, IMPR QUAL CAR NURS H; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; KANE RL, 1990, J AM GERIATR SOC, V38, P704, DOI 10.1111/j.1532-5415.1990.tb01432.x; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; LOCALIO AR, 1995, ANN INTERN MED, V122, P125, DOI 10.7326/0003-4819-122-2-199501150-00009; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; O'Leary D S, 1993, Jt Comm J Qual Improv, V19, P487; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RUDMAN D, 1993, J AM GERIATR SOC, V41, P1317, DOI 10.1111/j.1532-5415.1993.tb06482.x; RUDMAN D, 1993, AM J PHYS MED REHAB, V72, P276, DOI 10.1097/00002060-199310000-00005; RUDMAN D, 1993, J GEN INTERN MED, V8, P653, DOI 10.1007/BF02598281; SCHNEIDER DP, 1988, HLTH CARE FINANC REV, V10, P39; SCHWARTZ M, 1994, RISK ADJUSTMENT MEAS; *US AG HLTH CAR PO, 1992, PRESS ULC AD PRED PR; *US HLTH CAR FIN A, 1987, HCFA PUBL; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILKING SV, 1990, ANN M AM GER SOC ATL; WU AW, 1995, ANN INTERN MED, V122, P149, DOI 10.7326/0003-4819-122-2-199501150-00013; ZINN JS, 1993, MED CARE, V31, P475, DOI 10.1097/00005650-199306000-00001; 1990, INT J TECHNOL ASSESS, V6, P181	37	73	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					557	+		10.7326/0003-4819-124-6-199603150-00003	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597318				2022-12-01	WOS:A1996TZ52900003
J	Knekt, P; Jarvinen, R; Reunanen, A; Maatela, J				Knekt, P; Jarvinen, R; Reunanen, A; Maatela, J			Flavonoid intake and coronary mortality in Finland: A cohort study	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; DISEASE; WINE; RISK	Objective-To study the association between dietary intake of flavonoids and subsequent coronary mortality. Design-A cohort study based on data collected at the Finnish mobile clinic health examination survey from 1967-72 and followed up until 1992. Settings-30 communities from different parts of Finland. Subjects-5133 Finnish men and women aged 30-69 years and free from heart disease at baseline. Main outcome measure-Dietary intake of flavonoids, total mortality, and coronary mortality. Results-In women a significant inverse gradient was observed between dietary intake of flavonoids and total and coronary mortality. The relative risks between highest and lowest quarters of flavonoid intake adjusted for age, smoking, serum cholesterol concentration, blood pressure, and body mass index were 0.69 (95% confidence interval 0.53 to 0.90) and 0.54 (0.33 to 0.87) for total and coronary mortality, respectively. The corresponding values for men were 0.76 (0.63 to 0.93) and 0.78 (0.56 to 1.08), respectively. Adjustment for intake of antioxidant vitamins and fatty acids weakened the associations for women; the relative risks for coronary heart disease were 0.73 (0.41 to 1.32) and 0.67 (0.44 to 1.00) in women and men, respectively. Intakes of onions and apples, the main dietary sources of flavonoids, presented similar associations. The relative risks for coronary mortality between highest and lowest quarters of apple intake were 0.57 (0.36 to 0.91) and 0.81 (0.61 to 1.09) for women and men, respectively. The corresponding values for onions were 0.50 (0.30 to 0.82) and 0.74 (0.53 to 1.02), respectively. Conclusion-The results suggest that people with very low intakes of flavonoids have higher risks of coronary disease.	SOCIAL INSURANCE INST,CTR RES & DEV,HELSINKI,FINLAND; SOCIAL INSURANCE INST,CTR RES & DEV,TURKU,FINLAND; KUOPIO UNIV,DEPT CLIN NUTR,KUOPIO,FINLAND	University of Eastern Finland	Knekt, P (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							AROMAA A, 1981, SERIES AL, V17; Cohen J., 1983, APPL MULTIPLE REGRES, Vsecond, DOI 10.4324/9780203774441.; COX DR, 1972, J R STAT SOC B, V34, P187; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GAZIANO JM, 1994, NATURAL ANTIOXIDANTS; GRYGLEWSKI RJ, 1987, BIOCHEM PHARMACOL, V36, P317, DOI 10.1016/0006-2952(87)90288-7; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Herrmann K., 1976, Journal of Food Technology, V11, P433, DOI 10.1108/09566160010378107; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HERTOG MGL, 1994, THESIS WAGENINGEN; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; HUSSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489; JDRVINEN R, 1993, INT J EPIDEMIOL, V22, P520; KINSELLA JE, 1993, FOOD TECHNOL-CHICAGO, V47, P85; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KNEKT P, 1988, SERIES ML, V83; RANKIN SM, 1993, BIOCHEM PHARMACOL, V45, P67, DOI 10.1016/0006-2952(93)90378-A; REUNANEN A, 1983, ACTA MED SCAND S, V673, P1; STARKE H, 1976, Z LEBENSM UNTERS FOR, V161, P131, DOI 10.1007/BF01112856; Wildanger W., 1973, Zeitschrift fuer Lebensmittel-Untersuchung und -Forschung, V151, P103, DOI 10.1007/BF01842919; YUTING C, 1990, Free Radical Biology and Medicine, V9, P19	24	986	1025	1	46	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					478	481		10.1136/bmj.312.7029.478	http://dx.doi.org/10.1136/bmj.312.7029.478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX383	8597679	Green Published			2022-12-01	WOS:A1996TX38300023
J	Godfrey, K; Robinson, S; Barker, DJP; Osmond, C; Cox, V				Godfrey, K; Robinson, S; Barker, DJP; Osmond, C; Cox, V			Maternal nutrition in early and late pregnancy in relation to placental and fetal growth	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; SIZE	Objective-To assess how nutrient intakes of mothers in early and late pregnancy influence placental and fetal growth. Design-Prospective observational study. Setting-Princess Anne Maternity Hospital, Southampton. Subjects-538 mothers who delivered at term. Main outcome measures-Placental and birth weights adjusted for the infant's sex and duration of gestation. Results-Mothers who had high carbohydrate intakes in early pregnancy had babies with lower placental and birth weights. Low maternal intakes of dairy and meat protein in late pregnancy were also associated with lower placental and birth weights. Placental weight fell by 49 g (95% confidence interval 16 g to 81 g; P=0.002) for each log g increase in intake of carbohydrate in early pregnancy and by 1.4 g (0.4 g to 2.4 g; P=0.005) for each g decrease in intake of dairy protein in late pregnancy. Birth weight fell by 165 g (49 g to 282 g; P=0.005) for each log g increase in carbohydrate intake in early pregnancy and by 3.1 g (0.3 g to 6.0 g; P=0.03) for each g decrease in meat protein intake in late pregnancy. These associations were independent of the mother's height and body mass index and of strong relations between the mother's birth weight and the placental and birth weights of her offspring. Conclusion-These findings suggest that a high carbohydrate intake in early pregnancy suppresses placental growth, especially if combined with a low dairy protein intake in late pregnancy. Such an effect could have long term consequences for the offspring's risk of cardiovascular disease.			Godfrey, K (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Godfrey, Keith/0000-0002-4643-0618; Osmond, Clive/0000-0002-9054-4655; Robinson, Sian/0000-0003-1766-7269				[Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1995, PLACENTA, V16, P317, DOI 10.1016/0143-4004(95)90118-3; Bingham S. A., 1987, Nutrition Abstracts and Reviews. Series A-Human and Experimental, V57, P705; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; BOTTING B, 1993, POPULATION TRENDS, V74, P27; CAMPBELL D, IN PRESS BR J OBSTET; CRAWLEY H, 1988, FOOD PORTION SIZES; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; HEAP FC, 1967, J REPROD FERTIL, V13, P269, DOI 10.1530/jrf.0.0130269; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; Holland B., 1991, MCCANCE WIDDOWSONS C, V5; Holland B, 1991, MCCANCE WIDDOWSONS S; Holland B., 1989, MCCANCE WIDDOWSONS S; Holland B., 1988, MCCANCE WIDDOWSONS S; HOWE D, 1995, BRIT MED J, V310, P1601, DOI 10.1136/bmj.310.6994.1601b; HOWE DT, 1995, BRIT J OBSTET GYNAEC, V102, P213, DOI 10.1111/j.1471-0528.1995.tb09096.x; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; MAHOMED K, 1989, EFFECTIVE CARE PREGN, V1, P301; MARGETTS BM, 1989, INT J EPIDEMIOL, V18, P868, DOI 10.1093/ije/18.4.868; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MCKEOWN T, 1953, J ENDOCRINOL, V10, P73, DOI 10.1677/joe.0.0100073; OUNSTED M, 1966, NATURE, V212, P687; OWENS JA, 1988, FETAL NEONATAL GROWT, P49; PRENTICE A, IN PRESS EUR J CLIN; Robinson JS, 1994, EARLY FETAL GROWTH D, P317; ROBINSON SM, IN PRESS EUR J CLIN; ROSSO P, 1990, NUTR METABOLISM PREG, P175; RUSH D, 1989, EFFECTIVE CARE PREGN, V1, P301; SLEN SB, 1969, NUTR ANIMALS AGR I 2, P827; THOMAS WJK, 1970, LOWLAND SHEEP PRODUC; WILLETT WC, 1994, AM J CLIN NUTR S, V59, P171	34	442	447	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					410	414						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601112	Green Published			2022-12-01	WOS:A1996TW56400021
J	Lithell, HO; McKeigue, PM; Berglund, L; Mohsen, R; Lithell, UB; Leon, DA				Lithell, HO; McKeigue, PM; Berglund, L; Mohsen, R; Lithell, UB; Leon, DA			Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50-60 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; FETAL GROWTH; RISK-FACTORS; FOLLOW-UP; HYPERTENSION; RESISTANCE; MELLITUS; UPPSALA; DISEASE	Objective-To establish whether the relation between size at birth and non-insulin dependent diabetes is mediated through impaired beta cell function or insulin resistance. Design-Cohort study. Setting-Uppsala, Sweden. Subjects-1333 men whose birth records were traced from a cohort of 2322 men born during 1920-4 and resident in Uppsala in 1970. Main outcome measures-Intravenous glucose tolerance test at age 50 years and non-insulin dependent diabetes at age 60 years. Results-There was a weak inverse correlation (r=-0.07, P=0.03) between ponderal index at birth and 60 minute insulin concentrations in the intravenous glucose tolerance test at age 50 years. This association was stronger (r=-0.19, P=0.001) in the highest third of the distribution of body mass index than in the other two thirds (P=0.01 for the interaction between ponderal index and body mass index). Prevalence of diabetes at age 60 years was 8% in men whose birth weight was less than 3250 g compared with 5% in men with birth weight 3250 g or more (P=0.08; 95% confidence interval for difference -0.3% to 6.8%). There was a stronger association between diabetes and ponderal index: prevalence of diabetes was 12% in the lowest fifth of ponderal index compared with 4% in the other four fifths (P=0.001; 3.0% to 12.6%). Conclusion-These results confirm that reduced fetal growth is associated with increased risk of diabetes and suggest a specific association with thinness at birth, This relation seems to be mediated through insulin resistance rather than through impaired beta cell function and to depend on an interaction with obesity in adult life.	UNIV LONDON LONDON SCH HYG & TROP MED, EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND; UNIV UPPSALA, DEPT GERIATR, S-75125 UPPSALA, SWEDEN	University of London; London School of Hygiene & Tropical Medicine; Uppsala University			Berglund, Lars/AAA-3188-2019; Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010	Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762				BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DRAPER NR, 1966, APPL REGRESSION ANAL, P149; Gluckman P.D., 1986, OXF REV REPROD BIOL, V8, P1; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS M, 1979, DIABETES, V28, P1039; LITHELL H, 1984, ACTA MED SCAND, V215, P403; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MILLER HC, 1973, PEDIATRICS, V52, P504; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P592; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SJOLIN S, 1975, HLTH CARE MOTHERS CH, P229; SKARFORS ET, 1991, J HYPERTENS, V9, P217, DOI 10.1097/00004872-199103000-00004; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383	22	561	577	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	1996	312	7028					406	410						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601111				2022-12-01	WOS:A1996TW56400020
J	Agrawal, RK; Penczek, P; Grassucci, RA; Li, YH; Leith, A; Nierhaus, KH; Frank, J				Agrawal, RK; Penczek, P; Grassucci, RA; Li, YH; Leith, A; Nierhaus, KH; Frank, J			Direct visualization of A-, P-, and E-site transfer RNAs in the Escherichia coli ribosome	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; ANTICODON INTERACTION SITE; CRYSTAL-STRUCTURE; A-SITES; LOCALIZATION; RESOLUTION; TOPOGRAPHY; BINDING; SUBUNIT	Transfer RNA (tRNA) molecules play a crucial role in protein biosynthesis in all organisms. Their interactions with ribosomes mediate the translation of genetic messages into polypeptides. Three tRNAs bound to the Escherichia coli 70S ribosome were visualized directly with cryoelectron microscopy and three-dimensional reconstruction, The detailed arrangement of A- and P-site tRNAs inferred from this study allows localization of the sites for anticodon interaction and peptide bond formation on the ribosome.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA; SUNY ALBANY, DEPT BIOMED SCI, ALBANY, NY 12222 USA; MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Max Planck Society			Leith', Ardean/AAI-5163-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR01219] Funding Source: Medline; NIGMS NIH HHS [1R01 GM29169] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER D, 1994, J BIOL CHEM, V269, P30713; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BURMA DP, 1986, STRUCTURE FUNCTION G, P438; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KILL R, 1984, BIOCHEMISTRY-US, V25, P3245; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LULJAS A, 1991, BIOCHIMIE, V73, P1093; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NOLLER HF, 1990, RIBOSOME, P73; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Silberklang M, 1979, Methods Enzymol, V59, P58; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; SUSSMAN JL, 1976, BIOCHEM BIOPH RES CO, V68, P89, DOI 10.1016/0006-291X(76)90014-0; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1994, BIOCHIMIE, V76, P1235, DOI 10.1016/0300-9084(94)90054-X; Zhu J. N, UNPUB; ZIMMERMANN RA, 1990, RIBOSOME, P331	35	189	194	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					1000	1002		10.1126/science.271.5251.1000	http://dx.doi.org/10.1126/science.271.5251.1000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584922				2022-12-01	WOS:A1996TV70400053
J	Laudanna, C; Campbell, JJ; Butcher, EC				Laudanna, C; Campbell, JJ; Butcher, EC			Role of Rho in chemoattractant-activated leukocyte adhesion through integrins	SCIENCE			English	Article							GTP-BINDING-PROTEIN; HUMAN-NEUTROPHILS; ADP-RIBOSYLATION; CALPHOSTIN-C; GENE-PRODUCT; KINASE-C; BOTULINUM; STIMULATION; INHIBITION; VENULES	Heterotrimeric guanine nucleotide binding protein (G protein)-linked receptors of the chemoattractant subfamily can trigger adhesion through leukocyte integrins, and in this role they are thought to regulate immune cell-cell interactions and trafficking. In lymphoid cells transfected with formyl peptide or interleukin-8 receptors, agonist stimulation activated nucleotide exchange on the small guanosine triphosphate-binding protein RhoA in seconds. Inactivation of Rho by C3 transferase exoenzyme blocked agonist-induced lymphocyte alpha 4 beta 1 adhesion to vascular cell adhesion molecule-1 and neutrophil beta 2 integrin adhesion to fibrinogen. These findings suggest that Rho participates in signaling from chemoattractant receptors to trigger rapid adhesion in leukocytes.	STANFORD UNIV,CTR DIGEST DIS,STANFORD,CA 94305; VET AFFAIRS HLTH CARE SYST,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Laudanna, C (corresponding author), STANFORD UNIV,DEPT PATHOL,LAB IMMUNOL & VASC BIOL,STANFORD,CA 94305, USA.			Campbell, James/0000-0003-4252-5182	NCI NIH HHS [5T32 CA09302] Funding Source: Medline; NIAID NIH HHS [1F32 AI08930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CAMPBELL JC, UNPUB; CLARKE MSF, 1992, J CELL SCI, V102, P533; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HONDA S, 1994, J IMMUNOL, V152, P4026; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAUDANNA C, UNPUB; LEY K, 1993, J IMMUNOL, V151, P6347; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034	23	420	431	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					981	983		10.1126/science.271.5251.981	http://dx.doi.org/10.1126/science.271.5251.981			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584934				2022-12-01	WOS:A1996TV70400047
J	Abbott, A				Abbott, A			DNA chips intensify the sequence search	NATURE			English	Editorial Material																		1995, NATURE, V373, P372	1	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					392	392						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559237				2022-12-01	WOS:A1996TT30400017
J	Monini, P; deLellis, L; Fabris, M; Rigolin, F; Cassai, E				Monini, P; deLellis, L; Fabris, M; Rigolin, F; Cassai, E			Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS; CYTOKINES; GROWTH; CELLS	Background. Sequences of a novel herpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), have been identified in Kaposi's sarcoma tissue, but it is not known whether the virus is transmitted by sexual contact. Methods. Using the polymerase chain reaction (PCR), we searched for KSHV DNA sequences in ejaculates from 43 healthy men and tissue from the urogenital tract or prostate of 100 immunocompetent adults. Results. In an unblinded analysis, we identified KSHV DNA sequences in 2 of 20 tissue specimens from the urinary tract (10 percent; 15 men and 5 women), 3 of 46 specimens from the female genital tract (6.5 percent), 4 of 18 specimens from the glans or foreskin (22 percent), 7 of 16 specimens from the prostate (44 percent), and 30 of 33 ejaculates (91 percent), By contrast, such sequences were present in 1 of 18 samples of normal skin (5.5 percent) and 1 of 14 samples of peripheral-blood mononuclear cells (PBMCs; 7.1 percent), Ejaculates and PBMC samples from each of 10 study subjects were analyzed in a blinded, coded fashion, along with PBMCs and biopsy specimens of normal skin from 4 and 8 other patients, respectively. This analysis confirmed the presence of KSHV DNA sequences in semen, Viral DNA was not found in the sperm heads but was present in the fraction of the ejaculates that contained urothelial and other types of cells. Point mutations were found in PCR products amplified from both prostate tissue and sperm samples. Conclusions. KSHV infects a large proportion of healthy adults and is probably transmitted by sexual contact. (C) 1996, Massachusetts Medical Society.	ST ANNA HOSP,LAB ANAL,FERRARA,ITALY	University of Ferrara; Arcispedale Sant'Anna	Monini, P (corresponding author), UNIV FERRARA,INST MICROBIOL,VIA L BORSARI 46,I-44100 FERRARA,ITALY.		Monini, Paolo/K-1429-2016	Monini, Paolo/0000-0002-4941-6854				BARILLARI G, 1992, J IMMUNOL, V149, P3727; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BROOKS JJ, 1986, LANCET, V2, P1309; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COUTURIER E, 1990, LANCET, V335, P1105, DOI 10.1016/0140-6736(90)92685-B; DELELLIS L, 1995, J INFECT DIS, V172, P1605, DOI 10.1093/infdis/172.6.1605; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KYO S, 1994, J INFECT DIS, V170, P682, DOI 10.1093/infdis/170.3.682; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; REAL FX, 1985, NEW ENGL J MED, V313, P1659; ROIZMAN B, 1995, NEW ENGL J MED, V332, P1227, DOI 10.1056/NEJM199505043321810; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; VONBEROLDINGEN CH, 1989, PCR TECHNOLOGY PRINC, P209	18	217	225	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1168	1172		10.1056/NEJM199605023341805	http://dx.doi.org/10.1056/NEJM199605023341805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602183	Bronze			2022-12-01	WOS:A1996UG83100005
J	Lygerou, Z; Allmang, C; Tollervey, D; Seraphin, B				Lygerou, Z; Allmang, C; Tollervey, D; Seraphin, B			Accurate processing of a eukaryotic precursor ribosomal RNA by ribonuclease MRP in vitro	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; U1 SNRNA; SUBSTRATE; INVITRO; CONTAINS; MUTANT; GENE	Very few of the enzymes required for eukaryotic precursor ribosomal RNA (pre-rRNA) processing have been identified, Ribonuclease (RNase) MRP was characterized as a nuclease that cleaves mitochondrial replication primers, but it is predominantly nucleolar, Previous genetic evidence revealed that this ribonucleoprotein is required, directly or indirectly, for cleavage of the yeast pre-rRNA in vivo at site A(3). Here, an in vitro processing system that accurately reproduces this cleavage is described. Biochemical purification and the use of extracts depleted of the MRP RNA demonstrate that endonucleolytic cleavage of the pre-rRNA is directly mediated by RNase MRP, This establishes a role for RNase MRP in the nucleolus.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; Allmang, Christine/0000-0001-8883-0874; Seraphin, Bertrand/0000-0002-5168-1921				ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDAHL L, 1992, NUCLEIC ACIDS RES, V20, P295, DOI 10.1093/nar/20.2.295; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; LYGEROU Z, UNPUB; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; POTUSCHAK T, 1993, NUCLEIC ACIDS RES, V21, P3239, DOI 10.1093/nar/21.14.3239; Sambrook J., 1989, MOL CLONING; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHUAI K, 1991, NUCLEIC ACIDS RES, V19, P5059, DOI 10.1093/nar/19.18.5059; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; TRANGUCH AJ, 1994, BIOCHEMISTRY-US, V33, P1778, DOI 10.1021/bi00173a022; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; YIP MT, 1989, J BIOL CHEM, V264, P4045	29	211	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					268	270		10.1126/science.272.5259.268	http://dx.doi.org/10.1126/science.272.5259.268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602511				2022-12-01	WOS:A1996UE72900041
J	Wan, Y; Kurosaki, T; Huang, XY				Wan, Y; Kurosaki, T; Huang, XY			Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors	NATURE			English	Article							GENE-PRODUCT; PHOSPHORYLATES; FIBROBLASTS; CLONING; RAS	THE mitogen-activated protein kinase (MAPK) signalling cascade is a prominent cellular pathway used by many growth factors, hormones and neurotransmitters to regulate physiological responses(1,2). Although activation of the MAPK pathway by receptors with tyrosine kinase activity is well defined(3), the mechanism used by heterotrimeric G-protein-coupled receptors to activate this pathway is less clear. Here we show that in cells deficient in the Src-related tyrosine kinase Lyn, stimulation of MAPK kinase and MAPK by G(q)-coupled mi muscarinic acetylcholine receptors (mAChR) is blocked, whereas G(i)-coupled m2 mAChR-mediated stimulation is unaffected. In cells deficient in the tyrosine kinase SyK, both m(1) and m2 mAChRs failed to stimulate MAPK kinase and MAPK. This result indicates that Syk is essential for the G(i)-coupled pathway and that Lyn and Syk are necessary for the G(q)-coupled pathway.	CORNELL UNIV,COLL MED,DEPT PHYSIOL,NEW YORK,NY 10021; WYETH AYERST RES,DEPT ONCOL & IMMUNOL,PEARL RIVER,NY 10965	Cornell University; Pfizer								ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TAKATA M, 1995, FEBS LETT, V374, P407, DOI 10.1016/0014-5793(95)01160-G; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	27	264	268	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					541	544		10.1038/380541a0	http://dx.doi.org/10.1038/380541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606776				2022-12-01	WOS:A1996UE66300054
J	Davis, AW; Roote, J; Morley, T; Sawamura, K; Herrmann, S; Ashburner, M				Davis, AW; Roote, J; Morley, T; Sawamura, K; Herrmann, S; Ashburner, M			Rescue of hybrid sterility in crosses between D-melanogaster and D-simulans	NATURE			English	Article							TRANSPOSABLE ELEMENT MARINER; DROSOPHILA-MELANOGASTER; SPECIES COMPLEX; LETHAL SYSTEMS; GENETIC-BASIS; SUBGROUP	The genetic analysis of reproductive isolation between species of Drosophila has now reached the resolution necessary(1,2) to start answering one of the fundamental questions of evolution: what is the genetic basis of species differences? (ref. 3). A. H. Sturtevant, one of the founders of Drosophila genetics, was fascinated by this question(4) and thought he had found a way to analyse it when he realized that 'Drosophila melanogaster' was actually two species: D. melanogaster and D. simulans(5). By passing genes between these two species he hoped to investigate their genetic differences directly. No doubt he was disappointed to find that the D. melanogaster/D. simulans hybridization resulted only in unisexual sterile hybrids(6), a disappointment appreciated all the more by modern evolutionary biologists. Seventy-five years after Sturtevant's description of D. melanogaster/D. simulans hybrid sterility, we have discovered a strain of D. simulans that produces fertile female hybrids in crosses with D. melanogaster. Our discovery promises to bring the enormous resolution of D. melanogaster genetics to the study of reproductive isolation and species differences.			Davis, AW (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.							ASHBURNER M, 1989, DROSOPHILA LABORATOR; CACCONE A, 1988, GENETICS, V118, P671; COYNE JA, 1983, EVOLUTION, V37, P1101, DOI 10.1111/j.1558-5646.1983.tb00225.x; COYNE JA, 1994, SCIENCE, V265, P1461, DOI 10.1126/science.8073292; Dobzhansky T, 1937, GENETICS ORIGIN SPEC; GARZA D, 1991, GENETICS, V128, P303; HEY J, 1993, MOL BIOL EVOL, V10, P804; HUTTER P, 1990, GENETICS, V124, P909; HUTTER P, 1987, NATURE, V327, P331, DOI 10.1038/327331a0; JEFFS PS, 1994, MOL BIOL EVOL, V11, P287; LEMEUNIER F, 1976, PROC R SOC SER B-BIO, V193, P275, DOI 10.1098/rspb.1976.0046; LEMEUNIER F, 1984, GENET BIOL DROSOPHIL, P147; MARUYAMA K, 1991, GENETICS, V128, P319; MULLER HJ, 1940, NATURE, V146, P1969; PEREZ DE, 1995, GENETICS, V140, P201; PONTECORVO G, 1943, P R SOC EDINB B, V61, P385; PROVINE WB, 1991, GENETICS, V129, P1; Sambrook J., 1989, MOL CLONING LAB MANU; SAWAMURA K, 1993, GENETICA, V88, P175, DOI 10.1007/BF02424474; SAWAMURA K, 1993, GENETICS, V133, P307; SAWAMURA K, 1993, GENETICS, V133, P299; Sturtevant A. H., 1919, Psyche Boston, V26, DOI 10.1155/1919/97402; Sturtevant AH, 1920, GENETICS, V5, P488; WATANABE TK, 1979, JPN J GENET, V54, P325, DOI 10.1266/jjg.54.325; WU CI, 1994, ANNU REV GENET, V28, P283, DOI 10.1146/annurev.ge.28.120194.001435	25	78	79	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					157	159		10.1038/380157a0	http://dx.doi.org/10.1038/380157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600389				2022-12-01	WOS:A1996TZ97800050
J	Zeng, HK; Qian, ZW; Myers, MP; Rosbash, M				Zeng, HK; Qian, ZW; Myers, MP; Rosbash, M			A light-entrainment mechanism for the Drosophila circadian clock	NATURE			English	Article							MESSENGER-RNA LEVELS; PERIOD; GENE; MELANOGASTER; MUTANTS; PRODUCT; PROTEIN	Biochemical studies indicate that the Drosophila timeless protein (Tim) is a stoichiometric partner of the period protein (Per) in fly head extracts. A Per-Tim heterodimeric complex explains the reciprocal autoregulation of the proteins on transcription. The complex is under clock control, and many circadian features of the Tim cycle resemble those of the Per cycle. However, Tim is rapidly degraded in the early morning or in response to light, releasing Per from the complex. The Per-Tim complex is a functional unit of the Drosophila circadian clock, and Tim degradation may be the initial response of the clock to light.	BRANDEIS UNIV,HOWARD HUGHES MED INST,NATL SCI FDN SCI,WALTHAM,MA 02254; BRANDEIS UNIV,TECHNOL CTR BIOL TIMING,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NATL SCI FDN SCI,NEW YORK,NY 10021; ROCKEFELLER UNIV,TECHNOL CTR BIOL TIMING,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Brandeis University; Howard Hughes Medical Institute; Brandeis University; Brandeis University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University								CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LOROS J, 1995, NEUROSCIENCES, V7, P3; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; ROSBASH M, 1995, CURR OPIN GENET DEV, V5, P662, DOI 10.1016/0959-437X(95)80037-9; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	34	390	396	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					129	135		10.1038/380129a0	http://dx.doi.org/10.1038/380129a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600384				2022-12-01	WOS:A1996TZ97800041
J	Hvass, U; Juliard, JM; Assayag, P; Laperche, T; Pansard, Y; Chatel, D				Hvass, U; Juliard, JM; Assayag, P; Laperche, T; Pansard, Y; Chatel, D			Tricuspid autograft for mitral-valve repair	LANCET			English	Article							REPLACEMENT	Background Transferring the posterior leaflet of the patient's own tricuspid Valve with its subvalvular apparatus to the mitral valve is a new technique that allows a conservative approach to mitral-valve repair. The technique is based on the knowledge that the tricuspid valve can be remodelled from tricuspid to bicuspid, with a very low risk of significant dysfunction. Methods We describe six patients (age range 20-70 years) with mitral insufficiency in whom we have used the technique. Findings All patients survived the operation and were in sinus rhythm. Transoesophageal echocardiography before discharge showed trivial or no regurgitation at the site of mitral repair. Before operation, all patients were in New York Heart Association class Ill-IV; at follow-up after 6-13 months all patients were in class I-II Interpretation Compared with using segments of mitral homografts in similar situations, the intraoperative availability of the tricuspid's viable natural chordae and valvular leaflet means that there are no immunological disadvantages to the procedure. With this new operation, the patient is his own tissue bank.	HOP BEAUJON, DEPT CARDIOL, CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Hvass, U (corresponding author), HOP BICHAT, DEPT CARDIOL, F-75018 PARIS, FRANCE.		Assayag, Patrick/GPS-4910-2022	Assayag, Patrick/0000-0001-9406-4555				ACAR C, 1994, ANN THORAC SURG, V57, P746, DOI 10.1016/0003-4975(94)90582-7; CARPENTIER A, 1983, J THORAC CARDIOV SUR, V86, P323; CHAUVAUD S, 1991, J THORAC CARDIOV SUR, V102, P171; DAVID TE, 1991, J THORAC CARDIOV SUR, V101, P495; ELKINS RC, 1995, ANN THORAC SURG, V59, P269, DOI 10.1016/0003-4975(94)00974-C; Horskotte D, 1993, J Heart Valve Dis, V2, P150; HVASS U, 1986, ARCH MAL COEUR VAISS, V79, P103; KIRKLIN JW, 1993, CARDIAC SURG, P589; MATSUKI O, 1988, J THORAC CARDIOV SUR, V95, P705; OKADA Y, 1995, ANN THORAC SURG, V59, P658, DOI 10.1016/0003-4975(94)01008-0; 1967, LANCET, V2, P956	11	9	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1996	347	9002					659	661		10.1016/S0140-6736(96)91206-4	http://dx.doi.org/10.1016/S0140-6736(96)91206-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596382				2022-12-01	WOS:A1996TZ28500014
J	McMillan, TJ				McMillan, TJ			Gene manipulation in radiotherapy	LANCET			English	Editorial Material											McMillan, TJ (corresponding author), UNIV LANCASTER,INST ENVIRONM & BIOL SCI,DIV BIOL SCI,LANCASTER LA1 4YQ,ENGLAND.							HALLAHAN DE, 1994, NATURE MED, V1, P85; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SURESH A, 1994, CANCER GENE THER, V1, P85; VILE RG, 1993, CANCER RES, V53, P962; WEISCHELBAUM RR, 1991, EUR J CANCER, V27, P405	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					632	632		10.1016/S0140-6736(96)91196-4	http://dx.doi.org/10.1016/S0140-6736(96)91196-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596372				2022-12-01	WOS:A1996TZ28500004
J	Banner, DW; DArcy, A; Chene, C; Winkler, FK; Guha, A; Konigsberg, WH; Nemerson, Y; Kirchhofer, D				Banner, DW; DArcy, A; Chene, C; Winkler, FK; Guha, A; Konigsberg, WH; Nemerson, Y; Kirchhofer, D			The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor	NATURE			English	Article							EGF-LIKE DOMAIN; HUMAN FACTOR-IX; ACTIVE-SITE; FACTOR-X; CALCIUM-BINDING; CA2+ ION; RESOLUTION; SURFACE; LOCALIZATION; FLUORESCENCE	Blood coagulation is initiated when tissue factor binds to coagulation factor VIIa to give an enzymatically active complex which then activates factors IX and X, leading too thrombin generation and clot formation. We have determined the crystal structure at 2.0-Angstrom resolution of active-site-inhibited factor VIIa complexed with the cleaved extracellular domain of tissue factor. In the complex, factor VIIa adopts an extended conformation. This structure provides a basis for understanding many molecular aspects of the initiation of coagulation.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yale University	Banner, DW (corresponding author), F HOFFMANN LA ROCHE & CO LTD, DIV PHARMA, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND.							BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KIRCHHOFER D, 1995, PROTEINS, V22, P419, DOI 10.1002/prot.340220412; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEMERSON Y, 1988, BLOOD, V71, P1; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TUDDENHAM EGD, 1995, THROMB HAEMOSTASIS, V74, P313; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	51	664	697	3	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					41	46		10.1038/380041a0	http://dx.doi.org/10.1038/380041a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598903				2022-12-01	WOS:A1996TY87700048
J	Wang, YK; Schnegelsberg, PNJ; Dausman, J; Jaenisch, R				Wang, YK; Schnegelsberg, PNJ; Dausman, J; Jaenisch, R			Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin	NATURE			English	Article							REGULATORY GENE; EXPRESSION; MYOD; INACTIVATION; LETHALITY	The myogenic basic helix-loop-helix transcription factors, Myf5, MyoD, myogenin and MRF4, play key roles in skeletal muscle development(1,2). All of them induce myogenic differentiation in cultured non-muscle cells, suggesting that they might be functionally redundant. But the genes are expressed at different times during embryogenesis(3-6) and mice carrying a mutation in any of the genes have different phenotypes(7-13). A rib cage defect was observed in Myf5-deficient mice, which die perinatally(7). We investigated whether the rib cage defect was due to the failure of the early activation of the gene or to the unique interactions of Myf5 with specific downstream targets. For this we inserted a myogenin complementary DNA into the Myf5 locus by homologous recombination ,which simultaneously disrupted Myf5 function. We report here that mice homozygous for this myogenin gene knock-in (ki) developed a normal rib cage and were viable, therefore demonstrating functional redundancy of Myf5 and myogenin for rib formation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	Wang, YK (corresponding author), MIT, WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.							BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	21	126	134	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 29	1996	379	6568					823	825		10.1038/379823a0	http://dx.doi.org/10.1038/379823a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587605				2022-12-01	WOS:A1996TX50100058
J	Hennekens, CH; Lee, IM; Cook, NR; Hebert, PR; Karlson, EW; LaMotte, F; Manson, JE; Buring, JE				Hennekens, CH; Lee, IM; Cook, NR; Hebert, PR; Karlson, EW; LaMotte, F; Manson, JE; Buring, JE			Self-reported breast implants and connective-tissue diseases in female health professionals - A retrospective cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN	Objective. - To evaluate the association of breast implants with connective-tissue diseases. Design and Participants. - Retrospective cohort study of 395 543 female health professionals who completed mailed questionnaires for potential participation in the Women's Health Study. A total of 10 830 women reported breast implants and 11 805 reported connective-tissue diseases between 1962 and 1991. Cox proportional hazards regression models were used in analyses. Main Outcome Measure. - Self-reported connective-tissue diseases. Results. - Compared with women who did not report breast implants, the relative risk (RR) of the combined end point of any connective-tissue disease among those who reported breast implants was 1.24 (95% confidence interval, 1.08 to 1.41, P=.0015). With respect to the individual diseases, the finding for other connective-tissue diseases (including mixed) was statistically significant (P=.017), the findings for rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of borderline statistical significance (.05<P<.10), and the finding for systemic lupus erythematosus was not statistically significant (P=.44). There were no clear trends in RR with increasing duration of breast implants. Conclusion. - These self-reported data from female health professionals are compatible with prior reports from other cohort studies that exclude a large hazard, but do suggest small increased risks of connective-tissue diseases among women with breast implants. The very large sample size makes chance an unlikely explanation for the results, but bias due to differential overreporting of connective-tissue diseases or selective participation by affected women with breast implants remains a plausible alternative explanation. The major contribution of this and other observational analytic studies has been to exclude large risks of connective-tissue diseases following breast implants.	HARVARD UNIV,SCH MED,DIV PREVENT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV RHEUMATOL IMMUNOL,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Hennekens, CH (corresponding author), BRIGHAM & WOMENS HOSP,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.		Lee, I-Min/ABD-5409-2021		NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELL M, 1992, NEW ENGL J MED, V326, P1695, DOI 10.1056/NEJM199206183262510; BARTON TJ, 1983, ORGANOMETALLICS, V2, P1, DOI 10.1021/om00073a001; BORENSTEIN D, 1994, SEMIN ARTHRITIS RHEU, V24, P1, DOI 10.1016/0049-0172(94)90102-3; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BUSCH H, 1994, SEMIN ARTHRITIS RHEU, V24, P11, DOI 10.1016/0049-0172(94)90104-X; CHOW HY, 1995, ARTHRITIS RHEUM, V38, P264; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; COOK RR, 1994, ARTHRITIS RHEUM, V37, P153, DOI 10.1002/art.1780370202; COX DR, 1972, J R STAT SOC B, V34, P187; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; DUGOWSON CE, 1992, ARTHRITIS RHEUM S192, V35, pS566; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; FISHER JC, 1992, NEW ENGL J MED, V326, P1696, DOI 10.1056/NEJM199206183262511; FOREMAN J, 1992, BOSTON GLOBE    0125, P1; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; Hennekens CH, 1987, EPIDEMIOLOGY MED, P101; Hochberg M. C., 1994, Arthritis and Rheumatism, V37, pS369; Hochberg MC, 1995, LUPUS, V4, P454, DOI 10.1177/096120339500400606; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; Kolata Gina, 1995, N Y Times Web, P6; KOSSOVSKY N, 1994, SEMIN ARTHRITIS RHEU, V24, P18, DOI 10.1016/0049-0172(94)90105-8; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; LITTLE R, 1987, STATISTICAL ANAL MIS; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; STAR VL, 1993, ARTHRITIS RHEUM, V36, P510; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SWAN SH, 1995, LANCET, V345, P319, DOI 10.1016/S0140-6736(95)90307-0; VASSEY FB, 1994, SEMIN ARTHRITIS RHEU, V24, P22; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002	39	205	210	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					616	621		10.1001/jama.275.8.616	http://dx.doi.org/10.1001/jama.275.8.616			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594243				2022-12-01	WOS:A1996TW62700022
J	Ammala, C; Moorhouse, A; Gribble, F; Ashfield, R; Proks, P; Smith, PA; Sakura, H; Coles, B; Ashcroft, SJH; Ashcroft, FM				Ammala, C; Moorhouse, A; Gribble, F; Ashfield, R; Proks, P; Smith, PA; Sakura, H; Coles, B; Ashcroft, SJH; Ashcroft, FM			Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels	NATURE			English	Article							K+ CHANNEL; ATP	SULPHONYLUREAS are a class of drugs widely used to treat non-insulin-dependent diabetes mellitus. These drugs act by binding to a sulphonylurea receptor (SUR) in the pancreatic beta-cell membrane which inhibits an ATP-sensitive potassium (K-ATP) channel and thereby stimulates insulin secretion. There has been much debate as to whether SUR and the K-ATP channel are the same or separate proteins, whether SUR confers ATP-sensitivity on an ATP-insensitive pore-forming subunit, and whether sulphonylureas can also modulate other types of K-channel. We show here that SUR itself does not possess intrinsic channel activity but that it endows sulphonylurea sensitivity on several types of inwardly-rectifying K-channels. It does not necessarily confer ATP-sensitivity on these channels.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Moorhouse, Andrew J/B-8526-2011	Moorhouse, Andrew J/0000-0001-7957-2498; Smith, Paul/0000-0002-8710-6830; Gribble, Fiona/0000-0002-4232-2898; Proks, Peter/0000-0001-6097-3646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; THOMAS PM, 1995, SCIENCE, V268, P425; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; ZUNCKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	14	152	158	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					545	548		10.1038/379545a0	http://dx.doi.org/10.1038/379545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596634				2022-12-01	WOS:A1996TU69300052
J	Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Jencks, SF				Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Jencks, SF			Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes	ANNALS OF INTERNAL MEDICINE			English	Article						aspirin; myocardial infarction; age factors; patient care characteristics; patient care planning	AGE; TRIALS	Objectives: To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival. Design: Observational study. Setting: All 352 nongovernment, acute care hospitals in Alabama, Connecticut, Iowa, and Wisconsin. Patients: 5490 consecutive Medicare beneficiaries who survived an acute myocardial infarction, were hospitalized between June 1992 and February 1993, and did not have a contraindication to aspirin. Measurements: Medical charts were reviewed to obtain information on the prescription of aspirin at discharge, contraindications, patient demographic characteristics, and clinical factors. Results: 4149 patients (76%) were prescribed aspirin at hospital discharge. In a multivariable analysis, an increased prescribed use of aspirin at discharge was correlated with several indicators of better overall health status (better left ventricular ejection fraction, absence of diabetes, shorter length of hospital stay, higher albumin level, and discharge to the patient's home). The prescribed use of aspirin at discharge was also associated with several specific patterns of care, including the use of cardiac procedures, p-blocker therapy at discharge, and aspirin during the hospitalization. The prescribed use of aspirin at discharge was associated with a lower mortality rate 6 months after discharge compared with no prescribed aspirin (odds ratio, 0.77; 95% CI, 0.61 to 0.98), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the two groups. Conclusions: Aspirin was not prescribed at discharge to 24% of elderly patients who were hospitalized with an acute myocardial infarction and did not have a contraindication to aspirin. Several patient characteristics were associated with a higher risk for not being prescribed aspirin. Increasing the prescription of aspirin for these patients may provide an excellent opportunity to improve their care.	UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06030 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT 06457 USA; US HLTH CARE FINANCING ADM, BALTIMORE, MD 21207 USA; UNIV CONNECTICUT, SCH MED, FARMINGTON, CT 06030 USA	University of Connecticut; University of Connecticut	Krumholz, HM (corresponding author), YALE UNIV, SCH MED, CARDIOVASC SECT, 333 CEDAR ST, POB 208107, NEW HAVEN, CT 06520 USA.		, Harlan/AAI-2875-2020; Ellerbeck, Edward/I-8438-2014	Ellerbeck, Edward/0000-0002-7774-2729; Radford, Martha/0000-0001-7503-9557				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AUDET AM, 1993, ANN INTERN MED, V119, P1209, DOI 10.7326/0003-4819-119-12-199312150-00008; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D, 2013, APPL LOGISTIC REGRES; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; MOORE JG, 1991, GASTROENTEROLOGY, V100, P1626, DOI 10.1016/0016-5085(91)90661-4; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SILAGY CA, 1993, CLIN PHARMACOL THER, V54, P84, DOI 10.1038/clpt.1993.115	16	169	176	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					292	+		10.7326/0003-4819-124-3-199602010-00002	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554223				2022-12-01	WOS:A1996TR59600002
J	Livingston, G; Manela, M; Katona, C				Livingston, G; Manela, M; Katona, C			Depression and other psychiatric morbidity in carers of elderly people living at home	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE RATES; COMMUNITY; DEMENTIA; RELATIVES	Objective-To describe the mental health of a community sample of carers of elderly people with dementia, depression, or physical disability and to compare that with the mental health of other adults living in the household and of those living alone. Design-Assessment of psychiatric morbidity and physical disability with standardised questionnaire in randomly selected enumeration districts; subjects were interviewed at home. Setting-London Borough of Islington. Subjects-700 people aged greater than or equal to 65 and other co-residents. Main outcome measure-Depression measured with standardised interview. Results-The prevalence of depression was not significantly higher in carers overall (15%) than in coresidents (11%). Being a woman carer was a significant predictor of psychiatric illness. Depression was more common in the carers of people with a psychiatric disorder than in coresidents (24% v 11%, P < 0.05) and in those living alone (19%). Depression was most common (47%) in women carers of people with dementia. Conclusion-The increase in psychiatric morbidity reported in carers of people with psychiatric disorders may reflect the lack of a confiding relationship.			Livingston, G (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, MORTIMER ST, LONDON W1N 8AA, ENGLAND.		Livingston, G/C-7081-2008	Katona, Cornelius/0000-0001-7451-0167; Livingston, Gill/0000-0001-6741-5516				[Anonymous], 1993, ICD 10 CLASSIFICATIO; BERGMANN K, 1983, ELDERLY PEOPLE COMMU; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COLLINS C, 1992, RECENT ADV PSYCHOGER, P153; COPELAND JRM, 1987, BRIT J PSYCHIAT, V150, P815, DOI 10.1192/bjp.150.6.815; EAGLES JM, 1987, BRIT J PSYCHIAT, V150, P293, DOI 10.1192/bjp.150.3.293; Foulds G. A, 1976, HIERARCHICAL NATURE; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GURLAND B, 1984, J GERONTOL, V39, P166, DOI 10.1093/geronj/39.2.166; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KAY DWK, 1985, PSYCHOL MED, V15, P771, DOI 10.1017/S0033291700005006; LEVIN E, 1989, FAMILIES SERVICES CO; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LINDESAY J, 1989, BRIT J PSYCHIAT, V155, P317, DOI 10.1192/bjp.155.3.317; LIVINGSTON G, 1990, PSYCHOL MED, V20, P137, DOI 10.1017/S0033291700013313; MANELA M, IN PRESS INT J GERIA; Murray J., 1995, PREVENTION ANXIETY D; NORUSIS MJ, SPSSPC4; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; PARKER G, DHSS715 U YORK SOC P; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; WING JK, 1976, PSYCHOL MED, V6, P665; 1987, GENERAL HOUSEHOLD SU	24	111	111	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					153	156						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563534				2022-12-01	WOS:A1996TR32500022
J	Jernigan, DB; Cetron, MS; Breiman, RF				Jernigan, DB; Cetron, MS; Breiman, RF			Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP) - A strategy from the DRSP Working Group	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; PENICILLIN-RESISTANT; MICRODILUTION SYSTEM; MENINGITIS; FAILURE; SUSCEPTIBILITY; PNEUMOCOCCI; MEDIA	Emergence of drug-resistant Streptococcus pneumoniae (DRSP) presents a challenge to the medical and public health communities since the magnitude of the problem is not known, the clinical impact of DRSP infections is not well described, national vaccination rates are low, and antimicrobial drugs are often used excessively and inappropriately. To address the problem of DRSP, a working group sponsored by Centers for Disease Control and Prevention was formed in June 1994 consisting of public health practitioners, health care providers, and clinical laboratorians representing state and federal agencies and various professional organizations. Through periodic open meetings, the working group has developed a strategy for surveillance, investigation, prevention, and control of infections due to DRSP, The strategy focuses on (1) implementing an electronic laboratory-based surveillance (ELBS) system for reporting invasive DRSP infections and providing clinically relevant feedback to clinicians, (2) identifying risk factors and outcomes of DRSP infection, (3) increasing pneumococcal vaccination, and (4) promoting judicious antimicrobial drug use. Data received through ELBS will be used to make timely estimates of the community-specific prevalence of drug-resistant pneumococci. National, regional, and local trends will be made available to health care providers and clinicians to promote optimal antimicrobial drug use and increased vaccination in targeted areas. Once in operation, the ELBS network will be adaptable to other diseases, improving the comprehensiveness and timeliness of public health surveillance. The intended outcome of the strategy is to reduce complications of DRSP infection, such as long-ten sequelae of infection, health care expenditures, morbidity, and mortality.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; CARROLL K, 1991, J CLIN MICROBIOL, V29, P2651, DOI 10.1128/JCM.29.11.2651-2652.1991; CHANDY CJ, 1994, CLIN INFECT DIS, V18, P188; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; FEDSON DS, 1994, VACCINES, P543; GARRETT L, 1994, COMING PLAGUE, P411; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JERNIGAN DB, 1995, 35TH INT C ANT AG CH; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P2448, DOI 10.1128/JCM.32.10.2448-2459.1994; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; RADETSKY MS, 1981, LANCET, V2, P771; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SHANHOLTZER CJ, 1986, AM J CLIN PATHOL, V85, P626, DOI 10.1093/ajcp/85.5.626; Shlaes D, 1991, ASM NEWS, V57, P455; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; Tilghman RC, 1937, ARCH INTERN MED, V59, P602, DOI 10.1001/archinte.1937.00170200044004; 1995, MMWR-MORBID MORTAL W, V44, P513; 1995, MMWR-MORBID MORTAL W, V44, P506; 1994, MMWR-MORBID MORTAL W, V43, P216; 1995, MMWR-MORBID MORTAL W, V44, P737; 1994, PERFORMANCE STAND S5; 1992, EMERGING INFECTIONS, P92; 1994, PERFORMANCE STANDARD, P14; 1990, DHHS PHS9150213 PUBL; 1994, TIME            0912, V144, P62; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, MMWR-MORBID MORTAL W, V43, P223	36	156	158	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					206	209		10.1001/jama.275.3.206	http://dx.doi.org/10.1001/jama.275.3.206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604173				2022-12-01	WOS:A1996TP28200028
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC WORKSHOP ON PRESCRIPTION DRUG INFORMATION FOR PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0824, V60, P44182; 1995, JAMA-J AM MED ASSOC, V274, P1109	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-01	WOS:A1995TL16900010
J	Fiscella, K; Franks, P				Fiscella, K; Franks, P			Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-PRACTITIONERS ADVICE; CHEWING-GUM; CONTROLLED TRIAL; CIGARETTE-SMOKING; SMOKERS; EXPENDITURES; WITHDRAWAL; IMPACT	Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.-Costs (1995 dollars) per QALYs saved discounted by 3% annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.			Fiscella, K (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT FAMILY MED,HIGHLAND HOSP,PRIMARY CARE INST,ROCHESTER,NY 14642, USA.							ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205; ABELIN T, 1989, LANCET, V1, P7; ADAMS PF, 1992, VIT HLTH STAT, V184; BENITOCEPEDA A, 1993, J CONSULT CLIN PSYCH, V61, P822; BLONDAL T, 1989, ARCH INTERN MED, V149, P1818, DOI 10.1001/archinte.149.8.1818; BUCHKREMER G, 1989, ADDICT BEHAV, V14, P229, DOI 10.1016/0306-4603(89)90054-3; *CDC, 1989, CDC PUBL; Cummings K M, 1994, Arch Fam Med, V3, P682, DOI 10.1001/archfami.3.8.682; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161; FEE WM, 1982, PRACTITIONER, V226, P148; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; Gold MR., 1996, COST EFFECTIVENESS H; GOLD MR, 1994, MED DECIS MAKING, V14, P431; GOURLAY SG, 1994, BRIT MED J, V309, P842, DOI 10.1136/bmj.309.6958.842; HJALMARSON AIM, 1984, JAMA-J AM MED ASSOC, V252, P2835, DOI 10.1001/jama.252.20.2835; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; HUGHES JR, 1991, PREV MED, V20, P486, DOI 10.1016/0091-7435(91)90046-7; HURT RD, 1994, JAMA-J AM MED ASSOC, V271, P595, DOI 10.1001/jama.271.8.595; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; JARVIK ME, 1984, AM J PSYCHIAT, V141, P790; JARVIS MJ, 1982, BRIT MED J, V285, P537, DOI 10.1136/bmj.285.6341.537; JOHNSON RE, 1992, J FAM PRACTICE, V34, P61; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; LAM W, 1987, LANCET, V2, P27; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; LEU RE, 1983, SOC SCI MED, V17, P1907, DOI 10.1016/0277-9536(83)90168-5; LEU RE, 1985, SOC SCI MED, V21, P825, DOI 10.1016/0277-9536(85)90131-5; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MANNING W, 1991, COSTS POOR HLTH HABI; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; OSTER G, 1984, PREV MED, V13, P377, DOI 10.1016/0091-7435(84)90029-X; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PIERCE JP, 1995, J NATL CANCER I, V87, P87, DOI 10.1093/jnci/87.2.87; ROGERS RG, 1991, SOC SCI MED, V32, P1151, DOI 10.1016/0277-9536(91)90092-Q; RUSSELL MAH, 1983, BRIT MED J, V287, P1782, DOI 10.1136/bmj.287.6407.1782; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SACHS DPL, 1995, ARCH INTERN MED, V155, P1973, DOI 10.1001/archinte.155.18.1973; SCHAUFFLER HH, 1993, HEALTH EDUC QUART, V20, P185, DOI 10.1177/109019819302000211; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; STEWART PJ, 1982, CAN MED ASSOC J, V126, P1051; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; Torrance GW, 1987, METHODS EC EVALUATIO; *TREEAG SOFTW INC, 1995, DATA VERS 2 6; 1995, MED LETT DRUGS THER, V37, P6; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P504; 1995, STAT NOTES, V7, P1	53	160	161	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1247	1251		10.1001/jama.275.16.1247	http://dx.doi.org/10.1001/jama.275.16.1247			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601956				2022-12-01	WOS:A1996UF47800028
J	Toburen, LH				Toburen, LH			Electromagnetic fields, radon, and cancer	LANCET			English	Editorial Material									NATL RES COUNCIL,BOARD RADIAT EFFECTS RES,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	Toburen, LH (corresponding author), E CAROLINA UNIV,DEPT PHYS,GREENVILLE,NC 27858, USA.							Henshaw DL, 1996, INT J RADIAT BIOL, V69, P25, DOI 10.1080/095530096146156; *NAT RES COUNC COM, 1988, HLTH RISK RAD OTH IN; *NAT RES COUNC COM, 1994, HLTH EFFECTS EXPOSUR	3	1	1	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1059	1060		10.1016/S0140-6736(96)90274-3	http://dx.doi.org/10.1016/S0140-6736(96)90274-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602054				2022-12-01	WOS:A1996UG04200007
J	Moore, MS				Moore, MS			Generation of GTP-Ran for nuclear protein import	SCIENCE			English	Editorial Material											Moore, MS (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120	2	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					47	47		10.1126/science.272.5258.47	http://dx.doi.org/10.1126/science.272.5258.47			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600534				2022-12-01	WOS:A1996UD59700033
J	Thomas, SM; Davies, ARW; Birtwistle, NJ; Crowther, SM; Burke, JF				Thomas, SM; Davies, ARW; Birtwistle, NJ; Crowther, SM; Burke, JF			Ownership of the human genome	NATURE			English	Editorial Material									UNIV SUSSEX,DEPT BIOCHEM,BRIGHTON BN1 9RF,E SUSSEX,ENGLAND	University of Sussex	Thomas, SM (corresponding author), UNIV SUSSEX,SCI POLICY RES UNIT,BRIGHTON BN1 9RF,E SUSSEX,ENGLAND.							COLETURNER R, 1995, SCIENCE, V270, P52, DOI 10.1126/science.270.5233.52; DIXON D, 1995, NATURE, V378, P425; DIXON D, 1996, NATURE, V379, P574; *EUR COMM, 1994, EUR15897 EUR COMM; *OFF TECHN ASS, 1992, BIOT GLOB EC; SWINBANKS D, 1994, NATURE, V371, P731; THOMAS SM, 1995, RES POLICY, V24, P645, DOI 10.1016/S0048-7333(98)80001-2	7	28	28	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					387	388		10.1038/380387a0	http://dx.doi.org/10.1038/380387a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602236				2022-12-01	WOS:A1996UD59000035
J	Bernhard, JD				Bernhard, JD			Mastocytosis: For better and worse	LANCET			English	Editorial Material							SYSTEMIC MASTOCYTOSIS				Bernhard, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01605, USA.							AUSTEN KF, 1992, NEW ENGL J MED, V326, P639, DOI 10.1056/NEJM199202273260912; BERNHARD JD, 1994, ITCH MECHANISMS MANA, P251; DUFFY TP, 1993, NEW ENGL J MED, V328, P1333, DOI 10.1056/NEJM199305063281809; FRIEDMAN BS, 1994, J ALLERGY CLIN IMMUN, V93, P53, DOI 10.1016/0091-6749(94)90232-1; KENDALL ME, 1984, J AM ACAD DERMATOL, V10, P903, DOI 10.1016/S0190-9622(84)80443-0; Kors JW, 1996, J INTERN MED, V239, P157, DOI 10.1046/j.1365-2796.1996.440787000.x; KUTER I, 1992, NEW ENGL J MED, V326, P472; LEGRAIN V, 1994, ANN DERMATOL VENER, V121, P561; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; MAHOOD JM, 1982, ACTA DERM-VENEREOL, V62, P264; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; TUR E, 1990, DERMATOLOGICA, V181, P5, DOI 10.1159/000247849	13	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					705	705		10.1016/S0140-6736(96)90070-7	http://dx.doi.org/10.1016/S0140-6736(96)90070-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601995	Bronze			2022-12-01	WOS:A1996TZ98200003
J	Stearman, R; Yuan, DS; YamaguchiIwai, Y; Klausner, RD; Dancis, A				Stearman, R; Yuan, DS; YamaguchiIwai, Y; Klausner, RD; Dancis, A			A permease-oxidase complex involved in high-affinity iron uptake in yeast	SCIENCE			English	Article							WILSON DISEASE GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FERRIC REDUCTASE; PROTEIN; ATPASE	Iron must cross biological membranes to reach essential intracellular enzymes. Two proteins in the plasma membrane of yeast-a multicopper oxidase, encoded by the FET3 gene, and a permease, encoded by the FTR1 gene-were shown to mediate high-affinity iron uptake. FET3 expression was required for FTR1 protein to be transported to the plasma membrane. FTR1 expression was required for apo-FET3 protein to be loaded with copper and thus acquire oxidase activity. FTR1 protein also played a direct role in iron transport. Mutations in a conserved sequence motif of FTR1 specifically blocked iron transport.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BOMFORD A, 1976, Q J MED, V45, P611; BOTHWELL TH, 1995, METABOLIC MOL BASES, P2237; Brittenham Gary M., 1995, P492; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Cammack R, 1990, IRON TRANSPORT STORA, P17; CHANEY RL, 1988, J PLANT NUTR, V11, P1033, DOI 10.1080/01904168809363867; CONRAD ME, 1993, BLOOD, V81, P517; CRICHTON RR, 1991, INORGANIC BIOCH IRON, P144; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P770; DOOLING EC, 1995, NEUROLOGY, V45, P1138; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; *GEN COMP GROUP, 1994, PROGRMA MANUAL WISCO; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; HALLERVORDENSPA.EC, 1980, NEUROLOGY, V30, P1128; Halliwell B., 1991, FREE RADICALS BIOL M; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hofmann K., 1993, BIOL CHEM, V374, P166; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LI CY, 1994, J BIOL CHEM, V269, P10242; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P125; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; NIELANDS JB, 1981, ANNU REV NUTR, V1, P27; OREILLY S, 1968, NEUROLOGY, V18, P634, DOI 10.1212/WNL.18.7.634; OSAKI S, 1966, J BIOL CHEM, V241, P2746; RINE J, 1991, METHOD ENZYMOL, V194, P239; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; WANG X, 1995, J NEUROCHEM, V74, P1868; WEINBERG ED, 1985, J PHARMACOL-PARIS, V16, P358; WILLIAMS RJP, 1990, IRON TRANSPORT STORA, P2; Winkelmann G, 1987, IRON TRANSPORT MICRO; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YAMAGUCHIIWAI Y, UNPUB; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; YUAN DS, UNPUB	57	561	575	4	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1552	1557		10.1126/science.271.5255.1552	http://dx.doi.org/10.1126/science.271.5255.1552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599111				2022-12-01	WOS:A1996TZ98300032
J	Blendy, JA; Kaestner, KH; Weinbauer, GF; Nieschlag, E; Schutz, G				Blendy, JA; Kaestner, KH; Weinbauer, GF; Nieschlag, E; Schutz, G			Severe impairment of spermatogenesis in mice lacking the CREM gene	NATURE			English	Article							MAJOR CHROMOSOMAL PROTEIN; CDNA CLONE; MITOCHONDRIAL CAPSULE; MAMMALIAN SPERMATIDS; TRANSITION PROTEIN-1; NUCLEOTIDE-SEQUENCE; MOUSE PROTAMINE-1; MESSENGER-RNAS; SELENO-PROTEIN; EXPRESSION	Spermatogenesis is a complex developmental process that occurs in several phases. A large number of genes have been identified that are expressed during spermatogenesis(1,2), but the biological significance of many of these is not yet known. We have used gene targeting to selectively eliminate the transcription factor CREM (cyclic AMP-responsive element modulator), which is thought to be important for mammalian spermatogenesis(3-5). Male mice deficient for all CREM proteins are sterile, as their developing spermatids fail to differentiate into sperm, and postmeiotic gene expression in the testis declines dramatically. The cessation of sperm development is not accompanied by decreases in the levels of follicle-stimulating hormone or testosterone. Our findings indicate that the CREM gene is essential for spermatogenesis, and mice deficient for this transcription factor could serve as a model system for the study of idiopathic infertility in men.	GERMAN CANC RES CTR,MOL BIOL CELL DIV 1,D-69120 HEIDELBERG,GERMANY; UNIV MUNSTER,INST REPROD MED,D-48149 MUNSTER,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munster								ADHAM IM, IN PRESS DNA CELL BI; ANAKWE OO, 1991, MOL REPROD DEV, V29, P172, DOI 10.1002/mrd.1080290213; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANDOLIA RK, 1991, ACTA ENDOCRINOL-COP, V125, P547, DOI 10.1530/acta.0.1250547; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; ERIKSON RP, 1990, TRENDS GENET, V6, P264; ESCALIER D, 1991, DEVELOPMENT, V1133, P779; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; HEIDARAN MA, 1987, GENE, V54, P281, DOI 10.1016/0378-1119(87)90498-7; HEIDARAN MA, 1988, J CELL BIOL, V106, P1427, DOI 10.1083/jcb.106.5.1427; HURST HC, 1995, PROTEIN PROFILE, V2, P105; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KISTLE RMK, 1994, BIOL REPROD, V51, P1322; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KLEENE KC, 1990, DEV BIOL, V137, P395, DOI 10.1016/0012-1606(90)90263-I; KLEMM U, 1990, DIFFERENTIATION, V42, P160, DOI 10.1111/j.1432-0436.1990.tb00757.x; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NIESCHLAG E, 1993, CLIN ENDOCRINOL, V38, P123, DOI 10.1111/j.1365-2265.1993.tb00983.x; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P119; SHIH DM, 1992, MOL REPROD DEV, V33, P222, DOI 10.1002/mrd.1080330216; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; WEINBAUER GF, 1993, MOL BIOL MALE REPROD, P99; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	31	421	446	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					162	165		10.1038/380162a0	http://dx.doi.org/10.1038/380162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600391				2022-12-01	WOS:A1996TZ97800052
J	Sumner, AE; Chin, MM; Abrahm, JL; Berry, GT; Gracely, EJ; Allen, RH; Stabler, SP				Sumner, AE; Chin, MM; Abrahm, JL; Berry, GT; Gracely, EJ; Allen, RH; Stabler, SP			Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B-12 deficiency after gastric surgery	ANNALS OF INTERNAL MEDICINE			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; COBALAMIN DEFICIENCY; FOLATE-DEFICIENCY; NORMAL SERUM; MALABSORPTION; URINE; QUANTITATION; PLASMA; RISK	Objective: To determine the prevalence of vitamin B-12 deficiency in patients who have had gastric surgery. Design: Cross-sectional study. Setting: Philadelphia Veterans Affairs Medical Center. Participants: 61 patients who had had gastric surgery and 107 controls. Measurements: Serum levels of vitamin B-12 folate, methylmalonic acid, and total homocysteine measured before and after treatment in participants with vitamin B-12 deficiency. Vitamin B-12 deficiency was defined as one of the following: 1) a serum vitamin B-12 level less than 221 pmol/L and an elevated methylmalonic acid level; 2) a serum vitamin B-12 level less than 221 pmol/L and an elevated total homocysteine level that decreased with vitamin B-12 treatment; or 3) in patients unavailable for treatment, a serum vitamin B-12 level less than 221 pmol/L, a folate level greater than 9 nmol/L, and an elevated total homocysteine level. Results: Study patients and controls were similar in age, sex, and racial distribution. Nineteen patients (31%) and 2 controls (2%) had vitamin B-12 deficiency (P < 0.001). Twelve (63%) of the 19 vitamin B-12-deficient patients had elevated total homocysteine levels. In all participants with vitamin B-12 deficiency who received treatment (15 of 21). methylmalonic acid and total homocysteine levels decreased substantially, confirming the deficiency before treatment. Conclusion: Patients who have had gastric surgery have a high prevalence of vitamin B-12 deficiency. Prompt recognition and treatment of the deficiency with resultant normalization of elevated total homocysteine and methylmalonic acid levels may prevent the development of cardiovascular, hematologic, and neurologic abnormalities. Our data support both frequent screening and vitamin B-12 replacement therapy in patients who have had gastric surgery and have serum vitamin B-12 levels less than 221 pmol/L.	HAHNEMANN UNIV, PHILADELPHIA COLL PHARM & SCI, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV BIOCHEM DEV & MOLEC DIS, PHILADELPHIA, PA 19104 USA; UNIV COLORADO, HLTH SCI CTR, DIV HEMATOL, DENVER, CO 80262 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sumner, AE (corresponding author), MED COLL PENN, PHILADELPHIA VET AFFAIRS MED CTR, 3300 HENRY AVE, PHILADELPHIA, PA 19129 USA.		Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223; Berry, Gerard/0000-0001-5299-3313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021365] Funding Source: NIH RePORTER; NIA NIH HHS [AG00532, AG0983] Funding Source: Medline; NIDDK NIH HHS [DK-21365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1993, METABOLISM, V42, P978, DOI 10.1016/0026-0495(93)90010-L; ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; BADENOCH J, 1955, BRIT J HAEMATOL, V1, P339, DOI 10.1111/j.1365-2141.1955.tb05518.x; BAKER H, 1979, J AM GERIATR SOC, V27, P444, DOI 10.1111/j.1532-5415.1979.tb01724.x; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DELER DJ, 1963, LANCET, V2, P162; DOSCHERHOLMEN A, 1973, GASTROENTEROLOGY, V64, P913; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; HINES JD, 1967, AM J MED, V43, P555, DOI 10.1016/0002-9343(67)90179-9; KARNAZE DS, 1990, ARCH NEUROL-CHICAGO, V47, P1008, DOI 10.1001/archneur.1990.00530090082017; KLIPSTEIN FA, 1962, ANN INTERN MED, V57, P133, DOI 10.7326/0003-4819-57-1-133; KOLHOUSE JF, 1978, NEW ENGL J MED, V299, P785, DOI 10.1056/NEJM197810122991501; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MACLEAN LD, 1957, NEW ENGL J MED, V257, P262, DOI 10.1056/NEJM195708082570603; MAHMUD MB, 1971, J AMER MED ASSOC, V216, P1167; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MARCELL PD, 1985, ANAL BIOCHEM, V150, P58, DOI 10.1016/0003-2697(85)90440-3; MARCUARD SP, 1994, ANN INTERN MED, V120, P211, DOI 10.7326/0003-4819-120-3-199402010-00006; MARTIN DC, 1992, J AM GERIATR SOC, V40, P168, DOI 10.1111/j.1532-5415.1992.tb01939.x; MOLINOFF PB, 1990, PEPTIC ULCER DISEASE; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; Rowlands RA, 1932, LANCET, V2, P1202; RYGVOLD O, 1974, SCAND J GASTROENTERO, V9, P57; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; SCHADE SG, 1967, AM J CLIN NUTR, V20, P636, DOI 10.1093/ajcn/20.6.636; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STABLER SP, 1993, BLOOD, V81, P3404; STABLER SP, 1986, J CLIN INVEST, V77, P1606, DOI 10.1172/JCI112476; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG WM, 1980, DIGEST DIS SCI, V25, P188, DOI 10.1007/BF01308137; STREETER AM, 1974, AM J SURG, V128, P340, DOI 10.1016/0002-9610(74)90169-X; TALSTAD I, 1975, SCAND J GASTROENTERO, V10, P1; YALE CE, 1993, AM J HEMATOL, V42, P63, DOI 10.1002/ajh.2830420113	36	82	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					469	+		10.7326/0003-4819-124-5-199603010-00002	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602704				2022-12-01	WOS:A1996TW77300002
J	Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF				Jernigan, DB; Hofmann, J; Cetron, MS; Genese, CA; Nuorti, JP; Fields, BS; Benson, RF; Carter, RJ; Edelstein, PH; Guerrero, IC; Paul, SM; Lipman, HB; Breiman, RF			Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa	LANCET			English	Article							LEGIONELLA-PNEUMOPHILA SEROGROUP-1; POLYMERASE CHAIN-REACTION; PONTIAC FEVER; PNEUMONIA	Background Outbreaks of travel-related Legionnaires' disease present a public-health challenge since rapid, sensitive, and specific diagnostic tests are not widely used and because detection of clusters of disease among travellers is difficult. We report an outbreak of Legionnaires' disease among cruise ship passengers that occurred in April, 1994, but that went unrecognised until July, 1994. Methods After rapid diagnosis of Legionnaires' disease in three passengers by urine antigen testing, we searched for additional cases of either confirmed (laboratory evidence of infection) or probable Legionnaires' disease (pneumonia of undetermined cause). A case-control study was conducted to compare exposures and activities on the ship and in ports of call between each case-passenger and two or three matched control-passengers. Water samples from the ship, from sites on Bermuda, and from the ship's water source in New York City were cultured for legionellae and examined with PCR. Findings 50 passengers with Legionnaires' disease (16 confirmed, 34 probable) were identified from nine cruises embarking between April 30 and July 9, 1994. Exposure to whirlpool spas was strongly associated with disease (odds ratio 16.2, 95% CI 2.8-351.7); risk of acquiring Legionnaires' disease increased by 64% (95% CI 12-140) for every hour spent in the spa water. Passengers spending time around the whirlpool spas, but not in the water, were also significantly more likely to have acquired infection. Legionella pneumophila serogroup 1 was isolated only from the sand filter in the ship's whirlpool spa. This isolate matched a clinical isolate from the respiratory secretions of a case-passenger as judged by monoclonal antibody subtyping and by arbitrarily primed PCR. Interpretation This investigation shows the benefit of obtaining a recent travel history, the usefulness or urine antigen testing for rapid diagnosis of legionella infection, and the need for improved surveillance for travel-related Legionnaires' disease. New strategies for whirlpool spa maintenance and decontamination may help to minimise transmission of legionellae from these aerosol-producing devices.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,DIV EPIDEMIOL,TRENTON,NJ; HOSP UNIV PENN,PHILADELPHIA,PA 19104; TOMS RIVER COMMUNITY MED CTR,TOMS RIVER,NJ	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; University of Pennsylvania; Pennsylvania Medicine	Jernigan, DB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,MS CO9,1600 CLIFTON RD,ATLANTA,GA 30333, USA.		Paul, Steve/ABE-5400-2020; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279				AGUEROROSENFELD ME, 1988, J CLIN MICROBIOL, V26, P1775, DOI 10.1128/JCM.26.9.1775-1778.1988; BARON PA, 1986, ENVIRON RES, V39, P8, DOI 10.1016/S0013-9351(86)80003-2; EDELSTEIN PH, 1985, MANUAL CLIN MICROBIO, P373; EDELSTEIN PH, 1992, MANUAL CLIN LAB IMMU, P459; GOLDBERG DJ, 1989, LANCET, V1, P316; GOMEZLUS P, 1993, J CLIN MICROBIOL, V31, P1940, DOI 10.1128/JCM.31.7.1940-1942.1993; GRIST NR, 1979, ANN INTERN MED, V90, P563, DOI 10.7326/0003-4819-90-4-563; HOGE CW, 1991, EPIDEMIOL REV, V13, P329, DOI 10.1093/oxfordjournals.epirev.a036076; JOLY JR, 1986, J CLIN MICROBIOL, V23, P768, DOI 10.1128/JCM.23.4.768-771.1986; Joseph C A, 1994, Commun Dis Rep CDR Rev, V4, pR109; Joseph C A, 1993, Commun Dis Rep CDR Rev, V3, pR124; KALLINGS I, 1991, TRAVEL MED, V2, P228; KAUFMANN AF, 1981, AM J EPIDEMIOL, V114, P337, DOI 10.1093/oxfordjournals.aje.a113200; KOHLER RB, 1986, DIAGN MICR INFEC DIS, V4, pS47, DOI 10.1016/S0732-8893(86)80042-6; MANGIONE EJ, 1985, JAMA-J AM MED ASSOC, V253, P535; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; MILLER LA, 1993, J INFECT DIS, V168, P769, DOI 10.1093/infdis/168.3.769; PLOUFFE JF, 1995, CLIN INFECT DIS, V20, P1286, DOI 10.1093/clinids/20.5.1286; REINGOLD AL, 1984, J INFECT DIS, V149, P819, DOI 10.1093/infdis/149.5.819; SANDEN GN, 1993, J CLIN MICROBIOL, V31, P170, DOI 10.1128/JCM.31.1.170-172.1993; SPITALNY KC, 1984, AM J EPIDEMIOL, V120, P809, DOI 10.1093/oxfordjournals.aje.a113953; THOMAS DL, 1993, ARCH INTERN MED, V153, P2597, DOI 10.1001/archinte.153.22.2597; VOGT RL, 1987, ANN INTERN MED, V107, P596, DOI 10.7326/0003-4819-107-4-596_1; 1994, CRUISE IND OVERVIEW; 1985, US DEP HLTH HUMAN SE; 1994, COMMUNICAB DIS REP, V4, P25; 1989, US DEP HLTH HUMAN SE, P12; 1991, COMMUNICAB DIS REP, V1, P157; 1994, MMWR-MORBID MORTAL W, V43, P521; 1992, PROCEDURES RECOVERY	30	134	143	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					494	499		10.1016/S0140-6736(96)91137-X	http://dx.doi.org/10.1016/S0140-6736(96)91137-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596266	hybrid			2022-12-01	WOS:A1996TW69700008
J	Frenette, PS; Mayadas, TN; Rayburn, H; Hynes, RO; Wagner, DD				Frenette, PS; Mayadas, TN; Rayburn, H; Hynes, RO; Wagner, DD			Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins	CELL			English	Article							LEUKOCYTE ADHESION DEFICIENCY; MOUSE; EXPRESSION; MOLECULE-1; CLONING; INVIVO; RATS	We describe the phenotype of mice lacking both endothelial selectins after sequential ablation of the genes encoding P- and E-selectins. In contrast with the rather mild phenotypes observed in mice deficient in a single selectin gene, the doubly deficient mice present extreme leukocytosis, elevated cytokine levels, and alterations in hematopoiesis. Granulocytopoiesis is increased both in bone marrow and spleen, while erythropoiesis is partially translocated to the spleen. Virtual lack of leukocyte rolling and low extravasation at sites of inflammation make these animals susceptible to opportunistic bacterial infections, to which they succumb. Our results show that the absence of endothelial selectins severely affects leukocyte homeostasis and indicate that these two selectins are as important for normal leukocyte function as are the leukocyte beta 2 integrins.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School			Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922	NHLBI NIH HHS [HL53756, P01 HL41484, HL41002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL041002, R01HL041002, P01HL041484, R01HL053756] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BAKER M, 1974, MICROVASC RES, V7, P131, DOI 10.1016/0026-2862(74)90043-0; BARTOCCI A, 1987, P NATL ACAD SCI USA, V84, P6179, DOI 10.1073/pnas.84.17.6179; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRIES JWU, 1993, AM J PATHOL, V143, P725; FRYDMAN M, 1992, AM J MED GENET, V44, P297, DOI 10.1002/ajmg.1320440307; JOHNSON RC, 1995, BLOOD, V86, P1106; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEY K, 1991, BLOOD, V77, P2553; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOLINEUX G, 1990, BLOOD, V75, P563; ODELL TT, 1979, P SOC EXP BIOL MED, V160, P263; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SANDERS WE, 1992, BLOOD, V80, P795; SAWAI S, 1991, NEW BIOL, V3, P861; SCHOOLEY JC, 1972, BLOOD-J HEMATOL, V40, P662, DOI 10.1182/blood.V40.5.662.662; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; WELLER A, 1992, J BIOL CHEM, V267, P15176; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WILSON RW, 1993, J IMMUNOL, V151, P1571; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YAMADA S, 1995, BLOOD, V86, P3487, DOI 10.1182/blood.V86.9.3487.bloodjournal8693487; ZANNETTINO ACW, 1995, BLOOD, V85, P3466, DOI 10.1182/blood.V85.12.3466.bloodjournal85123466	32	450	459	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					563	574		10.1016/S0092-8674(00)81032-6	http://dx.doi.org/10.1016/S0092-8674(00)81032-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598043	Bronze			2022-12-01	WOS:A1996TX17600009
J	Leon, DA; Koupilova, I; Lithell, HO; Berglund, L; Mohsen, R; Vagero, D; Lithell, UB; McKeigue, PM				Leon, DA; Koupilova, I; Lithell, HO; Berglund, L; Mohsen, R; Vagero, D; Lithell, UB; McKeigue, PM			Failure to realise growth potential in utero and adult obesity in relation to blood pressure in 50 year old Swedish men	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL BIRTH COHORT; HYPERTENSION; FETAL; RISK; LIFE; ENVIRONMENT; CHILDHOOD; INUTERO; AGE	Objectives-To clarify the type of fetal growth impairment associated with increased blood pressure in adult life, and to establish whether this association is influenced by obesity and is mediated through impairment of insulin action. Design-Cross sectional survey with retrospective ascertainment of size at birth from obstetric archives. Subjects-1333 men resident in Uppsala, Sweden, who took part in a 1970 study of coronary risk factors at age 50 and for whom birth weight was traced. Main outcome measures-Systolic and diastolic blood pressure at age 50. Results-In the full study population for a 1000 g increase in birth weight there was a small change in systolic blood pressure of -2.2 mm Hg (95% confidence interval -4.2 to -0.3 mm Hg) and in diastolic blood pressure of -1.0 mm Hg (-2.2 to 0.1 mm Hg). Much stronger effects were observed among men who were born at term and were in the top third of body mass index at age 50, for whom a 1000 g increase in birth weight was associated with a change of -9.1 mm Hg (-16.4 to -1.9 mm Hg) systolic and -4.2 mm Hg (-8.3 to -0.1 mm Hg) diastolic blood pressure. Men who were light at birth (< 3250 g) but were of above median adult height had particularly high blood pressure. Adjustment for insulin concentrations reduced the associations of birth weight with systolic and diastolic blood pressure. Conclusions-A failure to realise growth potential in utero (as indicated by being light at birth but tall as an adult) is associated with raised adult blood pressure. Impaired fetal growth may lead to substantial increases in adult blood pressure among only those who become obese. Metabolic disturbances, possibly related to insulin resistance, may provide a pathway through which fetal growth affects blood pressure.	UNIV UPPSALA,INST GERIATR,S-75125 UPPSALA,SWEDEN; UNIV STOCKHOLM,SWEDISH INST SOCIAL RES,S-10691 STOCKHOLM,SWEDEN	Uppsala University; Stockholm University	Leon, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Berglund, Lars/AAD-3856-2019; Koupil, Ilona/AAC-9067-2020; Berglund, Lars/AAA-3188-2019; Leon, David A/G-2195-2010	Berglund, Lars/0000-0002-7437-9047; Koupil, Ilona/0000-0002-7034-1922; Leon, David A/0000-0001-9747-1762				ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; BAKKETEIG L, 1989, EFFECTIVE CARE PREGN, P765; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; COHEN MP, 1988, DIABETES, V37, P824, DOI 10.2337/diabetes.37.6.824; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; Gruenwald P, 1974, CIBA F S, V27, P3; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, SCI AM           JUL, P54; HEDSTRAND H, 1976, ACTA MED SCAND, V199, P281; HOLLAND FJ, 1993, J EPIDEMIOL COMMUN H, V47, P432, DOI 10.1136/jech.47.6.432; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARTYN CN, 1995, BRIT HEART J, V73, P116; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; SEIDMAN DS, 1993, ISRAEL J MED SCI, V29, P772; SKARFORS ET, 1991, J HYPERTENS, V9, P217, DOI 10.1097/00004872-199103000-00004; Stein Z., 1975, FAMINE HUM DEV DUTCH; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; 1993, STATA REFERENCE MANU	29	332	340	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					401	406						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601110	Green Published			2022-12-01	WOS:A1996TW56400019
J	HolgadoMadruga, M; Emlet, DR; Moscatello, DK; Godwin, AK; Wong, AJ				HolgadoMadruga, M; Emlet, DR; Moscatello, DK; Godwin, AK; Wong, AJ			A Grb2-associated docking protein in EGF- and insulin-receptor signalling	NATURE			English	Article							SUBSTRATE-1; DOMAIN; IRS-1; SH2; GRB2	THE protein Grb2 plays a central role in signalling by receptor protein-tyrosine kinases(1,2), where its SH2 domain binds to the receptor and its two SH3 domains link to effecters. One target effector is Sos, so Grb2 links receptor protein-tyrosine kinases with the Ras signalling pathway. The SH3 domains can also couple to other signalling proteins, including Vav(3), c-AbI(4) and dynamin(5), We have identified several bands in glial and medulloblastoma tumours that are recognized by Grb2 but these did not correspond to any known protein. Here we use recombinant Grb2 to isolate a complementary DNA called Gab1 (for Grb2-associated binder-1). Gab1 shares amino-acid homology and several structural features with IRS-1 (insulin-receptor substrate-1; refs 6,7), is a substate of the EGF and insulin receptors, and can act as a docking protein for several SH2-containing proteins, Overexpression of Gab1 enhances cell growth and results in transformation. We conclude that Gab1 is a new protein in EGF and insulin receptor signalling which could integrate signals from different systems.	JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA	Jefferson University; Jefferson University; Fox Chase Cancer Center								ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RON D, 1992, BIOTECHNIQUES, V13, P866; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	581	589	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	1996	379	6565					560	564		10.1038/379560a0	http://dx.doi.org/10.1038/379560a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596638				2022-12-01	WOS:A1996TU69300056
J	Amano, M; Mukai, H; Ono, Y; Chihara, K; Matsui, T; Hamajima, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K				Amano, M; Mukai, H; Ono, Y; Chihara, K; Matsui, T; Hamajima, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K			Identification of a putative target for Rho as the serine-threonine kinase protein kinase N	SCIENCE			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; MOLECULAR-WEIGHT	Rho, a Ras-like small guanosine triphosphatase, has been implicated in cytoskeletal responses to extracellular signals such as lysophosphatidic acid (LPA) to form stress fibers and focal contacts. The form of RhoA bound to guanosine triphosphate directly bound to and activated a serine-threonine kinase, protein kinase N (PKN). Activated RhoA formed a complex with PKN and activated it in COS-7 cells. PKN was phosphorylated in Swiss 3T3 cells stimulated with LPA, and this phosphorylation was blocked by treatment of cells with botulinum C3 exoenzyme. Activation of Rho may be linked directly to a serine-threonine kinase pathway.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Kobe University; Kirin Brewery Company Limited			Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Mukai, Hideyuki/0000-0002-0167-8695				AMANO M, UNPUB; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3	20	386	406	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					648	650		10.1126/science.271.5249.648	http://dx.doi.org/10.1126/science.271.5249.648			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571127				2022-12-01	WOS:A1996TT87000046
J	Coast, J; Inglis, A; Frankel, S				Coast, J; Inglis, A; Frankel, S			Alternatives to hospital care: What are they and who should decide?	BRITISH MEDICAL JOURNAL			English	Article							BEDS	Objective-To examine potential for alternatives to care in hospitals for acute admissions, and to compare the decisions about these alternatives made by clinicians with different backgrounds. Design-Standardised tool was used to identify patients who could potentially be treated in an alternative form of care. Information about such patients was assessed by three panels of clinicians: general practitioners without experience of general practitioner beds, general practitioners with experience of general practitioner beds, and consultants. Setting-One hospital for acute admissions in a rural area of the South and West region of England. Subjects-Of 620 patients admitted to specialties of general medicine and care of the elderly, details of 112 were assessed by panels. Main outcome measures-Proportion of hospitalised patients who could have received alternative care and identification of most appropriate alternative form of care. Results-Both general practitioner panels estimated that between 51 and 89 of the hospitalised patients could have received alternative care (equivalent to 8-14% of all admissions). Consultants estimated that between 25 and 55 patients could have had alternative care (5.5-9% of all admissions). General practitioner bed and urgent outpatient appointment were the main alternatives chosen by all three panels. Conclusion-About 10% of admissions to general hospital might be suitable for alternative forms of care. Doctors with different backgrounds made similar overall assessments of most appropriate forms of care.			Coast, J (corresponding author), UNIV BRISTOL,DEPT MED SOCIOL,BRISTOL BS8 2PR,AVON,ENGLAND.			Coast, Joanna/0000-0002-3537-5166				ANDERSON P, 1988, BRIT MED J, V297, P910, DOI 10.1136/bmj.297.6653.910; BEECH R, 1987, BRIT MED J, V294, P685, DOI 10.1136/bmj.294.6573.685; Cox D.R., 1958, PLANNING EXPT; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; INGLIS AL, 1995, MED CARE, V33, P952, DOI 10.1097/00005650-199509000-00006; JACOBS CM, 1992, ISD A REV SYSTEM ADU; LAURANCE J, 1993, TIMES           0111, P7; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; Torrance N, 1972, J R Coll Gen Pract, V22, P211; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; 1992, INDEPENDENT     0330, P9	12	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					162	166						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563538				2022-12-01	WOS:A1996TR32500026
J	Gough, A; Chapman, S; Wagstaff, K; Emery, P; Elias, E				Gough, A; Chapman, S; Wagstaff, K; Emery, P; Elias, E			Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome	BRITISH MEDICAL JOURNAL			English	Article							FAILURE; ACNE	Monocycline is the most widely prescribed systemic antibiotic for acne largely because it needs to be given only once or twice a day and seems not to induce resistance. Up to April 1994 11 cases of minocycline induced systemic erythematosus and cases of hepatitis been reported to Committee on Safety of Medicines. An analysis of these cases together with seven other cases shows the severity of some of these reactions. Two patients died while taking the drug for acne and a further patient needed a liver transplant. Acne itself can induce arthritis and is often seen in association with autoimmine liver disease, but the clinical and biochemical resolution seen after withdrawal of the drug, despite deterioration of the acne, suggests a drug reaction. In five cases re-exposure led to recurrence. Because reactions may be severe early recognition is important to aid recovery and also to avoid invasive investigations and treatments such as corticosteroids and immunosuppresants. Safer alternatives should be considered for treating acne.	UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND; HARROGATE DIST HOSP,DEPT RHEUMATOL,HARROGATE HG2 7SX,W YORKSHIRE,ENGLAND; UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND; SELLY OAK HOSP,DRUG INFORMAT UNIT,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,LIVER UNIT,DEPT HEPATOBILIARY MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Leeds; Keele University; University of Birmingham			emery, paul/B-3560-2013					BOCKER R, 1991, ANTIMICROB AGENTS CH, V35, P1434, DOI 10.1128/AAC.35.7.1434; BOUDREAUX JP, 1993, TRANSPLANT P, V25, P1873; BURETTE A, 1984, ARCH INTERN MED, V144, P1491, DOI 10.1001/archinte.144.7.1491; BYRNE PAC, 1994, BRIT J RHEUMATOL, V33, P674; DAVIES MG, 1989, BRIT MED J, V298, P1523, DOI 10.1136/bmj.298.6686.1523-c; DOLLERY C, 1991, THERAPEUTIC DRUGS; DOMZ CA, 1959, ANN INTERN MED, V50, P1217, DOI 10.7326/0003-4819-50-5-1217; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; GORARD DA, 1990, POSTGRAD MED J, V66, P404, DOI 10.1136/pgmj.66.775.404; HEALY E, 1994, BRIT MED J, V308, P831, DOI 10.1136/bmj.308.6932.831; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KNITZER RH, 1991, SEMIN ARTHRITIS RHEU, V20, P247, DOI 10.1016/0049-0172(91)90020-Z; MACDONALD H, 1973, CLIN PHARMACOL THER, V14, P852; MATSUURA T, 1992, LANCET, V340, P1553, DOI 10.1016/0140-6736(92)92810-3; MIN DI, 1992, PHARMACOTHERAPY, V12, P68; NELIS HJCF, 1981, LANCET, V2, P938; OTERO M, 1983, JAMA-J AM MED ASSOC, V250, P2602, DOI 10.1001/jama.1983.03340190016010; PETERS RL, 1967, AM J SURG, V113, P622, DOI 10.1016/0002-9610(67)90308-X; PUYANA J, 1990, ALLERGY, V45, P313, DOI 10.1111/j.1398-9995.1990.tb00502.x; ROBINSON MJ, 1970, AM J DIG DIS, V15, P857, DOI 10.1007/BF02236049; RUTENBURG AM, 1952, NEW ENGL J MED, V247, P797, DOI 10.1056/NEJM195211202472104; SCHULTZ JC, 1963, NEW ENGL J MED, V269, P999, DOI 10.1056/NEJM196311072691903; SOLDINGER AM, 1988, RHEUM CLIN N AM, V14, P187	23	235	235	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					169	172						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563540				2022-12-01	WOS:A1996TR32500028
J	Henry, RR; Genuth, S				Henry, RR; Genuth, S			Forum one: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			PROGRESSION; NEPHROPATHY; TRIAL	Purpose: To review issues about intensive management of non-insulin-dependent diabetes mellitus (NIDDM) and to formulate recommendations for goals and general approaches to implementation of intensive management. Method: A panel of clinical scientists and practitioners specializing in diabetes initially used a formal nominal process to identify the points of agreement on major issues. These points were further refined in a general conference discussion. Conclusions: 1) On the basis of data from intervention trials in IDDM that prove that intensive glycemic control reduces microvascular and neuropathic complications, coupled with epidemiologic and basic scientific data that support the strong likelihood of a similar benefit in NIDDM, the goal of treatment in NIDDM should be near-normal glycemia (glycohemoglobin level no higher than 1.0% above the upper normal limit); 2) glycemic targets should be adjusted individually according to clinical factors such as increased risk for hypoglycemia, advanced age, or reduced life expectancy from comorbid conditions; 3) some degree of comprehensive and repetitive instruction about diet and exercise and the use of blood glucose self-monitoring for all patients is essential to achieve the chosen targets; 4) intensive management of hyperglycemia should be instituted early and should initially emphasize diet and exercise therapy; staged introduction of oral hypoglycemic agents and finally insulin regimens of increasing complexity are recommended as needed to achieve glycemic targets; 5) comprehensive care must also include aggressive attempts to reduce cardiovascular risk factors (particularly hypertension, smoking, dyslipidemia, and obesity) as well as prevention of nephropathy and neuropathy; 6) the complex interaction among treatment regimens for hyperglycemia, dyslipidemia, obesity, and hypertension ideally requires a team approach, using a physician, diabetes educator, nurse, dietitian, and other health professionals; health insurers should make these resources available to generalists who currently care for most diabetic patients.	UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA USA; MT SINAI MED CTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH USA	University of California System; University of California San Diego; Case Western Reserve University	Henry, RR (corresponding author), VET AFFAIRS MED CTR, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.							[Anonymous], 1994, Diabetes Care, V17, P616; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; Genuth S M, 1995, Adv Intern Med, V40, P573; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; 1994, MED MANAGEMENT NON I, P26	12	37	38	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				175	177		10.7326/0003-4819-124-1_Part_2-199601011-00019	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554214				2022-12-01	WOS:A1996TL94400019
J	Blackburn, H				Blackburn, H			Olestra and the FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Blackburn, H (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.								0	24	24	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1996	334	15					984	986		10.1056/NEJM199604113341511	http://dx.doi.org/10.1056/NEJM199604113341511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD596	8596603				2022-12-01	WOS:A1996UD59600011
J	Kull, FJ; Sablin, EP; Lau, R; Fletterick, RJ; Vale, RD				Kull, FJ; Sablin, EP; Lau, R; Fletterick, RJ; Vale, RD			Crystal structure of the kinesin motor domain reveals a structural similarity to myosin	NATURE			English	Article							ACTIVE-SITE; MICROTUBULES; MOLECULES; MOVEMENT; RELEASE; COMPLEX	KINESIN is the founding member of a superfamily of microtubule-based motor proteins that perform force-generating tasks such as organelle transport and chromosome segregation(1,2). It has two identical similar to 960-amino-acid chains containing an amino-terminal globular motor domain, a central alpha-helical region that enables dimer formation through a coiled coil, and a carboxy-terminal tail domain that binds light chains and possibly an organelle receptor(1). The kinesin motor domain of similar to 340 amino acids, which can produce movement in vitro(3), is much smaller than that of myosin (similar to 850 amino acids) and dynein (1,000 amino acids), and is the smallest known molecular motor. Here, we report the crystal structure of the human kinesin motor domain with bound ADP determined to 1.8-Angstrom resolution by X-ray crystallography. The motor consists primarily of a single alpha/beta arrowhead-shaped domain with dimensions of 70x45x45 Angstrom. Unexpectedly, it has a striking structural similarity to the core of the catalytic domain of the actin-based motor myosin. Although kinesin and myosin have virtually no amino-acid sequence identity, and exhibit distinct enzymatic(4-6) and motile(7-10) properties, our results suggest that these two classes of mechanochemical enzymes evolved from a common ancestor and share a similar force-generating strategy.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [P01 AR042895-040005, P01 AR042895] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1994, MOTOR PROTEINS, V1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COPPIN CM, IN PRESS P NATL ACAD; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUJIWARA S, 1995, BIOPHYS J, V69, P1563, DOI 10.1016/S0006-3495(95)80028-7; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAMMAR JC, 1993, BIOCHEMISTRY-US, V32, P5752; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; NABER N, 1995, PROTEIN SCI, V4, P1824, DOI 10.1002/pro.5560040917; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PESKIN CS, 1995, BIOPHYS J, V68, pS202; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WELLS JA, 1979, P NATL ACAD SCI USA, V76, P4966, DOI 10.1073/pnas.76.10.4966; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	34	564	577	1	60	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					550	555		10.1038/380550a0	http://dx.doi.org/10.1038/380550a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606779	Green Accepted			2022-12-01	WOS:A1996UE66300057
J	vanGent, DC; Mizuuchi, K; Gellert, M				vanGent, DC; Mizuuchi, K; Gellert, M			Similarities between initiation of V(D)J recombination and retroviral integration	SCIENCE			English	Article							DNA STRAND TRANSFER; MECHANISM; SITE; PROTEIN	In the first step of V(D)J recombination, the RAG1 and RAG2 proteins cleave DNA between a signal sequence and the adjacent coding sequence, generating a blunt signal end and a coding end with a closed hairpin structure. These hairpins are intermediates leading to the formation of assembled antigen receptor genes. It is shown here that the hairpins are formed by a chemical mechanism of direct trans-esterification, very similar to the early steps of transpositional recombination and retroviral integration. A minor variation in the reaction is sufficient to divert the process from transposition to hairpin formation.	NIDDKD,NIH,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHOW SA, 1994, J VIROL, V68, P7869, DOI 10.1128/JVI.68.12.7869-7878.1994; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MAY EW, IN PRESS SCIENCE; MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P1037, DOI 10.1093/nar/22.6.1037; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RICE PR, UNPUB; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S	23	224	228	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1592	1594		10.1126/science.271.5255.1592	http://dx.doi.org/10.1126/science.271.5255.1592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599117				2022-12-01	WOS:A1996TZ98300044
J	Kandela, P				Kandela, P			Exposing the abuse of Chinese orphans	BRITISH MEDICAL JOURNAL			English	Article																		1996, DEATH DEFAULT POLICY	1	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1996	312	7029					495	496		10.1136/bmj.312.7029.495	http://dx.doi.org/10.1136/bmj.312.7029.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TX383	8597687	Green Published			2022-12-01	WOS:A1996TX38300033
J	DeLeo, GA; Dobson, AP				DeLeo, GA; Dobson, AP			Allometry and simple epidemic models for microparasites	NATURE			English	Article							POPULATION-DYNAMICS; TRANSMISSION; DENSITY	SIMPLE mathematical models for microparasites offer a useful way to examine the population dynamics of different viral and bacterial pathogens, One constraint in applying these models in free-living host populations is the paucity of data with which to estimate transmission rates. Here we recast a standard epidemiological model by setting the birth and death rates of the host population and its density as simple allometric functions of host body weight. We then use standard threshold theorems for the model in order to estimate the minimum rate of transmission for the parasite to establish itself in a mammalian host population, Transmission rates that produce different comparable values of the parasites' basic reproductive number, R(o), are themselves allometric functions of host body size. We have extended the model to show that hosts having different body sizes suffer epidemic outbreaks whose frequency scales,vith body size. The expected epidemic periods for pathogens in different mammalian populations correspond to cycles observed in free-living populations.			DeLeo, GA (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08544 USA.		De Leo, Giulio/AAC-5098-2019	De Leo, Giulio/0000-0002-4186-3369; Dobson, Andy/0000-0002-9678-1694				ANDERSON R M, 1991; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; ANDERSON RM, 1985, PHILOS T R SOC B, V310, P327, DOI 10.1098/rstb.1985.0123; ANDERSON RM, 1981, PHILOS T R SOC B, V291, P451, DOI 10.1098/rstb.1981.0005; ANTONOVICS J, 1995, AM NAT, V145, P661, DOI 10.1086/285761; Calder W. A, 1984, SIZE FUNCTION LIFE H; Chamov E. L., 1993, LIFE HIST INVARIANTS; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; GRENFELL BT, 1995, INFECT DIS; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; MOLLISON D, 1984, NATURE, V310, P224, DOI 10.1038/310224a0; PETERSON RO, 1984, SCIENCE, V224, P1350, DOI 10.1126/science.224.4655.1350; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SILVA M, 1995, AM NAT, V145, P704, DOI 10.1086/285764; THRALL PH, 1995, AM NAT, V145, P43, DOI 10.1086/285727	15	68	69	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					720	722		10.1038/379720a0	http://dx.doi.org/10.1038/379720a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602216				2022-12-01	WOS:A1996TW56700050
J	Dieci, G; Sentenac, A				Dieci, G; Sentenac, A			Facilitated recycling pathway for RNA polymerase III	CELL			English	Article							TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; BINDING PROTEIN; YEAST; INITIATION; COMPLEXES; INTERMEDIATE; REINITIATION; TERMINATION; CEREVISIAE	We show that the high in vitro transcription efficiency of yeast RNA poI III is mainly due to rapid recycling. Kinetic analysis shows that RNA polymerase recycling on preassembled tDNA . TFIIIC . TFIIIB complexes is much faster than the initial transcription cycle. High efficiency of RNA poI III recycling is favored at high UTP concentrations and requires termination at the natural termination signal. Runoff transcription does not allow efficient recycling. The reinitiation process shows increased resistance to heparin as compared with the primary initiation cycle, as if RNA polymerase was not released after termination. Indeed, template competition assays show that RNA poI III is committed to reinitiate on the same gene. A model is proposed where the polymerase molecule is directly transferred from the termination site to the promoter.	UNIV PARMA,IST SCI BIOCHIM,I-43100 PARMA,ITALY	University of Parma	Dieci, G (corresponding author), CEA SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.		Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961				ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BAKER SM, 1986, CELL, V47, P839, DOI 10.1016/0092-8674(86)90795-6; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHAMBERLIN MJ, 1974, ENZYMES, V10, P333; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUET J, 1985, J BIOL CHEM, V260, P5304; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	37	147	147	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					245	252		10.1016/S0092-8674(00)80979-4	http://dx.doi.org/10.1016/S0092-8674(00)80979-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565070	Bronze			2022-12-01	WOS:A1996TR59500011
J	Doolittle, RF; Feng, DF; Tsang, S; Cho, G; Little, E				Doolittle, RF; Feng, DF; Tsang, S; Cho, G; Little, E			Determining divergence times of the major kingdoms of living organisms with a protein clock	SCIENCE			English	Article							PHYLOGENETIC TREES; RIBOSOMAL-RNA; EVOLUTION; EUKARYOTES; SEQUENCE; GENE; ARCHAEBACTERIA; EUBACTERIA; ALIGNMENT; ORIGINS	Amino acid sequence data from 57 different enzymes were used to determine the divergence times of the major biological groupings. Deuterostomes and protostomes split about 670 million years ago and plants, animals, and fungi last shared a common ancestor about a billion years ago. With regard to these protein sequences, plants are slightly more similar to animals than are the fungi. In contrast, phylogenetic analysis of the same sequences indicates that fungi and animals shared a common ancestor more recently than either did with plants, the greater difference resulting from the fungal lineage changing faster than the animal and plant lines over the last 965 million years. The major protist lineages have been changing at a somewhat faster rate than other eukaryotes and split off about 1230 million years ago. If the rate of change has been approximately constant, then prokaryotes and eukaryotes last shared a common ancestor about 2 billion years ago, archaebacterial sequences being measurably more similar to eukaryotic ones than are eubacterial ones.			Doolittle, RF (corresponding author), UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA.				NHLBI NIH HHS [HL-26873] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026873, R37HL026873] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Carroll RL., 1988, VERTEBRATE PALEONTOL; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; DOOLITTLE RF, 1964, NATURE, V202, P147, DOI 10.1038/202147a0; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DOOLITTLE RF, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P241; DOOLITTLE RF, UNPUB; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FITCH WM, 1994, P NATL ACAD SCI USA, V91, P6802, DOI 10.1073/pnas.91.15.6802; FITCH WM, 1970, BIOCHEM GENET, V4, P579, DOI 10.1007/BF00486096; FITCH WM, 1976, FED PROC, V35, P2092; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gillespie J.H., 1991, CAUSES MOL EVOLUTION; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GUPTA RS, 1993, J MOL EVOL, V37, P573; HAN TM, 1992, SCIENCE, V257, P232, DOI 10.1126/science.1631544; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JOHNSON R, 1984, ELEMENTARY STATISTIC; JUKES T H, 1969, P21; JUKES TH, 1969, SPACE LIFE SCI, V1, P469, DOI 10.1007/BF00924238; KIMURA M, 1973, NATURE-NEW BIOL, V243, P199, DOI 10.1038/newbio243199a0; KIMURA M, 1972, J MOL EVOL, V2, P87, DOI 10.1007/BF01653945; Kimura M, 1971, Journal Molec Evol, V1, P1, DOI 10.1007/BF01659390; KLOTZ LC, 1981, J THEOR BIOL, V91, P261, DOI 10.1016/0022-5193(81)90233-2; KNOLL AH, 1994, P NATL ACAD SCI USA, V91, P6743, DOI 10.1073/pnas.91.15.6743; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; LANGLEY CH, 1974, J MOL EVOL, V3, P161, DOI 10.1007/BF01797451; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; MARGOLIASH E., 1965, P221; MARSHALL CR, 1990, J MOL EVOL, V30, P400, DOI 10.1007/BF02101112; MCLAUGHLIN PJ, 1970, SCIENCE, V168, P1469, DOI 10.1126/science.168.3938.1469; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nei M., 1987, MOL EVOLUTIONARY GEN; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; SARICH VM, 1973, SCIENCE, V179, P1144, DOI 10.1126/science.179.4078.1144; SCHOPF JW, 1976, SCIENCE, V193, P47, DOI 10.1126/science.193.4247.47; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; SOGIN ML, 1991, WIST SYMP S, V4, P175; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WOESE CR, 1991, EVOLUTION MOL MEN, P175; Zhang Zhongying, 1986, Journal of Micropalaeontology, V5, P9; ZUCKERKANDL EMILE, 1965, P97; 1987, J MOL EVOL, V26, P1; 1992, ENZYME NOMENCLATURE	57	462	484	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					470	477		10.1126/science.271.5248.470	http://dx.doi.org/10.1126/science.271.5248.470			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560259				2022-12-01	WOS:A1996TR32200031
J	Linnen, J; Wages, J; ZhangKeck, ZY; Fry, KE; Krawczynski, KZ; Alter, H; Koonin, E; Gallagher, M; Alter, M; Hadziyannis, S; Karayiannis, P; Fung, K; Nakatsuji, Y; Shih, JWK; Young, L; Piatak, M; Hoover, C; Fernandez, J; Chen, S; Zou, JC; Morris, T; Hyams, KC; Ismay, S; Lifson, JD; Hess, G; Foung, SKH; Thomas, H; Bradley, D; Margolis, H; Kim, JP				Linnen, J; Wages, J; ZhangKeck, ZY; Fry, KE; Krawczynski, KZ; Alter, H; Koonin, E; Gallagher, M; Alter, M; Hadziyannis, S; Karayiannis, P; Fung, K; Nakatsuji, Y; Shih, JWK; Young, L; Piatak, M; Hoover, C; Fernandez, J; Chen, S; Zou, JC; Morris, T; Hyams, KC; Ismay, S; Lifson, JD; Hess, G; Foung, SKH; Thomas, H; Bradley, D; Margolis, H; Kim, JP			Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent	SCIENCE			English	Article							NON-B-HEPATITIS; C VIRUS; NON-A; CDNA LIBRARIES; ANTIBODY; RNA; IDENTIFICATION; CONSTRUCTION; PROTEINASE; SEQUENCES	An RNA virus, designated hepatitis G virus (HGV), was identified from the plasma of a patient with chronic hepatitis. Extension from an immunoreactive complementary DNA clone yielded the entire genome (9392 nucleotides) encoding a polyprotein of 2873 amino acids. The virus is closely related to GB virus C (GBV-C) and distantly related to hepatitis C virus, GBV-A, and GBV-B. HGV was associated with acute and chronic hepatitis. Persistent viremia was detected for up to 9 years in patients with hepatitis. The virus is transfusion-transmissible. It has a global distribution and is present within the volunteer blood donor population in the United States.	GENELABS TECHNOL,REDWOOD CITY,CA 94063; CTR DIS CONTROL & PREVENT,HEPATITIS BRANCH,ATLANTA,GA 30333; NIH,DEPT TRANSFUS MED,BETHESDA,MD 20205; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894; HIPPOKRATEION HOSP,ACAD DEPT MED,ATHENS,GREECE; ST MARYS HOSP,SCH MED,DEPT MED,LONDON,ENGLAND; USN,MED RES INST,ROCKVILLE,MD 20852; NEW S WALES RED CROSS BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; BOEHRINGER MANNHEIM GMBH,D-68305 MANNHEIM,GERMANY	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Hippokration General Hospital; Imperial College London; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Australian Red Cross Blood Service			Thomas, Howard C/A-3152-2009	Karayiannis, Peter/0000-0001-5195-7863; Foung, Steven/0000-0001-7149-6160				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DECKER RH, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P795; DEKA N, 1994, J VIROL, V68, P7810, DOI 10.1128/JVI.68.12.7810-7815.1994; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HAYASHI N, 1993, J HEPATOL, V17, pS94, DOI 10.1016/S0168-8278(05)80432-5; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lim MY, UNPUB; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PURCELL RH, 1976, J IMMUNOL, V116, P349; REYES GR, 1991, MOL CELL PROBE, V5, P473, DOI 10.1016/S0890-8508(05)80020-9; RIZETTO M, 1980, LANCET, V1, P1215; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; WAGES J, UNPUB; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	31	1298	1395	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					505	508		10.1126/science.271.5248.505	http://dx.doi.org/10.1126/science.271.5248.505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560265				2022-12-01	WOS:A1996TR32200042
J	Eckstein, MB; Brown, DWG; Foster, A; Richards, AF; Gilbert, CE; Vijayalakshmi, P				Eckstein, MB; Brown, DWG; Foster, A; Richards, AF; Gilbert, CE; Vijayalakshmi, P			Congenital rubella in south India: Diagnosis using saliva from infants with cataract	BRITISH MEDICAL JOURNAL			English	Article									PHLS VIRUS REFERENCE DIV,ENTER & RESP VIRUS LAB,LONDON NW9 5HT,ENGLAND; ARAVIND EYE HOSP,MADURAI,TAMIL NADU,INDIA; POSTGRAD INST OPHTHALMOL,MADURAI,TAMIL NADU,INDIA		Eckstein, MB (corresponding author), INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND.			Foster, Allen/0000-0003-2368-4436				Banatvala JE, 1990, TOPLEY WILSONS PRINC, P502; FARACLEGAN H, 1987, J INFECT DIS, V155, P1073; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; SETH P, 1985, REV NFECT DIS, V7, P64	4	36	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					161	161						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563537				2022-12-01	WOS:A1996TR32500025
J	Pinner, RW; Teutsch, SM; Simonsen, L; Klug, LA; Graber, JM; Clarke, MJ; Berkelman, RL				Pinner, RW; Teutsch, SM; Simonsen, L; Klug, LA; Graber, JM; Clarke, MJ; Berkelman, RL			Trends in infectious diseases mortality in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY	Objective.-To evaluate recent trends in infectious diseases mortality in the United States. Design.-Descriptive study of infectious disease mortality, classifying International Classification of Diseases, Ninth Revision codes as infectious diseases, consequence of infectious diseases, or not infectious diseases. Multiple cause-of-death tapes from the National Center for Health Statistics for the years 1980 through 1992 were used, with a focus on underlying cause-of-death data and on codes that exclusively represent infectious diseases. Setting.-United States. Subjects.-All persons who died between 1980 and 1992. Main Outcome Measure.-Death. Results.-Between 1980 and 1992, the death rate due to infectious diseases as the underlying cause of death increased 58%, from 41 to 65 deaths per 100 000 population in the United States. Age-adjusted mortality from infectious diseases increased 39% during the same period. Infectious diseases mortality increased 25% among those aged 65 years and older (from 271 to 338 per 100 000), and 6.3 times among 25- to 44-year-olds (from six to 38 deaths per 100 000). Mortality due to respiratory tract infections increased 20%, from 25 to 30 deaths per 100 000, deaths attributed to human immunodeficiency virus increased from virtually none to 13 per 100 000 in 1992, and the rate of death due to septicemia increased 83% from 4.2 to 7.7 per 100 000. Conclusions.-Despite historical predictions that infectious diseases would wane in the United States, these data show that infectious diseases mortality in the United States has been increasing in recent years.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; TRANDES CORP,ATLANTA,GA; KLEMM ANAL GRP,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Simonsen, Lone/K-4531-2014	Simonsen, Lone/0000-0003-1535-8526				Bennett J. V., 1987, CLOSING GAP BURDEN U, P102; BONNEZ W, 1995, MANDELL DOUGLAS BENN, P1387; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; CAMPBELL GL, 1995, ANN INTERN MED, V122, P151, DOI 10.7326/0003-4819-122-2-199501150-00014; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Desenclos Jean-Claude A., 1992, Morbidity and Mortality Weekly Report, V41, P13; EWBANK D, 1986, MARCY ROSENAU PUBLIC, P75; FOHLMAN J, 1993, ANN MED, V25, P569; HADDIX A, 1996, PREVENTIVE EFFECTIVE; HELFAND RF, 1995, J INFECT DIS, V172, P1206, DOI 10.1093/infdis/172.5.1206; HERRINGTON CS, 1994, J CLIN PATHOL, V47, P1066, DOI 10.1136/jcp.47.12.1066; KOCHANEK KD, 1995, MONTHLY VITAL STATIS, V43, P70; Levins R., 1995, ECOSYST HEALTH, V1, P47; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MORRISON EA, 1995, CLIN INFECT DIS, V18, P172; REEVES WC, 1989, REV INFECT DIS, V11, P426; SOLL AH, 1993, GASTROINTESTINAL DIS, P580; WISE RP, 1988, AM J PREV MED, V4, P268, DOI 10.1016/S0749-3797(18)31160-7; 1994, MONTHLY VITAL STAT R, V42; 1992, EMERGING INFECTIONS; 1995, MMWR-MORBID MORTAL W, V44, P468; [No title captured]; 1992, VITAL STATISTICS MOR; 1995, WORLD DEV REPORT 199; 1995, MMWR-MORBID MORTAL W, V44, P381; 1995, MMWR-MORBID MORTAL W, V44, P535; 1995, MMWR-MORBID MORTAL W, V44, P475; 1993, MMWR-MORBID MORTAL W, V42, P869	29	401	414	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					189	193		10.1001/jama.275.3.189	http://dx.doi.org/10.1001/jama.275.3.189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604170				2022-12-01	WOS:A1996TP28200025
J	Lambe, M; Ekbom, A				Lambe, M; Ekbom, A			Cancers coinciding with childbearing: Delayed diagnosis during pregnancy?	BRITISH MEDICAL JOURNAL			English	Article											Lambe, M (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN.			Lambe, Mats/0000-0002-4624-3767				HAAS JF, 1984, INT J CANCER, V34, P229, DOI 10.1002/ijc.2910340214; JOHANSSON I, 1993, FERTILITY SWEDISH WO; MUSEY VC, 1986, J CLIN ENDOCR METAB, V64, P111; WALLACE N, 1983, FEDERAL RESERVE BANK, V7, P1; 1993, CANCER INCIDENCE SWE	5	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1607	1608		10.1136/bmj.311.7020.1607	http://dx.doi.org/10.1136/bmj.311.7020.1607			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555804	Green Published			2022-12-01	WOS:A1995TL42200021
J	Pirkle, JL; Flegal, KM; Bernert, JT; Brody, DJ; Etzel, RA; Maurer, KR				Pirkle, JL; Flegal, KM; Bernert, JT; Brody, DJ; Etzel, RA; Maurer, KR			Exposure of the US population to environmental tobacco smoke - The Third National Health and Nutrition Examination Survey, 1988 to 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCOTTISH HEART HEALTH; PASSIVE SMOKING; NONSMOKING WOMEN; URINARY COTININE; DIETARY NICOTINE; SERUM COTININE; LUNG-CANCER; BODY-FLUIDS; SALIVA	Objective.-To estimate the extent of exposure of the US population to environmental tobacco smoke and the contribution of the home and workplace environment to environmental tobacco smoke exposure. Design.-Nationally representative cross-sectional survey including questionnaire information from persons aged 2 months and older (n=16818) and measurements of serum cotinine (a metabolite of nicotine) from persons aged 4 years and older (n=10642). Setting/Participants.-Participants in the Third National Health and Nutrition Examination Survey, October 25, 1988, to October 21, 1991. Results.-Of US children aged 2 months to 11 years, 43% lived in a home with at least 1 smoker, and 37% of adult non-tobacco users lived in a home with at least 1 smoker or reported environmental tobacco smoke exposure at work. Serum cotinine levels indicated more widespread exposure to nicotine. Of non-tobacco users, 87.9% had detectable levels of serum cotinine, Both the number of smokers in the household and the hours exposed at work were significantly and independently associated (P<.001, multiple regression t test) with increased serum cotinine levels. Serum cotinine levels of children, non-Hispanic blacks, and males indicated that these groups had higher exposure to environmental tobacco smoke. Dietary variables showed no consistent association with serum cotinine levels, and dietary contribution to serum cotinine level, if any, appeared to be extremely small. Conclusions.-The high proportion of the population with detectable serum cotinine levels indicates widespread exposure to environmental tobacco smoke in the US population, Both the home and workplace environments significantly contribute to environmental tobacco smoke exposure in the United States.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Pirkle, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,MAILSTOP F20,ATLANTA,GA 30341, USA.		Etzel, Ruth A./N-5700-2019	Etzel, Ruth A./0000-0002-5236-3976; Flegal, Katherine/0000-0002-0838-469X				BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; BENOWITZ NL, 1995, CLIN PHARMACOL THER, V57, P159; Bernert John T. Jr., 1994, Clinical Chemistry, V40, P1075; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; CASTRO A, 1986, BIOCHEM ARCH, V2, P91; CUMMINGS KM, 1990, ARCH ENVIRON HEALTH, V45, P74, DOI 10.1080/00039896.1990.9935929; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; DAVIS RA, 1991, FOOD CHEM TOXICOL, V29, P821, DOI 10.1016/0278-6915(91)90109-K; DOMINO EF, 1993, NEW ENGL J MED, V329, P437, DOI 10.1056/NEJM199308053290619; EMMONS KM, 1994, PREV MED, V23, P35, DOI 10.1006/pmed.1994.1005; ETZEL RA, 1990, PREV MED, V19, P190, DOI 10.1016/0091-7435(90)90020-K; EZZATI TM, 1992, VITAL HLTH STAT, V113; FLEGAL KM, 1987, DIABETES, V36, P523; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HINDS WC, 1975, NEW ENGL J MED, V292, P844, DOI 10.1056/NEJM197504172921606; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; JARVIS MJ, 1994, BRIT MED J, V308, P62; JENKINS PL, 1992, ATMOS ENVIRON A-GEN, V26, P2141, DOI 10.1016/0960-1686(92)90402-7; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305; MURAMATSU M, 1984, ENVIRON RES, V35, P218, DOI 10.1016/0013-9351(84)90130-0; National Research Council, 1986, ENV TOB SMOK MEAS EX; OVERPECK MD, 1991, ADV DATA VITAL HLTH, V202; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; REPACE JL, 1994, BRIT MED J, V308, P61, DOI 10.1136/bmj.308.6920.61c; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SAS Institute Inc., 1990, SAS LANG REF VERS 6; SHAH BV, 1991, SUDAAN USERS MANUAL; SHEEN SJ, 1988, J FOOD SCI, V53, P1572, DOI 10.1111/j.1365-2621.1988.tb09328.x; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; TAYLOR JK, 1987, QUALITY CONTROL CHEM; TUNSTALLPEDOE H, 1991, J CLIN EPIDEMIOL, V44, P1411, DOI 10.1016/0895-4356(91)90102-F; *US DEPT HHS, 1986, PUBL PHS; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; WALL MA, 1988, AM J PUBLIC HEALTH, V78, P699, DOI 10.2105/AJPH.78.6.699; WATTS RR, 1990, ENVIRON HEALTH PERSP, V84, P173, DOI 10.2307/3430719; WILCOX RG, 1979, BRIT MED J, V2, P1026, DOI 10.1136/bmj.2.6197.1026; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, PREV MED, V21, P88, DOI 10.1016/0091-7435(92)90008-6; 1992, EPA600690006F OFF AI; 1994, VITAL HLTH STAT, V1	50	510	517	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1233	1240						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601954				2022-12-01	WOS:A1996UF47800026
J	Drgonova, J; Drgon, T; Tanaka, K; Kollar, R; Chen, GC; Ford, RA; Chan, CSM; Takai, Y; Cabib, E				Drgonova, J; Drgon, T; Tanaka, K; Kollar, R; Chen, GC; Ford, RA; Chan, CSM; Takai, Y; Cabib, E			Rho1p, a yeast protein at the interface between cell polarization and morphogenesis	SCIENCE			English	Article							RAS SUPERFAMILY GENES; SACCHAROMYCES-CEREVISIAE; BETA-(1->3)GLUCAN SYNTHETASE; WALL; BIOSYNTHESIS; GROWTH; DEFECT; GTP	The enzyme that catalyzes the synthesis of the major structural component of the yeast cell wall, beta(1-->3)-D-glucan synthase (also known as 1,3-beta-glucan synthase), requires a guanosine triphosphate (GTP) binding protein for activity. The GTP binding protein was identified as Rho1p. The rho1 mutants were defective in GTP stimulation of glucan synthase, and the defect was corrected by addition of purified or recombinant Rho1p. A protein missing in purified preparations from a rho1 strain was identified as Rho1p. Rho1p also regulates protein kinase C, which controls a mitogen-activated protein kinase cascade. Experiments with a dominant positive PKC1 gene showed that the two effects of Rho1p are independent of each other. The colocalization of Rho1p with actin patches at the site of bud emergence and the role of Rho1p in cell wall synthesis emphasize the importance of Rho1p in polarized growth and morphogenesis.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Osaka University; University of Texas System; University of Texas Austin			Drgonova, Jana/B-2903-2008; chan, cherry/GQY-4591-2022; Chen, Guang-Chao/P-1262-2019	Chen, Guang-Chao/0000-0002-4980-4718; Drgonova, Jana/0000-0002-4623-8466				CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, UNPUB; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DOUGLAS CM, 1994, P NATL ACAD SCI USA, V91, P12907, DOI 10.1073/pnas.91.26.12907; DRGONOVA J, UNPUB; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KANG MS, 1986, P NATL ACAD SCI USA, V83, P5808, DOI 10.1073/pnas.83.16.5808; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOL PC, 1994, J BIOL CHEM, V269, P31267; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	24	301	316	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					277	279		10.1126/science.272.5259.277	http://dx.doi.org/10.1126/science.272.5259.277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602514				2022-12-01	WOS:A1996UE72900044
J	Munk, MHJ; Roelfsema, PR; Konig, P; Engel, AK; Singer, W				Munk, MHJ; Roelfsema, PR; Konig, P; Engel, AK; Singer, W			Role of reticular activation in the modulation of intracortical synchronization	SCIENCE			English	Article							CAT VISUAL-CORTEX; OSCILLATORY NEURONAL RESPONSES; CROSS-CORRELATION; CONNECTIONS; MONKEY; HZ	During aroused states of the brain, electroencephalographic activity is characterized by fast, irregular fluctuations of low amplitude, which are thought to reflect desynchronization of neuronal activity. This phenomenon seems at odds with the proposal that synchronization of cortical responses may play an important role in the processing of sensory signals. Here, activation of the mesencephalic reticular formation (MRF), an effective way to ''desynchronize the electroencephalogram,'' was shown to facilitate oscillatory activity in the gamma frequency range and to enhance the stimulus-specific synchronization of neuronal spike responses in the visual cortex of cats.			Munk, MHJ (corresponding author), MAX PLANCK INST HIRNFORSCH,ABT NEUROPHYSIOL,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY.		Engel, Andreas K/C-7781-2012; Engel, Andreas K./AAH-6384-2019; Roelfsema, Pieter/J-6903-2013; König, Peter/ABB-2380-2020; Singer, Wolf/D-6874-2012	Engel, Andreas K/0000-0003-4899-8466; Engel, Andreas K./0000-0003-4899-8466; Roelfsema, Pieter/0000-0002-1625-0034; König, Peter/0000-0003-3654-5267; 				Abeles M., 1982, LOCAL CORTICAL CIRCU; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; COPE TC, 1987, J PHYSIOL-LONDON, V390, P161, DOI 10.1113/jphysiol.1987.sp016692; ECKHORN R, 1993, NEUROREPORT, V4, P243, DOI 10.1097/00001756-199303000-00004; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL A K, 1992, Current Biology, V2, P332, DOI 10.1016/0960-9822(92)90898-K; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; GRAY C M, 1987, Neuroscience, V22, pS434; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KONIG P, 1993, EUR J NEUROSCI, V5, P501, DOI 10.1111/j.1460-9568.1993.tb00516.x; KONIG P, 1995, P NATL ACAD SCI USA, V92, P290, DOI 10.1073/pnas.92.1.290; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; KREITER AK, IN PRESS J NEUROSCI; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Munk MHJ, 1995, J NEUROPHYSIOL, V74, P2401, DOI 10.1152/jn.1995.74.6.2401; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; Nowak LG, 1995, J NEUROPHYSIOL, V74, P2379, DOI 10.1152/jn.1995.74.6.2379; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SINGER W, 1990, BRAIN CHOLINERGIC SY, P314; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396	30	344	347	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					271	274		10.1126/science.272.5259.271	http://dx.doi.org/10.1126/science.272.5259.271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602512				2022-12-01	WOS:A1996UE72900042
J	Shilatifard, A; Lane, WS; Jackson, KW; Conaway, RC; Conaway, JW				Shilatifard, A; Lane, WS; Jackson, KW; Conaway, RC; Conaway, JW			An RNA polymerase II elongation factor encoded by the human ELL gene	SCIENCE			English	Article							ACUTE LEUKEMIAS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; SEQUENCE	The human ELL gene on chromosome 19 undergoes frequent translocations with the trithorax-like MLL gene on chromosome 11 in acute myeloid leukemias. Here, ELL was shown to encode a previously uncharacterized elongation factor that can increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by polymerase at multiple sites along the DNA. Functionally, ELL resembles Elongin (SIII), a transcription elongation factor regulated by the product of the von Hippel-Lindau (VHL) tumor suppressor gene. The discovery of a second elongation factor implicated in oncogenesis provides further support for a close connection between the regulation of transcription elongation and cell growth.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV OKLAHOMA,HLTH SCI CTR,WILLIAM K WARREN MED RES INST,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; Harvard University; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BERNARD OA, 1994, ONCOGENE, V9, P1039; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PRASAD R, 1993, CANCER RES, V53, P5624; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHILATIFARD A, UNPUB; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAN SY, 1994, BIOTECHNIQUES, V16, P824; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	25	288	294	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1996	271	5257					1873	1876		10.1126/science.271.5257.1873	http://dx.doi.org/10.1126/science.271.5257.1873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596958				2022-12-01	WOS:A1996UC77800049
J	Nightingale, SL				Nightingale, SL			Nicorette gum approved for over-the-counter marketing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-01	WOS:A1996UA56300010
J	Goodfellow, J; Ramsey, MW; Luddington, LA; Jones, CJH; Coates, PA; Dunstan, F; Lewis, MJ; Owens, DR; Henderson, AH				Goodfellow, J; Ramsey, MW; Luddington, LA; Jones, CJH; Coates, PA; Dunstan, F; Lewis, MJ; Owens, DR; Henderson, AH			Endothelium and inelastic arteries: An early marker of vascular dysfunction in noninsulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article							INSULIN		UNIV WALES COLL MED,DIABET RES UNIT,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED STAT & COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	Goodfellow, J (corresponding author), UNIV WALES COLL MED,CARDIOVASC SCI RES GRP,CARDIFF CF4 4XN,S GLAM,WALES.							COATES PA, 1993, DIABETES, V42, P1635, DOI 10.2337/diabetes.42.11.1635; OROURKE MF, 1989, J HUM HYPERTEN, V10, P47; RAMSEY MW, 1995, CIRCULATION, V92, P3212, DOI 10.1161/01.CIR.92.11.3212; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S	4	116	117	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					744	745						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605460				2022-12-01	WOS:A1996UC16600026
J	Ramirez, AJ; Graham, J; Richards, MA; Cull, A; Gregory, WM				Ramirez, AJ; Graham, J; Richards, MA; Cull, A; Gregory, WM			Mental health of hospital consultants: The effects of stress and satisfaction at work	LANCET			English	Article								Background Burnout and psychiatric morbidity among gastroenterologists, surgeons, radiologists, and oncologists in the UK have been estimated by means of a questionnaire-based survey. The relationship between consultants' mental health and their job stress and satisfaction, as well as their job and demographic characteristics, were also examined. Methods Psychiatric morbidity was estimated using the 12-item General Health Questionnaire. The three components of burnout-emotional exhaustion, depersonalisation, and low personal accomplishment-were assessed using the Maslach Burnout Inventory. Job stress and satisfaction were measured using study-specific questions. Findings Of 1133 consultants, 882 (78%) returned questionnaires. The estimated prevalence of psychiatric morbidity was 27%, with no significant differences between the four specialist groups. Radiologists reported the highest level of burnout in terms of low personal accomplishment. Job satisfaction significantly protected consultants' mental health against job stress. Three sources of stress were associated with both burnout and psychiatric morbidity: feeling overloaded, and its effect on home life; feeling poorly managed and resourced; and dealing with patients' suffering. Burnout was also associated with low satisfaction in three domains: relationships with patients, relatives, and staff; professional status/esteem; intellectual stimulation. In addition, being aged 55 years or less and being single were independent risk factors for burnout. Burnout was also more prevalent among consultants who felt insufficiently trained in communication and management skills. Interpretation Consultants' mental health is likely to be protected against the high demands of medical practice by maintaining or enhancing job satisfaction, and by providing training in communication and management skills.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Edinburgh								BANKS MH, 1980, J OCCUP PSYCHOL, V53, P187, DOI 10.1111/j.2044-8325.1980.tb00024.x; BLENKIN H, 1995, BRIT MED J, V310, P534, DOI 10.1136/bmj.310.6978.534; *BMA, 1992, STRESS MED PROF; *BMA, 1993, MORB MORT MED PROF; CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261; Charlton J., 1993, POPULATION TRENDS, V71, P34; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; FREUDENBERGER HJ, 1974, J SOC ISSUES, V30, P159, DOI 10.1111/j.1540-4560.1974.tb00706.x; Goldberg D., 1988, USERS GUIDE GEN HLTH; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; Maslach C., 1986, MBI MASLACH BURNOUT; SILVEY S, 1970, STAT INFERENCE, P108; SIMON R, 1986, ANN INTERN MED, V105, P49; 1994, LANCET, V344, P1583	14	612	628	1	112	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					724	728		10.1016/S0140-6736(96)90077-X	http://dx.doi.org/10.1016/S0140-6736(96)90077-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ982	8602002	Bronze			2022-12-01	WOS:A1996TZ98200010
J	Biver, N; Rauer, H; Despois, D; Moreno, R; Paubert, G; BockeleeMorvan, D; Colom, P; Crovisier, J; Gerard, E; Jorda, L				Biver, N; Rauer, H; Despois, D; Moreno, R; Paubert, G; BockeleeMorvan, D; Colom, P; Crovisier, J; Gerard, E; Jorda, L			Substantial outgassing of CO from comet Hale-Bopp at large heliocentric distance	NATURE			English	Article								When comet C/1995 O1 (Hale-Bopp) was discovered(1), at a distance of seven astronomical units from the Sun, it was more than one hundred times brighter than comet Halley at the same distance. A comet's brightness is derived from the reflection of sunlight from dust grains driven away from the nucleus by the sublimation of volatile ices. Near the Sun, sublimation of water ice (a main constituent of comet nuclei) is the source of cometary activity; but at its current heliocentric distance, Hale-Bopp is too cold for this process to operate. Other comets have shown activity at large distances(2), and in the case of comet Schwassmann-Wachmann 1, carbon monoxide has been detected in quantities sufficient to generate its observed coma(3,4). Here we report the detection of CO emission from Hale-Bopp, at levels indicating a very large rate of outgassing. Several other volatile species were searched for, but not detected. Sublimation of CO therefore appears to be responsible for the present activity of this comet, and we anticipate that future observations will reveal the onset of sublimation of other volatile species as the comet continues its present journey towards the Sun.	OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; IRAM, E-18012 GRANADA, SPAIN		Biver, N (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.		Jorda, Laurent/AAA-1718-2021					AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; AHEARN MF, 1995, 6244 IAU; BOCKELEEMORVAN D, 1990, ASTRON ASTROPHYS, V238, P382; BOCKELEEMORVAN D, 1994, ASTRON ASTROPHYS, V287, P647; COLOM P, 1992, ASTRON ASTROPHYS, V264, P710; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1994, IAU SYMP, P313; DAVIES J, 1995, 6225 IAU; DESPOIS D, IN PRESS PLANET SPAC; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FULLE M, 1992, NATURE, V359, P42, DOI 10.1038/359042a0; HALE A, 1995, 6187 IAU; HUEBNER WF, 1992, WORKSH ACT DIST COM; Jewitt D., 1990, Astrophysical Journal, V351, P277, DOI 10.1086/168463; KIDGER M, 1995, 6240 IAU; MATTHEWS HE, 1995, 6234 IAU; RAUER H, 1995, 6236 IAU; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WILD W, 1995, 30M MANUAL HDB IRAM; WOMACK M, 1995, 6276 IAU	21	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	1996	380	6570					137	139		10.1038/380137a0	http://dx.doi.org/10.1038/380137a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600385				2022-12-01	WOS:A1996TZ97800042
J	Hull, HF; Lee, JW				Hull, HF; Lee, JW			Sabin, Salk, or sequential?	LANCET			English	Editorial Material											Hull, HF (corresponding author), WHO,CH-1211 GENEVA,SWITZERLAND.							ANDRUS JK, 1995, B WORLD HEALTH ORGAN, V73, P33; BART KJ, IN PRESS B WHO; FRANKEL DH, 1995, LANCET, V346, P1151, DOI 10.1016/S0140-6736(95)91812-4; GHENDON Y, 1994, B WORLD HEALTH ORGAN, V72, P973; HEYMANN DL, 1987, B WORLD HEALTH ORGAN, V65, P495; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; WARD NA, 1995, LANCET, V345, P318, DOI 10.1016/S0140-6736(95)90305-4; 1995, WEEKLY EPIDEMIOL REC, V70, P169; 1994, WEEKLY EPIDEMIOL REC, V69, P293; 1995, WEEKLY EPIDEMIOL REC, V70, P341; 1995, WEEKLY EPIDEMIOL REC, V79, P325; 1994, WEEKLY EPIDEMIOL REC, V69, P377	12	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1996	347	9002					630	630		10.1016/S0140-6736(96)91194-0	http://dx.doi.org/10.1016/S0140-6736(96)91194-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ285	8596370				2022-12-01	WOS:A1996TZ28500002
J	Chao, DM; Gadbois, EL; Murray, PJ; Anderson, SF; Sonu, MS; Parvin, JD; Young, RA				Chao, DM; Gadbois, EL; Murray, PJ; Anderson, SF; Sonu, MS; Parvin, JD; Young, RA			A mammalian SRB protein associated with an RNA polymerase II holoenzyme	NATURE			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTION; PURIFICATION; YEAST; CTD	A large multisubunit complex containing RNA polymerase II, general transcription factors and SRB regulatory proteins initiates transcription of class II genes in yeast cells(1-4). The SRB proteins are a hallmark of this RNA polymerase II holoenzyme as they are found only in this complex, where they contribute to the response to regulators(4-8). We have now isolated a human homologue of the yeast SRB7 gene and used antibodies against human SRB7 protein to purify and characterize a mammalian RNA polymerase II holoenzyme containing the general transcription factors TFIIE and TFIIH. This holoenzyme is more responsive to transcriptional activators than core RNA polymerase II when assayed in the presence of coactivators.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; BRIGHAM & WOMENS HOSP, DIV MOLEC ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chao, DM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Murray, Peter J/K-4725-2018; Young, Richard A/F-6495-2012; Parvin, Jeffrey D/C-8955-2009	Murray, Peter J/0000-0001-6329-9802; Young, Richard A/0000-0001-8855-8647; Chao, David/0000-0001-9198-337X				BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; INOSTROZA JA, 1992, CELL, V70, P477; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLESKE AJ, IN PRESS METH ENZYM; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069	27	130	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					82	85		10.1038/380082a0	http://dx.doi.org/10.1038/380082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598913				2022-12-01	WOS:A1996TY87700062
J	Froster, UG; Jackson, L				Froster, UG; Jackson, L			Limb defects and chorionic villus sampling: Results from an international registry, 1992-94	LANCET			English	Article							PRENATAL-DIAGNOSIS; CONGENITAL-DEFECTS; REDUCTION DEFECTS; ABNORMALITIES; POPULATION; CVS; MALFORMATIONS; ANOMALIES; AMNIOCENTESIS	Background Several reports of limb defects occurring among infants exposed to chorionic villus sampling (CVS) during pregnancy resulted in concern about the safety of this procedure for prenatal diagnosis. To avoid publication bias and evaluate the true risk of limb defects in a CVS cohort, the World Health Organization initiated international registration of post-CVS limb defects in 1992. Methods From May, 1992, to May, 1994, 77 infants or fetuses with limb defects from 138 996 pregnancies having CVS were reported to the WHO CVS Registry. These cases were analysed by standardised methods-ie, exclusion of syndromes, inherited disorders, and defects occurring in previable fetuses. The included limb deficiencies were studied by pattern analysis. Findings Defects of the upper limbs were reported in 64.6%, of the lower limbs in 12.5%, and of both upper and lower limbs in 20.8% of cases, These figures are in agreement with the distribution of limb defects in several large population-based studies. Transverse limb defects occurred in 40.8% and longitudinal defects in 59.2%, compared with 42.7% and 57.3% in an unexposed population. Interpretation The analysis of this cohort did not show any differences from the background population in the overall frequency or pattern distribution of limb deficiencies. There was also no correlation between gestational age at CVS and severity of defects. Therefore these results do not indicate any increased risk of limb defects after CVS.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV MED GENET,PHILADELPHIA,PA 19107	Jefferson University	Froster, UG (corresponding author), UNIV SPITAL ZURICH,KLIN & POLIKLIN GEBURTSHILFE,DEPT FRAUENHEILKUNDE,FRAUENKLIN STR 10,CH-8091 ZURICH,SWITZERLAND.							[Anonymous], 1991, LANCET, V337, P1491; ARO T, 1982, INT J EPIDEMIOL, V3, P239; BAMFORTH JS, 1992, AM J MED GENET, V44, P281; BRAMBATI B, 1983, LANCET, V1, P586; BRAMBATI B, 1992, PRENATAL DIAG, V12, P789, DOI 10.1002/pd.1970121004; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BURTON BK, 1993, PEDIATRICS, V91, P989; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; DOLK H, 1992, LANCET, V339, P876, DOI 10.1016/0140-6736(92)90325-W; FIRTH HV, 1994, LANCET, V343, P1069, DOI 10.1016/S0140-6736(94)90182-1; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTER UG, 1993, AM J MED GENET, V45, P60, DOI 10.1002/ajmg.1320450116; FROSTER UG, 1993, AM J MED GENET, V46, P479, DOI 10.1002/ajmg.1320460502; FROSTER UG, 1993, AM J MED GENET, V46, P497, DOI 10.1002/ajmg.1320460507; FROSTER UG, 1992, LANCET, V339, P66, DOI 10.1016/0140-6736(92)90198-C; FROSTERISKENIUS UG, 1990, TERATOLOGY, V41, P23, DOI 10.1002/tera.1420410104; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GOLBUS MT, 1992, PRENATAL DIAG, V12, P313, DOI 10.1002/pd.1970120502; HOLZGREVE W, 1990, GYNAKOLOGE, V23, P261; HSIEH FJ, 1991, LANCET, V337, P1091; JAHODA MGJ, 1991, PRENATAL DIAG, V11, P559, DOI 10.1002/pd.1970110811; KALLEN B, 1984, TERATOLOGY, V29, P73, DOI 10.1002/tera.1420290109; KAPLAN P, 1990, AM J MED GENET, V37, P366, DOI 10.1002/ajmg.1320370315; KULIEV AM, 1993, PRENATAL DIAG, V13, P197, DOI 10.1002/pd.1970130307; KULIEV AM, 1992, LANCET, V340, P668, DOI 10.1016/0140-6736(92)92197-N; KULIEV AM, 1992, J ASSIST REPROD GEN, V9, P299, DOI 10.1007/BF01203947; LIN SP, 1992, J MED GENET, V51, pA261; LIPPMAN A, 1992, PRENATAL DIAG, V12, P385, DOI 10.1002/pd.1970120508; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; MONNI G, 1991, LANCET, V337, P1091; OLNEY RS, 1995, TERATOLOGY, V51, P20, DOI 10.1002/tera.1420510104; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; Stoll C, 1992, Paediatr Perinat Epidemiol, V6, P323, DOI 10.1111/j.1365-3016.1992.tb00773.x; Wapner R., 1996, American Journal of Obstetrics and Gynecology, V174, P310; 1993, PRENATAL DIAG, V13, P1051	37	69	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					489	494		10.1016/S0140-6736(96)91136-8	http://dx.doi.org/10.1016/S0140-6736(96)91136-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596265				2022-12-01	WOS:A1996TW69700007
J	Miyazaki, T; Wolf, P; Tourne, S; Waltzinger, C; Dierich, A; Barois, N; Ploegh, H; Benoist, C; Mathis, D				Miyazaki, T; Wolf, P; Tourne, S; Waltzinger, C; Dierich, A; Barois, N; Ploegh, H; Benoist, C; Mathis, D			Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; HLA-DR MOLECULES; SELECTION; GENES; EXPRESSION	We have generated mice lacking H2-M complexes, critical facilitators of peptide loading onto major histocompatibility complex class II molecules. Ab molecules in these mice matured into stable complexes and were efficiently expressed at the cell surface. Most carried a single peptide derived from the class II-associated invariant chain; the diverse array of peptides normally displayed by class II molecules was absent. Cells from mutant mice presented both whole proteins and short peptides very poorly. Surprisingly, positive selection of CD4(+) T cells was quite efficient, yielding a large and broad repertoire. Peripheral T cells reacted strongly to splenocytes from syngeneic wild-type mice, no doubt reflecting the unique peptide complement carried by class II molecules in mutant animals.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; CTR IMMUNOL MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Massachusetts Institute of Technology (MIT); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Miyazaki, T (corresponding author), UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,CU STRASBOURG,F-67404 ILLKIRCH GRAFFENS,FRANCE.				NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [2-P30-CA14051-24] Funding Source: Medline; PHS HHS [5-R01-AL34893, T32-AL07463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CEMAN S, 1992, J IMMUNOL, V149, P754; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EASTMAN S, 1996, IN PRESS EUR J IMMUN; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KROPSHOFER H, 1995, SCIENCE, V270, P1357, DOI 10.1126/science.270.5240.1357; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIANG MN, 1995, INT IMMUNOL, V7, P1397, DOI 10.1093/intimm/7.9.1397; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MIYAZAKI T, 1996, IN PRESS SCIENCE; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; RADLEY E, 1994, J BIOL CHEM, V269, P18834; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; TOUME S, 1995, EUR J IMMUNOL, V25, P1851; URBAN RG, 1995, J EXP MED, V180, P1851; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WHITE J, 1989, J IMMUNOL, V143, P1822; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	44	300	305	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					531	541		10.1016/S0092-8674(00)81029-6	http://dx.doi.org/10.1016/S0092-8674(00)81029-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598040	Bronze			2022-12-01	WOS:A1996TX17600006
J	Guler, ML; Gorham, JD; Hsieh, CS; Mackey, AJ; Steen, RG; Dietrich, WF; Murphy, KM				Guler, ML; Gorham, JD; Hsieh, CS; Mackey, AJ; Steen, RG; Dietrich, WF; Murphy, KM			Genetic susceptibility to Leishmania: IL-12 responsiveness in T(H)1 cell development	SCIENCE			English	Article							CD4+ T-CELLS; CUTANEOUS LEISHMANIASIS; INTERFERON-GAMMA; IFN-GAMMA; IMMUNOLOGICAL REGULATION; MURINE LEISHMANIASIS; MICE; INTERLEUKIN-4; INVITRO; RESISTANCE	The genetic background of T lymphocytes influences development of the T helper (T-H) phenotype, resulting in either resistance or susceptibility of certain mouse strains to pathogens such as Leishmania major. With an in vitro model system, a difference in maintenance of responsiveness of T cells to interleukin-12 (IL-12) was detected between BALB/c and B10.D2 mice, Although naive T cells from both strains initially responded to IL-12, BALB/c T cells lost IL-12 responsiveness after stimulation with antigen in vitro, even when cocultured with B10.D2 T cells, Thus, susceptibility of BALB/c mice to infection with L. major may derive from the loss of the ability to generate IL-12-induced T(H)1 responses rather than from an IL-4-induced T(H)2 response.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA	Washington University (WUSTL); Massachusetts Institute of Technology (MIT); Whitehead Institute					NIAID NIH HHS [AI31238, AI34580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031238, U19AI034580, U01AI034580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; GORHAM J, UNPUB; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; ROBERTS M, 1993, EUR J IMMUNOGENET, V20, P349, DOI 10.1111/j.1744-313X.1993.tb00154.x; SADICK MD, 1986, J IMMUNOL, V136, P655; SADICK MD, 1987, J IMMUNOL, V139, P1303; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TITUS RG, 1985, J IMMUNOL, V135, P2108; YANAGIDA T, 1994, J IMMUNOL, V152, P4919	33	331	334	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					984	987						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584935				2022-12-01	WOS:A1996TV70400048
J	Beale, J				Beale, J			Reconsidering an attenuated vaccine for AIDS	LANCET			English	Editorial Material																		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BEALE J, 1995, LANCET, V345, P1318, DOI 10.1016/S0140-6736(95)92532-5; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; HILLEMAN MR, 1995, NAT MED, V1, P1126, DOI 10.1038/nm1195-1126; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; RUD EW, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P217; SABIN AB, 1993, NATURE, V362, P212, DOI 10.1038/362212a0	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					344	345		10.1016/S0140-6736(96)90532-2	http://dx.doi.org/10.1016/S0140-6736(96)90532-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598696				2022-12-01	WOS:A1996TU69500004
J	Clemens, J; Brenner, R; Rao, M; Tafari, N; Lowe, C				Clemens, J; Brenner, R; Rao, M; Tafari, N; Lowe, C			Evaluating new vaccines for developing countries - Efficacy or effectiveness?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VI-CAPSULAR POLYSACCHARIDE; BOVINE ROTAVIRUS VACCINE; ENTERIC-COATED CAPSULES; TITER MEASLES-VACCINES; CONTROLLED FIELD TRIAL; ORAL CHOLERA VACCINES; CHILDHOOD TUBERCULOSIS; CONJUGATE VACCINE; TYPHOID VACCINE; ANTIBODY-RESPONSE	Despite the profusion of promising new vaccines against illnesses prevalent in developing countries, uncertainties about the balance between costs and benefits of new vaccines have retarded their use in public health practice. Conventional prelicensure trials of vaccine protection exacerbate these uncertainties by focusing on measurement of vaccine efficacy-the performance of a vaccine under idealized conditions. Vaccine effectiveness trials provide a more pragmatic perspective by addressing the performance of a vaccine under the ordinary conditions of a public health program, by capturing direct as well as indirect effects of vaccination, and by comprehensively addressing outcomes of public health concern. The use of effectiveness trials should enable more rational triaging of new vaccines for developing countries and may accelerate the introduction of new vaccines into public health practice by resolving speculative debates about practical costs and benefits.	NICHHD, DIV EPIDEMIOL STAT & PREVENT RES, BETHESDA, MD 20892 USA; NICHHD, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1988, LANCET, V2, P809; ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; [Anonymous], 1981, Int J Epidemiol, V10, P73; [Anonymous], 1993, WORLD DEV REPORT INV; [Anonymous], 1992, WKLY EPIDEMIOL REC, V67, P357; BASCH PF, 1994, VACCINES WORLD HLTH, P95; BEGG N, 1990, VACCINE, V8, P180, DOI 10.1016/0264-410X(90)90042-K; BINKIN N, 1982, LANCET, V2, P315; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLOK L, 1994, LANCET, V344, P1022; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; CLEMENS J, 1990, PROSPECTS PUBLIC HLT, P131; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515; CLEMENS JD, 1984, REV INFECT DIS, V6, P589; CLEMENS JD, 1988, LANCET, V1, P1375; CLEMENS JD, 1990, NEW GENERATION VACCI, P51; Clemens John, 1994, P425; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; COMSTOCK GW, 1994, EPIDEMIOL REV, V16, P77, DOI 10.1093/oxfordjournals.epirev.a036147; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; DEMOL P, 1986, LANCET, V2, P108; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; DRUMMOND MF, 1987, HEALTH POLICY, V7, P309, DOI 10.1016/0168-8510(87)90072-8; EGAN W, 1995, JAMA-J AM MED ASSOC, V273, P888; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FEDSON DS, 1990, PROSPECTS PUBLIC HLT, P131; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; GARENNE M, 1993, AM J EPIDEMIOL, V138, P182, DOI 10.1093/oxfordjournals.aje.a116844; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; Greenwood M, 1915, Proc R Soc Med, V8, P113; HALL AJ, 1989, LANCET, V1, P1057; HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777; HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004; HALLORAN ME, 1991, AM J EPIDEMIOL, V133, P323, DOI 10.1093/oxfordjournals.aje.a115884; HANLON P, 1987, LANCET, V1, P1342; HARRINGTON D, 1990, NEW GENERATION VACCI, P43; HENDRICKSE RG, 1975, T ROY SOC TROP MED H, V69, P31, DOI 10.1016/0035-9203(75)90007-3; HLADY WG, 1992, AM J PUBLIC HEALTH, V82, P1365, DOI 10.2105/AJPH.82.10.1365; HULL HF, 1983, LANCET, V1, P972; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; KLUGMAN KP, 1987, LANCET, V2, P1165; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; LAGOS R, IN PRESS PEDIATR INF; LANATA CF, 1989, J INFECT DIS, V159, P452, DOI 10.1093/infdis/159.3.452; LEE JW, 1994, SCIENCE, V266, P527, DOI 10.1126/science.7939695; LEVINE MM, 1987, LANCET, V1, P1049; LEVINE MM, 1990, LANCET, V336, P891; Markowitz LE, 1994, VACCINES, P229; MCINTYRE RC, 1982, B WORLD HEALTH ORGAN, V60, P767; MELNICK JL, 1994, VACCINES, P155; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PADUNGCHAN S, 1986, B WORLD HEALTH ORGAN, V64, P247; PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PICHICHERO ME, 1990, J INFECT DIS, V162, P753, DOI 10.1093/infdis/162.3.753; PIERCE NF, 1994, LANCET, V344, P1022, DOI 10.1016/S0140-6736(94)91682-9; REINGOLD AL, 1985, LANCET, V2, P114; ROBBINS A, 1993, PEDIATR INFECT DIS J, V12, P523, DOI 10.1097/00006454-199306000-00012; SACK DA, 1994, LANCET, V344, P616, DOI 10.1016/S0140-6736(94)92003-6; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SACKETT DL, 1983, CLIN TRIALS, P65; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHWARTZ D, 1980, CLIN TRIALS; SHAPIRO C, 1985, INT J EPIDEMIOL, V14, P441, DOI 10.1093/ije/14.3.441; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; SMITH PG, 1982, TUBERCLE, V63, P23, DOI 10.1016/S0041-3879(82)80006-8; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STANFORD JL, 1987, TUBERCLE, V68, P169, DOI 10.1016/0041-3879(87)90052-3; SWERDLOW DL, 1994, LANCET, V344, P1302, DOI 10.1016/S0140-6736(94)90793-5; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; VADHEIM CM, 1994, ARCH PEDIAT ADOL MED, V148, P51, DOI 10.1001/archpedi.1994.02170010053011; VESIKARI T, 1984, LANCET, V1, P977; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; Weinstein M. C., 1980, CLIN DECISION ANAL, P228; WHITTLE H, 1988, LANCET, V2, P811; 1985, EXPANDED PROGRAMME I, V7, P1; 1991, WKLY EPIDEMIOL REC, V66, P259; 1994, MMWR-MORBID MORTAL W, V43, P144; 1990, WIKLY EPIDEMIOL REC, V65, P2	87	134	138	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					390	397		10.1001/jama.275.5.390	http://dx.doi.org/10.1001/jama.275.5.390			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569019				2022-12-01	WOS:A1996TT30300033
J	Kizer, KW				Kizer, KW			Nasopharyngeal radium treatment of veterans	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Kizer, KW (corresponding author), DEPT VET AFFAIRS,OFF PUBL HLTH & ENVIRONM HAZARDS,810 VERMONT AVE NW,WASHINGTON,DC 20420, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					351	351						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569001				2022-12-01	WOS:A1996TT30300007
J	Dewsnup, DH; Galgiani, JN; Graybill, JR; Diaz, M; Rendon, A; Cloud, GA; Stevens, DA				Dewsnup, DH; Galgiani, JN; Graybill, JR; Diaz, M; Rendon, A; Cloud, GA; Stevens, DA			Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?	ANNALS OF INTERNAL MEDICINE			English	Article						coccidioidomycosis; meningitis, fungal; azoles; triazoles; recurrence	ITRACONAZOLE THERAPY; FLUCONAZOLE THERAPY; KETOCONAZOLE; ANTIFUNGAL; MYCOSES	Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral atole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to atole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom atole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular atole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving atole therapy and 2) that discontinuing atole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even longterm triazole therapy.	SANTA CLARA VALLEY MED CTR, DEPT MED, DIV INFECT DIS, SAN JOSE, CA 95128 USA; VET AFFAIRS MED CTR, DEPT MED, DIV INFECT DIS, TUCSON, AZ 85723 USA; UNIV TEXAS, HLTH SCI CTR, DEPT INFECT DIS, AUDIE MURPHY VET AFFAIRS HOSP, SAN ANTONIO, TX 78284 USA; UNIV ALABAMA, MED CTR, TUMOR INST, BIRMINGHAM, AL 35294 USA; CALIF INST MED RES, SAN JOSE, CA 95128 USA; STANFORD UNIV, SCH MED, STANFORD, CA 94305 USA; NIAID, MYCOSES STUDY GRP, BETHESDA, MD USA; UNIV ARIZONA, TUCSON, AZ USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; UNIV AUTONOMA NUEVO LEON, MONTERREY, MEXICO; UNIV HOSP, MONTERREY, MEXICO	Santa Clara Valley Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Texas System; University of Texas Health San Antonio; University of Alabama System; University of Alabama Birmingham; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Arizona; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon			A., Rendon/AAE-5931-2021; Rendon, Adrian/S-1531-2017; Galgiani, John/GLT-7012-2022	A., Rendon/0000-0001-8973-4024; Rendon, Adrian/0000-0001-8973-4024; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT J, 1990, FLUCONAZOLE OVERVIEW, P1; BORELLI D, 1979, POSTGRAD MED J, V55, P657, DOI 10.1136/pgmj.55.647.657; CAUWENBERGH G, 1990, J AM ACAD DERMATOL, V23, P549; DENNING DW, 1990, MYCOSES IN AIDS PATIENTS, P305; DEWSNUP DH, 1991, 31ST INT C ANT AG CH, P1156; DIAZ M, 1992, CLIN INFECT DIS, V14, pS68, DOI 10.1093/clinids/14.Supplement_1.S68; DUPONT B, 1988, 10TH P C INT SOC HUM, P197; EINSTEIN HE, 1961, CALIF MED, V94, P339; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; Graybill J R, 1988, Ann N Y Acad Sci, V544, P488, DOI 10.1111/j.1749-6632.1988.tb40446.x; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; Kelly PC., 1980, COCCIDIOIDOMYCOSIS T, P163; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; RESTREPO A, 1980, REV INFECT DIS, V2, P519; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; STEVENS DA, 1983, DRUGS, V26, P347, DOI 10.2165/00003495-198326040-00004; STEVENS DA, 1986, INFECTIOUS DISEASES; TUCKER RM, 1990, J AM ACAD DERMATOL, V23, P593, DOI 10.1016/0190-9622(90)70261-F; TUCKER RM, 1990, REV INFECT DIS, V12, pS380; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; 1993, MMWR-MORBID MORTAL W, V42, P21	23	130	135	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					305	+		10.7326/0003-4819-124-3-199602010-00004	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554225				2022-12-01	WOS:A1996TR59600004
J	Steegmans, PHA; Fekkes, D; Hoes, AW; Bak, AAA; vanderDoes, E; Grobbee, DE				Steegmans, PHA; Fekkes, D; Hoes, AW; Bak, AAA; vanderDoes, E; Grobbee, DE			Low serum cholesterol concentration and serotonin metabolism in men	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,SECT PATHOPHYSIOL BEHAV,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; KAPLAN JR, 1994, PSYCHOSOM MED, V56, P479, DOI 10.1097/00006842-199411000-00001; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; SALTER M, 1992, LANCET, V339, P1169	5	109	111	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					221	221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563588	Green Published			2022-12-01	WOS:A1996TT48600028
J	WiedauPazos, M; Goto, JJ; Rabizadeh, S; Gralla, EB; Roe, JA; Lee, MK; Valentine, JS; Bredesen, DE				WiedauPazos, M; Goto, JJ; Rabizadeh, S; Gralla, EB; Roe, JA; Lee, MK; Valentine, JS; Bredesen, DE			Altered reactivity of superoxide dismutase in farmilial amyotrophic lateral sclerosis	SCIENCE			English	Article							HYDROGEN-PEROXIDE; COPPER; ENZYME	A subset of individuals with familiar amyotrophic lateral sclerosis (FALS) possesses dominantly inherited mutations in the gene that encodes copper-zinc superoxide dismutase (CuZnSOD). A4V and G93A, two of the mutant enzymes associated with FALS, were shown to catalyze the oxidation of a model substrate (spin trap 5,5'-dimethyl-1-pyrroline N-oxide) by hydrogen peroxide at a higher rate than that seen with the wild-type enzyme. Catalysis of this reaction by A4V and G93A was more sensitive to inhibition by the copper chelators diethyldithiocarbamate and penicillamine than was catalysis by wild-type CuZnSOD. The same two chelators reversed the apoptosis-inducing effect of mutant enzymes expressed in a neural cell line. These results suggest that oxidative reactions catalyzed by mutant CuZnSOD enzymes initiate the neuropathologic changes in FALS.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INTERDEPARTMENTAL PROGRAM NEUROSCI, LOS ANGELES, CA 90095 USA; LA JOLLA CANC RES FDN, PROGRAM AGING, LA JOLLA, CA 92037 USA; LOYOLA MARYMOUNT UNIV, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90045 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21218 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Sanford Burnham Prebys Medical Discovery Institute; Loyola Marymount University; Johns Hopkins University			Lee, Michael K/D-9491-2013; Valentine, Joan S/B-6665-2008	Lee, Michael K/0000-0001-5865-9682; Valentine, Joan S/0000-0002-7174-925X	NIA NIH HHS [AG12282] Funding Source: Medline; NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM28222] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN RH, CELL, V687, P95; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; DAMANI LA, 1989, SULPHUR CONTAINING D, V3; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DURAND M M, 1990, Society for Neuroscience Abstracts, V16, P40; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GANDARA DR, 1995, J CLIN ONCOL, V13, P490, DOI 10.1200/JCO.1995.13.2.490; GOTO JJ, UNPUB; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JOYCE DA, 1993, AGENT ACTION SUPPL, V44, P203; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MISRA HP, 1979, J BIOL CHEM, V254, P1623; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; REINKE LA, 1994, FREE RADICAL RES, V21, P213, DOI 10.3109/10715769409056573; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	28	639	650	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					515	518		10.1126/science.271.5248.515	http://dx.doi.org/10.1126/science.271.5248.515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560268				2022-12-01	WOS:A1996TR32200045
J	Gravholt, CH; Juul, S; Naeraa, RW; Hansen, J				Gravholt, CH; Juul, S; Naeraa, RW; Hansen, J			Prenatal and postnatal prevalence of Turner's syndrome: A registry study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHROMOSOMAL MOSAICISM; 45,X/46,XY MOSAICISM; MATERNAL AGE; MONOSOMY-X; ABNORMALITIES; AMNIOCENTESIS; DIAGNOSIS; PREGNANCY; CHILDREN; ORIGIN	Objective-To study prevalence of Turner's syndrome in Denmark and to assess validity of prenatal diagnosis. Design-Study of data on prenatal and postnatal Turner's syndrome in Danish Cytogenetic Central Register. Subjects-All registered Turner's syndrome karyotypes (100 prenatal cases and 215 postnatal cases) during 1970-93. Main outcome measures-Prevalence of Turner's syndrome karyotypes among prenatally tested fetuses and Turner's syndrome among liveborn infants. Results-Among infant girls, prevalence of Turner's syndrome was 32/100000. Among female fetuses tested by amniocentesis, prevalence of Turner's syndrome karyotypes was 176/100000 (relative risk of syndrome, 6.74 compared with prevalence among untested pregnancies). Among female fetuses tested by chorion villus sampling, prevalence of syndrome karyotypes was 392/100000 (relative risk, 16.8). We excluded prenatal tests referred because of results of ultrasound scanning: among fetuses tested by amniocentesis revised relative risk was 5.68, while revised relative risk among fetuses tested by chorion villus sampling was 13.3. For 29 fetuses with prenatal diagnosis of possible Turner's syndrome, pregnancy was allowed to continue and 24 children were live born. Thirteen of these children were karyotyped postnatally, and diagnosis of Turner's syndrome had to be revised for eight, seven being normal girls and one boy, This gives tentative predictive value of amniocentesis in diagnosing Turner's syndrome of betmeen 21% and 67%. There was no significant relation between mother's age and risk of Turner's syndrome. Conclusions-Discrepancy between prenatal and postnatal prevalence of Turner's syndrome challenges specificity of prenatal examination in diagnosing Turner's syndrome.	AARHUS UNIV, DEPT EPIDEMIOL & SOCIAL MED, AARHUS, DENMARK; AARHUS UNIV HOSP, AARHUS KOMMUNEHOSP, PAEDIAT DEPT A, DK-8000 AARHUS C, DENMARK; AARHUS UNIV HOSP, AARHUS PSYCHIAT HOSP, DANISH CYTOGENET CENT REGISTER, DK-8000 AARHUS C, DENMARK	Aarhus University; Aarhus University; Aarhus University	Gravholt, CH (corresponding author), AARHUS UNIV HOSP, AARHUS KOMMUNEHOSP, MED DEPT M ENDOCRINOL & DIABET, DK-8000 AARHUS C, DENMARK.		Gravholt, Claus H./Z-1435-2018	Gravholt, Claus H./0000-0001-5924-1720				BERNASCONI S, 1994, ACTA PAEDIATR, V83, P292, DOI 10.1111/j.1651-2227.1994.tb18097.x; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CAROTHERS AD, 1980, ANN HUM GENET, V43, P355, DOI 10.1111/j.1469-1809.1980.tb01570.x; CHANG HJ, 1990, AM J HUM GENET, V46, P156; CONNOR JM, 1989, ACTA PAEDIATR SCAND, P77; GRAVHOLT CH, 1991, HUM GENET, V88, P49, DOI 10.1007/BF00204928; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; HOOK EB, 1989, AM J HUM GENET, V45, P855; IMAIZUMI K, 1993, INT CONGR SER, V1014, P3; JACOBS PA, 1974, ANN HUM GENET, V37, P359, DOI 10.1111/j.1469-1809.1974.tb01843.x; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; KAJII T, 1979, HUM GENET, V51, P147, DOI 10.1007/BF00287168; KEIDING N, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131b; KULKARNI R, 1989, PRENATAL DIAG, V9, P439, DOI 10.1002/pd.1970090610; LARSEN T, 1995, CLIN GENET, V48, P6; LIPPE B, 1991, ENDOCRIN METAB CLIN, V20, P121, DOI 10.1016/S0889-8529(18)30284-6; LORDASANCHEZ I, 1992, AM J MED GENET, V42, P487, DOI 10.1002/ajmg.1320420414; LOUGHLIN SAR, 1991, J MED GENET, V28, P156, DOI 10.1136/jmg.28.3.156; MARTIN RH, 1987, AM J HUM GENET, V41, P484; MIKKELSEN M, 1992, PRAENATALE UNDERSOGE, P1; MINY P, 1991, PRENATAL DIAG, V11, P581, DOI 10.1002/pd.1970110815; NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097; NISANI R, 1989, PRENATAL DIAG, V9, P223, DOI 10.1002/pd.1970090402; ROLAND B, 1990, PRENATAL DIAG, V10, P333, DOI 10.1002/pd.1970100509; SCHWINGER E, 1989, PRENATAL DIAG, V9, P639, DOI 10.1002/pd.1970090907; THARAPEL AT, 1989, PRENATAL DIAG, V9, P467, DOI 10.1002/pd.1970090703; TOMKINS DJ, 1989, PRENATAL DIAG, V9, P139, DOI 10.1002/pd.1970090210; VILLAMAR M, 1990, ANN GENET-PARIS, V33, P29; WARBURTON D, 1980, LANCET, V1, P167; WHEELER M, 1988, AM J MED GENET, V29, P565, DOI 10.1002/ajmg.1320290314	32	120	129	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					16	21		10.1136/bmj.312.7022.16	http://dx.doi.org/10.1136/bmj.312.7022.16			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555850	Green Published			2022-12-01	WOS:A1996TP20900017
J	Nightingale, SL				Nightingale, SL			New cancer therapy initiatives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-01	WOS:A1996UF47800009
J	Ball, JM; Tian, P; Zeng, CQY; Morris, AP; Estes, MK				Ball, JM; Tian, P; Zeng, CQY; Morris, AP; Estes, MK			Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein	SCIENCE			English	Article							HEAT-STABLE ENTEROTOXIN; ESCHERICHIA-COLI; GUANYLATE-CYCLASE; MURINE ROTAVIRUS; GNOTOBIOTIC PIGS; PATHOGENESIS; INFECTION; MICE; SITES; SEQUENCE	The rotavirus nonstructural glycoprotein NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope as subviral particles bud into the endoplasmic reticulum. NSP4 also causes an increase in intracellular calcium in insect cells. Purified NSP4 or a peptide corresponding to NSP4 residues 114 to 135 induced diarrhea in young (6 to 10 days old) CD1 mice. This disease response was age-dependent, dose-dependent, and specific. Electrophysiologic data from intestinal mucosa showed that the NSP4 114-135 peptide potentiates chloride secretion by a calcium-dependent signaling pathway. Diarrhea is induced when NSP4, acting as a viral enterotoxin, triggers a signal transduction pathway.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT INTEGRAT BIOL,HOUSTON,TX 77030	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston					NIDDK NIH HHS [DK 30144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030144, R56DK030144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL JM, 1994, J IMMUNOL METHODS, V171, P37, DOI 10.1016/0022-1759(94)90226-7; BOTH GW, 1983, J VIROL, V48, P335, DOI 10.1128/JVI.48.2.335-339.1983; BURGESS MN, 1978, INFECT IMMUN, V21, P526, DOI 10.1128/IAI.21.2.526-531.1978; BURNS JW, 1995, VIROLOGY, V207, P143, DOI 10.1006/viro.1995.1060; CARPINO LA, 1970, J AM CHEM SOC, V92, P5748, DOI 10.1021/ja00722a043; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLINS J, 1988, J PEDIATR GASTR NUTR, V7, P264, DOI 10.1097/00005176-198803000-00017; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; ESTES MK, 1983, CURR TOP MICROBIOL, V105, P123; FENG NG, 1994, J VIROL, V68, P7766, DOI 10.1128/JVI.68.12.7766-7773.1994; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GIANNELLA RA, 1983, AM J PHYSIOL, V245, pG492, DOI 10.1152/ajpgi.1983.245.4.G492; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GRAHAM DY, 1984, DIGEST DIS SCI, V29, P1028, DOI 10.1007/BF01311255; Greenberg H B, 1994, Curr Top Microbiol Immunol, V185, P255; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; HALVORSRUD J, 1980, SCAND J INFECT DIS, V12, P161, DOI 10.3109/inf.1980.12.issue-3.01; HOLZEL H, 1980, J INFECTION, V2, P33, DOI 10.1016/S0163-4453(80)91750-8; HOSHINO Y, 1995, VIROLOGY, V209, P274, DOI 10.1006/viro.1995.1255; JIANG X, 1990, Science (Washington D C), V250, P1580; JOHNSON GP, 1986, ANAL CHEM, V58, P1084; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAPIKIAN AC, 1996, VIROLOGY, pCH55; KRAUSE WJ, 1990, CELL TISSUE RES, V260, P387, DOI 10.1007/BF00318641; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LITTLE LM, 1982, INFECT IMMUN, V38, P755, DOI 10.1128/IAI.38.2.755-763.1982; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MCADARAGH JP, 1980, AM J VET RES, V41, P1572; MEBUS CA, 1976, AM J DIG DIS, V21, P592, DOI 10.1007/BF01464768; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; NOVITSKY TJ, 1984, OCEANUS, V27, P13; OSBORNE MP, 1988, J PEDIATR GASTR NUTR, V7, P236, DOI 10.1097/00005176-198803000-00014; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; RAMIG RF, 1988, MICROB PATHOGENESIS, V4, P189, DOI 10.1016/0882-4010(88)90069-1; REED L. J., 1938, AMER JOUR HYG, V27, P493; SAIF LJ, IN PRESS P SAPP INT; SEARS CL, 1995, INFECTIONS GASTROINT, pCH44; STARKEY WG, 1986, J GEN VIROL, V67, P2625, DOI 10.1099/0022-1317-67-12-2625; THEIL KW, 1978, AM J VET RES, V39, P213; TIAN P, 1995, J VIROL, V69, P5763, DOI 10.1128/JVI.69.9.5763-5772.1995; TIAN P, 1994, J VIROL, V68, P251, DOI 10.1128/JVI.68.1.251-257.1994; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; ZENG CQY, IN PRESS J VIROL; [No title captured]	45	479	509	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					101	104		10.1126/science.272.5258.101	http://dx.doi.org/10.1126/science.272.5258.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600515				2022-12-01	WOS:A1996UD59700047
J	Seiwert, SD; Heidmann, S; Stuart, K				Seiwert, SD; Heidmann, S; Stuart, K			Direct visualization of uridylate deletion in vitro suggests a mechanism for kinetoplastid RNA editing	CELL			English	Article							MITOCHONDRIAL EXTRACTS; LEISHMANIA-TARENTOLAE; MESSENGER-RNAS; MOLECULES; INVITRO; SITES	Deletion of uridylates from the 3'-most editing site of synthetic ATPase 6 pre-mRNA can be visualized directly by coincubation of a radiolabeled substrate RNA and a synthetic gRNA in 20S fractions of T. brucei mitochondrial lysates. Substrate RNA cleavage is gRNA directed and occurs 3' to the uridylates to be deleted. U residues appear to be sequentially removed from the 3' end of the 5' cleavage product prior to religation of the two pre-mRNA halves. gRNA/mRNA chimeric molecules are also produced. Time course experiments indicate that chimeras appear after cleavage intermediates and edited product. Furthermore, a mutant gRNA promotes formation of edited product but not detectable chimeras. Our results suggest a model for kinetoplastid RNA editing in which chimeric molecules are nonproductive end products of editing and not intermediates that serve as a repository for deleted U's.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Seiwert, SD (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.				NIGMS NIH HHS [GM42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTS GJ, 1993, EMBO J, V12, P1523, DOI 10.1002/j.1460-2075.1993.tb05796.x; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CORELL RA, 1996, MOL CELL BIOL, V16; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1991, CELL, V67, P637; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; PILLER KJ, 1995, MOL CELL BIOL, V15, P2916; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SEIWERT SD, 1995, PARASITOL TODAY, V11, P362, DOI 10.1016/0169-4758(95)80004-2; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SIMPSON AM, 1992, J BIOL CHEM, V267, P6782; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3276	33	177	179	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					831	841		10.1016/S0092-8674(00)81062-4	http://dx.doi.org/10.1016/S0092-8674(00)81062-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601307	Bronze			2022-12-01	WOS:A1996UC38100005
J	Thomas, DHV; Noyce, PR				Thomas, DHV; Noyce, PR			Over the counter drugs - The interface between self medication and the NHS	BRITISH MEDICAL JOURNAL			English	Article								Cost and convenience seem to be major factors in determining whether, given the choice, patients purchase a medicine over the counter or obtain it on prescription. With current arrangements, exemption from prescription charges provides an incentive to continue to obtain products on NHS prescription even when they are available over the counter. There is therefore no simple relation between the availability of over the counter medicines and the level of prescribing of deregulated products. The appropriate use of over the counter medicines-particularly those that have only recently been deregulated-places a burden of care on community pharmacists and calls for closer working relationships with general practitioners. In particular, systems for referral and for recording details of both prescribed and over the counter medicines need to be developed, and a direct route needs to be established for community pharmacists to report adverse drug reactions to over the counter products.	UNIV MANCHESTER,DEPT PHARM,MANCHESTER M13 9PL,LANCS,ENGLAND; ST JOHNS HLTH CTR,WOKING GU21 1TD,SURREY,ENGLAND	University of Manchester								BAHRA MS, 1994, PHARM J, V253, pR10; BLENKINSOPP A, 1991, BRIT J GEN PRACT, V41, P116; BRADLEY C, 1995, PRESCRIBER      0305, P75; *BRIT MARK RES BUR, 1987, EVERYDAY HLTH CARE C; COLWELL J, 1993, PHARM J, V251, P194; Consumers' Association, 1991, WHICH WAY HLTH, P191; HEAD S, 1994, BRIT MED J, V309, P957, DOI 10.1136/bmj.309.6959.957a; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; NOYCE PR, 1992, INT J PHARM PRACT, V1, P122; NOYCE PR, 1995, PARLIAMENTARY BREIF, V3, P85; *PROPR ASS GREAT B, 1995, OTC DIR 1995 6; Rogers PJ, 1994, INT J PHARM PRACT, V3, P6; ROGERS PJ, 1992, PHARM J, V248, P193; RYAN M, 1990, HEALTH POLICY, V16, P233, DOI 10.1016/0168-8510(90)90424-C; SCHAFHEUTLE EL, 1994, THESIS U MANCHESTER; TERMIN P, 1983, J HLTH EC, V2, P187; THOM C, 1994, PHARM J, V253, P616; 1994, OTG BUSINESS NE 0706, P13; 1994, READERS DIGEST	19	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					688	691						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597739				2022-12-01	WOS:A1996UB11000032
J	Grimm, S; Pflugfelder, GO				Grimm, S; Pflugfelder, GO			Control of the gene optomotor-blind in Drosophila wing development by decapentaplegic and wingless	SCIENCE			English	Article							SEGMENT-POLARITY GENE; PATTERN-FORMATION; IMAGINAL DISKS; BETA HOMOLOG; MELANOGASTER; EXPRESSION; MUTATIONS; TRANSCRIPT; DIRECTS; SYSTEM	Diffusible factors of several protein families control appendage outgrowth and patterning in both insects and vertebrates. In Drosophila wing development, the gene decapentaplegic (dpp) is expressed along the anteroposterior compartment boundary. Early wingless (wg) expression is involved in setting up the dorsoventral boundary. Interaction between dpp- and wg-expressing cells promotes appendage outgrowth. Here, it is shown that optomotor-blind (omb) expression is required for distal wing development and is controlled by both dpp and wg. Ectopic omb expression can lead to the growth of additional wings. Thus, omb is essential for wing development and is controlled by two signaling pathways.	UNIV WURZBURG,THEODOR BOVERI INST,BIOZENTRUM,LEHRSTUHL GENET,D-97074 WURZBURG,GERMANY	University of Wurzburg			Pflugfelder, Gert/ABG-9562-2021					BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BALLES J, UNPUB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BAUSENWEIN B, 1994, GENE DEV, V8, P2137; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; BOWNES M, 1981, DIFFERENTIATION, V18, P89, DOI 10.1111/j.1432-0436.1981.tb01108.x; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BRYANT PJ, 1993, SCIENCE, V259, P471, DOI 10.1126/science.8424169; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; BURATOVICH MA, 1995, DEV BIOL, V168, P452, DOI 10.1006/dbio.1995.1094; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GELBART WM, 1989, DEVELOPMENT, V107, P65; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1994, BIOESSAYS, V16, P627, DOI 10.1002/bies.950160906; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PFLUGFELDER GO, 1995, COMP BIOCHEM PHYS A, V110, P185, DOI 10.1016/0300-9629(94)00159-Q; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; POECK B, 1993, DEVELOPMENT, V117, P1017; POECK B, 1993, MOL GEN GENET, V238, P325, DOI 10.1007/BF00291990; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; SMITH JC, 1991, CELL, V67, P1; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; SUN YH, 1995, GENETICS, V141, P1075; TABATA T, 1995, DEVELOPMENT, V121, P3359; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	188	193	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1601	1604		10.1126/science.271.5255.1601	http://dx.doi.org/10.1126/science.271.5255.1601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599120				2022-12-01	WOS:A1996TZ98300047
J	Nordlee, JA; Taylor, SL; Townsend, JA; Thomas, LA; Bush, RK				Nordlee, JA; Taylor, SL; Townsend, JA; Thomas, LA; Bush, RK			Identification of a Brazil-nut allergen in transgenic soybeans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BERTHOLLETIA-EXCELSA; RICH PROTEIN; METHIONINE; EXPRESSION; ALBUMIN	Background The nutritional qulaity of soybeans (Glycine maul is compromised by a relative deficiency of methionine in the protein fraction of the seeds. To improve the nutritional quality, methionine-rich 2S albumin from the Brazil nut (Bertholletia excelsa) has been introduced into transgenic soybeans. Since the Brazil nut is a known allergenic food, we assessed the allergenicity of the 2S albumin. Methods. The ability of proteins in transgenic and nontransgenic soybeans, Brazil nuts, and purified 25 albumin to bind to IgE in serum from subjects allergic to Brazil nuts was determined by radioallergosorbent tests (four subjects) and sodium dodecyl sulfate-polyacrylamide-gel electrophoresis (nine subjects) with immunoblotting and autoradiography. Three subjects also underwent skin-prick testing with extracts of soybean, transgenic soybean, and Brazil nut. Results On radioallergosorbent testing of pooled serum from four subjects allergic to Brazil nuts, protein extracts of transgenic soybean inhibited binding of IgE to Brazil-nut proteins. On immunoblotting, serum IgE from eight of nine subjects bound to purified 2S albumin from the Brazil nut and to proteins of similar molecular weight in the Brazil nut and the transgenic soybean. On skin-prick testing, three subjects had positive reactions to extracts of Brazil nut and transgenic soybean and negative reactions to soybean extract. Conclusions. The 2S albumin is probably a major Brazil-nut allergen, and the transgenic soybeans analyzed in this study contain this protein. Our study shows that an allergen from a food known to be allergenic can be transferred into another food by genetic engineering.	PIONEER HI BRED INT INC,RES & PROD DEV,JOHNSTON,IA; UNIV WISCONSIN,DEPT MED,MADISON,WI; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; WILLIAM S MIDDLETON MEM VET AFFAIRS HOSP,MADISON,WI	DuPont; Pioneer Hi-Bred International, Inc.; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nordlee, JA (corresponding author), UNIV NEBRASKA,DEPT FOOD SCI & TECHNOL,LINCOLN,NE 68583, USA.		Taylor, Steve L./V-1341-2019					ALDOPHSON CR, 1986, MANUAL CLIN LAB IMMU, P652; ALTENBACH SB, 1987, PLANT MOL BIOL, V8, P239, DOI 10.1007/BF00015032; ALTENBACH SB, 1989, PLANT MOL BIOL, V13, P513, DOI 10.1007/BF00027311; ALTENBACH SB, 1992, PLANT MOL BIOL, V18, P235, DOI 10.1007/BF00034952; ARAGAO FJL, 1992, PLANT MOL BIOL, V20, P357, DOI 10.1007/BF00014508; ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; AUKRUST L, 1978, INT ARCH ALLER A IMM, V57, P253, DOI 10.1159/000232110; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; CAREY B, 1993, HEALTH, V7, P24; FOX JL, 1994, BIO-TECHNOL, V12, P568; GUERCHE P, 1990, MOL GEN GENET, V221, P306, DOI 10.1007/BF00259393; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melo Vania Maria Maciel, 1994, Food and Agricultural Immunology, V6, P185, DOI 10.1080/09540109409354829; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Norman P, 1986, MANUAL CLIN LABORATO, P660; SAALBACH I, 1994, MOL GEN GENET, V242, P226, DOI 10.1007/BF00391017; SNYDER J, 1992, LONGEVITY, V4, P52; SUN SSM, 1987, J AGR FOOD CHEM, V35, P232, DOI 10.1021/jf00074a016; TAYLOR SL, 1992, FOOD TECHNOL-CHICAGO, V46, P146; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND JA, 1994, J CELL BIOCH SA, V18, P78; Utsumi S, 1992, Adv Food Nutr Res, V36, P89, DOI 10.1016/S1043-4526(08)60105-9; 1992, FED REGISTER, V57, P22984	27	436	492	4	135	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					688	692		10.1056/NEJM199603143341103	http://dx.doi.org/10.1056/NEJM199603143341103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594427	Green Published			2022-12-01	WOS:A1996TZ52800003
J	Wetzel, FT				Wetzel, FT			Surgery for herniated vertebral disks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Wetzel, FT (corresponding author), UNIV CHICAGO,DEPT SURG,SECT ORTHOPAED SURG & REHABIL MED,CHICAGO,IL 60637, USA.							BODEN SD, 1990, ORTHOP T, V14, P66; BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013; Mixter WJ, 1934, NEW ENGL J MED, V211, P210, DOI DOI 10.1056/NEJM193408022110506; MORRIS EW, 1986, SPINE, V11, P436, DOI 10.1097/00007632-198606000-00007; MORRIS J, 1988, ORTHOPEDICS, V11, P1483; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; WILLIAMS RW, 1986, SPINE, V11, P851, DOI 10.1097/00007632-198610000-00023	8	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606464				2022-12-01	WOS:A1996TV56900011
J	Neal, KR; Scott, HM; Slack, RCB; Logan, RFA				Neal, KR; Scott, HM; Slack, RCB; Logan, RFA			Omeprazole as a risk factor for campylobacter gastroenteritis: Case-control study	BRITISH MEDICAL JOURNAL			English	Article									NOTTINGHAM HLTH AUTHOR,NOTTINGHAM NG1 6GN,ENGLAND		Neal, KR (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.							GIANNELLA RA, 1972, GUT, V13, P251, DOI 10.1136/gut.13.4.251; GLYNN JR, 1992, EPIDEMIOL INFECT, V109, P371, DOI 10.1017/S0950268800050366; NEAL KR, 1994, BRIT MED J, V308, P176; NORDBRING F, 1962, ACTA MED SCAND, V171, P783; 1993, INTERIM REPORT CAMPY	5	111	111	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					414	415						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601113				2022-12-01	WOS:A1996TW56400022
J	Friedmann, PD; Brett, AS; MayoSmith, MF				Friedmann, PD; Brett, AS; MayoSmith, MF			Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						cardiology; physicians, family; outcome and process; assessment (health care); risk; health promotion	CORONARY-ARTERY DISEASE; DECISION-MAKING; PHYSICIANS; PROBABILITY; SURVIVAL; JUDGMENT; SURGERY; TRIAL; CARE	Objective: To compare generalists' and cardiologists' estimates of baseline cardiovascular risk and the outcomes of preventive therapy. Design: Cross-sectional mail survey using written case simulations of typical patients from primary prevention trials for hypercholesterolemia and isolated systolic hypertension, and tertiary prevention studies of coronary artery bypass surgery for chronic stable angina with left main coronary stenosis, Participants: Nationally representative sample of 599 practicing family physicians, general internists, and cardiologists selected from the American Medical Association masterfile. Among eligible physicians, 84 (44%) of 191 family physicians, 77 (40%) of 194 general internists, and 66 (34%) of 194 cardiologists responded. Measurements: Estimates of risk at baseline and after therapy, and whether therapy generally would be recommended. Results: For both primary prevention case simulations (scenarios), cardiologists provided lower, more accurate estimates of baseline cardiovascular risk and of absolute therapeutic benefit than either family physicians or general internists. The range of the generalists' estimates was extremely wide. Perceptions of relative risk reduction and treatment recommendations for the primary prevention scenarios did not differ among specialties. Overall, generalists who would not recommend primary preventive therapy in these scenarios appeared to give more accurate estimates than did generalists who would recommend such therapy. Conclusions: Many generalists have inflated perceptions of cardiovascular risk without treatment and of the benefit of risk-modifying medical treatment. Further study should assess the reasons for these misperceptions and their effect on counseling about primary preventive therapy.	DEACONESS HOSP, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; VET AFFAIRS MED CTR, MANCHESTER, NH USA	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)								[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1991, MINITAB REFERENCE MA; ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; AYANIAN JZ, 1991, MED DECIS MAKING, V11, P154, DOI 10.1177/0272989X9101100302; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BERWICK DM, 1981, AM J MED, V71, P991, DOI 10.1016/0002-9343(81)90325-9; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Bursztajn HJ, 1981, MED CHOICES MED CHAN; CHAITMAN BR, 1981, AM J CARDIOL, V48, P765, DOI 10.1016/0002-9149(81)90156-9; CHRISTENSENSZALANSKI JJJ, 1981, J EXP PSYCHOL HUMAN, V7, P928, DOI 10.1037/0096-1523.7.4.928; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; DOLAN JG, 1986, MED DECIS MAKING, V6, P216, DOI 10.1177/0272989X8600600406; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; FREIDSON E, 1975, PROFESSION MED; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1995, J GEN INTERN MED, V10, P147, DOI 10.1007/BF02599671; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRELBE J, 1977, BRIT MED J, V2, P1572; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; MANU P, 1984, MED CARE, V22, P366, DOI 10.1097/00005650-198404000-00008; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARTIN BC, 1974, DONT SURVEY PHYSICIA; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PICKERING TG, 1983, JAMA-J AM MED ASSOC, V249, P399, DOI 10.1001/jama.249.3.399; POSES RM, 1991, MED DECIS MAKING, V11, P159, DOI 10.1177/0272989X9101100303; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; REDELMEIER DA, 1991, MED DECIS MAKING, V11, P169, DOI 10.1177/0272989X9101100304; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; REED WW, 1993, J GEN INTERN MED, V8, P591, DOI 10.1007/BF02599710; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Roback G, 1994, PHYSICIAN CHARACTERI; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCHWARTZ S, 1986, MED THINKING PSYCHOL, P162; TAKARO T, 1982, CIRCULATION, V66, P14, DOI 10.1161/01.CIR.66.1.14; TAMBOR ES, 1993, AM J PUBLIC HEALTH, V83, P1599, DOI 10.2105/AJPH.83.11.1599; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; 1990, SAS STAT USERS GUIDE; 1989, GUIDE CLIN PREVENTIV, pR28	51	107	107	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					414	+		10.7326/0003-4819-124-4-199602150-00005	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554250				2022-12-01	WOS:A1996TV22000005
J	Watanabe, G; Saito, Y; Madaule, P; Ishizaki, T; Fujisawa, K; Morii, N; Mukai, H; Ono, Y; Kakizuka, A; Narumiya, S				Watanabe, G; Saito, Y; Madaule, P; Ishizaki, T; Fujisawa, K; Morii, N; Mukai, H; Ono, Y; Kakizuka, A; Narumiya, S			Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho	SCIENCE			English	Article							BOTULINUM C3 EXOENZYME; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; ACTIVATION; REQUIRES; P21	The Rho guanosine 5'-triphosphatase (GTPase) cycles between the active guanosine triphosphate (GTP)-bound form and the inactive guanosine diphosphate-bound form and regulates cell adhesion and cytokinesis, but how it exerts these actions is unknown. The yeast two-hybrid system was used to clone a complementary DNA for a protein (designated Rhophilin) that specifically bound to GTP-Rho. The Rho-binding domain of this protein has 40 percent identity with a putative regulatory domain of a protein kinase, PKN. PKN itself bound to GTP-Rho and was activated by this binding both in vitro and in vivo. This study indicates that a serine-threonine protein kinase is a Rho effector and presents an amino acid sequence motif for binding to GTP-Rho that may be shared by a family of Rho target proteins.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN	Kyoto University; Kobe University				Mukai, Hideyuki/0000-0002-0167-8695				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISHIZAKI T, IN PRESS EMBO J; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABE G, UNPUB, P55215; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	33	352	375	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					645	648		10.1126/science.271.5249.645	http://dx.doi.org/10.1126/science.271.5249.645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571126				2022-12-01	WOS:A1996TT87000045
J	Vito, P; Lacana, E; DAdamio, L				Vito, P; Lacana, E; DAdamio, L			Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; T-CELL HYBRIDOMAS; DNA FRAGMENTATION; ENDONUCLEASE ACTIVATION; THYMOCYTE APOPTOSIS; IMMATURE THYMOCYTES; SUICIDE PROCESS; MESSENGER-RNA; DEATH; INITIATION	Two apoptosis-linked genes, named ALG-2 and ALG-3, were identified by means of a functional selection strategy. ALG-2 codes for a Ca2+-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-3, a partial complementary DNA that is homologous to the familial Alzheimer's disease gene STM2, rescues a T cell hybridoma from T cell receptor- and Fas-induced apoptosis. These findings suggest that ALG-2 may mediate Ca2+-regulated signals along the death pathway and that cell death may play a role in Alzheimer's disease.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,T CELL MOLEC BIOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			vito, pasquale/ABF-5505-2020	D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882; vito, pasquale/0000-0002-5721-7716				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BROWN KS, UNPUB; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CIFONE MG, 1993, J EXP MED, V177, P1547; COHEN JJ, 1984, J IMMUNOL, V132, P38; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGEYAMA H, 1989, BIOCHIM BIOPHYS ACTA, V1008, P255, DOI 10.1016/0167-4781(80)90018-4; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LACANA E, UNPUB; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OSHIMI Y, 1995, J IMMUNOL, V154, P599; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SARIN A, 1995, J IMMUNOL, V154, P5806; SHI YF, 1990, J IMMUNOL, V144, P3326; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; VITO P, UNPUB; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	55	459	477	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					521	525		10.1126/science.271.5248.521	http://dx.doi.org/10.1126/science.271.5248.521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560270	Green Submitted			2022-12-01	WOS:A1996TR32200047
J	Wilson, CJ; Chao, DM; Imbalzano, AN; Schnitzler, GR; Kingston, RE; Young, RA				Wilson, CJ; Chao, DM; Imbalzano, AN; Schnitzler, GR; Kingston, RE; Young, RA			RNA polymerase II holoenzyme contains SWI/SNF regulators involved in chromatin remodeling	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATORS; NEGATIVE REGULATOR; SNF6 PROTEINS; YEAST; GENES; EXPRESSION; SNF2/SWI2; DNA	The RNA polymerase II holoenzyme contains RNA polymerase II, a subset of general transcription factors and SRB regulatory proteins. We report here that SWI and SNF gene products, previously identified as global gene regulators whose functions include remodeling chromatin, are also integral components of the yeast RNA polymerase II holoenzyme. The SWI/SNF proteins are components of the SRB complex, also known as the mediator, which is tightly associated with the RNA polymerase II C-terminal repeat domain. The SWI/SNF components provide the holoenzyme with the capacity to disrupt nucleosomal DNA and thus facilitate stable binding of various components of the transcription initiation complex at promoters.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wilson, CJ (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Chao, David/0000-0001-9198-337X; Wilson, Christopher/0000-0002-9146-522X				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HAPPEL AM, 1991, GENETICS, V128, P69; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1996, IN PRESS METH ENZYMO; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, GENE DEV, V6, P2233; LAURENT BC, 1990, MOL CELL BIOL, V11, P5615; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SHELDON M, 1995, CURR BIOL, V5, P423; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREICH I, 1995, MOL CELL BIOL, V15, P4240; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	336	339	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					235	244		10.1016/S0092-8674(00)80978-2	http://dx.doi.org/10.1016/S0092-8674(00)80978-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565069	Bronze			2022-12-01	WOS:A1996TR59500010
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CHLORZOXAZONE WARNING ON HEPATOTOXICITY IS STRENGTHENED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-01	WOS:A1995TL16900012
J	Lee, A; Thomas, P; Cupidore, L; Serjeant, B; Serjeant, G				Lee, A; Thomas, P; Cupidore, L; Serjeant, B; Serjeant, G			Improved survival in homozygous sickle cell disease: Lessons from a cohort study	BRITISH MEDICAL JOURNAL			English	Article							BONE-MARROW TRANSPLANTATION; CHEST SYNDROME; ANEMIA; CHILDREN; TRANSFUSION; SEPTICEMIA	Objective-To examine whether simple interventions in a sickle cell clinic improve survival in sickle cell disease. Design-Survival curve analysis and hazard ratios in a cohort study followed from birth. Setting-MRC Laboratories (Jamaica) at the University of the West Indies, and Victoria Jubilee Hospital, Kingston, Jamaica. Subject-315 patients with homozygous sickle cell disease detected during the screening of 100 000 consecutive non-operative deliveries between June 1973 and December 1981 at the main government maternity hospital, Kingston, Jamaica. Interventions-Prophylactic penicillin to prevent pneumococcal septicaemia, parental education in early diagnosis of acute splenic sequestration, close monitoring in sickle cell clinic, Main outcome measures-Survival. Results-Survival appeared to improve, the log rank test for trend comparing the first, second, and last third of the study reaching borderline significance (P=0.05). Combined deaths from acute splenic sequestration and pneumococcal septicaemia-meningitis declined significantly (test for trend, P=0 . 02). Conclusion-Early diagnosis and simple prophylactic measures significantly reduce deaths associated with homozygous sickle cell disease.	UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA	University West Indies Mona Jamaica				Thomas, Peter/0000-0003-2478-4324				BEUTLER E, 1991, SEMIN HEMATOL, V28, P263; DAVIES SC, 1984, LANCET, V1, P36; EMOND AM, 1985, J PEDIATR-US, V107, P201, DOI 10.1016/S0022-3476(85)80125-6; FERSTER A, 1992, BRIT J HAEMATOL, V80, P102, DOI 10.1111/j.1365-2141.1992.tb06407.x; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; MALLOUH AA, 1988, AM J DIS CHILD, V142, P178, DOI 10.1001/archpedi.1988.02150020080034; MENTZER WC, 1994, AM J PEDIAT HEMATOL, V16, P27; POWARS D, 1983, PEDIATRICS, V71, P927; POWARS D, 1981, JAMA-J AM MED ASSOC, V245, P1839, DOI 10.1001/jama.245.18.1839; RUSSELL MO, 1984, BLOOD, V63, P162; SERJEANT BE, 1974, CLIN CHEM, V20, P666; SERJEANT GR, 1981, LANCET, V2, P595; STEVENS MCG, 1986, PEDIATRICS, V78, P124; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195	16	131	133	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1600	1602		10.1136/bmj.311.7020.1600	http://dx.doi.org/10.1136/bmj.311.7020.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555802	Green Published			2022-12-01	WOS:A1995TL42200019
J	Aitken, DA; Wallace, EM; Crossley, JA; Swanston, IA; vanPareren, Y; vanMaarle, M; Groome, NP; Macri, JN; Connor, JM				Aitken, DA; Wallace, EM; Crossley, JA; Swanston, IA; vanPareren, Y; vanMaarle, M; Groome, NP; Macri, JN; Connor, JM			Dimeric inhibin a as a marker for Down's syndrome in early pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SERUM ALPHA-FETOPROTEIN; CHROMOSOMALLY ABNORMAL PREGNANCIES; MATERNAL SERUM; UNCONJUGATED ESTRIOL; IMMUNOREACTIVE INHIBIN; RISK; AGE; CHORIOGONADOTROPIN; TRISOMY-18	Background. In screening for Down's syndrome in the second trimester of pregnancy, the concentrations of alpha-fetoprotein, the beta subunit of human chorionic gonadotropin, and intact human chorionic gonadotropin in maternal serum are widely used markers. We investigated a new marker, dimeric inhibin A, and compared its predictive value with that of the established markers. Methods. Serum samples were obtained at 7 to 18 weeks of gestation from 58 women whose fetuses were known to be affected by Down's syndrome, 32 whose fetuses were affected by trisomy 18, and 438 whose fetuses were normal, and the samples were analyzed for each marker. Individual serum concentrations of each marker were converted to multiples of the median value at the appropriate length of gestation in the women with normal pregnancies, and rates of detection of Down's syndrome by screening for inhibin A in various combinations with the other markers were estimated by multivariate analysis. Results. In the women with fetuses affected by Down's syndrome, the serum inhibin A concentrations were 2.06 times the median value in the women with normal pregnancies (P<0.001). This compared with 2.00 times the median for the beta subunit of human chorionic gonadotropin, 1.82 times the median for intact human chorionic gonadotropin, and 0.72 times the median for alphafetoprotein. The serum concentrations of inhibin A in the women with fetuses affected by Down's syndrome did not appear to be significantly elevated above normal until the end of the first trimester and were not significantly different from normal in the women with fetuses affected by trisomy 18 (P=0.17). The rate of detection of Down's syndrome was 53 percent and the false positive rate was 5 percent when alpha-fetoprotein, the beta subunit of human chorionic gonadotropin, and maternal age were used together as predictors. The detection rate increased to 75 percent when inhibin A was added (P=0.002). Conclusions. In the second trimester of pregnancy, measuring inhibin A in maternal serum, in combination with measurements of alpha-fetoprotein and the beta subunit of human chorionic gonadotropin, significantly improved the rate of detection of Down's syndrome. (C) 1996, Massachusetts Medical Society.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND; MRC,CTR REPROD BIOL,REPROD BIOL UNIT,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND; OXFORD BROOKES UNIV,SCH BIOL & MOLEC SCI,OXFORD,ENGLAND; NTD LABS,HUNTINGTON STN,NEW YORK,NY	University of Edinburgh; Oxford Brookes University	Aitken, DA (corresponding author), DUNCAN GUTHRIE INST MED GENET,GLASGOW G3 8SJ,LANARK,SCOTLAND.		Wallace, Euan M/K-6774-2015	Wallace, Euan M/0000-0002-4506-5233				AITKEN DA, 1993, PRENATAL DIAG, V13, P681, DOI 10.1002/pd.1970130804; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; BROCK DJH, 1990, PRENATAL DIAG, V10, P245, DOI 10.1002/pd.1970100406; Canick J. A., 1994, American Journal of Human Genetics, V55, pA9; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; Crossley J A, 1994, J Med Screen, V1, P180; CROSSLEY JA, 1991, PRENATAL DIAG, V11, P83, DOI 10.1002/pd.1970110204; CROSSLEY JA, 1993, PRENATAL DIAG, V13, P271, DOI 10.1002/pd.1970130406; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1994, PRENATAL DIAG, V14, P387, DOI 10.1002/pd.1970140508; CUCKLE HS, 1995, PRENATAL DIAG, V15, P385, DOI 10.1002/pd.1970150416; GOODBURN SF, 1994, PRENATAL DIAG, V14, P391, DOI 10.1002/pd.1970140509; GRAHAM GW, 1992, PRENATAL DIAG, V12, P505, DOI 10.1002/pd.1970120605; GROOME N, 1993, J IMMUNOL METHODS, V165, P167, DOI 10.1016/0022-1759(93)90342-5; GROOME NP, 1994, CLIN ENDOCRINOL, V40, P717, DOI 10.1111/j.1365-2265.1994.tb02504.x; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; MACINTOSH MCM, 1993, PRENATAL DIAG, V13, P563, DOI 10.1002/pd.1970130705; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, 1993, PRENATAL DIAG, V13, P557, DOI 10.1002/pd.1970130704; MACRI JN, 1994, PRENATAL DIAG, V14, P97, DOI 10.1002/pd.1970140204; MCLACHLAN RI, 1987, CLIN ENDOCRINOL, V27, P663, DOI 10.1111/j.1365-2265.1987.tb02949.x; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; QU JP, 1991, J CLIN ENDOCR METAB, V72, P862, DOI 10.1210/jcem-72-4-862; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; ROBERTSON DM, 1995, J ENDOCRINOL, V144, P261, DOI 10.1677/joe.0.1440261; SCHNEYER AL, 1990, J CLIN ENDOCR METAB, V70, P1208, DOI 10.1210/jcem-70-4-1208; SPENCER K, 1994, ANN CLIN BIOCHEM, V31, P447, DOI 10.1177/000456329403100504; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1993, BRIT MED J, V307, P1455, DOI 10.1136/bmj.307.6917.1455; SPENCER K, 1993, ANN CLIN BIOCHEM, V30, P219, DOI 10.1177/000456329303000226; TOVANABUTRA S, 1993, CLIN ENDOCRINOL, V38, P101, DOI 10.1111/j.1365-2265.1993.tb00979.x; VANLITH JMM, 1994, OBSTET GYNECOL, V83, P661; VANLITH JMM, 1992, PRENATAL DIAG, V12, P801, DOI 10.1002/pd.1970121005; WALD NJ, 1988, BRIT MED J, V297, P1029; WALD NJ, 1988, BRIT J OBSTET GYNAEC, V95, P334, DOI 10.1111/j.1471-0528.1988.tb06602.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALLACE EM, 1994, CLIN ENDOCRINOL, V41, P483, DOI 10.1111/j.1365-2265.1994.tb02579.x; WALLACE EM, 1995, PRENATAL DIAG, V15, P359, DOI 10.1002/pd.1970150410; ZEITUNE M, 1991, PRENATAL DIAG, V11, P847, DOI 10.1002/pd.1970111106	45	132	135	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1231	1236		10.1056/NEJM199605093341904	http://dx.doi.org/10.1056/NEJM199605093341904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606718				2022-12-01	WOS:A1996UJ05400004
J	Wang, Y; Reen, DJ; Puri, P				Wang, Y; Reen, DJ; Puri, P			Is a histologically normal appendix following emergency appendicectomy always normal?	LANCET			English	Article								Background Appendixes removed from patients with suspected appendicitis often appear normal on histological examination. We examined appendix specimens for expression of abnormal amounts of cytokines, an indicator of an inflammatory response. Methods Tumour necrosis factor alpha (TNF alpha) and interleukin-2 (IL-2) expression was measured by in-situ hybridisation in ten specimens from patients with acute appendicitis, 12 normal appendix specimens removed from patients undergoing elective abdominal surgery, and 31 appendix specimens from patients with a clinical diagnosis of appendicitis but an appendix histologically classified as normal. Cytokine-specific RNA antisense probes were prepared by in-vitro transcription and digoxigenin (DIG) labelled. In-situ hybridisation was done on 5 mu m paraffin sections. Tissue sections hybridised by sense probes acted as negative control for each cytokine. Following hybridisation, the probes were detected by alkaline phosphatase labelled anti-DIG monoclonal antibody and visualised by nitroblue tetrazolium staining. Findings All histologically proven acute appendicitis specimens demonstrated intense cellular TNF alpha mRNA expression in germinal centres and moderate levels of expression throughout the mucosa. IL-2 mRNA was strongly expressed in the lamina propria and only moderately expressed in germinal centres. Normal appendixes all showed almost complete absence of TNF alpha and IL-2 mRNA expression. Seven of the 31 histologically classified normal appendix specimens from patients with a clinical diagnosis of appendicitis demonstrated TNF alpha and IL-2 mRNA expression similar to acute appendicitis specimens in germinal centres, submucosa, and lamina propria layers. Interpretation TNF alpha and IL-2 mRNA expression is sensitive marker of inflammation in appendicitis. A substantial proportion of histologically normal appendixes showed clear evidence of an inflammatory response in the form of increased cytokine expression.	OUR LADYS HOSP SICK CHILDREN,CHILDRENS RES CTR,CRUMLIN 12,DUBLIN,IRELAND	Our Ladys Children Hospital Crumlin								BRAEGGER CP, 1994, ANN ALLERGY, V72, P135; COMMINIELLO C, 1994, ANGIOLOGY, V45, P1015; DAHLSTROM JE, 1994, AUST NZ J SURG, V64, P692, DOI 10.1111/j.1445-2197.1994.tb02059.x; DISEBASTIANO P, 1995, DIGEST DIS SCI, V40, P366, DOI 10.1007/BF02065423; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; FINE G, 1995, ANDERSONS PATHOLOGY, P1055; GURBINDO C, 1993, J PEDIATR GASTR NUTR, V17, P247, DOI 10.1097/00005176-199310000-00003; KARTTUNEN R, 1995, GUT, V36, P341, DOI 10.1136/gut.36.3.341; KONTAKOU M, 1994, GUT, V35, P1037, DOI 10.1136/gut.35.8.1037; Levine J.D., 1994, TXB PAIN, P45; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MAHUMMUD N, 1995, EUR J GASTROEN HEPAT, V7, P215; PARDUE ML, 1983, NUCLEIC ACID HYBRIDI, P179; PURI P, 1995, PEDIATR SURG INT, V10, P61; SHER ME, 1995, AM J SURG, V169, P133, DOI 10.1016/S0002-9610(99)80121-4; SIEGEL MJ, 1995, PEDIATR SURG INT, V10, P62; TSUJI M, 1993, J PEDIATR GASTR NUTR, V16, P43, DOI 10.1097/00005176-199301000-00008; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0	18	64	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1076	1079		10.1016/S0140-6736(96)90279-2	http://dx.doi.org/10.1016/S0140-6736(96)90279-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602058				2022-12-01	WOS:A1996UG04200012
J	Alvarez, FJ; DelRio, MC				Alvarez, FJ; DelRio, MC			Alcohol and driving	LANCET			English	Editorial Material											Alvarez, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/X-2294-2019; Alvarez, F. Javier/E-7204-2016	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				BIECHELER MB, 1995, 9403CN0130 EURICPALD; *DIR GEN TRANSP CO, 1995, VII3921995 DIR GEN T; DUNBAR JA, 1987, BRIT MED J, V295, P1458, DOI 10.1136/bmj.295.6611.1458; *EUR TRANSP SAF CO, 1995, RED TRAFF INJ RES AL; GUPPY A, 1994, BRIT MED J, V308, P1056; POLEN M R, 1988, Journal of the American Medical Association, V259, P77; WELLSPARKER E, 1995, ADDICTION, V90, P907, DOI 10.1046/j.1360-0443.1995.9079074.x; 1995, 9403CN01 EURICPALDT	8	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					985	986						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606608				2022-12-01	WOS:A1996UF38000004
J	Munroe, PB; Rapola, J; Mitchison, HM; Mustonen, A; Mole, SE; Gardiner, RM; Jarvela, I				Munroe, PB; Rapola, J; Mitchison, HM; Mustonen, A; Mole, SE; Gardiner, RM; Jarvela, I			Prenatal diagnosis of Batten's disease	LANCET			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS	Background Batten's disease is the most common progressive encephalopathy of childhood in Western countries. The major mutation is a 1 kb deletion, which is carried by 81% of Batten's disease patients. We report on the use of direct gene analysis in the prenatal diagnosis of this disease. Methods and findings A Finnish woman with a son with Batten's disease came for genetic counselling for her current pregnancy. Electron microscopy of a chorionic villus sample gave suggestive findings. We used PCR to look for the intragenic microsatellite marker D16S298; 96% of Finnish Batten's disease patients carry allele 6 at this marker. The fetus and the affected son both carried the same high-risk genotype, 6/6. Both were homozygous for the 1 kb deletion. The pregnancy was terminated. Electron microscopy of the fetus showed typical Batten's disease changes. Interpretation We have successfully used direct gene analysis in the prenatal diagnosis of Batten's disease.	NATL PUBL HLTH INST, LAB HUMAN MOLEC GENET, SF-00300 HELSINKI, FINLAND; UCL, SCH MED, RAYNE INST, DEPT PAEDIAT, LONDON, ENGLAND; UNIV HELSINKI, CHILDRENS HOSP, HELSINKI, FINLAND; TAMPERE UNIV HOSP, DEPT CLIN GENET, TAMPERE, FINLAND	Finland National Institute for Health & Welfare; University of London; King's College London; University College London; UCL Medical School; University of Helsinki; Tampere University; Tampere University Hospital			Jarvela, Irma E/L-5836-2013; Mitchison, Hannah M./C-1891-2008; Mole, Sara/C-2024-2008	Jarvela, Irma E/0000-0002-1770-6187; Mole, Sara/0000-0003-4385-4957; Munroe, Patricia/0000-0002-4176-2947; Mitchison, Hannah/0000-0002-3163-6293	NINDS NIH HHS [NS28722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARPENTER S, 1977, BRAIN, V100, P137, DOI 10.1093/brain/100.1.137; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; LAKE BD, 1995, 41 ANN M PAED PATH S; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; MITCHISON HM, 1994, GENOMICS, V22, P465, DOI 10.1006/geno.1994.1412; MITCHISON HM, 1995, AM J HUM GENET, V56, P654; RAPOLA J, 1990, PRENATAL DIAG, V10, P553, DOI 10.1002/pd.1970100902; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; SYVANEN AC, 1992, GENOMICS, V12, P590, DOI 10.1016/0888-7543(92)90452-X	9	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1014	1015		10.1016/S0140-6736(96)90148-8	http://dx.doi.org/10.1016/S0140-6736(96)90148-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606564				2022-12-01	WOS:A1996UF38000013
J	Pascher, T; Chesick, JP; Winkler, JR; Gray, HB				Pascher, T; Chesick, JP; Winkler, JR; Gray, HB			Protein folding triggered by electron transfer	SCIENCE			English	Article							THERMODYNAMICS; HYDRATION	Rapid photochemical electron injection into unfolded ferricytochrome c titrated with 2.3 to 4.6 M guanidine hydrochloride (GuHCl) at pH 7 and 40 degrees C produced unfolded ferrocytochrome, which then converted to the folded protein. Two folding phases were observed: a fast process with a time constant of 40 microseconds (4.6 M GuHCl), and a slower phase with a rate constant of 90 +/- 20 per second (2.3 M GuHCl). The activation free energy for the slow step varied linearly with GuHCl concentration; the rate constant, extrapolated to aqueous solution, was 7600 per second, Electron-transfer methods can bridge the nanosecond to millisecond measurement time gap for protein folding.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; HAVERFORD COLL, HAVERFORD, PA 19041 USA	California Institute of Technology; Haverford College								BABUL J, 1971, BIOPOLYMERS, V10, P2359, DOI 10.1002/bip.360101125; BABUL J, 1972, BIOCHEMISTRY-US, V11, P1195, DOI 10.1021/bi00757a013; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BALDWIN RL, 1994, BIOESSAYS, V16, P207, DOI 10.1002/bies.950160312; BALLEW RM, IN PRESS P NATL ACAD; BEALS JM, 1991, BIOCHEMISTRY-US, V30, P7680, DOI 10.1021/bi00245a004; BERTRAND P, 1995, BIOCHEMISTRY-US, V34, P11071, DOI 10.1021/bi00035a012; BIXLER J, 1992, J AM CHEM SOC, V114, P6938, DOI 10.1021/ja00043a062; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHEN BL, 1992, BIOCHEMISTRY-US, V31, P1464, DOI 10.1021/bi00120a025; CHEN LXQ, 1987, CHEM PHYS LETT, V139, P55, DOI 10.1016/0009-2614(87)80150-1; COHEN DS, 1995, J AM CHEM SOC, V117, P1675, DOI 10.1021/ja00111a001; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; FERSHT AR, 1995, CURR OPIN STRUC BIOL, V5, P79, DOI 10.1016/0959-440X(95)80012-P; GUTIN AM, 1995, P NATL ACAD SCI USA, V92, P1282, DOI 10.1073/pnas.92.5.1282; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MCLENDON G, 1978, J BIOL CHEM, V253, P4004; NOTLING B, 1995, P NATL ACAD SCI USA, V92, P10668; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; PHILLIPS CM, 1995, P NATL ACAD SCI USA, V92, P7292, DOI 10.1073/pnas.92.16.7292; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; SANTUCCI R, 1988, J AM CHEM SOC, V110, P8536, DOI 10.1021/ja00233a035; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sutin N, 1978, ADV CHEM SER, V168, P1; TANIGUCHI VT, 1980, PURE APPL CHEM, V52, P2275, DOI 10.1351/pac198052102275; WOODRUFF WH, 1994, BIOPHYS J, V66, pA397; YEE EL, 1979, J AM CHEM SOC, V101, P1131, DOI 10.1021/ja00499a013	32	317	318	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1558	1560		10.1126/science.271.5255.1558	http://dx.doi.org/10.1126/science.271.5255.1558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599112				2022-12-01	WOS:A1996TZ98300033
J	Thomas, T; Thomas, G; McLendon, C; Sutton, T; Mullan, M				Thomas, T; Thomas, G; McLendon, C; Sutton, T; Mullan, M			beta-Amyloid-mediated vasoactivity and vascular endothelial damage	NATURE			English	Article							ALZHEIMERS-DISEASE; PROTEIN	Deposits of beta-amyloid are apparent in ageing and Alzheimer's disease(1), but the role of this peptide in neurodegeneration is unclear(2). The free-radical theory of ageing may also account for Alzheimer-type degeneration and consequently links between free-radical generation and beta-amyloid have been sought(3). We demonstrate here that beta-amyloid interacts with endothelial cells on blood vessels to produce an excess of superoxide radicals, with attendant alterations in endothelial structure and function. The superoxide radical can scavenge endothelium-derived relaxing factor and produce potent oxidizing agents, which can cause lipid peroxidation and other degenerative changes(4). The alterations in vascular tone and endothelial damage are prevented by the oxygen-radical-scavenging enzyme superoxide dismutase. These observations suggest a normal vasoactive role for beta-amyloid as well as a mechanism by which beta-amyloid may play a role in vascular abnormalities and neurodegeneration mediated by free radicals.	UNIV S FLORIDA,COLL MED,DEPT PHYSIOL & BIOPHYS,TAMPA,FL 33613	State University System of Florida; University of South Florida	Thomas, T (corresponding author), UNIV S FLORIDA,ROSKAMP LABS,INST PSYCHIAT RES,TAMPA,FL 33613, USA.			Mullan, Michael/0000-0002-1473-7527				BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1992, JAP J PHARM S2, V58, P185; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MATTSON MP, 1995, NAT STRUCT BIOL, V2, P926, DOI 10.1038/nsb1195-926; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; Scholz W, 1938, Z GESAMTE NEUROL PSY, V162, P694, DOI 10.1007/BF02890989; TOMIMOTO H, 1994, J CEREB BLOOD FLOW M, V14, P563; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	14	625	648	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					168	171		10.1038/380168a0	http://dx.doi.org/10.1038/380168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600393				2022-12-01	WOS:A1996TZ97800054
J	MacLennan, AH; Wilson, DH; Taylor, AW				MacLennan, AH; Wilson, DH; Taylor, AW			Prevalence and cost of alternative medicine in Australia	LANCET			English	Article								Background To determine the prevalence and cost of alternative medicines and alternative practitioner use in an Australian population. Methods We conducted a representative population survey of persons aged 15 or older living in South Australia, which required 3004 personal interviews, We assessed the rates of use and types of alternative medicine and therapists used by this population in 1993, and correlations with other demographic and medical variables. Findings The overall use of at least one non-medically prescribed alternative medicine (excluding calcium, iron and prescribed vitamins) was 48.5%. The users were more likely to be perimenopausal females, better educated, have a higher alcohol intake, be of normal weight and more likely to be employed than non-users, 20.3% of respondents had visited at least one alternative practitioner, most commonly chiropractors (15%). The users of alternative practitioners were more likely to be younger, live in the country and be overweight, Women were more likely to consult naturopaths, iridiologists, and reflexologists than men. Interpretation Extrapolation of the costs to the Australian population gives a natural expenditure in 1993, for alternative medicines, of $621 million (Australian dollars) and for alternative therapists of $AU309 million per annum. This compares to the $AU360 million of patient contributions for all classes of pharmaceutical drugs purchased in Australia in 1992/93, The public health and economic ramifications of these huge costs are questioned in view of the paucity of sound safety and efficacy data for many of the therapies and products of the alternative medicine industry.	S AUSTRALIAN HLTH COMMISS,PUBL & ENVIRONM HLTH SERV,ADELAIDE,SA,AUSTRALIA		MacLennan, AH (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5000,AUSTRALIA.		Taylor, Anne w/F-5708-2010	Taylor, Anne w/0000-0002-4422-7974				CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; CUI J, 1994, LANCET, V344, P134, DOI 10.1016/S0140-6736(94)91322-6; DESMET PAGM, 1995, BRIT MED J, V310, P1023, DOI 10.1136/bmj.310.6986.1023; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1993, LANCET, V341, P1626, DOI 10.1016/0140-6736(93)90763-7; KELLY JL, 1988, USING ASCO SOCIO EC; LLOYD P, 1993, AUST J PUBLIC HEALTH, V17, P135; LOHR SL, 1994, J QUANT CRIMINOL, V10, P343, DOI 10.1007/BF02221280; MOULDS RFW, 1988, MED J AUSTRALIA, V149, P572, DOI 10.5694/j.1326-5377.1988.tb120789.x; ONEILL A, 1994, SOC SCI MED, V38, P497, DOI 10.1016/0277-9536(94)90246-1; PERHARIC L, 1993, LANCET, V342, P180, DOI 10.1016/0140-6736(93)91389-4; STARK DJ, 1981, MED J AUSTRALIA, V2, P676, DOI 10.5694/j.1326-5377.1981.tb113049.x; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; TORO T, 1992, NEW SCI, V1831, P10; WIESNER D, 1995, AUSTR DOCT       MAR, P44; 1994, AUSTR HLTH; 1990, 12220 AUSTR BUR STAT; 1986, INQUIRY ALTERNATIVE; 1990, 27100 AUSTR BUR STAT	19	664	672	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1996	347	9001					569	573		10.1016/S0140-6736(96)91271-4	http://dx.doi.org/10.1016/S0140-6736(96)91271-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596318				2022-12-01	WOS:A1996TX69400009
J	NostenBertrand, M; Errington, ML; Murphy, KPSJ; Tokugawa, Y; Barboni, E; Kozlova, E; Michalovich, D; Morris, RGM; Silver, J; Stewart, CL; Bliss, TVP; Morris, RJ				NostenBertrand, M; Errington, ML; Murphy, KPSJ; Tokugawa, Y; Barboni, E; Kozlova, E; Michalovich, D; Morris, RGM; Silver, J; Stewart, CL; Bliss, TVP; Morris, RJ			Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL GRANULE CELLS; DENTATE GYRUS INVITRO; II MUTANT MICE; MEMORY; MODULATION; LESIONS; RAT	The process of learning involves stable changes in synaptic efficacy for which long-term potentiation (LTP)(1) provides a widely adopted mammalian model. Synaptic modification induced by learning or LTP may involve the action of cell adhesion molecules(2-4). One such candidate is the ubiquitous neuronal glycoprotein Thy-1 (refs 5, 6). In mice in which the gene encoding Thy-1 has been inactivated, we find a regionally selective impairment of LTP in vivo in the hippocampal formation: LTP is normal in area CA1 but strongly inhibited in the dentate gyrus. Spatial learning by Thy-1-deficient mice, as assessed in the watermaze(7), is unimpaired. Thus LTP in the cortical input to the dentate gyrus seems not to be required for spatial learning.	NATL INST MED RES, DEPT NEUROBIOL, LONDON NW7 1AA, ENGLAND; NATL INST MED RES, DEPT NEUROPHYSIOL, LONDON NW7 1AA, ENGLAND; CORNELL UNIV, COLL MED, N SHORE UNIV HOSP, DIV MOLEC MED, NEW YORK, NY 11030 USA; UNIV ROMA LA SAPIENZA, DEPT HUMAN BIOPATHOL, I-00100 ROME, ITALY; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; UNIV EDINBURGH, CTR NEUROSCI, EDINBURGH EH8 9LE, MIDLOTHIAN, SCOTLAND; ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA; UNITED MED & DENT SCH, GUYS HOSP, DEPT EXPTL PATHOL, LONDON SE1 9RT, ENGLAND	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Cornell University; Northwell Health; North Shore University Hospital; Sapienza University Rome; Erasmus University Rotterdam; University of Edinburgh; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Murphy, Kerry/H-1934-2012; Morris, Richard G M/C-9982-2013	Michalovich, David/0000-0003-4452-5776; Kozlova, Elena/0000-0002-2234-0079				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CHO YH, 1995, NEUROBIOL LEARN MEM, V64, P285, DOI 10.1006/nlme.1995.0011; CONRAD CD, 1993, J NEUROSCI, V13, P2582, DOI 10.1523/JNEUROSCI.13-06-02582.1993; FAZELI MS, 1994, NEUROSCI LETT, V169, P77, DOI 10.1016/0304-3940(94)90360-3; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GORDON JA, 1994, SOC NEUR ABSTR, V20; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MORRIS R, 1992, BIOESSAYS, V14, P715, DOI 10.1002/bies.950141014; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; Naquet P, 1989, Immunol Ser, V45, P99; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOVITER RS, 1995, J NEUROSCI, V15, P811; Swanson LW, 1987, HDB CHEM NEUROANATOM, P125; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P59, DOI 10.1016/0166-4328(87)90036-2; WIGSTROM H, 1983, BRAIN RES, V275, P153, DOI 10.1016/0006-8993(83)90428-6	30	204	211	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 29	1996	379	6568					826	829		10.1038/379826a0	http://dx.doi.org/10.1038/379826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587606				2022-12-01	WOS:A1996TX50100059
J	Amakawa, R; Hakem, A; Kundig, TM; Matsuyama, T; Simard, JJL; Timms, E; Wakeham, A; Mittruecker, HW; Griesser, H; Takimoto, H; Schmits, R; Shahinian, A; Ohashi, PS; Penninger, JM; Mak, TW				Amakawa, R; Hakem, A; Kundig, TM; Matsuyama, T; Simard, JJL; Timms, E; Wakeham, A; Mittruecker, HW; Griesser, H; Takimoto, H; Schmits, R; Shahinian, A; Ohashi, PS; Penninger, JM; Mak, TW			Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; X-LINKED IMMUNODEFICIENCY; NECROSIS-FACTOR RECEPTOR; STERNBERG-REED CELLS; HYPER-IGM SYNDROME; KI-1 ANTIGEN; CD40 LIGAND; CD30 ANTIGEN; SELF-TOLERANCE; LYMPHOID-CELLS	CD30 is found on Reed-Sternberg cells of Hodgkin's disease and on a variety of non-Hodgkin's lymphoma cells and is up-regulated on cells after Epstein-Barr virus, human T cell leukemia virus, and HIV infections. We report here that the thymus in CD30-deficient mice contains elevated numbers of thymocytes. Activation-induced death of thymocytes after CD3 cross-linking is impaired both in vitro and in vivo. Breeding the CD30 mutation separately into alpha beta TCR- or gamma delta TCR-transgenic mice revealed a gross defect in negative but not positive selection. Thus, like TNF-receptors and Fas/Apo-1, the CD30 receptor is involved in cell death signaling. It is also an important coreceptor that participates in thymic deletion.	UNIV TORONTO, AMGEN INST, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M5G 2C1, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALZONA M, 1994, J IMMUNOL, V153, P2861; ANDREESEN R, 1984, BLOOD, V63, P1299; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; BINDER D, 1991, J IMMUNOL, V146, P4301; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CALIGARISCAPPIO F, 1995, CLIN EXP RHEUMATOL, V13, P339; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FONATSCH C, 1992, GENOMICS, V14, P825, DOI 10.1016/S0888-7543(05)80203-4; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FOY TM, 1995, J EXP MED, V182, P1377, DOI 10.1084/jem.182.5.1377; FROESE P, 1987, J IMMUNOL, V139, P2081; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAUSE A, 1991, BLOOD, V77, P1983; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRUSS HJ, 1994, BLOOD, V83, P2045; KEMPER O, 1991, HUM GENET, V87, P623; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KUNDIG TM, 1993, J VIROL, V67, P3680; KUNDIG TM, 1993, J IMMUNOL, V150, P4450; LATZA U, 1994, EUR J IMMUNOL, V24, P677, DOI 10.1002/eji.1830240329; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MANETTI R, 1994, J EXP MED, V180, P2407, DOI 10.1084/jem.180.6.2407; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MECHTERSHEIMER G, 1990, CANCER, V66, P1732, DOI 10.1002/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5; Merkenschlager M, 1989, Int Immunol, V1, P450, DOI 10.1093/intimm/1.4.450; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; PALLESEN G, 1990, HISTOPATHOLOGY, V16, P409, DOI 10.1111/j.1365-2559.1990.tb01151.x; PALLESEN G, 1988, AM J PATHOL, V133, P446; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PIRIS M, 1990, HISTOPATHOLOGY, V17, P211, DOI 10.1111/j.1365-2559.1990.tb00709.x; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHUURMAN HJ, 1989, THYMUS, V14, P43; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHI YF, 1991, J IMMUNOL, V146, P3340; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SKEEN MJ, 1993, J EXP MED, V178, P971, DOI 10.1084/jem.178.3.971; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; SPRENT J, 1995, CURR OPIN IMMUNOL, V7, P196, DOI 10.1016/0952-7915(95)80004-2; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TATSUMI Y, 1993, J IMMUNOL, V151, P3030; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	74	284	295	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 23	1996	84	4					551	562		10.1016/S0092-8674(00)81031-4	http://dx.doi.org/10.1016/S0092-8674(00)81031-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598042	Bronze			2022-12-01	WOS:A1996TX17600008
J	Weliky, M; Bosking, WH; Fitzpatrick, D				Weliky, M; Bosking, WH; Fitzpatrick, D			A systematic map of direction preference in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; ISO-ORIENTATION DOMAINS; FUNCTIONAL ARCHITECTURE; ORGANIZATION; SELECTIVITY; GEOMETRY; COLUMNS; AREA-18	NEURONS in the primary visual cortex respond selectively to the orientation of edges and their direction of motion. Orientation preference is mapped in a systematic fashion across the cortical surface, such that neurons in adjacent columns have similar but slightly shifted preferred orientations(1-7), Microelectrode studies have suggested that direction preference is also arranged in a systematic fashion(8-10), but exactly how this response property is mapped remains unclear. Here we show by optical imaging(4-5) of intrinsic signals(6-7,11-14) in ferret cortical area 17 that there is a mosaic-like map of direction preference, This map consists of numerous regions within which direction preference changes in a slow, continuous fashion, These regions are separated by winding boundaries (fractures) across which direction preference shifts abruptly, often by 180 degrees, Comparison of direction and orientation preference maps shows that these fractures subdivide iso-orientation domains into regions selective for opposite directions of motion.			Weliky, M (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,BOX 3209,DURHAM,NC 27710, USA.							BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BLASDEL GG, 1992, J NEUROSCI, V12, P3115, DOI 10.1523/JNEUROSCI.12-08-03115.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; BRAITENBERG V, 1979, BIOL CYBERN, V33, P179, DOI 10.1007/BF00337296; FITZPATRICK D, 1994, J SOC NEUR ABSTR, V20, P837; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; MALONEK D, 1994, P ROY SOC B-BIOL SCI, V258, P109, DOI 10.1098/rspb.1994.0150; PAYNE BR, 1981, BRAIN RES, V211, P445, DOI 10.1016/0006-8993(81)90971-9; SWINDALE NV, 1982, PROC R SOC SER B-BIO, V215, P211, DOI 10.1098/rspb.1982.0038; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TOLHURST DJ, 1981, EXP BRAIN RES, V44, P340; WELIKY M, 1994, J NEUROSCI, V14, P7291; WELIKY M, 1995, NEURON, V15, P541, DOI 10.1016/0896-6273(95)90143-4	17	194	194	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					725	728		10.1038/379725a0	http://dx.doi.org/10.1038/379725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602218				2022-12-01	WOS:A1996TW56700052
J	Leopold, DA; Logothetis, NK				Leopold, DA; Logothetis, NK			Activity changes in early visual cortex reflect monkeys' percepts during binocular rivalry	NATURE			English	Article								WHEN the two eyes view dissimilar images, we experience binocular rivalry, in which one eye's view dominates for several seconds and is then replaced by that of the other eye(1,2). What causes these perceptual changes in the absence of any change in the stimulus? We showed previously that some neurons in monkey cortical area MT show changes in activity during motion rivalry that reflect the perceived direction of motion(3). To determine whether perception-related modulation of activity occurs in other visual cortical areas, we recorded from individual neurons in V1, V2 and V4 while monkeys reported the perceived orientation of rival gratings of two orthogonal orientations. Many cells, particularly in V4, showed patterns of activity that correlated with the perceptual dominance and suppression of one stimulus. The majority were orientation-selective and could be driven equally well from either eye. It has been previously suggested that binocular rivalry involves reciprocal inhibition between monocular neurons within V1 (for example, see ref, 4), but our results do not support this view; rather, we propose that binocular rivalry arises through interactions between binocular neurons at several levels in the visual pathways, and that similar mechanisms may underlie other multistable perceptual states that occur when viewing ambiguous images.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Logothetis, Nikos/U-9282-2019	Leopold, David/0000-0002-1345-6360				BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; Breese BB., 1899, PSYCHOL REV-MONOGR S, V3, DOI [10.1037/h0092990, DOI 10.1037/H0092990]; CAMPBELL FW, 1972, J PHYSIOL-LONDON, V225, pP19; FOX R, 1967, PERCEPT PSYCHOPHYS, V2, P432, DOI 10.3758/BF03208783; Helmholtz H.von., 1924, PHYSL OPTICS; Levelt W., 1965, BINOCULAR RIVALRY; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; WALKER P, 1975, PERCEPT PSYCHOPHYS, V18, P467, DOI 10.3758/BF03204122; WHITTLE P, 1968, PERCEPT PSYCHOPHYS, V4, P183, DOI 10.3758/BF03210465	12	645	652	3	61	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					549	553		10.1038/379549a0	http://dx.doi.org/10.1038/379549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TU693	8596635				2022-12-01	WOS:A1996TU69300053
J	Nathanielsz, PW				Nathanielsz, PW			Fetal and neonatal environment has influence on brain development	LANCET			English	News Item														Nathanielsz, Peter/0000-0001-8410-6280					0	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					314	314		10.1016/S0140-6736(96)90479-1	http://dx.doi.org/10.1016/S0140-6736(96)90479-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569370	Bronze			2022-12-01	WOS:A1996TT48500020
J	Weber, GF; Ashkar, S; Glimcher, MJ; Cantor, H				Weber, GF; Ashkar, S; Glimcher, MJ; Cantor, H			Receptor-ligand interaction between CD44 and osteopontin (Eta-1)	SCIENCE			English	Article							T-CELL ACTIVATION; SECRETED PHOSPHOPROTEIN; OSTEO-SARCOMA; BONE; LINES; IMMUNOLOCALIZATION; ANTIBODIES; DEFINITION; EXPRESSION; PROTEIN	The CD44 family of surface receptors regulates adhesion, movement, and activation of normal and neoplastic cells. The cytokine osteopontin (Eta-1), which regulates similar cellular functions, was found to be a protein ligand of CD44. Osteopontin induces cellular chemotaxis but not homotypic aggregation, whereas the inverse is true for the interaction between CD44 and a carbohydrate ligand, hyaluronate. The different responses of cells after CD44 ligation by either osteopontin or hyaluronate may account for the independent effects of CD44 on cell migration and growth. This mechanism may also be exploited by tumor cells to promote metastasis formation.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ORTHOPED RES,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School	Weber, GF (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,DANA FARBER CANC INST,DIV IMMUNOPATHOL,BOSTON,MA 02115, USA.		Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012184, R01AI013600, R01AI012184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR034078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13600, AI12184] Funding Source: Medline; NIAMS NIH HHS [P01 AR34078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTHER UG, 1991, CELL, V65, P13; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARESU O, 1991, INVAS METAST, V11, P2; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; BEHREND EI, 1994, CANCER RES, V54, P832; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENNING SM, 1990, J IMMUNOL, V144, P7; HU MCT, 1992, COLD SPRING HARB SYM, V57, P291, DOI 10.1101/SQB.1992.057.01.034; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749-6632.1995.tb44614.x; ROTHMAN BL, 1991, J IMMUNOL, V147, P2493; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SCHMIDT J, 1988, DIFFERENTIATION, V39, P151, DOI 10.1111/j.1432-0436.1988.tb00090.x; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SPINELLA DG, 1987, J IMMUNOL, V138, P3991; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; WASS JA, 1981, J NATL CANCER I, V66, P927; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282	37	744	779	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					509	512		10.1126/science.271.5248.509	http://dx.doi.org/10.1126/science.271.5248.509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560266				2022-12-01	WOS:A1996TR32200043
J	Brennick, J; Mattia, A				Brennick, J; Mattia, A			Strongyloides stercoralis Infestation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Brennick, J (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1173	1173		10.1056/NEJM199605023341806	http://dx.doi.org/10.1056/NEJM199605023341806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602184				2022-12-01	WOS:A1996UG83100006
J	DeGroote, MA; Testerman, T; Xu, YS; Stauffer, G; Fang, FC				DeGroote, MA; Testerman, T; Xu, YS; Stauffer, G; Fang, FC			Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium	SCIENCE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CLONING VEHICLES; THRA GENE; CONSTRUCTION; DERIVATIVES; ACTIVATION; NITROGEN; DISEASE	Nitric oxide (NO) is associated with broad-spectrum antimicrobial activity of particular importance in infections caused by intracellular pathogens. An insertion mutation in the metL gene of Salmonella typhimurium conferred specific hypersusceptibility to S-nitrosothiol NO-donor compounds and attenuated virulence of the organism in mice. The metL gene product catalyzes two proximal metabolic steps required for homocysteine biosynthesis. S-Nitrosothiol resistance was restored by exogenous homocysteine or introduction of the metL gene on a plasmid. Measurement of expression of the homocysteine-sensitive metH gene indicated that S-nitrosothiols may directly deplete intracellular homocysteine. Homocysteine may act as an endogenous NO antagonist in diverse processes including infection, atherosclerosis, and neurologic disease.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,DENVER,CO 80262; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Iowa			Testerman, Traci L/AAI-1506-2020	Testerman, Traci L/0000-0002-3883-6407; Fang, Ferric/0000-0002-3243-110X	NIAID NIH HHS [AI32463] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032463] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOLIVAR F, 1977, GENE, V2, P75, DOI 10.1016/0378-1119(77)90074-9; BYERLY KA, 1991, J BACTERIOL, V173, P3547, DOI 10.1128/jb.173.11.3547-3553.1991; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DEGROOTE MA, UNPUB; EVANS TG, 1993, J IMMUNOL, V151, P907; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FORMICA S, 1994, IMMUNOLOGY, V82, P42; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; KATINKA M, 1980, P NATL ACAD SCI-BIOL, V77, P5730, DOI 10.1073/pnas.77.10.5730; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Miller JH., 1972, EXPT MOL GENETICS; MULLIGAN JT, 1982, J BACTERIOL, V151, P609, DOI 10.1128/JB.151.2.609-619.1982; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NAUCIEL C, 1992, INFECT IMMUN, V60, P450, DOI 10.1128/IAI.60.2.450-454.1992; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; SAINTGIRONS I, 1984, J BIOL CHEM, V259, P4282; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; URBANOWSKI ML, 1989, J BACTERIOL, V171, P3277, DOI 10.1128/jb.171.6.3277-3281.1989; ZAKIN MM, 1983, J BIOL CHEM, V258, P3028	30	153	167	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					414	417		10.1126/science.272.5260.414	http://dx.doi.org/10.1126/science.272.5260.414			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602531				2022-12-01	WOS:A1996UG25200048
J	Brunner, E; Smith, GD; Marmot, M; Canner, R; Beksinska, M; OBrien, J				Brunner, E; Smith, GD; Marmot, M; Canner, R; Beksinska, M; OBrien, J			Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BRITISH CIVIL-SERVANTS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; EMPLOYMENT GRADE; CLOTTING FACTORS; WHITEHALL-II; ADULT LIFE; MORTALITY	Background High plasma fibrinogen concentration is associated with an increased risk of coronary heart disease. We have investigated associations between plasma fibrinogen and factors operating in childhood and in adulthood, including the psychosocial characteristics of work. Methods In a cross-sectional study of Civil Servants in London, UK, 2095 men and 1202 women aged 45-55 years provided blood samples for fibrinogen measurement at the time of the Whitehall II study baseline. The participants completed a questionnaire on demographic characteristics, education, employment grade, parents' occupation, health behaviours, and work characteristics. Findings Measures of childhood environment (adult height, father's social class, and participant's education) were inversely associated with adult plasma fibrinogen concentration in both sexes. Lower socioeconomic status (as shown by employment grade) was associated with higher fibrinogen concentrations, with differences from top to bottom grade of 0.22 g/L (95% CI 0.13-0.31) in men and 0.37 g/L (0.18-0.56) in women (p<0.0001, both sexes). This association was not accounted for by measures of childhood circumstances. Control over work, assessed by personnel managers, was inversely related to fibrinogen in both sexes, and a similar relation was seen for self-rated control over work among men but not women. Men in the bottom third of the distribution for self-rated and externally assessed control over work had higher fibrinogen concentrations than those in the top third for both measures (difference 0.16 g/L [0.07-0.26]; p<0.001). There was no difference between these extremes among women (0.02 g/L [-0.16 to 0.19]). Current smokers had higher fibrinogen concentrations than non-smokers, and moderate alcohol consumers had lower concentrations than those who drank occasionally or never. Interpretation Although our study was cross-sectional, it provides evidence that adult fibrinogen concentration is determined by factors operating throughout life. Fibrinogen may be a marker of the biological pathways that mediate the inverse socioeconomic gradient in coronary disease.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL, AVON, ENGLAND; ST MARYS HOSP, PORTSMOUTH PO3 6AQ, HANTS, ENGLAND	University of Bristol	Brunner, E (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Brunner, Eric/H-2114-2011; Marmot, M G/Y-3920-2019; Davey Smith, George/A-7407-2013	Brunner, Eric/0000-0002-0595-4474; Marmot, M G/0000-0002-2431-6419; Davey Smith, George/0000-0002-1407-8314	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust)		ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; BAKER IA, 1988, INT J EPIDEMIOL, V17, P759, DOI 10.1093/ije/17.4.759; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1986, LANCET, V1, P1077; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRUNNER EJ, 1993, ATHEROSCLEROSIS, V102, P195, DOI 10.1016/0021-9150(93)90162-N; BULLERS S, 1994, WOMEN HEALTH, V22, P11; ELIASSON M, 1994, J CLIN EPIDEMIOL, V47, P513, DOI 10.1016/0895-4356(94)90298-4; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FERRARA A, 1994, AM J EPIDEMIOL, V140, P857, DOI 10.1093/oxfordjournals.aje.a117174; FOLSOM AR, 1993, AM J EPIDEMIOL, V138, P1023, DOI 10.1093/oxfordjournals.aje.a116821; FOLSOM AR, 1991, ATHEROSCLEROSIS, V191, P205; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT M, 1995, J EPIDEMIOL COMMUN H, V49, P124, DOI 10.1136/jech.49.2.124; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1987, HAEMOSTASIS THROMBOS, P697; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PECK MN, 1995, SOC SCI MED, V41, P733, DOI 10.1016/0277-9536(94)00379-8; POWER C, 1991, HLTH CLASS EARLY YEA; RABBANI LE, 1994, ATHEROSCLEROSIS, V105, P1, DOI 10.1016/0021-9150(94)90002-7; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	36	206	210	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	1996	347	9007					1008	1013		10.1016/S0140-6736(96)90147-6	http://dx.doi.org/10.1016/S0140-6736(96)90147-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606563				2022-12-01	WOS:A1996UF38000012
J	Kodandapani, R; Pio, F; Ni, CZ; Piccialli, G; Klemsz, M; McKercher, S; Maki, RA; Ely, KR				Kodandapani, R; Pio, F; Ni, CZ; Piccialli, G; Klemsz, M; McKercher, S; Maki, RA; Ely, KR			A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex	NATURE			English	Article							CRYSTAL-STRUCTURE; ONCOGENE; BINDING; MOTIF	THE Ets family of transcription factors, of which there are now about 35 members(1,2), regulate gene expression during growth and development. They share a conserved domain of around 85 amino acids(3) which binds as a monomer to the DNA sequence 5'-C/ AGGAA/T-3'. We have determined the crystal structure of an ETS domain complexed with DNA, at 2.3-Angstrom resolution. The domain is similar to alpha + beta (winged) 'helix-turn-helix' proteins and interacts with a ten-base-pair region of duplex DNA which takes up a uniform curve of 8 degrees. The domain contacts the DNA by a novel loop-helix-loop architecture, Four of the amino acids that directly interact with the DNA are highly conserved: two arginines from the recognition helix lying in the major groove, one lysine from the 'wing' that binds upstream of the core GGAA sequence, and another lysine, from the 'turn' of the 'helix-turn-helix' motif, which binds downstream and on the opposite strand.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; UNIV NAPLES FEDERICO II,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; NEUROCRINE BIOSCI,SAN DIEGO,CA 92121	Sanford Burnham Prebys Medical Discovery Institute; University of Naples Federico II; Neurocrine Biosciences				Piccialli, Gennaro/0000-0002-1313-2091; pio, frederic/0000-0003-2050-847X				BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PIO F, 1995, J BIOL CHEM, V270, P24258, DOI 10.1074/jbc.270.41.24258; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEMER MH, 1995, CELL, V83, P761; WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3	27	266	270	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					456	460		10.1038/380456a0	http://dx.doi.org/10.1038/380456a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602247				2022-12-01	WOS:A1996UD59000067
J	Schumacher, TNM; Mayr, LM; Minor, DL; Milhollen, MA; Burgess, MW; Kim, PS				Schumacher, TNM; Mayr, LM; Minor, DL; Milhollen, MA; Burgess, MW; Kim, PS			Identification of D-peptide ligands through mirror-image phage display	SCIENCE			English	Article							EPITOPE LIBRARY; N-15 NMR; PROTEINS; MOLECULES; SELECTION; DOMAIN; BIND; SRC; H-1	Genetically encoded libraries of peptides and oligonucleotides are well suited for the identification of ligands for many macromolecules. A major drawback of these techniques is that the resultant ligands are subject to degradation by naturally occurring enzymes. Here, a method is described that uses a biologically encoded library for the identification of D-peptide ligands, which should be resistant to proteolytic degradation, In this approach, a protein is synthesized in the D-amino acid configuration and used to select peptides from a phage display library expressing random L-amino acid peptides, For reasons of symmetry, the mirror images of these phage-displayed peptides interact with the target protein of the natural handedness, The value of this approach was demonstrated by the identification of a cyclic D-peptide that interacts with the Src homology 3 domain of c-Src. Nuclear magnetic resonance studies indicate that the binding site for this D-peptide partially overlaps the site for the physiological ligands of this domain.	MIT, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, DEPT CHEM, CAMBRIDGE, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Schumacher, TNM (corresponding author), MIT, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, DEPT BIOL, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Ueno, Hiroshi/C-3301-2009; Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOREK F, 1965, BIOCHEM J, V96, P577, DOI 10.1042/bj0960577; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFIMOV AV, 1994, FEBS LETT, V355, P213, DOI 10.1016/0014-5793(94)01194-X; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GILL TJ, 1963, NATURE, V197, P746, DOI 10.1038/197746a0; GOMEZ FA, 1994, J ORG CHEM, V59, P2885, DOI 10.1021/jo00089a038; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; JANEWAY CA, 1967, IMMUNOLOGY, V13, P29; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MAUER PH, 1965, J EXP MED, V121, P339; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; PASTEUR ML, 1860, RECHERCHES DISSYMETR; PRELOG V, 1976, SCIENCE, V193, P17, DOI 10.1126/science.935852; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHUMACHER TNM, UNPUB; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEYMOUR JF, 1995, SCI MED, V2, P48; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YU H, 1993, FEBS LETT, V324, P87, DOI 10.1016/0014-5793(93)81538-B; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZAWADZKE LE, 1993, PROTEINS, V16, P301, DOI 10.1002/prot.340160308; ZAWADZKE LE, 1992, J AM CHEM SOC, V114, P4002, DOI 10.1021/ja00036a073	51	282	327	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1996	271	5257					1854	1857		10.1126/science.271.5257.1854	http://dx.doi.org/10.1126/science.271.5257.1854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC778	8596952				2022-12-01	WOS:A1996UC77800043
J	Friedman, LN; Williams, MT; Singh, TP; Frieden, TR				Friedman, LN; Williams, MT; Singh, TP; Frieden, TR			Tuberculosis, aids, and death among substance abusers on welfare in New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MENS SHELTER; INFECTION; RISK; HIV; PROGRESSION	Background. In New York City, the incidence of tuberculosis has more than doubled during the past decade. We examined the incidence of tuberculosis and the acquired immunodeficiency syndrome (AIDS) and the rate of death from all causes in a very-high-risk group - indigent subjects who abuse drugs, alcohol, or both. Methods. In 1984 we began to study prospectively a cohort of welfare applicants and recipients 18 to 64 years of age who abused drugs or alcohol. The incidence rates of tuberculosis, AIDS, and death for this group were ascertained through vital records and New York City's tuberculosis and AIDS registries. Results. The cohort was followed for eight years. Of the 858 subjects, tuberculosis developed in 47 (5.5 percent), 84 (9.8 percent) were given a diagnosis of AIDS, and 183 (21.3 percent) died. The rates of incidence per 100,000 person-years were 744 for tuberculosis, 1323 for AIDS, and 2842 for death. In this group of welfare clients, the rate of newly diagnosed tuberculosis was 14.8 times that of the age-matched general population of New York City; the rate of AIDS was 10.0 times as high; and the death rate was 5.2 times as high. There was no significant difference in the rate of new cases of tuberculosis between subjects with positive skin tests and those with negative skin tests at examination in 1984. Conclusions. Among indigent alcohol and drug abusers in New York City, the rates of tuberculosis, AIDS, and death are extremely high. In this population, a single positive or negative skin test does not predict the development of tuberculosis, probably because both anergy and new infections are common. If programs to control tuberculosis and AIDS are to be effective in groups of indigent substance abusers, health services must be integrated into the welfare delivery system. (C) 1996, Massachusetts Medical Society.	MILFORD HOSP,DEPT QUAL MANAGEMENT,MILFORD,CT 06460; YALE UNIV,SCH MED,PULM & CRIT CARE SECT,NEW HAVEN,CT; NEW YORK CITY DEPT HLTH,BUR TB CONTROL,NEW YORK,NY 10013; NEW YORK CITY DEPT HLTH,OFF AIDS SURVEILLANCE,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341	Yale University; New York City Department of Health & Mental Hygiene; New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	Friedman, LN (corresponding author), MILFORD HOSP,DEPT INTENS CARE,2047 BRIDGEPORT AVE,MILFORD,CT 06460, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; AVINS AL, 1994, JAMA-J AM MED ASSOC, V271, P515, DOI 10.1001/jama.271.7.515; BALLA AK, 1994, ALCOHOL, V11, P99, DOI 10.1016/0741-8329(94)90050-7; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *BUR TUB CONTR, 1993, TUB NEW YORK CIT 199; CONCATO J, 1994, ARCH INTERN MED, V154, P2069, DOI 10.1001/archinte.154.18.2069; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; *DEP HLTH HUM SERV, 1994, REP TUB US 1993; Diem K., 1970, SCI TABLES, VSeventh; *DIV SUBST AB SERV, 1985, STAT COMPR 5 YEAR PL; FONG IW, 1994, CLIN INFECT DIS, V19, P337, DOI 10.1093/clinids/19.2.337; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; *HUM RES ADM, 1984, 9 HUM RES ADM MONTHL, V45; *HUM RES ADM CIT N, 1994, HRA FACTS DEC 1994; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P104; MAHLER J, 1994, AM J PSYCHIAT, V151, P439; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; *OFF VIT STAT EP, 1990, SUMM VIT STAT 1990 C; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PAUL EA, 1993, AM J PUBLIC HEALTH, V83, P1743, DOI 10.2105/AJPH.83.12.1743; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P3434; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1992, MMWR-MORBID MORTAL W, V41, P13; 1990, MMWR-MORBID MORTAL W, V39, P561; 1987, MMWR MORB MORTAL S1S, V36, pS3; 1986, MMWR-MORBID MORTAL W, V35, P74; 1991, MMWR-MORBID MORTAL W, V40, P485; 1987, MMWR-MORBID MORTAL W, V36, P785; 1992, MMWR-MORBID MORTAL W, V41, P1	38	92	95	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1996	334	13					828	833		10.1056/NEJM199603283341304	http://dx.doi.org/10.1056/NEJM199603283341304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB950	8596549				2022-12-01	WOS:A1996UB95000004
J	Mandel, H; Brenner, B; Berant, M; Rosenberg, N; Lanir, N; Jakobs, C; Fowler, B; Seligsohn, U				Mandel, H; Brenner, B; Berant, M; Rosenberg, N; Lanir, N; Jakobs, C; Fowler, B; Seligsohn, U			Coexistence of hereditary homocystinuria and Factor V Leiden - Effect on thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; PROTEIN-C ACTIVATION; CULTURED HUMAN-CELLS; VASCULAR-DISEASE; HOMOCYSTEINE	Background. Venous and arterial thromboembolism occurs in only about one third of patients homozygous for homocystinuria, which suggests that other, contributory factors are necessary for the development of thrombosis in these patients, Factor V Leiden, an R506Q mutation in the gene coding for factor V, is the most common cause of familial thrombosis and could be a potentiating factor. Methods. We determined activated partial-thromboplastin times in the presence and absence of activated protein C and tested for the factor V Leiden mutation in 45 members of seven unrelated consanguineous kindreds in which at least 1 member was homozygous for homocystinuria. Results. Thrombosis (venous, arterial, or both) occurred in 6 of 11 patients with homocystinuria (age, 0.2 to 8 years), All six also had the factor V Leiden mutation. One patient with prenatally diagnosed homocystinuria who was also heterozygous for factor V Leiden has received warfarin therapy since birth and has not had thrombosis (age, 18 months), Of four patients with homocystinuria who did not have factor V Leiden, none had thrombosis (ages at this writing, 1 to 17 years). Three women who were heterozygous for both homocystinuria and factor V Leiden had recurrent fetal loss and placental infarctions. Conclusions. Patients with concurrent homocystinuria and factor V Leiden can have an increased risk of thrombosis, Screening for factor V Leiden may be indicated in patients with homocystinuria and their family members. (C) 1996, Massachusetts Medical Society.	TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MED CTR,THROMBOSIS & HEMOSTASIS UNIT,IL-31096 HAIFA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,INST THROMBOSIS & HEMOSTASIS,DEPT HEMATOL,SHEBA MED CTR,IL-69978 TEL AVIV,ISRAEL; FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT,1081 HV AMSTERDAM,NETHERLANDS; UNIV BASEL,CHILDRENS HOSP,BASEL,SWITZERLAND	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Basel	Mandel, H (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MED CTR,DEPT PEDIAT,IL-31096 HAIFA,ISRAEL.							BAUER KA, 1995, THROMB HAEMOSTASIS, V74, P94; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOSS GR, 1985, J CLIN INVEST, V76, P213, DOI 10.1172/JCI111948; BURKE G, 1994, NEW ENGL J MED, V326, P69; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CUTZ E, 1989, NEW ENGL J MED, V320, P646, DOI 10.1056/NEJM198903093201006; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; Fenton W. A., 1995, METABOLIC MOL BASES, P3129; FOWLER B, 1994, ENZYME PROTEIN, V47, P180; GANDRILLE S, 1995, BLOOD, V86, P219, DOI 10.1182/blood.V86.1.219.bloodjournal861219; GRASBECK R, 1972, NEW ENGL J MED, V287, P358; GREENGARD JS, 1994, NEW ENGL J MED, V331, P1559, DOI 10.1056/NEJM199412083312305; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LINDBLAD B, 1994, LANCET, V343, P917, DOI 10.1016/S0140-6736(94)90035-3; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROSENBLATT DS, 1977, PEDIATR RES, V11, P1141, DOI 10.1203/00006450-197711000-00005; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; ROSENBLATT DS, 1987, AM J MED GENET, V26, P377, DOI 10.1002/ajmg.1320260216; Rosenblatt DS., 1995, METABOLIC MOL BASES, VSeventh, P3111; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Sweetman L, 1991, TECHNIQUES DIAGNOSTI, P143; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; UHLENDORF BW, 1968, SCIENCE, V160, P1007, DOI 10.1126/science.160.3831.1007; VANBOVEN HH, 1995, THROMB HAEMOSTASIS, V73, P1256; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	42	245	255	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					763	768		10.1056/NEJM199603213341204	http://dx.doi.org/10.1056/NEJM199603213341204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592550				2022-12-01	WOS:A1996TZ97900004
J	Rensch, MJ; Merenich, JA; Lieberman, M; Long, BD; Davis, DR; McNally, PR				Rensch, MJ; Merenich, JA; Lieberman, M; Long, BD; Davis, DR; McNally, PR			Gluten-sensitive enteropathy in patients with insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CELIAC-DISEASE; ANTIBODIES; RELATIVES; CHILDREN; GLIADIN	Objective: To determine the prevalence of celiac disease in a cohort of patients with insulin-dependent diabetes mellitus and to describe the clinical characteristics of patients with coexistent disease. Design: Prospective cohort study. Setting: U.S. Army medical center. Patients: 47 patients with insulin-dependent diabetes mellitus. Measurements: Antiendomysial antibody testing was used to screen for celiac disease. The diagnosis of celiac disease required histologic evidence of villous atrophy and crypt hyperplasia and a positive antiendomysial antibody test result. In patients identified as having coexistent disease, complete blood counts, multiphasic biochemical testing, D-xylose absorption testing, and bone mineral density estimates were done. Results: 3 of 47 patients with insulin-dependent diabetes mellitus (6.4%; 95% Cl, 1.4% to 17.5%) had positive antiendomysial antibody test results and small-bowel biopsy specimens consistent with celiac disease. The 95% Ci lies entirely above the estimated prevalence of celiac disease expected in the general U.S. population, which ranges from 0.02% to 0.1%. Mean bone mineral densities were 0.8 and 1.1 SD below age-, ethnicity-, and sex matched controls in each of the 2 antiendomysial anti body-positive patients tested. Small-bowel absorption was abnormal in 1 of the 2 patients tested by D-xylose. Anemia and hypoalbuminemia were not detected in any of the patients with coexistent disease. Only 1 of the 3 patients had symptoms of diarrhea. All patients were at or above their ideal body weights. Conclusions: Celiac disease appears to be more common among patients with insulin-dependent diabetes mellitus than in the general U.S. population (P < 0.001). Two of the three patients with coexistent disease in this study had subclinical or latent celiac disease.	FITZSIMONS ARMY MED CTR, DEPT MED, SERV GASTROENTEROL, AURORA, CO 80045 USA; FITZSIMONS ARMY MED CTR, DEPT CLIN INVEST, AURORA, CO 80045 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COLLIN P, 1989, SCAND J GASTROENTERO, V24, P81, DOI 10.3109/00365528909092243; CONGIA M, 1994, HUM IMMUNOL, V40, P138, DOI 10.1016/0198-8859(94)90059-0; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Kahn CR, 1994, JOSLINS DIABETES MEL; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KNUDTZON J, 1991, J PEDIATR GASTR NUTR, V12, P190, DOI 10.1097/00005176-199102000-00009; LINDH E, 1992, J INTERN MED, V231, P403, DOI 10.1111/j.1365-2796.1992.tb00951.x; MAKI M, 1995, GUT, V36, P239, DOI 10.1136/gut.36.2.239; MAKI M, 1991, LANCET, V337, P763, DOI 10.1016/0140-6736(91)91375-5; RUBIN CE, 1960, GASTROENTEROLOGY, V38, P28; SAVILAHTI E, 1986, J PEDIATR-US, V108, P690, DOI 10.1016/S0022-3476(86)81042-3; STROBER W, 1992, OXFORD MONOGRAPHS ME, V20, P279; TALLEY NJ, 1994, AM J GASTROENTEROL, V89, P843; VOLTA U, 1991, DIGEST DIS SCI, V36, P752, DOI 10.1007/BF01311232; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WATSON RG, 1994, GUT, V35, pW14	19	77	77	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1996	124	6					564	567		10.7326/0003-4819-124-6-199603150-00004	http://dx.doi.org/10.7326/0003-4819-124-6-199603150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ529	8597319				2022-12-01	WOS:A1996TZ52900004
J	Celenza, A; Fothergill, J; Kupek, E; Shaw, RJ				Celenza, A; Fothergill, J; Kupek, E; Shaw, RJ			Thunderstorm associated asthma: A detailed analysis of environmental factors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOYBEAN DUST; WEATHER; POLLEN	Objectives-To seek meteorological factors, pollutants or pollen, and an asthma epidemic which occurred in London on 24 and 25 June 1994 after a thunderstorm. Design-Retrospective study of patients' accident and emergency department records, with bivariate and multivariate analysis of environmental factors and data collection for the two months surrounding the epidemic. Setting-The accident and emergency department of St Mary's Hospital in west central London. Subjects-148 patients presenting with asthma between 1 June and 31 July 1994, of whom 40 presented in the 24 hours after the storm. Results-The asthma epidemic was significantly associated with a drop in air temperature six hours previously and a high grass pollen concentration nine hours previously. Non-epidemic asthma was significantly associated with lightning strikes, increase in humidity or sulphur dioxide concentration, a drop in temperature or high rainfall the previous day, and a decrease in maximum air pressure or changes in grass pollen counts over the previous two days. Conclusions-New episodes of asthma during the epidemic on 24 and 25 June 1994 were associated with a fall in air temperature and a rise in grass pollen concentration. Non-epidemic asthma was significantly associated with a greater number of environmental changes. This may indicate that the patients with thunderstorm associated asthma were a separate population, sensitive to different environmental stimuli.	ST MARYS HOSP, LONDON W2 1NY, ENGLAND	Imperial College London								ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; AYRES J, 1994, BRIT MED J, V309, P619, DOI 10.1136/bmj.309.6955.619; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; BROWN HM, 1983, LANCET, V2, P630; CAMPBELLHEWSON G, 1994, BRIT MED J, V309, P1086, DOI 10.1136/bmj.309.6961.1086a; EGAN P, 1985, MED J AUSTRALIA, V142, P330, DOI 10.5694/j.1326-5377.1985.tb113389.x; Ito S, 1989, Arerugi, V38, P1077; Lim T O, 1991, Med J Malaysia, V46, P230; LOGAN WPD, 1953, LANCET, V264, P336; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MONTEALEGRE F, 1993, J ASTHMA, V30, P219, DOI 10.3109/02770909309054520; MORRISON I, 1960, Med J Aust, V47(1), P850; MURRAY V, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131c; PACKE GE, 1985, LANCET, V2, P199; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; *SAS I, 1995, P243 SAS I; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133	19	150	153	2	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	1996	312	7031					604	607						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ840	8595333				2022-12-01	WOS:A1996TZ84000023
J	Zuckerman, AJ				Zuckerman, AJ			Alphabet of hepatitis viruses	LANCET			English	Editorial Material											Zuckerman, AJ (corresponding author), ROYAL FREE HOSP, SCH MED, WHO, COLLABORATING CTR REFERENCE & RES VIRAL DIS, LONDON, ENGLAND.							Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7; ZUCKERMAN AJ, 1995, LANCET, V345, P1453, DOI 10.1016/S0140-6736(95)91032-8	7	173	174	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1996	347	9001					558	559		10.1016/S0140-6736(96)91267-2	http://dx.doi.org/10.1016/S0140-6736(96)91267-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX694	8596314				2022-12-01	WOS:A1996TX69400005
J	Hugot, JP; LaurentPuig, P; GowerRousseau, C; Olson, JM; Lee, JC; Beaugerie, L; Naom, I; Dupas, JL; VanGossum, A; Orholm, M; BonaitiPellie, C; Weissenbach, J; Mathew, CG; LennardJones, JE; Cortot, A; Colombel, JF; Thomas, G				Hugot, JP; LaurentPuig, P; GowerRousseau, C; Olson, JM; Lee, JC; Beaugerie, L; Naom, I; Dupas, JL; VanGossum, A; Orholm, M; BonaitiPellie, C; Weissenbach, J; Mathew, CG; LennardJones, JE; Cortot, A; Colombel, JF; Thomas, G			Mapping of a susceptibility locus for Crohn's disease on chromosome 16	NATURE			English	Article							INFLAMMATORY BOWEL-DISEASE; COMPLEX SEGREGATION ANALYSIS; LINKAGE ANALYSIS; EPIDEMIOLOGY	Crohn's disease (CD) and ulcerative colitis are the major forms of chronic inflammatory bowel diseases in the western world, and occur in young adults with an estimated prevalence of more than one per thousand inhabitants'. The causes of inflammatory bowel diseases remain unknown, but genetic epidemiology studies(2-5) suggest that inherited factors may contribute in part to variation in individual susceptibility to Crohn's disease. A genome-wide search performed on two consecutive and independent panels of families with multiple affected members, using a non-parametric two-point sibling-pair linkage method, identified a putative CD-susceptibility locus on chromosome 16 (P < 0.01 for each panel). The localization was centred around loci D16S409 and D16S419 by using multipoint sibpair analysis (ref. 6, and J.M.O., manuscript submitted) (P < 1.5 x 10(-5)). This region of the genome contains candidate genes which may be relevant to the pathogenic mechanism of inflammatory bowel diseases.	INST CURIE,LAB GENET TUMEURS,INSERM,U434,F-75231 PARIS,FRANCE; CTR HOSP REG & UNIV LILLE,REGISTRE MALAD INFLAMMATOIRES TUBE DIGEST NORD QU,F-59037 LILLE,FRANCE; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44109; ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; HOP ROTHSCHILD,SERV GASTROENTEROL & HEPTAOL,F-75571 PARIS,FRANCE; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; HOP NORD AMIENS,SERV HEPATOGASTROENTEROL,F-80054 AMIENS,FRANCE; HOP ERASME,SERV GASTROENTEROL & HEPATOPANCREATOL,B-1070 BRUSSELS,BELGIUM; GRP ETUD THERAPEUT AFFECT INFLAMMATORIES DIGEST,F-75012 PARIS,FRANCE; HERLEV HOSP,DEPT MED GASTROENTEROL,COPENHAGEN,DENMARK; INST GUSTAVE ROUSSY,CANC EPIDEMIOL UNIT,F-94805 VILLEJUIF,FRANCE; GENETHON,CNRS,URA 1922,F-91002 EVRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Lille - ISITE; CHU Lille; Case Western Reserve University; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Universite Libre de Bruxelles; University of Copenhagen; Herlev & Gentofte Hospital; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			Mathew, Christopher G/G-3434-2015; CORTOT, Antoine/I-5796-2015; Gower-Rousseau, Corinne/I-2553-2018; CORTOT, ANTOINE/I-7739-2016; laurent-puig, pierre/B-2226-2013; Laurent-Puig, Pierre/K-3641-2019; Hugot, Jean-Pierre/F-6594-2012	Mathew, Christopher G/0000-0003-4178-1838; Gower-Rousseau, Corinne/0000-0002-3925-5364; CORTOT, ANTOINE/0000-0002-1067-8996; laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459; Hugot, Jean-Pierre/0000-0002-8446-6056				BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; CALKINS BM, 1986, EPIDEMIOL REV, V8, P60, DOI 10.1093/oxfordjournals.epirev.a036296; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DOGGETT NA, 1995, NATURE, V377, P335; GOWERROUSSEAU C, 1994, GUT, V35, P1433, DOI 10.1136/gut.35.10.1433; GREEN P, 1992, CYTOGENET CELL GENET, V59, P122, DOI 10.1159/000133221; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HETLAND G, 1994, IMMUNOLOGY, V82, P445; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; KUSTER W, 1989, AM J MED GENET, V32, P105, DOI 10.1002/ajmg.1320320122; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MALONEY MD, 1994, J EXP MED, V180, P191, DOI 10.1084/jem.180.1.191; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; ORHOLM M, 1993, BRIT MED J, V306, P20, DOI 10.1136/bmj.306.6869.20; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; RISCH N, 1987, AM J HUM GENET, V40, P1; RISH N, 1990, AM J HUM GENET, V46, P229; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P21, DOI 10.1016/0016-5085(95)90004-7; SONNENBERG A, 1991, GASTROENTEROLOGY, V101, P122, DOI 10.1016/0016-5085(91)90468-Z; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; 1994, STATISTICAL ANAL GEN	27	790	825	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					821	823		10.1038/379821a0	http://dx.doi.org/10.1038/379821a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587604				2022-12-01	WOS:A1996TX50100057
J	Wragg, M; Hutton, M; Talbot, C; Busfield, F; Han, SW; Lendon, C; Clark, RF; Morris, JC; Edwards, D; Goate, A; Pfeiffer, E; Crook, R; Prihar, G; Phillips, H; Baker, M; Hardy, J; Rossor, M; Houlden, H; Karran, E; Roberts, G; Craddock, N				Wragg, M; Hutton, M; Talbot, C; Busfield, F; Han, SW; Lendon, C; Clark, RF; Morris, JC; Edwards, D; Goate, A; Pfeiffer, E; Crook, R; Prihar, G; Phillips, H; Baker, M; Hardy, J; Rossor, M; Houlden, H; Karran, E; Roberts, G; Craddock, N			Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease	LANCET			English	Article								Background Mutations in the presenilin-1 (PS-1) gene are associated with early-onset Alzheimer's disease. 40-50% of the risk for late-onset disease has been attributed to alleles at the apolipoprotein E (ApoE) locus. We have looked for an association between PS-1 and late-onset disease. Methods We collected blood samples from 208 white cases of dementia of the Alzheimer type and from 185 age matched controls (mean ages 76.9 and 76.2 years, respectively; 58% female in each series). Clinical diagnostic accuracy for Alzheimer's disease in our patients is 96%. We also studied 29 African-American patients with dementia of the Alzheimer type and 50 age-matched controls (cases vs controls, 77.2 vs 72.0 years; 72 vs 77% female). We used PCR to test for an association between Alzheimer's disease and a polymorphism within the intron 3' to exon 8 of the PS-1 gene. The ApoE genotype of most of the cases and controls was known from previous investigations. Findings Homozygosity of the 1 allele in the PS-1 gene was associated with a doubling of the risk for late-onset Alzheimer's disease compared with the [12]/[22] genotype (odds ratio 1.97, 95% CI 1.29-3.00). The proportion of Alzheimer's disease cases in the white population that could be attributed to homozygosity at this locus, as estimated by the attributable fraction, was 0.22. This compares with 0.35 for a single copy of ApoE4 and 0.15 for two copies. The smaller African-American series showed similar distribution of PS-1 genotype between cases and controls. Interpretation In our white series of cases, PS-1 accounted for about half as much of the risk for late-onset Alzheimer's disease as did ApoE4.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63100; UNIV S FLORIDA,GERONTOL CTR,TAMPA,FL; WASHINGTON UNIV,SCH MED,DEPT NEUROL & OCCUPAT THERAPY,ST LOUIS,MO 63100; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT PSYCHIAT,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT PHARMACOL,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT BIOCHEM,TAMPA,FL; UNIV S FLORIDA,SUNCOAST ALZHEIMERS DIS LABS,DEPT NEUROL,TAMPA,FL; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT NEUROL,LONDON W2,ENGLAND; SMITHKLINE BEECHAM,DEPT MOL NEUROPATHOL,HARLOW,ESSEX,ENGLAND; UNIV WALES COLL CARDIFF,COLL MED,DEPT PSYCHOL MED,CARDIFF,S GLAM,WALES	Washington University (WUSTL); State University System of Florida; University of South Florida; Washington University (WUSTL); State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Imperial College London; GlaxoSmithKline; Cardiff University			Morris, John C/A-1686-2012; Rossor, Martin/C-1598-2008; Hardy, John/C-2451-2009; Houlden, Henry J/C-1532-2008	Hardy, John/0000-0002-3122-0423; Houlden, Henry J/0000-0002-2866-7777; Goate, Alison/0000-0002-0576-2472; Rossor, Martin/0000-0001-8215-3120; Talbot, Christopher/0000-0001-7406-8962; Phillips, Helen Margaret/0000-0003-4513-9148; Clark, Robert/0000-0001-5091-8280	NATIONAL INSTITUTE ON AGING [R01AG012028, R01AG011871] Funding Source: NIH RePORTER; NIA NIH HHS [AG12028, AG11871, AG00634] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		Berg Leonard, 1994, P9; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; HOULDEN H, 1993, NEURODEGENERATION, V2, P283; HUTTON M, IN PRESS NEUROREPORT; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PEREZTUR J, IN PRESS NEUROREPORT; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TALBOT CJ, IN PRESS NEUROREPORT; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; WISNIEWSKI T, 1995, LANCET, V346, P1366, DOI 10.1016/S0140-6736(95)92379-9	17	230	242	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 24	1996	347	9000					509	512		10.1016/S0140-6736(96)91140-X	http://dx.doi.org/10.1016/S0140-6736(96)91140-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW697	8596269				2022-12-01	WOS:A1996TW69700011
J	Cochran, AG; Kim, PS				Cochran, AG; Kim, PS			Imitation of Escherichia coli aspartate receptor signaling in engineered dimers of the cytoplasmic domain	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; BACTERIAL CHEMOTAXIS; LEUCINE ZIPPER; COVALENT MODIFICATION; COILED-COILS; CRYSTAL-STRUCTURE; SENSORY RECEPTOR; KINASE CHEA; TRANSDUCTION; COMPLEX	Transmembrane signaling by bacterial chemotaxis receptors appears to require a conformational change within a receptor dimer. Dimers were engineered of the cytoplasmic domain of the Escherichia coli aspartate receptor that stimulated the kinase CheA in vitro. The folding free energy of the leucine-zipper dimerization domain was harnessed to twist the dimer interface of the receptor, which markedly affected the extent of CheA activation. Response to this twist was attenuated by modification of receptor regulatory sites, in the same manner as adaptation resets sensitivity to ligand in vivo. These results suggest that the normal allosteric activation of the chemotaxis receptor has been mimicked in a system that lacks both ligand-binding and transmembrane domains. The most stimulatory receptor dimer formed a species of tetrameric size.			Cochran, AG (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Cochran, Andrea/0000-0001-6469-795X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007348] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07348-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOWIE JU, 1995, ACTA CRYSTALLOGR D, V51, P145, DOI 10.1107/S0907444994010498; CARR CM, 1995, THESIS MIT; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLLINS LA, 1992, J BACTERIOL, V174, P3667, DOI 10.1128/JB.174.11.3667-3675.1992; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOERING D, 1992, THESIS MIT; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JIN T, 1994, J MOL BIOL, V244, P477, DOI 10.1006/jmbi.1994.1746; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAPLAN N, 1988, J BACTERIOL, V170, P5134, DOI 10.1128/jb.170.11.5134-5140.1988; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90, DOI DOI 10.1007/S00249-009-0425-1; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARK CY, 1990, J BACTERIOL, V172, P7179, DOI 10.1128/jb.172.12.7179-7187.1990; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1992, J BIOL CHEM, V267, P19753; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; YEH JI, 1993, J BIOL CHEM, V268, P8789; ZITZEWITZ JA, 1995, BIOCHEMISTRY-US, V34, P12812, DOI 10.1021/bi00039a042	62	99	100	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1113	1116		10.1126/science.271.5252.1113	http://dx.doi.org/10.1126/science.271.5252.1113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599087				2022-12-01	WOS:A1996TW70100037
J	Paulusma, CC; Bosma, PJ; Zaman, GJR; Bakker, CTM; Otter, M; Scheffer, GL; Scheper, RJ; Borst, P; Elferink, RPJO				Paulusma, CC; Bosma, PJ; Zaman, GJR; Bakker, CTM; Otter, M; Scheffer, GL; Scheper, RJ; Borst, P; Elferink, RPJO			Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene	SCIENCE			English	Article							HEREDITARY-CONJUGATED HYPERBILIRUBINEMIA; ATP-DEPENDENT TRANSPORT; MUTANT RATS; CANALICULAR TRANSPORT; MEMBRANE-VESICLES; ORGANIC-ANIONS; EXCRETION; LIVER; TR	The human Dubin-Johnson syndrome and its animal model, the TR(-) rat, are characterized by a chronic conjugated hyperbilirubinemia. TR(-) rats are defective in the canalicular multispecific organic anion transporter (cMOAT), which mediates hepatobiliary excretion of numerous organic anions. The complementary DNA for rat cmoat, a homolog of the human multidrug resistance gene (hMRP1), was isolated and shown to be expressed in the canalicular membrane of hepatocytes. In the TR(-) rat, a single-nucleotide deletion in this gene resulted in a reduced messenger RNA level and absence of the protein. It is likely that this mutation accounts for the TR(-) phenotype.	NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1080 HV AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Paulusma, CC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR FO116,DEPT GASTROINTESTINAL & LIVER DIS,CTR LIVER & INTESTINAL RES,1105 AZ AMSTERDAM,NETHERLANDS.		Paulusma, Coen/AAR-7943-2021	Paulusma, Coen/0000-0001-7284-1974				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V8, P148; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CRAWFORD JM, 1993, DISEASE LIVER, V1, P42; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P588, DOI 10.1007/BF00260615; ELFERINK RPJO, 1987, HEPATOLOGY, V7, P1109; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; EVERS R, IN PRESS J CLIN INVE; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, GASTROENTEROLOGY, V93, P1094, DOI 10.1016/0016-5085(87)90574-9; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KUIPERS F, 1989, J LIPID RES, V30, P1835; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; Otter M, 1995, BIOCHEM MOL BIOL INT, V37, P563; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SMIT JJM, 1994, LAB INVEST, V71, P638; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1993, CANCER RES, V53, P1747	36	755	765	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1126	1128		10.1126/science.271.5252.1126	http://dx.doi.org/10.1126/science.271.5252.1126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599091				2022-12-01	WOS:A1996TW70100041
J	Grubmuller, H; Heymann, B; Tavan, P				Grubmuller, H; Heymann, B; Tavan, P			Ligand binding: Molecular mechanics calculation of the streptavidin biotin rupture force	SCIENCE			English	Article							DYNAMICS; PROTEIN; PROGRAM; ENERGY	The force required to rupture the streptavidin-biotin complex was calculated here by computer simulations. The computed force agrees well with that obtained by recent single molecule atomic force microscope experiments. These simulations suggest a detailed multiple-pathway rupture mechanism involving five major unbinding steps. Binding forces and specificity are attributed to a hydrogen bond network between the biotin ligand and residues within the binding pocket of streptavidin. During rupture, additional water bridges substantially enhance the stability of the complex and even dominate the binding interactions. In contrast, steric restraints do not appear to contribute to the binding forces, although conformational motions were observed.			Grubmuller, H (corresponding author), UNIV MUNICH,INST MED OPT,THERESIENSTR 37,D-80333 MUNICH,GERMANY.							BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724; Brunger A.T., 1988, X PLOR; EICHINGER M, UNPUB; EICHINGER M, 1995, E COMMUNICATION; ELBER R, IN PRESS NEW DEV THE; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GRUBMULLER H, 1995, PHYS REV E, V52, P2893, DOI 10.1103/PhysRevE.52.2893; Heller H, 1990, MOL SIMULAT, V5, P133, DOI 10.1080/08927029008022127; JORGENSON WL, 1983, J CHEM PHYS, V79, P927; KITAO A, 1993, J PHYS CHEM-US, V97, P10223, DOI 10.1021/j100141a052; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; NIEDERMEIER C, 1994, J CHEM PHYS, V101, P734, DOI 10.1063/1.468129; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722	23	739	744	16	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					997	999		10.1126/science.271.5251.997	http://dx.doi.org/10.1126/science.271.5251.997			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584939	Green Submitted			2022-12-01	WOS:A1996TV70400052
J	Bradbury, AW; Ruckley, CV				Bradbury, AW; Ruckley, CV			Angioplasty for lower-limb ischaemia: Time for randomised controlled trials	LANCET			English	Editorial Material									UNIV EDINBURGH,VASC SURG OFF,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Bradbury, AW (corresponding author), ST MARYS HOSP,PRAED ST,LONDON,ENGLAND.							BAKER SR, 1995, AUST NZ J SURG, V65, P166, DOI 10.1111/j.1445-2197.1995.tb00600.x; BUCKENHAM TM, 1993, EUR J VASCULAR SURG, V7, P21, DOI 10.1016/S0950-821X(05)80538-9; Creasy T S, 1990, Eur J Vasc Surg, V4, P135, DOI 10.1016/S0950-821X(05)80427-X; CURRIE IC, 1994, BRIT J SURG, V81, P191, DOI 10.1002/bjs.1800810209; DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; HUNINK MGM, 1994, ADV VASC SURG, V2, P135; LONDON NJM, 1994, EUR J VASCULAR SURG, V8, P148, DOI 10.1016/S0950-821X(05)80450-5; LONDON NJM, 1995, BRIT J SURG, V82, P1232, DOI 10.1002/bjs.1800820925; Pell J P, 1995, Health Bull (Edinb), V53, P34; PELL JP, 1994, BRIT J SURG, V81, P832, DOI 10.1002/bjs.1800810613; PORTER JM, 1995, J VASC SURG, V21, P995, DOI 10.1016/S0741-5214(95)70229-6; RAY SA, 1995, BRIT J SURG, V82, P1217, DOI 10.1002/bjs.1800820921; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2_Supplement.2S; VROEGINDEWEIJ D, 1995, EUR J VASC ENDOVASC, V10, P40, DOI 10.1016/S1078-5884(05)80197-2; WHITE GH, 1995, J VASC SURG, V21, P270, DOI 10.1016/S0741-5214(95)70268-7; WHYMAN MR, 1991, BRIT J SURG, V78, P643, DOI 10.1002/bjs.1800780603	16	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					277	278		10.1016/S0140-6736(96)90460-2	http://dx.doi.org/10.1016/S0140-6736(96)90460-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569356				2022-12-01	WOS:A1996TT48500003
J	Phillips, AN				Phillips, AN			Reduction of HIV concentration during acute infection: Independence from a specific immune response	SCIENCE			English	Article							VIRUS TYPE-1 INFECTION; DYNAMICS; VIREMIA; PLASMA	After infection with the human immunodeficiency virus (HIV), the concentration of the virus in the person's plasma increases. The subsequent decrease in concentration a few weeks later was thought to result from an HIV-specific immune response. This purported causal relation is investigated with a model of the dynamics of early HIV infection that incorporates no increase in the rate of removal of free virions or virus-infected cells. A pattern of changes in virus concentration similar to that observed in patients is predicted by the model. Thus, the reduction in virus concentration during acute infection may not reflect the ability of the HIV-specific immune response to control virus replication.			Phillips, AN (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,HIV RES UNIT,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; GOWDA SD, 1989, J IMMUNOL, V142, P773; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KATZENSTEIN TL, UNPUB; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P40; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; MCLEAN AR, 1991, AIDS, V5, P485, DOI 10.1097/00002030-199105000-00002; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; PAUL WE, 1985, FUNDAMENTAL IMMUNOLO; PEAKMAN M, 1995, CELL ACTIVATION APOP; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PERELSON AS, 1989, LECTURE NOTES BIOMAT, V82, P350; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; SHENZLE D, 1994, STAT MED, V13, P2067; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	22	255	260	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					497	499		10.1126/science.271.5248.497	http://dx.doi.org/10.1126/science.271.5248.497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560262				2022-12-01	WOS:A1996TR32200039
J	Bakken, JS; Krueth, J; WilsonNordskog, C; Tilden, RL; Asanovich, K; Dumler, JS				Bakken, JS; Krueth, J; WilsonNordskog, C; Tilden, RL; Asanovich, K; Dumler, JS			Clinical and laboratory characteristics of human granulocytic ehrlichiosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To characterize the clinical and laboratory features observed in patients with human granulocytic ehrlichiosis (HGE) and evaluate the utility of the diagnostic tools used to confirm the diagnosis. Design.-Retrospective case study of 41 patients with laboratory-diagnosed HGE. Setting.-A total of 228 patients from Minnesota and Wisconsin were evaluated between June 1990 and May 1995. Methods.-Cases were presumptively identified by a history of an influenzalike illness acquired in an area known to be endemic for ticks. Diagnostic laboratory testing included microscopic examination of Wright-stained peripheral blood smears for presence of neutrophilic morulae, polymerase chain reaction (PCR) analysis of acute-phase blood samples for the Ehrlichia phagocytophila/Ehrlichia equi group DNA, and evaluation of serological responses by indirect immunofluorescent antibody assay (IFA), using E equi as antigen. Results.-All patients presented with a temperature of at least 37.6 degrees C, and most had headache, myalgias, chills, and varying combinations of leukopenia, anemia, and thrombocytopenia. Eighty percent of the patients tested demonstrated morulae in the cytoplasm of peripheral blood neutrophils. Only 16 of 37 patients tested by PCR were positive for HGE, whereas serum IFA assays of acute or convalescent blood samples detected antibodies against E equi in 38 of 40 patients tested. Two patients died, and the calculated case fatality rate was 4.9%. Conclusions.-Human granulocytic ehrlichiosis is being increasingly recognized in Wisconsin and Minnesota. A more severe illness is associated with increased age, anemia, increased percentage of neutrophils and decreased percentage of lymphocytes in peripheral blood, and presence of morulae in neutrophils. The differential diagnosis for patients who develop an influenzalike illness following a tick bite should include HGE. Microscopic examination of the acute-phase blood smear to detect neutrophilic morulae is currently the quickest and most practical screening method for diagnosing HGE in the upper Midwest.	DULUTH CLIN LTD, DIV LAB MED, DULUTH, MN 55805 USA; DULUTH CLIN LTD, DIV EDUC & RES, DULUTH, MN 55805 USA; UNIV MARYLAND, SCH MED, DEPT PATHOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Bakken, JS (corresponding author), DULUTH CLIN LTD, INFECT DIS SECT, 400 E 3RD ST, DULUTH, MN 55805 USA.							ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BAKKEN JS, 1995, 33RD ANN M INF DIS S; BARLOUGH JE, 1995, J CLIN MICROBIOL, V33, P3333, DOI 10.1128/JCM.33.12.3333-3334.1995; BROUQUI P, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91544-3; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P593; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; DAWSON JE, 1990, J INFECT DIS, V162, P91, DOI 10.1093/infdis/162.1.91; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; DUMLER JS, 1995, 35TH INT C ANT CHEM; DUMLER JS, 1995, NOV ASS MOL PATH ANN; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISH D, 1995, AM J MED, V98, pS2, DOI 10.1016/S0002-9343(99)80038-2; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FOGGIE A, 1951, J PATHOL BACTERIOL, V63, P1, DOI 10.1002/path.1700630103; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; MADIGAN JE, 1995, J INFECT DIS, V172, P1141, DOI 10.1093/infdis/172.4.1141; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MAGNARELLI LA, 1995, J CLIN MICROBIOL, V33, P2710, DOI 10.1128/JCM.33.10.2710-2714.1995; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PANCHOLI P, 1995, 33RD ANN M INF DIS S; REED K, 1995, MARSHFIELD LAB NEWS, V18, P1; REED KD, 1995, JAMA-J AM MED ASSOC, V273, P23, DOI 10.1001/jama.273.1.23b; RICHTER PJ, IN PRESS J MED ENTOM; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; TELFORD SR, 1995, 35TH INT C ANT CHEM; 1993, US 1990 CENSUS W E N	28	366	385	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					199	205		10.1001/jama.275.3.199	http://dx.doi.org/10.1001/jama.275.3.199			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604172				2022-12-01	WOS:A1996TP28200027
J	Arno, PS; Brandt, AM; Gostin, LO; Morgan, J				Arno, PS; Brandt, AM; Gostin, LO; Morgan, J			Tobacco industry strategies to oppose federal regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH		HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC	Harvard University; Harvard Medical School; Georgetown University	Arno, PS (corresponding author), YESHIVA UNIV,ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467, USA.							ALBRIGHT CL, 1988, HEALTH EDUC QUART, V15, P225, DOI 10.1177/109019818801500207; CALIFANO JA, 1994, JAMA-J AM MED ASSOC, V272, P1217; CARTER B, 1995, NY TIMES        1111, pA39; Carter Bill, 1995, NY TIMES        1109, pA1; *CDCP, 1996, CDCP PUBL; COHEN SE, 1964, ADVERTISING AGE, V35, P82; COHEN SE, 1964, ADVERTISING AGE, V35, P1; COLLINS G, 1995, NY TIMES        0218, pD4; FEDER BJ, 1996, NY TIMES        0107; FRANKEL A, 1995, AM LAWYER        JUL, P68; FRITSCHLER AL, 1969, SMOKING POLITICS POL; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P1176, DOI 10.1001/jama.272.15.1176; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Goodin R. E., 1989, NO SMOKING ETHICAL I; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P904, DOI 10.1001/jama.269.7.904; GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; HOVENKAMP H, 1995, YALE J REGUL, V12, P549; JACOBSON PD, 1993, J HEALTH POLIT POLIC, V18, P787; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KENT C, 1995, AM MED NEWS     0911, P2; KENT C, 1996, AM MED NEWS, V39, P3; MOORE S, 1994, JAMA-J AM MED ASSOC, V272, P1171, DOI 10.1001/jama.272.15.1171; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; NEWBERGER MB, 1963, SMOKE SCREEN TOBACCO; POSNER RA, 1971, BELL J ECON, V2, P22, DOI 10.2307/3003161; Quirk PJ, 1981, IND INFLUENCE FEDERA; SHEPARD AC, 1995, AM JOURNALISM REV, V17, P28; SHEPARD AC, 1995, AM JOURNALISM REV, V17, P47; SHEPARD AM, 1965, AM JOURNALISM REV, V17, P30; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; *TOB I, 1990, ITS LAW TOB PROD RET; *TOB I, 1993, TAX BURD TOB; *US DEPT HHS, 1994, PREV TOB US AM YOUNG; *US DEPT HHS, 1995, PUBL PHS; *US DEPT HHS, 1988, HLTH CONS SMOK NIC A; *US DHEW, 1964, US PHS PUBL, V1103; Warner K, 1995, TOB CONTROL, V4, P180; WATERHOUSE P, 1992, EC IMPACT TOBACCO IN; 1994, MMWR-MORBID MORTAL W, V43, P925; 1964, FED REGISTER, V29, P530; 1984, TIMES           0409, P91; 1995, CANT KICK HABIT TOBA; PUBL L, V8992; 1965, CONSUM REP, V30, P488; 1995, FED REG         1016, V60, P41313	45	22	23	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1258	1262		10.1001/jama.275.16.1258	http://dx.doi.org/10.1001/jama.275.16.1258			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601958				2022-12-01	WOS:A1996UF47800030
J	Nightingale, SL				Nightingale, SL			Important new safety information for tramadol hydrochloride	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-01	WOS:A1996UF47800008
J	NobenTrauth, K; Naggert, JK; North, MA; Nishina, PM				NobenTrauth, K; Naggert, JK; North, MA; Nishina, PM			A candidate gene for the mouse mutation tubby	NATURE			English	Article							PHOSPHODIESTERASE	A MUTATION in the tub gene causes maturity-onset obesity, insulin resistance(1), and sensory (d)eficits(2,3). In contrast to the rapid juvenile-onset weight gain seen in diabetes (db) and obese (ob) mice, obesity in tubby mice develops gradually, and strongly resembles the late-onset obesity seen in the human population. Excessive deposition of adipose tissue eventually leads to a twofold increase of body weight. Tubby mice also suffer retinal degeneration and neurosensory hearing loss(2,3). The tripartite character of the tubby phenotype shows striking similarity to human obesity syndromes, such as Alstrom(4) and Bardet-Biedl(5). Here we report the identification of a G --> T transversion in a candidate gene that abolishes a donor splice site in the 3' coding region and results in a larger transcript containing the unspliced intron. This alteration is predicted to replate the 44-carboxy-terminal amino acids with a 20-amino-acid sequence not found in the wild-type protein. Additionally, a second, prematurely truncated transcript with the unspliced intron is observed in testis messenger RNA and a 2-3-fold increase in brain mRNA is observed in tubby mice compared to B6. The phenotypic features of tubby mice may be the result of cellular apoptosis triggered by expression of the mutated tub gene.	JACKSON LAB,BAR HARBOR,ME 04609; SEQUANA THERAPEUT INC,LA JOLLA,CA 92037	Jackson Laboratory								ALSTROM C H, 1959, Acta Psychiatr Neurol Scand Suppl, V129, P1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BRAY GA, 1995, OBES RES, V3, P383, DOI 10.1002/j.1550-8528.1995.tb00164.x; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FARBER DB, 1994, PROG RETIN EYE RES, V13, P31, DOI 10.1016/1350-9462(94)90004-3; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; JONES JM, 1992, GENOMICS, V14, P197, DOI 10.1016/S0888-7543(05)80308-8; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LOVETT M, 1994, CURRENT PROTOCOLS HU; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NORTH MA, 1993, MAMM GENOME, V4, P466, DOI 10.1007/BF00364779; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; VAMBUTAS V, 1994, BBA-GENE STRUCT EXPR, V1217, P203, DOI 10.1016/0167-4781(94)90036-1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066	20	270	284	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					534	538		10.1038/380534a0	http://dx.doi.org/10.1038/380534a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606774				2022-12-01	WOS:A1996UE66300052
J	Burns, JW; SiadatPajouh, M; Krishnaney, AA; Greenberg, HB				Burns, JW; SiadatPajouh, M; Krishnaney, AA; Greenberg, HB			Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity	SCIENCE			English	Article							INTESTINAL M-CELLS; RHESUS ROTAVIRUS; IMMUNOGLOBULIN-A; INFECTION; RESPONSES; DIARRHEA; PROTEINS; DEFENSE; VIRUS; MODEL	Rotaviruses are the leading cause of severe gastroenteritis and dehydrating diarrhea in young children and animals worldwide. A murine model and ''backpack tumor'' transplantatio n were used to determine the protective effect of anti bod ies against VP4 (an outer capsid viral protein) and VP6 (a major inner capsid viral protein). Only two non-neutralizing immunoglobulin A (IgA) antibodies to VP6 were capable of preventing primary and resolving chronic murine rotavirus infections. These antibodies were not active, however, when presented directly to the luminal side of the intestinal tract. These findings support the hypothesis that in vivo intracellular viral inactivation by secretory IgA during transcytosis is a mechanism of host defense against rotavirus infection.	STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; VET ADM, PALO ALTO HLTH CARE SYST, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Burns, JW (corresponding author), STANFORD UNIV, SCH MED, DEPT MED, MED SCH LAB SURGE BLDG, ROOM P304, STANFORD, CA 94305 USA.			greenberg, harry/0000-0002-2128-9080	NIAID NIH HHS [R37AI21362] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burns JK., UNPUB; BURNS JW, 1988, J VIROL, V62, P2164, DOI 10.1128/JVI.62.6.2164-2172.1988; BURNS JW, 1995, VIROLOGY, V207, P143, DOI 10.1006/viro.1995.1060; CHIBA S, 1986, LANCET, V2, P417; CHILDERS NK, 1989, ANNU REV MICROBIOL, V43, P503, DOI 10.1146/annurev.mi.43.100189.002443; DHARAKUL T, 1990, J VIROL, V64, P4375, DOI 10.1128/JVI.64.9.4375-4382.1990; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; FENG NG, 1994, J VIROL, V68, P7766, DOI 10.1128/JVI.68.12.7766-7773.1994; GLASS RI, 1994, SCIENCE, V265, P1389, DOI 10.1126/science.8073280; HERRMANN JE, IN PRESS ARCH VIROL; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; MACKOW ER, 1988, VIROLOGY, V165, P511, DOI 10.1016/0042-6822(88)90595-8; MACKOW ER, 1988, P NATL ACAD SCI USA, V85, P645, DOI 10.1073/pnas.85.3.645; MATSON DO, 1993, J INFECT DIS, V167, P577, DOI 10.1093/infdis/167.3.577; MATSUI SM, 1989, ADV VIRUS RES, V36, P181; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; MAZANEC MB, 1995, J VIROL, V69, P1339, DOI 10.1128/JVI.69.2.1339-1343.1995; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; McGhee J R, 1990, Infect Dis Clin North Am, V4, P315; MCNEAL MM, 1995, VIROLOGY, V211, P474, DOI 10.1006/viro.1995.1429; OFFIT PA, 1986, J VIROL, V58, P700, DOI 10.1128/JVI.58.2.700-703.1986; PADILLANORIEGA L, 1992, J CLIN MICROBIOL, V30, P1392, DOI 10.1128/JCM.30.6.1392-1397.1992; SHAW RD, 1986, VIROLOGY, V155, P434, DOI 10.1016/0042-6822(86)90205-9; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; WARD RL, 1992, J INFECT DIS, V166, P1251, DOI 10.1093/infdis/166.6.1251; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	29	399	428	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					104	107		10.1126/science.272.5258.104	http://dx.doi.org/10.1126/science.272.5258.104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600516				2022-12-01	WOS:A1996UD59700048
J	Frankel, SS; Wenig, BM; Burke, AP; Mannan, P; Thompson, LDR; Abbondanzo, SL; Nelson, AM; Pope, M; Steinman, RM				Frankel, SS; Wenig, BM; Burke, AP; Mannan, P; Thompson, LDR; Abbondanzo, SL; Nelson, AM; Pope, M; Steinman, RM			Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid	SCIENCE			English	Article							EPIDERMAL LANGERHANS CELLS; LYMPH-NODES; INFECTED PATIENTS; VIRUS; EXPRESSION; AIDS; LYMPHADENOPATHY; DISEASE; RNA; RESERVOIRS	Human immunodeficiency virus-type 1 (HIV-1) replicates actively in infected individuals, yet cells with intracellular depots of viral protein are observed only infrequently. Many cells expressing the HIV-1 Gag protein were detected at the surface of the nasopharyngeal tonsil or adenoid. This infected mucosal surface contained T cells and dendritic cells, two cell types that together support HIV-1 replication in culture. The infected cells were multinucleated syncytia and expressed the S100 and p55 dendritic cell markers. Eleven of the 13 specimens analyzed were from donors who did not have symptoms of acquired immunodeficiency syndrome (AIDS). The interaction of dendritic cells and T cells in mucosa may support HIV-1 replication, even in subclinical stages of infection.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,DIV AIDS,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT OTOLARYNG & ENDOCRINE PATHOL,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT HEMATOL & LYMPHAT PATHOL,WASHINGTON,DC 20306	Rockefeller University; United States Department of Defense; United States Department of Defense; United States Department of Defense; United States Department of Defense			Steinman, Ralph/F-7729-2012; Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432	NIAID NIH HHS [AI24775] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1984, LANCET, V2, P370; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAWCETT DW, 1986, TXB HIST; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; FRANKEL S, UNPUB; GIANNETTI A, 1993, J ACQ IMMUN DEF SYND, V6, P329; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAHN HJ, 1983, AM J CLIN PATHOL, V79, P341, DOI 10.1093/ajcp/79.3.341; KALTER DC, 1991, J IMMUNOL, V146, P3396; KANITAKIS J, 1989, AIDS RES HUM RETROV, V5, P293, DOI 10.1089/aid.1989.5.293; KLEIN J, 1990, IMMUNOLOGY, P52; Mosialos G, 1996, AM J PATHOL, V148, P593; MULLER H, 1993, RES VIROLOGY, V144, P59, DOI 10.1016/S0923-2516(06)80013-0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POPE M, 1995, J INVEST DERMATOL, V104, P11, DOI 10.1111/1523-1747.ep12613452; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; RACZ KT, 1988, AIDS, V2, P299; RACZ KT, 1985, LANCET, V1, P105; RUCO LP, 1995, J PATHOL, V176, P391, DOI 10.1002/path.1711760410; SCHUURMAN HJ, 1988, AM J PATHOL, V133, P516; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TAKAHASHI K, 1984, AM J PATHOL, V116, P497; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISER B, 1990, P NATL ACAD SCI USA, V87, P3997, DOI 10.1073/pnas.87.10.3997	29	269	270	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					115	117		10.1126/science.272.5258.115	http://dx.doi.org/10.1126/science.272.5258.115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600520				2022-12-01	WOS:A1996UD59700052
J	Chen, ZJ; Parent, L; Maniatis, T				Chen, ZJ; Parent, L; Maniatis, T			Site-specific phosphorylation of I kappa B alpha by a novel ubiquitination-dependent protein kinase activity	CELL			English	Article							DEGRADATION; ACTIVATION; LIGASE	Signal-induced activation of the transcription factor NF-kappa B requires specific phosphorylation of the inhibitor I kappa B alpha and its subsequent proteolytic degradation. Phosphorylation of serine residues 32 and 36 targets I kappa B alpha to the ubiquitin (Ub)-proteasome pathway. Here we report the identification of a large, multisubunit kinase (molecular mass similar to 700 kDa) that phosphorylates I kappa B alpha at S32 and S36. Remarkably, the activity of this kinase requires the Uh-activating enzyme (E1), a specific Ub carrier protein (E2) of the Ubc4/Ubc5 family, and Ub. We also show that a ubiquitination event in the kinase complex is a prerequisite for specific phosphorylation of I kappa B alpha. Thus, ubiquitination serves a novel regulatory function that does not involve proteolysis.	HARVARD UNIV,DEPT CELLULAR & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	Chen, ZJ (corresponding author), PROSCRIPT INC,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BROOKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clechanover A., 1994, CELL, V79, P13; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MENON SD, 1993, J BIOL CHEM, V268, P26805; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	48	851	889	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					853	862		10.1016/S0092-8674(00)81064-8	http://dx.doi.org/10.1016/S0092-8674(00)81064-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601309	Bronze			2022-12-01	WOS:A1996UC38100007
J	Chang, RW; Pellissier, JM; Hazen, GB				Chang, RW; Pellissier, JM; Hazen, GB			A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STOCHASTIC TREES; REPLACEMENT; ARTHRITIS; REVISION	Objective.-To quantify the trade-off between the expected increased short- and long-term costs and the expected increase in quality-adjusted life expectancy (QALE) associated with total hip arthroplasty (THA) for persons with functionally significant hip osteoarthritis. Design.-A cost-effectiveness study was performed from the societal perspective by constructing stochastic tree, decision analytic models designed to estimate lifetime functional outcomes and costs of THA and nonoperative managements. Main Outcome Measures.-A modified four-state American College of Rheumatology functional status classification was used to measure effectiveness. These functional classes were assigned utility values to allow the relative effectiveness of THA to be expressed in quality-adjusted life years (QALYs), Lifetime costs included costs associated with primary and potential revision surgeries and long-term care costs associated with the functionally dependent class. Data Used in the Cost-effectiveness Model.-Probability and incidence rate data were summarized from the literature. The THA hospital cost data were obtained from local teaching hospitals' cost accounting systems, Estimates of recurring medical costs for functionally significant hip osteoarthritis and for custodial care were derived from the literature. Results.-The THA cost-effectiveness ratio increases with age and is higher for men than for women, In the base-case scenario for 60-year-old white women who have functionally significant but not dependent hip osteoarthritis, the model predicts that THA is cost saving because of the high costs of custodial care associated with dependency due to worsening hip osteoarthritis and that the procedure increases QALE by about 6.9 years. In the base-case scenario for men aged 85 years and older, the average lifetime cost associated with THA is $9100 more than nonoperative management, with an average increase in QALE of about 2 years. Thus, the THA cost-effectiveness ratio for men aged 85 years and older is $4600 per QALY gained, less than that of procedures intended to extend life such as coronary artery bypass surgery or renal dialysis, Worst-case analysis suggests that THA remains minimally cost-effective for this oldest age category ($80 000/QALY) even if probabilities, rates, utilities, costs, and the discount rate are simultaneously varied to extreme values that bias the analysis against surgery. Conclusions.-For persons with hip osteoarthritis associated with significant functional limitation, THA can be cost saving or, at worst, cost-effective in improving QALE when both short- and long-term outcomes are considered, Further research is needed to determine whether this procedure is actually being used in this cost-effective manner, especially in older age categories.	NORTHWESTERN UNIV, INST HLTH SERV RES & POLICY STUDIES, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT PREVENT MED, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT MED, ARTHRITIS DIV, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT PHYS MED & REHABIL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, DEPT IND ENGN, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, INST HLTH SERV RES & POLICY STUDIES, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT PREVENT MED, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT MED, ARTHRITIS DIV, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT PHYS MED & REHABIL, EVANSTON, IL USA; NORTHWESTERN UNIV, DEPT IND ENGN, EVANSTON, IL USA; LOYOLA UNIV, DEPT MANAGEMENT SCI, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Loyola University Chicago	Chang, RW (corresponding author), NORTHWESTERN UNIV, MULTIPURPOSE ARTHRITIS & MUSCULOSKELETAL DIS CTR, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Hazen, Gordon/B-7463-2009		NIAMS NIH HHS [AR30692] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM AC ORTH SURG, 1993, ORTH KNOWL UPD, V4; *AM ASS HOM SERV A, 1994, BACKGR FACTS AG SERV; AMSTUTZ HC, 1982, CLIN ORTHOP RELAT R, V170, P21; ANDERSON M A, 1981, Orthopaedic Transactions, V5, P75; [Anonymous], 1995, JAMA, V273, P1950; BARBER TC, 1993, J BONE JOINT SURG AM, V75A, P321, DOI 10.2106/00004623-199303000-00002; BECKENBAUGH RD, 1978, J BONE JOINT SURG AM, V60, P306, DOI 10.2106/00004623-197860030-00005; BOOTH RE, 1988, TOTAL HIP ARTHROPLAS; BROUGHTON NS, 1982, ACTA ORTHOP SCAND, V53, P923, DOI 10.3109/17453678208992850; Cameron H U, 1981, Acta Orthop Belg, V47, P49; COLLIS DK, 1988, ORTHOP CLIN N AM, V19, P541; COVENTRY MB, 1974, J BONE JOINT SURG AM, VA 56, P273, DOI 10.2106/00004623-197456020-00005; COX DR, 1955, P CAMBRIDGE PHILOS S, V51, P313; DANIELSSON L, 1964, ACTA ORTHOP SCAND S, V66, P9; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESSES S, 1983, CAN J SURG, V26, P345; ESTOCK DM, 1994, CLIN ORTHOP RELAT R, P190; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FOWLER JL, 1988, ORTHOP CLIN N AM, V19, P477; FRIEDMAN B, 1993, MED CARE, V31, P581, DOI 10.1097/00005650-199307000-00002; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GUSTILO RB, 1984, P 12 ANN M HIP SOC S, P342; GUSTILO RB, 1988, CLIN ORTHOPAEDICS, V0235, P00111; HARRIS WH, 1990, NEW ENGL J MED, V323, P725, DOI 10.1056/NEJM199009133231106; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; HAZEN GB, 1993, MED DECIS MAKING, V13, P227, DOI 10.1177/0272989X9301300309; HAZEN GB, 1992, MED DECIS MAKING, V12, P163, DOI 10.1177/0272989X9201200302; HERBERTS P, 1989, CLIN ORTHOP RELAT R, V249, P48; HOOGLAND T, 1981, CLIN ORTHOP RELAT R, V161, P180; HUNTER GA, 1979, J BONE JOINT SURG BR, V61, P419, DOI 10.1302/0301-620X.61B4.500750; JAMES ETR, 1982, CLIN ORTHOP RELAT R, V170, P88; JINNAH RH, 1986, CLIN ORTHOP RELAT R, V211, P164; JONES JM, 1979, J BONE JOINT SURG AM, V61, P1029, DOI 10.2106/00004623-197961070-00010; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; KATZ JN, 1994, MED CARE, V32, P183, DOI 10.1097/00005650-199402000-00009; KAVANAGH BF, 1989, J BONE JOINT SURG AM, V71A, P1496, DOI 10.2106/00004623-198971100-00007; KAVANAGH BF, 1985, J BONE JOINT SURG AM, V67A, P517, DOI 10.2106/00004623-198567040-00003; KAVANAGH BF, 1987, J BONE JOINT SURG AM, V69A, P1144, DOI 10.2106/00004623-198769080-00006; KAVANAGH BF, 1985, CLIN ORTHOP RELAT R, V193, P133; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LAUPACIS A, 1994, J ARTHROPLASTY, V9, P481, DOI 10.1016/0883-5403(94)90093-0; LAUPACIS A, 1993, J BONE JOINT SURG AM, V75A, P1619, DOI 10.2106/00004623-199311000-00006; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MARTI RK, 1990, J BONE JOINT SURG AM, V72A, P346, DOI 10.2106/00004623-199072030-00005; MCCOY TH, 1988, ORTHOP CLIN N AM, V19, P467; MULROY RD, 1990, J BONE JOINT SURG BR, V72, P757, DOI 10.1302/0301-620X.72B5.2211749; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2, P12; PELLICCI PM, 1985, J BONE JOINT SURG AM, V67A, P513, DOI 10.2106/00004623-198567040-00002; PELLICCI PM, 1982, CLIN ORTHOP RELAT R, V170, P34; PELLISSIER JM, 1994, SOCIO ECON PLAN SCI, V28, P251, DOI 10.1016/0038-0121(94)90030-2; PELLISSIER JM, 1994, MED DECIS MAKING, V14, P439; REIGSTAD A, 1984, ARCH ORTHOP TRAUM SU, V103, P152, DOI 10.1007/BF00435545; Retpen J B, 1989, J Arthroplasty, V4, P311, DOI 10.1016/S0883-5403(89)80032-4; SANZEN L, 1988, CLIN ORTHOP RELAT R, P165; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCHULTE KR, 1993, J BONE JOINT SURG AM, V75A, P961, DOI 10.2106/00004623-199307000-00002; SCHURMAN DJ, 1989, CLIN ORTHOP RELAT R, V240, P172; SCHUTZER SF, 1988, J BONE JOINT SURG AM, V70A, P724, DOI 10.2106/00004623-198870050-00013; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHITE RH, 1990, J GEN INTERN MED, V5, P304, DOI 10.1007/BF02600396; WHITTLE J, 1993, CLIN ORTHOP RELAT R, V295, P119; [No title captured]; [No title captured]; [No title captured]; [No title captured]; 1994, EC INDICATORS, P23; [No title captured]	70	406	410	3	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					858	865		10.1001/jama.275.11.858	http://dx.doi.org/10.1001/jama.275.11.858			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ971	8596224				2022-12-01	WOS:A1996TZ97100029
J	Inouye, SK; Charpentier, PA				Inouye, SK; Charpentier, PA			Precipitating factors for delirium in hospitalized elderly persons - Predictive model and interrelationship with baseline vulnerability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; MINI-MENTAL STATE; MEDICAL PATIENTS; RISK-FACTORS; SEVERITY; ILLNESS	Objectives.-To prospectively develop and validate a predictive model for delirium based on precipitating factors during hospitalization, and to examine the interrelationship of precipitating factors and baseline vulnerability. Design.-Two prospective cohort studies, in tandem. Setting.-General medical wards, university teaching hospital. Patients.-For the development cohort, 196 patients aged 70 years and older with no delirium at baseline, and for the validation cohort, 312 comparable patients. Main Outcome Measure.-New-onset delirium by hospital day 9, defined by the Confusion Assessment Method diagnostic criteria. Results.-Delirium developed in 35 patients (18%) in the development cohort. Five independent precipitating factors for delirium were identified: use of physical restraints (adjusted relative risk [RR], 4.4; 95% confidence interval [CI], 2.5 to 7.9), malnutrition (RR, 4.0; 95% CI, 2.2 to 7.4), more than three medications added (RR, 2.9; 95% CI, 1.6 to 5.4), use of bladder catheter (RR, 2.4; 95% CI, 1.2 to 4.7), and any iatrogenic event (RR, 1.9; 95% CI, 1.1 to 3.2). Each precipitating factor preceded the onset of delirium by more than 24 hours. A risk stratification system was developed by adding 1 point for each factor present. Rates of delirium for low-risk (0 points), intermediate-risk (1 to 2 points), and high-risk groups (greater than or equal to 3 points) were 3%, 20%, and 59%, respectively (P<.001). The corresponding rates in the validation cohort, in which 47 patients (15%) developed delirium, were 4%, 20%, and 35%, respectively (P<.001). When precipitating and baseline factors were analyzed in cross-stratified format, delirium rates increased progressively from low-risk to high-risk groups in all directions (double-gradient phenomenon). The contributions of baseline and precipitating factors were documented to be independent and statistically significant. Conclusions.-A simple predictive model based on the presence of five precipitating factors can be used to identify elderly medical patients at high risk for delirium. Precipitating and baseline vulnerability factors are highly interrelated and contribute to delirium in independent, substantive, and cumulative ways.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510	Yale University; Yale University			Inouye, Sharon/R-7216-2019		NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER; NIA NIH HHS [P60AG10469] Funding Source: Medline; PHS HHS [K08AB00524] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BECK S, RAND PUBLICATION; BECKER PM, 1987, JAMA-J AM MED ASSOC, V257, P2313, DOI 10.1001/jama.257.17.2313; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; FEINSTEIN AR, 1987, CLINIMETRICS, P57; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOREMAN MD, 1989, RES NURS HEALTH, V12, P21, DOI 10.1002/nur.4770120105; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; HOSMER DW, 1989, APPL LOGISTIC REGRES, P131; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MCCULLAGH P, 1983, GEN LINEAR MODELS MO, P79; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; ROSIN AJ, 1966, J CHRON DIS, V19, P307, DOI 10.1016/0021-9681(66)90134-2; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; VENTRY IM, 1982, EAR HEARING, V3, P128, DOI 10.1097/00003446-198205000-00006; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P31, DOI 10.1002/nur.4770080107; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	31	860	883	2	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1996	275	11					852	857		10.1001/jama.275.11.852	http://dx.doi.org/10.1001/jama.275.11.852			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ971	8596223				2022-12-01	WOS:A1996TZ97100028
J	Luo, LQ; Hensch, TK; Ackerman, L; Barbel, S; Jan, LY; Jan, YN				Luo, LQ; Hensch, TK; Ackerman, L; Barbel, S; Jan, LY; Jan, YN			Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines	NATURE			English	Article							CALCIUM-BINDING PROTEIN; ELECTRON-MICROSCOPY; CEREBELLAR CORTEX; EXPRESSION; MOUSE; CLONING; BRAIN; GENE; MICE	Neurons contain distinct compartments including dendrites, dendritic spines, axons and synaptic terminals(1). The molecular mechanisms that generate and distinguish these compartments, although largely unknown, may involve the small GTPases Rac and Cdc42 (ref. 2), which appear to regulate actin polymerization(3). Having shown that perturbations of Rad activity block the growth of axons but not dendrites of Drosophila neurons(2), we investigated whether this also applies to mammals by examining transgenic mice expressing constitutively active human Rad in Purkinje cells. We found that these mice were ataxic and had a reduction of Purkinje-cell axon terminals in the deep cerebellar nuclei, whereas the dendritic trees grew to normal height and branched extensively. Unexpectedly, the dendritic spines of Purkinje cells in developing and mature cerebella were much reduced in size but increased in number. These 'mini' spines often form supernumerary synapses. These differential effects of perturbing Rac1 activity indicate that there may be distinct mechanisms for the elaboration of axons, dendrites and dendritic spines.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Luo, LQ (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Hensch, Takao/L-4182-2019	Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				AJIMA A, 1991, NEUROSCI RES, V12, P281, DOI 10.1016/0168-0102(91)90117-H; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BERRY M, 1976, BRAIN RES, V112, P1, DOI 10.1016/0006-8993(76)90331-0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; FAIREN A, 1992, MICROSC RES TECHNIQ, V23, P289, DOI 10.1002/jemt.1070230405; GUENET JL, 1983, J HERED, V74, P105, DOI 10.1093/oxfordjournals.jhered.a109729; HALL AA, 1994, REV CELL BIOL, V10, P31; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Hogan B., 1986, MANIPULATING MOUSE E; Ito M., 1984, CEREBELLUM NEURAL CO; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JANDE SS, 1981, NATURE, V294, P765, DOI 10.1038/294765a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MOLL J, 1991, ONCOGENE, V6, P863; OBERDICK J, 1993, NEURON, V10, P1007, DOI 10.1016/0896-6273(93)90050-2; Palay S.L., 1974, CEREBELLAR CORTEX CY; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; ROFFLERTARLOV S, 1979, BRAIN RES, V168, P75, DOI 10.1016/0006-8993(79)90129-X; SMEYNE RJ, 1995, MOL CELL NEUROSCI, V6, P230, DOI 10.1006/mcne.1995.1019; SOTELO C, 1990, J NEUROCYTOL, V19, P737, DOI 10.1007/BF01188042; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; WOOD TL, 1988, DNA-J MOLEC CELL BIO, V7, P585, DOI 10.1089/dna.1988.7.585	30	380	386	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					837	840		10.1038/379837a0	http://dx.doi.org/10.1038/379837a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587609				2022-12-01	WOS:A1996TX50100062
J	Moxham, CM; Malbon, CC				Moxham, CM; Malbon, CC			Insulin action impaired by deficiency of the G-protein subunit G(i alpha 2)	NATURE			English	Article							PHOSPHATASE-ACTIVITIES; PHOSPHORYLATION STATE; GLUCOSE-TRANSPORT; ANTISENSE RNA; DIABETIC RATS; PHOSPHOTYROSINE	Integration of information between tyrosine kinase(1) and G-protein-mediated pathways(2) is necessary, but remains poorly understood. Here we use cells from transgenic mice harbouring inducible expression of RNA antisense to the gene encoding G(i alpha 2) (refs 3, 4) to show that G(i alpha 2) is critical for insulin action. G(i alpha 2) deficiency in adipose tissue and liver produces hyperinsulinaemia, impaired glucose tolerance and resistance to insulin in vivo. Insulin resistance affects glucose-transporter activity and recruitment, counterregulation of lipolysis, and activation of glycogen synthase, all of which are cardinal responses to insulin(5). G(i alpha 2) deficiency increases protein-tyrosine phosphatase activity and attenuates insulin-stimulated tyrosine phosphorylation of IRS (insulin-receptor substrate 1) in vivo. G(i alpha 2) deficiency creates a model for the insulin resistance characteristic of noninsulin-dependent diabetes mellitus (NIDDM)(6), implicating G(i alpha 2) as a positive regulator of insulin action.			Moxham, CM (corresponding author), SUNY STONY BROOK,UNIV MED CTR,DEPT MOLEC PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794, USA.		malbon, craig/ABF-3604-2020					AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BOYLAN JM, 1992, J CLIN INVEST, V90, P174, DOI 10.1172/JCI115833; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; COHEN P, 1985, MOL BASIS INSULIN AC, P213; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOLEY JE, 1978, AM J PHYSIOL, V234, pE112, DOI 10.1152/ajpendo.1978.234.2.E112; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GAWLER D, 1987, NATURE, V327, P224; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; KAMIELI E, 1981, J BIOL CHEM, V256, P4772; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; LAVAN BE, 1994, BIOCHEM SOC T, V22, P676, DOI 10.1042/bst0220676; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAURO LJ, 1993, ADV PROT PHOSPHATASE, V7, P393; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYER MG, 1994, MOL CELL BIOL, V14, P3577; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIELAND O, 1974, METHOD ENZYMAT AN, V3, P1404	30	181	186	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					840	844		10.1038/379840a0	http://dx.doi.org/10.1038/379840a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587610				2022-12-01	WOS:A1996TX50100063
J	Faham, S; Hileman, RE; Fromm, JR; Linhardt, RJ; Rees, DC				Faham, S; Hileman, RE; Fromm, JR; Linhardt, RJ; Rees, DC			Heparin structure and interactions with basic fibroblast growth factor	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; MITOGENIC ACTIVITY; FACTOR FAMILY; BINDING; RECEPTOR; OLIGOSACCHARIDES; REFINEMENT; RESOLUTION; AFFINITY; CELLS	Crystal structures of heparin-derived tetra- and hexasaccharides complexed with basic fibroblast growth factor (bFGF) were determined at resolutions of 1.9 and 2.2 angstroms, respectively. The heparin structure may be approximated as a helical polymer with a disaccharide rotation of 174 degrees and a translation of 8.6 angstroms along the helix axis. Both molecules bound similarly to a region of the bFGF surface containing residues asparagine-28, arginine-121, lysine-126, and glutamine-135; the hexasaccharide also interacted with an additional binding site formed by lysine-27, asparagine-102, and lysine-136. No significant conformational change in bFGF occurred upon heparin oligosaccharide binding, which suggests that heparin primarily serves to juxtapose components of the FGF signal transduction pathway.	CALTECH,DIV CHEM & CHEM ENGN 14775CH,PASADENA,CA 91125; UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242	California Institute of Technology; University of Iowa					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, T32GM008346, R37GM045162, R01GM038060] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38060, GM45162, T32 GM08346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGO H, 1991, J BIOCHEM-TOKYO, V110, P360, DOI 10.1093/oxfordjournals.jbchem.a123586; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANE DA, 1989, HEPARIN; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lindahl, 1989, HEPARIN CHEM BIOL PR, P51; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stoddart J.F., 1971, STEREOCHEMISTRY CARB; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WALKER A, 1994, J BIOL CHEM, V269, P931; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	39	708	728	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1116	1120		10.1126/science.271.5252.1116	http://dx.doi.org/10.1126/science.271.5252.1116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599088				2022-12-01	WOS:A1996TW70100038
J	Ignatowicz, L; Kappler, J; Marrack, P				Ignatowicz, L; Kappler, J; Marrack, P			The repertoire of T cells shaped by a single MHC/peptide ligand	CELL			English	Article							RECEPTOR TRANSGENIC MICE; INVARIANT CHAIN; MONOCLONAL-ANTIBODY; POSITIVE SELECTION; ANTIGEN RECEPTOR; THYMUS; TOLERANCE; RECOGNITION; PEPTIDES; LACKING	Although the thymus produces many immature thymocytes, few of these cells mature. Positive selection has been thought to limit thymocyte development. In thymuses expressing a single MHC/peptide combination, however, surprisingly large numbers of thymocytes are selected to mature. Many of these react with the selecting MHC, bound to other self-peptides. Therefore, the number of thymocytes that mature is limited by the fact that positively selected cells die because they react too well with MHC bound to self-peptides that are not identical to those involved in positive selection. T cells that mature in thymuses expressing a single MHC/peptide ligand react frequently with foreign MHC, suggesting that the repertoire of alpha beta receptors may be more biased toward reaction with MHC than was previously thought.	NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80206	Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ignatowicz, L (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	PHS HHS [AL18785, AL17134, AL22295] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BLACKMAN M, 1986, CELL, V47, P349, DOI 10.1016/0092-8674(86)90591-X; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DIANZANI U, 1992, J IMMUNOL, V148, P678; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; FISCHERLINDAHL K, 1977, J EXP MED, V145, P508; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUMBLET C, 1994, INT IMMUNOL, V6, P1949, DOI 10.1093/intimm/6.12.1949; HUNIG T, 1980, J EXP MED, V151, P1288, DOI 10.1084/jem.151.5.1288; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; IGNATOWICZ L, 1995, J IMMUNOL, V154, P3852; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KAPPLER JW, 1976, NATURE, V262, P797, DOI 10.1038/262797a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KELLY KA, 1993, EUR J IMMUNOL, V23, P1922, DOI 10.1002/eji.1830230829; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUSOFF U, 1993, J IMMUNOL METHODS, V166, P287; LAMB CA, 1992, J IMMUNOL, V148, P3478; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LO D, 1986, IMMUNOL RES, V5, P221, DOI 10.1007/BF02919203; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SCHERER MT, 1995, J EXP MED, V182, P1493, DOI 10.1084/jem.182.5.1493; SCHUMACHER TNM, 1994, IMMUNITY, V1, P721, DOI 10.1016/S1074-7613(94)80013-8; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WHITE J, 1983, J IMMUNOL, V130, P1033; WHITE J, 1989, J IMMUNOL, V143, P1822; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1975, J EXP MED, V141, P1427, DOI 10.1084/jem.141.6.1427	55	381	392	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					521	529		10.1016/S0092-8674(00)81028-4	http://dx.doi.org/10.1016/S0092-8674(00)81028-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598039	Bronze			2022-12-01	WOS:A1996TX17600005
J	Amir, S; Stewart, J				Amir, S; Stewart, J			Resetting of the circadian clock by a conditioned stimulus	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; PHASE RESPONSE CURVES; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; SYRIAN-HAMSTER; C-FOS; RAT; RHYTHMS; IMMUNOREACTIVITY; PROJECTIONS	ENVIRONMENTAL, light is the dominant temporal cue for the entrainment of circadian rhythms. In mammals, light entrains circadian rhythms by daily resetting a pacemaker located in the hypothalamic suprachiasmatic nucleus (SCN)(1,2). Although it is widely held that phase resetting by light involves cellular elements within the SCN that are uniquely responsive to photic cues(1,3), we now report that non-photic cues that reliably precede the onset of light can, through associative learning, come to activate these elements. In rats, a neutral non-photic stimulus paired with light in pavlovian conditioning trials was capable of eliciting cellular and behavioural effects characteristic of phase-dependent resetting of the pacemaker by light, the expression of the transcription factor Fos in SCN cells, and phase shifts in free-running activity and temperature rhythms(4-7). Thus an associative learning process, pavlovian conditioning, provides a means whereby environmental cues that predict light onset can come to mimic the effect of light on the SCN pacemaker and thereby bring about entrainment of circadian rhythms.			Amir, S (corresponding author), CONCORDIA UNIV,DEPT PSYCHOL,CTR STUDIES BEHAV NEUROBIOL,1455 MAISONNEUVE BLVD,MONTREAL,PQ H3G 1M8,CANADA.		Amir, Shimon/AAE-4635-2022					AMIR S, 1995, NEUROSCIENCE, V69, P1005, DOI 10.1016/0306-4522(95)00393-W; CARD JP, 1982, J COMP NEUROL, V206, P390, DOI 10.1002/cne.902060407; CARD JP, 1989, J COMP NEUROL, V284, P135, DOI 10.1002/cne.902840110; CUTRERA RA, 1993, BRAIN RES, V602, P14, DOI 10.1016/0006-8993(93)90235-F; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; DAVIDOWA H, 1992, BEHAV BRAIN RES, V50, P127, DOI 10.1016/S0166-4328(05)80294-3; EDELSTEIN K, 1995, BRAIN RES, V690, P254, DOI 10.1016/0006-8993(95)00736-A; Harrington M E, 1986, J Biol Rhythms, V1, P309, DOI 10.1177/074873048600100405; HARRINGTON ME, 1987, BRAIN RES, V410, P275, DOI 10.1016/0006-8993(87)90325-8; HICKEY TL, 1976, EXP BRAIN RES, V24, P523; JANIK D, 1992, NEUROREPORT, V3, P575, DOI 10.1097/00001756-199207000-00007; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; MEAD S, 1992, J NEUROSCI, V12, P2516; MOGA MM, 1995, J COMP NEUROL, V359, P221, DOI 10.1002/cne.903590204; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1994, J COMP NEUROL, V344, P403, DOI 10.1002/cne.903440306; MORIN LP, 1994, BRAIN RES REV, V67, P102; MROSOVSKY N, 1988, J COMP PHYSIOL A, V162, P35, DOI 10.1007/BF01342701; PICARD GE, 1985, NEUROSCI LETT, V55, P211; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; RUSAK B, 1989, BRAIN RES, V493, P283, DOI 10.1016/0006-8993(89)91163-3; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SCHWARTZ WJ, 1994, NEUROSCIENCE, V58, P573, DOI 10.1016/0306-4522(94)90082-5; SHINOHARA K, 1993, NEUROSCIENCE, V56, P813, DOI 10.1016/0306-4522(93)90129-4; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; VANREETH O, 1989, NATURE, V339, P49, DOI 10.1038/339049a0; WICKLAND CR, 1991, AM J PHYSIOL, V261, pR1109, DOI 10.1152/ajpregu.1991.261.5.R1109; ZHANG Y, 1993, NEUROSCI LETT, V164, P203, DOI 10.1016/0304-3940(93)90892-O	29	72	72	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					542	545		10.1038/379542a0	http://dx.doi.org/10.1038/379542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596633				2022-12-01	WOS:A1996TU69300051
J	Gilsdorf, JR				Gilsdorf, JR			Do you have a minute?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					343	343						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8568996				2022-12-01	WOS:A1996TT30300002
J	Baird, AG; Jewell, D; Walker, JJ				Baird, AG; Jewell, D; Walker, JJ			Management of labour in an isolated rural maternity hospital	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PERINATAL-MORTALITY; DELIVERY; UNITS	Objectives-To evaluate the use of a maternity unit run by general practitioners and midwives, describing the outcome of labor in an unselected group of women and quantifying the contribution made by general practitioners. Design-Retrospective population based review of obstetric patients who had access to an isolated rural maternity unit. Setting-Rural area 120 km from a consultant maternity unit. Subjects-997 consecutive women delivered between January 1987 and May 1991. Main outcome measures-Mode of delivery and complications by place of booking and place of delivery; need for medical intervention and transfer. Results-530 women (53%) were booked for delivery in the rural unit; this group had a caesarean section rate of 3.8% and an unplanned transfer rate of 12.8% to the consultant unit in labour. Of the 462 who delivered in the low risk unit, 25 (5%) required a forceps delivery; postnatal complications requiring emergency medical support occurred in a further 33 (7%). Conclusions-Risk characterisation is possible, but medical support from general practitioners and obstetricians is required in almost a third of women at low risk for complications of delivery. Results of this study support the team approach to obstetric management but not the move towards isolated units without organised medical support.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV LEEDS,ST JAMES HOSP,DEPT OBSTET & GYNAECOL,LEEDS LS9 7TS,W YORKSHIRE,ENGLAND	University of Bristol; Saint James's University Hospital; University of Leeds	Baird, AG (corresponding author), WHITE HOUSE,SANDHEAD,STRANRAER DG9 9JA,WIGTOWN,SCOTLAND.		Baird, Gordon/AAN-8026-2020; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Baird, Gordon/0000-0002-8803-6520; Walker, James/0000-0002-8922-083X				BROWN DJ, 1994, BRIT MED J, V309, P777, DOI 10.1136/bmj.309.6957.777; Bull M J, 1980, J R Coll Gen Pract, V30, P208; CAVENAGH AJM, 1984, BRIT MED J, V288, P1438, DOI 10.1136/bmj.288.6428.1438; HEMMINKI E, 1985, SCAND J SOC MED, V13, P113, DOI 10.1177/140349488501300308; LOWE SW, 1987, J ROY COLL GEN PRACT, V37, P484; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; REYNOLDS JL, 1988, J ROY COLL GEN PRACT, V38, P307; ROSENBLATT RA, 1985, LANCET, V1, P429; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; TAYLOR GW, 1980, LANCET, V2, P1287; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; YOUNG G, 1990, BRIT MED J, V301, P665, DOI 10.1136/bmj.301.6753.665-b; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1990, BRIT MED J, V301, P983; 1993, CHANGING CHILDBIRT 1; 1994, 1988 90 DEP HLTH REP; 1993, PROVISION MATERNITY	19	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					223	226						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT486	8563590				2022-12-01	WOS:A1996TT48600030
J	Hsu, HL; Shu, HB; Pan, MG; Goeddel, DV				Hsu, HL; Shu, HB; Pan, MG; Goeddel, DV			TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; KAPPA-B; EXPRESSION; ACTIVATION; PROTEINS; DOMAIN; ALPHA	Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1). TRADD is a TNFR1-associated signal transducer that is involved in activating both pathways. Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively. A TRAF2 mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated NF-kappa B activation, but does not affect TNF-induced apoptosis. Conversely, a FADD mutant lacking its N-terminal 79 amino acids is a dominant-negative inhibitor of TNF-induced apoptosis, but does not inhibit NF-kappa B activation. Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.			Hsu, HL (corresponding author), TULARIK INC,270 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1994, J IMMUNOL, V152, P1751	45	1691	1778	0	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					299	308		10.1016/S0092-8674(00)80984-8	http://dx.doi.org/10.1016/S0092-8674(00)80984-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565075	Bronze			2022-12-01	WOS:A1996TR59500016
J	Becker, L; Poreda, RJ; Bada, JL				Becker, L; Poreda, RJ; Bada, JL			Extraterrestrial helium trapped in fullerenes in the sudbury impact structure	SCIENCE			English	Article							ION-MOLECULE REACTIONS; CIRCUMSTELLAR CHEMISTRY; ALLENDE METEORITE; ORGANIC-MOLECULES; INTERSTELLAR; CARBON; PARTICLES; DELIVERY; ORIGINS; GASES	Fullerenes (C-60 and C-70) in the Sudbury impact structure contain trapped helium with a He-3/He-4 ratio of 5.5 x 10(-4) to 5.9 x 10(-4). The He-3/He-4 ratio exceeds the accepted solar wind value by 20 to 30 percent and is higher by an order of magnitude than the maximum reported mantle value, Terrestrial nuclear reactions or cosmic-ray bombardment are not sufficient to generate such a high ratio. The He-3/He-4 ratios in the Sudbury fullerenes are similar to those found in meteorites and in some interplanetary dust particles. The implication is that the helium within the C-60 molecules at Sudbury is of extraterrestrial origin.	UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093; UNIV ROCHESTER,DEPT EARTH & ENVIRONM SCI,ROCHESTER,NY 14627	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Rochester	Becker, L (corresponding author), NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035, USA.							ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; ANDERS E, 1975, SCIENCE, V190, P1262, DOI 10.1126/science.190.4221.1262; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BECKER L, 1994, NATURE, V372, P507, DOI 10.1038/372507a0; BECKER L, 1994, SCIENCE, V265, P642, DOI 10.1126/science.11536660; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; BLACK DC, 1969, EARTH PLANET SC LETT, V6, P395, DOI 10.1016/0012-821X(69)90190-3; BOHME DK, 1992, CHEM REV, V92, P1487, DOI 10.1021/cr00015a002; CERLING TE, 1994, ANNU REV EARTH PL SC, V22, P273, DOI 10.1146/annurev.ea.22.050194.001421; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; FARLEY KA, 1995, NATURE, V376, P153, DOI 10.1038/376153a0; FOING BH, 1994, NATURE, V369, P296, DOI 10.1038/369296a0; HARE JP, 1992, ACCOUNTS CHEM RES, V25, P106, DOI 10.1021/ar00015a002; HEYMANN D, 1986, J GEOPHYS RES, V91, P135; JIMENEZVASQUEZ HA, IN PRESS J CHEM PHYS; JIMENEZVAZQUEZ HA, 1994, CHEM PHYS LETT, V229, P111, DOI 10.1016/0009-2614(94)01028-5; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; KROTO H, 1988, SCIENCE, V242, P1139, DOI 10.1126/science.242.4882.1139; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P38; LAL D, 1989, EARTH PLANET SC LETT, V96, P1, DOI 10.1016/0012-821X(89)90118-0; LEWIS RS, 1976, METEORITICS, V11, P320; MAMYRIN BA, 1984, HELIUM ISOTOPESNATUR; MATSUDA JI, 1980, GEOCHIM COSMOCHIM AC, V44, P1861, DOI 10.1016/0016-7037(80)90235-5; NIEMEYER S, 1981, P LUNAR PLANET SCI, V12, P1177; NIER AO, 1992, METEORITICS, V27, P166, DOI 10.1111/j.1945-5100.1992.tb00744.x; NIER AO, 1990, GEOCHIM COSMOCHIM AC, V54, P173, DOI 10.1016/0016-7037(90)90205-Y; OTT U, 1981, GEOCHIM COSMOCHIM AC, V45, P1751, DOI 10.1016/0016-7037(81)90009-0; OZIMA M, 1984, NATURE, V311, P449; OZIMA M, 1983, NOBLE GAS GEOCHEMIST; PETRIE S, 1993, ASTRON ASTROPHYS, V271, P662; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; RISON W, 1983, EARTH PLANET SC LETT, V66, P367; ROBL TL, 1993, ORG GEOCHEM, V20, P249, DOI 10.1016/0146-6380(93)90042-A; SAUNDERS M, 1993, SCIENCE, V259, P1428, DOI 10.1126/science.259.5100.1428; Saunders M, 1996, SCIENCE, V271, P1693, DOI 10.1126/science.271.5256.1693; SMALLEY RE, 1991, J PHYS CHEM-US, V95, P7564; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SWART PK, 1983, SCIENCE, V220, P406, DOI 10.1126/science.220.4595.406; SWINDLE TD, 1988, METEORITES EARLY SOL, P535; TIELENS AGGM, 1990, NASA CONF P, V3061, P59; WEISKE T, 1991, CHEM PHYS LETT, V193, P97; ZINNER E, 1995, METEORITICS, V30, P209, DOI 10.1111/j.1945-5100.1995.tb01115.x; ZINNER E, 1990, LUNAR PLANET SCI, V21, P1379	45	78	84	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					249	252		10.1126/science.272.5259.249	http://dx.doi.org/10.1126/science.272.5259.249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602508	Green Published			2022-12-01	WOS:A1996UE72900036
J	Damasio, H; Grabowski, TJ; Tranel, D; Hichwa, RD; Damasio, AR				Damasio, H; Grabowski, TJ; Tranel, D; Hichwa, RD; Damasio, AR			A neural basis for lexical retrieval	NATURE			English	Article							BRAIN; SYSTEMS; ORGANIZATION; RECOGNITION; LANGUAGE; APHASIA; ANATOMY; SPEECH; NOUNS; VERBS	Two parallel studies using positron emission tomography, one conducted in neurological patients with brain lesions, the other in normal individuals, indicate that the normal process of retrieving words that denote concrete entities depends in part on multiple regions of the left cerebral hemisphere, located outside the classic language areas. Moreover, anatomically separable regions tend to process words for distinct kinds of items.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, POSITRON EMISS TOMOG IMAGING CTR, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA	University of Iowa; University of Iowa; Salk Institute			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389				ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; Damasio A., 1994, LARGE SCALE NEURONAL, P61; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DAMASIO AR, 1992, NEW ENGL J MED, V326, P531, DOI 10.1056/NEJM199202203260806; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DAMASIO AR, 1992, SCI AM, V267, P89; DAMASIO AR, 1990, S QUANTITATIVE BIOL, V55, P1039; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAMASIO H, 1993, INT CONGR SER, V1030, P465; DANIELE A, 1994, NEUROPSYCHOLOGIA, V32, P1325, DOI 10.1016/0028-3932(94)00066-2; DEHAENE S, 1995, NEUROREPORT, V6, P2153, DOI 10.1097/00001756-199511000-00014; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GARRETT M, 1992, COGNITION, V42, P143, DOI 10.1016/0010-0277(92)90042-G; GOODGLASS H, 1986, CORTEX, V22, P87, DOI 10.1016/S0010-9452(86)80034-X; GRABOWSKI TJ, IN PRESS HUM BRAIN M; GRABOWSKI TJ, 1995, HUM BRAIN MAPP, V2, P123, DOI DOI 10.1002/HBM.460020302; HART J, 1992, NATURE, V359, P60, DOI 10.1038/359060a0; HART J, 1985, NATURE, V316, P439, DOI 10.1038/316439a0; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HICHWA RD, 1995, CHEMISTS' VIEWS OF IMAGING CENTERS, P401; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; HILLIS AE, 1995, J COGNITIVE NEUROSCI, V7, P396, DOI 10.1162/jocn.1995.7.3.396; Kosslyn S. M., 1994, IMAGE BRAIN; LEVELT WJM, 1992, COGNITION, V42, P1, DOI 10.1016/0010-0277(92)90038-J; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MCKENNA P, 1994, NEUROPSYCHOL REHABIL, V4, P255; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; Ono M, 1990, ATLAS CEREBRAL SULCI; Perani D., 1995, Society for Neuroscience Abstracts, V21, P1498; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Smith E., 1981, CATEGORIES CONCEPTS; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TRANEL D, 1995, J COGNITIVE NEUROSCI, V7, P425, DOI 10.1162/jocn.1995.7.4.425; Tranel D., 1995, Society for Neuroscience Abstracts, V21, P1497; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WORSLEY KJ, 1994, ADV APPL PROBAB, V26, P13, DOI 10.2307/1427576	49	1091	1110	1	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	1996	380	6574					499	505		10.1038/380499a0	http://dx.doi.org/10.1038/380499a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606767				2022-12-01	WOS:A1996UE66300041
J	Gomi, H; Kawato, M				Gomi, H; Kawato, M			Equilibrium-point control hypothesis examined by measured arm stiffness during multijoint movement	SCIENCE			English	Article							HUMAN ELBOW JOINT; TRAJECTORY FORMATION; VOLUNTARY MOVEMENTS; POSTURE; MODEL; COORDINATION; MAINTENANCE; CEREBELLUM; POSITION	For the last 20 years, it has been hypothesized that well-coordinated, multijoint movements are executed without complex computation by the brain, with the use of springlike muscle properties and peripheral neural feedback loops. However, it has been technically and conceptually difficult to examine this ''equilibrium-point control'' hypothesis directly in physiological or behavioral experiments. A high-performance manipulandum was developed and used here to measure human arm stiffness, the magnitude of which during multijoint movement is important for this hypothesis. Here, the equilibrium-point trajectory was estimated from the measured stiffness, the actual trajectory, and the generated torque. Its velocity profile differed from that of the actual trajectory. These results argue against the hypothesis that the brain sends as a motor command only an equilibrium-point trajectory similar to the actual trajectory.	ATR HUMAN INFORMAT PROC RES LABS, SEIKA, KYOTO, JAPAN		Gomi, H (corresponding author), NIPPON TELEGRAPH & TEL PUBL CORP, BASIC RES LABS, INFORMAT SCI RES LAB, WAKAMIYA 3-1, ATSUGI, KANAGAWA, JAPAN.		Gomi, Hiroaki/C-5269-2013; Gomi, Hiroaki/AEL-2645-2022	Gomi, Hiroaki/0000-0003-3541-2251				ABEND W, 1982, BRAIN, V105, P331, DOI 10.1093/brain/105.2.331; BENNETT DJ, 1992, EXP BRAIN RES, V88, P433, DOI 10.1007/BF02259118; BENNETT DJ, 1993, EXP BRAIN RES, V95, P488; BIZZI E, 1976, J NEUROPHYSIOL, V39, P435, DOI 10.1152/jn.1976.39.2.435; BIZZI E, 1984, J NEUROSCI, V4, P2738; DOLAN JM, 1993, IEEE T SYST MAN CYB, V23, P698, DOI 10.1109/21.256543; FELDMAN AG, 1966, BIOPHYS-USSR, V11, P565; FELDMAN AG, 1986, J MOTOR BEHAV, V18, P17; FLANAGAN JR, 1993, J MOTOR BEHAV, V25, P140, DOI 10.1080/00222895.1993.9942045; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; FLASH T, 1987, BIOL CYBERN, V57, P257, DOI 10.1007/BF00338819; FLASH T, 1990, EXP BRAIN RES, V82, P315; GOMI H, 1992, P 14 IEEE ENG MED BI, V4, P1628; GOMI H, 1995, ISRL954 NTT BAS RES; HOGAN N, 1985, BIOL CYBERN, V52, P315, DOI 10.1007/BF00355754; HOGAN N, 1984, J NEUROSCI, V4, P2745; HOLLERBACH JM, 1989, ROBOTICS SCI, P378; KATAYAMA M, 1993, BIOL CYBERN, V69, P353, DOI 10.1007/BF01185407; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, TRENDS NEUROSCI, V15, P445, DOI 10.1016/0166-2236(92)90008-V; KAWATO M, 1992, ATTENTION PERFORM, V14, P821; KELSO JAS, 1979, SCIENCE, V203, P1029, DOI 10.1126/science.424729; LACQUANITI F, 1993, J NEUROPHYSIOL, V69, P1443, DOI 10.1152/jn.1993.69.5.1443; MCINTYRE J, 1993, J MOTOR BEHAV, V25, P193, DOI 10.1080/00222895.1993.9942049; MORASSO P, 1981, EXP BRAIN RES, V42, P223; MUSSAIVALDI FA, 1985, J NEUROSCI, V5, P2732; NICHOLS TR, 1976, J NEUROPHYSIOL, V39, P119, DOI 10.1152/jn.1976.39.1.119; Paul R. P., 1981, ROBOT MANIPULATORS M; POLIT A, 1979, J NEUROPHYSIOL, V42, P183, DOI 10.1152/jn.1979.42.1.183; SCHWEIGHOFER N, 1995, THESIS SO CALIFORNIA; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; TSUJI T, 1995, BIOL CYBERN, V72, P475, DOI 10.1007/BF00199890; UNO Y, 1989, BIOL CYBERN, V61, P89, DOI 10.1007/BF00204593; WITNERS JM, 1990, MULTIPLE MUSCLE SYST, P69; 1993, J MOT BEHAV, V25; 1992, BEHAV BRAIN SCI, V15	36	340	345	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					117	120		10.1126/science.272.5258.117	http://dx.doi.org/10.1126/science.272.5258.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UD597	8600521				2022-12-01	WOS:A1996UD59700053
J	Guo, ZC; Viitanen, M; Fratiglioni, L; Winblad, B				Guo, ZC; Viitanen, M; Fratiglioni, L; Winblad, B			Low blood pressure and dementia in elderly people: The Kungsholmen project	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; POPULATION SURVEY; SENILE DEMENTIA; FLOW; DISORDER; GLUCOSE; SCALE; AGE	Objective-To examine the relation between blood pressure and dementia in elderly people. Design-Cross sectional, population based study. Setting-Kungsholmen district of Stockholm, Sweden. Subjects-1642 subjects aged 75-101 years. Main outcome measures-Prevalence and adjusted odds ratio of dementia by blood pressure. Results-People with systolic pressure less than or equal to 140 mmHg were more often diagnosed as demented than those with systolic pressure >140 mmHg: odds ratios (95% confidence interval) adjusted for age, sex, and education were 2.98 (2.17 to 4.08) for all dementias, 2.91 (1.93 to 4.38) for Alzheimer's disease, 2.00 (1.09 to 3.65) for vascular dementia, and 5.07 (2.65 to 9.70) for other dementias. Similar results were seen in subjects with diastolic pressure less than or equal to 75 mmHg compared with those with higher diastolic pressure. When severity and duration of dementia were taken into account, only moderate and severe dementia were found to be significantly related to relatively low blood pressure, and the association was stronger in subjects with longer disease duration. Use of hypotensive drugs and comorbidity with cardiovascular disease did not modify the results for all dementias, Alzheimer's disease, and other dementias but slightly reduced the association between vascular dementia and diastolic blood pressure. Conclusions-Both systolic and diastolic blood pressure were inversely related to prevalence of dementia in elderly people. We think that relatively low blood pressure is probably a complication of the dementia process, particularly Alzheimer's disease, although it is possible that low blood pressure may predispose a subpopulation to developing dementia.	KAROLINSKA INST,DEPT GERIATR MED,S-11382 STOCKHOLM,SWEDEN	Karolinska Institutet	Guo, ZC (corresponding author), STOCKHOLM GERONTOL RES CTR,DALAGATAN 9-11,S-11382 STOCKHOLM,SWEDEN.		Viitanen, Matti/AAY-5163-2020	Landin-Wilhelmsen, Kerstin/0000-0003-1998-5105				American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; [Anonymous], 1990, GUID ATC CLASS; ARONSON MK, 1993, ALZHEIMERS DIS ADV C, P55; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; BROWN WD, 1991, ALZ DIS ASSOC DIS, V5, P131, DOI 10.1097/00002093-199100520-00010; BUCHT G, 1983, ACTA MED SCAND, V213, P387; BURKE WJ, 1994, J AUTONOM NERV SYST, V48, P65, DOI 10.1016/0165-1838(94)90160-0; ELMSTAHL S, 1992, AGE AGEING, V21, P301, DOI 10.1093/ageing/21.4.301; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORETTE F, 1991, AM J MED, V90, pS14, DOI 10.1016/0002-9343(91)90430-6; FORSELL Y, 1992, ACTA PSYCHIAT SCAND, V86, P49, DOI 10.1111/j.1600-0447.1992.tb03225.x; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FRATIGLIONI L, 1992, ARCH NEUROL-CHICAGO, V49, P927, DOI 10.1001/archneur.1992.00530330049015; FRATIGLIONI L, 1992, NEUROEPIDEMIOLOGY, V11, P29, DOI 10.1159/000110958; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HARDY J, 1985, NEUROCHEM INT, V7, P545, DOI 10.1016/0197-0186(85)90050-6; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; LANDIN K, 1993, J INTERN MED, V233, P357, DOI 10.1111/j.1365-2796.1993.tb00684.x; OBRIEN JT, 1992, J NEUROL NEUROSUR PS, V55, P1182, DOI 10.1136/jnnp.55.12.1182; OBRIEN MD, 1994, DEMENTIA, V5, P133, DOI 10.1159/000106710; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; SCHEINBERG P, 1988, STROKE, V19, P1291, DOI 10.1161/01.STR.19.10.1291; *SPSS, 1994, SPSS ADV STAT 6 1; STRANDGAARD S, 1994, LANCET, V344, P519, DOI 10.1016/S0140-6736(94)91903-8; SULKAVA R, 1987, ACTA NEUROL SCAND, V76, P123, DOI 10.1111/j.1600-0404.1987.tb03555.x; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491	26	233	239	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					805	808		10.1136/bmj.312.7034.805	http://dx.doi.org/10.1136/bmj.312.7034.805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608286	Green Published			2022-12-01	WOS:A1996UD37800021
J	Nightingale, SL				Nightingale, SL			First product available for preventing serious RSV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-01	WOS:A1996UA56300009
J	Goldberg, J; Nairn, AC; Kuriyan, J				Goldberg, J; Nairn, AC; Kuriyan, J			Structural basis for the autoinhibition of calcium calmodulin-dependent protein kinase I	CELL			English	Article							LIGHT CHAIN KINASE; CATALYTIC SUBUNIT; INTRASTERIC REGULATION; INHIBITOR PEPTIDE; CRYSTAL-STRUCTURE; BINDING; COMPLEX; RECOGNITION; REFINEMENT; SEQUENCE	The crystal structure of calcium/calmodulin-dependent protein kinase I has been determined in the autoinhibited form. The C-terminal regulatory region of the enzyme forms a helix-loop-helix segment that extends across the two domains of the catalytic core, making multiple inhibitory interactions. Elements of the first regulatory alpha helix and the loop interfere with the binding site for peptide substrates, while the loop and the second helix interact with the ATP-binding domain to induce conformational changes that obstruct the nucleotide binding pocket. lane part of the calmodulin recognition element protrudes away from the catalytic domain and is potentially available for an initial interaction with calmodulin. The structure provides a view of an intact calmodulin target and suggests that substantial structural changes will accompany kinase activation by calmodulin binding to the regulatory region.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University	Goldberg, J (corresponding author), HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Nairn, Angus/0000-0002-7075-0195				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRAGG WL, 1954, ACTA CRYSTALLOGR, V7, P409, DOI 10.1107/S0365110X54001235; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FINDLAY WA, 1995, PROTEIN SCI, V4, P2375, DOI 10.1002/pro.5560041116; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRUNER SM, 1994, CURR OPIN STRUC BIOL, V4, P765, DOI 10.1016/S0959-440X(94)90177-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1994, STRUCTURAL ASPECTS P, P30; KEMP BE, 1991, PSEUDOSUBSTRATE BASE; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NALM AC, 1987, J BIOL CHEM, V262, P7273; NALM AC, 1994, SEMIN CANCER BIOL, V5, P295; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PARKER PJ, 1994, PROTEIN KINASES, P68; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICKERSGILL RW, 1987, ACTA CRYSTALLOGR A, V43, P502, DOI 10.1107/S0108767387099112; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MK, 1992, J BIOL CHEM, V267, P1761; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	69	265	273	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					875	887		10.1016/S0092-8674(00)81066-1	http://dx.doi.org/10.1016/S0092-8674(00)81066-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601311	Bronze			2022-12-01	WOS:A1996UC38100009
J	Grieco, D; Porcellini, A; Avvedimento, EV; Gottesman, ME				Grieco, D; Porcellini, A; Avvedimento, EV; Gottesman, ME			Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; XENOPUS-LAEVIS-OOCYTES; CELL-CYCLE; CATALYTIC SUBUNIT; AMPHIBIAN EGGS; CDC2; DEGRADATION; EXTRACTS; MPF; INACTIVATION	Cell cycle progression in cycling Xenopus egg extracts is accompanied by fluctuations in the concentration of adenosine 3',5'-monophosphate (cAMP) and in the activity of the cAMP-dependent protein kinase (PKA). The concentration of cAMP and the activity of PKA decrease at the onset of mitosis and increase at the transition between mitosis and interphase. Blocking the activation of PKA at metaphase prevented the transition into interphase; the activity of M phase-promoting factor (MPF; the cyclin B-p34(cdc2) complex) remained high, and mitotic cyclins were not degraded. The arrest in mitosis was reversed by the reactivation of PKA. The inhibition of protein synthesis prevented the accumulation of cyclin and the oscillations of MPF, PKA, and cAMP. Addition of recombinant nondegradable cyclin B activated p34(cdc2) and PKA and induced the degradation of full-length cyclin B. Addition of cyclin A activated p34(cdc2) but not PKA, nor did it induce the degradation of full-length cyclin B. These findings suggest that cyclin degradation and exit from mitosis require MPF-dependent activation of the cAMP-PKA pathway.	UNIV NAPLES,SCH MED 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE,SCH MED,CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Columbia University; Universita Mediterranea di Reggio Calabria	Grieco, D (corresponding author), UNIV NAPLES,SCH MED 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518; GRIECO, Domenico/0000-0002-7131-5742				CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; COSTA M, 1976, J BIOL CHEM, V251, P3313; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GRIECO D, UNPUB; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PORCELLINI A, UNPUB; SCHORDERETSLATKINE S, 1978, CELL, V15, P1269, DOI 10.1016/0092-8674(78)90052-1; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682	31	127	131	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1718	1723		10.1126/science.271.5256.1718	http://dx.doi.org/10.1126/science.271.5256.1718			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596931				2022-12-01	WOS:A1996UB15100044
J	Ridge, JP; Fuchs, EJ; Matzinger, P				Ridge, JP; Fuchs, EJ; Matzinger, P			Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells	SCIENCE			English	Article							ANTIGEN-PRESENTING FUNCTION; SMALL B-CELLS; TRANSPLANTATION TOLERANCE; SELF-TOLERANCE; PROTEIN ANTIGENS; IMMUNE-SYSTEM; LYMPHOCYTE-T; INDUCTION; MICE; INVIVO	For some time it has been thought that antigenic challenge in neonatal life is a tolerogenic rather than immunogenic event. Reexamination of the classic neonatal tolerance experiments of Billingham, Brent, and Medawar showed that tolerance is not an intrinsic property of the newborn immune system, but that the nature of the antigen-presenting cell determines whether the outcome is neonatal tolerance or immunization.			Ridge, JP (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,SECT T CELL TOLERANCE & MEMORY,GHOST LAB,BETHESDA,MD 20892, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ARNOLD B, 1991, ANNU REV IMMUNOL, V9, P297, DOI 10.1146/annurev.iy.09.040191.001501; BAL V, 1990, EUR J IMMUNOL, V20, P1893, DOI 10.1002/eji.1830200904; BANDEIRA A, 1989, P NATL ACAD SCI USA, V86, P272, DOI 10.1073/pnas.86.1.272; BELLGRAU D, 1981, J EXP MED, V153, P1660, DOI 10.1084/jem.153.6.1660; BILLINGHAM R, 1956, P ROY SOC LONDON, V239, P44; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1960, J IMMUNOL, V85, P14; BONNEY EA, UNPUB; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURNET FM, 1950, AUST J EXP BIOL MED, V28, P291, DOI 10.1038/icb.1950.29; Burnet FM., 1949, PRODUCTION ANTIBODIE, V2; BURNET FM, 1959, CLONAL SELECTION THE; BUSKER AE, 1990, CELL IMMUNOL, V125, P225, DOI 10.1016/0008-8749(90)90076-4; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHIAK J, 1978, IMMUNOLOGY, V34, P265; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; DONOHOE JA, 1983, TRANSPLANTATION, V35, P62, DOI 10.1097/00007890-198301000-00012; EYNON EE, 1991, TRANSPLANT P, V23, P729; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FINKLEMAN F, UNPUB; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; GOLLOB KJ, 1993, J IMMUNOL, V150, P3705; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HOFFMAN PM, 1984, J VIROL, V52, P734, DOI 10.1128/JVI.52.3.734-738.1984; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; ISHIZAKA ST, 1986, J IMMUNOL, V137, P2093; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JOHNSON LL, 1988, TRANSPLANTATION, V46, P167; JOHNSON LL, 1988, TRANSPLANTATION, V46, P170; Lafferty K J, 1986, Prog Clin Biol Res, V224, P87; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; LAUCHART W, 1980, TRANSPLANTATION, V29, P259, DOI 10.1097/00007890-198003000-00020; LECHLER RI, 1982, J EXP MED, V156, P1835, DOI 10.1084/jem.156.6.1835; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LU CY, 1979, NATURE, V282, P327, DOI 10.1038/282327a0; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; MORRISSEY PJ, 1983, J EXP MED, V158, P365, DOI 10.1084/jem.158.2.365; NOSSAL G. J. V., 1957, AUSTRALIAN JOUR EXPTL BIOL AND MED SCI, V35, P549, DOI 10.1038/icb.1957.57; POWELL TJ, 1990, J IMMUNOL, V144, P854; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RAMMENSEE HG, 1984, J IMMUNOL, V133, P2390; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; RIDGE JP, UNPUB; ROSER BJ, 1989, IMMUNOL REV, V107, P179, DOI 10.1111/j.1600-065X.1989.tb00009.x; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; SHEHADEH NN, 1993, SPRINGER SEMIN IMMUN, V14, P203; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x	62	638	659	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1996	271	5256					1723	1726		10.1126/science.271.5256.1723	http://dx.doi.org/10.1126/science.271.5256.1723			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB151	8596932	Green Submitted			2022-12-01	WOS:A1996UB15100045
J	Keiler, KC; Waller, PRH; Sauer, RT				Keiler, KC; Waller, PRH; Sauer, RT			Role of a peptide tagging system in degradation of proteins synthesized from damaged messenger RNA	SCIENCE			English	Article							N-END RULE; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; STABLE RNA; CLONING	Variants of lambda repressor and cytochrome b(562) translated from messenger RNAs without stop codons were modified by carboxyl terminal addition of an ssrA-encoded peptide tag and subsequently degraded by carboxyl terminal-specific proteases present in both the cytoplasm and periplasm of Escherichia coli, The tag appears to be added to the carboxyl terminus of the nascent polypeptide chain by cotranslational switching of the ribosome from the damaged messenger RNA to ssrA RNA.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Keiler, Kenneth/0000-0001-8753-335X; Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-15706, AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892, R01AI015706, R37AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONOV VK, 1993, CHEM PROTEOLYSIS, P36; BALZI E, 1990, J BIOL CHEM, V265, P7464; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Clechanover A., 1994, CELL, V79, P13; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HERSHEY JWB, 1987, CELLULAR MOL BIOL, P613; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; KELLER KC, 1996, J BIOL CHEM, V281, P2589; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; NIKKILA H, 1991, EUR J BIOCHEM, V202, P309, DOI 10.1111/j.1432-1033.1991.tb16377.x; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; RAY BK, 1979, MOL GEN GENET, V174, P25, DOI 10.1007/BF00433301; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1995, CELL, V83, P227, DOI 10.1016/0092-8674(95)90164-7; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392	30	857	895	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					990	993		10.1126/science.271.5251.990	http://dx.doi.org/10.1126/science.271.5251.990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584937				2022-12-01	WOS:A1996TV70400050
J	Kawashima, T; BerthetColominas, C; Wulff, M; Cusack, S; Leberman, R				Kawashima, T; BerthetColominas, C; Wulff, M; Cusack, S; Leberman, R			The structure of the Escherichia coli EF-Tu center dot EF-Ts complex at 2.5 angstrom resolution	NATURE			English	Article							POLYPEPTIDE ELONGATION-FACTOR; QBETA-REPLICASE; PURIFICATION; SEQUENCE; DOMAIN; RAS	The crystal structure of the EF-Tu . EF-Ts complex from Escherichia coli has been determined to a resolution of 2.5 Angstrom. The complex contains two subunits of each of the elongation factors. The two EF-Ts molecules form a tight dimer, but there is little contact between the two EF-Tu molecules. The interaction of EF-Ts with EF-Tu results principally in the disruption of the Mg2+ ion binding site, thereby reducing the affinity of EF-Tu for guanine nucleotides.	EUROPEAN MOLEC BIOL LAB, GRENOBLE OUTSTN, F-38042 GRENOBLE, FRANCE; EUROPEAN SYNCHROTRON RADIAT FACIL, F-38043 GRENOBLE, FRANCE	European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF)				Cusack, Stephen/0000-0002-9324-0796				AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; ARAI KI, 1972, J BIOL CHEM, V247, P7029; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; ERTEL R, 1968, ARCH BIOCHEM BIOPHYS, V128, P331, DOI 10.1016/0003-9861(68)90039-8; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1992, MOL REPLACEMENT, P92; KABSCH W, 1977, J MOL BIOL, V117, P999, DOI 10.1016/S0022-2836(77)80009-0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWASHIMA T, IN PRESS ACTA CRYSTA; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; LEBERMAN R, 1981, FEBS LETT, V124, P279, DOI 10.1016/0014-5793(81)80155-X; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LUCUSLENARD J, 1966, P NATN ACAD SCIUS, V55, P1562; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SCHICK B, 1994, ACTA CRYSTALLOGR D, V50, P563, DOI 10.1107/S0907444994001976; SCHNEIDER U, 1983, THESIS U FREIBURG GE; WEISSBACH H, 1970, ARCH BIOCHEM BIOPHYS, V137, P262, DOI 10.1016/0003-9861(70)90433-9; 1979, SERC4 DAR LAB COLL C	30	276	283	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 8	1996	379	6565					511	518		10.1038/379511a0	http://dx.doi.org/10.1038/379511a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596629				2022-12-01	WOS:A1996TU69300041
J	Tycowski, KT; Shu, MD; Steitz, JA				Tycowski, KT; Shu, MD; Steitz, JA			A mammalian gene with introns instead of exons generating stable RNA products	NATURE			English	Article							SMALL NUCLEOLAR RNAS	THE nucleoli of eukaryotic cells are the sites of ribosomal RNA transcription and processing and of ribosomal subunit assembly. They contain multiple small nucleolar RNAs (snoRNAs), several of which are essential for rRNA maturation(1). The U3, U8 and U13 snoRNA genes are transcribed independently, whereas U14-U24, as well as E3, are located within introns of protein-coding genes, most of whose functions are linked to translation. These snoRNAs are co-transcribed with their host pre-mRNAs and released by processing from excised introns(1,2). Here we show that, in addition to U22, seven novel fibrillarin-associated snoRNAs, named U25-U31, are encoded within different introns of the unusually compact mammalian U22 host gene (UHG). All seven RNAs exhibit extensive (12-15 nucleotides) complementarity to different segments of the mature rRNAs, followed by a C/AUGA ('U-turn') sequence. The spliced UHG RNA, although it is associated with polysomes, has little potential for protein coding, is short-lived, and is poorly conserved between human and mouse. Thus, the introns rather than the exons specify the functional products of UHG.			Tycowski, KT (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.							BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MAQUAT LE, 1995, RNA, V1, P453; MATTICK JS, 1994, CURR OPIN GENET DEV, V4, P823, DOI 10.1016/0959-437X(94)90066-3; MAXWELL ES, 1995, A REV BIOCH, V35, P899; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; PELLIZZONI L, 1994, NUCLEIC ACIDS RES, V22, P4607, DOI 10.1093/nar/22.22.4607; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025	16	247	258	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					464	466		10.1038/379464a0	http://dx.doi.org/10.1038/379464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559254				2022-12-01	WOS:A1996TT30400064
J	NIGHTINGALE, S				NIGHTINGALE, S			NEW INFORMATION SHEETS FOR IRBS AND CLINICAL INVESTIGATORS AVAILABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, S (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V272, P582	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-01	WOS:A1995TL16900009
J	Stanley, SK; Ostrowski, MA; Justement, JS; Gantt, K; Hedayati, S; Mannix, M; Roche, K; Schwartzentruber, DJ; Fox, CH; Fauci, AS				Stanley, SK; Ostrowski, MA; Justement, JS; Gantt, K; Hedayati, S; Mannix, M; Roche, K; Schwartzentruber, DJ; Fox, CH; Fauci, AS			Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; LYMPHOCYTES; AIDS; DISEASE; CELLS; VIREMIA; AGENTS; MODEL	Background. Activation of the immune system is a normal response to antigenic stimulation, and such activation enhances the replication of human immunodeficiency virus type 1 (HIV-1). We studied the effect of immunization with a common recall antigen on viral expression in HIV-1-infected patients, on the ability to isolate virus, and on the susceptibility to HIV-1 infection of peripheral-blood mononuclear cells (PBMCs) from control subjects not infected with HIV-1. Methods. Thirteen HIV-1-infected patients and 10 uninfected adults were given a 0.5-ml booster dose of tetanus toroid. Studies were performed to evaluate changes in the degree of plasma viremia, proviral burden, the ability to isolate HIV-1, and the susceptibility of PBMCs to acute infection in vitro. Two patients underwent sequential lymph-node biopsies for the assessment of viral burden in these tissues. Results. All 13 HIV-1-infected patients had transient increases in plasma viremia after immunization, and the proviral burden increased in 11. These changes did not correlate with the base-line CD4+ T-cell counts. The lymph-node tissue also had increases in the proviral burden and viral RNA after immunization. The virus was more easily isolated from PBMCs from nine of the patients after immunization than before immunization. Despite considerable variability in the results, PBMCs from 7 of the 10 normal subjects were more easily infected in vitro with HIV-1 after immunization than before immunization. Conclusions. Activation of the immune system by an ongoing antigen-specific immune response to an exogenous stimulus transiently increases the expression of HIV-1 and may enhance the susceptibility of uninfected subjects to HIV-1. (C) 1996, Massachusetts Medical Society.	NCI,DEPT NURSING,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,BETHESDA,MD 20892; MOL HISTOL INC,GAITHERSBURG,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stanley, SK (corresponding author), NIAID,IMMUNOREGULAT LAB,NIH,BLDG 30,RM 7A03,31 CTR DR,MSC-2520,BETHESDA,MD 20892, USA.			Hedayati, S Susan/0000-0001-8850-4729				BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; BRICHACEK B, 1995, 2 NAT C HUM RETR REL, P98; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BURKE AP, 1994, HUM PATHOL, V25, P248, DOI 10.1016/0046-8177(94)90196-1; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; COLEBUNDERS RL, 1991, AIDS, V5, pS103; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FOLKS T, 1986, J IMMUNOL, V136, P4049; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; JANOFF EN, 1991, J IMMUNOL, V147, P2130; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; NAGELKERKE NJD, 1990, AIDS, V4, P743, DOI 10.1097/00002030-199008000-00005; OBRIEN WA, 1995, BLOOD, V86, P1082; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POPOV J, 1992, J ACQ IMMUN DEF SYND, V5, P391; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; SCHWIEBERT R, 1994, J VIROL, V68, P5538, DOI 10.1128/JVI.68.9.5538-5547.1994; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; WACHTER H, 1986, LANCET, V2, P1216; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	31	320	324	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1222	1230		10.1056/NEJM199605093341903	http://dx.doi.org/10.1056/NEJM199605093341903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606717				2022-12-01	WOS:A1996UJ05400003
J	ORiain, MJ; Jarvis, JUM; Faulkes, CG				ORiain, MJ; Jarvis, JUM; Faulkes, CG			A dispersive morph in the naked mole-rat	NATURE			English	Article							BEHAVIOR; COLONIES	Close inbreeding is known for a variety of small mammal species(1-4) for which a high probability of mortality during dispersal makes helping and delayed maturation a relatively secure fitness option(5). Prolonged inbreeding, however, is usually associated with lowered fitness(6,7), and it has been shown that most highly inbred small mammals(8) and social insects(9) have inbreeding-avoidance mechanisms that promote some degree of outbreeding. However, previous field and laboratory research on the naked mole-rat (Heterocephalus glaber) suggested that this cooperatively breeding rodent is highly inbred(10-12), with new colonies forming by fission(13). Here we report the discovery of a dispersal phenotype that may occasionally promote outbreeding in naked mole-rats. These dispersers are morphologically, physiologically and behaviourally distinct from other colony members. They are laden with fat, exhibit elevated levels of luteinizing hormone, have a strong urge to disperse, and only solicit matings with non-colony members. These findings suggest that, although rare, a dispersive morph exists within naked mole-rat colonies.	ZOOL SOC LONDON,INST ZOOL,CONSERVAT GENET GRP,LONDON NW1 4RY,ENGLAND	Zoological Society of London	ORiain, MJ (corresponding author), UNIV CAPE TOWN,DEPT ZOOL,RONDEBOSCH 7700,SOUTH AFRICA.		Faulkes, Chris/B-8377-2008; Faulkes, Chris/O-8101-2019	O'Riain, M. Justin/0000-0001-5233-8327				ARMITAGE KB, 1986, ECOLOGY, V67, P1186, DOI 10.2307/1938674; BENGTSSON BO, 1978, J THEOR BIOL, V73, P439, DOI 10.1016/0022-5193(78)90151-0; BLOUIN SF, 1988, TRENDS ECOL EVOL, V3, P230, DOI 10.1016/0169-5347(88)90164-4; Brett R.A., 1991, P97; CLARKE KR, 1994, USER GUIDE PRIMER VE; Dobzhansky T., 1970, GENETICS EVOLUTIONAR; FAULKES CG, 1990, J ZOOL, V221, P87, DOI 10.1111/j.1469-7998.1990.tb03778.x; Hamilton William D., 1993, P429; HOECK HN, 1982, Z TIERPSYCHOL, V59, P177; JARVIS JUM, 1994, TRENDS ECOL EVOL, V9, P47, DOI 10.1016/0169-5347(94)90267-4; Lacey E.A., 1991, P275; LOVEGROVE BG, 1991, BEHAV ECOL SOCIOBIOL, V28, P37; MYLES TG, 1978, Q REV BIOL, V63, P1; ORIAIN MJ, IN PRESS ANIM BEHAV; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; SELANDER RK, 1970, AM ZOOL, V10, P53; Sherman P.W., 1991, BIOL NAKED MOLE RAT; Smith Andrew T., 1993, P329; SMITH AT, 1987, BEHAV ECOL SOCIOBIOL, V13, P37; STENSETH NC, 1984, ECOLOGY ANIMAL MOVEM, P63	20	222	227	0	81	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					619	621		10.1038/380619a0	http://dx.doi.org/10.1038/380619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602260				2022-12-01	WOS:A1996UF74100043
J	Qadota, H; Python, CP; Inoue, SB; Arisawa, M; Anraku, Y; Zheng, Y; Watanabe, T; Levin, DE; Ohya, Y				Qadota, H; Python, CP; Inoue, SB; Arisawa, M; Anraku, Y; Zheng, Y; Watanabe, T; Levin, DE; Ohya, Y			Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENES	1,3-beta-D-Glucan synthase [also known as beta(1-->3)glucan synthase] is a multi-enzyme complex that catalyzes the synthesis of 1,8-beta-linked glucan, a major structural component of the yeast cell wall. Temperature-sensitive mutants in the essential Rho-type guanosine triphosphatase (GTPase), Rho1p, displayed thermolabile glucan synthase activity, which was restored by the addition of recombinant Rho1p. Glucan synthase from mutants expressing constitutively active Rho1p did not require exogenous guanosine triphosphate for activity. Rho1p copurified with beta(1-->3)glucan synthase and associated with the Fks1p subunit of this complex in vivo. Both proteins were localized predominantly at sites of cell wall remodeling. Therefore, it appears that Rho1p is a regulatory subunit of beta(1-->3)glucan synthase.	UNIV TOKYO, DEPT BIOL SCI, GRAD SCH SCI, BUNKYO KU, TOKYO 113, JAPAN; JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA; NIPPON ROCHE RES CTR, DEPT MYCOL, KAMAKURA, KANAGAWA 247, JAPAN; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tokyo; Johns Hopkins University; Roche Holding; University of Tennessee System; University of Tennessee Health Science Center			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; Levin, David/0000-0003-0696-2860	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DOUGLAS CM, 1994, P NATL ACAD SCI USA, V91, P12907, DOI 10.1073/pnas.91.26.12907; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Inoue S., UNPUB; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MOL PC, 1994, J BIOL CHEM, V269, P31267; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, IN PRESS YEAST; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; SZANISZLO PJ, 1985, J BACTERIOL, V161, P1188, DOI 10.1128/JB.161.3.1188-1194.1985; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	22	376	394	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					279	281		10.1126/science.272.5259.279	http://dx.doi.org/10.1126/science.272.5259.279			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602515				2022-12-01	WOS:A1996UE72900045
J	Brown, DR; Schmidt, B; Kretzschmar, HA				Brown, DR; Schmidt, B; Kretzschmar, HA			Role of microglia and host prion protein in neurotoxicity of a prion protein fragment	NATURE			English	Article							SCRAPIE PRION; NITRIC-OXIDE; BRAIN; PRP; SUPEROXIDE; RESISTANT	THE prion protein PrPc is a glycoprotein of unknown function(1) normally found in neurons(2) and glia(3). It is involved in diseases such as bovine spongiform encephalopathy (BSE), scrapie and Creutzfeldt-Jakob disease(4). PrPSc, an altered isoform of PrPc that is associated with disease, shows greater protease resistance and is part of the infectious agent, the prion(5,6). Prion diseases are characterized by neuronal degeneration, gliosis and accumulation of PrPSc (ref. 7). Mice devoid of PrPc are resistant to scrapie(8). A fragment of human PrP consisting of amino acids 106-126 that forms fibrils in vitro is toxic to cultured neurons(9-11). Here we show that this toxic effect requires the presence of microglia which respond to PrP106-126 by increasing their oxygen radical production, The combined direct and microglia-mediated effects of PrP106-126 are toxic to normal neurons but are insufficient to destroy neurons from mice not expressing PrPc.	UNIV GOTTINGEN,INST NEUROPATHOL,D-37075 GOTTINGEN,GERMANY; UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,D-37075 GOTTINGEN,GERMANY	University of Gottingen; University of Gottingen			Brown, David/A-4083-2008					BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Herms JW, 1995, EUR J NEUROSCI, V7, P2508, DOI 10.1111/j.1460-9568.1995.tb01049.x; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; WILLIAMS AE, 1994, NEUROPATH APPL NEURO, V20, P47, DOI 10.1111/j.1365-2990.1994.tb00956.x	22	485	497	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					345	347		10.1038/380345a0	http://dx.doi.org/10.1038/380345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598929				2022-12-01	WOS:A1996UC37900060
J	Dobrowolski, JM; Sibley, LD				Dobrowolski, JM; Sibley, LD			Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite	CELL			English	Article							CYTOCHALASIN-B; COCCIDIAN SPOROZOITES; MALARIAL PARASITES; GONDII; MOTILITY; EXPRESSION; RESISTANT; JUNCTION; VACUOLES; FUSION	Toxoplasma gondii is an obligate intracellular parasite that invades a wide range of vertebrate host cells. We demonstrate that invasion is critically dependent on actin filaments in the parasite, but not the host cell. Invasion into cytochalasin D (CD)-resistant host cells was blocked by CD, while parasite mutants invaded wild-type host cells in the presence of drug. CD resistance in Toxoplasma was mediated by a point mutation in the single-copy actin gene ACT1. Transfection of the mutant act1 allele into wild-type Toxoplasma conferred motility and invasion in the presence of CD. We conclude that host cell invasion by Toxoplasma, and likely by related Apicomplexans, is actively powered by an actin-based contractile system in the parasite.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Sibley, L. David/C-4616-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036, T32AI007172] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34036, R01 AI034036, AI07172] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Dubey J.P., 1988, TOXOPLASMOSIS ANIMAL; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cellbio.8.1.333; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1173, DOI 10.1084/jem.136.5.1173; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; MORISAKI JH, 1995, J CELL SCI, V108, P2457; NICHOLS BA, 1981, LAB INVEST, V44, P324; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; PFEFFERKORN ER, 1977, J PROTOZOOL, V24, P449, DOI 10.1111/j.1550-7408.1977.tb04774.x; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; RUSSELL DG, 1981, J CELL SCI, V50, P345; RUSSELL DG, 1984, J CELL SCI, V65, P193; RYNING FW, 1978, INFECT IMMUN, V20, P739, DOI 10.1128/IAI.20.3.739-743.1978; SCHWARTZMAN JD, 1983, J PROTOZOOL, V30, P657, DOI 10.1111/j.1550-7408.1983.tb05339.x; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SIBLEY LD, 1995, TRENDS CELL BIOL, V5, P129, DOI 10.1016/S0962-8924(00)88964-3; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; TOYAMA S, 1988, J CELL BIOL, V107, P1499, DOI 10.1083/jcb.107.4.1499; WANG FW, 1990, GENE, V100, P195	31	503	526	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					933	939		10.1016/S0092-8674(00)81071-5	http://dx.doi.org/10.1016/S0092-8674(00)81071-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601316	Bronze			2022-12-01	WOS:A1996UC38100014
J	Hamblin, TJ				Hamblin, TJ			From dendritic cells to tumour vaccines	LANCET			English	Editorial Material							ANTI-IDIOTYPE ANTIBODY; LYMPHOMA				Hamblin, TJ (corresponding author), ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL & ONCOL,BOURNEMOUTH,DORSET,ENGLAND.							CHEN TT, 1994, J IMMUNOL, V153, P4775; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; HAMBLIN TJ, 1987, BLOOD, V69, P790; HAWKINS RE, 1994, BLOOD, V83, P3279; HSU FJ, 1993, ANN NY ACAD SCI, V690, P385; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; KOTERA Y, 1994, CANCER RES, V54, P2856; MARCHAND M, 1993, DERMATOLOGY, V186, P278, DOI 10.1159/000247375; MCCABE BJ, 1995, CANCER RES, V55, P1741; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAKAMIZAWA M, 1995, J CLIN INVEST, V95, P296, DOI 10.1172/JCI117654; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0	15	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					705	706		10.1016/S0140-6736(96)90071-9	http://dx.doi.org/10.1016/S0140-6736(96)90071-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601996				2022-12-01	WOS:A1996TZ98200004
J	Livingstone, AE; Shaddick, G; Grundy, C; Elliott, P				Livingstone, AE; Shaddick, G; Grundy, C; Elliott, P			Do people living near inner city main roads have more asthma needing treatment? Case-control study	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON LONDON SCH HYG & TROP MED,ENVIRONM EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Livingstone, AE (corresponding author), GILL ST HLTH CTR,LIMEHOUSE PRACTICE,LONDON E14 8HQ,ENGLAND.		Shaddick, Gavin B/B-3344-2011					DIGGLE PJ, 1994, J ROY STAT SOC A STA, V157, P433, DOI 10.2307/2983529; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WEILAND SK, 1994, ANN EPIDEMIOL, V4, P79; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596	5	65	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1996	312	7032					676	677						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB110	8597735				2022-12-01	WOS:A1996UB11000025
J	Klauck, TM; Faux, MC; Labudda, K; Langeberg, LK; Jaken, S; Scott, JD				Klauck, TM; Faux, MC; Labudda, K; Langeberg, LK; Jaken, S; Scott, JD			Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein	SCIENCE			English	Article							KINASE-C; POSTSYNAPTIC DENSITIES; REGULATORY SUBUNIT; PHOSPHATIDYLSERINE	Multivalent binding proteins, such as the yeast scaffold protein Sterile-5, coordinate the location of kinases by serving as platforms for the assembly of signaling units. Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79. Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN. The subcellular distributions of PKC and AKAP79 were similar in neurons. Thus, AKAP79 appears to function as a scaffold protein for three multifunctional enzymes.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946	Oregon Health & Science University					NCI NIH HHS [CA538841] Funding Source: Medline; NIGMS NIH HHS [GM50152, GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARR DW, 1992, J BIOL CHEM, V267, P16816; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COGHLAN VM, 1995, ADV PROTEIN PHOSPHAT, V8, P51; Corbin J D, 1974, Methods Enzymol, V38, P287; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FAUX MC, UNPUB; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLAUCK T, UNPUB; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIEBERMAN DN, 1994, SCIENCE, V369, P235; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; ORR JW, 1992, J BIOL CHEM, V267, P15263; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POTTER RL, 1978, ARCH BIOCHEM BIOPHYS, V190, P174, DOI 10.1016/0003-9861(78)90265-5; PRINTEN JA, 1994, GENETICS, V138, P609; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SARKAR D, 1984, J BIOL CHEM, V259, P9840; Scott J. I., UNPUB; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WOLF M, 1986, J BIOL CHEM, V261, P3327; WOLF M, 1986, BIOCHEM BIOPH RES CO, V140, P691, DOI 10.1016/0006-291X(86)90787-4	33	469	485	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1589	1592		10.1126/science.271.5255.1589	http://dx.doi.org/10.1126/science.271.5255.1589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599116				2022-12-01	WOS:A1996TZ98300043
J	Kitahata, MM; Koepsell, TD; Deyo, RA; Maxwell, CL; Dodge, WT; Wagner, EH				Kitahata, MM; Koepsell, TD; Deyo, RA; Maxwell, CL; Dodge, WT; Wagner, EH			Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; MULTICENTER AIDS COHORT; IN-HOSPITAL MORTALITY; VIRUS INFECTION; ZIDOVUDINE; PROPHYLAXIS; VOLUME; CARE; OUTCOMES; MEN	Background. Previous studies have found that patients with the acquired immunodeficiency syndrome (AIDS) who are admitted to hospitals that admit many such patients have lower mortality rates than patients in hospitals with less experience with AIDS. We examined the relation between physicians' experience with AIDS and the survival of their patients with AIDS. Methods. We studied 403 adult male patients enrolled in a staff-model health maintenance organization in whom first AIDS-defining illnesses were diagnosed from 1984 through mid-1994; we determined that these illnesses met the 1987 case definition of the Centers for Disease Control. We defined three levels of experience for the patients' 125 primary care physicians according to their experience with AIDS during residency training and the cumulative number of patients with AIDS they had cared for in their practices. Results. The median survival of the patients of physicians with the least experience in the management of AIDS was 14 months, as compared with 26 months for the patients of physicians with the most experience (P<0.001). Controlling for the severity of illness and the year of diagnosis, we found that the patients cared for by physicians with the most experience had a 31 percent lower risk of death than the patients cared for by physicians with the least experience (P<0.02). Among 244 patients with an AIDS-defining illness diagnosed from 1989 through 1994, after adjustment for the CD4+ cell count and the severity of illness, the risk of death was 43 percent lower for patients of the most experienced physicians than for patients of the least experienced (P<0.02). Conclusions. The experience of primary care physicians in the management of AIDS is significantly associated with survival among their patients.	UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Kitahata, MM (corresponding author), UNIV WASHINGTON,CTR AIDS & STD,DEPT MED,1001 BROADWAY,SUITE 215,SEATTLE,WA 98122, USA.							BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P856; BROWN BW, 1977, STATISTICS BIOMEDICA; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; COTTON DJ, 1989, JAMA-J AM MED ASSOC, V261, P3016, DOI 10.1001/jama.261.20.3016; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, ARCH INTERN MED, V155, P1613, DOI 10.1001/archinte.155.15.1613; GRAHAM NM, 1994, J CLIN EPIDEMIOL, V447, P1003; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HOLMBERG SD, 1993, AIDS, V7, P699, DOI 10.1097/00002030-199305000-00014; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LANG W, 1991, J ACQ IMMUN DEF SYND, V4, P713; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; MAKADON HJ, 1990, J GEN INTERN MED, V5, P446, DOI 10.1007/BF02599436; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; RAMSEY PG, 1994, PRIMARY CARE PATIENT; SHAPIRO MF, 1992, JAMA-J AM MED ASSOC, V268, P2698; SMITH MD, 1991, J GEN INTERN MED S1, V16, pS56; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P214; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P978; VELLA S, 1994, JAMA-J AM MED ASSOC, V271, P1197, DOI 10.1001/jama.271.15.1197; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1985, ANN INTERN MED, V103, P729, DOI 10.7326/0003-4819-103-5-729; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1S, V36; 1992, MMWR-MORBID MORTAL W, V41, P1	40	392	396	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					701	706		10.1056/NEJM199603143341106	http://dx.doi.org/10.1056/NEJM199603143341106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594430				2022-12-01	WOS:A1996TZ52800006
J	Catchpole, MA; Mercey, DE; Nicoll, A; Rogers, PA; Simms, J; Newham, J; Mahoney, A; Parry, JV; Joyce, C; Gill, ON				Catchpole, MA; Mercey, DE; Nicoll, A; Rogers, PA; Simms, J; Newham, J; Mahoney, A; Parry, JV; Joyce, C; Gill, ON			Continuing transmission of sexually transmitted diseases among patients infected with HIV-1 attending genitourinary medicine clinics in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether those who are aware of being infected with HIV continue to adopt behaviours that place others at risk of HIV infection. Design-Ongoing survey of current diagnosis of sexually transmitted disease and awareness of HIV infection among patients attending genitourinary medicine clinics. Setting-Six genitourinary medicine clinics in England and Wales (two in London and four outside) participating in unlinked anonymous HIV serosurveillance during 1990-3. Subjects-All attenders having blood drawn for syphilis serology for the first time during the calendar quarter of attendance. Main outcome measures-The proportion of syphilis serology specimens with antibody to HIV-1 detected by unlinked anonymous testing of the residue. The proportion of attenders infected with HIV-1 who remained clinically undetected, and the proportion who had another recently acquired sexually transmitted disease, Results-Of 85441 specimens tested, 2328 (2.7%) were positive for antibodies to HIV-1, About 30% of these specimens were from attenders whose HIV-1 infection remained clinically undetected, HIV-1 infection was found to coexist with another recently acquired sexually transmitted disease in 651 attenders, of whom 522 were homosexual or bisexual men. Of these, 245 (47%) already knew themselves to be infected with HIV-1, This proportion increased between 1990 and 1993. Conclusions-A considerable proportion of patients infected with HIV-1 are not identified by voluntary confidential HIV testing in genitourinary medicine clinics. Substantial numbers of homosexual or bisexual men attending genitourinary medicine clinics continue to practise unsafe sex despite being aware of their infection with HIV-1.	ACAD DEPT GENITOURINARY MED,MORTIMER MARKET CTR,LONDON WC 6AY,ENGLAND; PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND	Public Health England	Catchpole, MA (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.							DAY NE, 1996, CDR REV, V6, pR1; EVANS BG, 1993, BRIT MED J, V306, P426, DOI 10.1136/bmj.306.6875.426; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; GROSECLOSE SL, 1994, SEX TRANSM DIS, V21, P31, DOI 10.1097/00007435-199401000-00007; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; *HLTH ED AUTH, 1994, HLTH UPD, V4; JONES JL, 1993, SEX TRANSM DIS, V20, P334, DOI 10.1097/00007435-199320060-00006; MILLER E, 1995, BRIT MED J, V311, P545, DOI 10.1136/bmj.311.7004.545; NARDONE A, 1995, P MED RES COUNC 9 AN; Noone A, 1992, Commun Dis Rep CDR Rev, V2, pR21; STALL R, 1994, BRIT MED J, V309, P685, DOI 10.1136/bmj.309.6956.685; TOMLINSON DR, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93447-H; *UNL AN HIV SURV S, 1995, UNL AN HIV PREV MON; 1993, COMMUN DIS REP CDR R, V3, pR1; 1993, LANCET, V341, P863	15	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					539	542		10.1136/bmj.312.7030.539	http://dx.doi.org/10.1136/bmj.312.7030.539			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595282	Green Published			2022-12-01	WOS:A1996TY88500022
J	Pickering, WG				Pickering, WG			Does medical treatment mean patient benefit?	LANCET			English	Article																		BERN JL, 1988, BR J CLIN PHARM, V26, P679; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MEDAWAR C, 1992, POWER DEPENDENCE; PICKERING W, 1992, BRIT MED J, V304, P1516; Pickering W G, 1993, J Med Ethics, V19, P121, DOI 10.1136/jme.19.2.121-a; 1995, BRIT NATIONAL FORMUL, P219; 1994, PRESCRIPTION IMPROVE	8	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					379	380		10.1016/S0140-6736(96)90544-9	http://dx.doi.org/10.1016/S0140-6736(96)90544-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598708				2022-12-01	WOS:A1996TU69500016
J	Sumarsono, SH; Wilson, TJ; Tymms, MJ; Venter, DJ; Corrick, CM; Kola, R; Lahoud, MH; Papas, TS; Seth, A; Kola, I				Sumarsono, SH; Wilson, TJ; Tymms, MJ; Venter, DJ; Corrick, CM; Kola, R; Lahoud, MH; Papas, TS; Seth, A; Kola, I			Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice	NATURE			English	Article							BINDING; MOUSE	EXPRESSION of Ets2, a proto-oncogene(1) and transcription factor(2-5), occurs in a variety of cell types(6), During murine development it is highly expressed in newly forming cartilage, including In the skull precursor cells and vertebral primordia(7), Ets(2) is located on human chromosome 21 (ref. 8) and is overexpressed in Down's syndrome (trisomy 21)(9), Here we generate transgenic mice to Investigate the consequences of overexpression of Ets2, We find that mice with less than 2-fold Ets2 overexpression in particular organs develop neurocranial, viscerocranial and cervical skeletal abnormalities, These abnormalities have similarities with the skeletal anomalies found in trisomy-16 mice and humans with Down's syndrome, in which the gene dosage of Ets2 is increased(10,12), Our results indicate that Ets2 has a role in skeletal development and implicate the overexpression of Ets2 in the genesis of some skeletal abnormalities that occur in Down's syndrome.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOLEC GENET & DEV GRP,CLAYTON,VIC 3168,AUSTRALIA; PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA; MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOLEC & STRUCT BIOL,CHARLESTON,SC 29425; UNIV TORONTO,FAC MED,DEPT PATHOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON M5S 1A8,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S 1A8,CANADA	Monash University; Peter Maccallum Cancer Center; Medical University of South Carolina; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Kola, Ismail/C-5254-2013; Lahoud, Mireille/F-1299-2013	Lahoud, Mireille/0000-0001-8472-6201				ASCIONE R, 1992, INT J ONCOL, V1, P631; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; Bancroft JD, 1984, J PATH, V145, P355; CAFFEY J, 1978, PAEDIATRIC XRAY DIAG, V1, P155; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; Epstein L B, 1980, Ann N Y Acad Sci, V350, P171, DOI 10.1111/j.1749-6632.1980.tb20618.x; GRAUSZ H, 1991, MORPHOGENESIS DOWN S, P169; HART AH, 1995, ONCOGENE, V10, P1423; IANNELLO RC, 1994, REPROD FERT DEVELOP, V6, P599, DOI 10.1071/RD9940599; KAUFMAN MH, 1990, ATLAS MOUSE DEV, P495; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOLA I, 1995, ADV HUMAN REPROD, P309; KORENBERG JR, 1991, MORPHOGENESIS DOWN S, P43; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; PATTERSON D, 1987, SCI AM, V257, P42; REEVES RH, 1987, MOL BRAIN RES, V2, P215, DOI 10.1016/0169-328X(87)90028-3; REEVES RH, 1985, NAT GENET, V111, P177; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; THOMAS RS, 1995, ONCOGENE, V11, P2135; Tymms M J, 1995, Methods Mol Biol, V37, P31; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	23	167	168	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 8	1996	379	6565					534	537						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU693	8596630				2022-12-01	WOS:A1996TU69300048
J	Okuda, T; vanDeursen, J; Hiebert, SW; Grosveld, G; Downing, JR				Okuda, T; vanDeursen, J; Hiebert, SW; Grosveld, G; Downing, JR			AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; EMBRYONIC STEM-CELLS; DROSOPHILA SEGMENTATION GENE; ACUTE MYELOGENOUS LEUKEMIA; SL3-3 VIRUS ENHANCER; FUSION TRANSCRIPT; RECEPTOR-DELTA; NUCLEAR FACTOR; DNA-BINDING; RUNT	The AML1-CBF beta transcription factor is the most frequent target of chromosomal rearrangements in human leukemia. To investigate its normal function, we generated mice lacking AML1. Embryos with homozygous mutations in AML1 showed normal morphogenesis and yolk sac-derived erythropoiesis, but lacked fetal liver hematopoiesis and died around E12.5. Sequentially targeted AML1(-/-) ES cells retained their capacity to differentiate into primitive erythroid cells in vitro; however, no myeloid or erythroid progenitors of definitive hematopoietic origin were detected in either the yolk sac or fetal livers of mutant embryos. Moreover, this hematopoietic defect was intrinsic to the stem cells in that AML1(-/-) ES cells failed to contribute to hematopoiesis in chimeric animals. These results suggest that AML1-regulated target genes are essential for definitive hematopoiesis of all lineages.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Okuda, T (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Hiebert, Scott W/C-9979-2010; Downing, James R./N-8102-2018		NCI NIH HHS [CA-21765] Funding Source: Medline; PHS HHS [R01-64140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DOWNING JR, 1993, BLOOD, V81, P2860; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; ERICKSON P, 1992, BLOOD, V80, P1825; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GERGEN JP, 1986, CELL, V45, P289, DOI 10.1016/0092-8674(86)90393-4; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAJRA A, 1995, MOL CELL BIOL, V15, P4980; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIESCHKE GJ, 1994, BLOOD, V84, P27; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; LOSARDO JE, 1990, J VIROL, V64, P1756, DOI 10.1128/JVI.64.4.1756-1763.1990; MANLEY NR, 1993, J VIROL, V67, P1967, DOI 10.1128/JVI.67.4.1967-1975.1993; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERS S, 1996, IN PRESS CRIT REV EU; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SHURTLEFF SA, 1995, IN PRESS LEUKEMIA; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SONODA Y, 1990, BLOOD, V75, P1615; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; SUN WW, 1993, J VIROL, V67, P1976, DOI 10.1128/JVI.67.4.1976-1986.1993; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1992, GENOMICS, V12, P340, DOI 10.1016/0888-7543(92)90383-4; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZHU X, MOL CELL BIOL, V15, P1136; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	79	1545	1583	0	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					321	330		10.1016/S0092-8674(00)80986-1	http://dx.doi.org/10.1016/S0092-8674(00)80986-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565077	Bronze			2022-12-01	WOS:A1996TR59500018
J	Colwell, JA; Clark, CM				Colwell, JA; Clark, CM			Forum two: Unanswered research questions about metabolic control in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				The participants of Forum Two addressed the unanswered research questions about metabolic control and noninsulin-dependent diabetes mellitus (NIDDM). The most compelling issue was the effect of metabolic control on both the development and progression of macrovascular disease in patients with NIDDM. Associated questions that could be answered by a well-controlled clinical trial related to the goal of blood glucose control in NIDDM in the elderly and in persons with clinical vascular disease. The specific suggestion was a trial similar to the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Another important research issue that was discussed was the benefit of treating other risk factors such as hypertension and hyperlipidemia in diabetic patients. Yet another area discussed was the study of health services delivery to-examine the best care-delivery methods for diabetes and other chronic diseases. Other areas of discussion centered on basic research, that is, the fundamental cause of insulin resistance and the genetics of NIDDM and the loss of protection against atherosclerosis in postmenopausal women with diabetes.	REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Colwell, JA (corresponding author), MED UNIV S CAROLINA, 171 ASHLEY AVE, CHARLESTON, SC 29401 USA.								0	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				178	179		10.7326/0003-4819-124-1_Part_2-199601011-00020	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554215				2022-12-01	WOS:A1996TL94400020
